,ticker,content
0,ABBV,relative strength rs rating abbvie abbv enter higher percentile monday get lift look best stock buy watch factor watch closely be relative price strength ibd unique rating track market leadership worst best score grade show stock price behavior last week compare other stock database history reveal best stock often have higher rs rating launch largest run see abbvie continue rebound hit benchmark see ibd help make more money stocksabbvie be work consolidation buy point see clear price volume least higher normal keep mind later stage consolidation entail more risk take look revenue profit performance company have post quarters accelerate earning growth sale gain have also rise same period company be expect release next quarterly number jul abbvie earn rank peer medical ethical drug industry group jazz pharmaceutical jazz be top rank stock group get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
1,ABBV,abbvie abbv stock be trading north actual value analyst say monday far reach analysis pharmaceutical company leerink analyst geoffrey porge say pharmaceutical company current asset put fair value share stock market today abbvie stock rise end regular session stock be consolidate buy point accounting most uncertain part company valuation be return future unallocated research development expense get valuation share assume return say report biggest chunk value abbvie stock come humira imbruvica be worth share respectively say humira treat several form arthritis psoriasis imbruvica be cancer drug abbvie acquire pharmacyclic get newsletter deliver inbox more info product service privacy policy term useporge note abbvie have late early stage pipeline asset be uncertain see drug call elagolix risankizumab upadacitinib worth collective share today risk be worth say even earlier stage asset be worth add share say opportunity abbvie stock come demonstrate return expect future expense reveal material upside compare forecast current later pipeline program say humira see competition biosimilar copycat drug europe soon end year analyst say porge expect humira hit peak sale decline imbruvica be pharmaceutical company biggest drug contribution revenue pale comparison humira first quarter imbruvica account total sale humira generate close abbvie stock be year date have lose high have scuttle plan seek accelerate approval cancer drug dub rova follow poor result mid stage study march drop value abbvie stock exceed rova revenue be remove consensus stock currently trading sum part analysis suggest pullback have not be overdo porge say porge have price target abbvie stock be higher sum part analysis abbvie realize price target have enhance long term value creation internal licensing acquisition say get instant access more trading idea exclusive stock list ibd proprietary rating only related do spot major market top easy look heavy trade stock most penny stock fail make investor richlook next nvidia start simple routine
2,ABBV,abbvie abbv sank month low friday analyst suggest blockbuster arthritis treatment humira face increase sale pressure rival copycat drug later year stock market today abbvie lose close share be consolidate buy point stock pharmaceutical company rise fraction wrap regular session credit suisse analyst vamil divan note patent protect humira sale europe abbvie arthritis treatment be expect see biosimilar competition later year biosimilar be nearly identical copy biologic drug estimate suggest biologic blockbuster humira account abbvie total net present value remain cautious abbvie outlook front humira biosimilar competition divan say note client get newsletter deliver inbox more info product service privacy policy term also likely abbvie see competition arthritis treatment prior say note abbvie recently lower humira sale guidance cut represent additional pressure insurer less ability raise price say divan reiterate underperform rating abbvie comment follow decision thursday food drug administration withdraw reconfigure draft guidance develop biosimilar decision be intriguing say interpretation development be fda be learn be necessary order ensure safe effective also cost effective efficient development biosimilar unite state say divan expect fda issue update guidance come month thursday fda say decide withdraw guidance base public comment now plan rework guide develop biosimilar further consideration scientific regulatory issue fda commissioner scott gottlieb note potential biosimilar foster competition lower cost biologic treatment president donald trump have long argue competition help bring price drug american consumer yet market product be not advance quickly hope gottlieb say written statement re take fresh look draft recommendation evaluate analytical study order ensure guidance take consideration most current relevant science related do spot major market top easy look heavy trade stock most penny stock fail make investor richlook next nvidia start simple routine
3,ABBV,abbvie abbv biggest drug humira be trouble biosimilar take share europe begin year analyst say wednesday downgrade stock slash price target xon stock market today abbvie gain close announce preliminary result modify dutch auction tender offer abbvie expect acquire share common stock share total exclude fee credit suisse analyst vamil divan downgrade abbvie underperform neutral rating cut price target see humira biosimilar nearly identical biologic copy crop europe european sale take brunt early competition humira biosimilar divan say report expect decline humira sale outside dip abbvie expect get newsletter deliver inbox more info product service privacy policy term use expect relatively rapid erosion humira sale eu follow entry multiple biosimilar version drug fourth quarter say be already biosimilar approve eu believe be approve report often cite humira best selling drug product pharmaceutical company generate sale globally come humira treat several form arthritis psoriasis crohn disease divan further call rapid erosion humira sale begin pressure be already apparent abbvie recently lower humira sale guidance year year decline believe pressure intensify expect decrease ability company such abbvie extract price increase system future copay accumulator program also effectively further lower net price go forward say abbvie stock have outperformed share other pharmaceutical company january time have rise meanwhile share pharmaceutical company have advanced divan credit abbvie stock performance better insight competition humira biosimilar reach legal settlement potential rival firm be also enjoy low tax rate year trend time investor be also enthusiastic late stage pipeline addition loom humira competition late stage pipeline be stretched divan say late stage drug call risankizumab enter highly competitive psoriasis market further question safety differentiation upadacitinib potential psoriasis arthritis drug abbvie management still see more sale potential drug divan note tender offer news lead acute unpredictable volatility cautious outlook be drive longer term fundamental concern have story abbvie share be currently consolidate buy point stock pharmaceutical company collectively advanced related much money do need start investing long term retirement investing strategy buy stock ahead earning report
4,ABBV,important metric look stock be higher relative strength rating abbvie abbv now clear threshold jump wednesday re research best stock buy watch keep close eye relative price strength exclusive rating investor business daily track market leadership worst best score score show stock price performance last week stack other stock database year market history reveal best stock tend have higher rs rating launch biggest price move see ibd help make more money stocksabbvie be try complete consolidation buy point see stock break heavy volume later stage pattern investor be aware involve more risk term top bottom line number company have post quarters accelerate earning growth revenue gain have also rise same time frame abbvie earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz be also group highest rate stock get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
5,ABBV,abbvie abbv see improvement ibd smartselect composite rating wednesday upgrade mean stock be now outpace other stock term key performance metric technical strength market biggest winner often have higher score early stage new price run so good item have checklist look best stock buy watch abbvie be currently entry flat base look winning stock try simple stock earn ep rating mean recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show roughly equal amount buy selling institutional investor last week get newsletter deliver inbox more info product service privacy policy term usein company post earning growth have now post accelerate ep increase consecutive quarters top line growth increase prior report company have now post rise growth last report abbvie earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz be also group highest rate stock related company be now outperform stock see stock just come ibd top stock list
6,ABBV,abbvie abbv have relative strength rs rating upgrade friday try find best stock buy watch keep close eye relative price strength ibd proprietary rating measure market leadership worst best score rating show stock price movement trail week hold other stock database history reveal market biggest winner tend have rs rating begin biggest run look winning stock try simple routineabbvie be not currently offer proper buy opportunity see stock go form promising consolidation spark new run term fundamental abbvie have post rise ep growth last quarters revenue growth have also increase same time frame company hold rank peer medical ethical drug industry group zoetis zts be rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
7,ABBV,look best stock buy watch focus rise relative price strength stock fit bill be abbvie abbv have relative strength rs rating upgrade wednesday re research best stock buy watch be sure pay attention relative price strength ibd proprietary rating identify market leadership worst best score grade show stock price behavior last week compare other stock database year market history reveal best perform stock tend have rs rating north early stage move see ibd help make more money stocksabbvie be not currently offer proper buy opportunity see stock go build chart pattern launch new move term fundamental company have post quarters accelerate earning growth revenue gain have also increase same period abbvie be expect report next quarterly number apr abbvie earn rank peer medical ethical drug industry group zoetis zts be rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
8,ABBV,abbvie abbv attempt small rally friday share crater nearly thursday biopharma scuttle plan seek accelerate approval lung cancer drug perform poorly mid stage trial note friday leerink analyst geoffrey porge call stock reaction thursday excessive also suggest program be abbvie undoing oncology abbvie buy stemcentrx drug be study dub rova investor disappointment reflect unravele company overall solid tumor oncology strategy well question business development discipline judgement quality reliability management long term revenue forecast say stock market today abbvie slip close collapse thursday share have be form cup handle buy point crash far day move average thursday session get newsletter deliver inbox more info product service privacy policy term useporge cut revenue earning expectation respectively question rova ever get approve struggle lung blood toxicity result slash price target abbvie suggest separate note thursday fda tell company not filing accelerate approval give trial result risk benefit see study rova be test third treatment small cell lung cancer relapse doesn respond other therapy specific group patient independent review find best objective response rate be overall respond median month overall survival be median month month treatment probability survival be review find drug be tie number adverse event third patient experience fatigue sensitivity sunlight buildup excess fluid lung swell nausea firm say news release porge be concern affect other drug associate abbvie stemcentrx deal know antibody drug conjugate adcs turn safety liability undermine key component stemcentrx platform porge say adverse event appear be associate toxin include adc be liability adcs come stemcentrx abbvie say wouldn seek accelerate approval rova third treatment small cell lung cancer be still phase testing drug first second treatment same form advanced lung cancer datum trial be expect porge say piper jaffray analyst christopher raymond keep overweight rating price target abbvie note surprised today news company not seek accelerate approval third line small cell lung cancer several week abbvie have suggest objective response rate mid teen be sufficient file accelerate approval food drug administration raymond say report client thursday call abbvie decision head speaking company today understand durability month be issue think fda be look less variability metric accelerate approval say raymond argue stock reaction be overblown result rova third treatment form lung cancer be relatively line standard care other comparable drug trial opportunity be small abbvie sentiment take hit say related much volume look stock investing basic sell stocklooking next nvidia start simple routine
9,ABBV,question abbvie abbv have prove be pharmaceutical leader extremely healthy dividend boot company debut nyse january then stock have climb much same period have rally much abbvie therefore be live proof savvy dividend investor also seek capital appreciation achieve be key chicago base medical giant long term success first company focus important therapeutic area provide opportunity abbvie aim product tackle disease immunology cancer virology neuroscience company have produce medicine gain traction friday abbvie announce fda grant approval venclexta treatment combination rituximab treat patient chronic lymphocytic leukemia cll small lymphocytic lymphoma sll have receive least prior therapy phase iii clinical trial find combine regimen cut risk disease progression death vs standard abbvie total revenue grow top line be abbvie spinoff abbott lab earn share last year second solid dividend generator tend show stable increase earning abbvie excel year earning stability factor show tremendous stability scale accord william neil co datum wall street expect profit rise year abbvie paid cent share cash holder record april dividend translate vs year abbvie paid cent share feb third income investor gain advantage more fund be pile stock abbvie end march mutual fund hedge fund own abbvie share totale fund end second quarter total share ownership also grow same time frame rise share top rate fidelity contrafund ticker symbol fcntx boost ownership share share end year abbvie share be base mode be still trading time high stock be try hold support day move average aug last year abbvie rally week flat base heavy volume stock surpass proper entry rally go current base action related top growth stock today peek ibd best large cap stock today big cap investor corner find right buy point most stock
10,ABBV,abbvie abbv be rare jewel stock market debut january beaten pant rise more advanced same time frame pharmaceutical giant also deliver healthy payout further benefit long term holder feb north chicago base firm raise quarterly cash payout cent share annualize dividend share abbvie show yield vs same day company board also approve new stock repurchase program more company total market value abbvie have share outstanding top rate member ibd ethical drug industry group act so shareholder friendly strong fundamental be linchpin get newsletter deliver inbox more info product service privacy policy term useabbvie have increase earning past quarters past quarters growth have actually accelerate earning rise share then jump next cycle healthy revenue growth help boost bottom line abbvie be enjoy stronger profit margin indicate company be command strong pricing product find novel way reduce cost tax margin hit basis point vs year tax margin rise basis point abbvie appear be gain market share field immunology oncology virology neuroscience result abbott lab spinoff note global sale imbruvica treatment mantle cell lymphoma chronic lymphocytic leukemia rise fiscal note ibd stock checkup abbvie get accumulation distribution rating meaning institutional investor have be net accumulator share past week mutual fund hedge fund own share abbvie have expand total end first quarter same year total share own climb related top growth stock today peek ibd hot large cap stock ibd big cap
11,ABBV,novartis nvs be step closer take bite abbvie abbv blockbuster arthritis drug european committee friday recommend official approve novartis humira biosimilar abbvie meanwhile dip analyst downgrade same worry threat humira biosimilar competition pressure biggest product piper jaffray analyst christopher raymond drop abbvie neutral rating overweight specifically european biosimilar erosion model abound humira loom fourth quarter loss exclusivity important geography be well know think investor be still underestimate downside potential say report stock market today abbvie dip close stock be consolidate buy point novartis other hand jump be share pharmaceutical company lift get newsletter deliver inbox more info product service privacy policy term useearly friday novartis generic unit announce committee medicinal product human use recommend full european medicine agency approve humira biosimilar humira treat form arthritis psoriasis crohn disease ulcerative colitis positive chmp opinion biosimilar humira be important milestone million patient look reclaim health autoimmune disease diagnosis say richard francis chief executive novartis generic unit sandoz approve novartis be able sell humira biosimilar european country humira be abbvie biggest drug best selling drug ever generate sale more third come abbvie be soon see biosimilar competition expect mid meanwhile other headwind persist copay accumulator be take wind humira sail other threat rhetoric trump administration call incentive middleman exist likely reform be long way same be say copay accumulator make so discount provide pharmaceutical company help patient afford costly drug don apply patient deductible discount run patient pay full cost costly proposition medicine humira run thousand dollar month say very real draw revenue form copay accumulator have really yet be feel raymond say abbvie have already lower humira guidance once emerge threat wonder last hard make valuation argument abbvie raymond say cut price target next month possible abbvie gain approval drug treat female reproductive issue inflammatory condition arthritis model success board think re largely price stock already say raymond isn only step sideline abbvie earlier week credit suisse analyst vamil divan downgrade stock underperform rating also cut price target loom humira biosimilar competition europe related much money do need start investing investing basic sell stocklooking next nvidia start simple routine
12,ABBV,vertex pharmaceutical vrtx share rocket month high friday rival galapago glpg release disappointing result cystic fibrosis treatment lead partner abbvie abbv opt additional study stock market today vertex pop share galapago tumble abbvie stock lift broadly biotech stock rise galapago test drug glpg cystic fibrosis treatment patient specific genetic mutation patient have already receive vertex drug orkambi galapago goal show drug be part triple regimen cystic fibrosis fall short day patient treat glpg show improvement lung function receive placebo fail hit statistical significance also trail vertex datum drug vx vx show benefit respectively get newsletter deliver inbox more info product service privacy policy term use bar remain high raymond james analyst laura chico say report vertex already advance phase pivotal study triple regimen see few competitor be able challenge vertex intermediate term chico keep outperform rating biotech company stock improvement vs placebo have be competitive credit suisse analyst vamil divan say report glpg be also be test part triple regimen contain pair other drug galapago divan be now bearish study call falcon thursday datum raise significant concern falcon competitiveness entire cystic fibrosis franchise say galapago be partner abbvie cystic fibrosis effort abbvie be take knee cystic fibrosis raymond james chico note press release galapago say abbvie decide not proceed previously contemplated second triple regimen therapy now galapago be review future cf cystic fibrosis collaboration abbvie biotech company say release datum release galapago remove major overhang vertex stock rbc capital market analyst brian abraham say report expect vertex be dominant cystic fibrosis player foreseeable future abraham expect biotech company hit year cystic fibrosis treatment sale share earning have price target vertex stock leerink analyst geoffrey porge have price target vertex note galapago cystic fibrosis treatment result sweat chloride reduction be also materially lower vertex result experimental triple regimen sweat chloride be indicator cystic fibrosis none be particularly surprising say report however serve reminder difficulty do complex multicompound drug development project high wall vertex future value cystic fibrosis get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real invest stock free new apps aim term retirement investing strategy etfs
13,ABBV,vertex pharmaceutical vrtx be get breathe room analyst say thursday rival proteostasis pti tumble disappointing result study testing cystic fibrosis drug proteostasis test drug pti patient also take vertex drug orkambi regimen show improvement blood glucose sweat chloride indicator cystic fibrosis weight gain patient didn experience major improvement breathe not easy look leerink analyst geoffrey porge say note vertex share have dip quarter date competitive worry sell reverse competitive threat fade say vertex rise much intraday end regular session fraction share proteostasis crash stock market today galapago glpg rival see share lose proteostasis news get newsletter deliver inbox more info product service privacy policy term usea number cystic fibrosis drug work correct malfunctioning protein make cftr gene pti be know cftr corrector vertex have portfolio corrector work different patient base own genetic mutation vertex proteostasis galapago partner abbvie abbv be work combination drug treat cystic fibrosis study proteostasis be look determine best dose pti double triple pill study leerink analyst joseph schwartz say key metric test look improve be force expiratory volume second proteostasis study best result come milligram dose pti top orkambi improve force expiratory volume second percentage point lag vertex newly approve drug symdeko medicine regimen improve patient ability forcefully expel air leerink porge say now proteostasis competitive threat appear modest say proteostasis corrector bound different site cftr protein vertex medicine failure match high effectiveness bar establish vertex be testament difficult development path competitor small molecule therapy cystic fibrosis say galapago likely have datum later month study second generation corrector top orkambi result proteostasis suggest medicinal chemistry vertex indeed be durable competitive advantage company cystic fibrosis indication say galapago be successful vertex retrace back range june july related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
14,ABBV,minute dow jone industrial average component merck mrk be do battle fellow drugmaker bristol myer squibb bmy drug cancer next biotech giant amgen amgn sanofi sny be tussle court fate cholesterol bust drug meanwhile company gilead science gild be rake coal congress charge day treat hepatitis brave contentious new world pharmaceutical biotechnology company realm science be try develop landmark medicine cure cancer hepatitis other life threaten illness do delicate dance wall street regulator balancing public health issue demand shareholder investor find tricky navigate sector company rise fall drop hat bookmark page stay top latest news biopharma sector get newsletter deliver inbox more info product service privacy policy term useview more biotech pharma stock newsrelated best stock buy watch
15,ABBV,share abbvie abbv dip thursday analyst compare amazon amzn remove conviction list note bar execute now be much higher biopharma stock abbvie have perform line amazon past month clearly be different structural story goldman sachs analyst jami rubin say say retain buy rating view abbvie still most attractive name large cap biopharma coverage stock market today abbvie topple close earlier share fall much stock be consolidate buy point abbvie have rocket past month amazon have jump rubin keep price target abbvie note report add abbvie conviction list march then abbvie share have rise vs increase jump health care spdr xlv exchange trade fund get newsletter deliver inbox more info product service privacy policy term decision isn drive drug pricing concern be likely hang pharmaceutical company say more analysis abbvie strong stock move relative peer better look investment thesis rubin add abbvie conviction list believe company separate humira sale growth product sale humira be abbvie most important drug treat several form arthritis psoriasis well crohn disease investor long have be concern potential rival copycat case biosimilar wrest revenue humira massive blockbuster be often cite industry best selling drug last march worry have ease humira outlook now largely consensus view biosimilar entry be time frame say pipeline front investor appreciate company multiple phase drug include therapy inflammatory condition condition female reproductive system abbvie be also work grab new approval cancer drug venclexta imbruvica latter point abbvie say thursday regimen contain cancer drug imbruvica gazyva roche rhhby subsidiary genentech meet key goal improve progression free survival type blood bone marrow cancer regimen outperformed combination gazyva chemotherapy also march firm have meaningfully increase dividend also announce share buyback rubin say still see more upside stock drive earning momentum pipeline catalyst bar appease investor be high pipeline appreciation be greater today year bar execution be lot higher say believe investor continue gain confidence story company continue execute number pipeline take time play related much volume look stock long term retirement investing strategy etfsnew option strategy limit risk earning
16,ABBV,abbvie abbv share climb thursday biopharma announce raise dividend cent share authorize new stock repurchase program dividend increase cent share piper jaffray analyst christopher raymond boost price target abbvie keep overweight rating news follow abbvie guidance tax rate follow tax reform unexpected somewhat alarm midday trading halt abbvie announce board approve plan deployment capital follow tax reform include additional share repurchase authorization dividend increase say note client raymond also boost earning share outlook abbvie fiscal year respectively ibd take look invest biotech stock now rank fifth group ibd track head ibd university get in stock rating tip time market idea find evaluate strong stock cash dividend be payable stockholder record close business april abbvie say news release hour trading stock market today abbvie rise fraction advance regular session drug stock close day enjoy fifth day run black related biotech stock pop fda nod slam door woesteva pharma rocket berkshire hathaway reportedly take stakedow merck fail alzheimer drug shouldn hurt biogen
17,ABBV,gilead science gild tumble month low wednesday report part miss produce first significant disappointment large biotech earning season accord leerink analyst wall street estimate be too bullish total revenue hiv drug sale falter hepatitis franchise leerink analyst geoffrey porge say note client cut revenue forecast estimate be consistently too high fail incorporate increasingly acute reduction channel inventory net price dominate gilead first quarter result undermined report sale say result gilead total revenue lag porge model hepatitis drug sale miss estimate revenue hiv drug come lower expect get newsletter deliver inbox more info product service privacy policy term usein afternoon trading stock market today gilead shucked stock topple much earlier trade meanwhile biotech stock collectively rise fraction gilead hepatitis franchise have crumble weight own success high cure rate have lead fewer patient late tuesday gilead report biggest year year sale decline hepatitis drug start report unit separately estimate hepatitis drug sale beat expectation porge note sale be consensus model new patient volume fall sequentially gilead keep expectation business stabilize mid importantly company be totally frank investor appreciate believe be trough year mizuho analyst salim sy write note be first time knowledge company have specifically state hepatitis drug harvoni be hardest hit sale decline sequentially year year miss expectation accord several analyst report abbvie abbv drug mavyret be partially blame needham analyst alan carr say note new prescription mavyret recently surpass combine harvoni epclusa new prescription be now reach pass gilead hepatitis product combine say management believe drug pricing space have largely stabilize gilead still expect hepatitis drug sale come mizuho sy say gilead doesn typically adjust guidance much first quarter earning conference call note do math now pricing have largely stabilize gilead remain quarters perhaps look say basically hit low end range quarter hiv drug rake miss view exaggerate seasonal inventory effect rbc analyst brian william say note encouragingly volume share metric remain directionally favorable suggest core franchise be still healthy perform well rest year say biktarvy gilead newest hiv drug bring lag most bullish view william see number indicative strong contribution drug also possible biktarvy be already take share other drug company note volume be come patient switch biktarvy third be switch gilead own genvoya glaxosmithkline gsk drug tivicay triumeq gilead believe biktarvy become single tablet regimen ultimately mizuho analyst sy say gilead expect european regulator approve biktarvy third quarter related do spot major market top easy look heavy term retirement investing strategy buy stock ahead earning report
18,ABBV,abbvie abbv celgene celg regeneron pharmaceutical regn spike second half accelerate number drug approval launch analyst say wednesday reverse trend first half year see share biotech stock slip industry group track investor business daily group be rank fifth just week meanwhile pharmaceutical company be rank leerink analyst classify first half disappointing large cap biopharma company biotech stock pharmaceutical company face dearth clinical study result validate pipeline re price stock say second half year promise be more exciting small mid cap biopharma stock significant clinical event horizon include readout binary phase trial write note client get newsletter deliver inbox more info product service privacy policy term other biotech stock pharmaceutical company abbvie be expect report datum study drug upadacitinib researcher be look drug treatment form arthritis further food drug administration likely decide approve abbvie drug call elagolix treatment endometriosis condition female reproductive system fda also decide fate drug dub venclexta form leukemia stock market tracker also expect celgene unveil datum late stage study revlimid celgene partner acceleron pharma xlrn blood disease revlimid be celgene major cancer drug celgene also reveal more juno therapeutic acquisition be move class cancer therapy know car short chimeric antigen receptor cell therapy compete novartis nvs gilead science gild datum car development update define path forward product revlimid leerink analyst geoffrey porge say note porge also expect fda make decision regeneron sanofi sny dupixent asthma treatment physician already use dupixent treat eczema duo also have cemiplimab fda be consider advanced form skin cancer addition intra cellular therapy itci be work drug dub lumateperone schizophrenia treatment analyst focus fda accept application approval base mixed phase datum porge say intra cellular also report topline datum ongoing phase study bipolar depression second half look second indication lumateperone say porge expect zogenix zgnx have datum late stage study drug zx researcher be consider drug treatment type epilepsy call dravet syndrome gw pharmaceutical gwph drug epidiolex likely gain approval use june additionally dova pharmaceutical dova fibrogen fgen have catalyst chronic liver chronic kidney disease respectively dova expect fda soon decide approve drug fibrogen expect unveil topline datum study drug second half year fda be also take flexible stance orphan drug development leerink analyst joseph schwartz say note approval sarepta therapeutic srpt duchenne muscular dystrophy drug exondys trigger cascade noteworthy filing say continue believe fda continue evolution warrant positive sentiment rare disease focuse company particularly name amicus therapeutic fold sarepta uniqure qure long investigational drug be deem safe demonstrate strong effectiveness say related much money do need start investing look best stock buy watch start herestill rule stock investor always cut loss short
19,ABBV,vertex pharmaceutical vrtx slide week low friday food drug administration call additional test compound used potential cystic fibrosis treatment result potential drug regimen likely win enter market leerink analyst geoffrey porge say note client add fda requirement be also blessing vertex be rivale galapago glpg abbvie abbv treatment fda stance do provide reassurance vertex competitive position say fda be clearly signale be shortcut least traditional good drug development indication stock market today vertex dip close earlier stock fall much share be form flat base buy point galapago slip fraction abbvie rise get free access ibd digital april
20,ABBV,get premium stock list pass fail stock rating more start herevertex galapago be separately work bring drug regimen treat cystic fibrosis market vertex think treat cystic fibrosis patient treatment thursday vertex say send second regimen phase testing third potential combination be be hold vertex do additional study drug involved regiment know test moniker vx phase testing regimen vx tezacaftor other test drug vx vx improve patient ability forcefully expel air however give very little monotherapy dose range work have be do vx fda request additional clinical trial prior phase start needham analyst alan carr write report client guidance timing first quarter initiation seem feasible once daily regimen used vx be nice have far have first drug regimen rbc analyst brian abraham say note combination phase study be also daily regimen require single dose vertex kalydeco evening further delay vx regimen doesn mean other combination win pass muster fda analyst say vertex have total potential combo pivotal study piper jaffray analyst edward tenthoff say note see vertex year ahead galapago leerink porge now expect vertex first drug regimen be market first quarter previously predict late launch regimen change be not particularly meaningful forecast vertex primary competitor galapago seem closer pivotal trial be month say further galapago also be require run additional study go pivotal testing porge reduce sale view still see rapid revenue growth almost also cut price target vertex reiterate outperform rating vertex remain most uncomplicated growth story large cap biotech say expect recover recent weakness target price come month related chart read basic buy point mark time real invest stock free new apps aim term retirement investing strategy etfs
21,ABBV,abbvie abbv hepatitis franchise crushed first quarter analyst say thursday fellow drugmaker bristol myer squibb bmy report consensus top profit firm also increase sale adjust earning guidance stock market today abbvie pop close bristol myer add broadly drug stock rise analyst credit abbvie blockbuster humira drug hepatitis franchise first quarter sale beat total sale be increase operationally top estimate adjust profit rise share beat cent get free access ibd digital april
22,ABBV,get premium stock list pass fail stock rating more start hereworldwide humira sale be top analyst prediction piper jaffray analyst christopher raymond say sale grow year year operational basis decline sequentially typical seasonal trend meanwhile hepatitis drug viekira mavyret crushed raymond say report client together bring nearly double consensus view sale outside be beating view abbvie success hepatitis drug send gilead science gild stock fraction morning trading abbvie mavyret be consider formidable challenger gilead hepatitis franchise mavyret treat genotype hepatitis sale cancer drug imbruvica also narrowly top bring north view piper jaffray raymond say other franchise be mixed prostate cancer drug lupron respiratory disease drug synagis beating expectation hiv drug kaletra lag say firm also boost adjust earning outlook share share guidance assume effective tax rate year rise next year analyst have modeled adjust earning share abbvie first quarter result help stock failure lung cancer medicine call rova quarter leerink analyst geoffrey porge say note flop send share nearly day believe strong operate result improve outlook lead outperformance abbvie stock today say anticoagulant eliquis cancer drug opdivo drive growth bristol myer first quarter total revenue rise vs year earlier period opdivo bristol myer biggest drug hair grow eliquis rac growth bristol myer sale narrowly beat consensus analyst poll zack investment research other estimate be higher analyst poll factset have average expect poll yahoo call sale sale cancer drug yervoy decline markedly yervoy be combine opdivo treat several form cancer be immuno oncology drug immune system identify fight cancer cancer drug sprycel also decline bring sale bristol myer raise full year adjust earning target share even lower gaap target also raise sale view mid single digit growth earlier expectation low mid single digit growth consensus have modeled adjust profit share sale related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
23,ABBV,do lead pharmaceutical stock merck mrk abiom abmd abbvie abbv astrazeneca azn biogen biib have common be client medical software stock ipo veeva system veev lead mutual fund manager have take note veeva impressive client roster well company strong fundamental veeva have be
24,ABBV,gw pharmaceutical gwph pass second last hurdle get approval cannabis base seizure drug epidiolex thursday special food drug administration committee unanimously recommend now epidiolex go full fda june potential approval approve be first drug derive directly cannabis plant get fda stamp epidiolex used cannabidiol cbd treat seizure disorder know lennox gastaut dravet syndrome doctor tend diagnose patient condition re infant be pleased advisory committee unanimous recommendation approve epidiolex provide important treatment option patient lennox gastaut dravet chief executive justin grover say written statement get newsletter deliver inbox more info product service privacy policy term fda hold special advisory committee meeting weigh risk benefit drug committee schedule epidiolex half day meeting be good sign spokesperson tell investor business daily last month epilepsy foundation praise committee vote note epidiolex be likely be first drug approve treat dravet syndrome syndrome be rare tend resist many therapy foundation say dravet syndrome be deadly epidiolex represent hope many individual live intractable seizure rare epilepsy day face incredible challenge disable seizure live continual risk serious injury death foundation chief executive philip gattone say written statement earlier week look likely fda peripheral central nervous system drug advisory committee recommend epidiolex document post online show concern liver injury be ease monitoring notably gw work closely drug enforcement administration legally handle cannabis plant cannabis be schedule substance epidiolex used cbd be psychoactive other drug create lab abbvie abbv insys therapeutic insy use thc chemical associate marijuana euphoric high drug treat weight loss aids patient nausea chemotherapy patient stock market today gw lift close same time biotech stock collectively sank related chart read basic buy point mark time real do spot major market top easy look heavy term retirement investing strategy etfs
25,ABBV,gw pharmaceutical gwph spiked week high tuesday internal review hint likelihood food drug administration approve cannabis base seizure drug stock market today gw soar close earlier rise much touch high last see early february share be consolidate buy point briefing document come day special fda committee be set discuss benefit risk gw drug epidiolex epidiolex be cannabidiol cbd derive entirely cannabis plant synthetic drug abbvie abbv insys therapeutic insy meeting go well full fda consider approve drug june gw plan roll epidiolex treatment seizure disorder know lennox gastaut syndrome dravet syndrome regulator appear ready give drug blessing get newsletter deliver inbox more info product service privacy policy term use review be still ongoing risk benefit profile establish datum application appear support approval cannabidiol treatment seizure associate lennox gastaut syndrome dravet syndrome accord document biggest concern be risk liver injury document note physician manage monitoring liver enzyme level general risk associate cbd treatment appear acceptable particularly give finding clinical effectiveness lennox gastaut syndrome dravet syndrome be serious debilitating life threaten disorder reviewer say approve epidiolex be first drug market derive directly cannabis plant gw work closely drug enforcement administration ensure legally handle cannabis drug be schedule substance cbd be psychoactive so doesn carry same side effect associate marijuana drugmaker create other medicine call marinol syndro lab contain thc chemical responsible marijuana euphoric high related chart read basic buy point mark time real much money do need start investing long term retirement investing strategy etfs
26,ABBV,merck mrk pop month high monday goldman sachs suggest cancer drug keytruda be asset believe narrative company be quickly change success keytruda drive significant shift product mix large primary care evolve specialty biopharma goldman sachs analyst jami rubin write note client rubin upgrade merck buy rating neutral add stock brokerage americas conviction list also boost price target raise expectation keytruda also late monday european regulator accept merck application combination keytruda chemotherapy untreated lung cancer patient decision be make base result study present last week call keynote merck say get newsletter deliver inbox more info product service privacy policy term useon stock market today share dow jone component climb close earlier stock touch highest point late january meanwhile rival bristol myer squibb bmy dip finish hoopla surround merck follow american association cancer research annual meeting last week then regimen merck keytruda chemotherapy seemingly top combination bristol opdivo yervoy first treatment lung cancer keytruda chemo reduce risk death merck say combination opdivo yervoy cut risk cancer progression death similar group patient compare chemotherapy alone bristol say now analyst expect merck take lion share already large lung cancer market keytruda animal health unit drive merck value rubin say see bottom line get contribution higher keytruda sale rubin assume merck eventually have roughly half immuno oncology market earlier estimate immuno oncology medicine treat cancer teach immune system identify tumor cell keytruda bring stem sale first treatment advanced lung cancer predict rubin expect keytruda generate lone therapy keytruda likely get quarter market serve patient tumor have lot pd protein rubin say amount pd be thought predict well drug keytruda bristol opdivo work doesn expect bristol opdivo get market merck share combination market remain be determine say keytruda likely have access lung cancer market bristol roche rhhby be still run test rival combination be room further upside merck establish more leadership position still need see datum other combination trial give more credit say merck also seek merger further diversify especially diabetes drug januvia look likely see generic competition mid rubin say see potential merck be even better story management take step diversify address longer term growth post januvia complement keytruda say believe have more enough balance sheet firepower do so firm be now compelling mix margin improvement story say mostly be overlooked lung cancer discussion historically investor reward margin expansion story key example include abbvie abbv eli lilly lly related do spot major market top easy look heavy term retirement investing strategy etfssell take profit hold here be several guideline follow
27,ABBV,sylvie lammert have first seizure month old be rushed emergency room doctor couldn find apparent cause be first seizure have day last seizure take medical personnel minute bring baby tiny convulse body control be year doctor diagnose lammert debilitating condition later determine be rare form epilepsy know dravet syndrome even longer find medication help eventually be enrolled trial epidiolex cannabis base oil make base gw pharmaceutical gwph drug contain chemical cannabidiol cbd have make world difference lammert do same drugmaker now experiment cannabis base treatment first thing noticed start take cbd oil be have lot more clarity think process lammert mother kathleen corkin say interview investor business daily have ability express be much less fatigue seizure come control get newsletter deliver inbox more info product service privacy policy term usesmall biotech firm gw insys therapeutic insy zynerba pharmaceutical zyne be look cash green source recently be consider taboo june likely gw pharma epidiolex become first cross finish line approve treatment derive cannabis plant epidiolex be track become blockbuster accord research firm clarivate analytic other analyst say only reach status clarivate list epidiolex dozen drug expect launch become blockbuster year see epidiolex generate sale likely approval also stoke interest big pharma biotechs look get early jump cannabis market say dan ahren portfolio manager advisorshare investment vice exchange trade fund fund focus alcohol cannabis tobacco market almost call first mover ahren say interview get someone approve lot other biotech pharma company want get action cause additional interest movement space gw derive cbd epidiolex directly cannabis plant cbd be psychoactive so doesn carry same side effect associate marijuana differ approve drug abbvie abbv insys contain chemical thc be create lab thc be chemical responsible marijuana euphoric high approve epidiolex be first medicine specifically treat dravet syndrome gw operate greenwich bioscience also be testing seek approval epidiolex treat other condition epidiolex be take other seizure medicine instance lammert still take trio seizure medication corkin note daughter be now take lower dose gw begin pivot cannabis research seizure disorder base high unmet need market stephen schultz vice president investor relation say interview firm have be work cannabis decade condition seizure be uncontrolled schultz say not uncommon especially dravet patient pass away generally sleep so more reduce convulsive seizure certainly assume better prospect patient lammert wasn diagnosed dravet syndrome be preteen rare form epilepsy begin first year infant life child dravet often have developmental disability back day be time be hard get bed corkin say go school call come get be tired have more seizure science be still relatively immature lammert get diagnosis ensue year lammert try countless drug control seizure corkin say have device implanted critical nerve remove didn work also try special diet now lammert life lincoln mass attend school special need nearby lexington work library garden center also play basketball team plan attend school prom lammert still have seizure be much less frequent less severe corkin say past lammert have seizure lose consciousness drop suddenly year wear helmet prevent injury due sudden onset seizure be huge roller coaster never know have corkin say phase study unveil january show benefit epidiolex lennox gastaut epileptic disorder patient age suffer median drop seizure month take epidiolex week patient see reduction episode firm also test epidiolex dravet patient age median convulsive seizure month patient add epidiolex standard drug week patient see median decline convulsive seizure schultz emphasize epidiolex difference cbd sell dispensary state california arizona medical marijuana be legal epidiolex be clinically test specific consistent level doctor know interact other medication say do not vary be real problem artisanal dispensary base product say also insurance company likely cover epidiolex fda approve trial patient be take gram gram gram cbd day say find gram cbd dispensary go be very expensive gw also be testing epidiolex genetic disorder characterize noncancerous tumor infantile spasm outside gw drug call sativex treat spasticity multiple sclerosis patient sativex contain cbd thc well other chemical find cannabis plant so far gw remain class own cannabis insys zynerba be work synthetic cbd drug insys also sell syndro be similar abbvie marinol contain thc chemical find cannabis create synthetically insys be also study cbd form epilepsy infantile spasm genetic condition call prader willi syndrome further firm be do preclinical work thc treatment anorexia associate cancer agitation alzheimer disease zynerba be research use cbd thc several rare disorder include seizure condition tourette syndrome genetic condition call fragile syndrome same time cara therapeutic cara be look drug interact cannabinoid receptor brain gw work drug enforcement agency legally handle cannabis dea list schedule drug have currently accept medical use high potential abuse firm invest robust program prepare very intense regulatory protocol gw schultz say do take special skill special care say re very excited work re do here be hopefully go be very year launch first drug first plant derive cannabidiol medicine tuesday appear likely fda be lean approve epidiolex ahead special advisory committee meeting discuss risk benefit drug briefing document layer merit epidiolex seizure disorder risk benefit profile establish datum application appear support approval cannabidiol treatment seizure associate lennox gastaut syndrome dravet syndrome accord document thursday gw speak fda committee decide recommend epidiolex full agency full fda consider epidiolex approval june analyst be excited prospect epidiolex other cbd drug plant derive synthetic february report client leerink analyst paul matteis note patient enthusiasm be grow neurologist speaking recent panel say not day go patient physician doesn reach question regard cbd drug call excitement unprecedented matteis say neurologist question not epidiolex realistically live cannabidiol hype time matteis write however envision garner wide use emphasize high level awareness head launch dr jacqueline french professor nyu langone health medical center chief scientific officer epilepsy foundation say be now indisputable evidence cbd have beneficial impact seizure note clinical study have bear datum impact thc seizure cbd hype come few caveat say interview other medication have risk include sleepiness mixed other drug also cause upset stomach diarrhea other intervention new therapy say be very excited be drug other drug have side effect have do monitoring body chemistry doesn make less exciting just mean have treat drug patient see epidiolex natural remedy say lammert mother share opinion lammert go dramatic change begin take cbd oil corkin say acknowledge lammert be also older now be other factor have ease seizure basically seizure medicine be available sylvie probably try corkin say be little avail lammert enrolled study epidiolex new york university several year lammert doctor work french nyu comprehensive epilepsy center have treat be year old corkin understand societal stigma attach cbd medication say wasn difficult choice enroll lammert study think re point ve used option love one be struggle have chance try cbd oil guess be easy choice say super purify feel come natural substance related much volume look stock investing basic sell stocknew option strategy limit risk earning
28,ABBV,biogen biib win launch copycat humira june biotech giant go ahead copy overseas deal announce early thursday biogen partner samsung bioepis be clear launch copy humira critical moneymaker rival abbvie abbv october europe license agreement require samsung bioepis pay abbvie royalty sale version deal also follow settlement amgen amgn september amgen be allow launch humira biosimilar biologic copy january continue believe biosimilar play important role healthcare system also believe be important protect investment innovation abbvie spokeswoman laura say written statement get newsletter deliver inbox more info product service privacy policy term usea number company be work humira biosimilar abbvie be feverishly sue maker prevent launch humira treat several type arthritis psoriasis crohn disease boehringer ingelheim amgen have approve humira biosimilar food drug administration accept novartis nvs application biosimilar january humira bring sale grow biggest share come humira generate globally humira account abbvie sale be samsung bioepis biogen call humira biosimilar imraldi company expect launch imraldi europe oct biogen already have biosimilar europe accord ian henshaw company global head biosimilar plan introduction imraldi oct potentially expand patient choice offer physician more option meet need patient deliver significant saving health care system henshaw say written statement stock market today biogen drop close abbvie fall finish related much money do need start investing look best stock buy watch start buy stock ahead earning report
29,ABBV,gilead science gild viral franchise look strong head first quarter earning season fellow large cap biogen biib celgene celg be shakier ground analyst say wednesday rbc analyst brian abraham call gilead top expectation biogen likely miss bottom line celgene still reel sudden departure chief operate officer be typically weak first period clinical study business development be more important biotech say believe clinical trial success increase merger acquisition activity be more important help improve sentiment give renew drug pricing competitive life cycle concern sector say note client get newsletter deliver inbox more info product service privacy policy term usegilead gain close biogen climb celgene jump possible rebound drop wake sudden unexplained departure chief operate officer coo scott left late last week day biotech group be rank first just week fifth recently week now slip group track investor business daily share hit month high march have topple point abraham call strong quarter gilead hiv drug be become more important firm top line hepatitis market be stabilize more hiv patient be used regimen contain drug know tenofovir alafenamide taf abraham see genvoya descovy odefsey beating expectation take share own atripla stribild biktarvy drug treatment hiv be still early launch expect bring first quarter sale look be tracking ahead consensus project longer term say hepatitis drug harvoni epclusa be see beating view abraham model drug competition abbvie abbv new drug mavyret treat wide group hepatitis patient franchise perform expect see cent bottom line beat first quarter earning share tracking exceed consensus year believe help drive upside pipeline mature visibility increase earning growth year say abraham have outperform rating gilead share biogen look generally solid first quarter abraham expect sale be slightly consensus base prescription trend expect earning share come cent consensus multiple sclerosis drug tecfidera be experience steady erosion celgene experimental drug ozanimod have be delay multiple sclerosis meanwhile revenue spinal muscular atrophy drug spinraza be likely be line multiple sclerosis contract secure key competitor ozanimod delay temporary lull competitive spinal muscular atrophy news flow expect focus call be potential year growth driver say biotech be expect outline plan aducanumab be be test alzheimer disease recently biogen make change study drug investor also be likely key potential acquisition talk expect share trade line pending more clarity long term picture say abraham boost price target have sector perform rating stock first quarter tend be seasonally weak celgene believe be solid enough allay concern emerge follow departure president chief operate officer abraham say abraham boost expectation inflammation drug otezla first quarter year line consensus view otezla sale have be source pain past widely miss third period rebound fourth abraham lower view pomalyst cancer drug reflect weaker expect use pattern likelihood indirect erosion johnson johnson jnj darzalex investor focus be next step ozanimod regulator reject drug multiple sclerosis celgene also offer further detail acceleron pharma xlrn partner blood disease abraham cut price target have celgene top pick stock related much volume look stock long term retirement investing strategy etfsstill rule stock investor always cut loss short
30,ABBV,biogen biib abbvie abbv announce friday be pull jointly develop multiple sclerosis drug zinbryta market follow report brain inflammation patient used medication rbc analyst brian abraham say decision have material impact biogen zinbryta be expect bring revenue company less total sale zinbryta be not biogen core ms drug have be very marginal contributor mid approval due benefit risk profile even today new adverse event report have skewer unfavorably abraham say note client analyst note zinbryta be tie liver toxicity inflammatory immune toxicity case be number better option disease say biogen have suite multiple sclerosis drug decision pull zinbryta follow case encephalitis inflammation brain simultaneously resemble meningitis encephalitis say stock market today biogen gain close abbvie lift finish regular session biogen abbvie split profit zinbryta abraham say related investing basic sell buy stock ahead earning report basic analyze stock cup handle
31,ABBV,stock rally close monday facebook fb make impressive reversal underscore market attempt end nearly week tumble nasdaq composite surge mark best single day performance year so far software chip datum storage be most successful industry group today trading nasdaq fifth largest component facebook erased sharp loss social medium company slide lowest level july deepen sell user datum concern reversed higher close gain still too soon spot bottom stock dow jone industrial average leap technology component lead way microsoft msft jump nearly re-cover day move average morgan stanley raise price target microsoft reiterate overweight rating analyst see microsoft path market cap get newsletter deliver inbox more info product service privacy policy term usecisco system csco dow component find support latest pullback day move average rise extend rebound originated day move average friday dow get close own day line have spend most past week small cap russell climb volume be lower friday pace accord early datum winner beat loser ratio nyse nasdaq be few breakout lead stock reach secondary buy area salesforce com crm be find support pullback day move average volume be double usual pace smart global holding sgh rocket more monday add hot streak stock past buy point share be extend memory chip company have emerge new leader industry group downside abbvie abbv sank day move average try stop gash begin thursday announce disappointing trial result lung cancer treatment stock historically have trade calmly become noticeably more volatile hit record high late january related microsoft get big price target hike adobe datum scandal worsen ftc announce look now trump just score trade
32,ABBV,stock market end sharply lower thursday attention turn away wednesday federal reserve policy statement president trump decision hit china tariff chinese good money flow stock bond year treasury yield slump basis point wall street attention brewing trade war china dow jone industrial index take hit fall crash nasdaq composite fall russell small cap index give back preliminary datum show volume nyse nasdaq come higher wednesday nasdaq composite marked mild distribution day wednesday fall higher volume index likely get hit distribution day thursday investor be fearful put call ratio hit lofty level caterpillar cat boee ba mmm jpmorgan jpm take biggest hit dow loss elsewhere china name netease nte baidu bidu fall hard nasdaq loss more semiconductor stock also lag nasdaq share micron technology mu fall ahead earning report close share drugmaker abbvie abbv plunge nearly company scrap plan seek accelerate approval lung cancer drug drug perform poorly mid stage trial get newsletter deliver inbox more info product service privacy policy term usethere be good news stock market today share ibd sector leader jump retailer daily chart show cup handle entry alternate handle area be also valid be also member ibd sector leader ibd head thursday index be nearly year date compare gain top gainer ibd thursday include casa system casa healthequity hqy gain average daily dollar volume casa system be speculative side be standout performer december ipo share be recently trading marketsmith growth name upland software upld also buck trend rise nearly recent buy point yielded gain more less week meaning have potential be big market leader related trump tariff china import be less feareddropbox poise strong initial public offer trading fridayadd top rate apparel stock watch list wardrobe
33,ABBV,voyager therapeutic vygr continue rocket second day wednesday announce collaboration abbvie abbv develop alzheimer disease drug deal lead other disease treatment analyst say share voyager hit highest point december stock market today soar close be top tuesday gain deal abbvie be announce deal allow voyager work create abbvie call vectorized antibody time treatment produce tau antibody brain canaccord analyst sumant kulkarni write note client build tau protein be associate alzheimer recall tau protein be present brain healthy person alter form tend accumulate lead disease such alzheimer supranuclear palsy frontotemporal dementia say term deal voyager combine gene therapy platform abbvie monoclonal antibody form immunotherapy voyager be responsible phase cost abbvie have option license program track top stock market trend free ibd have option share clinical development cost exchange higher royalty rate kulkarni say abbvie pay voyager front firm be eligible preclinical development regulatory milestone piper jaffray analyst charle duncan wednesday boost price target voyager have overweight rating stock call deal savvy strategy allow voyager broaden use gene therapy platform collaboration include potential broader use company platform other disease provide external validation voyager technology write note client cash abbvie also help fund house development treatment advanced parkinson disease amyotrophic lateral sclerosis other duncan say firm be now phase testing parkinson drug duncan also boost value voyager broader platform view bolster balance sheet substantial infusion voyager internal pipeline believe external validation abbvie pave way not only future work collaborator also potential additional collaboration partner say related medtronic sink rival intuitive surgical delayedwhy be explosive year biotech mergersdow merck jump merger bandwagon buy
34,ABBV,get ready earning season focus stock potential buy range ahead next quarterly report abbvie abbv currently fit bill company be expect report jan trading buy point second stage flat base keep mind risky buy stock just report minimize exposure wait see company report market react see ibd help make more money stocksabbvie see earning sale growth rise last quarter earning share increase revenue rise consensus analyst estimate call earning growth quarter growth full year annual growth estimate be recently revise lower abbvie have composite rating hold rank peer medical ethical drug industry group zoetis zts grifol grfs be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earningsbiotech pharmaceutical industry stock news
35,ABBV,long costly process big pharma biotech stock abbvie abbv vertex pharmaceutical vrtx abbot laboratory get food drug administration approval new drug lead clinical research organization cro pra health science prah help drugmaker get new treatment market conduct clinical trial base
36,ABBV,future index nasdaq dow jone industrial average be mixed thursday morning china trade war fear hit stock wednesday alibaba baba archrival tencent tcehy visa abbvie abbv be set cup basis meanwhile tesla tsla stock be struggle technical challenge elon musk face executive exodus fresh manufacturing concern index future fall fraction vs fair value dow jone future rise nasdaq future be fair value tencent visa abbvie peaked jan sell early february then rebound strongly pull back modestly end last month hold support day move average mimic action major average peaked jan enter fierce brief correction then tencent abbvie visa have look combination index nasdaq composite nasdaq stock find support day line be now day stock haven hit new high get newsletter deliver inbox more info product service privacy policy term be clear example stock even highly rate one tencent visa abbvie tend follow market critical follow action major average lead stock read stock market today column big picture day keep sync market visa tencent abbvie be cup handle basis technically be day short week minimum cup handle pattern cup handle basis be valid week so stock clear handle thursday friday be slightly add risk case dow jone component visa have handle buy point settle wednesday abbvie close wednesday have handle entry tencent have handle buy point close wednesday alibaba tencent rival chinese internet dominance have similar chart pattern first glance midpoint handle be midpoint base so alibaba be cup handle base entry tesla fall wednesday trading stock tumble support line day day move average meanwhile tesla relative strength line be recent lows rs line track stock performance vs index have be gradually decline last june tesla have struggle model production level slash output goal several time last several month be many report significant manufacturing defect entry level luxury sedan tesla employee tell cnbc company be make high level faulty part require costly time consume fix meanwhile top tesla finance executive have left past week global sale service president exit february put more pressure musk manage tesla operation attract new high level staff be interested big picture bear hit year be stock nowwhy blue chip leader trigger key sell signalalibaba sweet spot online retail sale china acceleratetire high volatility try trading latest investor corner
37,ABBV,consider name put watch list look stock higher rs rating horizon pharma hznp just meet criterium new score look best stock buy watch factor watch closely be relative price strength ibd unique rs rating measure market leadership used worst best score indicate stock price performance last week match rest market decade market research show best stock typically have higher rs rating begin biggest price move look best stock buy watch start herehorizon pharma be build double bottom buy point see stock break heavy trade earning growth decrease most recent quarter revenue gain moved higher company earn rank peer medical ethical drug industry group abbvie abbv jazz pharmaceutical jazz zoetis zts be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
38,ABBV,friday jazz pharmaceutical jazz receive upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price action worst best score grade show stock price behavior trail week hold other stock database decade market research show top perform stock often have higher rs rating begin biggest climb see jazz pharmaceutical continue show renew price strength clear threshold look winning stock try simple routinejazz pharmaceutical be build consolidation buy point see stock break volume least average top bottom line growth moved higher last quarter earning be compare prior report revenue increase jazz pharmaceutical earn rank peer medical ethical drug industry group abbvie abbv be top rank stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
39,ABBV,vertex pharmaceutical vrtx have triple pill treatment cystic fibrosis early analyst say thursday biotech initiate first phase study test drug involved pivotal trial be short sweet leerink analyst geoffrey porge say note client vertex announce late wednesday begin trial combine drug know vx tezacaftor ivacaftor treat group cystic fibrosis patient timing be month ahead expectation even more importantly trial be shorter company prior pivotal study cystic fibrosis combination porge say total vertex plan enroll patient trial goal be improve patient ability forcefully expel air week treatment safety be evaluate week treatment then vertex file application approval porge expect trial enroll very quickly suggest regulatory submission occur early first half mean vertex start selling treatment early fourth quarter earlier expectation first quarter get ibd market prep tech report newsletter free goal be bring best triple combination patient rapidly possible first phase study combination tezacaftor ivacaftor be significant step goal vertex chief medical officer jeffrey chodakewitz say statement triple regimen treat patient cystic fibrosis vertex have say abbvie abbv galapago glpg also be work triple combination analyst say duo be lag vertex vertex be also plan test regimen vx tezacaftor ivacaftor group patient different genetic mutation regimen vx tezacaftor vx be test group patient different mutation porge keep outperform rating price target vertex stock rbc analyst brian abraham maintain outperform rating vertex abraham also expect trial move quickly expect approval end stock market today vertex lose fraction close related sangamo therapeutic make double digit gain gilead dealthese biotechs spring back market correction analystwhy payer win balk price tag vertex new drug
40,ABBV,wednesday horizon pharma hznp get upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength unique rating identify market leadership show stock price action last week measure other stock database history show best stock typically have better rs rating early stage move look winning stock try simple routinehorizon pharma be try complete consolidation buy point see break heavy volume ep growth decline company latest report top line rise horizon pharma hold rank peer medical ethical drug industry group zoetis zts abbvie abbv phibro animal health pahc be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
41,ABBV,ibd stock spotlight name be buy range buy point friday stock enanta enta ring central rng have earning due come week bigger name mastercard friday be trading more last session marked strongest week advance break stock month consolidation october credit payment processor wednesday report third straight quarter accelerate growth least analyst ratchete price target higher result mastercard share trade flat base buy point friday base be second stage pattern say other thing carry less risk failure later stage base enanta be small cap biotech focuse develop drug liver disease viral infection partner primarily abbvie abbv collect royalty antiviral drug glecaprevir used abbvie successful hepatitis treatment mavyret company direct nearly revenue back work broaden pipeline get newsletter deliver inbox more info product service privacy policy term debt free drugmaker run stiff expectation report tuesday close analyst consensus project leap earning revenue gain enanta have logged straight quarters loss turn profitable last year september quarter food drug administration approve mavyret august stock have climb breaking first stage base june last year share friday be near top buy range buy point month cup base base be second stage pattern suggest stock have room yet run ring central friday trade just even buy point late stage flat base analyst expect ep gain revenue advance company report late wednesday related do proper flat base look latest investor cornerdon try forecast market do instead
42,ABBV,company be pace return record shareholder year alone dividend payout share buyback accord dow jone index apple aapl alone be expect repatriate foreign profit come year iphone maker say late tuesday approve new repurchase program increase quarterly dividend cent news come day howard silverblatt senior index analyst dow jone index estimate release note estimate windfall give environment availability cash increase income expectation desire company show shareholder return return double digit actual cash payment gain year year seem feasible first dollar year dividend buyback write accord cnbc last month predict share buyback see record year potential top high surge total addition lower corporate tax rate tax overhaul also make cheaper bring profit make overseas back morgan stanley say november apple microsoft msft general electric ge pfizer pfe ibm ibm have most accumulate foreign earning meanwhile dividend be already look strong payout company increase net mark biggest bump dividend increase be sharply gain see year still well short increase economy be still rebound company increase dividend accord dow jone index company have cut dividend mark first decrease least company dow jone index track company make positive dividend move make negative one represent collective net payout increase record high dividend be typically event drive silverblatt tell ibd last month don have many negative event here get newsletter deliver inbox more info product service privacy policy term usesome biggest dividend hike come energy sector many energy company pull back payout due oil price crash begin company fall health care consumer discretionary tech sector also hike payout home depot hd february announce quarterly dividend increase best buy bby hike own yum brand yum january dividend increase health care abbvie abbv announce jump dividend payout chipmaker intel intc announce increase quarterly dividend january dividend payout company totale record december aerospace giant boee ba announce boost dividend ge halved dividend november even economy improve trump plan hit import tariff continue agitate investor cost go ve get raise price eat profit combination silverblatt say be interested apple new low end ipad student look thwart google sale taiwan urge china aggression growsdon look now trump just score trade
43,ABBV,market rebound week have be very positive rebound individual stock have be better other look name watch list best focus stock top notch relative strength meaning outperformance stock watch week be name high rs line netflix nflx ferrari race adobe system adbe abbvie abbv weight watcher wtw stock be not actionable good get habit tracking stock superior relative strength investor focus true market leader stock be outperform head market sell hold well brief stock market correction have post strong gain past week netflix have be massive run year be so far extend latest buy point head correction sell signal be ever trigger technical support level be question netflix share be close prior high relative strength line hit new time high thursday netflix rise shortly open stock market today recent market volatility ferrari never even come close touch day move average share dip buy range base be originally clear several week hold relatively well ferrari be now slightly extend buy zone hit new high relative strength line hit new short term high well ferrari share slide tuesday morning ibd survey new etfs see create find support day move average adobe be now extend buy point first clear close begin year relative strength line be hold high adobe look notch new weekly close high adobe fall tuesday morning only recent session have abbvie touch day line end stock reverse higher market share be now once again more extend flat base buy point rs line be now even prior high reach post earning move jan abbvie announce thursday new stock buyback program increase quarterly dividend cent share abbvie dip early tuesday sizable stake oprah winfrey oprah boost have lift weight watcher many quarters now stock be hardly impact bout volatility weight watcher share be time high cup handle buy point early january weight watcher rise tuesday morning also be interested stay sync marketis fang stock next apple stock buy watch top ipos big small cap growth stocksfang stock news quote facebook amazon netflix googledow jone industrial average dow stock news analysis
44,ABBV,gilead science gild break monday competitor abbvie abbv strong fourth quarter hepatitis drug sale reinforce recent commentary gilead market be stabilize close bell stock market today gilead pop close breaking cup base buy point share jump friday abbvie fourth quarter earning report close quarter abbvie report sale hepatitis drug include viekira product mavyret maviret analyst have suggest latter take share gilead treat genotype hepatitis patient abbvie say lion share success hepatitis stem maviret sale outside drug sell mavyret maviret outside international hepatitis drug sale be period line expectation sale miss rbc analyst brian abraham estimate abbvie estimate fourth quarter hepatitis drug sale represent market abraham say note client believe be positive gilead go earning reinforce prior commentary market stabilization downplay potential impact competition say note friday ibd take gilead be set report earning close feb analyst list likely top expectation uncertainty payer dynamic competition drug access hinder company guidance head ibd industry theme other prediction ahead earning season abraham expect patient flow pricing hepatitis drug be more predictable go forward abbvie disruptive launch mavyret maviret abbvie echo gilead commentary regard stabilization earning conference call say abraham model gilead pull fourth quarter hepatitis drug sale expect gilead guide revenue buy side expectation be likely closer note related biopharma merger activity become abbvie story celgene reverse fourth quarter otezla sale reboundbiogen revenue top spinraza ms drug deliver upside
45,ABBV,index dow jone industrial average nasdaq tumble week alphabet googl caterpillar cat mmm earning treasury yield spook investor stock market average pare loss strong earning amazon amzn facebook fb boee ba visa other index dow jone nasdaq find support day move average rebound close week fractional loss year treasury hit first time year hit week pull back short term yield continue rise faster long term rate squeeze yield spread alphabet googl expense ongoing chip weakness also hit stock amazon amzn facebook fb boee ba visa rally strong result intel intc microsoft msft initially hit buy point friday pull back amazon first quarter earning sky-rocket more double ep estimate revenue rise fifth straight quarter accelerate sale growth revenue amazon web service rise aw account most amazon overall operate profit amazon share shot record high friday pare gain advance ebay ebay stock drop report result fall short consensus estimate end quarter global active buyer facebook fb stock surge post first quarter result blow past expectation dash fear exodus user advertiser social medium giant twitter twtr report strong earning guidance share fall ceo make cautious comment slow growth get free access ibd digital april
46,ABBV,get premium stock list pass fail stock rating more start hereboee ba easily beat forecast raise full year guidance aerospace giant say aircraft completion center china be nearly finished downplay china trade war fear fellow dow jone stock unite technology utx report stronger expect earning sale industrial giant also raise full year adjust ep sale forecast lockheed martin lmt top first quarter estimate defense contractor raise ep revenue target maker didn raise cash flow expectation northrop grumman noc also report earning estimate northrop say didn submit bid air force gps iii contract leave lockheed likely lone bidder raytheon rtn raise full year earning forecast consensus earning revenue top estimate general dynamic gd beat earning meet revenue view share defense contractor sell sharply week software kingpin earn cent share year year sale fiscal third quarter analyst expect cent microsoft msft have be shift business desktop pc software cloud compute infrastructure application such office azure microsoft commercial cloud revenue rise fiscal software giant initially reclaim recent buy point friday pare gain intel intc earning rise sale grow well analyst view chip giant guide higher current quarter sale indicate third straight quarter top line growth share initially jump year high friday reversed close slightly lower texas instrument txn advanced micro device amd stm xilinx xlnx get boost upbeat earning report chip gear maker teradyne ter tumble warning weak demand equipment test mobile device western digital wdc make disk drife memory chip tumble friday beating fiscal view philadelphia semiconductor index fought support day move average google parent alphabet googl report earning revenue top view sharp rise capital spending margin pressure higher traffic acquisition cost spark sell internet search giant capex jump year period include real estate purchase manhattan traffic cost google pay partner website generate advertising revenue jump google have hike spending youtube video content cloud compute smart home consumer appliance artificial intelligence project paypal pypl top earning revenue expectation total payment volume rise year year vs estimate company raise revenue adjust ep guidance management point momentum partnership visa international bank technology platform such baidu bidu exxon mobil xom miss earning view output slip recent surge oil price chevron cvx fall short revenue conocophillip cop crushed estimate hess hes report shallower expect loss royal dutch shell rdsa report highest profit oil price crash energy information administration say crude inventory rise barrel vs drop analyst expect domestic production rise barrel day barrel increase crude oil future briefly top barrel highest level late trade little change week general motor gm ford motor fiat chrysler fcau beat quarterly estimate ford not invest traditional sedan north america go forward almost phase passenger car consumer migrate suvs light truck gm still see small car opportunity home abroad even too shift focus larger more profitable vehicle casino operator la vegas sand lvs top first quarter result estimate help strong demand global gaming hub macau singapore macau also help result wynn resort wynn overall macau sale disappoint analyst wynn resort also approve dividend increase earning report wynn be first steve wynn resign ceo sell stake follow allegation sexual misconduct mgm resort mgm narrowly beat stock tumble decline traffic location mgm be more focuse sand wynn amgen amgn alexion pharmaceutical alxn broadly top view amgen sale adjust profit outlook be bit soft midpoint sale alexion blockbuster soliris miss estimate share pop promising study new drug alxn biogen biib sale lag sluggish spinraza multiple sclerosis drug revenue prothena prta tank monday scrap rare disease drug fail phase study eli lilly lly broadly beat consensus diabetes drug chemotherapy help offset short sale psoriasis drug taltz glaxosmithkline gsk sale adjust profit lag abbvie abbv bristol myer squibb bmy top profit view raise full year guidance bristol sale miss estimate shire shpg say consider raise takeover bid japan takeda vertex pharmaceutical vrtx top view sale decline vs last year vertex say ll move triple pill regimen phase study domino dpz deliver ep gain revenue leap blow view share rise thursday chipotle grill cmg stock vault month high ep unexpectedly jump same store sale also top starbucks sbux be par earning ep rise cent rise sale outdo analyst prediction new oriental education edu earn cent share revenue grow total student enrollment rise year year ibd stock tal education tal ep jump cent share revenue soar student enrollment balloon vs year earlier new oriental tal share pop respective earning day be slightly lower week intraday friday pultegroup phm tuesday crushed view ep jump cent home sale revenue leap homebuilder stock be generally muted due rise interest rate horton dhi biggest builder thursday best view ep surge revenue swell homebuilder stock rally solid gain help cool treasury yield new home sale rise march annualize sale pace unit month high meanwhile exist home price rise february vs year earlier china search engine leader baidu bidu report profit blow past estimate lift share baidu still own majority iqiyi iq hold ipo march video stream iqiyi account roughly parent revenue share iqiyi fall release earning tandem baidu visa report ep gain revenue rise beating fiscal view credit debit card giant raise full year revenue outlook share leap thursday mmm meet ep view revenue rise just consensus dow jone giant slash full year ep target stock plunge caterpillar cat report strong earning sale share heavy construction equipment maker reversed sharply lower tuesday warning operate margin hit high watermark year servicenow now report profit revenue estimate customer now spend annually metric be year year edward lifescience ew top sale adjust profit view share tank sale transcatheter heart valve replacement lag illumina ilmn beat consensus adjust profit rise share sale swell align technology algn report adjust earning share revenue handily beating view cent respectively td ameritrade amtd deliver impressive ep revenue growth fall short lofty expectation share fall week trade financial etfc continue rise last week strong result first solar fslr hit year high earning top expectation due sale several solar project expand production proofpoint pfpt cybersecurity firm top adjust first quarter earning revenue view guide low profit share fall friday advanced protection solution nearly double make new add booking prior quarter
47,ABBV,be only handful marijuana stock direct exposure industry several household name have have get involved however peripherally be expect benefit more permissive marijuana law include jack box jack microsoft msft hp inc hpq cree cree lawn garden care company scott miracle gro smg also do business hydroponic practice soil less plant grow often used grow marijuana scott miracle gro say tuesday say buy sunlight supply large hydroponic distributor give fragile often patchwork state marijuana regulation pot industry be still very volatile drama prone scott miracle gro stock collapse january management say slower expect pace regulatory change california be harm hydroponic business lead company product appear list prefer indoor light option grower hydroponic set up led carry higher front cost other light produce less heat use less electricity sure microsoft offer software track cannabis sale state allow partnership hp work flowhub developer pot industry compliance software roll cash register terminal have flowhub software marijuana focuse etfs etfmg alternative harvest mj advisorshare vice etf act be exchange trade fund track cannabis industry alternative harvest holding include stock gw pharmaceutical gwph company make seizure fight drug contain cannabidiol cbd part cannabis plant doesn get high typically have relax effect fund also follow canada biggest publicly trade marijuana producer aurora cannabis crono group cron february become first pure play pot stock join nasdaq advisorshare vice etf largely follow booze tobacco industry holding marijuana stock aroma include scott miracle gro company abbvie abbv drug marinol be make partly synthetic cannabinoid year indirectly target appetite pot enthusiast burger taco chain jack box december directly advertised company time partner merry jane cannabis co founder snoop dogg launch promotional munchie meal commemorate legalization recreational cannabis california say meal cost be available select part state chain say partnership be more way connect late night customer cowen co also say pot legalization be good jack box research firm single top marijuana stock play fast food quick service note jack box have greatest exposure recreational marijuana use become more widely accept state have already legalize use store base well state upcoming legalize recreational use proposal state ballot november election store base cowen analyst andrew charle say report september latter be drive jack store base be locate california add cowen analyst see opportunity ulta beauty ulta expand hemp product offering customer gain wider understand cannabis lotion infuse psychoactive cannabidiol be already available dispensary be also cannabis bath soak ulta say be not able make someone available interview be interested marijuana industry overtake beer legalization spur innovation big tobacco become big cannabis marijuana business soar cannabis treat seizure biotechs say answer be apple store weed partner nasdaq first pot stockthese pot stock follow crono come nasdaq nyse soon
48,ABBV,valeant pharmaceutical vrx have relative strength rs rating upgrade monday welcome improvement still shy higher score prefer see try find best stock buy watch keep close eye relative price strength proprietary rating identify technical performance used worst best score identify stock price action trail week compare rest market year market history reveal stock go make biggest gain tend have higher rs rating begin largest climb see valeant pharmaceutical continue rebound hit benchmark look winning stock try simple routinevaleant pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new chart pattern follow buy opportunity week tight pullback day week move average company show earning growth most recent report revenue gain come company be expect report latest performance number company hold rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz abbvie abbv be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
49,ABBV,renew strength biotech drug industry pfizer pfe be surge multiyear high territory friday volume track well average blue chip drug stock boast quarters accelerate earning growth fundamental metric share many market top growth stock most recent quarter dividend leader grow earning
50,ABBV,buyout partnership news send biotechs fly monday novartis nvs bid take avexis avxs rumor emerge celgene celg swipe agio pharmaceutical agio ionis pharmaceutical ion partner astrazeneca azn make liver disease treatment close stock market today avexis rocket easily hit highest point go public february novartis lift agio surge celgene be flat be more hour meanwhile dow jone stock merck mrk pop end regular session datum show drug keytruda improve overall survival first treatment option lung cancer patient key rival bristol myer squibb bmy dip news acadium pharmaceutical acad hit lowest closure point june cnn story detail death patient take only approve drug nuplazid nuplazid treat psychosis patient parkinson disease be be test array other condition get newsletter deliver inbox more info product service privacy policy term usenovartis agree pay share avexis offer represent premium avexis close friday deal be premium avexis day volume weight average stock price avexis say news release avexis be develop avxs gene therapy treatment spinal muscular atrophy diagnosed young child drug rival biogen biib ionis spinraza be already approve treat condition biogen stock fall fraction rise extend trading rbc analyst brian abraham credit deal breathe life sector note biotech group have be pressure recently share sank much month low friday collectively advanced monday be merger acquisition kick start sector have await view say have be anticipation major deal trepidation drug pricing risk highlight negative catalyst have keep sentiment late transaction be expect close midyear price go share avexis stock novartis decide extend close date oct avexis terminate deal owe novartis fee novartis terminate deal owe avexis ptc therapeutic ptct jump news ptc be early stage make treatment spinal muscular atrophy roche rhhby asset remain early have show early positive signal see increase attention today give value big pharma be clearly willing place sma asset once be further risk rbc abraham say immuno oncology drug keytruda significantly outperformed chemotherapy patient advanced lung cancer merck say news release study dub keynote test keytruda single drug vs chemo patient have pd protein least tumor cell study examine overall survival interim analysis show keytruda keep patient alive longer chemotherapy lone treatment safety be line earlier study merck now continue study determine keytruda impact progression free survival patient have pd protein tumor represent overall market lung cancer evercore analyst umer raffat say note bristol rival drug opdivo fail improve progression free survival patient pd least tumor note bristol share touch month low intraday trading news re-cover somewhat close abbvie abbv run rise hour investigational drug upadacitinib beat own blockbuster humira study rheumatoid arthritis patient patient receive milligram upadacitinib daily milligram humira other week placebo abbvie examine patient week least improvement rheumatoid arthritis symptom clinical remission study show upadacitinib patient experience improvement symptom vs humira placebo patient respectively upadacitinib patient be clinical remission vs humira placebo patient be excited strong result add body evidence support potential upadacitinib be important treatment option patient rheumatoid arthritis abbvie spokesperson michael severino say prepared statement rumor emerge celgene be eyee takeover agio jounce therapeutic jnce agio pop jounce surge buyout follow celgene recent acquisition juno therapeutic cancer biotech report emerge financial time cite unnamed source celgene be reportedly hunting acquisition target promising drug offset loss patent protection key blockbuster revlimid celgene already partner agio jounce be work cancer drug agio have market cap eclipse jounce market cap remain jounce go public last year similar news ionis astrazeneca announce partnership develop drug treat nonalcoholic steatohepatitis term deal astrazeneca pay ionis license fee take responsibility development drug drug advance ionis be also eligible receive additional development regulatory milestone payment well tiered royalty low teen sale drug ionis stock advanced astrazeneca lift close menlo therapeutic mnlo acadium be biggest biotech stock loser monday share menlo tank fall just month go public stock have be form cup handle buy point share rise hour tumble follow news sunday menlo itch drug fail eczema study menlo find statistically significant difference drug serlopitant placebo chief executive steve basta note be still sign improvement serlopitant treat patient serlopitant be also be test skin condition know prurigo nodularis itch associate psoriasis chronic cough setback eczema doesn necessarily hurt menlo chance serlopitant prurigo nodularis piper jaffray analyst david amsellem say note prurigo nodularis be altogether different condition say larger point here be menlo decide run broad clinical program itch order have handful potential pathway market serlopitant amsellem keep overweight rating menlo meanwhile acadium dive cnn story outline death parkinson patient take nuplazid psychosis nuplazid be approve treat hallucination delusion associate parkinson approval patient continue experience hallucination side effect include death life threaten incident fall insomnia nausea fatigue cnn write approval more patient nuplazid have die last june nuplazid be only medicine list suspect least death report acadium note study have show difference number death report nuplazid placebo drug be acadium only approve medicine acadium be testing nuplazid dementia related psychosis schizophrenia depression related much volume look stock long term retirement investing strategy buy stock ahead earning report
51,ABBV,price volume be guitar bass stock trading really need rock roll market sufficient trading volume price fall flat key inflection point enter trade volume requirement inflection point depend time frame consolidation typical cup handle base require duration week volume buy point case generally be average volume last day swing trade rely shorter period time volume threshold also use shorter period day consolidation volume highest level entire consolidation be often enough more tell comparison day average volume stock set multiple time frame threshold require adjustment cup shape pattern span week be part handle larger week cup handle case volume buy point have volume approach higher threshold longer time frame take abbvie abbv recent consolidation try dec couldn gain traction market condition deteriorate pullback remain mild joined swingtrader watch list stock consolidated get support day move average buy point be set previous high day consolidation form abbvie dec crossed buy point however intraday volume be weak most day even huge spike final half hour trading only put volume day average have be acceptable short consolidation be highest volume last day however short consolidation be part larger base more week long expectation be higher send alert subscriber morning abbvie remain watch list wouldn be buy yet due lack volume weak close day follow loss more next day confirm validity decision stock remain watch list improve market give stock chance hit resistance just time so break level be meaningful especially volume more detail current past trade be accessible subscriber trialist swingtrader free trial be available related sherlock holme case miss volumevolume speak volume stock tradesshort term stock strategy have familiar rulessw trading strategy lesson
52,ABBV,astrazeneca azn see positive improvement relative strength rs rating thursday rise look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price action worst best score grade show stock price performance last week hold other stock database year market history show stock go make biggest gain often have rs rating launch largest price move see astrazeneca continue show renew price strength clear threshold see ibd help make more money be work cup handle entry see clear price volume least higher normal earning growth increase last quarter sale fall company be expect report latest result apr company hold rank peer medical ethical drug industry group zoetis zts abbvie abbv jazz pharmaceutical jazz be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
53,ABBV,abbvie abbv surge record high friday issue beat raise earning report include guidance tax rate prompt analyst suggest yet industry behemoth become acquisitive fourth quarter abbvie report adjust income share sale rise respectively metric top consensus analyst adjust profit share sale close bell stock market today abbvie soar close help drug stock rise collective guidance lower tax rate have be expect leerink analyst geoffrey porge write note client december white house approve legislation lower corporate tax rate tax rate company revenue growth margin performance expect significant increase free cash flow attendant leverage thus set stage more active business development activity yet industry behemoth say investor have previously expect abbvie guide tax rate porge say merger activity have be heating recently biopharma group week celgene celg say buy remainder juno therapeutic juno didn already own gilead science gild spend nearly acquire kite pharma abbvie expect effective tax rate increase next year due increase domestic income investment piper jaffray analyst christopher raymond say note client abbvie result sale humira treat several form arthritis crohn disease plaque psoriasis increase sale humira be abbvie most important drug sale beat consensus raymond say ibd take abbvie lead group ibd composite rating best possible make leader stock term key growth metric more drug stock rank visit ibd stock checkup cancer drug imbruvica bring revenue grow nearly be ahead analyst collective view raymond say worldwide sale abbvie hepatitis drug viekira mavyret advanced more vs year earlier period beating consensus say porge lower tax rate also boost other guidance year abbvie call adjust income share top consensus sale be expect approach street consensus view related intuitive surgical top fourth quarter sale earning viewscelgene reverse fourth quarter otezla sale reboundbiogen revenue top spinraza ms drug deliver upside
54,ABBV,vertex pharmaceutical vrtx beat fourth quarter sale expectation more have select pair cystic fibrosis treatment send late stage testing company say late wednesday vertex report adjust income cent share sale rise respective vs year earlier period metric beat consensus adjust profit cent share sale total sale vertex bring revenue cystic fibrosis treatment grow year year biggest drug orkambi increase kalydeco also know ivacaftor tack growth chief executive jeffrey leiden call outstanding year vertex written statement look vertex scientific expertise financial strength position advance key pipeline program cf include triple combination regimen bring forth potential new medicine multiple other serious disease hour trading stock market today vertex pop close regular session triple pill treatment be expect treat cystic fibrosis patient say jeffrey chodakewitz vertex executive vice president chief medical officer vertex plan send combo used drug know vx vx late stage testing year look forward conclude discussion regulator initiate phase development first half year goal bring triple regimen patient quickly possible chodakewitz say written statement excitement have be build surround potential triple pill target underlie genetic cause disease total vertex have potential combination be consider vertex have now narrow potential combination combination vx tezacaftor ivacaftor begin phase trial first half study investigate regimen effect patient group different genetic mutation ibd take vertex wasn always cystic fibrosis focuse company earliest day be focuse hepatitis gilead science launch massively successful drug call sovaldi do vertex escape crisis head new america more pending additional datum first half year vertex also plan send combination vx tezacaftor drug call vx phase testing once daily treatment group patient different genetic mutation vertex select treatment base ongoing study show absolute improvement patient ability forcefully expel air second treat vx vx regimen show improvement percentage point respectively week treatment cystic fibrosis patient triple combination be generally well tolerate study vertex say majority adverse event mild moderate severity discontinuation rate due adverse event be low vertex isn only firm seek make triple regimen treat cystic fibrosis abbvie abbv galapago glpg have also team make triple pill analyst have say duo be several year most see vertex triple get approval time frame february vertex expect get approval regimen tezacaftor ivacaftor treatment cystic fibrosis patient age older specific genetic mutation european regulator make determination second half vertex say issue guidance cystic fibrosis drug sale anticipate approval tezacaftor ivacaftor regimen feb analyst expect vertex offer outlook share adjust earning sale vertex be also plan move forward crispr therapeutic crsp used gene therapy treat blood disease know beta thalassemia sickle cell disease trial be expect begin year europe related biotech growth testing buy zone get new drug approvalwhich biotech stock surprise upside earning biotechs outperform hyper competition
55,ABBV,eli lilly lly issue strong guidance early wednesday follow footstep abbvie abbv dow pfizer pfe improve tax rate earning expectation fourth quarter beat lilly call tax rate result lilly now see adjust income share grow vs sale be expect be lilly cite tax legislation improve tax rate outlook adjust earning sale guidance top view respectively lilly stock drop close stock market today collectively drug stock tumble day amazon amzn berkshire hathaway brka jpmorgan chase jpm pledge cut health care cost evercore analyst umer raffat note lilly animal health business disappoint sale food animal product decline widely miss expectation say report client miss stem lilly be face competitive pressure product used cattle milk supplement call posilac nonsteroidal growth stimulant call optaflexx ibd take lilly have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup look other strong drug performer milk have be oversupplied market depress price raffat say production have be strong many customer be forgo posilac optaflexx be likely suffering rule china export trade deal meat contain optaflexx say outside animal health be very few miss leerink analyst seamus fernandez say note client sale plaque psoriasis drug taltz diabetes med humulin erectile dysfunction drug ciali lag consensus still total sale grow year year beat consensus adjust earning share increase top analyst view related dow pfizer tumble drug sector beat raiseamazon health care disruption fear clash realitygilead stock break abbvie earning here valeant climb month make sense biotech stock top bigger rival prevent migraine
56,ABBV,share dow pfizer pfe tumble tuesday sale breast cancer drug lag expectation fourth quarter culminate beat raise include dramatically improve tax rate close bell stock market today pfizer dove meanwhile drug stock broadly dip uncertainty amazon amzn berkshire hathaway brkb jpmorgan chase jpm announce collaboration lower healthcare cost fourth quarter pfizer report sale ibrance be approve treat breast cancer patient sale grow year year miss forecast leerink analyst seamus fernandez ibrance sale decline internationally period due time price adjustment european market pfizer say news release ibrance volume grow sequentially develop europe still ibrance growth be disappointment highlight need international growth investor await outcome ongoing adjuvant breast cancer study fernandez say note client more broadly pfizer bring adjust income cent share sale fourth quarter rise respectively metric beat consensus adjust profit cent share revenue fernandez call fourth quarter beat largely irrelevant instead focuse guidance sale adjust earning share consensus have modeled respectively ibd take alexion pharmaceutical gilead science vertex pharmaceutical be expect top fourth quarter expectation other continue struggle rival face biggest moneymaking drug head ibd industry theme more fourth quarter earn season hold pfizer also guide tax rate investor have expect lower tax guidance fernandez say december president sign massive tax cut corporation law last week abbvie abbv guide low tax rate key question call likely focus sustainability tax rate fernandez say consumer business be sell management plan deploy capital tax impact be pfizer cash hoard investor also look commentary pfizer split company large scale merger acquisition say pfizer say have decision sometime year sell consumer healthcare business quarter consumer healthcare sale be flat sale cholesterol drug lipitor grow nearly estimate xeljanz rheumatoid arthritis drug bring grow related gilead stock break abbvie earning here biopharma behemoth soon become acquisitivewhy insurer haven win push back rare disease drug
57,ABBV,ugly day turn even uglier key stock index fund sell hard thursday apple aapl facebook fb weigh nasdaq give day move average president trump announce new china tariff spdr dow jone industrial average dium plunge powershare qqq trust qqq drop spdr spy also lose foreign stock fared even ishare msci emerge market eem tumble small cap see bit less damage ishare core small cap ijr ishare russell iwm give bank metal miner technology be biggest sector fund loser stock market today technology select sector spdr xlk fall undercut day move average early february market correction xlk fall much then peak facebook stumble nearly price target cut stifel bank america other view decline buy opportunity apple breach day line wednesday give extend lose streak caterpillar cat boee ba plummet more dow utility be few sector fund gainer utility select sector spdr xlu advanced continue hold support day line real estate consumer staple reversed lower spdr gold share gld ishare gold trust iau shed rise gold future ounce bitcoin fall accord coindesk climb back earlier bitcoin investment trust gbtc sank late december high have be stick day line mid january look large cap growth fund not top apple aapl facebook fb other big cap tech stock first trust equity opportunity fpx be option fund didn own apple microsoft msft fang stock tuesday track ipox index include largest most liquid initial public offering holding be capped index be reconstitute quarterly basis information technology represent biggest sector weight just asset health care account consumer discretionary consumer staple financial smaller position industrial material energy service real estate make rest top holding include paypal pypl abbvie abbv fiat chrysler automobile fcau hewlett packard enterprise hpe stock have post year date gain respectively kraft heinz khc shire shpg also top be respective top name add nearly asset etf year date gain tuesday accord morningstar inc outpaced return average annual return past year slightly lag outperformed broader index past year fpx carry expense ratio get newsletter deliver inbox more info product service privacy policy term useon wednesday fund be testing day move average market volatility thursday gap support line broad market rout solid move line set future buy opportunity stock etf purchase be higher risk usual market uptrend pressure fpx be last featured etf column remain buy range flat base entry advanced jan intraday high wednesday pick powershare qqq trust qqq continue test day line global social medium socl advanced nearly be extend last pullback support line also be interested chinese fang be kraneshare china internet funddow slip chevron stock surge apple test key supportboeing intel power dow stock higher nvidia race ahead
58,ABBV,welcome move jazz pharmaceutical jazz see relative strength rating improve tuesday re research best stock buy watch be sure pay attention relative price strength ibd proprietary rs rating track technical performance show stock price action last week compare other stock database year market history reveal best stock typically have better rs rating early stage move see jazz pharmaceutical continue show renew price strength clear threshold look winning stock try simple routinejazz pharmaceutical be try complete consolidation buy point see stock break volume least average jazz pharmaceutical report earning growth most recent report sale growth come company earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
59,ABBV,dozen drug launch heavy hitter roche rhhby gilead science gild johnson johnson jnj be expect reach blockbuster status end analytic firm say clarivate analytic describe year blockbuster drug have launch be expect launch eventually bring north sale year period biggest number clarivate begin make forecast set be exciting year see valuable addition exist treatment well disruption certain market first class treatment option disease firm say report issue late thursday end drug roche gilead nordisk nvo be expect top annual sale remain likely account year revenue analyst say get newsletter deliver inbox more info product service privacy policy term be diabetes drug food drug administration approve medicine derive cannabis plant first series drug expect prevent migraine patient dozen drug be project collectively top sale roche hemlibra treatment patient hemophilia top list be expect generate north sale only hemophilia patient world roughly eligible hemlibra treatment cost first year year drug be approve month early launch december sale be forecast drug set reach blockbuster status forecast hemlibra be expect take share shire shpg feiba nordisk novoseven hemlibra also compete bioverativ bivv eloctate shire advate eloctate be forecast be blockbuster advate continue be market leader estimate sale however advate sale be forecast decline further thereafter clarivate report say gilead biktarvy grab approval february target estimate person globally live hiv be receive antiretroviral therapy suppress viral replication allow immune system strengthen biktarvy add gilead hiv franchise have long rivale glaxosmithkline gsk have trade market share gilead first enter market atripla gilead hiv drug be featured clarivate drug watch report biktarvy become blockbuster generate sale spiking decline report say trajectory be similar gsk drug triumeq be expect bring year year launch round top nordisk get approval diabetes drug ozempic december drug help stimulate body own insulin release limit much sugar get blood liver slow quickly food leave stomach ozempic be expect become blockbuster revenue way immuno oncology treatment novartis nvs gilead grab headline ability revolutionize treatment disease report say more half drug potential blockbuster list be cancer therapy just drug list expect blockbuster be cancer treatment erleada product dow jone component johnson johnson be approve february treat castration resistant prostate cancer hasn spread body fellow dow jone component pfizer pfe have drug treat same cancer once spread zytiga xtandi battle expand market share include market patient metastatic disease second generation oral androgen erleada become first approve set mid february clarivate say drug be project bring rise also be expand treat other form prostate cancer combination zytiga contribute blockbuster potential gsk shingle vaccine call shingrix rare disease drug alnylam pharmaceutical alny know patisiran be expect join blockbuster list sale respectively revenue be expect hit respective gw pharmaceutical gwph be expect grab approval summer first cannabidiol drug derive cannabis plant treat patient seizure disorder drug call epidiolex be expect generate sale approve epidiolex likely encounter bureaucratic barrier distribution political hurdle associate cannabis derive medicine particularly strict guideline use medicinal cannabis exist report say biotech isn alone market cara pharmaceutical cara insys therapeutic insy zynerba pharmaceutical zyne be also work treatment base cannabis plant migraine drug amgen amgn novartis aimovig be project bring sale spiking sale drug other seek prevent migraine block specific peptide group amino acid approve aimovig be first drug know cgrp market ahead teva pharmaceutical teva aldr eli lilly lly allergan agn also be work area first class mover advantage be crucial aimovig competition other subcutaneously administer monoclonal antibody target cgrp be not far clarivate say lilly teva file fda approval drug late last year meanwhile be phase testing drug analyst be worry falter submit application fda co founder randall schatzman unexpectedly step chief executive role tuesday other area shire lanadelumab treatment swell disorder be forecast bring next be abbvie abbv elagolix treatment painful symptom associate menstruation round list pfizer merck mrk diabetes drug steglatro indivior opioid dependence drug sublocade be forecast become blockbuster sale respectively related chart read basic buy point mark time real much money do need start investing build long term profit stock take many gain
60,ABBV,relative strength rs rating astrazeneca azn climb higher percentile monday get lift ibd unique rs rating identify market leadership show stock price movement last week measure other stock database history reveal best stock tend have better rs rating begin largest run see astrazeneca continue rebound clear threshold look winning stock try simple break earlier have fall back prior entry consolidation stock re tracking clear buy point then retreat more original entry price consider fail base stock set new chart pattern entry price also keep mind most recent pattern be later stage base involve more risk revenue growth fall last quarter ep grow previous report astrazeneca earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
61,ABBV,tuesday zoetis zts get upgrade ibd smartselect composite rating new score indicate company be now outperform stock term most important fundamental technical stock pick criterium zoetis be now buy range clear buy point flat base look winning stock try simple stock earn ep rating meaning recent quarterly annual earning growth top stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company report earning growth top line growth climb prior quarter mark quarter rise revenue gain company next quarterly report be expect feb zoetis hold rank peer medical ethical drug industry group abbvie abbv be rank stock group related company be now outperform stock
62,ABBV,imagine editing gene cure debilitating disease small biotech company combine annual sale less crispr therapeutic crsp intellium therapeutic ntla edita medicine edit say soon be reality biotech stock go public bet big simple premise alter specific gene create curative medicine estimate disease be cure change target gene say former intellium chief executive nessan bermingham world health organization have higher estimate be know monogenic disease say actually north person have be talk personalize medicine year yet ve never have system allow do bermingham tell investor business daily step role dec first time ever actually have system do system be base personalize genome system be know crispr crispr intellium edita be putt chip cheaper faster gene editing method accord bermingham key advance personalize medicine analyst think crispr technology provide platform next generation giant biotech company crispr technology not be confused crispr therapeutic company build project sequence human genome first map cost be complete then cost map individual genome have drop precipitously come just hundred dollar next few year bermingham say large datum analytic also have part play sifting genome ibd take biotech company account large share recent ipo stock yet investing have profit sale be risky learn identify best ipos trade potential big gain first human genome be map investigator be absolutely horrify find just gene human body code protein bermingham say be estimate essentially protein coding gene serve word genetic language investigator also find region dna be initially thought have purpose be controversially call junk dna do not code protein turn sequence do have key purpose regulate expression gene together better understand human genome have allow biotech company utilize crispr acronym technology know cluster regularly interspaced short palindromic repeat be caveat however january paper publish biorxiv say be evidence human immune system fight major form genome editing used enzyme call cas thus render science ineffective paper however have yet be peer review process develop various university essentially used specialize strand dna act molecular scissors scissors be capable editing other dna specific point allow biotech company edit add remove faulty gene responsible disease be vary type scissors crispr intellium edita be used cas crispr technology ark invest analyst manisha samy tell ibd estimate cas reach human genome develop new scissors expand reach more gene disease say gene editing isn new add older technique call talen zinc finger nuclease have be time notably biotech company bluebird bio blue be used variation talen sangamo therapeutic sgmo be used method zinc finger nuclease liken crispr technology word processor think crispr gene editing be analogous dna word processor function find delete say january report addition scientist be work rudimentary paste function allow crispr insert appropriate dna code repair mutation older technology used biotech company be more old fashion typewriter require actual cut paste say crispr technology be also cheaper easier use talen zinc finger say jmp security analyst mike king so powerful crispr be so easy use tell ibd high school student be do experiment biology lab knock gene zinc finger take lot talent time have fiddle lot system create crispr be quite robust january biorxiv online archive distribution service unpublished report life science field publish paper cast doubt durability crispr gene therapy time suggest body build immunity analyst biotech company be not worry however say be nonissue time science catch many company work crispr be do so used cas enzyme short crispr associate protein cas be derive bacterium cause infection human high rate meaning immune system have develop immunity crispr gene editing used enzyme work patient depend crispr therapeutic say follow email ibd important note lead investigator writer biorxiv paper be matthew porteus scientific founder advisory board member crispr therapeutic gene editing be do ex vivo outside body cas enzyme be degraded therefore essentially go time cell be reintroduce patient crispr tell ibd vivo application gene editing be do body crispr therapeutic say used several approach ensure transient expression cas enzyme do not expect pre exist immunity cas cause issue firm say ark samy also note other enzyme be use edita be also used cpf enzyme enzyme be derive other bacterium overcome immunity challenge involve cas intellium tell ibd follow email clinical testing delivery system treatment rodent human primate have yet falter further intellium note used advanced form cas none donor have pre exist immunity study datum be still early edita have do own work immune response crispr genome editing present paper future jmp king say jan note client management have indicated find immune response be much lower report other paper immune response be not uncommon samy say scientist have work decade evade immune recognition be numerous workaround be implement reduce potential side effect cas have prove number other therapeutic modality biotech company crispr therapeutic be ahead competition regulatory standpoint dec firm submit first application clinical trial testing gene therapy know ctx blood disorder know beta thalassemia company be work vertex pharmaceutical vrtx beta thalassemia well sickle cell disease therapy be part crispr ex vivo program gene editing be do cell outside body be reintroduce patient crispr be also look vivo therapy liver muscle lung accord crispr news release trial be set begin europe adult patient be expect be first human trial gene editing treatment base crispr technology crispr also plan file application begin testing ctx treat sickle cell disease intellium also have vivo ex vivo program gene editing also be work sickle cell disease furthest partnership regeneron pharmaceutical regn therapy treat know transthyretin amyloidosis condition characterize buildup abnormal protein deposit body alnylam pharmaceutical alny ionis pharmaceutical ion also be work separately treat disease used different method call rna interference antisense technology respectively meanwhile edita be work inject treatment inherited eye disease know leber congenital amaurosis be characterize severe loss vision birth be also used gene editing sickle cell disease beta thalassemia intellium edita also be expect start human trial analyst say intellium have not say begin testing regulator be get more comfortable idea gene editing crispr therapeutic president sam kulkarni tell ibd benefit gene editing potential trouble be meant be permanent fix biotech company be work ensure hit bull eye time ve show make edit do precise fashion used target industry call molecular zip code say eliminate edit happen outside place want happen manufacture high quality fashion understand pharmacology kulkarni intellium bermingham be succeed john leonard former abbvie abbv executive say room big player group sizing market be challenge ark samy say matter slice number be big lot depend disease company target set pricing crispr be able address monogenic disease diagnosed year market globally say address disease person already live diagnosis be market product be not go cure everything say re see volatility main crispr company doesn really make sense room more come crispr kulkarni say unlikely market remain just publicly trade biotech company crispr technology long run technology be just remarkable once lifetime be little bit stretch maybe not say definitely once generation type advance field last time kind excitement happened biotech field be antibody be apply therapeutic modality basis technology company genentech now own roche rhhby be create add here have basis crispr platform create next big biotech giant related top biotech company innovation earn recognition new awardswhy bluebird downgrade send rival best stock buy watch nowmeet best broker overall investor need
63,ABBV,relative strength rs rating novartis nvs head higher percentile friday get lift ibd proprietary rating identify market leadership worst best score score show stock price movement last week compare other stock database decade market research show best stock tend have rs rating north early stage move see novartis continue show renew price strength hit benchmark see ibd help make more money stocksnovartis be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase novartis hold rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
64,ABBV,abbvie abbv follow footstep gilead science gild celgene celg analyst suggest monday abbvie guide unexpectedly low tax rate expect narrative stock come month develop buy story similar gilead celgene more recently leerink analyst geoffrey porge write note client acquisition narrative follow abbvie fourth quarter earning friday biopharma giant top quarterly expectation beat guidance prediction also guide tax rate tax rate term also follow announcement last week celgene acquire juno therapeutic juno sanofi sny acquire biogen biib spinoff bioverativ bivv today sanofi also say buy ablynx ablx abbvie do seek acquisition likely be neuroscience early stage immuno oncology solid tumor medicine porge say abbvie seek deal build complement early stage alzheimer disease pipeline ahead key readout so far abbvie be play card close vest firm doesn seem incline make large disruptive transaction porge say credit suisse analyst vamil divan note firm be constantly look asset believe already have strong pipeline further do not have burn platform need acquire asset say isn compelling need company be deal many other thing probably be not best time do merger acquisition ibd take celgene abbvie have already report fourth quarter earning slew biopharmas be still slate issue report head ibd industry theme closer look analyst expect biotech drug group put abbvie slightly different boat gilead celgene gilead acquire kite pharma slow hepatitis drug sale last week celgene say buy juno year begin lose exclusivity cancer drug revlimid divan comment follow conversation abbvie management post fourth quarter earning analyst suggest lower expect tax rate mean abbvie have extra cash hand engage merger acquisition abbvie say look earlier stage single asset build pipeline find anything timeframe even neuroscience readout not necessarily feel need divan say note client divan boost price target abbvie keep neutral rating porge also up price target downgrade abbvie market perform rating outperform current valuation prefer celgene abbvie larger cap name coverage say growth name such vertex pharmaceutical vrtx alexion pharmaceutical alxn regeneron pharmaceutical regn continue offer more upside view abbvie close bell stock market today abbvie dip fraction related celgene reverse fourth quarter otezla sale sanofi ablynx deal spur biopharma buy spree biotech merger spigot turn juno bioverativ
65,ABBV,tech stock china base name lead steep early decline thursday expect white house trade policy announcement drive investor defensive stance nasdaq composite dow jone industrial average open china base netease nte post worst decline nasdaq stock caterpillar cat boee ba take hardest hit blue chip shed open trade cruise line carnival ccl make index strongest move drugmaker abbvie abbv collapse bottom list uncertainty left new federal reserve chief jerome powell wednesday press conference last ditch battle republican push spending bill factor thursday premarket session market be most wary pending news trump administration prepared possibly unveil thursday be expect be upwards fresh tariff chinese make good news report say announcement tariff be addition impose february china steel aluminum trade be delay measure not take effect immediately china market dig second day ahead expect trade sanction hong kong hang seng index drop shanghai composite lose japan tokyo market reopen day vernal equinox holiday nikkei jump europe market continue deepen loss braced possible news tariff afternoon trade frankfurt dax cac paris be more london ftse be get newsletter deliver inbox more info product service privacy policy term tariff thursday other economic news open first time unemployment claim increase bit more week end march accord labor department consensus estimate project downtick claim federal housing finance agency housing price index be expect et researcher markit release preliminary purchasing manager index estimate march et conference board deliver lead economic indicator report et apple aapl shed fang stock tech leader drop more early trade facebook fb trim open loss less investor value latest installment social medium giant datum invasion saga founder chief executive mark zuckerberg offer facebook post medium broadcast apology late wednesday facebook share start recover tuesday lows be week wednesday close feb high china base name generally hunker premarket session internet content giant tencent holding tcehy crumble news report say south african medium internet firm nasper early tencent investor plan liquidate piece position loss drive share far week move average damage month base effort other china base name ibd stock alibaba group holding baba trade baidu bidu dip chinese tech leader be buy point valid basis weibo wb also ibd name slip stock be testing support week move average cup base january chip stock trade broadly lower israel tower semiconductor tsem more half philadelphia semiconductor index stock more early action earning news be mixed thursday craft retailer michael mik tumble china base solar play jinkosolar jks slump report quarterly result jinko have end wednesday february low attempt shape right side month consolidation upside apparel brand guess ge surge more report strong fourth quarter performance late wednesday ep gain rise revenue top analyst target broad margin give los angele base brand best combine advance more year gap gain moved share buy point week cup base package food leader conagra cag rise fiscal third quarter report be interested fed rate hike be surprise stock market weaken powell big picture reason market reversal wasn so badsee stock just get add cut ibd top stock list trump china trade war start get real thursday
66,ABBV,ibd stock screen be regularly update add new growth stock watch well weed have start show weakness new feature publish weekday evening market close ll see stock have be add remove list ibd sector leader ibd big cap screen be base proprietary slim investing system look stock display common trait typically share best perform stock early stage big price move check column day help build maintain watch list alert most recent change never buy stock just ibd list be sure do own research run stock idea buy checklist use ibd simple step routine quickly track general market trend find stock watch pinpoint best time buy sell change make march pm et ibd flagship screen lead growth stock give company show strong relative price strength top notch fundamental decide stock buy always check new innovative stock historically far outperform get newsletter deliver inbox more info product service privacy policy term useibd most stringent powerful screen sector leader highlight best stock ibd sector sector leader show outstanding earning sale growth recent quarters be strong many other fundamental price performance metric daily screen uncover top rate large cap growth stock consideration big cap company deliver outsize gain volatility smaller growth stock stock market newest company be find biggest winning stock time initial public offering ipos be typically early stage growth big earning growth generally fuel stock price performance ipo leader have special screening criterium find come stock strong fundamental technical trait daily stock list ibd seek good stock buy top fundamental be get ready break use glean emerge industry sector trend market view prior ibd stock list also look next big stock start herewhich company be now outperform stock buy stock buy checklistwhen sell stock selling checklist
67,ABBV,relative strength rs rating astrazeneca azn enter higher percentile friday get lift ibd proprietary rs rating identify technical performance used worst best score show stock price performance trail week compare rest market history reveal stock go make biggest gain often have rs rating north early stage move see astrazeneca continue rebound clear threshold see ibd help make more money be buy range clear buy point consolidation once stock move higher original entry consider extend buy range earning growth fall most recent report revenue gain moved higher next quarterly number be expect feb astrazeneca hold rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
68,ABBV,state street stt pra health science prah abbvie abbv be leader pass buy point touch new high wednesday investor be aware very different circumstance stock recent market have see biotechs other drugmaker launch bottle rocket announce positive trial result
69,ABBV,stock extend gain friday lift dow jone industrial record high intel intc nvidia nvda lead chip sector powershare qqq trust qqq lead gain spdr spy rise spdr dow jone industrial average dium add stock market today emerge market outperformed ishare msci emerge market eem advanced chip biotech health care be top sector fund gainer vaneck vector semiconductor smh ishare phlx semiconductor soxx rally more thursday sharp downward reversal intel biggest dow gainer gap soar year high chip giant late thursday report better expect result hike dividend lift guidance graphic chip designer nvidia drive ahead new high oil play rise west texas intermediate crude price be barrel unite state oil uso powershare db oil dbo gain more trade best level november utility bank real estate underperform also lag bitcoin slip accord coindesk cryptocurrency have rise high earlier bitcoin investment trust gbtc give trade spend week day move average coincheck big digital exchange japan say suspend withdrawal halter trading digital currency bitcoin get hack lose more ve dismiss stock kohl kss target tgt seagate technology stx want take look ve not only outperformed broader market year also pay market beating dividend spdr portfolio high dividend spyd have bounce day move average own name many more exchange trade fund pull back day move average jan find support stage rebound remain potential buy zone be just new high reach earlier week share advanced late october bounce line dec intraday high fund celebrate year anniversary october track high dividend index index aim measure performance top dividend pay stock company index usually have market cap least time inclusion real estate account biggest sector weighting jan nearly asset utility follow consumer discretionary information technology energy just north remain sector represent less retailer kohl target be fund top holding drugmaker abbvie abbv tech stock cisco system csco seagate also make top stock have outpaced year jan seagate lead gain kohl target abbvie cisco ytd gain be also ahead ibd take make money catch etf uptrend require knowledge read chart learn ibd university however spyd ytd return jan accord morningstar direct lag gain year return also trail benchmark index advance fund deliver goal provide high dividend portfolio investor annualize yield pay dividend yield spyd carry expense ratio thursday pick ishare msci brazil capped ewz be now extend buy point vaneck vector brazil small cap brf be still range entry related apple lose support dow high bitcoin play go positivestock tumble apple ge weigh dow gold outshine bitcoinstock rise senate vote biotech soar bitcoin drop
70,ABBV,chip china name lead stock strong start friday earning report stir early trade investor weigh fourth quarter gdp datum commerce department dow jone industrial average open aim press new high intel intc nike nke handled early heavy lift nasdaq pop trading wednesday high intel maxim integrate product mxim trip chip rally jd com jd head advance lead china base stock add russell be early trade economic news fourth quarter gdp rise accord initial estimate commerce department be gain third quarter economist consensus view advance consumer spending surge big jump third quarter estimate beating forecast gain december durable good order be better expect nearly double november increase clobber expectation rise transportation be primary factor beat transport good order rise month well november rise line expectation intel power ahead almost lead dow nasdaq heel fourth quarter report clean beat include dividend increase upgrade outlook stock have be struggle news security lapse affected nearly product make past year news kill attempt send stock lower early january stock have be fight hold support week move average lead chip developer maxim integrate jump almost late thursday report show line earning revenue fiscal second quarter third quarter guidance top consensus view stock have pull back just buy point flat base other chipmaker see buy spillover xilinx xlnx advanced micro device amd rise more apple aapl open lower amazon com amzn lead fang stock tech leader gain many china name moved higher hong kong market end strong week alibaba group holding baba weibo wb trade stock have end thursday buy zone online retail giant jd com vault breaking buy point bloomberg report jd com plan enter market be seek finance expansion part deal shareholder tencent holding tcehy buy logistic unit tencent rise open trade post strong advance china market friday drugmaker abbvie abbv punch nearly clear analyst revenue earning target wide margin fourth quarter result share be extend flat base buy point intuitive surgical isrg drop early action fourth quarter revenue earning well analyst forecast late thursday report also show charge related re-form tax rule intuitive end thursday buy point flat base starbucks sbux dive coffee house chain late thursday report beat earning miss revenue guide earning consensus view founder chief executive howard schultz chat future cryptocurrency conference call investor heavy volume loss drive share back buy point month saucer handle base trade financial etfc slump top fourth quarter earning sale estimate announce plan acquire retail brokerage account capital financial cof trade share have be trading tight high december asia stock market be sharply mixed friday tokyo nikkei slip dollar continue dive vs yen china hong kong hang seng index power apparently help morgan stanley report boost price target china bank due higher net interest margin improve asset quality accord south china morning post nikkei end week hang seng finished seventh straight weekly gain european market extend early gain afternoon trade cac paris london ftse ahead frankfurt dax show gain other important market news friday big picture blue chip advance breakout sparse lesson today volatile action china name buy range find strength flaw intel beat fourth quarter target offer cheery outlook
71,ABBV,index later nasdaq composite fall sharply day move average join dow jone industrial average key support president donald trump impose big china tariff provide sweeping exemption delay earlier tariff steel aluminum earlier facebook fb crash datum privacy scandal drag google parent alphabet googl other techs tencent tcehy plunge revenue miss big investor selling oracle orcl dove decelerate cloud revenue growth federal reserve keep rate hike outlook step economic forecast plan raise concern nasdaq composite tumble dow jone index president trump china tariff announcement trigger sharp sell thursday friday facebook crash week take alphabet other big consumer internet tencent sell hit many chinese internet especially industrial such boee ba heavy china exposure investor also be worry hawkish forecast federal reserve meanwhile treasury yield fall safe haven flow stock dove trade war fear crude oil price rise significantly chief executive mark zuckerberg day silence respond wave criticism cambridge analytica obtain million user profile abuse social medium giant datum sharing ability post facebook page zuckerberg say responsible happen platform then layer step company take prevent further abus facebook share plunge google parent alphabet googl twitter twtr sell respectively get newsletter deliver inbox more info product service privacy policy term fed raise key rate quarter point expect slim majority fed policymaker still expect rate hike see total hike more project end last year step pace reflect expectation stronger economy propel tax cut federal spending hike now policymaker expect core inflation rise next year just fed target tencent holding tcehy report fourth quarter earning ahead expectation sale growth come short chinese messaging gaming giant send stock wednesday major early investor company nasper next day announce sell tencent share worth cut stake nasper say sell share fund other business have plan further reduce holding next year tencent plunge thursday alibaba baba other top china internet tumble database software giant top quarterly earning view oracle reveal reveal transition cloud be progress slower expect cloud revenue growth be less expect decelerate once again oracle say cloud gain fall further quarter share plunge salesforce com crm make biggest acquisition date purchasing mulesoft mule cash stock salesforce paid high multiple nearly time mulesoft estimate revenue set high bar other potential deal involve saas software service company mulesoft sale jump last year deal be expect be earning dilutive mulesoft software automate integration new tool legacy enterprise platform speed application development salesforce com share fall announcement abbvie abbv crater nearly thursday scuttle plan seek accelerate approval lung cancer drug perform poorly midstage trial drug rova be be test third treatment achieve objective response rate median month overall survival be median month drug be still be test first second treatment same form cancer memory chip giant earn adjust share fiscal second quarter year year sale quarter end march analyst expect current quarter micron technology mu expect earn adjust share sale wall street be modele micron see strong demand continue dram flash memory chip cite cloud datum center smartphone automotive chip growth driver invest boost production facility micron share tumble friday smart global holding sgh smaller player rate datum storage group include micron also easily beat quarterly estimate guide higher share soar friday arena pharmaceutical jump tuesday wednesday ulcerative colitis drug prove strong phase trial component scale patient achieve clinical remission vs just placebo patient drug belong same class celgene celg drug ozanimod regulator refuse review last month multiple sclerosis southwest airline luv cut first quarter unit revenue outlook cite part competitive fare environment analyst cowen see direct result unite airline ual plan expand flight regain relevance market share share southwest other airline fall unite also suspend pet cargo travel fly few dog wrong destination die be store overhead bin carrier say hope complete review pet cargo travel program report ep revenue same store sale rise beating analyst expectation ep revenue focuse discounter see ep cent view cent revenue also view issue full year ep revenue analyst estimate also approve stock repurchase program rise thursday near buy zone nike nke report flat earning share exclude tax related charge defy view drop sale grow also top view china sale pop lead gain geographic segment revenue important north america segment slide ceo mark parker point significant reversal trend north america share initially jump friday close only stock undercut day line thursday datum storage service firm shot friday pricing ipo share upwardly revise range dropbox dbx sell share late thursday raise dropbox let user store share collaborate document photo other file online many user opt free service dropbox have pay subscriber macy say retail conference shoptalk store mobile checkout system be location year end look keep tech savvy rival online player summer macy store offer virtual reality furniture shopping same conference walmart wmt commerce head marc lore reiterate not be go anywhere holiday online sale slowdown be largely plan entry home specialist earn cent share dime view revenue rise slightly miss view net order rise more expect strong start spring selling season strong demand be give kb home kbh pricing power offset higher commodity cost kb home stock climb meanwhile new home sale fall third straight month december january figure be revise higher exist home sale climb accenture acn report fiscal adjust earning rise year revenue rise top consensus estimate accenture raise full year profit target margin be hit few big contract renewal health public service field be less profitable well higher acquisition cost area share fall thursday fedex fdx beat earning revenue forecast raise full year ep outlook shipping giant set shop walmart wmt store year general mill gis report ep cent line view revenue fall just short cereal maker lower growth outlook rise cost stock sank nearly year lows general mill be latest package food giant weaker growth report send several peer fall sharply well china ipo lexinfintech lx fall far short estimate earn adjust cent share revenue share tumble be hold ipo price online lender cater educate young chinese adult winnebago wgo plunge rv maker miss fiscal earning view sale beat surge demand smaller towable rvs tesla tsla shareholder vote approve massive pay package chief executive elon musk design ensure iconic leader remain electric car maker next year darden restaurant dri owner olive garden report fiscal earning beat expectation revenue same store sale come short full year ep outlook imply weak darden stock leap ibd stock healthequity hqy make big gain beating fourth quarter estimate monday close report ep cent revenue health saving account asset account jump share rise child place plce struggle recover plunge tuesday weak guidance beating earning post ep share revenue share fall apple aapl reportedly be develop own display used microled technology likely be several year start show device such apple watch iphone chip gear maker kla tencor klac announce agreement acquire orbotech orbk cash stock kla tencor be seek diversify business process control system equipment used production print circuit board flat panel display semiconductor device be interested best growth stock buy watch see update ibd stock listsnews analysis dow jone industrial average component invest stock market start simple routine
72,ABBV,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
73,ABBV,key stock index fund be lower afternoon trade tech heavy qqqs turn negative blue chip fall most boee ba johnson johnson jnj weigh powershare qqq trust qqq dip spdr spy give spdr dow jone industrial average dium fall stock market today utility gold miner technology be top sector fund gainer spdr utility xlu rise retake day move average first time month vaneck vector gold miner gdx vaneck vector junior gold miner gdxj be health care select sector spdr xlv reversed loss unitedhealth group unh be dow biggest gainer early fall nearly cisco system csco hold gain biggest loser include boee undercut day move average trigger sell signal dowdupont dwdp johnson johnson apple aapl slip day hit new record high then reverse lower back buy point shape cup handle boee other industrial giant be get hit continue tariff related concern homebuilder bank metal miner lead downside sector fund spdr bank kbe spdr regional banking kre fall track extend loss third straight session etfs be nearly recent high bitcoin sank accord coindesk open level bitcoin investment trust gbtc gap tumble session lows month low mostly decline try retake day line march be now december peak dow stock johnson johnson unitedhealth group be blue chip show healthy gain tuesday spdr health care xlv remain potential buy range retake day move average friday be form new base buy point too keep mind broader market have be volatile lately fund undercut day line early february market correction now appear be overall uptrend share advanced last time xlv be featured etf column time fund be just buy point flat base etf celebrate anniversary december track health care select sector index pharmaceutical represent biggest segment holding march nearly asset biotech be next category account health care equipment supply health care provider service life science tool service health care technology make rest get newsletter deliver inbox more info product service privacy policy term top holding include dow jone industrial average health care name johnson johnson pfizer pfe unitedhealth group merck mrk dow stock top be abbvie abbv together top account roughly third stock portfolio dow quartet year date performance range abbvie however have soar year xlv year date gain march be line return etf average annual return past year lag outperformed broader index past year xlv bear expense ratio tuesday pick guggenheim pure growth rpg reversed lower session close just buy point also be interested dow stock turn red ge weigh apple reverse record highai robotic blockchain hot new etf industry sector do market pro expect outperform year
74,ABBV,tuesday horizon pharma hznp get positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength unique rating identify market leadership show stock price movement last week compare other stock database year market history show best perform stock tend have better rs rating begin biggest run look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock manage offer clear appropriate buy point sale growth fall last quarter bottom line grow prior report horizon pharma earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
75,ABBV,mile white be name ceo abbott laboratory be youngest head major health care company today longest serve chief health care have make reputation master strategist know make bold move abbott none be more dramatic spun research base pharmaceutical half firm abbvie abbv abbott have market capitalization half industry leader pfizer pfe merck mrk seem crazy many white perceive develop new drug have completely different business rhythm new abbott now focus device diagnostic nutritional product brand generic drug result abbott stock have rise share share give market cap abbvie share increase share share give value approach creation combine be now worth far more pfizer merck white have be rank barron world best ceo straight year keep company current relevant white tell ibd continually shape business ensure re need opportunity be future instance recent acquisition st jude medical make leader range grow medical device category new technology make huge difference patient investor white grow la vegas earn bachelor science mechanical engineering stanford mba year later joined mckinsey co chicago consultant feel work be fascinating project client come go white say want something feel connect longer term be more fulfill white be hire abbott base north chicago suburb abbott park ill director sale diagnostic year later be offer chance head division grow asia pacific region prestigious position year old turn meant move japan wife want open child bookstore white say be big believer work life balance be confident other opportunity advancement come way indeed year later be choose be new ceo follow year add title chairman board wife run bookstore year selling abbott have rarely do acquisition divestiture founding whirlwind change follow white take helm include be dramatic traumatic abbott acquire kos pharmaceutical maker cardiovascular drug cash deal sell core laboratory point care diagnostic division general electric ge fall white decide revive challenged division instead investing research development streamline operation reorganize product service new diagnostic division august begin launch family next generation instrument informatic service common software hardware platform design be easy use more efficient white call game changer industry other acquisition abbott paid pharmaceutical unit belgium base solvay expand presence emerge market same year plan be announce purchase unit piramal healthcare make abbott biggest pharmaceutical company india success company acquisition largely depend ability anticipate consumer medical need understand practice medicine be head aggressively position company benefit internal external investment not just acquire company white say do do more business make better improve exist operation ve develop very discipline integration process learn best bring new asset abbott help expand reach potential faster better have more be just preliminary spin half company abbott take third quarter charge abbvie be officially list new york stock exchange jan make white such savvy deal maker ask jim cramer mad money show cnbc november have real talent anticipate consumer future medical need then aggressively position company benefit year become ceo abbott release humira go treat form arthritis plaque psoriasis crohn disease other ailment now part abbvie make sale make best selling drug world white have foresight spin part company ahead explosion debate drug price guide global enterprise massive change result mistake abbott biggest occur midst drama lead split october abbott be fine marketing depakote brand valproic acid world most widely prescribe epileptic drug condition not approve food drug administration part settlement cost total company agree strengthen internal control separate abbvie january new abbott emerge focus not only diagnostic product service medical device nutritional line brand generic medicine latter be establish pharmaceutical division sell develop market brand name be trust more unknown due high quality efficacy standard doesn have high cost base pharma division now offer more product development acquire cfr pharmaceutical more double latin american brand generic pharmaceutical presence abbott be also world leader adult nutritional product include ensure zoneperfect well leader baby nutrition similac other line special dietary need glucerna juven company be also leader diabetes care introduce revolutionary continuous glucose monitoring device freestylelibre september company purchase st jude medical cash stock establish abbott leader medical device arena also close alere make leader point care diagnostic market ve reinvent company multiple time past year white say continuous process shape company future work very deliberately ensure remain relevant current person serve change take place environment re several different business today be decade be choose specifically relevance science be go demographic socioeconomic factor be go customer be go re still grow strong stock be time high today abbott employ worker country revenue be net income be ceo chairman abbott laboratory global leader medical device diagnostic nutritional product brand generic medicine overcome fail sale challenged diagnostic business turn investing innovation become highly profitable consistent grower company lesson envision long term big goal work detailed step get even mean defy industry consensus need continually ask be better way answer be always yes even exactly not yet be apparent more leader success pam nicholson drife global growth enterprise holdingstaco bell founder change america fast food menumeet man hire take amazonphil knight clear hurdle make nike merchandising champion
76,ABBV,here investing action plan tuesday need know investor come day bitcoin wild ride first week bitcoin future trading cboe global market cboe continue grab headline noise obscure new potential buy signal big name microsoft msft
77,ABBV,here weekly investing action plan need know investor come week earning season get first taste result silicon valley lead netflix nflx intel intc other chip company biogen biib celgene celg lead report biotechs northrop grumman noc raytheon rtn
78,ABBV,strong open stock market tuesday see dow jone industrial average cross level early gain fade badly close rise early dow fade loss less nasdaq composite also give back healthy gain fall give back nearly small cap underperform russell preliminary datum show volume nyse nasdaq come higher friday level stock market today result distribution day nasdaq higher volume decline haven be issue broad market recent week always important pay attention sign institutional selling arise even percentage decline aren severe money flow stock do not translate bond inflow year treasury yield be mostly unchanged strong showing merck mrk unitedhealth unh help dow early share merck gap day move average rise nearly company say late stage trial blockbuster cancer drug keytruda combination chemotherapy treatment be effective treat patient advanced lung cancer share unitedhealth meanwhile gain company report earning give solid outlook wall street also like look quarterly result citigroup share rise try clear flat base entry come short tuesday session serve early breakout many top rate growth name include ibd name atlassian team align technology algn well weibo wb name look lot major stock index close result atlassian be due thursday close share rise ahead result clear buy point end buy point share weibo rise more end just cup handle buy point note handle be only visible daily chart not weekly latest be late stage base align technology also break early close whimper share rise close just entry abbvie abbv turn solid performance recent buy point share rise stock have be watch list ibd leaderboard related top tech stock hit buy point only hold upapplied material lam research boost upgrade asml break outgeneral motor jump strong earning bullish outlook bofa goldman alcoa pick earning season pace investing action plan
79,ABBV,beleaguered biotech investor likely have get relief trial datum drug approval help stoke ember formerly red hot group take analyst say be relief horizon don expect anything earth shatter say next quarter half be likely feature significant disclosure number company coverage be unlikely be period strongly stock move event leerink analyst geoffrey porge write recent note client porge view follow third quarter large cap struggle historic moneymaker catch double whammy increase competition pricing concern meanwhile smaller cap crushed expectation result ibd company biotech industry group rank first just month be now list group ibd track share touch month high october have lose nearly however flow event be set accelerate early first quarter offer more opportunity meaningful value inflection company stock leerink analyst write recent note frustration depress biotech stock group have post impressive number new approval year jmp security analyst mike king say accord food drug administration original application drug biologic have be approve year need product approval tell investor business daily even most jaded observer sector have say sector whole have produce very satisfactory result come major trial readout don see change regard tack drug approval successful datum readout be key company celgene celg gilead science gild pair large biotech leader face grow field competitor moneymaker revlimid hepatitis drug respectively celgene be set have readout type hodgkin lymphoma have car development partner bluebird bio blue juno therapeutic juno car drug treat cancer used patient own re engineer immune cell be important celgene have long enjoy revenue gain chemotherapy revlimid analyst have be expect generic competition dr reddy laboratory rdy recently dr reddy miss key deadline file generic still less ideal celgene rely so heavily stream revenue fbb partner analyst mike bailey say celgene have be prepare replace patent challenged revlimid sale crohn disease drug firm say october win initiate phase trial drug bull case celgene previously be have new drug limit risk revlimid tell ibd take away risk management piece focus be drug be go go generic point similarly gilead have hiv combination used drug bictegravir set gain potential approval february accelerate hiv sale start second quarter porge say same time ark invest analyst manisha samy say gilead likely get further car gilead also announce thursday acquisition cell design lab privately hold car player october gilead acquire kite pharma nearly follow fda approval kite drug dub yescarta treat large cell lymphoma adult due individualized nature car drug aren likely rake same sale gilead now falter hepatitis drug year line be huge revenue maker tell ibd ibd take big cap struggle third quarter isn surprising consider patent cliff next year be set hit annual sale blockbuster drug say analyst head industry snapshot more biotechs fared period yescarta win replace gilead hepatitis franchise peak grow steadily bailey say guess be hepatitis be go shrink really quickly say point expect car replace hepatitis sale way peak be once ever term gilead do never be big next several month leerink porge look abbvie abbv regeneron pharmaceutical regn disclose pivotal trial regulatory event vertex pharmaceutical vrtx report more value confirm event abbvie have datum inflammatory treatment know upadacitinib say result add more detail evolve landscape be know jak inhibitor treat psoriasis rheumatoid arthritis ulcerative colitis number condition regeneron be deck file result drug dupixent asthma drug be already approve treat eczema firm also report datum eye drug eylea immuno oncology drug cemiplimab type skin cancer also look vertex provide phase datum triple pill combination treat cystic fibrosis total vertex be testing potential regimen bring phase trial firm be also likely gain approval drug combination february big pharma world leerink analyst seamus fernandez say be few significant stock move catalyst left first half be busy dow merck mrk bristol myer squibb bmy astrazeneca azn have immuno oncology combo result lung cancer bristol merck incyte incy be set deliver result regimen melanoma bristol also offer interim datum trial immuno oncology drug opdivo yervoy first treatment lung cancer outside major immuno oncology catalyst thankfully be limit say high bar bristol interim datum require nothing short stopping study early extreme effectiveness unlikely so expectation be probably low say nonetheless early stop be major validation bristol strategy likely drive stock view say continuation study likely increase concern bristol strategy ultimate success study final analysis possibly push stock parp inhibitor yet class cancer drug be set have trial result well astrazeneca have result drug lynparza first maintenance treatment ovarian cancer think parp space be quite large jmp king say hard tell real world doctor see drug better so start produce satisfactory sale figure related biotechs sell drove be investor seek merger biotech just near year high strong cancer regimenthis cancer biotech be fall bayer deal
80,ABBV,monday lead drugmaker abbvie abbv announce positive phase trial result psoriasis treatment risankizumab tuesday ibd big cap be fractionally potential new buy zone result ongoing study show nearly half risankizumab patient achieve complete skin clearance pasi vs
81,ABBV,thursday horizon pharma hznp earn upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track market leadership worst best score score show stock price behavior trail week stack other stock database history reveal best stock often have rs rating least early stage move see horizon pharma continue rebound clear threshold look best stock buy watch start herehorizon pharma be not currently show potential entry point see stock go build promising consolidation kick new climb earning growth increase company latest report top line fall horizon pharma earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
82,ABBV,have be very mixed year big drugmaker north chicago ill base abbvie abbv climb monday session nearly time pace overall industry group xthat not bad dividend play yielding annually stock trade buy point week flat base
83,ABBV,important metric look stock be higher relative strength rating nordisk nvo clear benchmark friday jump friday exclusive rating investor business daily measure share price movement worst best score score show stock price behavior trail week stack other stock database decade market research show stock go make biggest gain tend have rs rating early stage move see ibd help make more money stocksnovo nordisk have rise more past entry first stage flat base meaning now proper buy range look stock create new chance get week tight pullback day week line top bottom line growth moved higher last quarter earning be compare prior report revenue increase nordisk earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
84,ABBV,key stock market index extend gain friday boost apple aapl cisco csco intel intc microsoft msft powershare qqq trust qqq rise spdr spy spdr dow jone industrial average dium advanced respectively emerge market also rally ishare msci emerge market eem rise spy reclaim day move average have be hit resistance feb market sell dium remain just support line qqq have hold solidly day line recover feb big cap techs be blue chip leader intel cisco microsoft apple score gain more apple have hold day line feb be shape right side base potential buy point now be iphone maker be reportedly get ready batch spring product launch oil utility semiconductor lead upside sector fund stock market today west texas intermediate crude price surge barrel vaneck vector semiconductor smh ishare phlx semiconductor sox rise nearly etfs be move support day line be january peak chip giant intel soar homebuilder biotechs be lag positive bitcoin climb accord coindesk open rise high bitcoin investment trust gbtc gain remain day line be trading jan french market regulator thursday say online trading platform cryptocurrency derivative be bar advertising product electronically re draw outperformer such apple boee ba nvidia nvda here exchange trade fund worth closer look diversify stock etf gain ishare edge msci usa momentum factor mtum be potential buy zone retake day move average last week mtum advanced late august rebound day line jan intraday high fund be last featured etf column aug test support line keep mind however share fall sharply day line recent market correction broader market track dow jone industrial average be hit resistance day line fund track msci usa momentum index mark fifth anniversary april provide access large midcap equity exhibit relatively higher price momentum accord ishare help target stock display strong recent performance include mentioned well name jpmorgan jpm bank america bac drugmaker abbvie abbv apple be largest component fund information technology account biggest sector weight feb asset follow financial health care industrial consumer discretionary represent smaller position material consumer staple real estate make rest sign free ibd newsletter market prep tech reportmtum year date gain feb be well ahead return accord morningstar direct year average annual return also outpace benchmark index advance etf sport expense ratio thursday pick financial select sector spdr xlf continue test support day move average strong bounce line set buy opportunity related cat lead dow apple pare gain chance buy buffett stocksdow stock index reverse apple turn red bitcoin slumpsdoe matter buy sell etf
85,ABBV,build watch list look stock higher rs rating bristol myer squibb bmy just meet criterium new score ibd proprietary rs rating measure market leadership show stock price movement last week compare other stock database year market history reveal market biggest winner tend have rs rating least early stage move see ibd help make more money stocksbristol myer squibb have moved more past entry first stage flat base meaning now proper buy zone look stock create new chance pick share week tight pullback day week line earning growth increase last quarter top line fall bristol myer squibb earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
86,ABBV,friday zoetis zts get upgrade ibd smartselect composite rating revise score mean stock currently top other stock term key performance metric technical strength winning stock often have higher grade early stage new price run zoetis be currently extend proper buy zone breaking buy point flat base see ibd help make more money stock earn ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show heavy buy institutional investor last week company post earning growth have now post accelerate ep growth consecutive quarters top line growth climb prior report company have now post rise growth last report zoetis earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related company be now outperform stock
87,ABBV,grifol grfs have relative strength rs rating upgrade tuesday welcome improvement still short higher score look unique rating measure technical performance used worst best score indicate stock price performance trail week compare other publicly trade company year market history reveal stock go make biggest gain often have rs rating early stage move see grifol continue rebound clear threshold see ibd help make more money stock be not proper entry right now see be able form break proper chart pattern company show earning growth last quarter revenue rise next quarterly result be expect mar company hold rank peer medical ethical drug industry group abbvie abbv be top rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
88,ABBV,horizon pharma hznp have relative strength rs rating upgrade tuesday welcome improvement still short higher score look ibd proprietary rs rating identify technical performance used worst best score indicate stock price performance last week match other stock year market history show stock go make biggest gain typically have higher rs rating begin largest run see horizon pharma continue rebound hit benchmark see ibd help make more money stocksnow be not ideal time jump isn proper buy zone see stock manage form base break ep growth drop prior quarter top line grow prior report look next report feb company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
89,ABBV,here weekly investing action plan need know investor come week focus earning season come holiday shorten week shift away tech sector pivot retail heavyweight walmart wmt home depot hd restaurant chain shale producer continental resource clr still
90,ABBV,bristol myer squibb bmy see positive improvement relative strength rs rating friday rise unique rating identify technical performance show stock price movement last week measure other stock database decade market research reveal stock go make biggest gain often have rs rating north launch largest run see bristol myer squibb continue show renew price strength clear threshold look best stock buy watch start herebristol myer squibb be build flat base buy point see stock clear price volume least average revenue growth fall last quarter ep grow prior report company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
91,ABBV,go stock market more year gradual solid gain investor suddenly discover stock go sharply dow jone industrial average index nasdaq composite see more week heavy selling whipsaw action breaking key support line leave high feb market close lead stock crumple selling pressure breathless coverage record loss dow stock market have not have historic meltdown unusually calm major average be midst biggest pullback year pullback correction be normal part healthy market market have now moved correction major average have rally past session be track gain wednesday encourage investor look further evidence assume new market uptrend be underway here depth analysis recent stock market action respond investor stock market hasn crash not know news loss signale change market direction immediate term several month gradual steady advance stock rise sharply first few week dow jone industrial index nasdaq composite rise amazon amzn netflix nflx energy stock big winner follow strong few hiccup stock market investor become complacent stock market rise never suffering bad loss jan index hadn fall more last august market hadn have cumulative pullback even presidential election eventually have change big change affect market be interest rate have climb sharply multiyear high world economy have picked steam surprising jump wage gain intensified concern inflation likelihood more aggressive federal reserve week congressional budget deal boost federal spending sharply heel big trump tax cut push year treasury yield year high year bond have end dow other major stock market index hit record high jan be already dow industrial nasdaq amazon netflix have sprint feb ibd switch stance market direction confirm uptrend uptrend pressure market have finished mixed day session follow few mild distribution day day selling average volume market top ibd take stay sync market direction be most important thing investor do investor business daily let reader know glance current state stock market be market pulse graphic big picture column let know market be confirm uptrend uptrend pressure correction subscriber also find market direction arrow clearly display investor com home page meanwhile more lead stock show weakness alibaba baba tumble earning several other top china internet stock struggle well homebuilder rv maker lead group begin sell sharply stock market top continue slide yet be still new breakout switch market direction be clear warning sign investor market direction be critical let know be look buy stock take profit move cash confirm uptrend most stock be likely rise lead stock be more likely deliver huge gain correction bear market even top rate stock find hard make headway market be pressure breakout occur be more likely fail other lead stock struggle friday feb january employment report show average hourly wage rise biggest annual gain much higher expect push yield even higher raise odd more aggressive fed just jerome powell take chairman janet yellen meanwhile apple lead sell broader iphone ecosystem weak handset sale current quarter guidance fellow dow stock exxon mobil xom chevron cvx plunge earning stock sell significantly include dow ominous point tumble cap worst weekly percentage loss year major average next monday feb stock plunge violent action talk erupt dow fall point biggest point loss ever point loss reflect fact dow be so much higher be prior drop such percentage term dow fall be biggest august only largest perspective dow plunge black monday crash oct still feb loss be significant drop be also worst august nasdaq composite be biggest post brexit vote sell june technical basis market undercut important support area major average fall day move average many lead stock laggard apple aapl undercut day line stock market have clearly worsen thursday feb market fear gauge cboe volatility index vix sky-rocket multiyear high psychological indicator vix be secondary market gauge major average lead stock be contrarian signal fear hit extreme level often sign least short term bottom ibd left market direction uptrend pressure stock market go wild ride tuesday part volatility related vix related product stock sell sharply intraday close higher nasdaq lead stock retook day line good stock market day isn meaningful fact most best percentage gain history be midst deep correction bear market wednesday stock whipsaw again time close lower renew rise treasury yield spook investor again nasdaq fall back day line dow industrial find resistance chip energy china stock be notable loser thursday share open higher quickly turn lower treasury yield moved back recent multiyear high dow jone fall nasdaq undercut tuesday intraday lows lead stock reel week negative action most stock breakout last several week have fail longer term winner be slash gain fall support area combination negative action trigger shift market correction signale investor move sideline thursday close dow industrial be high traditional level correction friday big swing continue dow tumble intraday tuesday feb low join other key index index briefly undercut day average first time mid major average then rebound strongly close gain even gain dow nasdaq fall just week worst performance year return confirm market uptrend major average rebound several day least strong gain heavy volume friday rally be encourage tuesday rebound show good day isn enough major average rise more monday close friday intraday high pass early test stock rise modestly tuesday rebound morning loss wednesday major average open lower hot inflation datum stock soon reversed higher even year yield hit nasdaq composite rise more afternoon trading move back day move average dow jone advanced more modestly still key support level meanwhile cboe volatility index fall sharply look rally attempt be confirm more price gain heavy volume least major average dow industrial get lot popular attention index represent only stock broader nasdaq composite index be usually gauge focus confirm sign market uptrend be lead stock break basis buy zone nothing buy market be tell too soon return lead stock be enter reclaim buy point hit new high wednesday back december start new year ibd explain stock market gain be smaller more correction year rally last year double historical norm be only time index have return more such strong year stock typically rise not much only case be stronger gain be only time next year be negative average gain be meanwhile few sign indicate bear market be loom bear market be typically associate recession seem unlikely term economic growth strong globe first time several year bond yield be rise result inflation be still low federal reserve aim raise rate more normal level fed other central banker do not want unnerve financial market earning be robust more company beating profit view time company be hike earning forecast new trump tax cut person say re due year bull market end stock market cycle don follow set calendar bear market typically be precede sharp ascent good example include tail end dot com rally early housing bubble run january be strong month much last year major average be just grind higher be few climax run lead stock square sq exhibit climax characteristic stock be turbocharge part bitcoin climax top december harbinger bear market big year year increase margin debt also be relatively low however rise double triple leverage etfs mean margin level not reflect speculation investor exposure well market have moved full blow bear often defined stock market more see sustain heavy selling breaking multiple support area heavy volume rebound attempt be short live vast majority stock fall lead stock breaking en masse pay attention market follow major average lead stock ibd daily market analysis include stock market today article big picture keep sync dow industrial nasdaq well top stock group don fight stock market most stock move market so correction be time sell stock move sideline determine stay invest probably take least partial profit follow sell rule stock fall buy point just sell don let stock have run more turn loser remember get stock bounce back ll get chance buy ll have capital quality stock keep mind rule apply individual stock come diversify mutual fund etfs long term investor take different approach specific stock not bounce back next upturn broad market eventually recover investor use market pullback correction add holding diversify fund still be way fund investor reduce loss capture gain next upturn market timing etf market strategy used current market direction ibd market pulse feature determine buy sell broad stock index etf powershare qqq qqq stock market clearly resume uptrend next week month now want be ready market turn very quickly new rally take hold first lead stock break often turn be big uptrend winner so stay engage stock market be great time build watch list buy right solve most hold selling problem look highly rate company strong rise relative strength line rs line track stock performance vs index market correct move sideway stock set bullish pattern be leader next uptrend good example top stock rs line record high include adobe system adbe servicenow now abbvie abbv more help find quality stock check ibd premium product leaderboard marketsmith also look stock find support day line didn give too much ground great place find potential stock watch downturn be ibd stock list include ibd big cap sector leader keep editing watch list correction stock hold well initially break other begin outperform everyone be bullish nobody want sell be longer many person left buy excessive bullishness mark least short term top market rise wall worry need investor come sideline buy stock so dose fear investor be healthy pullback correction clear deck set stage new strong uptrend lead stock set basis buy first mover major average confirm new stock market rally original version story publish feb also be interested sell stock rule help protect profit avoid lossesis time get stock market spot major stock market top easy way stock market forecast smaller price gain
92,ABBV,zoetis zts see welcome improvement relative strength rs rating tuesday rise exclusive rating investor business daily track share price action worst best score grade show stock price behavior trail week stack other stock database decade market research show market biggest winner typically have rs rating north begin biggest climb look best stock buy watch start herezoetis have rise more past entry first stage flat base meaning now proper buy zone look stock offer new chance get week tight pullback day week line earning grow last quarter prior report revenue also increase zoetis earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
93,ABBV,important metric look stock be higher relative strength rating grifol grfs clear benchmark tuesday jump tuesday proprietary rating measure market leadership used worst best score show stock price action last week match other publicly trade company year market history reveal best stock often have better rs rating early stage move look winning stock try simple routinegrifol be not currently offer proper buy opportunity see stock go build sound pattern spark new run earning share growth decline prior quarter revenue rise previous report next quarterly result be expect nov company hold rank peer medical ethical drug industry group abbvie abbv be top rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
94,ABBV,astrazeneca azn have relative strength rs rating upgrade friday welcome improvement still higher score look ibd proprietary rating identify share price action worst best score score show stock price performance trail week stack other stock database year market history reveal best stock typically have rs rating begin biggest price move see astrazeneca continue show renew price strength clear threshold look best stock buy watch start hereastrazeneca be try complete consolidation entry see stock clear price volume least average company see earning sale growth rise last quarter earning share increase revenue rise look next report nov company hold rank peer medical ethical drug industry group abbvie abbv grifol grfs nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
95,ABBV,do abbvie abbv overpay scoop pharmacyclic time few eyebrow ve be raise price tag acquisition look be right move abbvie primary therapeutic area include immunology oncology virology neuroscience past quarters abbvie have deliver sale growth
96,ABBV,gilead science gild top sale adjust profit view third quarter share drop late thursday hepatitis drug franchise decline again narrowly miss consensus expectation xin hour trading stock market today gilead fall share close biotech stock widely sell close bell thursday follow celgene celg sale miss guidance cut total sale decline top consensus analyst poll zack investment research adjust profit come share beat expectation adjust earning share sale hiv hepatitis drug climb nearly flagship hiv drug genvoya post yearly gain beat consensus rbc analyst brian abraham write note client gilead hepatitis drug meanwhile continue struggle fall third miss analyst view loncar investment chief executive brad loncar say note follow entry abbvie abbv mavyret treat genotype hepatitis rbc abraham note hepatitis drug harvoni come considerably lighter expectation vs consensus epclusa also miss post be consensus ibd take gilead currently have ibd relative strength rating best possible earlier month rs rating rise high visit ibd datum story more go rating stock even explicit guidance believe directionally help bring street hepatitis number next year welcome reduction lessen overhang share abraham say other product sale include drug treat high blood pressure lung angina fungal infection decline gilead increase low end net product sale guidance see hepatitis drug sale comprise firm also lower top end hepatitis guidance reflect sale related biotechs amgen sarepta vertex top third quarter scientific dife abbott rivalry hit pacemaker salescelgene crash sale miss alexion bristol result mixed
97,ABBV,abbvie abbv launch record high thursday settle patent dispute amgen amgn require biotech pay abbvie royalty sale humira copycat xby close bell stock market today abbvie pop earlier trade share be much record high amgen stock lift fractionally close settlement amgen drug know amgevita launch europe october version amjevita launch january drug be biosimilar abbvie drug humira inflammatory med biosimilar be biologic copy drug amgen pay royalty abbvie specific term be confidential abbvie say news release litigation pending be dismiss abbvie grant patent license amgen country country basis humira be abbvie most important drug bring total sale second quarter end june other drug firm be work humira biosimilar include biogen biib novartis nvs dow pfizer pfe mylan myl evercore analyst umer raffat say note client ibd take abbvie galapago be also work together cystic fibrosis drug vertex pharmaceutical say have strong lead analyst don disagree head new america breakdown market vertex be lead pack consensus be call amgen humira biosimilar first approve bring worldwide sale just set launch europe still be patent remain abbvie use extend litigation raffat say rbc analyst kennen mackay boost view success amgevita amjevita expect amgen drug penetrate peak humira biosimilar market europe respectively mackay model peak global sale amgevita amjevita hit sale share basis expect amgen have humira biosimilar market depend royalty rate keep sector perform rating price target amgen related biotechs beating market be buy range company gain trump foreign profit relief plan passeswhy amgen lilly be interested small biotechsabbvie new hepatitis drug chip away gilead share
98,ABBV,relative strength rs rating astrazeneca azn jump new percentile friday get lift ibd unique rs rating track market leadership used worst best score indicate stock price performance trail week stack other stock database year market history reveal stock go make biggest gain tend have rs rating least begin largest price move see astrazeneca continue rebound clear threshold look best stock buy watch start herewhile not currently ideal time jump see stock be able form base break earning growth rise last quarter sale fall company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
99,ABBV,horizon pharma hznp have relative strength rs rating upgrade thursday welcome improvement still higher score prefer see ibd unique rs rating measure technical performance show stock price action last week compare other stock database history reveal best stock often have rs rating north launch largest price move see horizon pharma continue show renew price strength clear threshold look best stock buy watch start herewhile stock be not proper buy point right now see be able form break proper chart pattern earning growth drop company most recently report quarter revenue grow prior report look next report feb company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts jazz pharmaceutical jazz be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
100,ABBV,grifol grfs have relative strength rs rating upgrade thursday welcome improvement still better score prefer see exclusive rating investor business daily track price action worst best score grade show stock price performance last week hold other stock database year market history reveal best stock typically have better rs rating begin largest run see grifol continue rebound hit benchmark see ibd help make more money stocksnow be not ideal time jump isn proper buy zone see stock be able offer clear appropriate buy point grifol post ep growth most recent report sale growth come look next report mar company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts jazz pharmaceutical jazz be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
101,ABBV,stock arrive proper buy point investor buy same stock bring different expectation investor be gun gain intention take profit move next second regard gain something
102,ABBV,sanofi sny second deal week spur robust buy period biopharma analyst say monday french drugmaker outbid nordisk nvo belgium ablynx ablx deal come week sanofi say spend acquire biogen biib spinoff bioverativ bivv hemophilia drug specialist also last week celgene celg say buy juno therapeutic juno leerink analyst seamus fernandez say signal begin active time biopharma deal view sanofi aggressiveness merger acquisition precede more robust period deal biopharma effect tax reform be feel valuation late stage asset continue drive higher say note client specifically sanofi plan spend acquire ablynx ablynx be near approval drug treat rare blood clot disorder be already partner abbvie abbv dow merck mrk sanofi other number potential drug various partnership program offer upside prospect ablynx wholly own asset fernandez say note drug fight virus cause infection lung respiratory tract be expect have phase datum second half year ibd take analyst don expect payer push back drug treat rare disease consider small population tend treat see company be work arena visit industry snapshot acquisition also add drug know caplacizumab sanofi pipeline drug be be test treatment acquire thrombotic purpura rare clot disorder cause impair activity enzyme ablynx estimate market disorder also know acquire ttp be euro expect gain approval europe sanofi fall close stock market today ablynx other hand rocket finish nordisk lose chance acquire ablynx sank nordisk have put bid earlier month ablynx related biopharma behemoth soon become surgical dip lackluster guidance analyst bullishwhy biotech stock outperform peer
103,ABBV,jeffrey leiden office shelve be plaster accoutrement expect chief executive biotech award letter accommodation inevitable family photo emerge theme gratitude leiden vertex pharmaceutical vrtx currently aim treat cystic fibrosis patient globe cystic fibrosis be progressive genetic lung condition survive adulthood generally don live past age accord most estimate xin vertex set change success see medicine soon be market have generate piece mail plaster leiden shelve re letter thank graduate newlywed get letter email week patient family thank do leiden tell investor business daily know patient most be kid teenager watch grow be part family not company vertex wasn always cystic fibrosis play earlier day be focuse treat hepatitis launch drug know incivek then gilead science gild launch drug sovaldi launch be most successful history also nearly put vertex business incivek become blockbuster drug shortly launch vertex pull market demand withered leiden describe time crisis company be middle crisis say have go be hepatitis company dollar drug literally year essentially revenue be very few company frankly survive kind crisis simply so hard pivot new area drug year division company san diego have be quietly work cystic fibrosis arena indication fit leiden strategy investing scientific innovation create medicine serious disease large unmet medical need specialty area vertex specialty focus allow keep sale marketing force slim turn allow reinvest nearly dollar revenue back research development sell cystic fibrosis drug sale force fewer leiden say fast forward vertex have drug market kalydeco orkambi second quarter sale kalydeco first approve cystic fibrosis drug grow year year orkambi rocket year date vertex stock have more double rise share begin form cup handle buy point late july meanwhile broader biotech industry group have rise be rank eighth group track just week share vertex dip close friday vertex be rarity biotechs way pipeline be almost solely cystic fibrosis drug pipeline not already license bigger pharmaceutical be cystic fibrosis leiden acknowledge risk portfolio standpoint product simply don make sense vertex say vertex have farm drug flu cancer dow johnson johnson jnj merck kgaa enormous sale contingent take sell drug indication take away reinvest science reinvest science have allow vertex do something else unique medicine other firm target symptom cystic fibrosis vertex be work correct genetic underlie cause disease eventually prevent infant diagnosed ever fully develop underlie science focus genetic mutation be divide bucket leiden say kalydeco treat patient orkambi combination kalydeco drug know lumacaftor treat eventually vertex plan treat patient get third bucket patient require prong treatment strategy already backbone triple be be consider approval europe combination kalydeco drug call tezacaftor look likely be approve february top kalydeco tezacaftor vertex be add next generation corrector drug fix other abnormality gene treat patient vertex have strong phase datum next generation corrector combination kalydeco tezacaftor fourth ready read soon eventual goal be decide possible triple pill combination provide most efficient treatment few side effect vertex plan use gene editing treat last cystic fibrosis patient traditional small molecule medicine win work leiden win comment expect triple pill get approval see pivotal trial begin next year most analyst take mean food drug administration approve triple pill vertex vertex goal triple be prevent infant less year age develop cystic fibrosis know today adult already have lung damage kalydeco have be show improve lung function week time slow rate decline lung function ibd take vertex be several leader near buy zone head ibd list stock buy zone other term opportunity include entertainment stock financial service play rather decline year decline year lung function leiden say not sound significant sort compound interest take lifetime make enormous difference survival quality life quality life improvement be huge leiden say used go hospital time year now time year say used be transplant list now re not transplant list used be able walk block now walk mile not just longevity quality life galapago glpg abbvie abbv have team follow vertex step leiden jmp security analyst liisa bayko be doubtful duo catch get fda approval triple pill combo show strong datum component first bayko estimate galapago be several year even do make market triple pill have have outstanding efficiency persuade vertex patient switch new medicine vertex have do good job continually improve med tell ibd keep move bar higher make challenge person want go drug be just good vertex want do just get vertex drug be more bearish jeffery analyst michael yee see galapago eventually get cystic fibrosis market still note vertex have create strong setup make barrier enter market high deliver strong medicine other question vertex do cystic fibrosis well run dry leiden acknowledge cystic fibrosis journey be near end say vertex have plan shift other rare disease sickle cell genetic lung liver condition deadly nerve disorder alpha antitrypsin deficiency lung liver condition look lot cystic fibrosis leiden say have technology know go bear skeptical vertex cystic fibrosis pipeline group analyst investor say well really great want do ll see re able skeptical say reason weird be ve already do ve proven do ve proven model don think question anymore think ve demonstrated work related biotech catch rally add celgene break biotech giant close buy pointstop biotech stock buy zone fda drug approval
104,ABBV,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
105,ABBV,zoetis zts see positive improvement relative strength rs rating friday rise proprietary rating measure market leadership show stock price movement last week measure other stock database history reveal best stock tend have higher rs rating begin biggest run zoetis be still buy range climb entry flat base once stock move higher original entry consider extend buy range relative strength line have moved new high territory positive sign market leadership company show ep growth last quarter sale growth come company hold rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
106,ABBV,relative strength rs rating bristol myer squibb bmy jump new percentile friday rise ibd unique rs rating identify technical performance show stock price action last week compare other stock database decade market research show market biggest winner typically have rs rating north begin biggest run stock be work cup handle entry see break heavy volume company report ep growth latest quarterly report sale increase company hold rank peer medical ethical drug industry group abbvie abbv be top rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
107,ABBV,drugmaker be begin gain steam drug trial result begin determine winner loser industry merck mrk be next break move higher ethical drug industry have jump industry group ranking last week time merck
108,ABBV,novartis nvs see welcome improvement relative strength rs rating friday rise proprietary rating measure technical performance show stock price movement last week measure other stock database history reveal market biggest winner tend have better rs rating early stage move see novartis continue show renew price strength clear threshold see ibd help make more stocksnovartis be work flat base entry see stock break volume least higher normal company top line growth fall last quarter bottom line grow prior report novartis earn rank peer medical ethical drug industry group abbvie abbv grifol grfs nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
109,ABBV,potential cancer cure disclosure propel loxo oncology loxo stock day june additional day september indicate innovation cancer research treatment many investor say keep loxo aloft potential blockbuster cancer treatment make loxo be recognize investor business daily inaugural ibd biotech innovator award lead drug look medically promising target relatively small patient population so annual revenue be expect fall short define commercial blockbuster get close loxo stock make big leap june company disclose progress phase phase trial lead drug candidate larotrectinib leap loxo stock follow word disclose phase trial datum tumor fighter annual meeting international association study lung cancer set start saturday oct loxo stock touch time high company expect file new drug application larotrectinib early food drug administration approve nda month loxo expect company begin sale specific patient almost immediately ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report loxo focus develop highly selective precision medicine patient genetically defined cancer be gain ground researcher patient doctor fund manager rather look attack specific cancer say used compound lung tumor sometimes don work healthy cell too loxo used increasingly popular gene sequence identify patient host specific gene mutation result tropomyosin receptor kinase trk fusion be abnormal protein tell tumor cell grow used loxo novel compound inhibit trk fusion activity call trk inhibitor kinase inhibitor loxo clinical trial therapy demonstrated improvement patient different type cancer hence loxo larotrectinib be gain attention research clinic wall street well become first drug initially approve fda target mutant protein many cancer rather target cancer loxo spokesman dan budwick call approach tumor agnostic note merck mrk keytruda be indeed approve treatment unresectable metastatic solid tumor specific genetic quality first fda keytruda be initially approve metastatic melanoma then small cell lung cancer then head neck squamous cell carcinoma be already widespread use merck apply fda also use keytruda gene sequence tumor agnostic approach rather old tumor specific approach contrast loxo larotrectinib be first time fda initially approve cancer drug used tumor agnostic gene sequence approach ibd take loxo recently hit time high company be do so moment ibd new high list track mover also rank ibd composite rating loxo potential have wall street attention number mutual fund hold loxo share jump support market cap secondary offer late june marked straight quarters rise fund ownership loxo late sport highest possible ibd relative strength rating putt top stock price performance past month week loxo june report american society clinical oncology asco meeting chicago world biggest cancer conference loxo sell more share common stock secondary offer pricing share stock have trade well recently november company raise expense stock performance loxo rival be rival however have be spotty time most be roll late loxo peer ignyta rxdx go public early month loxo have mostly trade ipo price thursday ignyta stock touch month high loxo partner array biopharma arry peaked shortly ipo stock be way touch year low february month hit month high blueprint medicine bpmc loxo develop kinase inhibitor go public hit new time high september run asco june loxo report objective response rate tumor size be reduce patient many cancer type clinical trial patient tumor hold trk fusion larotrectinib deliver consistent durable response trk fusion patient age regardless tumor context do so few side effect dr david hyman research team principal investigator loxo larotrectinib trial tell asco conference hyman be chief early drug development memorial sloan ketter cancer center way larotrectinib trk fusion story fulfill promise precision medicine tumor genetic rather tumor site origin define treatment approach cowen analyst eric schmidt say loxo estimate patient annually benefit larotrectinib treatment trial datum disclose asco patient greatest tumor shrinkage include soft tissue sarcoma lung colon cancer melanoma salivary gland cancer type cancer be be treat trial patient have least thing common gene mutation cause kinase trk fusion tell cancer cell grow larotrectinib earn breakthrough therapy designation fda july meaning fda give priority early trial suggest new therapy offer serious advantage exist treatment person life threaten disease breakthrough be not necessarily fda highest priority however fast track priority review designation accelerate approval pathway be fda urgent alternative larotrectinib then call loxo receive breakthrough designation unresectable metastatic solid tumor neuronal trk fusion protein adult pediatric patient require systemic therapy have progressed worsen follow prior treatment have acceptable alternative treatment note friend cancer research nonprofit count fda breakthrough designation include larotrectinib target cancer analyst schmidt say recent efficacy datum larotrectinib be best ever have see oncology estimate peak larotrectinib market annual sale year morgan stanley analyst matthew harrison see larotrectinib peak annual sale loxo go public august share conceivably get acquire blockbuster premium buyout talk have surface biotechs end be purchase most be acquire become profitable say schmidt cowen estimate loxo win escape red ink thing have transpire asco june be celgene celg pricing idhifa month new high niche oncology market schmidt tell ibd give loxo breathe room perhaps lead consider higher price larotrectinib idhifa be approve fda aug treat aml most common form acute leukemia adult celgene estimate new aml case be diagnosed annually june secondary offer more double loxo cash pile nearly june help loxo make acquisition bruton tyrosine kinase btk inhibitor program redx pharma rename redx drug candidate loxo loxo acquisition release chief business officer jacob van naarden call deal program pipeline so nicely align larger strategic vision capability redx team have create novel chemical matter selectively reversibly inhibit btk validate molecular target numerous cell leukemias lymphomas analyst schmidt tell ibd price tag look right btk target be validate be unmet need patient fail imbruvica abbvie abbv johnson johnson jnj commercial name ibrutinib treat complication stem cell bone marrow transplant know chronic graft versus host disease gvhd research note morgan stanley harrison praise btk acquisition call logical addition loxo pipeline rate loxo stock overweight price target cowen schmidt rate loxo outperform doesn offer price target cowen analyst be unfazed loxo financial loss greater estimate cash burn biotech earning rarely be interesting schmidt say loxo report wider loss share cent loxo be slate post result oct cash hoard loxo be danger run money year investor expect sale profit then cowen schmidt meet least twice recently loxo top brass say company be track speedy approval larotrectinib loxo be work other potential drug include btk inhibitor buy redx target leukemia lymphoma pipeline partner array biopharma kinase inhibitor target too early suggest approach blockbuster status related get detail biotech innovator award winning company loxo oncology stock hit record small cap biotech stock pop new high
110,ABBV,stock watch week be technology health care stock be near clear buy point form long basis gilead science gild take interactive break monday morning take faltered vertex pharmaceutical vrtx have be form long base clear buy point friday pull back monday wellness software firm mindbody mb be hover buy point gilead science rise heavy volume monday stock market trading clear buy point cup base go back september share surge friday jeffery upgrade gilead buy hold raise price target gilead science be rally hepatitis drug optimism rival abbvie abbv report strong hep sale friday ibd take look actionable high quality growth stock investor business daily do work check leaderboard market team curate analyze list top notch name take free trial leaderboard take interactive rise high clear cup handle buy point consolidation be take shape early november share reversed close gaming software company stock have be somewhat rangebound past few week trading day line buy point meanwhile vertex pharmaceutical break past entry late friday trading session rise market surge more new high volume be normal see volume rise least average monday vertex reversed lower lose back entry volume be modestly normal action come ahead earning wednesday vertex have be consolidate last july biotech have be steady rise december wellness service software company mindbody sank monday work consolidation form november shortest base group mindbody lose support day line several time build base have be able quickly recover stock have now form handle lower buy point slightly be important note major index have continue surge higher base build technology health care stock have relative strength line be lag rs line measure stock price performance vs stock break want see rs line hit short term high not time high vertex rs line have rise very short term level so have gilead rs line be interested facebook google breakout internet stock enter buy zonethese stock composite rating have earning apple stock chart be tell ahead earning guidance leader top buy point breakout be not create equaleven big week stock leader issue key sell signalsthese ibd tech stock be buy rangestock buy watch top ipos big small cap growth stock
111,ABBV,tuesday grifol grfs receive positive adjustment relative strength rs rating ibd proprietary rs rating identify market leadership show stock price movement last week measure other stock database year market history reveal best perform stock typically have better rs rating launch biggest climb look winning stock try simple routinegrifol be trading buy zone move past entry cup handle proper buy range be initial entry once stock move range best hold investing set buy opportunity grifol post earning growth most recent report sale growth come company earn rank peer medical ethical drug industry group abbvie abbv be top rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
112,ABBV,index other major average hit record high wave earning weaker dollar greenback rebound somewhat netflix nflx sky-rocket blowout subscriber growth bullish outlook celgene celg buy juno therapeutic juno intel intc surge earning outlook texas instrument txn other top chip fail impress quarterly financial apple aapl continue lag grow chorus concern regard iphone sale production airline stock plunge unite airline ual say expand rapidly set stage renew price war index dow industrial nasdaq rally solidly hit fresh record high earning season heated fall dollar have act tailwind multinational stock profit rebound year lows thursday president trump say expect stronger greenback netflix nflx be big earning winner intel intc also do texas instrument txn lam research lrcx be several lead chip stock struggle earning airline stock plunge unite airline ual apple aapl iphone related stock sell several analyst cite evidence weaker iphone demand share rocket record high netflix nflx add stream subscriber worldwide crush fourth quarter target internet tv stream giant end total stream subscriber analyst predict netflix subscriber gain come netflix implement price hike service plan europe netflix credit hit original content such tv series stranger thing crown movie bright subscriber gain period march quarter netflix be predict add net new subscriber chipmaker intel intc maxim integrate product mxim stm xilinx xlnx beat december quarter target get mixed reviews investor texas instrument txn post line result share be punish sector continue wrestle concern chip cycle have ebb top chip gear maker lam research lrcx kla tencor klac beat view sell news meanwhile xilinx joined nvidia nvda amd amd benefit sale high performance chip mining bitcoin other cryptocurrency related intel beat fourth quarter target offer cheery outlookbiotech merger heated celgene celg agree pay car drug developer juno therapeutic juno didn already own sanofi sny reach deal biogen biib hemophilia spinoff bioverativ bivv celgene acquisition come prepare lose exclusivity cancer drug revlimid juno rival gilead science gild novartis nvs make car drug treat blood cancer sanofi deal follow fail merger early wednesday novartis nvs report core earning share sale respective constant currency basis easily beating consensus thursday biogen biib report sale grow top consensus adjust earning grow be short also thursday celgene beat lower analyst view abbvie abbv friday top expectation adjust profit sale climb sale unite airline ual send airline stock tailspin carrier tell analyst plan expand flight coverage investor fear move do part regain relevance smaller city unite once abandon risk more competition cheaper fare help passenger threaten profit american airline aal earning call signale wouldn change profit growth target base unite ambition now southwest airline luv jetblue jblu alaska air alk also report general electric ge miss earning disclose sec probe core unit do well ge keep outlook industrial member dow industrial caterpillar cat mmm unite technology utx report strong earning guidance insurer traveler trv consumer product giant procter gamble pg also beat earning view verizon vz miss ep top revenue johnson johnson jnj top view fall patent ruling vs blockbuster arthritis fighter remicade president trump slap tariff import large washing machine part solar panel tax washing machine decrease then expire year duty solar cell module phase year solar technology provider suniva solarworld charge china be provide unfair subsidy financing solar producer whirlpool whr complain korean maker be dump washing machine excessively low price whirlpool also report quarterly earning rally first solar fslr initially pop close less china base daqo new energy dq lose crude top barrel brent edge briefly oil inventory continue drop oilfield service provider halliburton hal crushed quarterly forecast international growth outpace domestic growth share shot clear buy point baker hughe bhge edge past earning estimate be upbeat spending customer share fall nearly market price possibility ge fully spin business northrop grumman noc raytheon rtn general dynamic gd top profit forecast raytheon general dynamic miss revenue northrop give strong guidance lift dividend raytheon gd say order backlog be strong defense firm surge record high lockheed martin lmt boee ba report next week steel dynamic stld earning rise top view modestly sale climb rank company ibd steel producer industry group say be shape be good year thank more moderate inventory level improvement global demand pricing incremental investment drive tax cut specialty steel producer allegheny technology atus nearly double profit estimate revenue grow fuel high performance material jet engine freeport mcmoran fcx benefit higher copper price boost earning ahead estimate revenue grow negotiation indonesia ownership massive grasberg mine be progress haven erased uncertainty company outlook casino operator wynn resort wynn la vegas sand lvs put result beat top bottom line help rebound macau world largest gaming market sand ceo sheldon adelson cite acceleration mass gaming market chinese administrative region only area nation gamble be legal wynn share plunge friday erase nearly weekly gain report allegation serious sexual misconduct ceo steve wynn ford motor see ep climb cent revenue grow analyst have expect ep cent sale accord zack investment research ford be buy mobility startup autonomic transloc share extend sell prior week ford outlook disappoint investor fiat chrysler fcau deliver strong result generally affirm ambitious financial target send share fresh week high new oriental education edu logged ep growth short view sale gain narrowly beat fiscal estimate student enrollment grow china base school education provider offer guide sale view higher share tumble recoup loss end week tal education tal meanwhile surge nearly thursday retake day ep jump revenue growth tal enrollment swell td ameritrade amtd trade financial etfc beat top bottom line fiscal earning share jump td ameritrade revenue expand see full year earning exclude item vs expectation td ameritrade also say allow customer buy sell certain etfs day week trade report ep revenue ll also acquire retail brokerage account capital financial cof asset share online broker fall modestly week millennial focuse free investing app robinhood let person buy sell bitcoin other cryptocurrency commission intuitive surgical isrg report adjust income share sale rise respective metric top expectation robot surgery gear maker give cautious guidance homebuilder nvr nvr miss earning sale view share tumble crash week line first time more year huge volume doj subpoena mortgage unit lennar len bigger expect new home sale decline other homebuilder also suffer notable decline
113,ABBV,alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx be likely beat fourth quarter earning estimate analyst predict biotech guidance be cautious windfall tax reform fourth quarter earning report season kick next week dow johnson johnson jnj novartis nvs weigh tuesday wednesday pharma side celgene celg biogen biib be deck early thursday abbvie abbv trail friday leerink analyst geoffrey porge expect cautious prediction begin note example celgene pre announcement earlier month uncertainty payer dynamic competition drug access be likely play forecast factor imminent return more challenge political environment suggest management team be more typically cautious guidance first provide financial community earning call say note client fourth quarter porge call vertex cystic fibrosis drug orkambi kalydeco gilead hepatitis hiv drug regeneron pharmaceutical regn eylea dupixent latter eye disease eczema treatment respectively surprise upside ibd take biotechs suffer third quarter high profile drug miss expectation smaller player take headline beating view head industry snapshot more happened prior quarter history be expect repeat see older drug amgen amgn include psoriasis arthritis med enbrel risk disappointing investor biogen multiple sclerosis drug avonex plegridy abbvie cancer med imbruvica also disappoint say needham analyst alan carr see investor focuse merger fourth quarter call week rumor emerge celgene be consider takeover juno therapeutic juno biogen be consider putt bid acorda therapeutic acor continue believe pharma have bias risk asset be market case still regulatory review write note client first half expect food drug administration approve vertex cystic fibrosis regimen kalydeco tezacaftor well hiv combination gilead abbvie neurocrine bioscience nbix also get drug treat severe menstrual pain alnylam pharmaceutical alny be also likely grab approval patisiran drug treat condition abnormal protein deposit body cause systemic problem achaogen akao tetraphase pharmaceutical ttph be also near approval antibiotic related celgene rumore acquisition juno actually make sensedow merck do face release cancer trial hospital plan put pressure generic drug maker
114,ABBV,stock bond dollar fall wednesday report china be slow halter purchase sovereign bond bloomberg news say china biggest buyer see debt less attractive vs other asset report send bond price boost year treasury yield settle powershare qqq trust qqq lose spdr spy slide spdr dow jone industrial average dium give emerge market lag ishare msci emerge market eem bond fund ishare year treasury bond tlt fall intraday slide further day move average tumble tuesday breach support line ishare year treasury bond iei also extend loss prior session tlt re-cover most wednesday loss iei reversed slightly higher homebuilder semiconductor real estate lead downside sector fund stock market today bank metal miner retail advanced gold etfs rise gold future rise ounce bitcoin climb accord coindesk slightly earlier high bitcoin investment trust gbtc slump third straight decline sky-rocket last year have have far tamer start year gain meantime cryptocurrency aim track continue make daily headline so far year south korea have announce probe bank curb speculation jpmorgan ceo jamie dimon say regret comment last year call bitcoin fraud billionaire investor warren buffett tell cnbc wednesday have interest cryptocurrency berkshire hathaway brka ceo say go definitely come bad end talk fresh start new year cannabis focuse exchange trade fund be soar more state legalize marijuana sale not newly mint etf etfmg alternative harvest mjx have run so far year jan accord morningstar direct far ahead gain fund hit new intraday high tuesday perked jump dec mjx begin trading new objective ticker have soar then date mjx trade ticker lare be tierra xp latin america real estate etf late october etfmg notified investor change latin america index prime alternative harvest index track marijuana stock instead mjx now boast asset own canadian pot stock such crono group canopy growth aurora cannabis also have position medical company such gw pharmaceutical gwph base developer marijuana derive drug treat cancer other disease insys therapeutic insy product target cancer pain handful tobacco maker include british american tobacco japan tobacco altrium group mo round holding portfolio fund begin trading new objective ticker week isn really track record currently extend buy point mjx carry expense ratio ibd take even investor cannabis industry try get ground floor investing space be tricky advisorshare vice etf act isn pure play marijuana fund name imply broader theme dec cannabis stock account portfolio alcohol tobacco make remain respectively act have attract dec launch top holding include alcoholic beverage producer constellation brand stz drugmaker abbvie abbv agricultural chemical firm scott miracle gro smg constellation brand rise more tuesday news related work canopy growth corp canadian medical marijuana company develop nonalcoholic cannabis drink beer wine giant october announce take stake canopy act be flat year bear expense ratio tuesday pick ishare phlx semiconductor soxx spdr semiconductor xsd remain just respective buy point related pot stock play fall here jeff session not matter muchstock market close record high be bitcoin longer fraud stock move nvidia tesla drive techs bitcoin ripple dive
115,ABBV,wednesday grifol grfs hit important technical milestone relative strength rs rating move percentile improvement day unique rating identify technical performance show stock price action last week compare other stock major index year market history show stock go make biggest gain typically have rs rating launch biggest run look winning stock try simple routinegrifol be try complete cup handle buy point see stock break volume least average grifol show ep growth last quarter sale growth come company hold rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
116,ABBV,wednesday grifol grfs earn positive adjustment relative strength rs rating ibd proprietary rating identify market leadership worst best score score show stock price performance last week compare other stock database history reveal top perform stock often have rs rating north begin biggest climb stock be build flat base entry see stock clear price heavy volume earning share growth decrease last quarter revenue rise company earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
117,ABBV,biogen biib gilead science gild sarepta therapeutic srpt build momentum biotech sphere beat wall street expectation third quarter analyst predict friday large cap biotech stock have be strong head third quarter report period credit suisse analyst alethia young write note client be focuse biogen spinraza regeneron pharmaceutical regn dupixent gilead hepatitis drug close bell stock market today investor business daily company biotech industry group dip collective group be rank first group track ibd hit month high earlier week momentum likely continue third quarter most large cap young say call biogen gilead sarepta possibly unite therapeutic uthr beat top line biogen be set report quarterly result early oct young call spinraza spinal muscular atrophy drug develop ionis pharmaceutical ion beat consensus view forecast sale cure sma report estimate patient have be dose spinraza third quarter be trial expand access program young write suggest be commercial patient period see patient spinraza third quarter ibd take biotech stock have trend north past several week healthy dose good news several key player head ibd industry theme closer look stock help send group month high do think point spinraza surprise downside patient switch much less expensive maintenance dose vs load dose say however think quarter spinraza very much still be launch phase top line young model biogen report sale adjust income share metric top consensus analyst poll zack investment research respectively multiple sclerosis franchise be likely face more headwind quarter quarter basis tecfidera total prescription fall third quarter price increase result young model tecfidera be consensus view young forecast gilead beating third quarter expectation strong sale drug treat hepatitis hiv help biotech shuck quarters hepatitis malaise still abbvie abbv new hepatitis regimen have impact gilead be set report late oct abbvie mavyret gain approve august treat genotype hepatitis patient typically dose week shorter duration rival drug be price roughly half price competitor wholesale basis reason young drop forecast gilead hepatitis drug sale factor risk abbvie remain bullish third quarter model total sale consensus view forecast be drive consensus top view sale harvoni sale epclusa hiv estimate be largely line consensus view model miss hiv drug truvada estimate consensus due entry generic outside bottom line young call adjust profit share vs consensus analyst poll zack young call regeneron sarepta narrowly beat wall street forecast benefit eczema drug dupixent duchenne muscular dystrophy drug exondys respectively regeneron be set report earning early nov deliver slight beat vs consensus sanofi sny partner eczema drug young model sale dupixent earlier view street dupixent weekly total prescription be average third quarter vs prior period dupixent end third quarter outstanding total prescription young write forecast quarter quarter growth drug third quarter model eylea approve treat number eye condition be trail consensus sarepta again surprise upside exondys second quarter sarepta crushed expectation third quarter young call exondys sale consensus further full year guidance sale be likely conservative young say note management sound upbeat launch trend related abbvie new hepatitis drug chip away gilead biotech break month high keep go regeneron patent be amgen think
118,ABBV,abbvie abbv newly launch hepatitis drug mavyret have already grab total new prescription further chip away gilead science gild struggle hepatitis franchise analyst say friday xas result wall street see gilead hepatitis drug sale decline vs year earlier period evercore analyst umer raffat write note client drop be sharper plunge sale be expect fall wholesale basis mavyret be price roughly half competitor month vs gilead epclusa sovaldi harvoni respectively dow stock merck mrk zepatier abbvie viekira pak cost respective monthly gilead contend discount rebate mavyret be price similarly harvoni differ treatment duration wide array hepatitis drug mavyret treat genotype have shortest treatment duration week most patient ibd take novartis be first finish line car drug do mean gilead plan acquire kite head ibd industry theme deeper dive segment contend likelihood further erosion hepatitis franchise gilead be pivot cellular therapy acquisition kite pharma kite kite doesn have approve drug merger be announce day rival drug novartis nvs gain approval novartis drug be approve treat form acute lymphoblastic leukemia patient age analyst now expect similar drug kite treatment aggressive form hodgkin lymphoma grab approval later year bluebird bio blue juno therapeutic juno be partner celgene celg work similar treatment know car therapy create drug immune cell be extract patient reprogram fight cancer cell be reintroduce related abbvie gauntlet squeeze gilead drug hepatitis cure cancer look bloodwhy biotech catch rally add september be make break month partnership bit dust gilead kite competition
119,ABBV,novartis nvs have relative strength rs rating upgrade friday welcome improvement still higher score look exclusive rating investor business daily measure market leadership worst best score grade show stock price behavior last week hold other stock database decade market research reveal best stock tend have rs rating north early stage move see novartis continue show renew price strength hit benchmark stock be build flat base buy point see stock clear price volume least higher normal company top line growth fall last quarter earning share grow prior report novartis earn rank peer medical ethical drug industry group abbvie abbv grifol grfs nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
120,ABBV,regeneron pharmaceutical regn topple thursday rival abbvie abbv reveal strong result phase trial eczema drug chip away regeneron sanofi sny potential blockbuster dupixent afternoon trading stock market today regeneron sank sanofi lose fraction abbvie pop soar time close high abbvie drug know upadacitinib achieve main goal improve eczema area severity vs placebo week half patient achieve clear almost clear skin milligram once daily dose be excited result study show upadacitinib have potential be important treatment option patient atopic dermatitis say michael severino abbvie chief scientific officer statement upadacitinib be set go phase testing phase study drug reduce itch first week improve skin condition first week common side effect include respiratory tract infection eczema acne ibd take abbvie paid acquire become major blockbuster arthritis drug much do gamble pay head income investor more make dividend leader winner approve abbvie drug chip away sale dupixent injection treat eczema patient condition doesn improve topical cream dupixent bring second quarter sale sale be record regeneron profit loss be split sanofi regeneron sanofi be also phase testing dupixent asthma phase trial be look dupixent treatment chronic allergic immune condition white blood cell build line esophagus related dow member bayer face battle augment fail late stage trial so benefit generic drug stock catch break mylan crash
121,ABBV,galapago glpg stock pop monday vertex pharmaceutical vrtx detriment figured piece triple combination puzzle treat cystic fibrosis analyst say galapago still have long road truly challenge vertex treat cystic fibrosis accord leerink analyst geoffrey porge vertex already have potential triple pill combo midstage testing galapago just have potential piece triple late sunday galapago say drug know glpg be safe tolerable group patient cystic fibrosis drug also help reduce chloride patient sweat test cystic fibrosis increase patient ability forcefully expel air lung function result be inferior vertex result tezacaftor ivacaftor fail phase trial porge say sweat chloride glpg be inferior vertex tezacaftor alone phase trial same patient population be vast amount work front galapago potential partner abbvie abbv challenge vertex category say result do not yet compel cystic fibrosis market ibd take vertex start hepatitis effort be dampen gilead science massive hepatitis franchise so moved cystic fibrosis see transition firm crisis visit new america porge currently forecast galapago have chance success cystic fibrosis maintain outperform rating price target vertex vertex be plan use drug tezacaftor ivacaftor backbone triple close bell stock market today galapago lift end trading day vertex dip finish related roche cancer trial be kick tooth dow stock merckvertex pop analyst question rival have viable drug biotech firm top third quarter view only pop
122,ABBV,horizon pharma hznp see welcome improvement relative strength rs rating wednesday upgrade exclusive rating investor business daily measure price action worst best score grade show stock price movement trail week stack other stock database decade market research reveal top perform stock tend have rs rating least launch largest climb see horizon pharma continue show renew price strength clear threshold look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock go establish enter buy zone heavy trade earning growth fall company most recently report quarter revenue grow previous report company hold rank peer medical ethical drug industry group abbvie abbv be top rank stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
123,ABBV,wall street analyst downgrade megacap tech leader apple aapl didn ruffle feather institutional investor even major stock index cool mildly tuesday apple still hover only newest buy point flat base apple be also still extend prior buy point stem week cup handle apple be also more break first stage cup handle early january cup handle be part long bottom base pattern most bullish chart pattern help investor time new buy correctly stock have make devastate correction nomura instinet cut rating apple neutral concern iphone sale be already incorporate stock price jeffrey kvall also note historically full multiple meanwhile bitcoin investment trust gbtc take well need break show wild action bitcoin tracking exchange trade fund careen new time high intraday low intraday range bitcoin investment be definitely not faint heart yet embrace time proven chart pattern have show greatest stock market winner go back late century bitcoin investment be act just expect bolt deep yet well form cup handle gain nov have now exceed buy point be derive add cent highest price week handle et nasdaq composite rebound bit cut loss lead equity index be also still week follow monday boost investor be show unwillingness dump stock house representative pass major tax reform package tuesday senate be expect do same early tuesday evening send white house president trump signature christmas ease almost finance reit utility solar automaker stock lead downside volume be run lower vs same time monday main exchange dow jone industrial average be nearly just more component addition apple point more visa goldman sachs gs goldman have gain nearly clear buy point month saucer handle notice daily chart goldman break past proper entry nov gain volume expand higher day average good sign street expect giant fix income commodity trading merger acquisition increase profit share microsoft msft tech component dow drop light trade be mildly buy point new flat base cloud compute business software xbox giant initiate slow yet steady advance late july past buy point month flat base part longer saucer pattern note investor corner column saucer pattern require patience part investor proper new buy point finally emerge microsoft hold solid composite rating ibd stock checkup apple sport composite support part stronger ep rating microsoft apple scale microsoft ep rating mean apple be superior company ibd database term term quarterly long term annual profit growth back bitcoin investment trust etf have simply sky-rocket surge interest alternative currency reason bitcoin perhaps have not yet reach bubble condition be fact cboe cme group have only recently begin trading future respective exchange total value bitcoin be trade globally be say be only fraction total value trading bond stock commodity forex third reason bitcoin see future growth be professional money manager be show increase appetite bitcoin com news report hedge fund manager bill miller former star legg mason value trust mutual fund currently have half asset bitcoin biotech share have not have merry fourth quarter biogen biib stand large cap firm potentially break stock get hammer so so result earning share revenue just sell be limit biogen notch week peak then stock have be form flat base also stretch pattern biogen earning have nearly quintuple share last year however growth be expect slow stiff competition treatment multiple sclerosis other chronic medical condition analyst survey thomson reuter see earning rise just share year ibd big cap current list showcase just medical stock abbvie abbv other financial market investor dump government bond follow federal reserve third hike short term interest rate year dec fed fund rate rise target range december utility stock fall en masse dow utility average sink dow transport edge higher bump crude oil price wti term future rise barrel related identify major stock market top yes here easy wayalso stock market today bitcoin etf reach hot growth stock one ibd be form new basis stock buy zone
124,ABBV,franchise be safe large cap biotechs be feel pressure food drug administration speed approval rival brand generic medicine analyst say monday theme be continuation leerink analyst geoffrey porge say note client record number drug approval large cap sector fall favor investor name more punish concentrated product portfolio loom brand generic competitor say head management confidence be low revenue trajectory high profile product face slowdown courtesy payer competitive pressure porge doesn see uncertainty lift possibly not ever competitive pressure slug like celgene celg gilead science gild celgene be feel pain inflammation unit mount competition eli lilly lly novartis nvs gilead see rival hepatitis drug sale abbvie abbv early next year porge expect guidance lion share large cap biotechs be conservative most stock move guidance come alexion pharmaceutical alxn gilead predict alexion be work drug dub alxn treat pair rare blood disease also undergo restructure meanwhile gilead hepatitis franchise again come microscope even attempt pivot further hiv drug bictegravir believe be share value gilead stock hepatitis stock price move hepatitis revenue guidance meaningfully differ consensus estimate porge say ibd take small cap biotechs perform well third quarter large cap suffer mount competitive concern see translate stock price visit industry snapshot note abbvie plan hepatitis product be likely hurt gilead stock abbvie recently launch mavyret treat genotype hepatitis abbvie likely provide guidance fourth quarter call ahead gilead porge expect sale outlook celgene alexion vertex pharmaceutical vrtx gilead amgen amgn abbvie miss analyst estimate biogen biib provide outlook encompass analyst view say later year large cap universe face political pressure porge predict midyear congressional midterm election be underway campaign be likely renew focus pharmaceutical company pricing policy say continue favor stock company be structural demand growth story product protected commercial scientific clinical legal barrier entry top pick be vertex alexion leerink analyst michael schmidt peg clovis oncology clvs puma biotechnology pbyi top pick small midsize biotechs focuse treat cancer group stock have outperformed broader biotech market thus far schmidt write note client dynamic be set continue favorable regulatory environment large cap expand portfolio acquisition incyte incy seattle generic sgen exelixis exel clovis agio pharmaceutical agio puma array biopharma arry be set launch key product count group set unveil pivotal trial result pending regulatory decision total firm emerge technology remain interest car therapy train patient immune cell fight cancer precision oncology have strong success immuno oncology combination cancer vaccine certain antibody have only be modest think next generation antibody drug conjugate be re emerge area interest represent clinically validate category significant room upside schmidt say antibody drug conjugate be antibody link cell kill agent antibody bound specific mark surface cancer cell immunogen imgn mersana therapeutic mrsn seattle be work area latter furthest say related big pharma biotech company be gird pricing knife fight teva restructure plan case be here do generic drug maker face pricing issue other pharmas don
125,ABBV,wednesday bristol myer squibb bmy receive positive adjustment relative strength rs rating ibd proprietary rating measure market leadership worst best score rating show stock price movement last week hold other stock database decade market research show stock go make biggest gain often have better rs rating begin largest run see bristol myer squibb continue rebound clear threshold stock be not proper buy point right now see be able form break proper consolidation bristol myer squibb report ep growth most recent report sale growth come bristol myer squibb earn rank peer medical ethical drug industry group abbvie abbv grifol grfs nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
126,ABBV,major stock index be mixed mostly unchanged afternoon trading thursday money flow bond again year treasury yield be lower basis point yield plunge basis point tuesday take longer term support level economic news weekly jobless claim jump last week well consensus estimate much jump be due hurricane harvey meanwhile consumer confidence hit month high september accord latest read ibd tipp economic optimism index financial lag badly again financial select sector spdr xlf slump nearly give day move average longer term support level stock market today share gopro gpro surge lift outlook current quarter early august maker adventure camera raise sale guidance gopro thursday say sale be high end forecast rh rh vault report solid earning thank fewer product promotion shift membership model makeover distribution network stock be not picture technical health head earning recently find support day move average pullback share abbvie abbv jump positive midstage result trial eczema drug upadacitinib good news abbvie be bad new regeneron regn fall nearly regeneron make compete eczema treatment be approve fda march share abbvie be now extend flat base entry ibd china stock do heavy lift again new oriental education edu surge weibo wb yy yy sina sina show gain range related ibd tipp economic optimism index finally snap year slumpbreaking rh big talk carpe say ceo trump debt deal democrat sink tax cut hope goldman sachs
127,ABBV,build watch list look stock higher rs rating jazz pharmaceutical jazz just clear benchmark upgrade ibd unique rating track share price performance worst best score score show stock price movement trail week hold other stock database decade market research show market biggest winner typically have rs rating early stage move stock be work flat base buy point see clear price volume least higher normal jazz pharmaceutical show ep growth most recent report sale growth come company earn rank peer medical ethical drug industry group abbvie abbv nordisk nvo zoetis zts be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
128,ABBV,novartis nvs see positive improvement relative strength rs rating friday increase ibd proprietary rating measure price movement worst best score grade show stock price movement trail week stack other stock database history show best stock typically have better rs rating launch biggest price move see novartis continue rebound hit benchmark stock be work flat base buy point see stock break volume least higher normal earning growth increase last quarter sale fall company earn rank peer medical ethical drug industry group abbvie abbv nordisk nvo zoetis zts be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
129,ABBV,warning big cap have lose advantage late july big cap be year date tie nasdaq pop be dow jone industrial average small cap be only year xsince then market tilt have change
130,ABBV,horizon pharma hznp have relative strength rs rating upgrade friday proprietary rating identify technical performance used worst best score identify stock price action last week match other stock year market history reveal best stock tend have higher rs rating early stage move look best stock buy watch start herewhile stock be not proper entry right now see go form break proper chart pattern earning growth decrease prior quarter revenue grow previous report company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
131,ABBV,horizon pharma hznp see positive improvement relative strength rs rating thursday increase ibd proprietary rating identify market leadership worst best score score show stock price movement last week stack other stock database year market history reveal market biggest winner often have higher rs rating early stage move see horizon pharma continue show renew price strength clear threshold look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock go form base break earning growth fall most recent quarter sale moved higher company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts nordisk nvo be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
132,ABBV,invest disruptor advice wall street giant biotech company incumbent big pharma be brace get crushed more innovative cheaper new drug start continue analyst say generic drug approval be rise interesting new medicine be start take market share legacy maker medication consumer use frequently include big pharma biotech company blockbuster drug represent estimate annual sale be set lose patent protection next decade analyst say disruption come generic drug innovative new biologic alternative come market be brutal jmp security analyst mike king tell investor business daily be knife fight market cholesterol lower drug king expect amgen amgn regeneron pharmaceutical regn sanofi sny feel heat like esperion therapeutic espr medicine co mdco alnylam pharmaceutical alny meanwhile inflammatory treatment celgene celg otezla gain blockbuster status miss sale forecast wide cut third quarter analyst say newly approve drug treat same condition eli lilly lly novartis nvs be take market share gilead science gild be still feel pain mature hepatitis drug unit europe rapid pace gilead hepatitis sale decline be expect slow somewhat newer medicine abbvie abbv mavyret be likely swipe sale big pharma isn get help regulator food drug administration head scott gottlieb continue increase approval copycat drug stoke competition brand generic drug face new rival firm try undercut price big pharma company pfizer pfe be forefront feel sting generic take sale earlier month teva pharmaceutical teva be allow launch generic copy blockbuster erectile dysfunction drug viagra generic drug tend be cheaper brand counterpart viagra be pricey drug tablet accord accessrx pfizer lose exclusivity viagra canada europe worldwide sale fall today generic europe have slash price drug contain same active ingredient viagra generic version viagra cost third price canada viagra price also fall trend repeat generic market teva meanwhile be struggle debt end third quarter thursday teva announce plan cut workforce more quarter close several manufacturing facility suspend dividend ordinary share firm be also plan review generic drug portfolio most specifically change price discontinue product ibd take see giant biotechs fared vs smaller player third quarter visit industry snapshot hint quarter be classify alarm large cap biotech be trouble see more competition traditional moneymaker board spending prescription drug increase just person accord report express script esrx rise represent drop growth rate trend be likely continue fbb capital partner analyst mike bailey tell ibd credit gottlieb decline generic price gottlieb be run fda business allow cycle more approval more competition lower price center medicare medicaid service use tool influence pricing unlikely president trump use executive power enact sweeping drug pricing reform such allow medicare negotiate price enact pricing control bailey say wouldn expect major change trump administration pricing say think mechanically politically difficult get pricing law system politically more acceptable just get more generic drug approval jmp king count drug treat rheumatoid arthritis psoriatic arthritis crowd area drug class cost average prescription benefit increase utilization unit cost accord express script third quarter thing begin look dour like celgene miss expectation inflammation drug otezla lag be even sharper analyst suggest celgene be force take price concession celgene also cut guidance terminate trial drug treat crohn disease condition result chronic inflammation digestive tract now see inflammation immunology drug bring combine outlook issue biotech company big pharma need get realistic pricing competitive arena king say same be say company make treatment hepatitis multiple sclerosis high cholesterol be highly saturate market latter point expect price drug know pcsk inhibitor repatha amgen praluent regeneron sanofi be microscope drug lower bad ldl cholesterol blood evidence show also have benefit cardiovascular outcome repatha be list year praluent cost rival be close medicine co alnylam be work cholesterol drug know inclisiran meanwhile analyst expect bempedoic acid esperion be cheaper big pharma biotech company be probably go get arm twisted lot king say pricing umbrella have create opportunity new company come scale market share be careful own incumbent invest disruptor other area be seemingly immune pricing pressure analyst say price multiple sclerosis drug rise average continue trend fbb bailey say price increase have be so egregious house democrat launch investigation august note many drug carry price tag north year investigation be launch rep elijah cumming peter welch center bayer bayry biogen biib emd sereno novartis roche rhhby sanofi teva pharmaceutical biotech company teva milligram dose copaxone have increase most rise approval annual price today accord national multiple sclerosis society novartis gilenya approve be highest price investigation be year too late say more difficult push price control specialty market multiple sclerosis be massive market now stakeholder view specialty market rare disease innovative cancer therapy also seem immune pricing control analyst say example earlier year novartis gilead acquisition kite pharma gain approval car drug know kymriah yescarta respectively car drug be develop used patient own immune system cell be trained seek destroy cancer cell kymriah go year yescarta be list ark invest analyst manisha samy write recent post gene therapy be begin cure cancer come price cause sticker stock say say compare traditional therapy suppress do not cure cancer cost benefit analysis gene therapy be compelling pricing shock tend tamp excitement really compelling drug bailey say prime example be biogen ionis pharmaceutical ion spinraza first spinal muscular atrophy drug approve cost first year subsequent year sentiment biotech company share be already say so drug pricing concern shouldn be big stock killer past biotech stock go quickly get new drug person be excited lot time someone throw grenade drug pricing bailey say sentiment be already even concern drug pricing see little less downside ibd company biotech industry group be now rank group track have fall first just month share collectively near year high october have shucked almost point same time amgen celgene biggest biotechs have see share price dive respectively regeneron have take hit gilead have tumble meanwhile alnylam esperion look likely rival psck inhibitor drugmaker amgen regeneron have lift respectively abbvie recently launch rival gilead hepatitis franchise be novartis lilly be compete celgene treat inflammatory condition have see share retreat smaller degree respectively share price be match dip ibd company ethical drug industry group generic drug stock rank group have actually broadly rise mid october respective dip teva mylan myl biggest name related teva restructure plan case be here do generic drug maker face pricing issue other pharmas don ttop biotech company innovation earn recognition new award
133,ABBV,drugmaker pfizer pfe be approach potential buy point tuesday most recent quarter dow stock year year earning growth come first double digit gain revenue rise vs year period snap quarter streak decline sale company continue see weakness
134,ABBV,vertex pharmaceutical vrtx galapago glpg stock diverged friday analyst suggest galapago have interesting molecular formula not have viable cystic fibrosis drug hand xby close bell stock market today vertex pop finish galapago fall close biotechs make presentation friday north american cystic fibrosis conference indianapoli galapago have well research molecule have intriguing activity variety laboratory system molecular model cystic fibrosis so far be difficult know molecule actually make viable drug leerink analyst geoffrey porge say note client biotechs be work triple pill combination treat genetic lung condition analyst mostly estimate galapago be several year vertex already have potential triple pill combination midstage testing catch galapago appear be compress attempt skip many traditional aspect clinical testing have raise question investor porge say give lack progress combination don foresee sort rapid development timeline galapago combination be propose plan europe say ibd take point vertex look be go go bust work pivot cystic fibrosis hepatitis drug tank visit new america more vertex transition next presentation galapago indicated plan introduce molecule single drug add study first then advance novel triple combination trial very rapidly porge say goal be seemingly avoid traditional phase trial food drug administration hasn endorse strategy mean current soon start trial galapago combination be conduct only europe say still galapago be aim advance combination phase testing abbvie abbv acquire right galapago cystic fibrosis combination program term deal abbvie have fund execute phase trial abbvie likely prefer more traditional complete path expensive phase testing say abbvie have decide opt deal abbvie discontinue delay decision go forward be view negatively galapago positively vertex say such decision doesn seem imminent be fortunate galapago make challenge time galapago abbvie opt doesn advance combination porge have outperform rating price target vertex stock related biotech firm top third quarter view only popsionis rebound beating alnylam drug application exelixis juno stock rocket crush view
135,ABBV,growth slow again abbvie abbv key humira prod share dip early friday abbvie otherwise strong second quarter sale earning beat xon stock market today abbvie sank share top buy point june flat base stock extend point have retreat gain buy point total sale grow beating consensus adjust income share be year year top analyst view cent humira pricing commentary spook investor evercore analyst umer raffat tell investor business daily second quarter end june humira grow vs year earlier quarter humira sale grow elsewhere world humira grow just humira sale growth decelerate third straight quarter sale still top expectation jpmorgan analyst chris schott write note client abbvie see healthy humira outlook major access change say chief executive richard gonzalez say conference call analyst abbvie continue be careful conservative pricing accord reuter negotiation insurer cover humira have already wrapped humira be face biosimilar competition outside analyst expect hit peak sale face sale erosion judge tossed key patent staving competition ibd take biotechs be hot streak recently merger acquisition send higher head ibd industry theme look be sale buy investor be count imbruvica cancer drug be abbvie next biggest growth driver quarter imbruvica bring tack growth outside imbruvica sale rise sale grow smaller drug face double digit decline vs year earlier period parkinson drug call duodopa grow vs year earlier period be also smallest bring abbvie also confirm full year adjust earning share outlook be abbvie third consecutive year double digit earning growth jpmorgan schott say look pivotal study abbvie drug know abv be be look treatment rheumatoid arthritis crohn disease ulcerative colitis atopic dermatitis psoriatic arthritis related gilead hepatitis franchise topple again share beatbiotech fever cool player dip longer term beat stock dife drug failure more report
136,ABBV,jazz pharmaceutical jazz have relative strength rs rating upgrade wednesday welcome improvement still shy higher score prefer see exclusive rating investor business daily measure share price action worst best score score show stock price behavior last week stack other stock database history show stock go make biggest gain typically have higher rs rating early stage move see jazz pharmaceutical continue show renew price strength clear threshold jazz pharmaceutical be work flat base buy point see break heavy volume jazz pharmaceutical post ep growth latest quarterly report sale rise company earn rank peer medical ethical drug industry group nordisk nvo abbvie abbv phibro animal health pahc be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
137,ABBV,celgene celg abbvie abbv be likely be biggest beneficiary inflammatory bowel disease market be expand rapid clip analyst say wednesday biologic market disease generate sale leerink analyst geoffrey porge write note client abbvie humira johnson johnson jnj remicade tnf drug used fight inflammation dominate market today believe market be likely continue exceed recent growth rate significant share value likely accrue celgene offset value available also abbvie inevitable erosion abbvie dominant humira franchise say new class inflammatory bowel disease drug be arise like celgene roche rhhby galapago gplg gilead science gild abbvie be look make mark drug now phase trial crohn disease ulcerative colitis common form disease earlier trial benefit clinical datum back be have difficulty recruit patient porge say many trial also exclude sicker patient include patient ve stop respond current treatment ibd take earlier year abbvie say expect humira hit peak international sale face erosion head ibd technology page breakdown abbvie see biggest drug go plan offset competition tnfs humira remicade be first truly disease modify treatment approach many patient don respond stop respond tnf drug porge say study suggest tnf patient don respond lose response year estimate show be patient inflammatory bowel disease have crohn disease have ulcerative colitis patient number europe be higher provide large opportunity drug base new mechanism write related perrigo beat raise lift generic drug buck teva mylan trendcould small biotech break tie eli lilly abbvie topple humira sale brake third straight quarter
138,ABBV,late stage failure regeneron pharmaceutical regn bolster biotech rival abbvie abbv treat infant infected serious lung disease analyst say late monday xregeneron drug know suptavumab be be develop treatment respiratory syncytial virus common virus lead mild coldlike symptom adult older child be serious infant suptavumab prove efficient subgroup preterm infant test phase trial didn meet goal study regeneron say news release regeneron discontinue development drug find company have decide discontinue development program presumably base limit opportunity such subgroup offer cost conduct pivotal trial leerink analyst geoffrey porge say regeneron failure be abbvie benefit porge say drug be meant be more convenient option abbvie synagis be give patient virus season start month season suptavumab be test milligram single dose dose week apart ibd take ibd company biotech industry group be rank sixth group spiked higher monday biotech fever have chill sector hit month peak late july head ibd industry theme closer look affect sector porge cut revenue forecast regeneron eliminate potential upside catalyst regeneron year cut price target keep outperform rating note strength dupixent eczema drug remain positive regeneron stock base expectation long term dupixent trajectory positive upcoming catalyst dupixent asthma datum supplemental biologic license application say dupixent be approve eczema treatment march be develop regeneron sanofi sny agreement set end year analyst be bullish dupixent be also be look asthma treatment remove suptavumab forecast porge say sale expectation be still ahead consensus porge revenue forecast be north consensus respectively tuesday close regeneron have slip abbvie lose stock market today related generic drug stock catch break mylan crash alnylam report lag sale wider expect lossesthe surprising reason regeneron topple beat raise
139,ABBV,key index fund be moderately higher tuesday rise new record high xspdr dow jone industrial average dium spdr spy gain powershare qqq trust qqq add small cap lead upside ishare russell iwm oil financial homebuilder lead upside stock market today utility real estate biotech lag spdr oil gas exploration production xop surge reclaim day move average vaneck vector oil service oih rise also retake day line west texas intermediate crude price be barrel spdr regional banking kre spdr bank kbe gain goldman sachs gs jump announce plan boost annual revenue technology select sector spdr xlk have apple aapl top hold be flirt flat line apple reversed higher much anticipate product launch event get way iphone maker share remain buy range flat base entry market pullback set potential buy opportunity day week line rebound yield base such dividend fund be territory give stock market solid bounce monday session quality dividend growth dgrw clear flat base buy point monday close time high remain buy range entry share rise april flat base january fund track index same name be comprise company dividend index rank highest term combine growth quality factor factor include long term earning growth expectation year historical average return equity return asset information technology health care account biggest sector weighting asset industrial weigh nearly next largest sector be consumer discretionary consumer staple respective top holding include johnson johnson jnj apple microsoft msft mcdonald mcd fund have outperformed year date vs gain accord morningstar direct also ahead past year dgrw annualize yield be line expense ratio be ibd take apple be big hold many big cap equity fund be worthy watch list way find be consult ibd stock checkup tell stock rank industry group proshare dividend arisocrat nobl close just shy buy point also flat base monday fund be featured july etf column seek support day move average advanced bounce pull back broader market form flat base fund track dividend aristocrat index be make company have increase dividend year consecutive year consumer staple industrial health care be biggest sector weight respectively consumer discretionary make abbvie abbv brown forman bfb chevron cvx target tgt be top holding nobl lag ytd gain slightly lead benchmark index year average annual return vs etf bear expense ratio monday pick spdr biotech xbi first trust nyse arca biotechnology index fbt edge higher monday remain squarely buy zone respective entry related hot biotech play reach be apple still buy range dow lead thank stock idea tap emerge marketsnew chance buy hot chip stock nvidia be come
140,ABBV,friday nordisk nvo earn positive adjustment relative strength rs rating proprietary rating identify market leadership show stock price movement last week compare other stock database history reveal stock go make biggest gain typically have better rs rating begin biggest price move nordisk be buy range climb buy point flat base proper buy range be initial entry once stock move range best set buy opportunity earning growth decrease most recent report revenue gain moved higher nordisk hold rank peer medical ethical drug industry group phibro animal health pahc abbvie abbv be also group highest rate stock related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
141,ABBV,stock open higher monday weak read new york manufacturing activity april dow jone industrial average nasdaq climb be bank financial remain big piece week report news quarterly result due week bank america bac goldman sachs gs morgan stanley ms visa other bank mtb rolled monday early earning report rise more result easily top analyst first quarter expectation company repurchase share quarter raise annual dividend cent cent mcdonald mcd rise apple aapl dow well fargo upgrade mcdonald outperform market perform apple gain rbc capital raise price target maintain outperform rating pacific crest security raise concern difficulty fingerprint sensor apple upcoming iphone pfizer pfe gilead science gild abbvie abbv rise incyte incy drop more early action wilmingon del base biotech report friday food drug administration deny application incyte eli lilly lly rheumatoid arthritis treatment baricitinib estimate have put annual value drug incyte share plunge day move average heavy volume trigger sell signal eli lilly share drop also break day line remain buy point gilead gain abbvie jump pfizer be flat pfizer gilead abbvie compete market rheumatoid arthritic treatment
142,ABBV,china alibaba group hold baba climb open financial unit ant financial raise offer global payment service moneygram international mgi ant initial offer be top euronet worldwide eeft place offer march moneygram share rise open euronet share rise ibd leaderboard stock alibaba be buy range alternative handle buy point medical diagnostic product maker alere alr open waltham mass base company announce friday abbott laboratory have mutually dismiss compete lawsuit abbott have reduce takeover offer share deal now value alere be expect close third quarter abbott drop open manufacturing slow sharply new york region april send new york federal reserve empire state manufacturing survey read read be still positive march far economist expectation well level post nearly new order retreat unfilled order slow delivery time lengthen shipment edge gauge employment hour work remain firm national association home builder release builder confidence survey et gauge be april internationally readout global stock market today be spotty due holiday schedule japan tokyo nikkei post gain monday hold back dollar weaken yen concern north korea china shanghai composite end top regulator pledge resolute crackdown risky market action hong kong stock exchange remain close holiday europe exchange london paris frankfurt remain close holiday related big week dow stock earning investing action planinvestor unfazed north korea netflix unite continental earning tap
143,ABBV,be just year formula seem right biogen biib fourth largest company industry mix biotechnology megamerger biogen multiple sclerosis franchise lineup drug include tecfidera tysabri be grow tecfidera biogen most important drug bring further hemophilia sale small grow just brand name drug eloctate alprolix spinraza spinal muscular atrophy drug grab fda approval just day christmas plot thicken biogen chief executive george scango resign july leave company susceptible takeout like merck mrk allergan agn eli lilly lly pfizer pfe takeout rumor abound biogen stock end make cheaper asset buy thought last year be really time happen leerink analyst geoffrey porge say biogen offer last year be relatively stable ms business be still grow robust cash flow scheme opportunity spinraza hemophilia franchise so acquirer say get fast forward today picture be entirely different biogen be see increase competition ms market payer be balk spinraza price company have already take hemophilia drug equation now only wall street see biogen potential takeout candidate accord mizuho survey porge say biogen probably have see deal roll ever think have become significantly less likely porge say so happened incredibly successful multiple sclerosis include launch zinbryta abbvie abbv biogen ms unit be face loom competition like roche rhhby celgene celg porge tell investor business daily note client april porge call roche ocrevus game changer ocrevus be approve late march treat relapse remit primary progressive form ms separate pack be only approve relapse remit form ms physician patient community have be eagerly await ocrevus launch porge say drug high efficacy reasonable safety profile convenient month dose schedule be major factor drug positive reception spell trouble biogen tecfidera have comprise total product sale well ms unit biogen be actually partner roche ocrevus royalty win be enough offset erosion own ms franchise analyst say porge expect ocrevus get primary progressive ms market year relapse remit ms market porge see erosion tysabri erosion tecfidera novartis nvs gilenya sale meanwhile celgene be work ms drug call ozanimod phase testing function ozanimod be closest novartis gilenya also rival tecfidera sanofi sny aubagio tecfidera gilenya aubagio respectively lead ms market term sale celgene want buy sale force have something overnight help sell ozanimod biogen be company porge tell ibd biogen likely suffer erosion roche competition ms look less probable silver line biogen win patent interference case forward pharma fwp tecfidera be settlement fee forward stock topple decision now lose major royalty biogen spinraza have different set trouble develop ionis pharmaceutical ion spinraza be first only drug approve rare neurological disorder cause muscle weakness wasting infant child wall street largely thought spinraza slam dunk have profound efficacy august study infant child drug be so effective biogen ionis end study early ionis chief executive stanley crooke tell ibd december spinraza be approve dec fairly broad label approve use child adult spinal muscular atrophy remain only drug approve disease crooke call catastrophic drug thing be rapidly adopt widely reimburse porge say have happened be appear be good fortune label have turn liability payer become concern too many patient start drug so restrict access mizuho analyst salim sy call largely spinraza story biogen be set report first quarter earning april be particularly tell follow launch spinraza earlier year analyst say payer be push back hard reimbursement drug insurer anthem antm humana hum be only reimburse patient spinraza most severe form disease type unitedhealth group unh have broader policy cover type patient be spinraza cost treatment first year subsequent year make pricey drug consensus be project first quarter spinraza sale sy say porge lower expectation spinraza sale result first quarter be especially tell tell ibd north patient drug be pretty good long re see continue start then biogen hemophilia drug lineup february biogen spun hemophilia franchise bioverativ bivv then bioverativ share be be great bioverativ company consider biogen takeover think again unit porge say ibd take bioverativ isn standard biotech startup head new america find bioverativ have yet announce quarterly result have only be public early february company be set release first quarter earning result last full quarter biogen hemophilia unit bring year year now porge say be smart biogen also spin multiple sclerosis unit turn focus alzheimer alzheimer biogen be follow eli lilly merck have notable failure december february biogen alzheimer play be strongest sector analyst say march rbc analyst michael yee tell ibd pfizer merck be likeliest player make bid biogen be interested more brand drug particularly alzheimer pipeline biogen be work class alzheimer drug work remove plaque buildup brain associate alzheimer call bace inhibitor eisai bace inhibitor aim prevent plaque buildup porge say biogen likely have see renew takeover interest biogen be expect release result phase trial aducanumab bace inhibitor elenbecestat be also phase trial result expect september eli lilly solanezumab work theory remove plaque buildup call beta amyloid brain merck verubecestat be bace inhibitor fail be only handful potential alzheimer drug development now meanwhile axovant science axon be work different theory treatment doesn involve beta amyloid expect have phase datum drug intepirdine later year too change alzheimer landscape potentially further dent biogen chance merger still biogen board place high premium alzheimer pipeline ever come acquisition table porge say everything else have fail development cost aducanumab elenbecestat have head billion dollar porge say re willing take risk alzheimer still make sense acquisition ve hear person industry be re struggle bridge gap say board want be paid alzheimer go work related roche game changer drug chip away biogen novartisbiogen dife takeover buzz fade drug hit small cap biotech take gilead celgene biogen alzheimer
144,ABBV,abbvie abbv stock hit month high friday upgrade goldman sachs estimate growth asset bring sale next year stock market today abbvie share rise earlier rise much touch high last time abbvie share eclipse be august abbvie stock outperformed kempharm kmph nexvet nvet smaller firm now trade drugmaker friday goldman sachs analyst jami rubin urge abbvie separate humira growth unit humira bring lion share abbvie sale sale humira account abbvie total revenue believe abbvie benefit unlock trap value separate business segment report purpose return cash shareholder recur humira dividend buyback investor growth product mature say rubin have buy rating abbvie stock moved conviction list also boost price target abbvie stock rubin estimate humira be worth share abbvie stock price growth asset oncology immunology woman health be worth share today share debt write research report ibd take biotechs biogen hemophilia spinoff bioverativ be look sale year ambitious month market maybe not head new america closer look bioverativ next year rubin expect asset grow sale meantime humira act cash flow generator repatriation cash overseas make access funding easier abbvie doesn appear likely see merger say recent comment management lack interest large deal suggest alternative used cash be consider say didn offer suggestion use abbvie have extra cash related gilead be pay price actually cure diseaseabbvie stronger bet gilead amgen least reach dividend leader list hit buy point
145,ABBV,acadium pharmaceutical acad intercept pharmaceutical icpt lexicon pharmaceutical lxrx be cusp be acquire analyst say friday examine historical merger pattern big pharma small midsize biotech company approve drug be attractive acquisition target due reduce development regulatory risk needham analyst alan carr write research report trio just grab first fda approval acadium nuplazid be approve april psychosis associate parkinson ocaliva intercept be approve liver disease lexicon xermelo get approval february carcinoid syndrome neurocrine bioscience nbix look likely get approval next month ingrezza drug aim treat involuntary movement associate long term use certain medicine disorder be know dyskinesia be number earlier stage company buy last year doesn tend be trend third small midsize company approval have be acquire carr write however acquire company have previously launch drug somewhere interpret risk mitigation acquire company say be acquire shortly first fda approval nearly year ibd take anyone catch beauty giant medical aesthetic least company be try read ibd industry snapshot biotechs half company acquire january more upfront cash have least approve market drug have phase datum drug fda review time announcement drugmaker target oncology infectious disease be ripest takeover then infection oncology have be acquire most rare disease company remain independent today allergan agn japanese pharmaceutical firm be most likely acquire earlier stage firm carr say overall allergan astella pharma daiichi sankyo sumitomo dainippon pharma collectively acquire company january today europe abbvie abbv merck mrk novartis nvs have acquire earlier stage company january related do beauty giant just solve acne challenge lilly merck allergan top analyst view pharma
146,ABBV,valeant pharmaceutical vrx have relative strength rs rating upgrade tuesday ibd proprietary rs rating track market leadership show stock price movement last week compare other stock database history reveal market biggest winner typically have rs rating begin new climb see ibd help make more money stocksvaleant pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average valeant pharmaceutical report negative growth sale earning last quarter company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
147,ABBV,re look dividend stock invest source steady income so much emphasis put fundamental lot want steady income want own best dividend stock company offer market yield solid earning stock price track record boot case ibd income investor column help day investor com week ibd weekly column feature more company meet criterium have potential rise price put stock more growth income camp vs simply income be important pay attention earning yield other factor company hit tough patch profit falter hurt ability keep make payout find income take big riskstop dividend fund manager expect growth growth stock yield solid income toowhat do trump tax cut mean dividend general electric ge provide recent example share dive session diversify giant halved prize dividend lower outlook dividend cut be shock investor ve be rely income yield fall stock fall lowest level nearly year predividend cut annual payout cent share stock decline year offset payout earn past year ge earning have be volatile past few year fall sharply increase last year be expect fall year steady earning track record be key be dividend growth rate most income investor likely prefer see company raise dividend rate instead reduce keep same addition daily column ll find accompany screen online income investor page weekly edition dividend utility reit leader offer other stock meet same criterium company featured column mini chart list provide further detail stock mini chart appear only print edition access dividend screen investor com go home page click stock list tab broadest screen be dividend leader feature name such blackstone group bx paid total share past quarters share stock trading amount annualize dividend yield company sport dividend growth rate share be year line yield just blackstone be not grandfather dividend stock few other standout name list term ytd price gain be cisco system csco toronto dominion bank td abbvie abbv steady eddie name know steady earning track record dependable dividend coca cola ko chevron cvx often make cut too stock be dividend aristocrat company have increase dividend least past consecutive year utility leader show utility stock be know defensive nature tend hold well growth stock be weaken reliable revenue stream also enable most utility pay steady dividend ibd take cisco have outperformed broader market year do rank industry group find now ibd stock checkup utility real estate investment trust reit offer relative safe haven volatile market reit be structure way allow avoid pay corporate taxe pass bulk earning shareholder do form cash dividend many income investor favor reit not immune slow economy company enjoy fairy stable revenue stream rent payment lease proceed building other real estate asset own operate say keep mind utility reit also fall sharply stock market enter steep slide instance dow utility average drop bear market such severe correction important cut stock loss raise cash screen offer plenty dividend stock idea have meet certain fundamental technical criterium investor conduct further due diligence narrow choice subscriber marketsmith sister company ibd have access proprietary metric earning stability metric be calculate used company quarterly share earning past year result number run scale most stable least stable accompany table show stock dividend yield higher earning stability lower general number be consider stable further detail metric be derive read investor corner column related red bull air race champion winning stocksyielding higher power dividend fed rate hikescan big dividend retail stock have joyous holiday season
148,ABBV,dow component merck mrk slide friday keep tumble hour disappointing third quarter sale withdrawal application europe advanced lung cancer treatment xin hour trading stock market today merck fall additional share close bristol myer squibb bmy make rival drug opdivo lift late friday close abbvie abbv also miss third quarter sale expectation beat profit view advanced close bell late friday merck say decision withdraw european application be base datum study dub keynote cohort didn offer specific regard finding regimen be already approve first treatment advanced lung cancer merck be confident clinical datum rigorously conduct trial demonstrated specific improvement overall response rate progression free survival keytruda combination regimen compare chemotherapy alone firm say news release immuno oncology drug keytruda be combine chemotherapy treat lung cancer earlier day merck report adjust income share beating view analyst poll zack investment research share sale decline lag analyst model investor have zero keytruda merck give increasingly challenge hepatitis environment leerink analyst seamus fernandez say thursday gilead science gild report hepatitis drug sale fall third expect question focus almost entirely evolution keytruda uptake first treatment small cell lung cancer timing readout study call keynote confirm keytruda chemotherapy advanced lung cancer fernandez say note client still merck hepatitis be bright spot quarter sale zepatier post yearly sale gain growth only paled comparison cancer drug keytruda bring ibd take merck share begin form flat base buy point early march flat base be several way identify potential stock head investor corner more read pattern merck biggest product diabetes drug call januvia janumet decline other big decline include dip sale cholesterol drug zetia vytorin slide revenue human papillomavirus drug gardasil gardasil sale be reduce due change center disease control prevention gardasil vaccine cyberattack hit merck quarter revenue also take hit lose sale market cyberattack firm raise narrow full year guidance see adjust earning prior target analyst view also forecast sale earlier view consensus see abbvie quarter be just leerink analyst geoffrey porge say note client earn share exclude various item top consensus sale lag consensus grow year period more importantly abbvie outlined ambition current product late stage pipeline porge say firm see humira treat rheumatoid arthritis psoriatic arthritis spinal arthritis crohn disease plaque psoriasis approach sale prior target porge say year abbvie now expect adjust profit share touch low end consensus forecast abbvie guide adjust income share lag analyst view humira be abbvie biggest drug quarter sale grow be consensus porge say cancer drug imbruvica post yearly sale gain imbruvica sale beat analyst view porge say gilead struggle hepatitis drug franchise abbvie hepatitis unit beat analyst average sale decline follow approval august mavyret treat genotype hepatitis related celgene result call alarm alexion bristol mixedboston scientific dife abbott rivalry hit pacemaker biotech firm top third quarter view only pop
149,ABBV,valeant pharmaceutical vrx see positive improvement relative strength rs rating thursday rise ibd proprietary rs rating track market leadership used worst best score show stock price performance last week match other stock history reveal best stock tend have higher rs rating launch biggest climb look winning stock try simple routinevaleant pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average company report negative growth sale earning last quarter company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
150,ABBV,valeant pharmaceutical vrx see welcome improvement relative strength rs rating wednesday rise ibd proprietary rating measure share price action worst best score rating show stock price performance last week stack other stock database history reveal stock go make biggest gain tend have rs rating north begin biggest price move see valeant pharmaceutical continue show renew price strength clear threshold look best stock buy watch start herevaleant pharmaceutical have moved more past entry first stage cup handle meaning now proper buy range look stock offer new chance get week tight pullback day week line company post negative growth sale earning last quarter company earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
151,ABBV,monday valeant pharmaceutical vrx earn positive adjustment relative strength rs rating ibd unique rs rating measure market leadership show stock price movement last week measure other stock database history show market biggest winner tend have higher rs rating early stage move see valeant pharmaceutical continue show renew price strength clear threshold see ibd help make more money stocksvaleant pharmaceutical have climb more past entry first stage cup handle meaning now proper buy zone look stock offer new chance pick share week tight pullback day week line valeant pharmaceutical report negative growth sale earning last quarter company hold rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
152,ABBV,dow jone component merck mrk remain credit suisse top pick head european society medical oncology conference october drugmaker allergan agn eli lilly lly also look strong brokerage say monday time merck be expect unveil result trial dub keynote testing immuno oncology drug keytruda chemotherapy previously untreated patient advanced lung cancer combo receive accelerate approval expect continue discussion potential used keytruda await top line datum confirmatory keynote study september october time frame expect be positive credit suisse analyst vamil divan say second quarter conference call july merck confirm cyberattack delay product year say full recovery cyberattack take time still merck be best position remainder divan say note client merck share end regular trading session investor seem prefer abbvie abbv bristol myer squibb bmy divan be place bet allergan lilly still be several month allergan be expect unveil datum migraine trial say lilly offer diverse pipeline more interest be nordisk nvo trial know sustain be look diabetes drug semaglutide vs lilly trulicity divan see trulicity safer drug lilly be expect unveil datum trial drug abemaciclib breast cancer upcoming oncology conference divan say lilly be also plan file application migraine drug be drive adoption new drug cancer plaque psoriasis ibd take biotechs have struggle lately be now rank seventh group track ibd fifth last week sector hit week low thursday hit month high july head ibd industry theme more happened meanwhile divan isn bullish commercial potential drug abbvie inflammatory disease immuno oncology also call relatively rapid erosion sale key drug humira once generic enter market likely bristol case rumor become takeover target have limit stock term early asset immuno oncology potential approval kidney liver cancer drive upside time divan argue credit suisse also reinstate coverage dow stock johnson johnson jnj july divan note valuation be limit investor interest likely change release datum compass trial european society cardiology meeting meeting be set later month be look ability anticoagulant xarelto prevent major adverse cardiac event include cardiovascular death heart attack stroke patient heart disease expect compass be star meeting have potential dramatically increase uptake xarelto come quarters something move needle even company size divan write divan also note downgrade pfizer pfe teva pharmaceutical teva neutral rating outperform quarter dow stock pfizer be struggle term catalyst lack acquisitive appetite potential tax reform teva other hand be range bound new leadership team be place strategy reduce debt be more certain more clarity potential generic version copaxone multiple sclerosis drug milligram be obtain write related pfizer cancer drug help grow merger generic drug be rebound teva mylan free fallperrigo beat raise lift generic drug buck teva mylan trend
153,ABBV,hurricane harvey irma index other major index edge lower week prior week big gain walt disney comcast cmcsa alert medium news old medium be old news bank tumble fall interest rate tax cut hope unite technology utx agree buy rockwell collin col boee ba objected equifax efx say american be expose massive cyber intrusion index fall week nasdaq composite dow jone industrial average big gain prior week nasdaq test day move average tuesday close key level bank stock break key support treasury yield hit postelection lows medium stock tumble warning be several breakout setup lead stock unite technology utx announce buy aircraft supplier rockwell collin col share share cash rest stock include assume debt make biggest aerospace deal ever boee ba indicated try block deal look keep share lucrative maintenance repair business analyst say unite tech sell build business help unlock more shareholder value unite tech share fall related boee challenge unite tech buyout rockwell credit tracking service discover massive intrusion july disclose incident late thursday american be expose name birthday social security number other datum threaten credit card number consumer certain dispute document personal identify information approximately consumer be also expose top exec include cfo sell share day breach discovery equifax efx claim be not aware cyberattack equifax tumble thursday several cybersecurity stock rally pare gain friday close related equifax american affected huge datum breachwalt disney ceo bob iger say los angele base medium conference earning share current fiscal year end september be line fiscal analyst have see gain disney also say expect stream network now set late have exclusive online right marvel star war content dash hope extend deal netflix nflx meanwhile comcast cmcsa same conference warn video subscriber loss disney share tumble low thursday comcast lose several other medium stock sell well related disney warn profit keep star war marvel netflixcomcast stock plunge video subscriber loss hurricane impactdelta air line dal unite airline ual southwest luv spirit airline save jetblue jblu cut third quarter unit revenue forecast steeper airfare competition rise fuel cost spirit be engage fare war unite cowen say last mid say discounting have spread market represent sale base impact hurricane irma remain unclear friday follow hurricane harvey unite say deliver largest operational impact ve have company history crude stockpile rise barrel latest week energy information administration say slightly more expect gasoline inventory fall barrel less view refinery capacity run well normal many gulf mexico site shut ahead hurricane harvey domestic crude output fall barrel day barrel day week prior crude future edge higher week give nearly gain friday hurricane irma close florida gasoline future tumble spiking prior week luxury furnishing retailer rh rh earn cent share revenue adjust net revenue well estimate cent ep comparable brand revenue grow also top rh up outlook management have bold word ceo tout revolutionary new retail model include restaurant store distribution house last mile delivery initiative share spiked thursday biotech stock be relatively flat rise ibd group track eighth several rise sharply result strong clinical trial datum tuesday insm insm bellerophon therapeutic blph ligand pharmaceutical lgnd pop strong drug trial datum cellect biotechnology apop lift fda grant orphan drug status treatment organ transplant rejection sarepta therapeutic srpt hit month high positive datum duchenne muscular dystrophy trial thursday alnylam pharmaceutical alny sank suspend testing hemophilia trial celgene celg astrazeneca azn rise fda putt several cancer trial full partial clinical hold abbvie abbv rally positive trial datum eczema drug hit share regeneron regn have own eczema treatment largest pure play grocer narrowly top sale same store sale forecast earning come just view margin come pressure kroger kr other grocer be face intense competition long threat online deliver amazon amzn have already cut price just acquire whole food wal mart wmt largest grocery seller have be key driver food price deflation kroger share fall friday related kroger report mixed result shadow amazon wal martthe nissan nsany leaf debut tuesday give popular electric vehicle long overdue design refresh japanese automaker tout new model longer range lower price better performance semi autonomous technology sale nissan leaf have drop fourth place ev segment year tesla tsla model model general motor gm chevy bolt accord edmund tesla less expensive model just roll initial reviews new leaf be mixed call big improvement model tesla sale begin early hewlett packard enterprise hpe report fiscal adjust earning revenue expectation restructure continue ceo meg whitman say not go anywhere have interview uber ceo position recently hpe update guidance account sale software business do not discuss plan return cash shareholder bank america downgrade maker computer networking datum storage system say free cash flow growth be challenged next year hpe share fall arcade restaurant chain dave buster splay raise full year net income guidance previously cut same store sale growth forecast prior view comp growth fall well short estimate ep jump cent easily top view cent revenue climb narrowly miss view share sank nearly week insurance industry software provider guidewire software gwre earn cent share exclude item fiscal fourth quarter year year revenue analyst expect cent fiscal first quarter guidewire guide loss cent share sale wall street be modele profit cent share sale however full year outlook be ahead view guidewire share rise record high close coupa software coup report narrower expect fiscal loss revenue top view competition oracle orcl sap sap enterprise software firm stock initially pop close week fractionally higher target tgt announce friday be slash price thousand item retail competition get tougher target share fall wal mart wmt lose mobile tmus announce exclusive partnership netflix nflx include popular video stream service family plan provide unlimited datum start line monthly exist mobile netflix customer also opt have wireless firm pay bill mastercard touch record high thursday credit card giant raise full year adjust net revenue outlook growth high end low double digit compare earlier outlook low double digit growth china solar company jinko solar jks report second quarter revenue beating consensus adjust earning cent miss consensus estimate cent solar module shipment rise gigawatt industrial distributor hd supply hds report ep rise just beating view adjust revenue climb line management see ep cent better consensus cent revenue midpoint slightly consensus
154,ABBV,september be make break month number biotechs include alnylam pharmaceutical alny axovant science axon versartis vsar be expect present phase datum upcoming week xbiotech stock be poise run say loncar investment chief executive brad loncar year date ve rise hit month high share have rise follow gilead science gild announcement acquire kite pharma kite come incredibly newsworthy september feature least major medical conference least big investor conference nearly dozen phase trial expect read loncar tell investor business daily be most newsworthy month biotech history say so amazing september be be ton phase trial be schedule read company be go succeed fail trial readout count be make break company loncar say loncar count key trial readout september principal note be alnylam be expect unveil result trial drug dub patisiran rare disease cause buildup abnormal material call amyloid body success be major catalyst technology know rna interference antisense essentially turn malfunctioning gene leerink analyst paul matteis write note client tuesday ibd take novartis ibd relative strength rating be boost friday best possible grade show stock price moved past week other stock database head ibd datum story see novartis stack rival ionis pharmaceutical ion be also work phase drug know inotersen treat disease call ttr amyloidosis matteis call upside depend magnitude success safety downside drug prove effective mixed safety see downside alnylam drug fail completely trial accord loncar most person be convince go succeed cite note see range failure success putt alnylam stock price share close tuesday company window say be bellwether biotech company everyone be count succeed probably trial fail stock crash alnylam loncar note axovant be expect announce result drug dub intepirdine mild moderate alzheimer disease recently biogen biib stock break strong phase datum alzheimer trial axovant be work different theory treat alzheimer intepirdine be know serotonin receptor antagonist have potential cognition memory learn enhance side effect be originally develop glaxosmithkline gsk sell axovant so far nothing have work alzheimer so always excitement trepidation trial readout disease loncar say last december eli lilly lly topple drug solanezumab fail phase trial alzheimer axovant do succeed see stock go day say axovant close tuesday extreme kind euphoria alzheimer create also note trial versartis zogenix zgnx growth hormone deficiency form epilepsy know dravet syndrome respectively win just be september chock full catalyst leerink analyst write note client tuesday solid year return biopharma stock be still number catalyst back half year large cap leerink geoffrey porge note abbvie abbv have datum trial inflammatory cancer drug alexion pharmaceutical alxn be expect grab approval drug soliris treat disease immune system attack healthy cell amgen amgn update label ldl cholesterol lower drug repatha include add benefit cardiovascular outcome meanwhile regeneron pharmaceutical regn sanofi sny be appeal court decision vs amgen rival drug praluent celgene celg have readout ulcerative colitis form hodgkin lymphoma fibrogen fgen be expect have datum fibrosis anemia drug analyst expect vertex pharmaceutical vrtx provide update datum cystic fibrosis trial gilead kite car drug likely be approve treat aggressive form hodgkin lymphoma november follow approval novartis nvs kymriah car drug treat form acute lymphoblastic leukemia patient age expect car remain most closely follow emerge area biotech second half leerink analyst michael schmidt write note launch kymriah read drug bluebird bio blue juno therapeutic juno adaptimmune therapeutic adap related biogen alzheimer drug show promise break partnership bit dust gilead kite break biotech giant close buy novartis cancer approval validate gilead kite dealgilead kite deal boost biotech etf clear buy point
155,ABBV,stock extend loss tuesday afternoon heighten north korea related geopolitical tension xspdr dow jone industrial average dium powershare qqq trust qqq tumble spdr spy give stock market today emerge market lead downside ishare msci emerge market eem sank country etfs ishare msci south korea capped ewy gap fall japan hedge equity dxj post gap oil gold play rally west texas intermediate crude price surge nearly barrel unite state oil uso vaneck vector oil service oih gap leap nearly powersharesdb oil dbo add gold future rise ounce investor seek safe haven vaneck vector junior gold miner gdxj vaneck vector gold miner gdx rise respectively spdr gold share gld ishare gold trust iau powershare db gold dbo gain more apiece financial chip biotechs lead downside spdr regional banking kre spdr bank kbe lose nearly recent stock market pullback continue create new opportunity investor buy equity first trust equity opportunity fpx be featured aug etf column moved closer day move average line solid rebound support line have set chance buy fall day few time next week then not only make lose ground have come back score time high market have rebound shape right side flat base fpx clear friday slip entry tuesday market sell etf gain late april flat base start most recent pattern fund track ipox index be launch april ipox be market cap weight index largest most liquid initial public offering put weighting cap component stock be reconstitute quarterly basis biggest sector weighting aug be technology health care consumer cyclical financial service accord morningstar direct top holding include abbvie abbv kraft heinz khc paypal pypl fpx have outperformed broader market ytd gain aug vs return year performance also outpace benchmark index average annual etf bear expense ratio ishare russell midcap growth iwp climb past flat base buy point intraday friday close just entry fund be highlighted july etf column near flat base buy point clear entry next session turn south broader market late july year old fund have amassed technology account asset aug industrial consumer cyclical health care top holding drugmaker zoetis zts chipmaker analog device adi gene sequence system maker illumina ilmn iwp ytd year average annual return respectively be ahead period fund expense ratio be thursday pick vanguard growth vug ishare russell growth iwf manage slight gain ahead labor day holiday vug be cusp flat base buy point iwf be still buy range past flat base entry learn more invest check page related biotechs extend gain breakout put apple amazon focusthese sector lead upside market beater close buy pointgold rally stock fall be too late buy gold
156,ABBV,gilead science gild end do nothing oncology right takeover deal doesn present chief executive john milligan reportedly tell analyst wednesday third largest biotech market cap gilead have struggle decline sale hepatitis drug several quarters first quarter gilead hint be look buy oncology player gilead remain mum potential merger recent second quarter appear gilead be look acquisition leerink analyst geoffrey porge write note client meeting biotech management wednesday firm be struggle identify such opportunity ceo john milligan explain didn think make much sense buy something small today hope grow something large porge say instead milligan be look company substantial datum value scale analyst have suggest gilead look acquire company tesaro tsro incyte incy clovis oncology clvs kite pharma kite cancer vertex pharmaceutical vrtx cystic fibrosis recently unite therapeutic uthr spiked potential gilead take ibd take biotech industry be await merger acquisition spike higher say industry observer do gilead fit visit ibd industry theme closer look gilead also note still interested fibrosis program buy firm nonalcoholic steatohepatitis nash program phenex pharmaceutical nimbus therapeutic nash be liver disease meantime gilead be call decline hepatitis unit beating view second quarter porge see revenue hepatitis drug fall then dip annually decline be likely accelerate better competitive hepatitis regimen come market write outlook company hiv business remain positive be not sufficient offset dynamic hepatitis business competitive regimen abbvie abbv mavyret gain approval earlier month treat genotype hepatitis gilead acknowledge abbvie biggest advantage be treatment genotype rivale gilead epclusa sovaldi chief operate officer kevin young say contract cycle be now full swing doesn mean payer defer abbvie mavyret gilead drug mavyret be be price discount gilead harvoni epclusa porge say note last week hiv unit gilead remain bullish chance fend glaxosmithkline gsk be work drug combination recently concern have emerge regard safety glaxo double drug hiv question infection ability adapt treatment gilead stock close stock market today related gilead be make acquisition not thinkhow abbvie gauntlet squeeze gilead drug hepatitis cgilead hepatitis franchise topple again share beat
157,ABBV,biotechnology giant gilead science gild buy pharmasset inherited compound then know wall street analyst expect bring peak sale just year later launch name sovaldi north pill rake sale alone prove be nearly foolproof cure hepatitis virus hcv year gilead flagship hcv drug pull more also double company net margin push past level point mid trouble be gilead didn just treat hepatitis most part cure patient month sovaldi have unheard success rate hepatitis patient follow treatment harvoni prove more effective case eventually patient pool be bound get smaller have sovaldi harvoni sale fall respective think open blockbuster movie hollywood person line rbc analyst michael yee tell investor business daily thus be less come right now now pressure be gilead produce big hit drive growth biotech investor story be cautionary tale look initial fanfare hot new drug consider cost deliver promise hepatitis hiv alzheimer disease many type cancer be short term temporary condition say kevin young gilead chief operate officer company feb earning conference call analyst gilead say fewer patient be start hcv regimen do be healthier past patient thank harvoni hcv be cure little week genotype patient young say refer most common type hepatitis gilead confirm worry hepatitis slowdown feb release fourth quarter earning share topple next day nearly touch year low whisper loom dip hcv drug sale have plague gilead stock better part year climb rapidly gilead stock start slip lose analyst issue report report modele gilead look hcv today gilead see hiv unit grow last year next big enterprise have describe hiv drug bictegravir future mount everest still sentiment hasn be negative gilead stock pharmasset acquisition say evercore analyst mark schoenebaum then analyst survey schoenebaum say gilead paid too much pharmasset later analyst miss potential immediate demand sovaldi didn even account harvoni last time sentiment gilead management be bad investor be wrong very wrong schoenebaum write feb research report more half november survey say pharmasset buy destroy gilead value sentiment obviously improve sovaldi old school hepatitis treatment weren effective often come flu side effect anemia sovaldi be so successful gilead launch harvoni see similar result harvoni sale year newest addition hepatitis line epclusa bring gilead stock fly wall street perform degree turn sovaldi ahead launch activist group patient be incense discussion bump sovaldi price expectation drug be wall street dynamo harvoni launch even bigger price tag gilead take lump headline price rbc analyst yee say price tag weren particularly egregious consider prior treatment cost high cost treatment be not high relative exist prior therapy be significantly better tell ibd email cost have come give competition other rebate fourth quarter gilead chief executive john milligan note harvoni now sell meanwhile rivalry merck mrk abbvie help curb price merck signale expectation lighter hcv sale february take impairment charge uprifosbuvir merck acquire uprifosbuvir idenix pharmaceutical company cut value estimate uprifosbuvir leerink analyst geoffrey porge say merck be signale reduce value participation market be consistent decline market overall merck have successfully defend patent hcv med zepatier gilead abbvie be work next generation drug set launch sometime wall street suspect hcv decline be come modeled total gilead sale hepatitis franchise revenue gilead company guidance total sale hepatitis drug revenue paint starker picture guidance gilead say expect patient start hcv regimen drop gilead estimate patient start hepatitis drug fewer hcv sale get push large commercial payer open access marketing campaign department veteran affair gilead young doesn expect time driver repeat guidance imply lower ep earning share consensus be modele rbc yee write feb research report think stock be probably range bound hit least quarters demonstrate handle forecast visibility yee also echo other analyst call acquisition bolster top line gilead work hcv decline work launch drug hiv nash nonalcoholic steatohepatitis unit yee see incyte incy smart unlikely deal gilead withstand pressure pharmasset buy win bend public pressure evercore schoenebaum say feb video investor be question ceo milligan none have identify specific deal miss have prevent hcv decline ibd take strong drugmake bet check incyte analyst say incyte pipeline be brim potential blockbuster opportunity head new america deeper dive incyte upcoming catalyst have here be company not just go go do deal so press release say do deal hope get sugar high stock say re only go do deal have high degree confidence work high degree confidence re underpay asset meanwhile gilead be bolster hiv nash unit gilead recently pit hiv drug bictegravir glaxosmithkline gsk incumbent dolutegravir approve sell brand name tivicay phase trial show bictegravir be numerically stronger gsk drug certain combination price be bigger concern gsk medication be cheaper combine generic med meaning hiv regimen be price vs likely price tag attach gilead solution yee say feb report other analyst say gilead hiv nash unit be too late offer little value leerink analyst geoffrey porge say feb expect hepatitis sale topple then annually outlook hiv be positive sale aren hcv trajectory porge say be not sufficient offset unusual dynamic hcv business relatively modest contribution other product offer little mitigate boom bust hcv write opportunity appear be arrive too late too little value view yee say gilead isn fill hole left decline hcv unit merely come massive bolus hundred thousand person come first year drug be still set do be largest drug world not exactly hole say related gilead clobber hep little value too late nash hiv unitscan gilead swivel hiv flounder hep sale gsk rivalry gilead hiv drug top gsk combo rivalry intense gsk doublet
158,ABBV,gilead science gild see hiv drug bictegravir mount everest rival merck mrk glaxosmithkline gsk be able price rival drug cheaper analyst say thursday leerink analyst geoffrey porge note merck glaxo be work hiv regimen include generic drug gilead other hand have establish premium pricing fix dose combination base brand component pricing porge write research report result gilead struggle gain share hiv much need sector lucrative hepatitis franchise continue dwindle year sale gilead hepatitis drug see sale decline biotech be guide further decline past year gilead have dominate hiv landscape porge say hiv unit bring sale competitive landscape be shift hiv new drug set launch gilead bictegravir base formula be likely be gold standard first second line hiv treatment porge write gilead unlikely budge pricing ability hold share price erode predict ub analyst carter be more bullish gilead hiv enterprise street expect bictegravir eventually get different brand name pull sale peak sale combine substance now know filgotinib filgotinib be drug develop galapago glpg downgrade gilead stock neutral rating buy cut price target cite company struggle hepatitis guidance suggest dip hepatitis drug sale fewer patient start gilead hepatitis drug year be line gilead note fourth quarter earning conference call old school hepatitis medication weren effective gilead sovaldi harvoni carry number side effect today be fewer patient many be healthier thus put treatment ibd take gilead hepatitis drug downfall didn come blue analyst have predict better part year be warning sign visit ibd industry theme closer look gilead be also experience competitive pressure like merck abbvie abbv merck have successfully fought patent litigation vs gilead hcv drug zepatier abbvie be set launch next generation asset merger win fix gilead problem write gilead acquire triangle pharma pharmasset respectively stock trend roughly month announcement gilead stock be now year rbc analyst michael yee disagree argue gilead do number string pearl acquisition improve pipeline visibility kite pharma kite be interesting acquisition say meanwhile tail hepatitis sale be significant enough sustain demand yee have outperform rating gilead stock close bell stock market today gilead stock fall merck be marginally glaxo add related pharma be beating pack get drug marketabbvie strong bet gilead amgen least analystgilead glaxo pit hiv battle struggle vs standard drug
159,ABBV,prescription gilead science gild hepatitis drug have plunge jan leave least analyst wait industrywide revenue remedy hit bottom even competition loom rival merck mrk abbvie abbv total prescription harvoni sovaldi epclusa be flat week week have fall begin quarter jan rbc analyst michael yee write note client cite health care tracker im new prescription be vs last week meanwhile merck hepatitis drug zepatier have flourished total zepatier script be quarter date new prescription climb week week total prescription be vs last week zepatier now have new prescription market yee write merck have say expect grow share overseas launch japan europe fourth quarter zepatier list price treatment be roughly cheaper gilead alternative little more half list price harvoni many drugmaker however have not be get list price drug company suggest country be open more access more yee write be good gilead well even merck isn immune weaken hepatitis market last week merck say take impairment charge uprifosbuvir hepatitis drug acquire ibd take biotechs incyte be strong bet number potential blockbuster pipeline analyst say incyte keep lead visit new america deep dive company stock gilead be first market new class highly effective hepatitis drug prescription company lineup top major year run time gilead net margin more double roughly level peak disease be curable meaning get harder find new patient new patient be often healthier procrastinate begin treatment gilead have say gilead abbvie hepatitis drug sale also be struggle week abbvie viekira pak hepatitis fall be quarter date yee write new prescription grow week week abbvie be essentially niche player now second generation drug be competitor yee write drug be approve year end gilead yet competitor slow market earlier year gilead guide hepatitis drug sale miss expectation guidance actually be conservative gilead need hit couple quarter see script stabilize investor gain confidence yee say be watch hcv script flatten slope curve inflect stabilize order establish bottom franchise midday trading stock market today gilead stock be fraction share merck abbvie be fraction respectively related gilead abbvie perk merck hep downfall leerinkabbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drug
160,ABBV,eli lilly lly pipeline have best bang buck analyst say wednesday comparison pit lilly rival pfizer pfe merck mrk bristol myer squibb bmy leerink analyst seamus fernandez say lilly be outperform pack achieve best balance investment limit external investment past year bristol pfizer trail merck struggle metric write still drugmaker lilly have struggle gain fda approval only drug pharma pipeline have gain approval contrast biotechnology company abbvie abbv gilead science gild have be more successful conversion rate top drugmaker bristol myer lilly have have considerably more success phase drug meanwhile pfizer have only converted late stage pipeline drug sell market pfizer have broadest pipeline group disclose new drug fernandez write have struggle fall megamerger disruption limit scale productivity merck be lowest pharma universe ibd take american fund recently up stake bristol myer squibb stock else receive american fund vote confidence find ibd mutual fund page analysis fernandez also look churn turnover new drug burn percentage attrition portfolio bristol have highest burn rate lowest churn rate company appear be focuse more internal asset partnership early stage mid late stage external agent fernandez write note conversely merck churn rate be highest group merck high overall expense be drive part large cubist idenix deal have so far struggle generate sizable return management have hope well company extraordinary investment keytruda write merck isn alone struggle partnership acquisition big drugmaker biotechs only gilead purchase pharmasset appear have succeed fernandez write pharmasset begin development sovaldi hepatitis drug rocket gilead sale gilead hepatitis franchise begin falter high cure rate trio drug sovaldi harvoni epclusa close bell stock market today lilly finished trading bristol myer rise meanwhile merck slip pfizer also lose related gilead hepatitis sale plunge merck swipe share analystabbvie stronger bet gilead amgen least leerinkmerck roche gouge bristol share lung cancer approval
161,ABBV,here investing action plan friday need know investor come day busy earning week continue quarterly result oil major exxon xom chevron cvx france total tot italy eni pharmaceutical giant merck mrk abbvie abbv also report consumer credit report agency transunion tru report market open exxon mobil chevron merck be member dow jone industrial average estimate earning cent revenue accord zack investment research stock chevron close flat thursday stock market today still just buy range undercut entry point last week break even price likely be major topic report oil stay barrel company look lower cost maintain dividend investor expect chevron say break even year barrel accord wall street journal crude future be trading barrel brent crude just total say be able break even oil fall not include dividend cost exxon doesn disclose break even estimate ep see soar cent revenue expect rise stock exxon mobil rise thursday ibd take read ibd big picture column day stay top market direction key indicator let know be aggressive move sideline estimate ep fall revenue dip stock merck dip share be consolidate long flat base entry point merck have be trend nearly reach buy point mid september stock be now day day move average earlier month merck announce win submit application approval cholesterol drug anacetrapib find accumulate fat tissue estimate ep revenue rise stock abbvie sank thursday share break flat base buy point late august enter profit take range earlier month abbvie be top rank company ibd medical ethical drug group credit report agency also report busy early morning estimate ep jump cent revenue stock share rise hit record high intraday transunion briefly sell last month rival equifax efx disclose massive hack related energy stock industry news oil gas solar coaldow jone industrial average dow stock news analysis
162,ABBV,treatment common eye disease make regeneron pharmaceutical star now new dermatitis medication bring superstardom fast grow biotechnology company xother breakthrough regeneron regn drug treat arthritis cholesterol company be develop promising asthma cancer treatment be just reason investor business daily name regeneron winner inaugural ibd biotech innovator award regeneron financial back optimism earning share various item shot last year impressive company post loss revenue have sky-rocket more tenfold last year regeneron have be fantastically successful company story say piper jaffray analyst edward tenthoff tenthoff begin cover company stock be change now estimate total revenue ep share rise ibd choose biotech innovator award winner ibd ask equity analyst etf mutual fund manager university professor identify top biotech company base innovative research ask focus company pioneer drug likely launch next several year reach blockbuster blockbuster sale more year award winner select ibd editor be most cite company find profile award winner detail work go full biotech innovator special report even regeneron stock be roll have trade recently meteoric decade find share peak august stock hit month high june now trade take hit potential competition eczema abbvie abbv tenthoff price target be regeneron ascent begin approval drug eylea treat disease call wet eye age related macular degeneration major cause blindness elderly relationship french drug giant sanofi sny suite key development tool focus pure science have enabled regeneron grow biotech titan future family antibody drug be used treat number common disease thus address multibillion dollar market human have antibody protein fight disease antibody drug be protein manufacture fight specific disease science be heart regeneron corporate culture success accord analyst company executive ve take mantle purest scientific company industry say geoffrey porge analyst leerink partner pride rigor scientific enquiry rate stock outperform buy price target porge say regeneron commitment research development be virtually unique industry regeneron spend total revenue well norm largest pharma company averaged revenue last year accord april report online newsletter fierce biotech tarrytown base regeneron have have help funding thank relationship other company include year relationship sanofi regeneron sanofi have agreement ongoing development immunotherapy cancer drug agreement antibody drug development licensing terminate end pact regeneron get funding sanofi certain licensing right end pact pose problem say analyst regeneron executive regeneron have become so big really don need sanofi analyst tenthoff say make discovery own commercialize true say regeneron have become very self sufficient end end house david regeneron senior vice president global clinical development tell ibd be self reliant own income stream such don need sanofi contribution research say termination sanofi pact enable regeneron set more partnership make sense cite company development platform build internally key enable rapidly identify therapy regeneron key drug development tool be velocigene velocimmune first aim rapid automate manipulation mouse dna speed modele human disease other aim help identify multitude optimized antibody drug candidate efficiently directly immunize mouse technology allow very quickly screen lot antibody find one have characteristic want say re not huge company term overall size say technology allow go large number target simultaneously wind drug development portfolio regeneron science focus help attract top talent say live motto science come first be not many place say scientist take novel study approach ibd take industry snapshot give depth look most popular industry include recent look rise medtech decline pharma regeneron grant employee stock option say so employee share company success regeneron take biggest drugmaker include roche hold rhhby novartis nvs amgen amgn august company report jump revenue record earning share item rise analyst poll zachs call analyst poll zachs be call ep year earlier quarter eylea continue drive financial sale beat wall street view tenthoff say sale end year see eylea sale rise eylea be sell regeneron partner drug german drug giant bayer bayry regeneron have exclusive right sale eylea bayer have exclusive marketing right outside company share equally profit sale eylea japan regeneron receive royalty net sale eylea be present many industry observer say dupixent be future be be sell treat atopic dermatitis gain fda approval march now regeneron seek eu approval treatment hope drug go much further dupixent have potential number other disease say be used treat asthma nasal polyp multiple allergy include peanut allergy esophageal inflammation more drug very well be pipeline say regeneron be conduct phase trial dupixent treat asthma seek fda approval next year dupixent be big not bigger eylea say analyst tenthoff rate regeneron stock overweight buy just treatment asthma alone annual global sale be say dupixent do well asthma study be most notable new drug year amy brown research firm evaluate pharma write august report other temper enthusiasm dupixent be big drug person have come overvalue say brian skorney analyst baird equity research skorney downgrade regeneron underperform neutral august regeneron have other potential drug hit year fda approve drug kevzara treat rheumatoid arthritis ra affect american accord arthritis foundation american college rheumatology regeneron drug praulent be used treat high level bad cholesterol amgen have sue say drug violate patent amgen compete drug repatha time injunction prevent regeneron selling praulent injunction be stay ruling lawsuit come soon skorney say praulent be pull market still be surprise wall street tenthoff be not worry say lawsuit risk be already baked regeneron stock price related get detail award winning biotech innovator workreason recent biotech stock rallyregeneron pharmaceutical eczema drug rival show promise
163,ABBV,relative strength rs rating astrazeneca azn climb new percentile wednesday get lift ibd proprietary rs rating track technical performance used worst best score indicate stock price action trail week compare other publicly trade company history show best stock typically have higher rs rating begin largest price move see astrazeneca continue rebound hit benchmark look winning stock try simple be build consolidation buy point see stock break volume least average earning growth drop last quarter revenue rise astrazeneca earn rank peer medical ethical drug industry group abbvie abbv zoetis zts grifol grfs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
164,ABBV,biotech industry behemoth celgene celg gilead science gild struggle third quarter accord quarter report result left room smaller player neurocrine bioscience nbix exelixis exel juno therapeutic juno swipe headline crush street even large cap beat sale earning expectation
165,ABBV,biotech stock topple last week follow disappointing third quarter result like celgene celg gilead science gild analyst say monday note competition pricing concern start take toll arrival new competition form abbvie abbv mavyret force gilead hepatitis drug franchise lose share third quarter meanwhile celgene note otezla treat psoriasis psoriatic arthritis be increasingly competitive market gilead top total sale view revenue hepatitis drug decline third narrowly miss analyst forecast celgene alarm result be drive major miss sale otezla lead total sale lag guidance cut instinet analyst christopher marai say competitive pricing concern take hit broad biotech market nasdaq biotechnology index finished nasdaq wrapped week less higher meanwhile ibd company biotech industry group lose nearly slip third group track ibd last week have be rank first then second ibd take celgene cut many element guidance include inflammation immunology drug head ibd industry theme more celgene result mean broader group alnylam pharmaceutical alny avexis avxs be more expose competitive concern marai say note client alnylam be work drug call patisiran treat rare disease cause buildup abnormal material rival ionis pharmaceutical ion prothena prta avexis be work therapy spinal muscular atrophy rival biogen biib ionis sell spinraza treat same condition marai list spinraza sarepta therapeutic srpt exondys duchenne muscular dystrophy fundamentally strong launch continue look strength select name opportunity take profit biotech reinvest less macro expose name be rich potential stock catalyst next month say avoid price perfection name include alnylam avexis next year marai see prothena deciphera pharmaceutical dcph cellectis cll macrogenic mgnx have slew potential catalyst related dow merck plunge month low grow keytruda worriesgilead beat third quarter sale earning viewsthree biotech firm top third quarter view only pop
166,ABBV,abbvie abbv humira franchise be safe patent settlement amgen amgn analyst say monday upgrade abbvie predict profit outgrow other large cap pharmas xleerink analyst geoffrey porge upgrade abbvie outperform rating up price target note upgrade miss abbvie recently strong performance believe be still further upside valuation abbvie be alter base extend market exclusivity humira model previously settlement amgen write note client settlement amgen pay abbvie royalty sale humira copycat humira be abbvie most important drug bring total sale second quarter humira be inflammatory med close bell stock market today abbvie climb finish share break flat base buy point late august have rise hit point ibd take abbvie be also work galapago develop treatment cystic fibrosis analyst say vertex pharmaceutical have large lead head new america closer look market breakdown settlement allow amgen launch biologic copy humira know amgevita europe next october version amjevita be set launch january other rival be likely be offer same market entry deal porge say boehringer ingelheim coherus bioscience chrs be closest entry biologic copy humira boehringer cyltezo be approve august firm be patent battle abbvie coherus be still work submit application regulator dow component merck mrk pfizer pfe addition novartis nvs momenta pharmaceutical mnta be bound file approval biologic copy humira come quarters likely infringe abbvie humira patent lawsuit likely be resolve mid remove risk launch right settlement date porge say result believe certainty humira patent protection be nearly porge increase humira sale view longer term humira estimate increase respectively expect abbvie hit operate margin project abbvie earning share command annual growth rate top large cap pharma peer project mature biopharmas set mid single digit growth growth horizon company increasingly visible late stage pipeline suggest abbvie stock continue re rate range large cap biopharma peer porge say related amgen drug send abbvie stock company gain trump foreign profit relief plan passesabbvie new hepatitis drug chip away gilead share
167,ABBV,here weekly investing action plan need know investor come week biggest name tech defense energy automotive telecom restaurant industry report include fang stock facebook fb amazon amzn alphabet googl federal reserve hold policy meeting opec
168,ABBV,abbvie abbv throw gauntlet gilead science gild approval hepatitis drug further hammer gilead multibillion dollar franchise analyst say friday xlate thursday food drug administration approve abbvie drug dub mavyret coveted week label genotype hepatitis patient most hepatitis drug be take week period abbvie be pricing treatment week deeper discount prominent drug now be prescribe condition gilead harvoni epclusa leerink analyst geoffrey porge estimate mavyret be offer discount gilead see revenue prescribe course harvoni discount epclusa competitive dynamic now solidify fda agree forecast market share price erosion gilead modeled rebound abbvie hepatitis revenue begin porge write note client porge call gilead remain competitive patient harvoni be give week still lose share base contract payer population patient treat mavyret undergo treatment week other patient likely migrate mavyret base convenience week regimen predict gilead drug epclusa vosevi be dose week harvoni be prescribe week patient be treat week ibd take gilead make acquisition be linchpin send biotech sector higher industry observer say head ibd industry theme closer look company gilead be consider mavyret broad label give abbvie access vast majority hepatitis patient exception ve fail drug dow component merck mrk johnson johnson jnj drug bristol myer squibb bmy fda be not require genotype testing be big advantage gilead other participant market write mavyret do have black box warning label risk hepatitis reactivation patient infection patient undergo pretreatment testing hepatitis infection then monitoring be find have hepatitis hepatitis porge say isn significant burden most hepatitis patient have already be screen hepatitis abbvie likely focus early effort government segment mavyret wholesale price be line harvoni undercut epclusa conversely abbvie pricing mean revenue contribution mavyret be likely be limit largely consistent exist forecast say stock market today abbvie close flat gilead fall related gilead be make acquisition not thinkgilead hepatitis franchise topple again share abbvie hammer gilead hepatitis franchise
169,ABBV,biogen biib cling gain early tuesday ionis pharmaceutical ion partner spinal drug nearly triple expectation second quarter lead guidance boost xsale spinraza biogen ionis drug used treat spinal muscular atrophy come obliterate analyst view evercore analyst umer raffat write note client revenue drug grow quarter quarter sale comprise biogen have also build inventory raffat caution not read too far spinraza sale be front load first week cost patient next week second quarter end june biogen report adjust income share revenue top consensus view share sale year year basis revenue grow profit sank stock market today biogen fall close gain much open share hit highest point april biotech stock be generally flat early tuesday ibd take biotechs be now rank fourth group ibd track send higher head ibd industry theme look regulatory trend clinical trial potential merger acquisition instance biogen slide be already flagging expect revenue growth slow write biogen up revenue guidance adjust income be expect be share year biogen multiple sclerosis business bring brand drug interferon total sale grow tecfidera grow year year offset flat tysabri sale quarter benefit addition zinbryta launch abbvie abbv last year related biotechs find strength number treat multiple sclerosisthese drug giant buy range just beat earning view star align biotechs crush earning consensus
170,ABBV,here investing action plan friday need know investor come day xan initial read second quarter gdp be due oil giant exxon mobil xom chevron cvx report drug giant merck mrk abbvie abbv quarterly result american airline aal also round earning
171,ABBV,life be simple rachel martin day work accounting firm way become cpa night run start notice foot feel strangely stiff xthat lead bit news day soon be good yet odd still stack day get notice multiple sclerosis get notice sell condo get notice receive cpa license tell investor business daily number haven go martin way ever be diagnosed half lifetime hasn work year have spend hour life work cpa take least medication treat ms exactly none have fully contain ailment barrage new drug be take aim ms however offer hope martin other debilitating illness medication be offer lower cost expect market heat offer prospect fewer side effect most critically greater effectiveness several heavy hitter industry be get involved biopharma battle roche rhhby have new drug swipe share market leader biogen biib meanwhile celgene celg number generic drug manufacturer be expect pile pressure mainstay field novartis nvs roche share be fractionally monday close biogen tick finish celgene be marginally novartis be slightly ms sector have be dominate biogen bring just shy sale medication arsenal include inventory be ms drug martin recently stop used avonex well other top seller tysabri tecfidera now paradigm shift especially roche ms drug ocrevus be concern accord michael analyst evercore ocrevus be approve earlier year treatment relapse remit primary progressive form ms offer medication primary progressive be breakthrough form ms comprise just market have not be target treatment past ocrevus twice year infusion look attractive patient martin discontinue used certain drug due ms related tremor martin first medication be interferon be medicine month shake hand become so severe couldn administer injection analyst say roche drug put biogen tysabri tecfidera greatest risk market share loss wall street estimate see ocrevus take away tysabri sale tecfidera revenue year ocrevus market have threat share be steal tell ibd also have possibility look generic version novartis gilenya teva pharmaceutical teva copaxone so lot move part ibd take ibd company biotech industry group be now rank fourth group track share have rise year ride high june rally still see upside accord estimate benefit spike head ibd industry theme closer look novartis case celgene be heap pressure company potential blockbuster ms drug now have test phase name ozanimod celgene biotech market cap be bill ozanimod safer version gilenya be target latter half file application approval food drug administration ozanimod gilenya class drug call receptor modulator work prevent specific white blood cell move central nervous system do so have be show improve outcome reduce ms relapse ms be disease central nervous system disrupt flow information brain brain body patient fatigue easily have difficulty walking go run walking walker then wheelchair say martin wasn muscular ability add be balance be able exercise hold something say medication have bring martin moderate success point generally walk cane belong ms group call let play los angele disease be steady say doctor take time physical therapy experimentation medicine medicine cause debilitating headach be chemotherapy today doctor know cause heart damage martin manage avoid martin current medication be make bayer bayry sell novartis require self injection other day begin used medicine april quit used biogen avonex year due headach biogen have most lose battle sale tysabri tecfidera avonex line second quarter be expect be biogen first real test mizuho analyst salim sy tell ibd result be due be report tuesday biogen drug tysabri roche ocrevus be consider highly efficient ms treatment tysabri label contain black box warning deadly virus attack brain ocrevus label doesn case virus progressive multifocal also call pml have be record single ocrevus user patient have just come tysabri year have only be treat once ocrevus most analyst don consider case be related ocrevus risk pml be likely enough prod number tysabri patient switch ocrevus sy say further biogen have estimate third patient tysabri test positive ailment know john cunningham virus patient have weak immune system be more susceptible pml analyst say erosion tysabri use be slow biogen isn particularly worry ms franchise franchise grow expand include zinbryta launch partner abbvie abbv first quarter end march biogen ms drug sale grow just sale tysabri zinbryta fall chief executive michel vounatsos doesn see biogen ms drug decline franchise evercore analyst umer raffat write june note client meeting vounatsos believe biogen lose market share roche ocrevus believe be plenty opportunity grow top line raffat say vounatsos do not believe generic copaxone teva drug generic gilenya novartis drug impact biogen ms franchise copaxone gilenya face own battle celgene other celgene ozanimod successfully reduce relapse rate vs traditional interferon treatment phase trial company present milligram milligram oral dose be safe tolerable year period novartis gilenya also have own safety issue mizuho sy say label patient undergo monitoring hour immediately follow first dose ensure heart rate don slow dangerous level gilenya have also be show have toxic effect liver enzyme so gilenya be not perfect drug say celgene say be safer gilenya just see top line datum ozanimod go come market get approve so ozanimod successful gouge gilenya sale analyst say second quarter gilenya sale grow constant currency basis follow major growth exclude impact foreign exchange rate celgene be optimistic chance multiple sclerosis market report leerink analyst geoffrey porge note management hasn commit first dose monitoring say unique dose schedule minimize need requirement safety celgene management expect show multiple point safety differentiation gilenya safety profile have label be consistent phase result say then potential generic competition novartis face slew generic have be approve pending patent litigation like teva mylan myl analyst consensus model see gilenya sale drop generic approve tentatively gilenya price point wait break evercore raffat say video raffat say unlikely gilenya go generic patent litigation likely push generic entry even then gilenya have patent set expire hasn really be vet say patent cover dose schedule only currently face challenge earlier stand challenge apotex novartis be also study low dose version gilenya milligram gilenya be now approve milligram dose trial work likely very patentable raffat say fda review fda say not clear milligram dose work alone be reason know milligram dose do work novartis trial be patentable not obvious new patent gilenya be obstacle generic competition evercore say note nullify gilenya go generic help broader ms industry stave cheaper generic tug drug pricing market ultimately competition be godsend patient martin be hopeful better ms medicine fewer side effect multiple sclerosis be something difficult describe person most look re do well martin say bubble look fine outside don feel fine related biogen takeover prospect soured mere novartis ms drug stomp celgene even hit market roche game changer drug chip away biogen novartis
172,ABBV,abbvie abbv be likely swipe significant hepatitis drug share gilead science gild week regimen week shorter triple pill treatment gilead analyst say wednesday food drug administration tuesday approve gilead combination sofosbuvir velpatasvir voxilaprevir week regimen patient genotype combo have be recommend approval week course europe be approve patient ve already try drug meanwhile abbvie combination glecaprevir pibrentasvir look likely gain approval week regimen genotype hepatitis patient ve never undergo treatment gilead harvoni be approve week regimen only subset patient label place gilead competitive disadvantage rival abbvie abbvie be likely get approval genotype week course leerink analyst geoffrey porge say note client approval genotype be uncertain note gilead be pricing triple pill be brand vosevi bottle bottle month run week price be less costly gilead harvoni sovaldi more expensive zepatier dow component merck mrk ibd take hepatitis drug franchise decline gilead have say be open acquisition cancer space biotech buy be better purchase say analyst visit ibd technology page closer look gilead buy most patient take vosevi fail respond harvoni zepatier abbvie drug combination abbvie drug other hand be likely grab approval regimen patient have never undergo treatment porge expect abbvie price pill drug viekira pak hepatitis combination go month abbvie aggressively market drug combo gilead harvoni epclusa say strategy be likely result significant market share abbvie give convenience excellent efficacy drug combination say note client porge forecast sale vosevi second half year expect see gradual decline outside expect vosevi pull annually same time porge model gilead harvoni epclusa lose market share abbvie call gilead hepatitis drug franchise represent just total sale fall half sale stock market today gilead share climb close abbvie pop finish related vertex hit record high result cystic fibrosis trialcould biotech stir takeover interest cancer drug approval star align biotechs crush earning consensus
173,ABBV,biogen biib be pay bristol myer squibb bmy upfront license palsy drug market opportunity potential use treat alzheimer analyst say thursday deal be announce early thursday conjunction separate agreement roche rhhby roche license duchenne muscular dystrophy drug bristol accord news release bristol agreement be expect close second quarter licensing asset biogen roche enable bristol myer squibb prioritize other promising opportunity asset development have advanced diversify portfolio say mike burgess head bristol cardiovascular fibrosis immuno science development close bell stock market today investor only reward biogen gain bristol be fraction roche stock fall biogen deal biotech pay bristol milestone payment tiered double digit royalty license drug know only bms drug just complete phase testing progressive supranuclear palsy palsy also call steele richardson olszewski syndrome be rare brain disorder cause difficulty walking balance eye movement accord mayo clinic drug biogen be licensing be know tau taus have be investigate treatment alzheimer alzheimer taus be protein build brain process cause tangle nerve cell breaking communication expert say bristol biogen drug cut tau plaque buildup brain healthy volunteer phase testing ibd take biogen share have be flat base reach high aug stock get composite rating investor business daily meaning outperform stock currently rank ibd medical biom biotech group celgene celg top spot phase trial patient be underway readout expect mid palsy drug biogen see market evercore analyst umer raffat estimate market be bigger alzheimer biogen be already work other drug used tau palsy alzheimer treatment biogen face abbvie abbv abbvie be also phase testing drug know abbv be similar timeline raffat note phase trial begin january patient second deal roche license bristol drug call bms drug be be develop treatment duchenne muscular dystrophy rare disease characterize muscle degeneration weakness roche pay upfront potential milestone payment tiered double digit royalty drug be approve related roche game changer drug chip away biogen novartisthese biotechs save drug sector dow stock merck undercut astrazeneca lung cancer
174,ABBV,xcelgene celg stock topple thursday biotech miss otezla sale expectation lead overall revenue come light profit top view nickel stock market today celgene stock be earlier dip much share be form flat base possible buy point first quarter end march celgene report sale vs year earlier period lag consensus adjust profit share climb top view cent key product multiple myeloma drug pomalyst imnovid grow sale cancer drug revlimid abraxane grow sale respectively otezla drug psoriasis psoriatic arthritis grow sale lag analyst mizuho analyst salim sy note research report keep buy rating price target celgene stock note biotech expand share psoriasis vs prior quarter ibd take want latest ibd biotech pharma stock coverage head biotech pharma industry stock news page freshest news company cite market contraction psoriasis psoriatic arthritis increase gross net adjustment small inventory drawdown first quarter miss otezla sale otezla bring international sale grow celgene raise adjust earning share target earlier view line consensus expectation celgene also expect have datum phase study multiple sclerosis drug ozanimod end second quarter also thursday astrazeneca azn top earning view have line sale alexion pharmaceutical alxn bristol myer squibb bmy abbvie abbv top metric acorda therapeutic acor have miss late wednesday amgen amgn report better expect earning sale fall short amgen share drop hit soon open early tuesday biogen biib top earning sale forecast biogen fall thursday related amgen trip rival sale miss earning topbiogen earning top drug start wellabbvie hover buy point earning sale top
175,ABBV,very busy week news stock rally solidly market worldwide cheer result first round france presidential election amazon com amzn alphabet googl dow stock mcdonald mcd hit record high earning intel intc starbucks sbux tumble hundred other company report president trump big tax cut plan have lift market anticipation didn move needle outline be finally release major market average jump monday tuesday emmanuel macron lead first round voting french presidential election poll suggest easily defeat nationalist marine le pen early runoff stock largely consolidated gain rest week individual stock sector be active flurry earning internet chip restaurant casino be leader baidu bidu intel starbucks show even lead group have loser nasdaq composite hit record high week climb dow jone industrial average rise index be just time best commerce giant say adjust income rise year year share beating consensus estimate revenue rise top view maintain steady streak double digit revenue gain go back more year amazon web service amazon cloud compute unit continue deliver huge gradually slow growth amazon share rise record high friday clear new buy point close well intraday peak earning google parent alphabet rise revenue rise analyst expect company report earning share sale revenue google other advertising business include cloud compute unit pixel smartphone play store rise mobile advertising growth be bright spot google rise traffic acquisition cost be concern tac refer google pay partner website carry ad pay partner apple aapl generate search traffic alphabet share gap fresh record high friday mcdonald first quarter result beat view burger giant talk tech effort include expand delivery try mobile order pay new digitize restaurant layout share jump record high domino pizza dpz also beat say be testing gps tracking technology chipotle grill cmg beat well analyst debate progress follow food bear illness scare starbucks match profit expectation miss sale worry stall growth starbucks share undercut recent buy point intraday friday close level software leader microsoft msft deliver earning share view fiscal third quarter sale come tad short sale guidance june quarter also be analyst estimate microsoft earn cent share exclude item year year adjust revenue march quarter analyst expect cent current quarter microsoft guide sale wall street have be modele intel earning top chip giant sale fall shy weakness datum center market send share gapping friday macom technology solution mtsi mellanox technology mlnx kla tencor klac skywork solution swks be chip play retreat cavium cavm monolithic power system mpwr rally chipmaker top earning gear maker teradyne ter ultra clean uctt boom result lockheed martin lmt see more international demand fighter missile defense system global tension heat raytheon rtn see significant demand signal munition increase military operation syrium lockheed sale fall short expectation give weak guidance northrop grumman noc general dynamic gd top ep sale defense stock be buy range point week friday close be slightly entry area core boee ba earning jump beating view revenue fall defense revenue fall free cash flow soar aerospace giant raise full year ep outlook midpoint still fall analyst view industrial conglomerate unite technology utx top slim ep sale gain otis elevator revenue aerospace system sale pratt whitney jet engine sale rise boee share rise flat base buy point unite tech be month high edge buy range western digital wdc seagate technology stx largest provider disk drife have differ earning seagate revenue miss estimate stock fall reaction western digital earning beat top bottom line announce very bullish guidance send share friday wynn resort wynn pull ahead forecast cent ep sale macau gaming activity continue rebound la vegas sand lvs ep rise cent top revenue growth meeting view mgm resort mgm top handily top bottom line help takeover borgata hotel casino spa mgm national harbor open wynn resort hit year high mgm rise best share buy range sand advanced consolidation exxon mobil xom report mixed first quarter result say have plan adjust capital expenditure guidance oil major have identify capture capital efficiency exxon warn still need be cautious rebalance oil market chevron cvx swung profit revenue beat wall street estimate overall production rise management say oil remain barrel then future spending be low end capex forecast oil price be modestly barrel baker hughe announce oil rig operation rise straight week foreshadow further production gain mobile tmus top earning estimate continue streak grab most new subscriber wireless operator mobile add postpaid phone subscriber vs year earlier period top estimate mobile share rise new high buy range be expect ramp advertising bundle wireless pay tv offer report line ep revenue fall more expect lose wireless postpaid subscriber more expect subscriber growth directv now stream service help offset surprising weakness directv traditional pay tv business share fall low separately cable giant comcast cmcsa rise new high strength movie business customer gain recall cost slow sale hurt ford earning fall still beat view ford say higher commodity cost particularly steel weigh worst hit profit cost year likely happened general motor gm beat forecast solid truck crossover sale fiat chrysler fcau hold full year outlook keep debt check result come concern slow auto sale rise inventory fall used car price dow jone industrial average equipment maker caterpillar cat earn share more double estimate raise revenue range vs estimate caterpillar good news come lack progress president trump infrastructure program border wall initiative have make caterpillar trump stock ahead earning caterpillar finally break month streak fall retail sale gain be drive construction equipment sale asia pacific region caterpillar share soar buy zone biotechs drugmaker report en masse thursday abbvie abbv alexion pharmaceutical alxn bristol myer squibb bmy deliver board beat pump stock day astrazeneca azn top earning sale slide adjust profit grow top cent top biotechs amgen amgn celgene celg report lag sale thursday acorda therapeutic acor stock hit year low light sale cent share loss ex item also miss even house make push repeal obamacare plan include steep cut medicaid raft insurer moved buy zone flirted breakout push new high catalyst be especially strong earning report anthem antm investor have judge trumpcare remain doom humana hum preview earning raise guidance centene cnc top estimate ceo michael neidorff say expect medicaid heavy insurer thrive reform be pass congress note republican senator come state expand medicaid pultegroup phm top earning estimate revenue fall short meanwhile president trump impose tariff canadian softwood import raise construction cost home new home sale rise march second fastest rate current business cycle pulte tumble do not close prior buy point horton dhi lennar len fall day line well
176,ABBV,drug sector have be upswing recent week result addition dividend leader list abbvie abbv have dividend yield annualize basis be week winning streak indicate ethical drug company be do fall try brother
177,ABBV,xhere weekly investing action plan need know investor come week market get broader view economy lead edge company tech heavy industry defense energy medical sector have turn earning microsoft msft amazon com amzn alphabet googl boee ba caterpillar cat exxon mobil xom
178,ABBV,vertex pharmaceutical vrtx stock pull back friday analyst upgrade share likelihood vertex succeed competitor galapago glpg treat cystic fibrosis needham analyst alan carr upgrade vertex stock buy rating price target top biotech market cap work complete triple pill combination treat genetic mutation tie cystic fibrosis lung disease cf landscape continue favor vertex give substantial lead market few competitor carr write research report expect vertex triple pill combination cystic fibrosis launch late vertex stock fall stock market today biotechs take breather rapid day run carr expect vertex identify least safe effective triple pill cystic fibrosis company be currently testing candidate combination drug know ivacaftor tezacaftor ibd take biotechs be run week generalist investor return space subside worry trump work bring drug price number company see double digit high single digit gain rundown visit ibd industry theme other program be underway galapago abbvie abbv proqr prqr proteostasis therapeutic patient recruitment cystic fibrosis be challenge carr say give vertex lead competitor be likely progress slowly say earlier week galapago say hold trial own triple pill treat cystic fibrosis fourth quarter put galapago more year vertex janney analyst say wednesday related galapago stock fire delay key vertex rivale drugwhy biotech rally still tack upsidebiotechs hit pause day rally regeneron bluebird topple
179,ABBV,bellwether johnson johnson jnj second quarter report bode well biotech sector analyst say tuesday dow component top profit expectation narrowly lag sale view stock market today stock climb biotech stock drop nearly group generic drugmaker inched leerink analyst geoffrey porge remain bullish biotech sector needham analyst mike matson say second quarter result point stable period medtech player boston scientific bsx medtronic mdt stryker syk zimmer biomet zbh quarter drug sale grow sequentially fall vs year earlier period porge partially blame time positive rebate adjustment eliminate year year volume price growth second quarter sale remicade decline year year rivalry biosimilar contribute just decline be lower guidance decline porge write note client ibd take cancer rare disease specialist be expect do well second half positive sentiment return biotech space visit ibd industry snapshot look outperform second quarter also expect currency headwind subside second half call acceleration pharmaceutical unit well positive trend sale outside base presume currency impact firm raise outlook adjust profit share outside drug sale grow sequentially second quarter beating view growth porge say support expectation sequential outside revenue growth company due weaken dollar second quarter say porge expect guidance increase biotechs second quarter earlier week call regeneron pharmaceutical regn easily beat june quarter sale view gilead science gild handily top profit expectation cover company not be negatively impact same prior period adjustment current imminent biosimilar competition surprise consensus remicade market dynamic be view proxy say abbvie abbv see pain sale cancer drug imbruvica grow outside say be partner abbvie imbruvica typically book imbruvica sale porge say translate abbvie imbruvica sale be miss vs consensus estimate say abbvie imbruvica be consider largest growth driver humira patent cliff continue miss consensus expectation repeat second quarter be negative stock related star align biotechs crush earning consensusthese drug giant buy range just beat earning novartis fda cancer also be boon rival
180,ABBV,biotech galapago glpg have shot make dent cystic fibrosis market lag vertex pharmaceutical vrtx analyst say wednesday galapago push key trial analyst head galapago research development event tuesday expect firm outline timeline trial examine pill series treat cystic fibrosis janney analyst debjit chattopadhyay say note client instead galapago be hold trial fourth quarter pending regulatory guidance chattopadhyay say closest rival vertex plan roll triple combo datum third quarter putt galapago more year positive side cf portfolio have multiple shot goal program do get green light galapago be plan execute multiple triple combination mimic competitor vertex say midmorning trading stock market today galapago stock fall close share vertex jump firm be take triple pill approach treat cystic fibrosis disease lung digestive system triplet combination be expect be able treat genetic mutation tie cystic fibrosis ibd take vertex stock be biotechs be watchlist now head ibd industry theme closer look vertex strongest peer galapago be work narrow potential contender final triplet delay begin trial likely mean galapago partner abbvie abbv finalize selection chattopadhyay say credit suisse analyst vamil divan anticipate delay give relatively aggressive timeline company have layer previously galapago first focus market expand triplet other country say note client accord cystic fibrosis market galapago drug need show improvement drug placebo be clinically meaningful trial see galapago grab open prove drug be equivalent vertex also see potential place new player market give increase flexibility give patient physician term enrolling patient new clinical trial prescribe medicine once be available commercially divan say related amgen gilead biogen win lead biotech boom so vertex rocket month high cystic fibrosis drug resultsgalapago cystic fibrosis drug trial vertex mega franchise rbc
181,ABBV,xbiotech stock clovis oncology clvs soar monday strong trial result ovarian cancer drug rubraca meanwhile big pharma stock abbvie abbv moved recent buy zone have relative strength rs rating upgrade year market history reveal stock go make biggest gain typically have rs rating north launch biggest climb see abbvie continue show renew price strength clear threshold abbvie have moved more past entry first stage flat base meaning now proper buy range look stock offer new chance get week tight pullback day week line company see earning sale growth rise last quarter earning share increase revenue rise abbvie earn rank peer medical ethical drug industry group zoetis zts jazz pharmaceutical jazz be also group highest rate stock related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
182,ABBV,clovis oncology clvs tesaro tsro deliver blockbuster ovarian cancer drug grab takeover interest analyst say friday ahead key trial clovis expect later month duo rival bigger astrazeneca azn market cap be more time clovis tesaro combine clovis tesaro joined astrazeneca parp inhibitor market last year parp inhibitor work block family enzyme cancer cell use proliferate pfizer pfe abbvie abbv be also work parp inhibitor credit suisse analyst alethia young see class drug also have impact prostate breast lung cancer think parp inhibitor market be big enough clovis have blockbuster product well write strongly believe company be likely attractive target large global biopharma company later month clovis be expect unveil result phase trial dub ariel drug rubraca tesaro previously set high bar trial drug zejula have benefit patient regardless specific genetic top line basis think ariel work group focus be potential commercial difference use biomarker safety write note client young expect tesaro stock be volatile follow clovis trial note lift overhang share have outperform rating tesaro clovis stock rate tesaro stock price target clovis price target stock market today clovis stock rise tesaro stock gain astrazeneca pfizer abbvie stock be respectively ibd take american society clinical oncology layer battlefield fight cancer company merck bristol myer squibb incyte roche be work combine drug immuno oncology spectrum get more ibd industry theme share fellow cancer biotech incyte incy topple sustain price target cut leerink analyst michael schmidt trim price target incyte stock incyte eli lilly lly rheumatoid arthritis treatment be delay april food drug administration delay approval drug call baricitinib instead ask more information trial now schmidt say expect sale see drug launch schmidt be bullish seattle genetic sgen stock small biotech bristol myer squibb bmy unveil strong datum combination drug adcetris opdivo classical hodgkin lymphoma sign cancer disappear patient series trial combination potentially provide chemotherapy free treatment option patient hodgkin lymphoma relapse be treat surgery schmidt have outperform rating seattle genetic bristol myer stock related tesaro crash beating astrazeneca stronger databristol incyte match beat dow merck combination spotlight drug giant donnybrook cancer treatment
183,ABBV,slew biotechs drugmaker take closer look epizyme epzm small cap biotech present strong datum lymphoma trial wednesday switzerland analyst say thursday finding international conference malignant lymphoma attract like gilead science gild abbvie abbv celgene celg johnson johnson jnj roche rhhby leerink analyst geoffrey porge say note client epizyme be testing drug dub tazemetostat form hodgkin lymphoma interim datum show tazemetostat have clinically meaningful benefit patient call follicular lymphoma buildup cell lymph node tumor shrink follicular lymphoma patient patient aggressive form hodgkin lymphoma specific genetic mutation tazemetostat prove safe patient population leerink porge call study proof principle expect drug accelerate approval food drug administration follicular lymphoma accelerate approval allow drug be market still clinical trial few cancer drug have response rate clinical benefit rate disease say investor debate big group patient really be long treatment duration be not be surprised see epizyme start show potential takeout candidate list epizyme be appeal abbvie celgene roche porge write roche be leader immuno oncology method treat tumor block certain interaction hide cancer cell gilead be better know virology drug include target hepatitis hiv gilead hepatitis franchise decline high cure rate now gilead have say open seek acquisition oncology incyte tesaro be also rumore takeout candidate now molecule tazemetostat have be risk expect more investor get involved stock build position ahead further datum disclosure porge say ibd take seattle genetic chief executive clay siegall say company be aim change year method treat hodgkin lymphoma head ibd technology page exclusive ceo same conference see bristol myer squibb bmy seattle genetic sgen team phase trial classical hodgkin lymphoma also robust result only epizyme stock spiked news bristol myer seattle genetic too have strong datum classical hodgkin lymphoma tumor shrink patient treat combination bristol opdivo seattle adcetris sign cancer disappear patient combo prove safe well bristol say afternoon trading stock market today epizyme stock soar more share have run past day bristol myer stock other hand dip less seattle genetic stock be flat related analyst plead gilead buy have seattle genetic adcetris grab blockbuster status trial dow merck pause cancer trial investigate keytruda tie death
184,ABBV,abbvie abbv be stronger stock bet gilead science gild amgen amgn leerink analyst geoffrey porge say thursday compare biopharmas earning trajectory typical turnover analysis suggest abbvie offer more attractive fundamental base earning momentum dividend yield be only company be likely show sustain improvement operate margin cash flow next year porge write research report gilead abbvie earning growth be largely base operate revenue increase porge note increase be due volume growth humira imbruvica viekira gilead have boost operate revenue increase price franchise hepatitis drug sale say company derive lion share sale single segment gilead see sale spike hepatitis drug sovaldi harvoni hcv be curable disease sale plunge humira abbvie inflammatory have be stronger sale rise be also pit patent battle abbvie claim amgen biosimilar drug infringe humira patent abbvie be shore defend ip humira analyst expect biosimilar come online next few year ibd take biotechs analyst broadly see incyte strong stock option number potential blockbuster drug pipeline read new america better insight firm abbvie be certainly face growth quality issue outlook humira become increasingly uncertain company face generic biosimilar brand threat challenge current blockbuster product franchise porge write still earning momentum look good abbvie january abbvie guide earning share ex item be midpoint outlook didn chip consensus view be gilead forecast have decline significantly past month porge write possible estimate decline more give recent trend note amgen other hand appear stable abbvie stock close stock market today gilead amgen rise abbvie stock be just day line just day line year date basis amgen stock be outperform peer abbvie gilead stock nearly respectively related gilead crash hep sale decline view metric topabbvie merck pressure gilead hep unit gsk battle hiv bizgilead hiv drug top gsk combo rivalry intense gsk doublet
185,ABBV,gilead science gild abbvie abbv benefit merck mrk decision take impairment charge hepatitis drug market price shrink leerink analyst geoffrey porge say friday merck also cut value estimate uprifosbuvir hepatitis drug acquire idenix pharmaceutical base upcoming drug regimen change view whole hepatitis market regulator say merck complete separate trial show add benefit triplet high dose doublet regimen porge say complicate matter high dose doublet be phase testing triplet also suggest remain value rest idenix be now very small porge write research report merck be also seemingly indicate significantly reduce value future participation market be consistent decline market overall ibd take analyst project downfall hepatitis drug sale be warning sign be other market risk read ibd industry theme gilead abbvie johnson johnson jnj bristol myer squibb bmy compete hepatitis market merck charge signal drugmaker expect have lighter sale smaller share initially forecast drugmaker be struggle grow pain follow boom subsequent bust hepatitis drug sale gilead be poster child phenomenon sale sovaldi harvoni topple now gilead be bet hiv drug bictegravir merck too note change patient population dynamic company determine recent change product profile well change expectation pricing market opportunity take together constitute trigger event require company evaluate uprifosbuvir intangible asset impairment merck write filing security exchange commission late thursday morning trading stock market today merck stock be fraction close bell share abbvie inched gilead gain related abbvie stronger bet gilead amgen least leerinkgilead glaxo pit hiv battle struggle vs standard drugscan gilead swivel hiv flounder hep sale gsk rivalry
186,ABBV,satisfy trump administration call deal high drug cost industry leader be propose president lead negotiation drugmaker restrain price allergan agn chief executive brent saunder cite tactic used president john kennedy decade keep steel price administration also waive federal antitrust rule currently prohibit drugmaker discuss pricing so put together guideline follow say voluntary agreement restrain price be very practical solution doesn view do anything impede innovation saunder say wednesday interview bloomberg headquarters new york convince fellow drugmaker agree however be challenge be difficult saunder say big pharma be intense pressure come way reduce price president trump accuse company get away murder threaten use government buy power force price saunder have be outspoken excessive price hike own industry allergan company product range wrinkle treatment botox stomach schizophrenia medicine ceo have implement social contract cap increase annually trump model something pharmaceutical industry maybe look something social contract saunder say easy suggest re already do just be transparent add ask target amount restraint agreement say low single digit rate inflation pharmaceutical giant include novartis nvs japan takeda pharmaceutical abbvie abbv also have take voluntary action cap price increase johnson johnson jnj merck mrk have take step increase transparency price industry have moved quite bit month month saunder say need big push saunder allergan have transform specialty pharmaceutical behemoth series acquisition sale generic business attempt merge pfizer pfe inc megadeal be abandon last year allergan have focuse smaller purchase allergan share be compare rest industry last month ve lose compare gain company standard poor pharmaceutical biotechnology life science index include allergan rather deal saunder be more interested build allergan main therapeutic area include medical aesthetic dermatology eye care central nervous system past month make acquisition worth combine add allergan aesthetic medicine cosmetic surgery line hair restoration skin quality be next frontier say company be currently do research area be huge unmet need say ask valeant pharmaceutical international vrx asset include bausch lomb eye care company once lead saunder say not interested not even piece valeant didn respond request seek comment
187,ABBV,abbvie abbv merck mrk be pressure gilead science gild already burden hepatitis unit rbc analyst michael yee say monday day ahead gilead much anticipate earning report guidance broadly analyst anticipate gilead guide sale assume hep sale guide lower indicate dip hep sale slough earning share item yee say investor likely have little confidence higher revenue so be see risky guidance yee write research report so way think gilead need guide hit quarters hcv need stabilize gilead stock be hammer january follow report market tracker im hep prescription fall sequentially month share have re-cover minimally be now flat year stock market today gilead stock edge cent biotech market cap amgen amgn be slate report earning close tuesday ibd take big biotech leader analyst have be most bearish gilead report slow hepatitis drug sale dive issue ibd industry theme analyst expect gilead post sale ep item vs year earlier period analyst expect sale ep item year respectively guidance be key especially consider struggle hep unit evercore analyst mark schoenebaum write research note monday hep drug sale harvoni sovaldi epclusa comprise gilead total product sale past gilead have comment new patient be healthier schoenebaum say gilead be also likely experience competitive pressure merck zepatier hep pill approval abbvie week regimen yee expect investor key hiv drug sale gilead be likely have phase datum hiv drug bictegravir annual conference retroviruse opportunistic infection croi feb seattle gilead face competitive glaxosmithkline gsk gsk dolutegravir brand name tivicay be already approve food drug administration gilead have say put everything launch gilead yee write be mt everest year come yee have outperform rating price target gilead stock related hcv dip virtually mirror gilead view laggilead clobber hep little value too late nash hiv unitsgilead bulk hiv nash unit hep slump stock week dip
188,ABBV,tesaro tsro stock rocket record high wednesday report cancer biotech be curry takeover interest several drugmaker accord source cite reuter stock market today tesaro stock jump boost ibd company biom biotech industry group gain day tesaro isn seek bid have hire several investment bank include citigroup help explore respond offer insider tell reuter still significant gap bid tesaro valuation tesaro have extensive cancer immuno oncology pipeline only drug phase testing be niraparib niraparib belong class drug call parp inhibitor block specific enzyme order treat cancer ibd take tesaro stock grow lead biotech industry group stock start year have minimum average daily trading volume share else reign head ibd industry theme niraparib be be examine treatment ovarian breast cancer likely compete other parp inhibitor astrazeneca azn clovis oncology clvs abbvie abbv medivation mdvn additional clinical trial niraparib year help close gap tesaro bidder view biotech valuation insider tell reuter tesaro decline comment ibd late last year food drug administration grant niraparib priority review analyst say niraparib hit market early related tesaro astrazeneca shrink clovis ovarian drug cancer pool
189,ABBV,regeneron pharmaceutical regn gilead science gild be most likely beat wall street view june quarter sale profit analyst say monday xleerink analyst geoffrey porge say star align widespread beat biopharma result large cap also see abbvie abbv celgene celg biogen biib gilead most likely top revenue expectation quarter quarter sale abbvie alexion pharmaceutical alxn biogen vertex pharmaceutical vrtx be likely be slow say abbvie biogen be face competition pricing pressure alexion vertex be still high growth company temporary slow revenue growth trajectory pending new indication formulation product write note client health tracker im see abbvie leukemia drug imbruvica testosterone gel androgel likely come materially north consensus humira landing street view other major project be expect miss im datum suggest biogen multiple sclerosis drug tysabri tecfidera beat porge estimate respectively tecfidera however be expect miss street ms drug plegridy avonex be forecast be light come grow competition ms field like roche rhhby novartis nvs sanofi sny roche drug ocrevus be approve earlier year treat relapse remit well primary progressive ms first industry ibd take biotech stock be rank group track sentiment tick ahead second quarter earning season make sure bookmark ibd biotech stock watch pharma industry news latest sector major drug celgene be expect top consensus chemotherapy revlimid likely come consensus porge write pomalyst drug treat blood cancer be expect be higher consensus gilead be likely be biggest second quarter surprise im datum gilead sale top be largely dependent reliability recent hepatitis datum have be unreliable past hepatitis drug sale topple high cure rate accounting highly variable sale hepatitis drug gilead total sale miss porge forecast analyst consensus target same time gilead genvoya hiv drug beat consensus porge write note client amgen amgn be most likely match slightly underperform consensus porge say rheumatoid arthritis drug enbrel be expect be line consensus view top porge view much im datum bone health drug prolium bone marrow stimulating aranesp be project beat help offset expect sale miss bone health drug xgeva other bone marrow stimulant drug porge say however change price dynamic many amgen product make im adjustment factor less reliable porge write call amgen hike price july bump price cancer drug kyproli april adjust profit share side gilead have chance beat consensus view porge say regeneron vertex also top expectation respectively biogen miss earning view due time research development expense not fully recognize analyst estimate porge say abbvie too be likely miss adjust earning share say afternoon trading stock market today ibd medical biom biotech group be fractionally related surprise spike beleaguered biotech stock gilead acquire biotech vertex be still better analystwhy biotech be poise run topple june
190,ABBV,dow jone industrial average continue hit high nasdaq take breather xthat help new buy opportunity take shape etfs big weighting paypal pypl apple aapl be poise buy point first trust equity opportunity fpx be pull back day move average mark record high last week gain early july bounce support line peak fund track ipox index be market cap weight index biggest most liquid initial public offering index set cap weighting constituent be reconstitute quarterly fpx turn april have gather asset biggest sector weighting aug be technology health care consumer defensive top holding include drugmaker abbvie abbv kraft heinz khc paypal pypl paypal have rally year abbvie have advanced kraft heinz be slightly negative top holding account nearly asset fund outperformed vs gain aug accord morningstar inc lag benchmark index past year have outpaced year basis fpx have expense ratio ishare edge msci quality factor qual gain june past buy point june peak be testing support day line second time solid rebound line set buy opportunity fund marked fourth anniversary last month trail year gain year average annual return be just ahead benchmark index advance qual featured column june count top holding monday altrium group mo johnson johnson jnj microsoft msft apple aapl apple leap tuesday heel quarterly earning report qual carry expense ratio wednesday pick remain slightly respective buy point ishare edge min vol usa usmv be just shy flat base entry flexshare quality dividend index fund qdf be less away flat base buy point key index fund be mixed stock market today spdr dow jone industrial average dium spdr spy powershare qqq trust qqq give respectively health care utility retail etfs hold modest gain spdr health care xlv advanced top buy range flat base entry fund be draw close day line set buy opportunity solid bounce oil play be lower west texas intermediate price dip barrel unite state oil fund uso powershare db oil fund dbo gain nearly vaneck vector oil service oih be spdr oil gas exploration production xop sank nearly track fifth straight slide energy bank gold miner also lag spdr gold trust gld ishare gold trust iau be slightly higher foreign etfs ishare msci south korea capped ewy gap fall kospi composite index tumble move send ewy share test day line find support rebound line set potential buy opportunity related dow hold oil reverse higher big dividend play breakoutdow keep streak alive foreign play breaking apple watch big etfs potential breakoutsnap first trust etf be first pick red hot snap ipo
191,ABBV,biotech stock topple midday thursday line broader index include pitfall large player vertex pharmaceutical vrtx unite therapeutic uthr spark therapeutic once long term view look weak uncertain xon stock market today vertex dove unite therapeutic fall spark dip broadly ibd company biotech industry group lose reflect major index trend follow beat amgen amgn biogen biib gilead science gild vertex celgene celg alexion pharmaceutical alxn week vertex increase guidance vertex keep full year view see slowdown third quarter leerink analyst geoffrey porge trim third quarter view vertex cut sale forecast keep outperform rating vertex price target stock get haircut second quarter sale cystic fibrosis drug orkambi kalydeco beat expectation porge note be due inventory stocking ahead anticipate summer slowdown vertex be also work triple pill cystic fibrosis outside cystic fibrosis franchise vertex say earning conference call look make small technology base early stage acquisition likely avoid large stage large investment many investor fear porge say report unite therapeutic second quarter sale be highest company have ever see resumption growth be not guarantee leerink analyst joseph schwartz say note client unite be work drug treat rare blood disease know pulmonary arterial hypertension pah schwartz increase third fourth quarter sale model strong second quarter report ibd take biotechs be now rank fourth group track ibd merger acquisition send higher vertex consider takeover target acquirer circle get deep dive ibd industry theme due lack curative therapy pah provide suite pah medicine keep patient transition unite product say however be reluctant assume rebound product sale quarter materialize resumption growth trajectory other unite product also thursday alexion celgene top expectation alexion rise celgene still dip investor be likely look celgene raise top line guidance instead celgene lift adjust profit forecast year share main surprise result be lack increase top line guidance normally have expect time year leerink porge say second quarter be only time celgene have not increase revenue guidance second quarter elsewhere biotech analyst be more bullish gilead see hepatitis drug sale fall collective slower revenue harvoni sovaldi beat analyst view predict fall porge say raise price target magnitude beat point stabilize hepatitis drug sale say windfall be short live however abbvie abbv next generation doublet be set enter market week be likely represent first real competition gilead hepatitis dominant market position related astrazeneca beat stock dife drug failure more reportthis biotech nearly triple street expectation key druggilead hepatitis franchise topple again share beat
192,ABBV,breakout biotech stock celgene celg clovis oncology clvs bioverativ bivv ireland base ethical drug firm jazz pharmaceutical jazz be try return former wall street glory launch big run developer specialty drug narcolepsy oncology pain psychiatry earn upgrade relative strength rs rating friday year market history reveal best perform stock tend have rs rating least early stage move jazz pharmaceutical make big multus year move run steam february long slump stock have be climb last december be now build flat base buy point see stock break heavy trading revenue growth fall last quarter bottom line grow prior report company earn rank peer medical ethical drug industry group abbvie abbv be rank stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
193,ABBV,medical sector have be gain steam recent week abbvie abbv appear ready capitalize strengthen industry trend recent setback abbvie be face increase competition rival biggest drug humira lose key patent battle coherus bioscience chrs loss allow coherus create similar
194,ABBV,gilead science gild be better acquire vertex pharmaceutical vrtx oncology asset tesaro tsro incyte incy analyst suggest friday lament gilead cautious approach merger biotech market cap have show interest make oncology centric buy struggle decline hepatitis drug sale hepatitis franchise bring north year fall first time leerink analyst geoffrey porge say gilead turn away obvious cancer biotech buy tesaro incyte clovis oncology clvs kite pharma kite instead set sight vertex say likely gilead ignore advice view acquisition grow largely risk revenue stream such vertex much more positively comparable investment set investment intensely competitive technologically uncertain field oncology say vertex offer gilead rare disease portfolio robust pipeline vertex be now work triple pill combination treat cystic fibrosis lung disease year ahead nearest rival galapago glpg abbvie abbv regimen look likely launch gilead have cash meaning company wouldn have stretch too much make acquisition porge say vertex have market cap gilead market cap porge expect gilead pay share vertex stock still make acquisition accretive year realistic synergy together vertex gilead feasibly expand growth time slow grow major pharmas ibd take big biotechs gilead struggle recent biotech rally instead analyst say keep eye biotechs highlighted industry snapshot vertex tow gilead reverse revenue trajectory project decline compound annual growth rate transaction similarly improve expect fractional decline earning estimate growth rate year more likely gilead make series small transaction relatively early stage asset porge say note client win be enough diversify gilead hepatitis roller coaster even help nascent hiv drug bictegravir have be apparent gilead need major acquisition possibly even then be inexplicable company have be so faint hearted exercise cash flow advantage now say company still appear be respond opportunity present rather initiate create opportunity ahead availability even gilead go obvious oncology asset investor question company be pay premium today potential company be apparent last year price be current level porge have market perform rating price target gilead stock valuation say be time low otherwise justify recommendation substantial termination uncertainty make hard see stock recover multiple foreseeable future close bell stock market today gilead stock dip fraction vertex pop much settle be incyte stock fall tesaro stock lose related biotech rally still tack upsideare sanofi gilead bidding war small cap upgrade couldn save vertex biotech deluge
195,ABBV,name abbvie abbv celgene celg tear past week many biotech sector etfs hit week longer high friday take breather retain bulk big weekly gain most biotech fund be extend buy point several be still have pull back respective buy zone instance ishare nasdaq biotechnology ibb rise much entry ease friday be top buy range fund have rally year june accord morningstar inc well slight week decline ytd return same period bioshare biotechnology clinical trial bbc ytd be buy range cup base entry fund be thinly trade average daily volume share vaneck vector biotech bbh nearly year be waffle top buy zone entry year old fund have attract asset analyst attribute rally subside drug price concern be further growth ahead cfra be positive fundamentally biotech industry see strong revenue growth aid robust pipeline todd rosenbluth director etf mutual fund research cfra tell ibd email have buy recommendation abbv amgen amgn biogen biib biomarin pharmaceutical bmrn celg gilead science gild stock fall big cap category market cap north be more favorable larger cap biotechs such think ibb offer best exposure stock say other etfs offer more stock diversification smaller cap exposure provide potential reward also additional risk leverage etfs try magnify return double triple benchmark index day post double digit gain week end june instance direxion daily biotech bull labu seek investment result triple performance biotechnology select industry index lead return bring year date haul proshare ultrapro nasdaq biotechnology ubio aim time nasdaq biotechnology index daily performance rally week ytd return proshare ultra nasdaq biotechnology bib score gain ytd return be well extend such leverage play make big gain go be good tend carry higher risk most traditional biotech sector fund other end spectrum be inverse etfs be design give opposite performance index track fund provide result similar shorting stock index show accompany chart have see loss biotechs have rally likely outperform sector head south don have view leverage inverse etfs other investor easily get hurt hold too long rosenbluth say risk be compound much faster investor appreciate related biotech stock keep new lead top biotech stock remain just buy range
196,ABBV,abbvie abbv expect biggest drug humira hit peak international sale then face erosion cheaper biosimilar enter market analyst say tuesday ub analyst marc goodman keep buy rating price target abbvie stock close stock market today back day line humira be face biosimilar competition outside price decline be year goodman write note client outside remain volume drive business abbvie have more pricing leeway competition erode humira sale outside abbvie plan curtail sale marketing spending specific country commensurate sale erosion goodman say follow meeting abbvie executive ub global healthcare conference hit peak outside sale abbvie expect sale erosion year ibd take first quarter earning just wrapped number drugmaker include abbvie visit ibd technology page closer look outperformed fall meanwhile push mid late stage pipeline include elagolix be be develop neurocrine bioscience nbix treat endometriosis uterine fibroid abbvie be track file application food drug administration elagolix endometriosis third quarter abbvie be also look drug venclexta combination fda approve rituxan johnson johnson jnj pharmacyclic pcyc imbruvica leukemia lymphoma longer term have growth opportunity other form lymphoma leukemia goodman write note client related regeneron sanofi undercut amgen abbvie rheumatoid arthritisabbvie lose key humira patent battle small cap biotech
197,ABBV,exchange trade fund offer market beating dividend be new high ground firmly buy zone spdr dividend sdy break past flat base buy point june remain buy range entry first climb buy point intraday june then pull back ahead occur follow week month pattern begin form week february flat base advanced basis
198,ABBV,fund track high yield dividend aristocrat index comprise company have raise dividend least straight year sdy be underperform broader market year return june vs gain accord morningstar inc etf year average annual return be almost step year period sdy have return average slightly ahead etf annualize dividend yield be ahead benchmark index payout top holding fund include target tgt abbvie abbv company offer annualize dividend yield respectively also make sdy top be longtime warren buffett favorite coca cola ko be pay annualize coca cola have form long saucer handle base buy point start pattern date back april sdy top sector weighting be financial service consumer defensive industrial consumer cyclical account roughly asset follow utility just sdy net expense ratio be largecap dividend dln track index same name also own coca cola hold several other buffett stock such apple aapl johnson johnson jnj procter gamble pg underlie index be make large cap stock be weight value dividend company be project pay next year top hold apple have come pressure recently stock have be trading day move average past week follow drop june news report apple upcoming iphone series handset have slower datum download speed vs rival device market also get hit several analyst downgrade share be still well extend cup handle entry clear january apple coca cola be top holding buffett berkshire hathaway brka portfolio apple annualize dividend yield be johnson johnson offer payout procter gamble yield dln launch june have attract nearly asset have slightly underperform index ytd year year average annual return respectively dln annualize yield be net expense ratio be share climb past flat base entry june ease buy point follow session break again june remain slightly entry etf gain prior flat base february start current pattern march consumer defensive name account nearly dln total asset technology health care financial service stock make apiece follow industrial related apple dife nearly find support day move best pick include bond emerge market etfs big cap robotic outperform outlook china
199,ABBV,tesaro tsro stock plunge thursday sticker shock plan annual price tag ovarian cancer drug zejula putt premium clovis oncology clvs rubraca stock market today tesaro stock dove week low lose much settle share have trade day move average mid march meanwhile share tesaro closest rival clovis oncology astrazeneca azn lift respectively make ovarian cancer drug call parp inhibitor work block specific enzyme cancer cell janney analyst debjit chattopadhyay call reaction tesaro mere sticker shock tesaro list monthly price milligram daily dose zejula approve milligram dose cost be higher clovis rubraca not patient need full milligram dose total patient enrolled earlier study need dose reduction receive milligram dose receive miligram dose receive full dose same number hold real world set blended wholesale acquisition cost decline year original assumption chattopadhyay write note client ibd take tesaro have middling ibd composite rating meaning underperform slightly more half stock term key growth metric better biotech bet be celgene lead cr head ibd stock checkup next pick leerink analyst seamus fernandez estimate tesaro price premium clovis give frequency dose reduction estimate average pricing month say cut price target tesaro stock tesaro zejula launch come wednesday hour news abbvie abbv parp inhibitor veliparib have fail phase trial leerink analyst geoffrey porge say veliparib be not competitive other product class abbvie be testing veliparib combine chemotherapy advanced lung cancer triple negative breast cancer so far parp inhibitor be largely approve ovarian cancer clovis astrazeneca drug be approve patient brca gene mutation have always consider veliparib be weaker potency more limit value other parps porge say note client still view abbvie have best pipeline slow grow large cap stock remove veliparib abbvie pipeline cut sale estimate porge say abbvie be continue testing veliparib lung cancer breast cancer ovarian cancer porge take expectation abbvie succeed cut price target abbvie stock share be unfazed rise related clovis advantage squash tesaro ovarian cancertesaro creep rival cancer drug merger unlikelytesaro sell astrazeneca ovarian cancer trial overdo analyst
200,ABBV,abbvie abbv stock plummet low early friday drugmaker report light sale earning meet wall street expectation abbvie maintain guidance stock market today abbvie stock fall earlier fall much share last hit level early december continue trade day day move average abbvie report sale item vs year earlier quarter miss analyst view earning share item rise meet consensus similarly abbvie sale ex item be short consensus analyst poll thomson reuter ep item year rise meet view abbvie also keep earlier guidance ep item bracketing consensus view bit light midpoint guide ep item be midpoint guidance ibd take rival abbvie be top growth stock other be ipos head ibd industry theme name related gilead clobber hep little value too late nash hiv unitsamgen gouge top pick abbvie humira biosimilar myer gain lung cancer square vs merck jeffery
201,ABBV,gilead science gild amgen amgn abbvie abbv underperform leerink analyst geoffrey porge predict monday fourth analyst week hammer gilead decline hepatitis drug sale stock market today gilead stock slip share have fall past trading day wall street chatter hep sale market tracker im say hep drug prescription decline hepatitis drug harvoni sovaldi bring total product sale decline total product sale drug sale topple year year gilead launch epclusa third hep drug last summer gilead be face competitive pressure hep unit treatment time be shortening porge say see gilead hep sale decline then year decline be be drive patient presentation dynamic price duration share trend gilead be likely accelerate better competitive hcv regimen come market write research report ibd take gilead be expect struggle decline hep drug sale cancer biotech incyte be poise outperform broader industry dig new america more incyte needham analyst alan carr last week say gilead bulk again hiv nash nonalcoholic steatohepatitis unit porge isn bullish opportunity be arrive too late too little value say outlook company hiv business remain positive be not sufficient offset unusual dynamic hcv business relatively modest contribution other product offer little mitigate effect boom bust hcv say porge expect gilead major unit narrowly miss consensus expectation im datum suggest better expect harvoni sale expect epclusa sale im datum also predict major product abbvie amgen miss consensus respectively write porge keep market perform rating share gilead amgen abbvie boost price target gilead stock amgen maintain price target abbvie amgen have form cup handle base buy point fall monday abbvie stock slip related gilead boost hiv nash drug hep slump stock week dipgilead merck alexion view hazy biogen surge analystgilead outlook hamstrung hep rbc bullish amgen biogen
202,ABBV,drugmaker roche rhhby merck mrk pfizer pfe likely disappoint guidance abbvie abbv stock remain top pick jeffery analyst jeffrey holford say friday research report rundown ahead earning stock market today abbvie stock fall ibd company medical ethical drug industry group fall fall day move average week abbvie be face pressure amgen amgn biotech market cap prep deploy humira biosimilar abbvie humira world top selling drug be used treat array disease include rheumatoid arthritis psoriatic arthritis crohn disease ulcerative colitis abbvie patent protect dose scheme humira be set be deliberate court feb patent administer milligram antibody day be set expire june patent likely be upheld bar entrant first filer amgen holford say ibd take low holford totem pole merck step eli lilly biogen deliver new drug approval else curry fda support head ibd industry theme more see patent block patent potential humira biosimilar give be assume biosimilar be develop be dose same concentration frequency write worst case scenario amgen launch humira biosimilar mid assume first filer doesn launch risk holford see share downside humira biosimilar launch give consensus expectation launch abbvie holford list novartis nvs bristol myer squibb bmy astrazeneca azn strong pick pfizer merck nordisk sanofi sny be opposite end holford list expect disappointing guidance nearly big cap drugmaker expect disappointing guidance majority eu large cap pharma roche novartis pfizer astrazeneca likely disappointing revenue guidance pfizer astrazeneca merck roche also expect disappoint earning share guidance write upcoming catalyst include datum roche aphinity trial examine perjeta regimen positive breast cancer holford lean positive outcome sense high degree uncertainty write merck keytruda combination eli lilly lly alimta be also pique investor interest combination immunotherapy chemotherapy be grant priority review first line small cell lung cancer month holford note fda accept application small datum set therefore combo be unlikely see wide use also see consensus too bullish combo undervalue immunotherapy combination like bristol myer astrazeneca first line small cell lung cancer related gilead outlook hamstrung hep rbc bullish amgen biogenbristol myer dife opdivo setback get keytruda royaltiesfda track record bode well merck keytruda chemo leerinktrump disastrous pharma view doesn rattle jpmorgan drug conference
203,ABBV,biotech industry be slate close double digit top performer cancer specialist rivale astrazeneca azn abbvie abbv ipos be prep end year triple digit gain biotech market cap tesaro tsro outlast bigger rival amgen amgn biogen biib top ibd company medical biom biotech industry group tesaro stock rise group contrast fall tesaro performance make seventh best perform stock year stock start year have minimum average daily trading volume share month tesaro win priority review food drug administration ovarian cancer drug niraparib niraparib belong class drug call parp inhibitor company be study inhibit enzyme be key treat cancer ibd take donald trump election cause biotech pharma stock wall street first relief wouldn battle rise drug price then worry president elect pledge take fight typically have be lead democratic party tesaro fda come day fda approve clovis oncology clvs ovarian cancer drug previously astrazeneca be alone market have parp inhibitor approve used medivation mdvn abbvie too be testing parp inhibitor dermatologic biotech novan novn gene therapy firm avexis avxs follow tesaro top performer ibd biotech group novan jump september ipo rise friday avexis stock rise follow initial public offer february immuno oncology biotech merus mrus file ipo rise stock market today merus stock fall remain extend buy point achieve dec merus compete merck bristol myer squibb bmy roche rhhby astrazeneca other immuno oncology market immunotherapy target body immune system help fight cancer reata pharmaceutical reta also file ipo rise nearly fall friday reata work primarily oxidative inflammatory drug top then come theravance biopharma tbph supernus pharmaceutical supn xencor xncr ibd company medical ethical drug industry group year only august ipo protagonist therapeutic ptgx land list top performer year protagonist stock rise related tesaro bolt ovarian cancer drug vs astrazeneca abbvie
204,ABBV,medical behemoth amgen amgn biogen biib square acquire muscle biologist cytokinetic cytk more dozen potential player prep donnybrook small cap pharmaceutical adms needham analyst suggest friday biotech fodder heated week allergan agn announce back back deal acquire vitae pharmaceutical vtae tobira therapeutic tbra tobira deal give allergan leg battle nonalcoholic steatohepatitis nash gilead gild intercept icpt pharmaceutical also compete ibd company biotech industry group have climb group track just week collectively group have market cap group group fall friday first decline past trading day group be week needham analyst review pipeline business development area interest activity large company gauge interested big pharma be biotechs important theme biotech space write research report allergan amgen bristol myer squibb bmy johnson johnson jnj merck mrk pfizer pfe roche rhhby shire shpg valeant vrx have be most acquisitive buy prep buy more company collectively shire have be most active acquisition believe late development stage commercial stage biotech company be particularly attractive acquisition target write research report title do big pharma want buy peak area interest include oncology cardiovascular needham research show not be big pharma take beaucoup buck needham analyst suggest central nervous system cns player acadium pharmaceutical liver disorder drugmaker intercept be prime acquisition interest firm overlap potential interest acadium abbvie abbv allergan eli lilly lly lundbeck merck novartis pharmaceutical nvs teva pharmaceutical industry teva takeda pharmaceutical needham list potential acquirer allergan make particular sense consider duo already partner next generation formulation memantine fix dose combination product namzaric battle alzheimer year end plan file new drug application food drug administration ad treatment levodopa induced dyskinesia involuntary movement parkinson disease patient multiple sclerosis walking impairment needham write meanwhile acadium potential suitor be interested nuplazid drug ease psychosis associate parkinson launch earlier year needham suggest acadium be look expand label other used similarly intercept draw interest nearly dozen potential buyer include gilead biotech market cap thursday rbc analyst posit intercept continue lead gilead allergan battle nash ibd take biotech stock notch higher week last week check ibd industry theme
205,ABBV,recent wall street darling sarepta therapeutic srpt isn only potential takeover candidate hot potentially hot biotech company say rbc capital market research report wednesday rbc analyst list ariad pharmaceutical aria spark therapeutic once biomarin pharmaceutical bmrn aerie pharmaceutical aeri intra cellular therapy itci tesaro tsro incyte incy puma biotechnology pbyi well sarepta top takeover contender late stage fda approve blockbuster franchise sarepta stock rocket monday fda approve drug treat duchenne muscular dystrophy first drug approve treat rare disease sarepta stock hit time high wednesday first time march sarepta close stock market today close sarepta announce plan offer stock finance further trial production other drug effort share be little change late ibd company medical biom biotech industry group rise wednesday sixth straight gain touch month high intraday group rank group track just week second half be likely prove rally point biotech stock rbc analyst say biotech sentiment continue improve investor climb wall worry get year past election believe have be mostly base political rhetoric analyst write ibd take many biotechs fair number stock overall have recently hit week high check stock list composite rating ibd new high list be good feature check winning stock furor have be heating biotech sector past month biotech acquisition value have be announce rbc say smattering smaller deal tuesday allergan agn announce agreement acquire liver disease drugmaker tobira therapeutic tbra much big deal pending pfizer pfe be buy medivation mdvn june buy anacor pharmaceutical also abbvie abbv be acquire privately hold stemcentyrx shire shpg baxalta complete merger june related sarepta soar fda approve drug treat muscular stock hot sarepta provide shot arm
206,ABBV,american airline aal cut annual share buyback more sharply next year ease capital return have be more aggressive rival raymond james say research note wednesday american second quarter return more shareholder buyback quarterly dividend payment american return dividend buyback prediction smaller repurchase come day microsoft msft repurchase program dividend increase cent overall firm spend share buyback smallest quarterly total factset say come set post recession high apple aapl lead buyback last quarter follow general electric ge microsoft msft drugmaker abbvie abbv factset say report tuesday american share fall stock market today rebound intraday loss major average rebound fed left rate unchanged delta air line dal close higher unite airline ual dip ibd take company have be take advantage low interest rate borrow money stock repurchase also help boost company earning share thin supply outstanding share
207,ABBV,raymond james also downgrade american airline market perform outperform due valuation relative rival slash earning share target largely due new labor agreement be bigger expect firm cut ep target american labor deal announce august provide significant pay increase maintenance fleet service other employee carrier say time other airline have attempt strike deal worker oil glut lower fuel cost cushion carrier profit labor cost pressure be be feel industry unit cost casm headwind american be unlikely be highest follow year industry increase raymond james analyst savanthi syth write note lower oil price prompt wave competitive growth hurt unit revenue much money airline make compare available seat flight flight coverage however delta southwest luv have signale more operational discipline be horizon potentially improve much watch metric american unit revenue be also likely improve recent credit card deal better result latin american region be also likely help raymond james add however expect similar favorable trend legacy peer syth say additionally follow departure scott kirby consider architect last year ultra low cost carrier pricing strategy believe investor question american pricing strategy move forward syth write expect roll product similar delta basic economy remain priority potential upside estimate southwest share rise low cost carrier spirit airline save edge related profit delta american unite suffer unite airline rebound next yeardelta say flight cancellation cost cite other industry airline beat delta unite american revenue recovery
208,ABBV,facebook fb chipmaker advanced micro device amd have price target raise armour uaa have price target cut amgen amgn be upgrade social networking leader have price target raise rbc capital market maintain sector perform rating facebook report fourth quarter earning market close wednesday beat wall street expectation revenue rise also top view rbc say facebook continue benefit surge advertiser demand drive newer ad format such video improve ad target tool facebook stock fall close stock market today briefly go positive advanced micro device have price target raise canaccord genuity buy rating late tuesday chipmaker deliver better expect result give strong guidance amd stock rise close follow pop wednesday amgen be raise buy neutral bofa lynch price target ahead quarterly report close thursday biotech giant amgen be putt pressure abbvie abbv amgen prep deploy humira biosimilar abbvie humira world top selling drug be used treat array disease include rheumatoid arthritis psoriatic arthritis crohn disease ulcerative colitis amgen stock slip cent end regular trading session share climb shortly close bell telsey advisory group slash price target armour maintain market perform rating armour report fourth quarter earning late tuesday disappoint say cfo chip molloy be step due personal reason key holiday shopping season armour logged revenue growth weakest gain year send share tuesday armour stock be hit fresh year low
209,ABBV,here investing action plan thursday need know investor come day busy week earning reach high point report amazon amzn amgen amgn royal dutch shell rdsa chipotle cmg visa mks instrument mksi retail chain also issue january same store sale figure largely disastrous holiday
210,ABBV,here weekly investing action plan need know investor come week earning appetizer market sample past few week shift rich meaty entree heavyweight alphabet googl alibaba baba microsoft msft intel intc boee ba mcdonald mcd starbucks sbux chevron cvx report quarterly result president trump
211,ABBV,biotechs have lot ride drug datum ibd company medical biom biotech industry group plunge rocky election year relief hillary clinton lose white house spiked group nearly week follow election gain have dissipate donald trump pledge tackle rise drug price group have face challenge day move average april meanwhile large cap amgen amgn vertex pharmaceutical vrtx be trading pipeline valuation accord rbc analyst michael yee tug sentiment month low require strong drug datum remain potential coil spring catalyst company go play many large pharmas continue be hunt yee write dec research report see ariad pharmaceutical aria incyte incy tesaro tsro biomarin bmrn possible acquisition target outside yee say lack material catalyst get sector move ibd take top biotechs end triple digit gain outplay broader industry be biotech pick list check ibd industry theme deeper dive nearly dozen biotech company year be slate post key drug trial datum just key arena drug treat spinal muscular atrophy drug treat cystic fibrosis parp inhibitor treat several type cancer therapy treat lymphoma success turn sentiment positive second failure weigh many drug stock spinal muscular atrophy result wasting away muscle lead early death see least new datum sector also host yee recent research report call overall drug industry only new real launch year biogen biib ionis pharmaceutical ion team develop spinraza brand name nusinersen drug target single rna treat symptom sma ionis ceo stanley crooke tell ibd recent biogen exercise worldwide right spinraza august food drug administration approve spinraza late december first sma treatment get fda approval crooke say expect biogen bring drug market early year describe sma diabolical disease chemically denervate body be fatal infant progress toddler rob ability walk eat breathe own affect motor nerve cell spinal cord accord cure sma spinraza launch midcap cytokinetic cytk be expect release result phase trial ck describe novel skeletal muscle troponin activator help treat sma patient other suffering similar degeneration ck differ spinraza aim slow rate calcium release regulatory troponin complex fast skeletal muscle fiber phase trial examine sma patient look patient chronic lung disease trial result latter further future cytokinetic be lightly trade small cap have ibd relative strength rating best possible stock buy zone late december hit entry point cup handle formation have slip thursday close trigger sell rule anytime stock fall least buy point share rise handful cystic fibrosis trial be expect wrap vertex triple pill have spark most analyst chatter yee credit suisse analyst vamil divan say phase datum vx vx be likely be available latter half trial result sooner vx vx vx be be investigate prong treatment cystic fibrosis genetic disease cause mucus collect block airway damage digestive system vx be phase testing result patient population expect first half year yee estimate vx vx vx add long term sale vertex see fairly good chance triple work second half drive company growth note investor remain wary vertex stock fall be year fall thursday vertex be far alone cystic fibrosis game many other publicly trade biotechs be expect release clinical trial datum mid cap biotech pct therapeutic pctc appear furthest phase datum translarna due quarter pct trial examine cf patient nonsense mutation accord cystic fibrosis news translarna potentially make cellular protein machinery run so call stop sign cf cause cftr gene replace amino acid similar enough allow protein do work clovis oncology clvs pull ahead tesaro late december fda grant accelerate approval parp inhibitor rupacarib day later fda give tesaro parp inhibitor niraparib priority review be duke rival lynparza parp inhibitor approve astrazeneca azn be deadlock race treat ovarian breast cancer clovis be track unveil phase datum rupacarib sell brand name rubraca patient brca mutation latter half brca mutation be often associate breast cancer tesaro niraparib be deck phase breast cancer phase ovarian cancer datum second half niraparib have prescription drug free user pdufa date june accord biopharma catalyst fda tracker niraparib rupacarib olaparib chemical name astrazeneca lynparza class drug call parp inhibitor several form cancer be dependent parps type enzyme inhibit enzyme company clovis tesaro astrazeneca hope treat several cancer abbvie abbv pfizer pfe acquisition medivation also be work parp inhibitor abbvie veliparib miss several endpoint include progression free survival pfs phase trial recurrent metastatic breast cancer brca mutation unveil early december phase testing be underway veliparib be also be investigate treatment small cell lung cancer nsclc pfizer acquire medivation september medivation talazoparib be development treat breast cancer germ line brca mutation neither abbvie pfizer parp inhibitor be expect have datum ariad kite pharma kite seattle genetic sgen look poise lead lymphoma battle many publicly trade biotechs be expect present datum year vary drug next month kite kte likely come away solid month durability datum diffuse large cell lymphoma dlbcl say rbc yee lead roll biologic license agreement bla pdufa date year end kte belong class drug call car cell therapy drug patient immune system fight specific cancer kite drug be be investigate treatment refractory hodgkin lymphoma relapse refractory mantle cell lymphoma ariad pharma other hand already have pdufa date april brigatinib treatment anaplastic lymphoma kinase positive alk metastatic small cell lung cancer nsclc resistant crizotinib pfizer chemotherapy pdufa date be april first line datum win be available competitor roche rhhby have similar datum rival drug due same time frame ariad complete new drug application nda brigatinib october also seattle genetic be angle fourth indication approve adcetris adcetris be be examine treatment cutaneous cell lymphoma ctcl also unveil result yearlong phase trial adcetris chemotherapy front line hodgkin lymphoma seattle genetic be try establish redefine front line therapy hodgkin lymphoma nearly year same therapy ceo clay siegall tell ibd recent interview related investor siphon biogen ionis gain spinal disease drug okionis pharma eye sustainable profitability fda approvalamgen plan robust alzheimer migraine oncology ceo myer win seek accelerate opdivo lung cancer
212,ABBV,drugmaker thursday dividend leader have plenty go re not screamer mean be grow nicely compelling pipeline solid dividend yield pfizer pfe look poise clear long consolidation last month share slump nearly week end aug report second straight quarter double digit earning
213,ABBV,drugmaker abbvie abbv pfizer pfe be featured ibd daily income investor column last month be know steady grow dividend well consistent profit growth name have come selling pressure recent week bellwether income stock group be trading tightly high deserve closer look ibdchart symbol mrk
214,ABBV,typically slow stretch late august biotech news be bound pick company prepare fall season conference investor day most stock move event likely be update key clinical trial several expect september celgene celg be due release long await midstage trial result ged mongersen drug crohn disease license drug initially spark excitement wall street strong week remission rate beat even lead inject tumor necrosis factor drug such abbvie abbv humira johnson johnson jnj remicade amgen amgn enbrel next datum set cover full year evaluate patient endoscopy rather just symptom investor confidence be somewhat shake celgene refuse provide interim analysis trial interpreted lack confidence number leerink analyst geoffrey porge write close inspection earlier datum also raise red flag trial be consistent earlier phase ii result original investment be make endoscopic remission rate be range be well see even best biological immunomodulator porge write july research note fact assessment earlier result lack crp reactive protein response be biomarker crohn disease inflammatory activity suggest result be materially lower tnfs remission rate more likely be range note ged be oral rather inject still find market niche not be mega blockbuster initially hope ibd take medical biotech group have be roll lately rise ibd industry group ranking last week see other industry be hot follow industry theme column kite pharma kite be expect release headline datum zuma phase trial car cell therapy kte diffuse large cell lymphoma car cell chimeric antigen receptor cell be genetically engineer attack cancerous cell trial result be crucial kite hope use file fda approval treatment make first car therapy hit market next year rbc capital market analyst michael yee estimate friday study yield overall response rate percent tumor shrank perhaps complete response rate tumor disappearance base earlier datum initiation report tuesday btig analyst dane leone write much depend datum stack result competitor juno therapeutic juno novartis nvs be yet unknown novartis present pivotal datum set ash potential first datum cd specific antibody write leone refer american society hematology conference december juno be also expect present clinical update ongoing cd trial vertex pharmaceutical vrtx provide report triplet pill cystic fibrosis consist already market drug ivacaftor kalydeco combine experimental drug vx additional drug vx vx trial ivacaftor vx alone recently fail do present clean safety profile analyst have be expect triplet be next generation treatment case also month fda be due render verdict expand label vertex already market cf drug orkambi child age related be epipen price fda fault hold new generic novartis close cell therapy unit car stock tumblebiotech stock seesaw hope meet new pricing fear
215,ABBV,big pharmas abbvie abbv merck mrk trade higher friday report estimate beating result friday french counterpart sanofi sny close virtually flat abbvie quarterly sale grow year earlier quarter pass analyst consensus largely strength sale immunology drug humira sale blood cancer drug imbruvica also beat expectation abbvie slightly increase tighten full year ep guidance call growth last year share finished higher stock market today merck also beat estimate more narrowly raise low end full year ep guidance range merck also announce friday hepatitis drug zepatier have be approve european union month approval zepatier sell beating consensus evercore isi analyst mark schoenebaum note merck best selling diabetes drug januvia seem be hold competition eli lilly lly jardiance cancer drug keytruda beat consensus largely international sale recall merck recently announce success keynote trial first line nsclc small cell lung cancer attention investor come year focus performance indication schoenebaum write email merck stock edge ibd take abbvie rank ibd medical ethical drug group solid financial decent stock performance group overall be just total check ibd industry theme take temperature stock industry group sanofi meanwhile miss sale estimate quarter affirm full year ep guidance contrast merck sanofi diabetes franchise have be shrink face competition drop worldwide other noteworthy news japan astella marketing partner sanofi takeover target medivation mdvn report quarterly financial suggest medivation lead drug xtandi miss sale consensus globally be line medivation stock rise hit month high edge past buy point sanofi close cent
216,ABBV,specialty drugmaker insys therapeutic insy pop tuesday fda approve cannabis derive drug aids related weight loss nausea induced chemotherapy drug syndro be liquid formulation dronabinol pharmaceutical version active ingredient marijuana capsule form drug call marinol be sell abbvie abbv insys ceo john kapoor say press release liquid form be easy swallow allow dosage be titrated clinical effect once syndro have be open do not need be refrigerate day insys say expect convert large portion dronabinol market syndro launch sometime year end announcement continue recent march good news cannabinoid follow gw pharmaceutical gwph positive trial result different cannabinoid treat epilepsy area insys be also study insys stock jump much stock market today touch month high stock close just just stock day move average last week stock be aug time high dog issue related lead product subsys form opioid painkiller fentanyl company employee have be investigate marketing drug indication cancer related pain serious issue number person have die fentanyl overdose include pop star prince bad publicity contribute sale miss estimate fall year year first time company go public
217,ABBV,official start summer just few day away mid large cap fund have turn best performance so far year small cap techs go early break take beating week contribute market outlook downgrade market uptrend pressure dow jone industrial average have continue climb new high lead diversify stock fund be ishare edge msci usa momentum factor mtum month gain june accord morningstar inc etf boost year date return well ahead advance also capture ibd relative strength rating second best top perform diversify stock etfs other top performer month period include vanguard dividend appreciation vig guggenheim pure growth rpg vaneck vector morningstar wide moat moat click here see list best perform etfs be expectation earning head second quarter earning momentum be strong richard turnill blackrock global chief investment strategist write june note prospect tax reform have be fading depress expectation lower bar positive surprise value financial technology select health care dividend grower also have positive view overseas earning europe european central bank recently maintain dovish policy stance point lift growth forecast trimming inflation outlook see global reflation improve earning outlook support cyclical exporter particularly industrial multinational emerge market exposure say see level support populism european election partly shape investor sentiment here be etfs key asset class have produce big gain so far year past month mtum mentioned come first diversify stock etfs top holding include blue chip such apple aapl bank america bac jpmorgan jpm microsoft msft heavy tech presence biggest sector weighting mtum be still time high be well extend february subsequent bounce day line fund turn year old april have outperformed longer haul year average annual return be vs benchmark index gain tech stock get batter recently tech focuse fund be top sector performer social medium robotic semiconductor make show medical tech play spdr biotech xbi rise month bring ytd return june thank part big recent gain stock such abbvie abbv regeneron pharmaceutical regn fund launch january have produce solid return respective year period share be flat base buy point climb past entry intraday wednesday foreign stock space spdr china gxc gain month ytd return year old etf have attract asset count top holding tencent tcehy alibaba baba jd com jd recent economic datum show sign china economy be slow blackrock turnill doesn expect hard landing be good news china slower growth say modest slowdown first quarter unexpectedly strong pace be welcome view china rebalance economy downshift more sustainable pace growth less reliant credit related strategist best pick include bond emerge market etfssocial medium china internet stock fuel top etfs
218,ABBV,regeneron regn sanofi sny rheumatoid arthritis drug be cheaper rival drug amgen amgn abbvie abbv roche rhhby analyst say tuesday duo kevzara grab food drug administration approval kevzara approval come month fda delay approval issue manufacturing french factory drug be filled approval be patient moderate severe rheumatoid arthritis don respond other rheumatic drug approval come time label more less match expectation leerink analyst geoffrey porge say note client kevzara be prescribe alone combination fda approve methotrexate be self administer injection roche actemra belong same class drug kevzara be associate increase risk serious minor infection liver issue injection site reaction also discount actemra annually discount offer cost effective treatment option payer set porge say kevzara cost less amgen enbrel abbvie humira be widely prescribe rheumatoid arthritis different drug class ibd take regeneron be lead biotech resurgence year analyst say head ibd technology page deeper dive amgen gilead science gild biogen biib aren expect be forefront revitalization regeneron sanofi expect european approval come later year see kevzara hit market few week porge see drug minimal driver forecast sale year grow number drug class address rheumatoid arthritis note field be likely become more crowd later year dow component johnson johnson jnj add drug sirukimab lineup more class dub jak inhibitor arrive kevzara contribute approximately expect sale joint sanofi regeneron product fall long term expect growth eczema drug dupixent even cholesterol lower drug praluent rapidly eclipse kevzara importance porge say consensus forecast kevzara sale year grow hit stock market today regeneron stock rise sanofi stock fall share rival amgen abbvie be respectively roche dip related comeback kid regeneron survive amgen cholesterol squeeze regeneron pop better fear eye cholesterol drug sale
219,ABBV,coherus bioscience chrs stock rocket month high wednesday board tossed key patent protect abbvie abbv most important drug arthritis medication humira thus clear obstacle similar treatment coherus late tuesday patent trial appeal board rule abbvie patent review invalidate dose patent humira rheumatoid arthritis increase chance launch coherus be know biosimilar generic biosimilar be intend be cheaper alternative patented drug be produce used live material rather chemical small cap biotech coherus biotech amgen amgn be work copycat abbvie top moneymaker humira be approve food drug administration treat rheumatoid arthritis psoriatic arthritis plaque psoriasis crohn disease arthritis affect spine do not mean coherus amgen anyone launch tomorrow do trigger process be likely result launch least year possibly year earlier consensus expect leerink analyst geoffrey porge say still porge keep market perform rating price target abbvie stock close stock market today coherus be month high abbvie stock fall ibd take abbvie stock have ibd composite rating meaning be outperform nearly stock term key growth metric still trail zoetis zts stock cr best possible head ibd stock checkup latest humira bring sale accounting abbvie total revenue last year patent protect humira composition matter expire so patent invalidate tuesday be see main obstacle biosimilar biosimilar now use same weekly milligram injection technique abbvie used humira infringe abbvie patent abbvie also have prevailed protect formulation patent set expire be upheld biosimilar need try work raffat write note client knowledge coherus have be very public intent do so meanwhile abbvie be also fend patent battle amgen amgen biosimilar amjevita be approve september amgen have say win launch litigation district court trial date have be schedule fall technically just act go district court appeal court drag time frame raffat say credit suisse analyst alethia young say decision be simply positive coherus negative abbvie note coherus be also work copy amgen bone marrow stimulant neulasta young question abbvie pipeline be robust enough offset decline humira sale evercore raffat note abbvie be enter very datum rich period pipeline related vertex big winner biopharma abbvie astrazeneca dip
220,ABBV,exchange trade fund offer market beating dividend be new high ground hover buy point spdr dividend sdy climb past flat base buy point intraday friday settle just entry monday close fractionally lower current month pattern begin form week february flat base advanced basis fund track high yield dividend aristocrat index comprise company have raise dividend least consecutive year sdy be underperform broader market year return june vs gain accord morningstar inc etf year average annual return be closer year period sdy have return average just ahead etf annualize dividend yield be ahead benchmark index payout top holding fund include target tgt abbvie abbv company offer annualize dividend yield respectively also make sdy top be longtime warren buffett favorite coca cola ko be pay annualize friday stock price largecap dividend dln track index same name also own coca cola hold several other buffett stock such apple aapl johnson johnson jnj procter gamble pg underlie index be make large cap stock be weight value dividend company be project pay next year fund launch june have attract asset slightly underperform index ytd year year average annual return respectively dln annualize yield be share clear flat base entry friday close monday penny buy point etf gain prior flat base february start current pattern march check monday etf pick india focuse fund close largely unchanged remain buy range recent rebound respective day line be ishare msci india inda powershare india portfolio pin vaneck vector india small cap scif india earning fund epi related play offer chance ride india stock market rallymiss thursday breakout fresh idea market hit high etfs watch hold buffett dividend stock
221,ABBV,loxo oncology loxo stock defy broad biotech dip monday spiked record high show drug larotrectinib shrink tumor number different cancer share loxo end monday regular session catapult higher follow presentation saturday american society clinical oncology annual meeting chicago company eli lilly lly merck mrk bristol myer squibb bmy roche rhhby be attendance loxo drug belong class immuno oncology agent aim inhibit family protein loxo be now set begin phase trial larotrectinib adult colon cancer child tissue tumor respond treatment big cap name weren big winner wall street instead company bluebird bio blue surge bluebird stock get jump present strong datum drug dub bb treat multiple myeloma monday bluebird say patient trial bb respond treatment relapse therapy be well tolerate leerink analyst michael schmidt say report have outperform rating bluebird stock ibd take supernus pharmaceutical supn stock have ibd composite rating best possible base key growth metric lead ibd company biom biotech industry group keep tab industry leader ibd stock checkup puma biotechnology pbyi stock lift rival roche unveil result yearlong test drug specific group breast cancer patient result be low end investor expectation rbc analyst matthew eckler say bode well puma be work drug call neratinib address same group patient eckler say roche drug herceptin perjeta be test adjuvant treatment treatment be add decrease risk relapse now assume adoption neratinib be largely unencumbered adjuvant use herceptin perjeta eckler write note client keep sector perform rating puma stock boost price target however puma bio share close well intraday high highest november tg therapeutic tgtx stock also cut wide berth monday rise much give gain back close earlier day tg have positive result trial abbvie abbv johnson johnson jnj form leukemia related dow merck clearly win vs bristol roche cancer trialstesaro crash beating astrazeneca stronger datum
222,ABBV,big biotech gilead science gild beat earning estimate lower full year revenue guidance late monday send stock more hour trading gilead sale earning decline last year hepatitis drug sovaldi outperformed expectation newer cousin harvoni come short epclusa next generation hcv pill be approve just day end quarter already bring gilead price epclusa much lower previous drug reflect new competition abbvie abbv merck mrk sovaldi harvoni officially retain higher price tag gilead have be rebate heavily say monday rebate have continue increase hiv franchise be also mixed bag perennially popular truvada beating estimate most other drug underperform company trim full year product sale guidance now also lower guidance sale general administrative expense raise research development guidance slightly leave overall cost look more less same gilead do not provide ep guidance lower sale suggest possible margin squeeze gilead stock rise monday regular session share be year
223,ABBV,here investing action plan need know investor come week more tech giant apple aapl facebook fb amazon amzn alphabet googl report earning do biggest name oil such exxon mobil xom chevron cvx fast food leader mcdonald mcd aerospace giant boee ba federal reserve policymaker
224,ABBV,food drug administration tuesday approve gilead science gild latest hepatitis pill company price significantly lower previous drug drug epclusa improve gilead previous drug sovaldi harvoni treat major genotype hepatitis virus hcv enlarge market eliminate need genotype testing most patient regime be pill day week patient decompensate cirrhosis very advanced liver disease take ribavirin standard generic hcv medicine gilead representative cara miller tell ibd email wholesale price week regimen drug be quite bit sovaldi harvoni raise outcry drug be launch respectively hcv business however have get more competitive then abbvie abbv merck mrk launch treatment significant discount treatment be genotype strain make market merck zepatier also be approve genotype miller note current standard treatment patient genotype be sovaldi combine bristol myer squibb bmy daklinza together cost twice much epclusa gilead have say position epclusa mainly genotype treatment be most difficult treat sound obviate need sovaldi harvoni company have engage extensive rebate keep drug competitive also many patient take harvoni only week gilead say have plan study shorter duration treatment epclusa gilead position anticipate cannibalization sovaldi revenue gt gt patient harvoni revenue gt patient due more friendly regimen potential omit ribavirin shorter duration gt patient write leerink analyst geoffrey porge research note porge forecast epclusa sale year jump next year expect quick drop next generation treatment start come note estimate be almost double consensus however fda approval be widely expect gilead stock shot stock market today gilead stock hit year low monday share tumble friday monday brexit vote fallout
225,ABBV,biotech tesaro tsro soar record high early trading wednesday drug candidate ace late stage trial ovarian cancer tesaro divide patient have recurrent ovarian cancer respond platinum therapy group base type cancer have germline mutation brca gene better know association breast cancer have median progression free survival pfs rate month be tesaro drug niraparib compare just month control arm patient do not have mutation also enjoy longer pfs not much month vs month control group patient homologous recombination deficient hrd tumor identify myriad genetic mygn mychoice hrd test show pfs month tesaro stock more double close stock market today myriad genetic rise result be bit surprise class drug niraparib belong call parp inhibitor have checker history previous candidate fail clinical trial astrazeneca azn manage conditional approval drug lynparza re analysis previous datum lynparza be still market ovarian cancer fail trial stomach cancer last month other parp inhibitor testing include abbvie abbv veliparib late stage testing breast lung cancer medivation mdvn talazoparib also late stage testing breast cancer medivation ibd stock finished wednesday abbvie add astrazeneca gain
226,ABBV,swiss pharma giant novartis nvs cut licensing deal california biotech xencor xncr early stage blood cancer treatment be worth company announce tuesday novartis agree pay upfront rest clinical regulatory sale milestone drug candidate xmab xmab make market candidate acute myeloid leukemia cell malignancy be set begin clinical development year novartis pay royalty foreign sale xencor retain right novartis also have right select more candidate development use xencor bispecific antibody technology develop more drug bispecific antibody be fragment different antibody used direct body immune system attack cancer cell deploy body cell new technology be pursue several company include amgen amgn make own licensing deal xencor september well abbvie abbv regeneron pharmaceutical regn view favorable term receive xencor consistent thesis bispecific antibody be poise play more important role cancer immunotherapy write leerink analyst michael schmidt research note praise great economic deal xencor deal also enlarge novartis toolkit blood cancer company have be leader develop much watch chimeric antigen receptor cell therapy most advanced candidate be ctl acute lymphoblastic leukemia xencor stock catapult close stock market today touch month high novartis stock be
227,ABBV,bristol myer squibb bmy astrazeneca azn roche rhhby pressure merck mrk slew lung cancer drug design chip keytruda share jeffery analyst jeffrey holford say monday downgrade merck stock stock market today merck fall bristol myer squibb climb merck bristol myer be lock battle small cell lung cancer market drug leverage patient immune system battle cancer holford downgrade merck stock underperform price target expect strong keytruda performance follow pressure rival drug bristol astrazeneca roche chip away keytruda market ibd take next year be marked new presidency path donald trump take drug price merck screen poorly many valuation metric have downgrade share underperform holford write research report same note upgrade bristol stock buy price target holford expect opdivo trial secure bristol future more broadly prefer abbvie abbv eli lilly lly stock astrazeneca novartis nvs stock europe see pfizer pfe johnson johnson jnj merck sanofi sny nordisk nvo least prefer stock related gilead pay merck hep patent agio stock anemic
228,ABBV,federal jury late thursday order gilead science gild pay royalty ruling merck mrk patent hepatitis drug be valid gilead say appeal verdict gilead sovaldi horavni have cure rate more be very expensive merck have own hepatitis drug zepatier didn get approval gilead treatment well viekira pak abbvie abbv gilead science fall friday open bell stock market today merck rise separately agio pharmaceutical agio tumble premarket say late thursday be discontinue second candidate pyruvate kinase deficiency rare form anemia discussion fda liver toxicity agio pharma be still continue work pkd candidate ibd take drug price fear have weigh pharmaceutical stock year pre elect trump push sweeping drug price control breaking fellow republican
229,ABBV,share abbvie abbv have be act lot more bullish past week make sharply improve chart slumping mid august stock gap oct drugmaker third quarter earning miss expectation company sale humira drug rheumatoid arthritis psoriasis irritable bowel disorder be disappointing humira be key product
230,ABBV,orasure technology osur stock be set cup handle formation thursday unveil hepatitis contract foreign government likely add sale canaccord analyst mark massaro estimate late afternoon trading stock market today orasure stock rise defy day tech stock general share remain entry point be past month ibd company medical product industry group year fall thursday day most tech drug group fall massaro keep buy rating orasure stock boost price target follow company analyst day wednesday orasure didn identify foreign government say other government be expect order hep test kit up sale view model earning share ex item cent cent consensus analyst poll thomson reuter currently model cent ibd take biotech drug stock initially rise donald trump election help pull several related etfs etfs be often proxy broader market visit etf center best bet trump presidency basically raise revenue estimate be related announcement orasure officially complete large hcv hiv order large international government seek eradicate hepatitis country massaro write note contract be product testing treatment program eradicate hep country orasure provide oraquick hcv rapid antibody test oraquick rapid hiv antibody test outside hep hiv orasure announce personal genomic firm helix use saliva dna collection device orasure subsidiary genotek exclusive contract massaro classify helix decision major platform orasure helix be form illumina ilmn provide individual sequence affordable price backed warburg pincus kleiner perkin other next year massaro expect firm add thousand new customer perform more test orasure think helix become revenue year customer year write helix orasure announce be also work china face company include wuxinextcode wegene genesis healthcare orasure didn announce replacement abbvie abbv be withdraw hep co promotion agreement orasure end month duo agree end agreement july be originally slate run related amgen gilead eli lilly eat abbvie humira sale analyst
231,ABBV,regeneron regn eylea become default blurry eye drug ophthotech opht fovista fail late stage trial monday send stock record low rbc analyst adnan butt say ophthotech stock plummet stock market today regeneron stock other hand rise rival news retake day move average news have little impact roche rhhby novartis nvs novartis acquire right ex sale genentech drug lucentis genentech be acquire roche ophthotech trial test fovista conjunction lucentis ibd take biotech drug stock be underperform recent rally donald trump election president elect say go rise drug price get full scoop ibd technology page novartis roche stock dip respectively monday duo have split outside sale ophthotech fovista aim treat wet age related macular degeneration amd ophthotech test fovista lucentis vs lucentis alone patient combination regimen gain mean letter vision early treatment diabetic retinopathy study etdrs chart year monthly treatment counterpart lucentis monotherapy gain average letter result weren statistically significant ophthotech say secondary endpoint change baseline combination patient gain more etdrs letter month mark compare lucentis monotherapy patient follow ophthotech flop rbc butt posit regeneron rival treatment eylea become standard care wet amd diabetic macular edema butt have outperform rating price target way regeneron stock overhang be fovista success approval disrupt market eylea more doctor try combine nearly free avastin label fovista improve outcome patient write research report still other overhang persist butt write regeneron remain patent litigation ldl buster praluent develop sanofi sny amgen amgn amgen repatha be approve summer also belong class drug call pcsk inhibitor manufacturing concern linger regard eczema treatment dupilumab rheumatoid arthritis med sarilumab butt note sarilumab be develop conjunction sanofi compete abbvie abbv humira currently drug sale related ophthotech eye disease med beat rival pharmaceutical fall combo therapy eylea alone
232,ABBV,drug giant eli lilly lly be poise jolly december datum ruling come positive credit suisse analyst vamil divan say eye be new datum eli lilly solanezumab alzheimer disease drug predict have probability success legal decision regulatory ruling surround lilly jardiance alimta trulicity also be expect next month eli lilly stock use year end bounce share be year fall stock market today ibd company medical ethical drug industry group fall more tuesday phase datum lilly sola be due day now definitely year end divan write research report tuesday sola act neuroprotector patient alzheimer success boost rival biogen biib have similar drug development divan predict lilly stock soar more sola show significant functional benefit show trend function even show functional benefit predict drop sola miss cognition ibd take december be jolly more just eli lilly drug stock have rally election donald trump be see more business friendly hillary clinton happen trump make good promise repeal affordable care act outlook isn certain grab ibd industry theme deeper dive addition food drug administration be due make decision december expand label jardiance type diabetes med risk be skewer downside most observer be expect fda approval divan say also patent litigation be ongoing lilly alimta chemotherapy cancer lung most expect patent expire regardless divan note also come week lilly be due release interim analysis study type diabetes drug trulicity news flow win end initial guidance be expect jan fda approve baricitinib rheumatoid arthritis drug conjunction incyte incy mid january write baricitinib belong class drug call jak inhibitor gilead science gild be work jak inhibitor be abbvie abbv pfizer pfe have approve be currently trial expand use incyte also have jak inhibitor market janus kinase jak be family enzyme drugmaker believe block enzyme treat certain cancer inflammatory disease editor note correct last graph company be work jak inhibitor already have market related gilead scoop incyte cancer drug prove not good enough amgen gilead eli lilly eat abbvie humira sale analyst
233,ABBV,average earning growth rate past quarters abbvie abbv be income stock solid profit fact pharmaceutical company ep rating be best stock friday dividend leader screen result year average ep growth rate annual earning increase past year other dividend leader have ep rating even abbvie pay quarterly dividend cent share annualize yield last year abbvie have make rapid increase dividend hike time cent share early highest dividend growth rate ibd database company do have big debt burden develop new drug long term debt lease obligation totale more time shareholder equity abbvie biggest product be humira drug various digestive ailment account sale second quarter more adjust total revenue few day food drug administration warn recurrence hepatitis patient be take newer medicine hepatitis wall street journal report include abbvie viekira pak be part new generation drug cure hepatitis week course much less time older treatment last year stock have be long consolidation peaked july have decline much be not severe institutional quality stock stock be volatile second half share be decline have be trading much more steadily especially june low indicate larger participation major investor be ultimately stock abbvie be doubt institutional favorite be hold more mutual fund include dozen ibd performance rating
234,ABBV,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
235,ABBV,ethical drug industry group have be see increase strength past week wednesday abbvie abbv be discuss ibd income investor column potential beneficiary merck mrk be strong candidate merck keytruda drug continue show substantial sale growth april vs prior month market share rise same
236,ABBV,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
237,ABBV,vertex pharmaceutical vrtx be big winner friday wake slew biotechs drugmaker issue first quarter report thursday stock market today vertex rise climb much best level january meanwhile ibd company biom biotech industry group edge higher celgene celg bristol myer squibb bmy rise respectively abbvie abbv stock drop buy point temporarily achieve thursday share fall friday astrazeneca azn stock fall vertex investor be now key triple pill treatment cystic fibrosis leerink analyst geoffrey porge say report friday see chance vertex successfully bring triple pill regimen market ibd take navigate biotech trading world be tricky relatively unknown name esperion therapeutic espr launch nearly mere month head ibd technology page primer industry player look good vertex decide phase strategy triple regimen latter half biotech be currently evaluate next generation drug be used combination tezacaftor ivacaftor cystic fibrosis drug porge raise price target keep outperform rating vertex stock note investor likely prod vertex stock raise guide cystic fibrosis drug kalydeco separate report porge boost price target celgene stock keep market perform rating miss sale psoriasis psoriatic arthritis drug otezla lead overall sale miss porge note catalyst celgene future celgene portfolio be undoubtedly broader peer management appear be focuse create long term shareholder value focus later stage clinical program write note celgene have key trial multiple myeloma hodgkin lymphoma brain tumor crohn disease have generally be cautious view several late stage candidate celgene pipeline however now expect several key inflection point late stage candidate celgene pipeline next couple year say abbvie buck rocky earning season trend meeting consensus view first quarter sale grow revenue humira porge say report adjust income beat cent result other biopharma name drug immuno oncology market have be volatile notable miss mainly attribute overall market weakness say abbvie result suggest part trend also come share loss give solid performance humira abbvie biggest moneymaker porge be more constructive abbvie outlook year year abbvie see sale top porge boost price target abbvie stock keep market perform rating related acorda topple year low street lag sale lossesalexion beat first quarter sale profit top cent
238,ABBV,abbvie abbv stock rocket month high hover thursday top drugmaker report first quarter sale profit top wall street expectation stock market today abbvie rise close buy point flat base begin mid march share rise high intraday first quarter end march abbvie report adjust income share sale respective vs year earlier period analyst have modeled share sale sale humira abbvie biggest moneymaking drug grow humira sale be consensus view line leerink analyst geoffrey porge view pricing volume challenge note biopharma company immunology drug do not seem have impact humira same degree suggest humira formulatory position have remain largely unchanged reduce risk subsequent revenue miss say ibd take johnson johnson jnj first quarter report be expect have highlighted multiple issue biotechs drugmaker thursday bristol myer squibb bmy alexion pharmaceutical alxn also deliver board beat head ibd technology page deeper dive result porge keep market perform rating abbvie stock imbruvica cancer drug bring sale year year basis imbruvica bring line consensus view leerink forecast porge write note client abbvie note fda accept application imbruvica treatment graft versus host disease quarter graft versus host disease occur foreign tissue be introduce body organ transplant drug be be develop johnson johnson company later confirm guidance adjust earning share midpoint guidance also thursday celgene celg report better expect first quarter earning sale come short fellow biotech giant amgen amgn beat earning miss revenue late wednesday celgene amgen fall respectively related amgen trip rival sale miss earning topcelgene earning top biotech sale missbiogen earning top drug start well
239,ABBV,biogen biib report better expect first quarter earning sale early tuesday help strong start new drug consensus consensus be biogen report sale adjust earning share result biogen report adjust earning share nearly revenue sale drug spinraza only medication approve treat spinal muscular atrophy reach first quarter payer be push back first year treatment cost spinraza be approve type spinal muscular atrophy most payer be only reimburse cost patient most severe form stock action biogen stock rise close stock market today tysabri drug sale rise worldwide most biogen multiple sclerosis franchise show decline ms drug soon see competition roche rhhby roche drug ocrevus be approve late march primary progressive relapse remit form ms drug biogen abbvie abbv novartis nvs sanofi sny be only approve relapse remit form ms ocrevus be enter nascent primary progressive ms market be only drug approve ocrevus be likely gouge share rival second quarter analyst have say ibd take biogen be consider takeover last year strong multiple sclerosis franchise potential spinraza still air month span chief executive today biogen look much different head ibd technology page look biogen be still strong acquisition candidate related street watch see drug boost biogen result
240,ABBV,abbvie abbv get breathe room rheumatoid arthritis eli lilly lly incyte incy drug be hit delay food drug administration weekend leave lilly instead focus pfizer pfe rivale breast cancer med friday fda ask more dose information lilly incyte rheumatoid arthritis drug baricitinib cause be lengthy delay release so lilly breast cancer drug know abemaciclib be now especially important lilly leerink analyst seamus fernandez say abemaciclib compete pfizer ibrance novartis nvs kisqali cdk inhibitor market drug aim inhibit specific set enzyme thought be tie breast cancer lilly model be currently forecasting global sale abemaciclib overall cdk market reach more fernandez write note client fernandez say abemaciclib be next major catalyst lilly stock phase datum abemaciclib be expect june believe abemaciclib ability dose continuously together safe manageable tolerability profile likely make abemaciclib highly competitive novartis kisqali provide opportunity differentiate pfizer ibrance secondary efficacy measure response rate fernandez say analyst keep outperform rating price target lilly stock lilly share topple much stock market today close day ling buy point incyte stock tumble delay baricitinib mean likely win get fda approval launch remove term rival abbvie humira also put lilly incyte year pfizer xeljanz more line generic competition analyst expect drug be delay least year share lilly incyte topple early monday baricitinib already have be approve use europe baricitinib be likely delay fernandez expect peak sale be approve lilly still benefit sale europe drug have attain approval ibd take ibd company ethical drugmaker industry group have rise group track just week head ibd stock checkup list top rate drugmaker other analyst agree year delay baricitinib be more cautious lilly breast cancer drug bmo analyst alex arfaei call abemaciclib biggest remain uncertainty lilly see datum likely disappoint still have not see much datum indicate cdk inhibitor be meaningfully differentiate write report datum american association cancer research suggest abemaciclib be not selective ribociclib kisqali ibrance arfaei cut price target lilly stock maintain forecast sale growth lilly diabetes drug trulicity jardiance basaglar psoriasis drug talz drug offset decline mature franchise write however forecast revenue compound annual growth rate lilly guidance partly more conservative assumption mature franchise related eli lilly incyte stock break key level fda drug biogen takeover prospect soured mere monthsbiotech split axovant ride ceo swap celgene partner dife
241,ABBV,drug stock topple month low tuesday dow component johnson johnson jnj report first quarter pharma sale only advanced offer weak harbinger sector late afternoon trading stock market today ibd company ethical drug industry group be fraction earlier lose much touch low not see november biotech stock be less injured be still collectively lose much report light first quarter sale cent beat bottom line leerink analyst geoffrey porge say result highlight multiple issue large biotechs worldwide pharma sale grow just vs year earlier quarter miss expectation international drug sale beat pharma sale miss porge write research report oncology sale lead growth legacy product remicade stelara xarelto offset volume decline low growth price hike alexion pharmaceutical alxn abbvie abbv celgene celg derive large portion sale international market benefit worldwide pharma growth be reflect sector porge have outperform rating alexion stock market perform rating abbvie celgene stock ibd take ibd ethical drug industry group be now rank group track just week biotech industry group be perform much better rank seventh week head ibd stock checkup list strongest stock higher utilization independent patient assistance program timing medicare part cost higher drug access discount leave celgene amgen amgn vulnerable biotechs porge say cite commentary have market perform rating amgen stock pricing power appear remain strong do report lower price government manage care channel impact annual comparison write do not anticipate issue be isolate alone impact broader biopharma industry drugmaker evercore analyst umer raffat note struggle diabetes unit invokana sale be year year be reflect eli lilly lly diabetes franchise leerink analyst seamus fernandez earlier say unit help lilly overcome struggle rheumatoid arthritis drug raffat note pricing pressure cardiovascular drug xarelto be reflect bristol myer squibb bmy eliquis xarelto sale fall vs year earlier period silver line report year year growth imbruvica cancer drug partnership abbvie company be now look have imbruvica approve treat patient suffering graft versus host disease occur foreign tissue be introduce body organ transplant related dow johnson johnson set lackluster result lilly survive rheumatoid arthritis flop breast cancer drug
242,ABBV,eli lilly lly incyte incy share plunge monday morning food drug administration fail approve rheumatoid arthritis drug baricitinib say more datum be need eli lilly incyte disagree fda friday decision come somewhat surprise european regulator approve baricitinib february lilly incyte have conduct more clinical trial satisfy fda delay set drug several rival lilly reaffirm earning sale guidance year incyte discuss matter conference call eli lilly fall close stock market today eli lilly have fall buy point clear early march incyte tumble plunge day move average setback lilly incyte be good news dow jone industrial average component pfizer pfe have only oral jak inhibitor rheumatoid arthritis market xeljanz gilead science gild have similar oral drug baricitinib phase trial fellow dow component johnson johnson jnj abbvie abbv amgen amgn have injectable drug pfizer gilead amgen johnson johnson abbvie rise less morning action
243,ABBV,goldman sachs add biopharma abbvie abbv conviction list hike price target susquehanna fbr capital rate marathon oil mro outperform btig research downgrade verifone system pay neutral goldman sachs add abbvie conviction list hike price target view investor continue underappreciate substantial cash flow generation humira treat crohn disease next year company diversify late stage pipeline say jami rubin goldman sachs analyst report abbvie stock rise stock market today related merck glaxo undercut gilead next mount everest drug susquehanna upgrade marathon oil outperform fbr capital initiate coverage outperform rbc capital hike price target marathon oil stock climb friday jump thursday reach agreement canadian natural resource cnq purchase stake athabasca oil sand project related dow exxon mobil royal dutch shell announce energy deal oil undercut btig research downgrade verifone neutral buy raymond james hike price target payment company verifone stock fall related square pop record high earning show momentumpiper jaffray lower price target finisar stifel cut price target fiber optic component maker share plunge friday finisar late thursday report fiscal third quarter earning revenue miss expectation related finisar flub earning revenue outlook miss stock plungesin other analyst move jeffery hike price target rignet rnet rbc capital upgrade lhc group lhcg buy hike price target
244,ABBV,drug giant eli lilly lly gilead science gild face key food drug administration action tuesday affect future lead disease treatment franchise advisory committee fda meet discuss expand label jardiance lilly year old drug treat type diabetes lilly want add label be drug also reduce death cardiovascular cause hospitalization heart failure risk death general claim be base large long term trial call empa reg result surprised industry last year patient jardiance show reduction death cardiovascular cause reduction hospitalization heart failure cut death cause fda approve label expansion lilly sale rep be able use marketing drug problem accord leerink analyst seamus fernandez be be not primary endpoint trial be secondary exploratory endpoint primary endpoint be point measurement major adverse cardiac event mace time first cardiovascular related death fatal heart attack fatal stroke result be more mixed only first point do jardiance achieve statistically significant difference fatal stroke incidence be actually slightly higher placebo group fda release briefing document panel friday morning fact conclusion affirm study do show reduction cv death advise include mace heart failure cause death info label be nonetheless interpreted positively analyst lilly stock be stock market today general brexit sell panel also consist substantial portion cardiologist help tilt balance highlight cv benefit panel view fernandez write research note friday preview event june fernandez have predict panel be battle statistical purist vs clinician add clinically large consistent cv death benefit see empa reg trial be view be precedent set precedent also be interest nordisk nvo recently report similar study diabetes drug victoza also bring reduction cardiovascular death not extent jardiance do nordisk have say also file label addition hasn yet decide language danish diabetes specialist fall friday tuesday also be deadline fda decide approve gilead latest hepatitis pill gilead last hepatitis launch sovaldi harvoni break financial record be restrict certain genotype virus new pill be approve genotype not only enlarge market also remove need test patient genotype writing prescription wall street have doubt fda approve drug interesting question be gilead price launch december sovaldi gain notoriety price week regimen harvoni launch october be more however abbvie abbv launch compete viekira pak december company start rebate war hit gilead income then january merck mrk price new hcv drug zepatier well gilead abbvie acknowledge hit financial remain be see gilead value pan genotypic nature new drug gilead stock be friday hit year low abbvie sank merck
245,ABBV,jerry dodson parnassus endeavor fund parwx prove have socially responsible cake eat too mutual fund favor company provide employee outstanding workplace so do other fund parnassus investment dodson founder include thing offer worker profit sharing time work parent paid time volunteer work fair treatment clear communication investment team parnassus have management also screen company engage extraction exploration production manufacturing refine fossil fuel none criterium have prevent endeavor outperform peer broad market past year be top perform environmental social corporate governance esg fund year end june average annual return decade say morningstar inc averaged yearly gain span fund also rank top large cap growth mutual fund period top past year be ibd best mutual fund award winner glow category equity fund growth fund large cap outperformed year period end dec be ahead roughly diversify stock fund so far year dodson affinity esg investing have deep root founder parnassus investment age goal mind earlier work be harbinger be come political science major uc berkeley get mba harvard business school then go work nonprofit outfit help minority own business help organize continental saving america become president ceo develop innovative product depositor invest solar energy project dodson be lead manager parnassus fund parnx parnassus asia fund pafsx sole manager endeavor office san francisco year old dodson talk investor business daily in out investment approach begin use social screen ibd re juggle tough task not only use esg criterium also run concentrated portfolio be tougher dodson know hard part be get philosophy tweak simulation be do many year once understood strategy work size portfolio just follow ll be surprised take advice journalist size strategy be social friend milton moskowitz be writing news story start book be best place work look return be publicly trade thought start fund base milton thought stick company disagree say screw anyway take year look fundamental metric correlated good stock performance take year back testing paper then more year run portfolio open public ibd aside esg criterium look seek large cap company wide moat strong competitive advantage quality management team act best interest shareholder have get right dodson succinctly ibd information technology be largest sector weighting march be typical exposure tech dodson usually be largest sector not normally reason be know sector well silicon valley be road more more right here city also term workplace technology company seem step ahead provide good environment google alphabet googl now have generous maternity leave gym work day do charitable event compare say steel industry workplace issue score stronger tech company ibd speaking alphabet be trend sideway late april do still stock dodson start buy december now low think make more gain re right be pretty flat regard long term hold get great moat good social story ibd do think have more room run dodson primarily moat look develop new product have huge cash stake talented workforce search engine give revenue earning stability don know new idea re work know re look new product ll find something ibd general emphasize esg criterium more other right dodson be more focuse workplace company treat employee then environment workplace be component social ibd be workplace part social dodson word social cover lot mean company treat employee mean safety record privacy policy relationship community company operate diversity program good clear honest communication ibd do ever invest stock feature be very attractive even financial performance be not so bright dodson past ve do do endeavor fund parnassus fund parnx stock be control datum supercomputer company hire former prisoner do great social thing business strategy be just invest be worst mistake ever have cure pick environmental social reason alone ibd let talk individual holding latest disclosure citrix system ctxs earning share rise past quarters lot person think enterprise software developer specialize desktop virtualization lose focus reorganization have involved layoff staff contractor do situation look dodson reason invest be gotomeeting app be be spun gotomeeting be similar citrix xenapp be thousand mile away server do application use smartphone laptop deliver safely mobile device make successful person want application company deliver want ibd stake apply material amat be be satisfied progress dodson be doldrum initiate position equipment used make semiconductor tend be volatile sale earning be very cyclical try buy time stock have fall then ride now rise believe apply benefit significant order growth lead etch deposition tool ibd ciena cien earning share have slow growth quarters growth decline past frame everything dodson ve own quite more volatile expect make communication glass wire equipment move impulse be voice datum transmission line earning have be lumpy time have equipment maker have up down ve hold cycle more volatile expect company think have more upside ibd do own robinson worldwide chrw not tech story revenue have decline quarters row dodson freight forwarder focuse trucking re right hasn do well primarily shipping have not picked much anticipate economy be grow annualize rate less get trucking freight forwarding grow economy have grow more so play economic recovery accelerate average cost be stock be mid so ve do well ibd charle schwab schw ep grow have accelerate quarters share price have be weak play here dodson re tie pay schwab customer come key lot brokerage firm include schwab collect interest margin loan interest rate so low don make much interest rate increase then huge earning increase schwab mid now go economy get better rate go schwab take ibd intel intc ep growth be speeding growth computer chip come dodson make chip personal computer smartphone other application also make chip server sale be go ve be try year get mobile device market finally have semiconductor go iphone re try get more communication other growth area apple aapl chip other mission re banking move intel higher ibd procter gamble pg be classic defensive stock revenue share have decline quarters be want dodson re right revenue decline ve get amazing brand crest tide gillette head shoulder need new growth engine re look do have growth ahead haven reach conclusion ibd ibm ibm ep be straight quarters sale be frame row invest
246,ABBV,dodson only defense be warren buffett own lot more do first buy end expect turn cut emphasis hardware point growth consult software offset decline hardware hasn happened yet time forward earning believe share price be bargain table ibd be buffett selling dodson look filing ve see sign buffett selling sure have same regret have ibd grainger gww ep sale finally notch gain decline quarters share be not make headway dodson grainger make everything sun maintenance sense be play overall economy economy grow fast enough grainger do well product touch almost sector economy ibd gilead science gild ep revenue growth have slow recent quarters do still stock dodson be expect sale increase quite bit hepatitis product have cut price competition abbvie abbv merck mrk make therapy hep gilead be great lab develop new therapy time company do well ibd fund begin different name name change jerry dodson way pick stock hasn change start workplace fund have good performance early name workplace fund be not get attention thought person staff say get strange reaction broker advisor weren sure name meant not pick more general name say say get more shareholder money more acceptance ibd be fund concentrated dodson primarily find enough company be undervalue meet workplace social criterium ibd fund have name typical be dodson have name re look more last couple year go so ibd fund have cash weighting be hard find kind stock dodson correct try stay fully invest possible ibd jerry make day run fund do run totally pc fund know only invest ammo tobacco oil dodson endeavor manage include longer exist other parnassus fund prior find manager founder parnassus investment prior work year president small bank san francisco spend year foreign service officer department state serve panama vietnam ibd be investment style embraced esg dodson ve embraced esg firm be founder be founding principle ibd get esg dodson personal philosophy have always revolve esg wasn sure be used business philosophy continental start program allow saver put money special saving account be lend solar energy installation much pleasant surprise program be very popular convince be market investor want make positive impact money lead founding work asset money fund take esg factor account investing money market security turn lead formation parnassus investment take esg experience then add value oriented philosophy benjamin graham writing admire strain form basis parnassus investment philosophy ibd do come parnassus name dodson live street parnassus avenue san francisco look mythology mount parnassus greece discover be site oracle delphi like image oracle often go prevailing wisdom fit contrarian value oriented investment philosophy ibd re do have plan retire dodson plan retire chief executive officer however plan stay indefinitely manager endeavor find someone well qualify take
247,ABBV,big pharma abbvie abbv tumble stock market today so so datum newly acquire cancer drug spark downgrade sunday annual american society clinical oncology asco meeting researcher present early stage datum rova drug be develop stemcentrx abbvie agree acquire april study treat patient recurrent refractory small cell lung cancer sclc show high expression biomarker dll abbvie say patient show tumor shrinkage be alive year median overall survival os be month be significant give year survival rate sclc be only still result compare unfavorably month os study combine bristol myer squibb bmy drug opdivo yervoy latter have toxicity issue similar chemotherapy rova appear deliver response be transient don translate long term survival benefit write cowen analyst steve scala note downgrading abbvie stock market perform outperform contrast bristol myer combo show more durable response early sign os curve flatten abbvie fall stock market today undercut recent buy point abbvie stock break last week reach month high friday intraday reflect high expectation rova datum accord analyst bristol myer squibb stock rise soar long time high consolidate several week bristol myer clear consolidation april
248,ABBV,william blair initiate coverage amazon com amzn outperform rating rbc capital hike price target apply material amat wedbush lower target wesson swhc bmo capital market downgrade drug maker abbvie abbv william blair initiate coverage amazon com outperform rating cite potential growth company amazon web service business amazon stock have gain nearly have ibd composite rating possible william blair also initiate coverage blue nile nile wayfair market perform rating amazon share close friday reuter also report just close amazon launch stream music service rbc capital raise price target semiconductor equipment gear maker new buyback program reduce share count generate cent upside fiscal ep estimate say rbc report apply material be also largest maker machine produce flat panel display speculation apple aapl other smartphone maker start use new type screen base organic light emit diode oled technology apply material stock have gain have ibd composite rating share finished lower friday bmo capital market downgrade abbvie market perform morgan stanley have also downgrade maker immunology drug humira wednesday concern increase competition abbvie stock be even so far drug maker have ibd composite rating share edge friday wedbush lower price target wesson maintain neutral rating wesson stock be hammer last week firearm background check rough gauge industrywide sale drop vs april share reversed lower close rally bell other analyst move oppenheimer raise price target visa citigroup initiate coverage harris hrs buy rating fbr capital upgrade joy global joy outperform price target goldman sachs initiate coverage allegion alle outperform rating rbc capital start hubspot hub outperform rating price target
249,ABBV,french drugmaker sanofi sny danish pharmaceutical firm nordisk nvo see stock diverge sharply friday firm differ outlook decline insulin price american drugmaker abbvie abbv topple sale miss nordisk stock plunge close stock market today splitting sanofi stock instead rise sweeping beat upbeat guidance abbvie stock fall abbvie report sale earning share ex item respectively vs year earlier quarter ep top consensus analyst poll factset sale miss model abbvie humira bring sale year year miss consensus expectation evercore analyst john scottus write research report late thursday rival amgen amgn report light sale enbrel compete note abbvie also narrow full year view ep item still bracket analyst model increase quarterly dividend cent cent begin february ibd take ibd company medical ethical drug industry group have see slightly better day topple group track just week other sector be precipice rebound keep tab industry snapshot find industry be heating already be red hot sanofi nordisk diverged friday result sanofi boost ep view announce euro repurchase program end other hand expect low single digit growth total sale acknowledge decline insulin sale price important market insulin sale decline now expect growth local currency robust sale diabetes treatment victoza tresiba also contend contract loss usa novolog novolog mix loss exclusivity product hormone replacement therapy usa further intensify competition diabetes especially usa company say press release report sale dkk danish krone roughly ep item respective vs year earlier quarter sale miss consensus analyst poll factset sale dkk ep ex item beat view however sanofi top analyst expectation euro roughly sale vs last year ep item year year analyst poll factset have broadly modeled euro base strong sanofi expect total ep grow constant exchange rate related eli lilly abbvie top ranking pfizer astrazeneca flail
250,ABBV,eli lilly lly pfizer pfe gilead science gild be chip away abbvie abbv humira sale credit suisse analyst vamil divan say monday abbvie miss expectation friday primarily decline humira sale divan downgrade abbvie stock neutral cut price target model humira pull sale decline respectively humira account abbvie sale drug be used treat rheumatoid arthritis psoriasis irritable bowel disorder market brand rival be already market biosimilar be pressure abbvie patent humira abbvie be work protect patent divan expect amgen amgn other have biosimilar market be other year point humira start decline divan write research report cope humira decline miss expectation abbvie have late stage drug capable bring combine sale ibd take abbvie earning have grow average past quarters have also decline last period get full scoop ibd income investor pfizer eli lilly incyte incy gilead be work class drug call jak inhibitor compete arthritis celgene celg novartis nvs eli lilly have il il inhibitor psoriasis expect become blockbuster drug year launch johnson johnson jnj already have jak inhibitor be il field abbvie have own il drug development be enter crowd market have more competitive pricing challenge say divan irritable bowel disorder market celgene mongersen ozanimod put pressure humira sale soon divan write ub analyst marc goodman say pressure abbvie stock be overdo share touch month low friday abbvie report earning fall stock market today abbvie stock fall goodman keep buy rating price target abbvie stock company earning guidance growth imply be lower wall street view still goodman write base management commentary humira volume pricing think concern appear overdo earning next year be little light think investment pipeline drive growth longer term related eli lilly abbvie top ranking pfizer astrazeneca flail
251,ABBV,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
252,ABBV,main index be volatile friday facebook fb google parent alphabet googl give nasdaq lift nasdaq quickly erased midday gain be alphabet rise strong volume add room buy point company beat estimate late thursday facebook be most active trading today market climb back buy point week old amazon com amzn big component nasdaq act drag online retailer gap day move average heavy volume miss profit expectation also fall dow jone industrial average be lower small cap russell be however volume be lower compare same time thursday ellie mae elli surge heavy volume be back buy point nearly extend entry support day move average be doubt thursday now look have work late thursday mortgage process software company beat expectation raise full year forecast medical stock be rout sector continue go bad earning season mckesson mck be single most heavily sell stock share volume time higher normal quarterly result miss estimate drug distributor sharply cut full year forecast pricing pressure peer cardinal health cah plunge sympathy fall lowest level abc plunge damage spread drug distribution industry generic drug biotech manage care medical service be health care industry group more bottom rung friday performance table abbvie abbv gap sharply volume more time average earning top view sale miss analyst target nordisk nvo gap lowest level november accelerate price deterioration start august drugmaker miss sale estimate cite decline sale price insulin related bottom line google cash machine amazon free spenderellie mae have track help mortgage lender go digital mckesson draghunt sector earning miss lower outlookabbvie topple humira miss sanofi diverge insulin panic
253,ABBV,tesaro tsro stock rocket time high monday phase result show ovarian cancer drug benefit patient make parp inhibitor beat accord rbc analyst adnan butt tesaro stock fly much stock market today close day share more double june thank earlier niraparib ovarian cancer drug ibd take tesaro stock wasn alone hit new high monday check ibd list new high late stage trial tesaro say niraparib increase progression free survival pfs subset patient ovarian cancer regardless have brca gene homologous recombination deficient hrd tumor germline mutation brca gene associate breast cancer top group median pfs be half month better control arm group benefit meaning niraparib potentially treat ovarian cancer patient vs brca hrd positive biomarker have be require butt write research report tolerability also appear manageable less patient drop experience grade adverse effect anemia neutropenia be resolve dose change butt write tesaro plan complete roll new drug application patient recurrent platinum sensitive ovarian cancer file food drug administration broad appeal butt write butt see term rival niraparib parp inhibitor accord bmc medicine publisher peer review journal parps be enzyme used repair damage dna company tesaro be study inhibit enzyme be key treat ovarian breast other cancer astrazeneca azn parp inhibitor lynparza win conditional approval clovis oncology clvs stock lose friday datum show ovarian cancer drug be inferior lynparza clovis share rise monday tesaro stock pull medivation mdvn abbvie abbv too be testing parp inhibitor abbvie stock rise fraction monday medivation be basically flat butt keep outperform rating tesaro stock boost price target least other analyst hike price target monday tesaro stock
254,ABBV,vertex pharmaceutical vrtx remain ahead galapago glpg develop triple drug treat cystic fibrosis rbc analyst michael yee say thursday galapago unveil positive phase datum first cf pill galapago glpg lower fev line datum vertex kalydeco fev be ratio used diagnosis obstructive restrictive lung disease glpg kalydeco class drug call potentiator develop triple be easy feat yee write research report galapago abbvie abbv backup potentiator moved phase testing earlier year corrector glpg be currently phase testing be only cf drug order have triple pill company have have drug look good combination together patient have minimal drug drug interaction safety issue dose once yee write galapago third piece triple pill hasn yet start phase testing yee write phase test involved only patient have previously be treat kalydeco little early say glpg have be derisked yee say so drug not be combination back half view write estimate vertex be year ahead already derisk drug vx vx contention become third begin phase testing year end yee keep outperform rating vertex stock see mega franchise cf have potential upside vertex stock fall close stock market today hit lowest more year galapago fall ibd take biotech sector isn look so hot now ibd company medical biom biotech industry group sank group track week company aerospace defense industry group be better bet keep eye industry theme potential winner relatedeli lilly abbvie top ranking pfizer astrazeneca flailingtesaro bolt ovarian cancer drug vs astrazeneca abbviepharma leader abbvie earning growth excel dividend screen
255,ABBV,bristol myer squibb vs merck pfizer vs lilly unique treatment abbvie abbv take spotlight next week biggest drug conference focuse treatment biggest disease cancer annual meeting american society clinical oncology chicago june be prime opportunity check potential blockbuster drug abstract most presentation be release public give gist study result leave detail conference most interesting item investor be late breaking abstract past several asco meeting battle immunotherapy be major theme market pd inhibitor bristol myer squibb bmy opdivo merck mrk keytruda be already big seller skin lung cancer opdivo ahead market share ongoing research give idea true market potential well stack other be often case cancer drug opdivo keytruda be approve advanced case disease first largest market opportunity be front line treatment newly diagnosed patient cancer largest market opportunity be small cell lung cancer nsclc bristol myer merck be target first abstract release merck keynote study keytruda combination chemotherapy yielded improvement progression free survival pfs month overall month patient tumor show high expression pd ligand pd inhibitor indirectly target here continue see solid orr overall response rate percentage tumor shrank pfs datum look meeting better understand durability response longer period time write credit suisse analyst vamil divan research note bristol myer be also conduct first line nsclc study most significant be checkmate combine opdivo bristol myer immunotherapy drug yervoy prove be most effective combo then be huge company bristol myer wholly own treatment thus gain revenue be new checkmate info early abstract analyst hope be late breaking datum morningstar analyst damien conover say also want see datum tecentriq roche rhhby entry sister class drug target pd ligand directly coincidence fda approve tecentriq type bladder cancer call urothelial carcinoma same day asco abstract be release be first file bladder cancer conover tell ibd bladder big indication not big lung cancer have niche roche really help drive drug sale leerink analyst seamus fernandez however note tecentriq soon have competition show other asco presentation initial datum bristol myer opdivo astrazeneca azn durvalumab show higher response rate indication fernandez write research note smaller patient number datum set baseline characteristic be present asco be closely watch newer battle seem be shape different drug class call cdk inhibitor used treat breast cancer cdk stand cyclin dependent kinase enzyme tie cell division encode gene cdk cdk inhibitor help stop cancer cell multiply first pfizer pfe ibrance launch early take last year expect swell billion eventually eli lilly lly however have make noise cdk inhibitor abemaciclib show much higher response rate refractory patient do ibrance asco abstract lilly monarch trial month treatment number be only still better ibrance slight disappointment wall street lilly day tuesday company say also be present month datum asco so still be upside surprise nonetheless evercore isi analyst mark schoenebaum write lilly executive didn seem enthusiastic lilly seem not want boost investor expectation regard month datum therefore reiterate orr result report month ask schoenebaum write email client additionally lilly encourage investor also look overall clinical benefit duration response presentation asco hover background not asco be novartis nvs announcement have stop late stage trial own cdk drug early have already hit primary endpoint improvement pfs detail have later medical meeting also positive development space analyst divan tell ibd room more winner meanwhile pfizer score hit treatment late stage datum show ibrance combination estrogen blocker letrozole yielded pfs more month month more letrozole alone prod analyst fernandez raise sale estimate whole cdk class estimate ibrance sale alone late breaking datum other field study many wall street be eyee be midstage trial rova drug abbvie be acquire buyout biotech stemcentryx rova be treatment small cell lung cancer sclc smaller market enormous nsclc population definite opportunity lack specifically approve treatment previous study have show response rate relapse patient high expression delta protein dll appear sclc patient tumor presentation asco be particularly important stemcentryx be report long term survival datum be gold standard cancer trial far fda be concern analyst schoenebaum say rova have improve survival enough differentiate know chemotherapy produce month os overall survival set re testing rova schoenebaum say video record client know be datum asco abstract show pd yervoy produce month lot toxicity punchline be need see os datum well excess month abbvie have estimate peak annual sale rova hit
256,ABBV,big pharma abbvie abbv say tuesday recently license drug candidate succeed phase trial crohn disease company seek refresh blockbuster immunology franchise late morning digestive disease week conference san diego abbvie researcher present result ongoing phase study risankizumab drug abbvie license boehringer ingelheim first quarter crohn disease say week treatment patient be remission depend dose compare just placebo group treat group also have fewer adverse event placebo group risankizumab be newer group drug target interleukin small protein cell associate inflammation protein be tnf tumor necrosis factor result be particularly encourage difficult treat population study researcher brian feagan say statement patient have endoscopically confirm moderate more severe disease activity study entry majority have previously fail treatment more tnf antagonist most popular tnf blocker happen be humira abbvie flagship drug treat crohn disease well other immunological condition rheumatoid arthritis psoriasis humira patent be fire however last week abbvie stock tumble patent board agree review challenge method patent bring coherus bioscience chrs other drug target interleukin include novartis nvs cosentyx launch early last year psoriasis well eli lilly lly taltz approve psoriasis march drug target interleukin il risankizumab target il novel mechanism action efficacy drug look be good perhaps even better il evercore isi analyst john scottus say video client record remember cosentyx peak sale consensus right now be abbvie stock end trading stock market today share past week have find support day move average line
257,ABBV,investor scoff sell go away adage send stock etfs higher past month sharp oil rally offset dismal employment report more evidence corporate america profit be get crushed spdr spy set string high june stock market build rebound february market bottom still caution be word world largest investment manager click here see list top perform etfs latest job growth figure weakest almost year cast doubt recover economy ability absorb interest rate hike summer key june referendum decide britain stay european union uncertainty add big risk global market accord blackrock believe now be good time dial equity credit risk richard turnill blackrock global chief investment strategist write june research note favor dividend grower unstable environment be find exchange trade fund such proshare dividend aristocrat nobl nobl invest exclusively company longest track record year year dividend growth aristocrat include medical device maker medtronic mdt drugmaker abbvie abbv month end last tuesday unite state oil uso best perform etf add commodity etf invest crude future june surge highest level nearly year equity technology stock emerge recent help lead higher ishare phlx semiconductor soxx jump past month hold broadcom avgo climb week high fiscal report ambarella amba part supplier gopro gpro also soar earning report spy post gain past month market resume uptrend ishare msci eafe efa hold foreign develop market stock rise same time vanguard ftse emerge market vwo tack etf investor key question be hold resistance level second half ask money manager best investing idea so portfolio aren range bound even broad market move sideway kimberly woody senior portfolio manager globalt investment atlanta ga asset advisement roughly remain sandwich multiyear trading range call more nimble tactical trading not large strategic tilt choice american voter be stark ever far reach implication economy well multiple industry believe unlikely market race higher global risk abate more clarity be see political front positive development global economy currency commodity market have lead calmer global equity bond market remain hopeful increase economic momentum more evidence recovery be need justify increase risk portfolio robert davis partner chief investment officer round table wealth management new york city asset management term view be cautious relate stock earning have be significantly reduce start year valuation remain premium certain defensive sector growth be not absent however small cap growth sector be demonstrate increase earning believe be area opportunity meaningful sell first half year also view high yield bond attractive area security be higher capital structure provide meaningful yield get investor be flat market lead presidential election
258,ABBV,stock rally modestly janet yellen signale june rate hike be table oil price rise barrel gain reversed tesla motor tsla face new safety concern share still rise hope meet production target apple aapl revamp app store business model amazon com amzn double india american airline aal other carrier rise mixed news niche retailer lululemon lulu dave buster play report strong earning stock rally much week hike hope rise month high less time best nasdaq approach first time year dow top share pull back slightly thursday especially friday bond yield hit near record lows world brexit fear revive close week nasdaq dow industrial eke gain day dismal job report fed chairwoman janet yellen say economy be make progress drop hint late hike be appropriate come month yellen comment cautious statement other policymaker signale june meeting move be table cme fedwatch tool now see chance move next week chance late july september fact odd don favor move december meeting job report investor see chance june move july meanwhile april job opening rise match record high reach last july number actual hire fall lowest last august layoff fall lowest september number quit worker dip national highway traffic safety administration say thursday be look possible model suspension problem well troublesome nondisclosure agreement tesla friday dismiss suppose safety concern tesla also revive low end version model person model meanwhile confidence grow tesla meet production goal least short term pacific crest baron capital founder ron baron make positive comment tesla stock jump production optimism then sell nhtsa news drop back day day line tesla close rise high apple now cut take app store revenue customer subscriber more year sign multiple year apple be hope subscription base model need higher revenue concern analyst speculate app store revamp good news like netflix nflx pandora time warner twx own hbo alphabet googl reportedly be plan adopt similar model android apps alphabet google play charge new subscription not only be more year apple kick worldwide developer conference monday crude jump first time month week close week just oil price initially get boost militant attack nigerian oil infrastructure political struggle venezuela weigh global supply demand india be rise energy information administration say weekly crude inventory fall barrel production edge barrel day barrel week earlier first uptick week continental resource clr say be start restart unfinished well win begin new drill price be higher royal dutch shell rdsa lower capital spending original estimate shell exit country country currently have operation plan focus effort country include brazil australia devon energy dvn announce plan sell nearly asset field texas oklahoma hercule offshore hero say first lien debt holder accept prepackage chapter plan announce last month bristol myer squibb bmy hit year high american society clinical oncology asco conference monday give back gain week bristol myer trial result show combination opdivo yervoy be competitive merck mrk drug keytruda chemotherapy treat newly diagnosed small cell lung cancer bristol meyer stock fall week merck rise bristol opdivo yervoy combo also succeed small cell lung cancer detriment abbvie abbv recent buyout deal stemcentryx be question stemcentryx lead drug rova miss expectation trial treat same disease abbvie fall week valeant pharmaceutical vrx hit year low tuesday earning miss consensus cut guidance again dermatology drug once sell disgrace pharmacy philidor aren do well valeant new deal walgreen wba bowel drug xifaxan be also struggle valeant admit recent scandal have harm reputation valeant do file tardy avoid debt default valeant share be lows be still week biogen biib tumble tuesday potentially multiple sclerosis drug lingo fail clinical trial expectation be low go company need good news older ms drug have flag lately biogen stock be week side sarepta therapeutic srpt soar say fda have request more biopsy datum make much delay decision approve ms drug eteplirsen observer interpreted fda look way approve drug weak datum set sarepta filing sarepta stock be week airline stock get bump week analyst report find carrier have raise airfare delta air line dal say unit revenue key metric have fall industrywide part lower fare market be likelier come closer low range forecast drop american airline hold outlook unit revenue decline southwest airline luv say still expect modest increase operate unit revenue jetblue jblu cut full year capacity growth outlook follow footstep rival american say aug change frequent flier program dole mile base airfare paid opposed flight length american air stock rise southwest unite jetblue even delta restaurant gaming chain report first quarter result easily beat wall street expectation dave buster also hike full year revenue comparable sale forecast share touch new high result lead jump higher margin gaming revenue make more half sale result come much traditional restaurant business slow april share leap week breaking new high india prime minister narendra modi visit address congress meeting president obama visit coincide commercial diplomatic deal amazon com invest india year top previous investment look challenge local commerce player such flipkart snapdeal expand international sale overall amazon be also open numerous small distribution center india handle local delivery formally declare india be major defense partner lead more arm sale defense deal world most populous democracy lululemon athletica ep decline cent penny shy projection revenue rise view same store sale include direct consumer grow constant dollar basis yogawear retailer see cent ep sale share climb week hit best level late nike nke be snap week lose streak armour ua be hd supply hds adjust earning jump cent share top view cent net revenue rise vs consensus bad weather hurt sale atlanta base industrial supply distributor forecast sale expectation cent diluted ep view cent hd supply share rise high just cent time high set july pare gain end week flat verifone system pay report earning share rise cent miss cent share revenue grow just consensus verifone guide ep revenue view smaller retailer resist new chip card reader share dive week fall lowest level september restoration hardware rh stunned wall street report cent share loss analyst expect cent share profit upscale home furnishing chain note impact market hurt energy downturn currency headwind general slowdown luxury consumer market revenue grow edge projection share plunge week
259,ABBV,alphabet googl get mixed analyst commentary wednesday cowen co raise price target chip maker micron mu verifone pay guidance lead slew analyst downgrade price target reduction morgan stanley raise pt alphabet parent company google be raise gross revenue estimate now see google website grow ex currency very healthy business expect generate gross ad revenue respectively greater ad revenue flow high incremental margin be also adjust model better cost discipline lead increase adjust ebitda estimate raise pt maintain overweight rating meanwhile maxim group lower price target alphabet alphabet stock tumble report first quarter earning revenue miss wall street expectation share have generally be trading day average day line alphabet finished higher stock market today retake day average jpmorgan barclay pacific crest security compass point downgrade verifone neutral payment process company late tuesday cut full year guidance post weaker expect profit revenue rbc capital wedbush stifel lower price target san jose calif base verifone verifone stock plunge miller tabak downgrade apparel maker retailer hold buy ralph lauren rl tuesday lower revenue guidance announce be cut job close store ralph lauren stock close tuesday share fall re-cover intraday loss cowen co raise price target memory chip maker view pending acquisition taiwan base inotera improve free cash flow closure inotera deal likely next week estimate micron purchase remain inotera consist taiwan bank debt loan nanya equity nanya remainder cash say cowen report micron stock fall other analyst move deutsche bank downgrade liberty medium lmca hold morgan stanley lower abbvie abbv equal weight buy jeffery drop equity residential eqr hold meanwhile canaccord genuity initiate coverage cubic cub buy rating rw baird upgrade dov outperform neutral
260,ABBV,share big pharma abbvie abbv nosedive monday patent trademark office agree review challenge patent best selling drug patent trial appeal board accept request parte review ipr generic drug startup coherus bioscience chrs patent method patent rheumatoid arthritis treatment humira patent be due expire coherus be successful launch biosimilar version humira earlier not happen too soon review normally take year be then open appeal abbvie stock have open flat stock market today abruptly drop news come mid morning end tuesday session coherus more lightly trade stock jump abbvie be industry group find more ibd stock checkup humira be currently top selling drug world sale last year coherus be several company develop biosimilar humira other include privately hold boehringer ingelheim have outstanding ipr request several different patent amgen amgn ipr request different humira patent be deny back january coherus have also file ipr request other patent keep mind abbvie also have method patent cover other approve humira indication such crohn disease expect additional iprs litigation commence prior potential biosimilar approval amgen humira biosimilar be approve later year write evercore isi analyst mark schoenebaum email thus iprs likely be first many legal action abbvie method patent estate
261,ABBV,leerink swann analyst geoffrey porge be tired wait gilead science gild acknowledge slow hepatitis patient volume competition rival abbvie merck porge downgrade gilead stock market perform rating outperform cut price target long cautious porge be now bearish flash pan hepatitis market cut hepatitis sale expectation exist hcv estimate be already materially consensus write research report now think hcv revenue decline faster farther previously estimate consensus currently forecast briefly have stranglehold market gilead now face competition abbvie abbv have sell viekira pak april merck mrk shake market even more start selling own medication well high cost gilead abbvie earlier year gilead cause stir biotech world release first hepatitis drug sovaldi late drug cost pill week regimen offer guarantee patient used drug be cure gilead see triple digit jump profit result late gilead release harvoni follow sovaldi cost even more profit continue grow double digit pace slow single digit increase first quarter year drop profit second quarter share company now trade reach peak more mid abbvie start selling viekira pak same price sovaldi merck zepatier go much less stock market today gilead stock dip hit lowest point week fall key day move average support line straight day ibd take gilead stock have composite rating meaning underperform stock term key growth metric ibd company medical biom biotech industry group be recent hot streak potential big pharma hepatitis market appear be steady secular decline porge say large pool treatable patient europe likely only see patient apiece annually long term vs record high porge forecast patient erosion year erosion revenue unit dip treatment erosion also expect gilead lose market share see hepatitis sale topple nearly peak sale gilead have see come porge say say gilead have be surprised slow patient volume world well price erosion other develop market fear company have become paralyzed size good fortune uncertainty outlook capability write gilead appear unwilling match market price high quality asset invest pipeline future outside hepatitis porge have kinder word gilead hiv business be contingent success development bictegravir currently model sale bictegravir combination gilead also have rheumatoid arthritis treatment filgotinib porge see probability success related gilead allergan see trail intercept ongoing nash battlepfizer buy cancer drugmaker medivation
262,ABBV,cash rich apple aapl lead stock buyback second quarter information technology sector overall lead field apple be follow general electric ge buyback then come microsoft msft drugmaker abbvie abbv factset research say report tuesday close tuesday microsoft say director have authorize new stock buyback program much company reaffirm be track complete current buyback authorization year end microsoft stock be more hour trading buyback announcement overall firm spend share buyback smallest quarterly total factset say come set post recession high aggregate buyback represent decline largest year year decrease decline come quarter see index hit record high ibd take share repurchase be popular way return capital shareholder tend boost stock share earning dividend put cash shareholder hand strategy have be embraced firm outside investor drife share price improve share earning reduce number share outstanding current annual earning be key ibd slim aggregate share buyback fall last quarter be still big spender apple lead worth share purchase year earlier quarter general electric buy back worth share repurchase less stock year quarter factset say ge have used massive repurchase program be funded sale ge capital microsoft spend buyback abbvie shell buyback help contribute reduction total share outstanding factset say company buy back share usual lead way sector buyback fall year year industrial consumer discretionary sector rank buyback respectively
263,ABBV,share big pharmas eli lilly lly abbvie abbv be move opposite direction thursday jpmorgan upgrade downgrade other analyst chris schott write risk reward ratio be look favorable go release late stage trial result lilly alzheimer disease drug solanezumab expect december point lilly have deep pipeline alzheimer drug solanezumab well new drug other disease area see range new product opportunity lilly support company growth target be forecasting top line growth exclude risk adjust solanezumab sale support number product opportunity such trulicity jardiance taltz baricitinib abemaciclib schott write research note upgrading lilly stock overweight neutral aggregate forecast recent upcoming new product launch generate sale lilly stock be late afternoon trading stock market today ibd take jpmorgan action abbvie be rate ibd medical ethical drug group lilly be see read slim investing system meanwhile schott downgrade abbvie neutral overweight say still like long term prospect aren enough term catalyst offset erosion lead drug humira face biosimilar competition be possible humira see limit biosimilar competition expect little clarity potential outcome next month schott write abbvie stock be late afternoon trading thursday related lilly breast cancer drug study roll
264,ABBV,biotechs celgene celg agio pharmaceutical agio be trading wednesday company say ll be filing fda approval blood cancer drug earlier expect agio say sec filing ahead presentation citi annual biotech conference year end celgene file application enasidinib ag acute myeloid leukemia aml previously timeline filing be unclear newest batch clinical trial datum isn expect next year last batch come year datum cancer drug ag also be year end agio celgene also file early approval drug filing say agio stock catapult nearly close stock market today stock have take even bigger beating most biotechs last month analyst commentary have generally be cautious face strong look competition aml abbvie abbv roche rhhby venetoclax well seattle genetic sgen sgn cd celgene stock be close ibd take celgene have be crank steady financial growth stock be still look buy point spending year consolidate learn find buy point see buy stock related agio upgrade anemia drug datum soothe safety concern
265,ABBV,load player nasdaq make record high tuesday extend already stretched advance composite close higher have be much climb too trim gain come just shy make own record high small cap russell lead increase
266,ABBV,here investing action plan friday need know investor come day exxon mobil xom chevron cvx report second quarter earning investor have be focuse energy development july oil price continue fall thursday hit month lows re high up up drugmaker merck mrk
267,ABBV,week bring boatload earning large cap drugmaker here be popular stock face turn point company growth cycle key unknown hep front be much veteran administration have be buy isn available analyst usual source prescription datum ibd take ibd slim investment system stand new new management new condition other new thing such new product so wise keep abreast upcoming drug trial datum biotech company gilead share have languish company be expect release key datum possibly big hep drug later year ibd report va have budget hcv drug spending fiscal year write evercore isi analyst mark schoenebaum email friday note gilead have historically have share va prescription va revenue quarter be important help gilead not miss consensus estimate gilead science share rise late morning trade stock market today leerink analyst seamus fernandez lift opdivo sale estimate preview note last week together yervoy bristol myer maintain share checkpoint inhibitor market fernandez write refer class cancer drug opdivo belong base trend have increase full year opdivo sale expect strong uptake japan improve royalty revenue ono bristol myer squibb stock fall intraday have lower term estimate keytruda januvia franchise base sale prescription datum respectively however see greater long term opportunity relative previous forecast fernandez write recent announcement overall survival benefit keytruda keynote trial raise prospect drug first line small cell lung cancer nsclc merck share fall nearly intraday leerink analyst geoffrey porge write july note trial bring significant revenue upside revlimid succeed lead addition diffuse large cell lymphoma dlbcl exist product label study be controversial write be start development testing more responsive less responsive patient also treatment regimen not be best use revlimid disease nonetheless porge assessed modest positive outcome most likely celgene stock fall monday morning abbvie rise
268,ABBV,drugmaker be lag term industry group performance handful boast solid earning track record abbvie abbv share second best earning share rating other ibd ethical drug group also pay big dividend shareholder last week chicago base company key product include immunology drug humira cancer drug imbruvica
269,ABBV,fda panel unanimously endorse amgen amgn biosimilar version abbvie abbv blockbuster immunology drug humira late tuesday make approval likely not clear launch member panel endorse approve amgen abp condition apply include rheumatoid arthritis psoriasis irritable bowel disease ulcerative colitis amgen do not apply most recent indication humira have acquire include pediatric crohn disease uveitis re still cover regulatory exclusivity essentially panel find be meaningful clinical difference abp humira drug be not identical humira be currently world best selling drug take worldwide last year so abbvie have be vigorously defend intellectual property amgen other challenger court therefore even fda approve abp deadline amgen not take risk launch abbvie prevail trial humira be patent protected amgen have be face biosimilar competition drug europe last summer novartis nvs sandoz unit launch zarxio version amgen neupogen be first biosimilar drug be clear wednesday novartis go fda panel defend biosimilar version enbrel amgen flagship rheumatoid arthritis drug analyst have expect approval amgen novartis biosimilar give broad support pfizer pfe celltrion biosimilar remicade receive fda earlier year datum have see biosimilar expect similar level support biosimilar next week ongoing legal process likely be better determinant see biosimilar actually enter market write credit suisse analyst vamil divan research note last wednesday
270,ABBV,be huge week earning apple aapl facebook fb alphabet googl amazon amzn beat forecast mcdonald mcd ford motor indicated weakness demand tech step include verizon vz deal buy yahoo yhoo core asset economy be grow lot slower expect oil price be near barrel nasdaq composite rise best level early december fuel strong earning apple facebook alphabet amazon hit new record high friday close week fractionally dow jone industrial average fall also snap week uptrend weaker oil price earning report hit energy sector federal reserve statement term economic risk have diminish seem have little impact investor iphone maker earn share year year sale be apple second straight decline earning revenue iphone sale be still better expect apple current quarter revenue target be midpoint wall street consensus iphone be expect be release mid september apple stock rise week just retake day line amazon ep shatter estimate revenue rise amazon web service continue boom revenue guidance also be strong operate income be light amazon stock rise week hit record intraday friday ibd take amazon be leaderboard stock hit new high growth boom only rate ibd retail internet group see go ibd stock checkup facebook report revenue maintain streak double digit growth go back more year ep jump cent shatter consensus cent be fourth straight quarter accelerate earning growth facebook stock rise hit record high still range buy point twitter twtr report ep top view revenue fall short revenue guidance also miss estimate twitter stock fall close week day line bounce back miss alphabet report ep revenue blow past expectation google parent earning item rise share total revenue climb google size still deliver growth say mark mahaney analyst rbc capital be now straight quarter ish year year revenue growth do mention acceleration say report alphabet stock rise close just entry point rise high ford motor send signal long auto industry bull market be auto sale stall higher incentive hit profit margin automaker earning share revenue rise ep growth be weakest quarters sale growth be slimmest quarters ford cite downside risk global growth offer further evidence slow auto part maker lear lea miss sale warn revenue gentherm thrm earning miss volkswagen vlkay sale edge net profit plunge vs year early struggle recover emission test cheating scandal involve diesel engine model ford stock fall federal reserve left interest rate unchanged day policy meeting expect policymaker say term economic risk have diminish suggest baby step raise rate analyst say open door slightly september rate increase fed meeting weak gdp datum investor push back expectation next hike next month economy rise annual rate less half wall street expect downwardly revise pace consumer spending be very strong climb residential investment fall even separate report show new exist home sale hit multiyear high business investment contract third straight quarter oil price fall back barrel corporate spending remain weak go forward crude oil future tumble barrel hit month lows crude tumble july crude gasoline supply rise again accord energy information administration also report higher production number oil rig operation rise fifth straight week suggest further production gain glut gasoline refine product suggest less refinery demand crude ahead meanwhile exxon mobil xom chevron cvx conocophillip cop report weaker expect result mobileye mbly report ep jump cent revenue grow top view maker driver assistance system say relationship tesla motor tsla be end news send mobileye tuesday stock pare loss week tesla rise boee ba report first quarterly loss year due various charge wasn deep fear free cash flow be better expect big jet delivery northrop grumman noc report modest earning sale growth top view weaker tech service revenue hurt margin raytheon rtn beat view raise profit guidance general dynamic gd top earning raise ep guidance revenue miss mcdonald earn share beating analyst expectation total revenue fall vs year earlier analyst have expect global same store sale exclude currency effect rise vs estimate same store sale rise just management say be not immune consumer unease be finance election general unsettled world have hurt other restaurant quarter share fall week tumble day day move average buy point stifel nicolaus downgrade large number restaurant stock jeffery predict recession hit sector top rate texas roadhouse txrh report earning come week fall wednesday steakhouse chain find support day line close week unite technology utx maker pratt whitney brand aircraft engine otis elevator other product report second quarter earning share revenue beat estimate raise ep estimate stock hit year high buy point caterpillar cat ep revenue fall mining construction equipment giant deal energy mining downturn stock hit roughly year high rise entry point chemical giant dupont dd be merge dow chemical dow crushed earning estimate be light revenue share rise highest point mid december trigger buy point meanwhile mmm make tape adhesive medical supply other product also report higher ep lower revenue beating estimate share fall analog device adi agree buy linear technology lltc cash stock deal worth create microchip industry giant deal be expect close first half meanwhile oracle orcl say buy cloud service provider netsuite deal oracle larry ellison be lead shareholder netsuite meanwhile citrix system ctxs merge go meeting unit logmein logm citrix be already plan spin go meeting verizon communication acquire struggle core asset yahoo nearly include stock compensation cost massive execution challenge ahead yahoo acquisition demonstrate verizon recognize own limitation consumer brand say research firm diffusion group verizon report revenue miss view line ep add fewer wireless postpaid phone subscriber expect mobile tmus add postpaid phone subscriber top sprint verizon lose postpaid phone subscriber mobile earning fall still beat expectation revenue rise nearly tmus revenue growth continue significantly outpace peer say matthew niknam deutsche bank analyst report armour ua meet top line bottom line expectation report share earning penny prior year revenue growth nike nke rival announce several assertive plan include takeover fao schwarz space manhattan well partnership kohl kss share tumble week amgen amgn beat raise stock slip growth continue be drive price increase rather volume celgene celg meanwhile jump only third growth be price drive make hit earlier week drug revlimid fail lymphoma trial abbvie abbv merck mrk alexion pharmaceutical alxn also rise solid report astrazeneca azn be biggest winner stock wise jump thursday rumor swiss pharma novartis nvs be think acquire biggest loser be gilead science gild trim guidance hepatitis franchise continue decline meanwhile top rate medical device company edward lifescience ew orthopedic giant zimmer biomet zbh hit new high beating estimate raise guidance big cap stalwart boston scientific bsx hit year high report strongest quarter sale growth nearly decade
271,ABBV,big biotech amgen amgn biosimilar form abbvie abbv humira seem get support fda friday agency release briefing document advisory committee panel meeting tuesday panel discuss abp knockoff abbvie mega blockbuster used treat several form arthritis crohn disease psoriasis ulcerative colitis ankylose spondylitis biosimilar generic pharmaceutical be not identical drug re copy approval process isn simple generic briefing document fda sound convince amgen have make case consider totality evidence datum submit amgen support demonstration abp be highly similar license humira notwithstanding minor difference clinically inactive component support demonstration be clinically meaningful difference abp license humira term safety purity potency product support demonstration abp be biosimilar license humira study indication ra rheumatoid arthritis pso psoriasis say document amgen share climb stock market today abbvie meanwhile add amgen abbvie share be approach month high fda have make ultimate decision approval win necessarily mean immediate launch amgen abbvie be currently tie litigation humira intellectual property generic drugmaker have launch risk such suit be settle more certainty recall amgen go patent dance abbvie abbvie have say plan file public case amgen next few month assert many patent evercore isi analyst mark schoenebaum write email client abbvie be file subsequently preliminary injunction amgen be bar marketing litigation complete biosimilar be ultimately find not infringe expiry infringe patent abbvie be grant permanent injunction thus least depend patent coherus bioscience chrs novartis nvs pfizer pfe also have humira biosimilar development coherus stock rise friday novartis advanced pfizer pfizer set year close high
272,ABBV,big cap drugmaker regeneron pharmaceutical regn merck mrk be move opposite direction thursday trading earning report company raise guidance regeneron quarterly revenue rise year earlier period beating analyst consensus accord thomson reuter earning share be penny short estimate last year crucial metric sale flagship drug eylea regeneron report growth beating consensus company raise full year growth estimate vs previous earning miss stem higher spending selling general administrative cost spending guidance year remain unchanged also cholesterol drug praluent be launch last july miss consensus again number remain small company await result cardiovascular outcome trial praluent rival amgen amgn repatha later year regeneron say payer coverage praluent be good so far commercially insure medicare have access drug regeneron stock be midday trading stock market today merck post earning cent share year earlier period beating consensus cent sale decline miss wall street number merck stock be midday thursday merck add few cent ep guidance range now also raise low end revenue guidance now echo number global pharmas earning season merck cite improve foreign exchange rate revenue shortfall be spread number different drug include blockbuster diabetes drug januvia immunology drug remicade more interesting analyst be come cancer drug keytruda miss estimate beat slightly worldwide especially rival bristol myer squibb bmy opdivo beat consensus last week bristol myer also moved report date trial opdivo first line treatment lung cancer previously guide erode advantage merck expect report result similar trial keytruda midyear drug be now approve only previously treat patient so first line approval significantly expand market merck also report sale hepatitis drug zepatier just launch late january tiny compare report market leader gilead science gild gilead abbvie abbv say earning call last week merck aggressive discounting have affected own business nonetheless rbc capital market analyst michael yee write not have be directly responsible gilead miss merck suggest negotiation important parity access remain ongoing exception veteran administration market have good access interestingly suggest many commercial payor access deal be impact contract be already complete yee write research note so gilead say lower sale be mostly due just higher gross net healthier patient come not so much competition be true realize price competition be still ongoing come need be watch
273,ABBV,giant cardiac device agree merge thursday abbott laboratory announce agreement acquire st jude medical stj deal worth abbott agree pay abbott share st jude share base abbott day average share price deal value st jude share apiece st jude stock be more morning trading stock market today abbott stock be more abbott say deal add cent ep next year cent follow year expect save cost combination abbott also assume refinance st jude debt move greatly enlarge abbott cardiovascular device business now represent revenue st jude medical strong position heart failure device atrial fibrillation cardiac rhythm management complement abbott lead position coronary intervention transcatheter mitral repair say abbott press release together company compete nearly area cardiovascular market hold position large high growth cardiovascular device market leerink analyst danielle antalffy agree st jude flat negative sale growth last few year picked write research note set continue abbott look be grow only low single digit antalffy also write compete bid be unlikely most logical buyer abbott view be johnson johnson jnj antalffy write meeting mid management emphasize company be not interested deem value market medtech specifically call cardiac rhythm management nearly st jude total sale drug eluting stent deal announcement come busy day medical field biotech medivation mdvn confirm have receive unsolicited bid big pharma sanofi sny abbvie abbv used be abbott biopharma division be spun agree buy cancer focuse biotech stemcentrx
274,ABBV,stock tumble mixed trade thursday morning earn report economic news overseas factor have say early action nasdaq hold gain buoy primarily facebook fb dow jone industrial average drop dip volume rise mildly nyse higher nasdaq vs action same time wednesday stock market today feel early pressure overseas market trade generally lower bank japan hold monetary policy unchanged send yen soar tokyo nikkei loss thursday economic news increase weight labor department estimate gdp growth sharply growth consensus view nearly dow stock decline open unitedhealth group unh lead few advance issue dupont dd shoulder heaviest loss more possibly affected investor response result pending merger mate dow chemical dow dow result top expectation economic outlook appear wobbly dow share slip facebook easily lead nasdaq advance facebook earning report late wednesday trigger handful analyst price target increase thursday morning gain send share past buy point cup handle base weak end nasdaq chipmaker xilinx xlnx tank company report late wednesday earning revenue narrowly top consensus view management guide ep line view guidance flat revenue disappoint expectation acquisition news power healthy piece early trade st jude medical stj open higher fellow heart device maker abbot lab agree buy company deal abbott share fall more facebook technical fundamental vital sign be avaible used ibd stock checkup featurebiom medivation mdvn scribe early advance ignited takeover proposal france sanofi sny sanofi share shed chicago base drugmaker abbvie abbv slump almost announce plan acquire privately hold cancer treatment biom stemcentrix deal value outside medical territory comcast cmcsa seal deal ingest dreamwork animation dwa dreamwork trade flat thursday spiking news wednesday session comcast trade fraction lower thursday be week haynesbrand hbi jockeyed higher announce pay acquire lead australian undergarment maker pacific brand company schedule report today close include amazon com amzn baidu bidu netsuite linkedin lknd western digital wdc many other
275,ABBV,slate thursday be quarterly earning report amazon amzn linkedin lnkd baidu bidu gilead science gild close market open investor get first look first quarter economic growth commerce giant be expect earn cent share swing profit cent loss last year revenue be project climb last quarter amazon fall well short earning estimate come light revenue send share much high follow week cloud compute division amazon web service be bright spot haul revenue quarter year year share be flirt be lower boundary buy range cup handle base buy point initially break few week amazon fall fall intraday professional social network earning be project grow cent ex item sharp drop growth see prior quarter revenue be expect jump share drop linkedin last quarterly report show weak guidance linkedin stock have climb low reach follow day be now trading week high social networking leader facebook fb crushed earning revenue projection late wednesday send share late trade facebook positive action continue thursday session stock likely be buy range cup handle base buy point china internet giant baidu be project see ep ex item fall rmb cent revenue be estimate rise rmb baidu mobile ecosystem be strong accord itg research analyst henry guo say week firm datum indicate baidu mobile search app dominate mobile search market more installation penetration chinese mobile user well ahead key competitor sogou search qihoo technology qihu search baidu be trading just buy range cup handle base break recently trading week high biotech earning be estimate rise share slower last quarter growth revenue be see rise also deceleration prior quarter comparison be get tougher gilead earning sale sky-rocket hepatitis treatment gilead retook day line last week breach level wednesday session share be trading week high fellow big cap biotech amgen amgn also report quarterly result thursday analyst expect ep gain amgen fall thursday be buy point cup shape base market open biotechs alexion pharmaceutical alxn celgene celg report big pharma bristol myer squibb bmy abbvie abbv make rival hepatitis treatment not great gain couple ongoing issue regard strong dollar weak energy sector sluggish manufacturing weak growth be expect wall street expect scant annualize gain
276,ABBV,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit bring merck mrk ionis pharmaceutical ion have result somewhat lower damage award wall street have expect also note weekly prescription datum im health im suggest gilead hepatitis drug sovaldi harvoni be hold reasonably well face competition merck zepatier launch late january point be make more emphatically monday research note leerink analyst geoffrey porge call merck pretender hcv hepatitis virus throne porge note survey top payer plan backed week launch zepatier sovaldi harvoni retain relatively favorable position top largest commercial plan top largest government plan relative abbvie abbv viekira pak respectively zepatier porge write further top medicare plan harvoni be cover plan plan do not cover viekira pak none cover zepatier porge affirm outperform rating gilead stock price target midday trading stock market today gilead stock be more earlier rise stock have climb month low hit feb still have weak ibd relative strength rating meaning stock perform lowest stock past month emphasis most recent month merck stock be fraction midday monday
277,ABBV,big biotech gilead science gild hit month high monday analyst deliver bullish outlook company sunday rbc capital market analyst michael yee lift ep estimate due stock buyback note several recent piece incremental good news cite late friday successful patent suit merck mrk ionis
278,ABBV,biotech agio pharmaceutical agio get couple upgrade monday present promising early datum anemia drug weekend however new datum seattle genetic sgen abbvie abbv bring new competition cancer drug saturday european hematology association meeting agio present datum drive pk ongoing midstage study ag drug candidate treat sufferer rare genetic form anemia call pyruvate kinase deficiency pkd patient have be treat least week agio say have achieve proof concept due increase hemoglobin level least gram be increase level sex hormone man drug appear be well tolerate answer concern raise last week potential follow drug call ag thursday agio stock plunge case drop platelet count appear small trial day treatment agio stock rise stock market today early rise much canaccord genuity analyst john newman upgrade agio pharma stock buy hold lift price target writing now appear be event estimate peak annual sale drug jpmorgan analyst anupam rama raise rating overweight neutral price target note positive datum stock sell fulfilled previously state condition get more constructive stock add be still outstanding question program include long term impact elevated sex hormone patient be frequently diagnosed childhood reality be hemoglobin increase observed drive pk ag be meaningful believe be derisk pkd program overall rama write research note leerink analyst seamus fernandez raise peak annual sale estimate pkd franchise same time lower estimate agio cancer drug ag ag ag leave market perform rating unchanged latter move come base seattle genetic multiple presentation same conference drug sgn cd acute myeloid leukemia aml treat similar population agio drug abbvie partner roche rhhby also publish datum similar population treat drug venetoclax competitor be initiate pivotal trial ahead agio putt agent market earlier agio compound earlier stage disease fernandez write research note result change have decrease estimate ag ag ag seattle genetic stock fall monday abbvie stock skid
279,ABBV,better big dividend big dividend get even bigger company make dividend leader list offer yield well north average payout today column highlight highest dividend growth rate cisco system csco top list long term cash payout growth rate
280,ABBV,big pharma bristol myer squibb bmy motor year high stock market monday company continue roll positive trial datum cancer drug merck mrk be putt stiff competition say analyst annual american society clinical oncology asco meeting weekend bristol myer present number study used new immunotherapy drug opdivo treat various cancer most closely watch be checkmate trial opdivo combination bristol myer drug yervoy treat newly diagnosed case small cell lung cancer nsclc result be particularly strong patient tumor expressed pd opdivo target order destroy cancer cell ability protect immune system patient take yervoy week opdivo week be still alive year patient greater pd expression median progression free survival pfs be month merck combination similar drug keytruda chemotherapy first line patient show pfs month high pd expressor month patient overall study be relatively small however so wall street be still watch outcome larger study clarify have advantage potential opdivo yervoy combination remain controversial eye many investor be very impressed see weekend credit suisse analyst vamil divan write research note assume positive datum present merck keytruda chemotherapy combination first line nsclc lead wonder limit bristol myer potential indication highlight size overall market believe degree exclusivity bristol myer large portion market be significant long term positive bristol myer also present positive result combo gastric colorectal small cell lung cancer sclc latter smaller market nsclc also underserved underwhelm report abbvie abbv potential competitor rova also have boost bristol myer stock monday bristol myer stock rise much early trading stock market today touch year high second straight trading day share close bristol myer stock hit time high october merck rise
281,ABBV,share pharma major abbvie abbv be slide wednesday morgan stanley downgrade concern increase competition analyst david risinger downgrade abbvie stock equal weight lower price target note nature abbvie pipeline have become clearer day june presentation cancer drug weekend include negatively receive report rova meantime abbvie still depend immunology drug humira analyst say sale humira be world best selling drug generate abbvie total sale estimate vast majority profit risinger write humira not only face challenge several biosimilar player include amgen amgn novartis nvs sandoz pfizer pfe also novel brand injectable oral abbvie score string patent litigation victory allay investor concern be unable make call risinger write humira market exclusivity already suffer setback last month patent board agree review challenge humira patent bring biosimilar developer coherus bioscience chrs likely take year resolve risinger write newer class drug treat same condition humira do include novartis cosentyx eli lilly lly taltz baricitinib slow humira growth term threat gain support wednesday novartis say presentation european league rheumatism conference run wednesday saturday be new long term analysis suggest cosentyx lead higher response humira improve sign symptom person live ankylose spondylitis psoriatic arthritis psa week novartis say initiate head head trial confirm say abbvie own novel autoimmune disease product help offset moderation include jak il risankizumab risinger write expect launch abbvie stock fall close stock market today share touch month high friday
282,ABBV,here investing action plan friday need know investor come day monthly job report be due friday top drugmaker bristol myer squibb bmy merck mrk roche rhhby eli lilly lly abbvie abbv discuss new cancer treatment payroll datum labor department monthly job report be due et
283,ABBV,market open mildly higher monday global market be tightly mixed dow jone industrial average climb nasdaq comment federal reserve chair janet yellen appear likely be centerpiece otherwise uneventful day economic news stock market yellen be schedule speak et world affair council philadelphia economic outlook monetary policy investor hint rate hike outlook yellen comment particularly weak payroll report friday increase uncertainty fed act policy meeting schedule next week nasdaq start week weekly advance belt breathe room day move average end last week flat week advance wal mart wmt be active premarket trading rise russian eastern europe telecom provider vimpelcom vip base netherlands spiked be low price stock oil mining issue pressed higher chesapeake energy chk freeport mcmoran fcx be drug maker abbvie abbv be nearly disappointing trail result small cell lung cancer treatment rova oil price strengthen putt west texas intermediate back barrel gold rise fraction ounce dollar firm bond backed lift year yield basis point day few earning report be schedule close thor industry tho top list thor end friday session buy range past buy point cup base
284,ABBV,here investing action plan need know investor come week crude price barrel next meeting organization petroleum export country add upward momentum smack market back meanwhile apple aapl supplier broadcom avgo medtronic mdt report earning drugmaker discuss cancer fight
285,ABBV,abbvie abbv say year pass begin accrete earning purchase stemcentrx abbvie stock reversed early loss be early thursday afternoon company announce acquisition abbvie stock fall much early stock market today be fraction afternoon trading record high set july south san francisco calif base stemcentrx lead late stage asset be call rovalpituzumab tesirine rova already registrational trial small cell lung cancer sclc abbvie say pay purchase price cash rest stock stemcentrx also receive cash milestone payment abbvie expect transaction be approximately cent dilutive ongoing earning share accretion begin company say announcement lower ep guidance abbvie say execute accelerate share repurchase program soon completion purchase be expect quarter meanwhile abbvie early thursday report earning beat wall street estimate fall tad short revenue abbvie say earn share item cent better analyst expect sale analyst poll thomson reuter have expect global humira sale rise exclude foreign exchange impact abbvie say humira be abbvie best seller generate total revenue treat immunological disorder primarily rheumatoid arthritis psoriasis thursday research note investor evercore isi analyst mark schoenebaum cite approximately beat humira sale largely offset miss global viekira revenue primarily drive miss possibly due competition merck mrk well abbvie put total humira sale sale viekira treat hepatitis be abbvie drug generate globally total sale abbvie say abbvie ceo richard gonzalez say purchase stemcentrx be mark abbvie innovation oncology critical component long term growth area significant need million patient worldwide stemcentrx trial drug rova have be submit fda breakthrough therapy designation too be investigation third line treatment sclc have approve therapy abbvie say rova be first predictive biomarker base therapy associate drug efficacy small cell lung cancer be big deal difficult disease charle rudin chief thoracic oncology memorial sloan ketter cancer center say abbvie announcement stemcentrx also have novel compound clinical trial triple negative breast cancer ovarian cancer small cell lung cancer other compound advance clinical trial proprietary technology platform leverage stem cell biology identify screen potential target live tumor tissue more predictably advance discovery development new asset abbvie say brian slingerland be privately hold stemcentrx co founder ceo scott dylla be co founder chief scientific officer
286,ABBV,big biotech amgen amgn beat wall street estimate raise guidance thursday close stock go sideway hour trading peer gilead science gild however be sharply weak quarter amgen report adjust earning share year earlier quarter cent ahead analyst consensus accord thomson reuter revenue increase more consensus company lift full year guidance not quite much beat ep range be now revenue guide be vs last year amgen make ep revenue amgen best selling drug enbrel rheumatoid arthritis beat expectation grow almost consensus accord evercore isi second biggest drug neulasta neutropenia modestly beat estimate gain other hand amgen newer drug come short cancer drug kyproli grow be still shy consensus sale newly launch cholesterol drug repatha continue take gilead meanwhile report earning share exclude time item last year cent wall street average estimate revenue rise consensus gilead nonetheless make change full year guidance call product sale gross margin gilead blockbuster hepatitis drug harvoni sovaldi account most shortfall opposite reason harvoni miss badly outperformed abroad sovaldi do opposite earlier day abbvie abbv report harvoni chief competitor viekira also come short consensus company attribute merck mrk unexpectedly aggressive pricing recently launch rival zepatier merck report quarter also bring screeching halt gilead year stretch double triple digit sale profit growth start dec launch sovaldi analyst expect growth totally flatten company make acquisition gilead stock be more hour thursday close regular session
287,ABBV,big money be move medical field thursday giant company announce attempt multibillion dollar buyout abbott laboratory announce agreement acquire fellow cardiac device maker st jude medical stj deal worth meanwhile abbvie abbv used be abbott biopharma division be spun agree buy biotech stemcentrx upfront milestone payment cancer focuse biotech medivation mdvn confirm have receive unsolicited bid big pharma sanofi sny week rumor abbott agree pay abbott share st jude share base abbott day average share price deal value st jude stock apiece abbott say deal add cent ep next year cent follow year expect save cost combination abbott also assume refinance st jude debt move greatly enlarge abbott cardiovascular device business now represent revenue st jude medical strong position heart failure device atrial fibrillation cardiac rhythm management complement abbott lead position coronary intervention transcatheter mitral repair abbott say press release together company compete nearly area cardiovascular market hold position large high growth cardiovascular device market leerink analyst danielle antalffy agree st jude flat negative sale growth last few year picked write research note set continue abbott look be grow only low single digit nonetheless abbott share fall close st jude rise ibd take healthy be abbott lab stock find ibd stock checkupabbvie sanofi meanwhile be big pharmas look fill pipeline innovative drug lead product face slowdown abbvie immunology drug humira be best selling drug world patent start expire year sanofi have have scale back expectation diabetes franchise increasingly competitive space have push price stemcentrx lead late stage asset be call rovalpituzumab tesirine rova already registrational trial small cell lung cancer abbvie say pay purchase price cash rest stock stemcentrx also receive cash milestone payment drug successfully clear regulatory development hurdle meantime however be financial drain abbvie expect transaction be approximately cent dilutive ongoing earning share accretion begin company say announcement lower ep guidance meanwhile abbvie early thursday report earning beat wall street estimate fall tad short revenue abbvie say earn share item cent better analyst expect sale analyst poll thomson reuter have expect global humira sale rise exclude foreign exchange impact abbvie say thursday research note investor evercore isi analyst mark schoenebaum cite approximately beat humira sale largely offset miss global viekira revenue primarily drive miss possibly due competition merck mrk well abbvie put total humira sale sale viekira treat hepatitis be abbvie drug generate globally total sale abbvie say abbvie stock end higher stock market today sanofi unsolicited offer be share cash medivation make deal worth medivation have be subject takeover rumor recent week astrazeneca azn sanofi rumore suitor medivation sole commercial product be prostate cancer drug xtandi market japan astella xtandi success launch have help drive medivation stock excellent composite rating propose purchase price represent premium medivation month volume weight average price buyout talk begin sanofi say medivation stock rise thursday suggest investor think bid go higher sanofi stock finished image provide shutterstock
288,ABBV,abbott laboratory agree buy st jude medical stj deal value maker heart device make biggest ever acquisition industry consolidate gain bargaining power hospital st jude medical shareholder receive cash share abbott common stock represent total approximately share accord statement thursday medical device maker be merge get access new technology hospital push lower price st jude last year acquire thoratec add left ventricular pump device take fail heart combine abbott st jude medical company have pipeline new medical device product cardiovascular diabetes vision neuromodulation patient care accord statement abbott say statement have financing st jude medical plan acquisition alere alr send alere share higher early trading stock market today abbott chief executive officer mile white decline reiterate commitment alere deal last week company earning call alere hasn yet file report regulator have be subpoena justice department st jude medical close wednesday give company market value stock jump market open new york abbott drop percent early trading alere rise percent acquisition further reshape abbott split brand name pharmaceutical business abbvie abbv then company have shy away major acquisition pursue many smaller deal even ceo talk often desire larger purchase abbott have cash hand obtain selling generic drug business medicine market europe develop world mylan myl
289,ABBV,horizon pharma hznp offer expect sale guidance tuesday morning first second quarters send share gapping day line drugmaker deliver net sale guidance range indicate year year growth midpoint net sale outlook growth midpoint well current estimate revenue gain growth previous year management say earning call see have highest operate expense percentage sale year leverage build move year result lower adjust ebitda earning interest taxe depreciation amortization margin first quarter expect sequentially increase move year horizon also confirm full year sale guidance analyst poll thomson reuter anticipate revenue year share slide crash stock market today slice downward key move average stock have be trading day level september company be member ibd medical ethical drug industry group joined abbvie abbv pfizer pfe group leader zoetis zts abbvie share rise pfizer zoetis related egregious depome soar activist starboard target drugmaker
290,ABBV,update apple aapl stock rise wednesday morning retake day move average several big cap peer do so tuesday iphone maker finally close level turn resistance support netflix nflx schlumberger slb abbvie abbv mastercard rise day move average tuesday apple share continue close just support level not huge surprise several big cap stock retook day line nasdaq also do so tuesday dow have be level week still key step road recovery netflix report earning monday rise stock market today best level late january netflix have run resistance several session just day netflix have be consolidate peak dec netflix jump wednesday morning highest mid january schlumberger rally energy sector crude future rise barrel month high schlumberger rise tuesday top day line time last june schlumberger rise fractionally wednesday morning abbvie rise tuesday just get day line hasn be consistently hold level last august late monday fda approve leukemia drug abbvie roche rhhby unit genentech wednesday morning abbvie fall once again drop day mastercard rise tuesday stock have be find support day line past few week stock be form cup handle base go back nov wednesday morning mastercard rise apple share rise tuesday just day line apple crossed day april intraday have yet close level early november then only briefly
291,ABBV,be busy week business economic investing news stock market come more pressure apple aapl report first sale decline facebook fb amazon amzn turn gas federal reserve signale rush raise rate economy crawl market rally come more pressure slew earning report big economic news nasdaq tumble week fall day line thursday day average friday loser such apple twitter twtr first solar fslr trump big gain facebook amazon dow be well support level also tumble loss come thursday friday oil price continue march higher help weaker dollar further decline production year treasury yield give much recent gain healthy be share amazon facebook do compare rival find ibd stock tech titan certainly wasn growth company fiscal second quarter report first revenue decline iphone unit sale tumble earning share fall expect apple give weak guidance current quarter apple hasn have huge product big screen iphone smartphone sale generally be stagnate point apple be so huge be hard new product really move needle sign shift rapid growth more mature model apple add additional shareholder return program more buyback higher dividend meanwhile activist investor carl icahn decide cash apple stock so do other apple stock fall week nearly settle worst close mid apple chip supplier generally fared relatively well part due diversify away apple smartphone generally apple investor worry glory day be federal reserve expect vote leave interest rate unchanged latest policy meeting give hint tighten fall earliest fed note labor market have strengthen even economic growth slow true now economy rise annual rate first quarter weakest year meanwhile jobless claim be year lows economy be barely grow hard see continue add job month analyst be expect friday april employment report fed go slow approach couple bank japan unexpected decision not increase stimulus effort push dollar big loss boost multinational profit give further lift dollar price oil other commodity commerce giant see sale largely wall st view gain midpoint mark slowdown pop highest nearly year still be faster be typical past year earning also crushed estimate cloud unit amazon web service remain hot china version amazon alibaba baba report thursday alphabet googl unit google ford motor uber lyft volvo announce tuesday formation coalition advocate self drive car lobbying effort come automaker race develop autonomous technology alphabet be late stage talk fiat chrysler fcau partnership regard autonomous car accord multiple report meanwhile tesla motor tsla already have self drive feature electric car have not unveil plan join coalition tesla report earning wednesday autonomous tech firm mobileye mbly thursday social networking king facebook linkedin have good week post earning top estimate send stock higher facebook report third straight quarter accelerate earning revenue growth concern slow user engagement advertiser be definitely used facebook mobile advertising account facebook ad revenue facebook stock spiked thursday record high pull back close week modestly buy point linkedin renew investor confidence harrowing see stock plunge linkedin turn solid earning investor applaud global economy grow tepid pace company be stress cost cut prop earning revenue flatline fall latest week defense contractor lockheed martin snack giant mondelez international mdlz procter gamble pg announce recent new effort curb expense restructure sell asset join like coca cola ko banking giant jpmorgan chase jpm bank america bac cut help company short run need stronger top line growth fuel earning longer term shift priority medium company come play last week handful megamerger capture spotlight serve attempt keep grow simply cling survival cable content titan comcast cmcsa seek grow foreign market deal buy dreamwork animation dwa studio responsible shrek kung fu panda meanwhile look comcast rival charter communication chtr be able keep bid buy time warner cable twc win regulatory approval survival struggle newspaper industry be mind usa today parent gannett gci bid buy tribune publish tpub owner los angele time chicago tribune crude oil future continue rise hit high big oil be still adjust lower price saudi arabia aim reduce oil dependence float less saudi ipo value world largest oil company excess meanwhile conocophillip cop slash capital spending even further bp bp say be consider further cut baker hughe bhi warn american rig count still have room fall count stabilize later year chevron cvx swung loss production fall overall output most major rise even investment fall exxon xom lose aaa rating still keep commitment dividend raise cent cent quarterly result shale player continental resource clr eog eog carrizo crzo be week medical merger activity take thursday abbott laboratory inked buyout deal cardiac device giant st jude medical stj abbott former biopharma arm abbvie abbv agree buy biotech startup stemcentrx possible milestone payment big french pharma sanofi sny make unsolicited cash bid smaller drugmaker medivation mdvn medivation reject sanofi offer sanofi vow press medivation stock trade investor be expect sanofi perhaps bidder go higher stemcentrx medivation be focuse cancer treatment field have provide biggest drug launch recent year chipotle grill cmg recovery be slow go april same store sale date surprising many burrito king logged first ever quarterly loss cent share wall street expect revenue decline miss view comp plummet fast casual chain panera bread pnra report strong result stock be set short consolidation go back march burger king parent restaurant brand international qsr turn mixed result domino pizza dpz miss completely dunkin brand dnkn edge past forecast
292,ABBV,most stock retreat investor dive haven asset include gold dollar deadly terrorist attack brussel kill least person nasdaq composite index edge higher drugmaker climb transport related share lead standard poor index lower benchmark loss be ease somewhat advance health care technology company pound slide speculation explosion brussel airport departure hall downtown subway station boost case britain leave european union gold advanced first time day yield year german bund touch lowest level almost week treasury fall federal reserve bank chicago chief charle evan call economic fundamental really quite good fall gauge still trading highest level year transportation stock post biggest decline group royal caribbean cruise rcl carnival cuk lose least biotechnology technology hardware company such apple aapl amgen amgn abbvie abbv contribute most gain benchmark measure tuesday nasdaq composite index rise fifth straight gain cap longest advance month activity be light again holiday shorten week monday marked lowest volume year trading exchange list share be month average follow slowest session last monday tuesday fed march meeting stock market be close holiday friday bloomberg dollar spot index track greenback major peer add third day gain gauge slide last week fed dial back outlook interest rate increase year president san francisco atlanta fed say monday tighter borrow condition be warrant soon april give improvement economy benchmark german bund rise belgian bond be little change year german yield fall much basis point percentage point rate belgian debt due decade drop basis point yield similar maturity treasury add basis point fall low
293,ABBV,drug candidate regeneron pharmaceutical regn sanofi sny jointly develop have beaten abbvie abbv best selling rheumatoid arthritis ra drug late stage study company say friday regeneron france base sanofi say monoclonal antibody sarilumab meet trial main goal improve symptom week biweekly dose regimen patient sarilumab achieve
294,ABBV,drug candidate regeneron pharmaceutical regn sanofi sny jointly develop have beaten abbvie abbv best selling rheumatoid arthritis ra drug late stage study company say friday regeneron sanofi say monoclonal antibody sarilumab meet trial main goal improve symptom week biweekly dose regimen patient sarilumab achieve least improvement sign symptom base american college rheumatology criterium contrast patient humira group group experience same rate negative side effect sarilumab group show higher rate neutropenia lower white blood cell humira be currently top selling ra drug indeed top selling drug kind world today number competitor be rise last fall baricitinib drug eli lilly lly incyte incy co develop also beat humira head head trial injectable humira sarilumab be deliver orally roche rhhby intravenous medicine actemra have also best humira trial regeneron sanofi have already apply fda approval sarilumab base earlier datum decision due oct rbc capital market analyst adnan butt call news modest positive add investor be still concern nearer term issue regeneron stock be pilot program test change medicare part announce week affect great deal reimbursement regeneron flagship drug eylea patent lawsuit amgen amgn file monoclonal antibody regeneron sanofi partnership praluent else be equal beating humira be certainly better not beating least discuss overhang need clear pipeline receive more credit write butt research note late morning stock market today abbvie stock be almost sanofi be regeneron stock be fraction
295,ABBV,big pharma abbvie abbv say monday be acquire right immunology drug develop german counterpart boehringer ingelheim stock be flat goldman sachs warn increase competition abbvie agree pay upfront undisclosed milestone payment royalty right commercialize drug late stage testing psoriasis earlier testing crohn disease psoriatic arthritis asthma phase trial compare head head johnson johnson jnj remicade find month treatment patient boehringer drug have clear almost clear skin compare remicade arm abbvie also acquire right earlier stage drug attack cd protein be connect lupus nephritis crohn disease ulcerative colitis abbvie say press release decide go forward drug completion certain undisclosed clinical achievement abbvie say success develop commercialize humira currently world top selling immunology drug give expertise do same boehringer product humira be near end patent life lead much speculation wall street biosimilar competitor launch much impact have goldman sachs analyst richter take pessimistic view matter monday say current political focus lower drug price probably encourage cheap humira knock off be not change abbvie forecast continue believe humira remain durable asset free biosimilar least end decade richter write remove abbvie stock conviction buy list cut price target however adjust terminal value growth rate model faster decline curve post introduction humira biosimilar abbvie stock fall much early trading stock market today midday be flat meanwhile richter put biomarin pharmaceutical bmrn conviction buy list abbvie place set price target biomarin richter note have guide go black next year even contribution recently fda reject muscular dystrophy drug kyndrisa show opex restraint commitment profitability add several datum release year bring upside medication include biomarin gene therapy hemophilia treatment rare disease achondroplasia biomarin stock be midday monday image provide shutterstock
296,ABBV,company be still desirable less popular target acquisitive mood first quarter come close merger be year year mark nation lowest total global share january march time frame compete bid buy starwood hotel hot accord dealogic target merger acquisition volume totale reduction last year target comprise total volume quarter overall global volume fall compare year slip number deal have fall year tough comparison first quarter be biggest deal make record high merger europe middle east africa emea fall least major global region dealogic track emea target comprise global total highest quarterly share second quarter asia pacific target merger comprise global total par first quarter chinese company be biggest appetite deal make chemchina bid buy syngenta syt be largest record quarter johnson control jci bid buy tyco international tyc be quarter largest telecom deal overall telecom deal fall deal lowest first quarter volume starwood hotel hot find middle merger love triangle sort china insurance bid compete marriott international mar bid rival hotel chain dine lodging sector have biggest first quarter merger announce deal much total dollar amount boost starwood bid technology be quarter top sector spend deal year year contain highest first quarter real estate be second largest sector deal be compare health care merger plunge lowest volume year victim tough comparison sector have back back record breaking year oil gas volume be deal year year lowest volume lowest first quarter activity transcanada trp purchase columbia pipeline cpgx be biggest canadian outbound deal energy sector record finance total deal make global total highest share sector deutsche boerse deal acquire london stock exchange group be largest security commodity exchange target record goldman sachs gs lead global bank advise deal follow jpmorgan chase jpm ub ub comparison megadeal first quarter be merger kraft heinz khc abbvie abbv bid pharmacyclic unitedhealth group unh deal buy pharmacy benefit manager catamaran
297,ABBV,apple aapl get price target cut early monday ambarella amba also get lower price target sluggish gopro gpro sale chipotle grill cmg get price target hike abbvie abbv be downgrade pacific crest lower price target apple maintain overweight rating stock cite weaker demand iphone apple share close stock market today ambarella price target be lower chardan capital market have neutral rating stock last week chipmaker post mixed result cut fiscal guidance weak sale wearable sport camera make gopro ambarella client share ambarella fall gopro rise chipotle price target be hike credit suisse have outperform rating stock recent poll find trouble burrito chain lose popularity younger customer last year fast food giant mcdonald mcd rise popularity chipotle tick higher drugmaker abbvie be downgrade buy goldman sachs have price target stock share add share micron technology mu fall monday be downgrade reduce neutral nomura security also lower price target hewlett packard enterprise hpe price target be raise maxim group rate stock hold share rise cardinal health cah be upgrade conviction buy buy goldman sachs share rally
298,ABBV,drug stock boom newer biotech company tend get most play growth stock last year top perform large cap drugmaker be none other year old eli lilly other big pharmas lilly lly have spend last few year climb earning trough bring loss patent protection biggest drug growth be still slow investor have get ever more interested company pipeline lilly late stage drug candidate solanezumab bring breakthrough currently untreatable disease alzheimer psoriasis treatment ixekizumab be expect launch anytime now eventually achieve blockbuster sale immunology drug baricitinib lilly co develop incyte incy be also recently file fda meanwhile already market diabetes drug jardiance shock wall street last year reduce death heart failure large scale study call empa reg recently lilly ceo john lechleiter sit ibd explain lilly strategy ibd interested immunology strategy give be lot medicine area do see fitting space lechleiter well think only way enter space lay claim disease area be offer something better believe datum have ixekizumab be il antibody psoriasis be excellent look clearance rate person study have clearance plaque so be competitor feel very good profile product think baricitinib study establish superiority methotrexate be current first line standard care study superiority term sign symptom ra rheumatoid arthritis abbvie abbv humira be biggest drug world think re bring something new category case ra know person cycle different course therapy think question even drug have space today still unmet need ibd diabetes area have impressive datum jardiance person be wonder be go be class effect be do have point differentiation lechleiter well think first person be ask class effect meaning entire class drug perform same be person don have jardiance fact be have datum anything else other one be speculation so think advantage have be first mover advantage obviously soon get label change exercise file fda expect get update labele reflect outcome empa reg later year ibd overall diabetes market have be pressure lately sanofi sny nordisk nvo have be warning slower growth be true market general just certain segment lechleiter think several category be still grow diabetes space very competitive drug category have different player happen be only company have complete spectrum treatment paradigm boehringer ingelheim growth insulin be slow bit believe more more person used insulin be used sglt inhibitor jardiance be lower insulin requirement so think interplay drug also know sglt category growth be come expense many case generic sulfonylurea so brand category be expand think market standpoint lot competition great consumer great physician remain differentiate product compete mix ibd build complete portfolio diabetes medicine be advantage be marketing advantage lechleiter well fundamental level work physician address right drug give patient vs do fit patient drug make sense let understand diabetes be progressive disease so understand patient be journey medicine best help patient be agnostic choice physician make have offer step way ultimately also hopefully better understand right combination be have fix dose combination dpp jardiance re only company offer today have not just oral have insulin have not just insulin glp drug trulicity so think advantage term be able optimize treatment ultimately be marketplace advantage have full basket product think negotiating payer insurer example ibd alzheimer have different program go do anticipate be multiple drug category lechleiter first solanezumab be positive ll know end year go generate tremendous amount interest company develop bace inhibitor antibody other drug believe ultimately probably be treat combination not way diabetes be treat today not way cancer be treat be antibody oral bace inhibitor example re also develop agent act tau protein be downstream aspect disease progression remain be see best guess be be combination solanezumab be successful other follow aim be group ibd oncology again think position be lot drug industry activity cancer talk strategy lechleiter pillar oncology business go back year be alimta still be today buy imclone october ve have drug approve imclone pipeine cyramza now have indication gastric cancer colorectal cancer lung cancer then late last year get approval portrazza indicated squamous cell small cell lung cancer type lung cancer first line have not see improvement survival year so re excited have third imclone product ve commence filing fda call olaratumab be soft tissue sarcoma have drug clinic today have immune system component associate begin build immuno oncology portfolio also have drug think everyone be excited call abemaciclib cdk inhibitor ll have phase datum breast cancer year also have phase trial underway also have phase underway cdk inhibitor lung cancer so re focuse immuno oncology be cyramza other word angiogenesis drug cell cycle inhibitor so prong approach think ve get good portfolio product pipeline address
299,ABBV,share fitbit fit sank early tuesday series downgrade follow weak profit forecast twitter twtr be upgrade solarcity scty be downgrade fitbit stock price close stock market today follow number negative analyst call stifel downgrade stock hold buy robert baird downgrade neutral outperform pacific crest downgrade sector weight overweight mizuho lower price target fitbit monday maker wearable fitness tracker beat fourth quarter sale earning view offer profit guidance well consensus twitter stock price finished unchanged be upgrade outperform raymond james twitter share have rebound hit record low feb stock be still well week high set april solarcity be downgrade neutral overweight jpmorgan last week solar city choose electric automaker tesla tsla provide battery power solar project work kaua island utility cooperative solarcity share lose tesla stock price dip share micron technology mu fall even price target be raise mizuho abbvie abbv ease be upgrade buy citigroup also raise price target stock groupon grpn be initiate neutral wedbush give price target share groupon fall image provide shutterstock
300,ABBV,dividend fund have underperform past year outperform first year outperformed more growth oriented big cap benchmark early part decade suffer smaller price setback year financial crisis then bull market begin early
301,ABBV,big biotech gilead science gild beat analyst estimate tuesday guidance be soft send stock more hour trading day several large drugmaker report gilead earning rise year earlier quarter share top analyst ep consensus cent accord thomson reuter revenue increase vs analyst expectation full year ep rise revenue gain gilead guide product sale cover nearly revenue analyst have expect product sale total revenue gilead do not provide total revenue ep guidance do provide guidance expense be slightly expectation sale general administrative line evercore isi analyst mark schoenebaum calculate imply ep guidance be miss consensus hepatitis drug sovaldi harvoni beat estimate entirely due sale outside analyst have less visibility next year expect revenue decline be due anticipate decline hcv market have enormous lift drug be approve have flattened ever larger number patient have be cure disease conference call analyst commercial operation chief paul carter say expect hcv market behave similarly do second half essentially flat grow foreign market be still be launch say see growth payer seem be loosen restriction drug initially strained finance due high price enormous volume patient however acknowledge revenue patient be likely fall less sick patient come require shorter treatment carter also sound confident gilead ability fend competition get new entrant last week merck mrk zepatier be approve last week price well gilead abbvie abbv hcv drug re confident label be very strong re very much support real world datum ve see launch harvoni carter say earlier day big pharma pfizer pfe say revenue rise year earlier quarter beating analyst consensus earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share analyst schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact capital iq analyst jeffrey loo raise rating pfizer buy hold say valuation have become attractive almost other drug stock have sell recent month view growth global innovative product unit positively drive prevnar ibrance loo write research note expect pending acquisition allergan agn be complete second half pfizer stock close mallinckrodt mnk rise close specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance baxter international bax leader dialysis product also beat expectation most recent quarter pull sharp increase earning decline sale fourth quarter profit continue operation jump cent share cent past wall street consensus revenue drop baxter stock rise tuesday close baxter say expect ep year beating consensus forecast current quarter be street however cent
302,ABBV,big pharma abbvie abbv deliver mixed earning report affirm guidance early friday stock fall company face new competition hepatitis front merck mrk abbvie report earning share exclude time item be year earlier quarter penny analyst consensus accord
303,ABBV,fda say thursday require warning liver damage be put label abbvie abbv hepatitis treatment viekira pak technivie send abbvie share plunge month low gilead science gild sharply review adverse event report fda adverse event report system faer database
304,ABBV,big pharma eli lilly lly biotech partner incyte incy say wednesday rheumatoid arthritis drug outperformed abbvie abbv market lead humira clinical trial send stock higher
305,ABBV,study primary endpoint drug baricitinib be simply do better placebo measure acr test signify least improvement symptom drug also outperformed humira arc disease activity score test week treatment week beat humira measure joint damage lilly incyte do not give exact number say detailed datum come future medical meeting publication
306,ABBV,be fourth successful late stage clinical trial drug be janus kinase jak inhibitor class include incyte already market cancer drug jakafi well pfizer pfe rheumatoid arthritis drug xeljanz evercore isi analyst mark schoenebaum note history xeljanz provide reason caution
307,ABBV,efficacy result be positive baricitinib think efficacy result be consistent datum pfizer jak inhibitor xeljanz high unapproved dose mg twice daily thus largely expect xeljanz mg twice daily be not approve due question risk benefit profile dose safety trial press release report serious adverse event baricitinib be similar placebo lower humira schoenebaum write email client therefore interested detailed efficacy datum be particularly interested detailed safety datum trial also long term safety believe be major driver uptake chronic therapy ra
308,ABBV,abbvie humira be world best selling drug pull last year xeljanz launch have yet crack mark even have advantage be pill humira have be inject
309,ABBV,take together believe datum support superiority label claim eu support upside street peak sale estimate incyte earn estimate cost free royalty sale write nomura analyst ian somaiya research note
310,ABBV,incyte stock be more late morning trading stock market today lilly stock initially rise late morning be flat abbvie be also flat
311,ABBV,follow amy reeve twitter ibd_areeve facebook big pharma eli lilly lly biotech partner incyte incy say wednesday rheumatoid arthritis drug outperformed abbvie abbv market lead humira clinical trial send stock higher study primary endpoint drug baricitinib be simply do better placebo measure acr test signify least improvement symptom drug also outperformed humira arc disease activity score test week treatment week beat humira measure joint damage lilly incyte do not give exact number say detailed datum come future medical meeting publication be fourth successful late stage clinical trial drug be janus kinase jak inhibitor class include incyte already market cancer drug jakafi well pfizer pfe rheumatoid arthritis drug xeljanz evercore isi analyst mark schoenebaum note history xeljanz provide reason caution efficacy result be positive baricitinib think efficacy result be consistent datum pfizer jak inhibitor xeljanz high unapproved dose mg twice daily thus largely expect xeljanz mg twice daily be not approve due question risk benefit profile dose safety trial press release report serious adverse event baricitinib be similar placebo lower humira schoenebaum write email client therefore interested detailed efficacy datum be particularly interested detailed safety datum trial also long term safety believe be major driver uptake chronic therapy ra abbvie humira be world best selling drug pull last year xeljanz launch have yet crack mark even have advantage be pill humira have be inject take together believe datum support superiority label claim eu support upside street peak sale estimate incyte earn estimate cost free royalty sale write nomura analyst ian somaiya research note incyte stock be more late morning trading stock market today lilly stock initially rise late morning be flat abbvie be also flat follow amy reeve twitter ibd_areeve facebook
312,ABBV,medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate
313,ABBV,say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus
314,ABBV,company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat
315,ABBV,device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter
316,ABBV,pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note
317,ABBV,single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum
318,ABBV,imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year
319,ABBV,product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus
320,ABBV,device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company
321,ABBV,also announce stock buyback plan be finance debt issuance
322,ABBV,stock open few point late morning be flat
323,ABBV,follow amy reeve twitter ibd_areeve facebook medical giant johnson johnson jnj get earning season shaky start medical stock tuesday miss revenue estimate beating ep view only due lower tax rate say earning totale share exclude time item year earlier quarter beating analyst consensus cent accord thomson reuter revenue shrank short consensus company raise low end full year ep guidance nickel now however rbc capital market analyst glenn novarro write quarter earning include tax benefit worth cent share accounting beat device diagnostic business have be soft number quarters usually pharma business have make didn happen quarter pharmaceutical revenue year year report constant currency miss consensus estimate owing expect oncology portfolio result write novarro research note single biggest oncology product be prostate cancer drug zytiga sale shrank miss consensus say novarro sale blood cancer drug imbruvica launch year more triple be roughly line consensus accord evercore isi analyst mark schoenebaum imply potential net sale abbvie abbv report schoenebaum write email client abbvie inherited profit sharing arrangement acquire imbruvica developer pharmacyclic earlier year product launch diabetes drug invokana miss consensus grow year year single biggest selling drug remicade miss fellow immunology drug stelara simponi beat consensus device business miss estimate board face competition surgery medtronic mdt newly enlarged area covidien buyout spinal market various player orthopedic novarro write company be lose share such rival stryker syk zimmer biomet zbh overall market be soft thus negative company also announce stock buyback plan be finance debt issuance stock open few point late morning be flat follow amy reeve twitter ibd_areeve facebook
324,ABBV,health care giant johnson johnson jnj bristol myer squibb bmy get upgrade buy tuesday analyst see bright future drug current market pound ub analyst marc goodman raise price target bristol myer upgrade stock buy neutral lift sale estimate
325,ABBV,big biotechs amgen amgn regeneron pharmaceutical regn be trading wednesday morning pharmacy benefit manager express script esrx say late tuesday include new cholesterol bust drug prefer formulary express script have long be say make effort keep price amgen repatha regeneron praluent
326,ABBV,batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock
327,ABBV,unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance
328,ABBV,unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale
329,ABBV,pfizer ep
330,ABBV,pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view
331,ABBV,pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus
332,ABBV,result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus
333,ABBV,good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin
334,ABBV,bristol lead pd battle
335,ABBV,bristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise
336,ABBV,bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly
337,ABBV,pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale
338,ABBV,big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client
339,ABBV,bristol myer stock be midday tuesday
340,ABBV,merck sale line
341,ABBV,bristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise
342,ABBV,merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year
343,ABBV,merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation
344,ABBV,merck stock be more midday trading
345,ABBV,follow amy reeve twitter ibd_areeve facebook batter drug industry get blast good news tuesday morning big pharmas sizable biotech beat wall street expectation send stock unite therapeutic uthr be midday trading stock market today report revenue year earlier quarter beating analyst consensus more accord thomson reuter earning exclude time item rise share penny consensus usual do not provide guidance unite therapeutic have be lose investor confidence even recent drug stock sell recent launch drug orenitram oral version blockbuster lung drug remodulin initially go slower wall street have expect however orenitram sale rise beating consensus unite therapeutic other market drug beat consensus well unituxin new treatment rare childhood cancer call neuroblastoma come line expectation sale pfizer ep pharma giant pfizer pfe be midday tuesday report earning exclude time item cent share year earlier quarter beating consensus cent revenue shrank beat view pfizer add full year revenue guidance now vs last year ep guidance range be now dime previous guidance few cent last year number be current analyst consensus result include day business hospira generic drugmaker pfizer acquire bring revenue pfizer also note earning release exclude foreign exchange impact revenue rise company credit pneumonia vaccine prevnar be recently approve adult be enjoy increase demand preparation upcoming flu season accord press release ibrance breast cancer drug launch february take beating consensus good expense management also help quarterly performance slightly higher tax rate negatively impact net income write credit suisse analyst vamil divan research note add pfizer also beat expectation operate margin bristol lead pd battlebristol myer squibb bmy report earning cent share cent wall street average estimate revenue rise consensus exclude foreign exchange impact sale rise bristol myer add cent full year ep guidance range now be consensus flat modestly last year expect full year sale high side consensus slightly pd inhibitor opdivo launch melanoma late last year have be pick lung cancer indication then handily beat consensus sale bristol myer hepatitis franchise be overshadowed bigger drug gilead science gild abbvie abbv also trounce consensus sale big miss be yervoy ex vs consensus see last quarter appear consistent lumpiness bristol myer have say expect launch pd antibody write evercore isi analyst mark schoenebaum email client bristol myer stock be midday tuesday merck sale linebristol myer chief competitor pd business be merck mrk also report solid early tuesday merck earning rise year earlier quarter cent share exclude time item beating consensus cent revenue fall line estimate exclude forex impact sale rise merck raise lower end full year revenue guidance now last year also raise ep guidance beating wall street represent growth few percentage point last year merck compete drug opdivo keytruda totale capital iq analyst jeffrey loo write be lower expect see sale accelerate be approve additional indication next several year merck biggest selling drug januvia have also be competitive pressure lately rise modestly beating expectation merck stock be more midday trading follow amy reeve twitter ibd_areeve facebook
346,ABBV,tyson food tsn boee ba be company expect benefit tran pacific partnership trade agreement drugmaker biotechs primarily develop brand drug have emerge top loser nation accord include mexico canada japan australia vietnam be agree monday still require ratification congress agreement give brand
347,ABBV,big pharma eli lilly lly beat earning expectation raise ep guidance early thursday company ceo defend industry drug pricing lilly revenue be more mixed bag firm continue struggle foreign exchange headwind stock be flat lilly lly make cent share exclude time item
348,ABBV,gilead science gild say monday drug combo have succeed different genotype hepatitis virus hcv late stage clinical trial gilead study combine sofosbuvir be sell separately sovaldi be also ingredient harvoni new drug candidate call velpatasvir cohort take ribavirin older hcv pill
349,ABBV,big pharma abbvie abbv say friday advance rheumatoid arthritis drug successful midstage clinical trial also bail similar drug be develop belgian biotech galapago glpg send latter stock tumble abbvie conduct trial testing various dose placebo study patient respond inadequately methotrexate
350,ABBV,banking giant citigroup biotech abbvie abbv receive analyst upgrade monday apple aapl chip supplier qorvo qrvo be downgrade
351,ABBV,jeffery upgrade citigroup buy price target credit suisse upgrade stock outperform give price target however citi share close stock market today broader sell
352,ABBV,qorvo supply chip apple iphone sank be downgrade sector perform overweight pacific crest friday new apple iphone hit store shelve apple sell more iphone handset open weekend company say monday apple share lose monday
353,ABBV,abbvie stock price fall be upgrade neutral sell citigroup last week biotech stock get slam democratic presidential hopeful hillary clinton unveil proposal cap prescription drug expense sell continue monday
354,ABBV,boston scientific bsx be upgrade buy hold needham medical device maker share still lose monday
355,ABBV,india base service provider infosys infy be upgrade hold societe generale share finished higher
356,ABBV,micron technology mu decline price target be cut cowen co have market perform rating stock chipmaker be due report fiscal result thursday close analyst poll thomson reuter expect year year decline earning
357,ABBV,bp bp be initiate outperform bmo capital oil gas giant stock price still fall
358,ABBV,share mindbody mb decline be downgrade equal weight overweight morgan stanley mindbody developer cloud base business management software wellness industry have ipo june
359,ABBV,medical device maker stryker syk fall be downgrade hold needham
360,ABBV,follow vance cariaga twitter ibd_vcariaga banking giant citigroup biotech abbvie abbv receive analyst upgrade monday apple aapl chip supplier qorvo qrvo be downgrade jeffery upgrade citigroup buy price target credit suisse upgrade stock outperform give price target however citi share close stock market today broader sell qorvo supply chip apple iphone sank be downgrade sector perform overweight pacific crest friday new apple iphone hit store shelve apple sell more iphone handset open weekend company say monday apple share lose monday abbvie stock price fall be upgrade neutral sell citigroup last week biotech stock get slam democratic presidential hopeful hillary clinton unveil proposal cap prescription drug expense sell continue monday boston scientific bsx be upgrade buy hold needham medical device maker share still lose monday india base service provider infosys infy be upgrade hold societe generale share finished higher micron technology mu decline price target be cut cowen co have market perform rating stock chipmaker be due report fiscal result thursday close analyst poll thomson reuter expect year year decline earning bp bp be initiate outperform bmo capital oil gas giant stock price still fall share mindbody mb decline be downgrade equal weight overweight morgan stanley mindbody developer cloud base business management software wellness industry have ipo june medical device maker stryker syk fall be downgrade hold needham follow vance cariaga twitter ibd_vcariaga
361,ABBV,share big biotech gilead science gild be more midday wednesday attorney general massachusett threaten legal action company drug pricing boston globe report attorney general maura healey have send letter gilead say pricing hepatitis drug sovaldi harvoni constitute unfair trade practice violation massachusett law sovaldi be launch december week round treatment harvoni be launch october equivalent length treatment large minority patient have be successfully treat week gilead defender have argue price be justified vast superiority drug previous treatment cure upward patient prevent expensive medical problem road however healey curative power drug only make high price more egregious pricing treatment manner effectively allow hepatitis continue spread vulnerable population opposed eradicate disease altogether result massive public harm price gilead drug have be criticize ever launch fact senate investigation last year culminate december report say price place inordinate burden state medicaid program be also focus healey letter however be able do anything expect abbvie abbv compete treatment viekira pak spark rebate war gilead december launch thus drug still have same official price tag re actually selling less analyst be expect further price erosion arrival merck mrk own compete treatment be due fda decision thursday gilead have say last few earning call hepatitis market have flattened be plan launch new version treatment june potentially treat genotype disease thereby broaden market gilead stock have be hammer re ignition drug price debate presidential race last fall have focuse more practice specialty drugmaker turing pharmaceutical valeant pharmaceutical vrx raise price older drug improvement quality house committee oversight government reform have plan hearing subject tuesday big east coast blizzard lead reschedule feb
362,ABBV,drug stock have be take beating hard east coast lately last year worry drug pricing compound so so pre announcement forecast last month week however big drugmaker haven pre announce result have chance beat expectation usual johnson johnson jnj kick season
363,ABBV,alphabet world internet search leader be prospect core business strike success health care world company glucose monitoring contact lens diabetic be inch closer drugstore shelve sale self stabilize spoon design help person uncontrollable hand tremor eat comfortably top first month google restructure last year become largest operate unit new parent alphabet googl buy biotech company lift lab just few month health focuse startup begin product sale point broaden emphasis other health medical advancement alphabet last month rename google life science division verily life science division bring together clinician scientist be focuse understand improve chronic condition impact massive number person health issue include cardiovascular disease diabetes cancer disease mental health be development health care think be far reach be long last be see period convergence technology company health care company california life science association trade group ceo sara radcliffe tell ibd say change drive health care tech firm partnership include explosion big datum result demand way manage patient information growth access datum internet cloud mobile technology such fitbit fit wearable be shift health care maintain tracking health rather simply treat disease say company team uprecent notable health tech partnership include alphabet verily division team last month johnson johnson jnj develop surgical robot news follow september announcement google life science spinoff calico have enter year collaboration north chicago ill base pharmaceutical firm abbvie abbv research age related disease verily have partner too medical device firm dexcom link verily create new class disposable glucose monitoring system be faster cheaper smaller product be currently available johnson johnson verily announce last year have create verb surgical develop new surgical robotic device smaller less expensive intuitive surgical isrg da vinci system now control minimally invasive surgery segment other look join force health tech divide include medical device maker medtronic mdt be collaborate big datum solution provider ibm ibm watson health analyze wave information glean diabetes insulin pump datum vs be not only tech heavyweight seek blend medical altruism big datum big moneymaking plan apple aapl microsoft msft other be also used deep technology expertise create medical related product service year apple introduce health tracking tool monitor user footstep heart rate sleep activity microsoft samsung already offer number so call wearable device also allow person monitor daily movement advance mobile compute artificial intelligence new analytic software be drive effort recent year have be increase interest health care application company traditionally be see be consumer focuse company say iain simpson drug delivery specialist cambridge consultant company such google apple facebook fb amazon com amzn have build consumer focuse business base creation compelling sustainable user experience now simpson say various tech company be head health drive increase relevance capability market create new high value business opportunity particularly work collaboration establish health care player such pharma medical device company health care spending weigh project reach accord california health care foundation profit potential be obvious incentive other factor be also work part reason alphabet focus move needle parkinson treatment be personal google co founder now alphabet president sergey brin mother eugenia have parkinson brin be diagnosed carry mutation lrrk gene have be associate higher rate degenerative disorder central nervous system generally pace medical research be glacial compare used internet brin tell wire interview google amplify process be look lot place collect lot information see pattern lead somewhere legislative change be factor have help open door tech firm put massive compute muscle health care datum drive medicine be key element affordable care act federal law ushered president barack obama health care reform be major force center boom new health technology law provide major financial incentive doctor hospital prove care be effective value base payment rule be spark demand new software track analyze patient datum say lynne dunbrack research vice president idc health insight patient prescribe example dunbrack say hospital be find cheaper send medicare patient have congestive heart failure home weight scale electronic tablet connect app rather risk too many readmission day discharge result hospital get federal reimbursement rate cut have be real financial incentive health care organization purchase use technology be then help drive demand be company be now see new opportunity dunbrack say shift value base care other top area focus health care industry include sequence human genome digitize health care datum say cowen co analyst john blackledge september report alphabet health care strategy health care trend be not occur vacuum be be accommodate technology advance area such social mobile analytic cloud compute be area google expertise blackledge say swirl change tech advance be also help fuel medical ambition tech heavyweight apple annual worldwide developer conference june apple introduce new healthkit app monitor user heart rate sleep weight blood pressure other health related measurement let home health device such heart monitor fitness monitor exchange datum healthkit allow clinician mayo clinic send health information user app turn transmit datum user physician healthkit be logical extension apple exist product digital ecosystem keep user engage increase apple app store business also keep apple product service relevant grow increasingly competitive consumer health market say simpson cambridge consultant apple tech framework researchkit let person want remotely participate clinical medical trial do so used specially design apps iphone instead have show person march apple display apps say help diagnose range condition diabetes heart disease apple say win see datum transmit person opt sharing researcher want researchkit help address few problem medical research current state such limit patient participation infrequent datum sampling apple jeff william now chief operate officer say time person sign single medical study stanford university first hour release researchkit apple ceo tim cook tell cnbc march put perspective stanford have tell have take normally medical center entire year sign many participant so researchkit be absolute game changer say cook call discover cure disease push life expectancy much longer currently be alphabet google have own initiative call fit include developer tool online platform collect datum connect michele chandler twitter ibd_mchandler facebook
364,ABBV,only few stock remain ibd ipo leader screen reflection difficulty new issue be have market correction index exchange trade fund etfs tracking new issue aren do much better fact investor be better pick individual stock screen used fund ibd new issue index be prior high week touch lowest level october index track stock go public past year have not fared much better couple etfs follow ipo market first trust ipo index fund fpx be peak earlier week sank lowest level november exclude aug mini crash renaissance ipo ipo be high time lows exclude aug etfs be flagging difference top component have affected performance renaissance ipo largest holding include stock have sell sharply such synchrony financial syf nearly fund alibaba baba citizen financial group cfg jd com jd stock be least week high first trust ipo top holding such facebook fb fund kraft heinz khc be prior high abbvie abbv top hold have swoon hurt fund relatively more renaissance ipo top component have ipos first trust ipo have company go public farther back general motor gm certainly new kid block be first trust portfolio start trading again reorganization ipo leader screen physician realty trust doc have faltered clear buy point cup handle last month share be just prior high store capital stor be new high extend past rexford industrial realty rexr have be try break new high stock be real estate investment trust have fared better defensive investment
365,ABBV,positive overseas action earning result weak read gdp growth left stock future mixed ahead friday open dow future be uptick future be steady nasdaq future shed early gain slip narrow loss stock market today prepare open feel healthy lift overseas market top index japan china jump friday european market push gain midday trade start friday session week nasdaq open hole small cap also get weak start russell open vs last friday close preliminary estimate commerce department put gdp growth sharply gain miss expectation increase gdp price index eke advance vs forecast growth labor department report employment cost index gain unchanged equal economist estimate pending economic news include kingsbury international chicago purchasing manager index expect et university michigan release final consumer sentiment index tally january san francisco federal reserve president john william join panel discussion et city dollar gain bond fall oil be mixed west texas intermediate brent trading barrel baker hughe bhi report weekly rig count head dow microsoft msft power merck mrk jump microsoft report strong fiscal result late thursday earning sale comfortably top expectation sale cloud software rise annualize run rate midpoint management revenue guidance be just consensus expectation microsoft share end thursday week move average week deep consolidation skywork solution swks microsoft lead nasdaq index premarket trade skywork jump result report late thursday earning revenue beat analyst consensus view straight quarter double digit earning gain quarter double digit revenue growth management ep revenue guidance be expectation skywork be deep month consolidation amazon com amzn reel lower earning increase stop far short analyst expectation diversify online retailer content provider report thursday close fourth quarter revenue rise also shy consensus forecast company continue invest heavily operate cost rise nearly membership amazon prime subscription service estimate have more member jump amazon rise heavy trade thursday rebound test support week move average other stock premarket motion report earning include sony sne fortinet ftnt flextronic flex gain electronic art ea tumble abbvie abbv drop image provide shutterstock
366,ABBV,generic drug giant mylan myl agree develop biosimilar drug biotech momenta pharmaceutical mnta friday also announce retirement cfo momenta get upgrade result mylan agree pay upfront milestone payment candidate be successful exchange right momenta have option co commercialize support commercial role approve product unite state accord company statement momenta didn name candidate expect be biosimilar version bristol myer squibb bmy rheumatoid arthritis drug orencia orencia sell last year be project sell momenta ceo craig wheeler say conference call analyst however main patent be due expire so wheeler expect launch commercially momenta stock rise nearly early trading stock market today late afternoon be more momenta partner novartis nvs launch first biosimilar last year future be uncertain baxalta bxlt decide not pursue more joint project momenta follow development biosimilar abbvie abbv humira maxim group analyst jason kolbert lift rating momenta hold sell recall element sell thesis be base view move away complex generic copaxone biosimilar be significant transition momenta kolbert write research note upfront commitment mylan be validate mylan meanwhile announce cfo john be retire april year company have not yet find successor mylan stock be more late afternoon trading friday follow amy reeve twitter ibd_areeve facebook
367,ABBV,past few year have bring groundbreaking drug launch such record breaking gilead science rollout hepatitis medicine first pd cancer fighter merck bristol myer squibb bmy year look be somewhat slower front drug firm aim most new launch smaller market build
368,ABBV,alphabet world internet search leader be prospect core business strike success health care world company glucose monitoring contact lens diabetic be inch closer drugstore shelve sale self stabilize spoon design help person uncontrollable hand tremor eat comfortably top first month google restructure last year become largest operate unit new parent alphabet googl buy biotech company lift lab just few month health focuse startup begin product sale point broaden emphasis other health medical advancement alphabet last month rename google life science division verily life science division bring together clinician scientist be focuse understand improve chronic condition impact massive number person health issue include cardiovascular disease diabetes cancer disease mental health be development health care think be far reach be long last be see period convergence technology company health care company california life science association trade group ceo sara radcliffe tell ibd say change drive health care tech firm partnership include explosion big datum result demand way manage patient information growth access datum internet cloud mobile technology such fitbit fit wearable be shift health care maintain tracking health rather simply treat disease say company team uprecent notable health tech partnership include alphabet verily division team last month johnson johnson jnj develop surgical robot news follow september announcement google life science spinoff calico have enter year collaboration north chicago ill base pharmaceutical firm abbvie abbv research age related disease verily have partner too medical device firm dexcom link verily create new class disposable glucose monitoring system be faster cheaper smaller product be currently available johnson johnson verily announce last year have create verb surgical develop new surgical robotic device smaller less expensive intuitive surgical isrg da vinci system now control minimally invasive surgery segment other look join force health tech divide include medical device maker medtronic mdt be collaborate big datum solution provider ibm ibm watson health analyze wave information glean diabetes insulin pump datum vs be not only tech heavyweight seek blend medical altruism big datum big moneymaking plan apple aapl microsoft msft other be also used deep technology expertise create medical related product service year apple introduce health tracking tool monitor user footstep heart rate sleep activity microsoft samsung already offer number so call wearable device also allow person monitor daily movement advance mobile compute artificial intelligence new analytic software be drive effort recent year have be increase interest health care application company traditionally be see be consumer focuse company say iain simpson drug delivery specialist cambridge consultant company such google apple facebook fb amazon com amzn have build consumer focuse business base creation compelling sustainable user experience now simpson say various tech company be head health drive increase relevance capability market create new high value business opportunity particularly work collaboration establish health care player such pharma medical device company health care spending weigh project reach accord california health care foundation profit potential be obvious incentive other factor be also work part reason alphabet focus move needle parkinson treatment be personal google co founder now alphabet president sergey brin mother eugenia have parkinson brin be diagnosed carry mutation lrrk gene have be associate higher rate degenerative disorder central nervous system generally pace medical research be glacial compare used internet brin tell wire interview google amplify process be look lot place collect lot information see pattern lead somewhere legislative change be factor have help open door tech firm put massive compute muscle health care datum drive medicine be key element affordable care act federal law ushered president barack obama health care reform be major force center boom new health technology law provide major financial incentive doctor hospital prove care be effective value base payment rule be spark demand new software track analyze patient datum say lynne dunbrack research vice president idc health insight patient prescribe example dunbrack say hospital be find cheaper send medicare patient have congestive heart failure home weight scale electronic tablet connect app rather risk too many readmission day discharge result hospital get federal reimbursement rate cut have be real financial incentive health care organization purchase use technology be then help drive demand be company be now see new opportunity dunbrack say shift value base care other top area focus health care industry include sequence human genome digitize health care datum say cowen co analyst john blackledge september report alphabet health care strategy health care trend be not occur vacuum be be accommodate technology advance area such social mobile analytic cloud compute be area google expertise blackledge say swirl change tech advance be also help fuel medical ambition tech heavyweight apple annual worldwide developer conference june apple introduce new healthkit app monitor user heart rate sleep weight blood pressure other health related measurement let home health device such heart monitor fitness monitor exchange datum healthkit allow clinician mayo clinic send health information user app turn transmit datum user physician healthkit be logical extension apple exist product digital ecosystem keep user engage increase apple app store business also keep apple product service relevant grow increasingly competitive consumer health market say simpson cambridge consultant apple tech framework researchkit let person want remotely participate clinical medical trial do so used specially design apps iphone instead have show person march apple display apps say help diagnose range condition diabetes heart disease apple say win see datum transmit person opt sharing researcher want researchkit help address few problem medical research current state such limit patient participation infrequent datum sampling apple jeff william now chief operate officer say time person sign single medical study stanford university first hour release researchkit apple ceo tim cook tell cnbc march put perspective stanford have tell have take normally medical center entire year sign many participant so researchkit be absolute game changer say cook call discover cure disease push life expectancy much longer currently be alphabet google have own initiative call fit include developer tool online platform collect datum connect michele chandler twitter ibd_mchandler facebook
369,ABBV,big biotech gilead science gild agree license immunology drug smaller counterpart galapago glpg thursday deal be worth more galapago drug be filgotinib be due start phase trial rheumatoid arthritis crohn disease next year gilead agree pay license fee buy galapago stock upfront promise milestone payment drug succeed clear regulatory process launch gilead pay tiered royalty start sale split profit filgotinib be jak inhibitor class abbvie abbv several other drugmaker be develop abbvie once have own licensing deal galapago september opted right license filgotinib so focus develop house drug time abbvie cite rat study indicate filgotinib be toxic testicle lead galapago discussion fda proceed new trial however phase result human be positive competitive other rheumatoid arthritis drug development write rbc capital market analyst michael yee research note add crohn disease result seem lag celgene celg ged hard compare cross trial different geography galapago stock jump early trading stock market today midafternoon be more gilead stock be flat follow amy reeve twitter ibd_areeve facebook
370,ABBV,long await report senate finance committee gilead science gild pricing hepatitis drug come tuesday expect be highly critical sen ron wyden ore chuck grassley iowa say spring investigate gilead pricing policy gilead price new hepatitis drug sovaldi week regimen criticism price lead gilead nearly other biotech stock brief nose dive group re-cover presidential candidate hillary clinton raise drug pricing issue more broadly september tuesday report senator say examine more page internal gilead document interview dozen health care expert conclude gilead price sovaldi successor harvoni maximum profit rather broad access say fact gilead have underestimated much health insurer pharmacy benefit manager restrict access confront widespread initiation access restriction gilead refuse offer substantial discount do not significantly modify contract strategy improve patient access senator go press release summarize report finding example gilead offer medicaid program supplemental rebate percent however offer come precondition state have drop access restriction state already face steep financial burden accept precondition most case have increase budgetary impact rather ease senator admit price sovaldi harvoni have drop abbvie abbv launch compete treatment last december say concern remain particularly public payer community high cost treat million person infected hepatitis well budgetary effect future single source innovator not face competition quickly not surprisingly gilead disagree conclusion world more individual have be treat gilead hcv medication introduction gilead say email statement gilead responsibly thoughtfully price sovaldi harvoni product be initially price line previous standard care rebate discount now place price today be less cost prior regimen even therapy have significantly higher cure rate very few side effect gilead stock react little news dip fraction late afternoon stock market today follow amy reeve twitter ibd_areeve facebook
371,ABBV,hillary clinton have promote drug pricing plan way take industry say be guilty outrageous price friend medium take hit clinton plan wouldn go far have suggest ban consumer direct drug advertising effect tax advertising dollar be tax profit hope be do so restrain unnecessary prescription drug spending patient wouldn ask doctor be try wonder cure learn tv read newspaper ostensibly decrease pharma ad spending order make brand drug less prevalent mind consumer cheaper generic write cowen co health care analyst charle rhee even more certain result be hit medium company profit expansion loss last year drugmaker spend tv ad magazine ad newspaper ad accord kantar medium pfizer pfe spend more ad roughly same combine total next biggest advertiser abbvie abbv eli lilly lly astrazeneca azn yet rhee write even overall pie be shrink think more ad pie shift favor digital advertiser even accelerate manner advertiser seek greater return investment particular rhee name webmd wbmd everyday health evdy potential winner scenario see unlikely come pass republican dominate congress still maybe hope hillary plan help great friend blogosphere
372,ABBV,small biotech xencor xncr say wednesday have enter cancer drug collaboration amgen amgn be worth much amgen agree pay upfront license xencor xmab bispecific technology platform preclinical program aim treat cancer well inflammatory disease succeed amgen owe
373,ABBV,last year hepatitis have produce most epic drug launch history fanfare die investor face key question much longer drug pipeline pop question be ground sheer success exist treatment gilead science gild sovaldi harvoni abbvie abbv viekira pak
374,ABBV,biotech startup coherus bioscience chrs be more friday say late thursday biosimilar version amgen amgn neulasta take longer test previously expect coherus say decide increase number subject immunogenicity study require approval ch biosimilar version amgen white blood cell boost
375,ABBV,week announce corporate restructure break search leader wide range operation smaller most focuse piece google googl say have separated life science division stand alone entity give division more freedom search firm year old life science group have graduate hush hush google experimental unit dedicate big technology breakthrough moonshot reside google new parent firm alphabet google co founder sergey brin write google post late thursday google stock however be afternoon trading stock market today andy conrad head google life science be ceo new life science group brin write report structure be different goal remain same ll continue work other life science company move new technology early stage clinical testing hopefully transform way detect prevent manage disease brin say team be relatively new very diverse include software engineer oncologist optic expert write be type company hope thrive part alphabet see do next google life science development include glucose monitoring contact lens year collaboration chicago base pharmaceutical firm abbvie abbv research age related disease last week google life science wing announce partnership san diego calif base dexcom maker continuous glucose monitoring system develop bandage size disposable patch patient adult onset type diabetes restructure google announce last week alphabet become corporate parent core google company various moonshot effort google co founder larry page be ceo alphabet brin be president sundar pichai senior vice president product google become google ceo start core google company report financial result separately other alphabet division connect michele chandler twitter facebook
376,ABBV,patent trademark office rule wednesday patent challenge biogen biib blockbuster drug tecfidera hold hope denial similar challenge other drug hedge fund manager kyle bass biogen stock rise uspto decline hold trial response bass request parte review ipr tecfidera patent number end expire office cite failure establish likelihood success challenged claim reason challenge shorter live patent be still pending patent expire ipr filing be make coalition affordable drug group create bass part short activist strategy claim also reduce drug price group have also file iprs jazz pharmaceutical jazz xyrem abbvie abbv imbruvica celgene celg revlimid shire shpg lialda gattex other last month however uspto also deny ipr acorda therapeutic acor amypra biogen ruling be further evidence strategy win work write rbc capital market analyst michael yee research note today be unexpected positive expect decision mid nov base filing date come heel acorda consensus ipr institution yee write street view further positive derivative give less credit other iprs file similar patent group yee note however drug startup forward pharma fwp be also challenge patent have develop own similar drug biogen stock have be severely batter massive guidance cut back july ibd relative strength rating just ep rank afternoon trading stock market today biogen stock be follow amy reeve twitter ibd_areeve facebook
377,ABBV,be year distinct part drug stock first month continue bull run last year sudden resurface drug pricing debate lead rocky month overall group come ahead top perform big cap show solid story make political worry eye investor incyte incy be wednesday close year steady gain lone market product jakafi well pipeline potential blockbuster march jakafi win eu approval blood cancer polycythemia vera be already approve blood cancer myelofibrosis disease be rare incyte be shooting much bigger market late stage candidate baricitinib epacadostat baricitinib incyte be develop partnership eli lilly lly test successfully phase trial rheumatoid arthritis placebo methotrexate current market leader abbvie abbv humira nov initiation report incyte goldman sachs analyst richter estimate peak annual sale more expect launch richter add more important future driver share likely be incyte entry bud field immuno oncology incyte have be testing lead candidate field epacadostat combination merck mrk keytruda variety cancer early november incyte stock fall small study combo patient advanced cancer disappoint wall street richter write likely bring more clarity more result come incyte have be operate loss due research spending analyst expect turn first annual profit next year stock current ibd composite rating be danish diabetes giant nordisk nvo be end year flat base follow early gain march stock rise sharply say refile approval long act insulin analogue tresiba shorter act sister drug ryzodeg drug suffer surprise rejection fda seek more datum possible risk heart time agency be convince approve also boost stock early year be february release positive clinical trial datum latest glucagon peptide glp receptor agonist og have be selling earlier glp agonist victoza market have get more competitive last couple year new glp launch sanofi sny glaxosmithkline gsk eli lilly drug be injectable however new candidate be oral announce further positive result drug july september financial result currency suffer foreign exchange headwind hit global drugmaker year still manage solid ibd ep rank relative strength rating regeneron pharmaceutical regn continue multiyear run stock market hit lifetime high aug get catch larger biotech sell still year regeneron flagship eye drug eylea continue perform well aid new approval diabetic retinopathy march draw more attention be launch cholesterol drug praluent july praluent be not only first new class cholesterol drug be follow shortly market amgen amgn repatha also first number novel monoclonal antibody regeneron have be develop partnership sanofi next entry dupilumab be late stage testing asthma eczema be also expect attain multibillion dollar annual sale regeneron be also highest rate stock list highest possible composite rating eli lilly be top perform traditional big pharma year gain sale growth have be flat due age drug well currency headwind company have improve profit margin cost control get lot investor excited pipeline note partnership incyte have bear fruit baricitinib trial lilly doesn have much presence rheumatoid arthritis other immunology disease lilly be plan change not only baricitinib ixekizumab psoriasis treatment plan launch next year be expect sell billion eventually lilly already launch diabetes drug jardiance yielded pharma biggest upside surprise year giant study effect cardiovascular health show reduce death heart failure drive stock year high september turn cup handle base stock hold cr baxalta bxlt be start trading july spin baxter international bax seek unlock shareholder value biopharma arm just day later company receive unsolicited buyout offer british drugmaker shire shpg see baxalta hemophilia franchise ideal addition rare disease portfolio baxalta reject offer situation remain unresolved last week rumor be buzz shire bid hasn yet baxalta financial have be slow steady lead ep rank acquisition hope have lift stock rs rating
378,ABBV,market be close weekend market move news continue yahoo yhoo board director investor pressure put core operation sale go ahead ceo marissa mayer plan spin company lucrative alibaba baba stake meanwhile slew blood cancer drug datum novartis nvs bluebird bio blue abbvie abbv several other be present key ash conference yahoo alibaba future fluxyahoo board likely decide company future weekend accord kara re code yahoo board meet past week mull various option director reaffirm plan spin alibaba holding separately trade company aabaco lead proxy fight starboard starboard initially push alibaba change mind ir decide not rule advance move be rule tax free starboard now say yahoo instead sell core operation such yahoo mail yahoo have market cap include alibaba share yahoo japan stake several cash market essentially value yahoo core operation least mayer current strategy negative value cancer fight gold ash meanwhile american society hematology ash begin day conference saturday orlando blood cancer drug notably cut edge chimeric antigen receptor cell car treatment car treatment engineer immune cell so recognize cancer cell presentation cellectis cll bluebird bio juno therapeutic juno novartis kite pharma kite be ash car presentation many car treatment be similar so investor be look indication regulatory approval first also present be abbvie tout new research imbruvica abbvie paid pharmacyclic mostly hope imbruvica johnson johnson still share imbruvica revenue follow ed carson twitter ibd_ecarson facebook
379,ABBV,big biotech amgen amgn be trading friday announce cancer collaboration merck mrk file first biosimilar approval tepid initiation report well fargo amgen merck say be launch study combine merck keytruda be currently used treat melanoma small cell lung cancer amgen leukemia drug
380,ABBV,biggest medical meeting year be weekend american society hematology ash convene orlando fla hear latest attack world most intractable blood cancer already abstract presentation release ahead conference have make splash tiny french biotech cellectis cll offer detail
381,ABBV,big pharmas merck mrk eli lilly lly johnson johnson jnj be trading tuesday get upgrade barclay abbvie abbv seesaw downgrade analyst geoff meacham assume coverage newly combine pharmaceutical sector barclay coverage left most rating same make few tweak lilly be upgrade overweight equal weight price target lift base promising pipeline management commitment lower expense meacham say lilly be build major autoimmune disease franchise late stage drug candidate ixekizumab psoriasis baricitinib rheumatoid arthritis drug develop incyte incy base solid phase datum view baricitinib have significant market share potential rheumatoid arthritis meacham write model conservatively project risk adjust sale vs peak sale pfizer pfe xeljanz meacham call diabetes drug jardiance lilly most important commercial asset intermediate term recent study result show sharply reduce death heart failure admit have be overhang merck derive lot revenue compete drug jardiance argue stock have overreact acknowledge be multiple headwind risk make merck show story think even most potential negative scenario be too much underlie value ignore meacham write raise merck rating overweight equal weight hike price target even pipeline asset aren blockbuster add be nearly free current valuation lilly stock be almost afternoon trading stock market today merck stock be meacham also raise overweight equal weight price target rise merck feel market be undervalue have underperform drg past month due concern impact biosimilar remicade low term earning growth lack significant term pipeline catalyst meacham write have lead call break conglomerate believe be premature meacham view be better acquire growth asset especially pharma stock be afternoon trading meanwhile meacham downgrade abbvie equal weight overweight trim price target many analyst thought abbvie projection recently acquire blood cancer drug imbruvica similar drug pipeline year peak be too high imbruvica other oncology asset likely succeed field be highly competitive meacham write abbvie stock initially drop almost tuesday trading afternoon be follow amy reeve twitter ibd_areeve facebook
382,ABBV,manager columbia mid cap growth fund spun wheel bit difficult third quarter have keep mutual fund course outperform broad stock market peer group track morningstar first second quarters mutual fund lag peer come holding energy sector cope fund have cut energy weighting also see energy holding lose value energy weighting be more percentage point lower year earlier case trim proceed be recycle stock manager see better risk reward opportunity investor say lead manager george myer invest growth company aren willing overpay myer say approach have work long term well recently fund gain year go tuesday top peer be fund carry month performance rating ibd have perform top mutual fund period stock add be signature bank sbny be ibd leaderboard bank big bank competitor offer customer single point contact myer say don get pass person bank continue take market share myer say bank pay package attract talented employee bring book business signature stand benefit federal reserve interest rate hike weather fund aim growth stock be able grow earning matter be economic cycle do company need unique least superior product service example higher interest rate win impact person need buy product incyte incy oncology rheumatoid arthritis company myer say manager prospect incyte build revenue new product addition cancer treatment jakafi be work develop cancer immunotherapy myer say test have be promising rheumatoid arthritis drug be develop partnership eli lilly lly think incyte product be superior abbvie abbv humira sell north globally say linkedin lnkd be stock manager long term thesis be talent solution segment be business be better person expect say co manager brian neigut marketing solution segment be pressure also continue do better wall street expect base new product update ancillary product roper technology rop be favorite fund shift money co manager william chamberlain like company knack make accretive acquisition such legal software firm aderant october also like wide variety product chamberlain call roper industrial firm increasingly think tech stock ultimate software group ulti be fund favorite company benefit ongoing shift payroll service cloud expect accelerate revenue growth set apart many other tech company myer say
383,ABBV,biotech stock acorda therapeutic acor soar early trading stock market today day court dismiss patent challenge move have wider implication drug space late monday acorda announce patent trial appeal board ptab have decline institute parte review ipr request
384,ABBV,biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday
385,ABBV,price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical
386,ABBV,rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday
387,ABBV,biotechs lead drug sell
388,ABBV,ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose
389,ABBV,regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter
390,ABBV,leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat
391,ABBV,politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round
392,ABBV,have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism
393,ABBV,clinton impact see limit
394,ABBV,ultimately political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war
395,ABBV,so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely
396,ABBV,even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client
397,ABBV,still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment
398,ABBV,investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write biotech stock tumble monday presidential candidate hillary clinton say propose plan address high drug price tuesday price gouge specialty drug market be outrageous clinton write twitter account monday morning tomorrow ll lay plan take clinton link new york time article daraprim drug price be hike more fold be acquire privately hold turing pharmaceutical rbc capital market analyst michael yee write note other reason biotechs rough monday be confirmation progressive multifocal pml case associate biogen biib multiple sclerosis franchise also say biotechs have be trading inversely crude price jump monday biotechs lead drug sell ishare nasdaq biotech etf ibb fall monday biogen stock skid gilead science gild start day slightly report good drug trial news lose regeneron regn fall amgen amgn regeneron partner sanofi sny amgen recently win separate approval new class cholesterol fighter leader other drug group also fall allergan agn sank valeant pharmaceutical vrx drug pricing policy have draw criticism retreat politician have be criticize drug cost year price have keep go especially specialty drug segment drug prescribe specialist instead primary care doctor gilead sovaldi be target such criticism march company price week round have written extensively specialty drug segment account prescription dollar spend vs year leonard yaffe manage health care hedge fund kessel capital management write email give dramatic rise spending drug average annually past decade annual cost often excess year represent easy target criticism clinton impact see political furor sovaldi didn lead actual legislation wasn government drive sovaldi price competition abbvie abbv unveil rival regimen december company get rebate war so clinton really make difference terry haine evercore isi policy analyst former washington lobbyist find unlikely even democratic president be assume congress almost certainly not approve drug pricing regulation legislation haine write note client still wasn drug stock need struggle recover ibd medical biotech group dive july high aug low broader macroeconomic valuation concern analyst yee write continue current environment investor prepare drug pricing volatility noise go have say drug pricing noise turn due election year write
399,ABBV,halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug
400,ABBV,halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product
401,ABBV,san diego base halozyme be also testing product call pegph combination other drug treatment various cancer
402,ABBV,analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year
403,ABBV,recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention
404,ABBV,ibd have drug delivery product hylenex enhanze seem similar be difference
405,ABBV,torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin
406,ABBV,product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic
407,ABBV,hylenex be product halozyme go get approve promote small field force have
408,ABBV,basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue
409,ABBV,now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule
410,ABBV,ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection
411,ABBV,same base sugar just license call enhanze product call hylenex
412,ABBV,ibd drug re develop cancer treatment be also base same substance
413,ABBV,torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein
414,ABBV,so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day
415,ABBV,example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient
416,ABBV,exactly re try do here have drug last longer so doesn have be give frequently
417,ABBV,ibd so be necessarily combine drug do do anything
418,ABBV,torley pegph have modest cancer effect type effect believe be important patient need be used therapy
419,ABBV,ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed
420,ABBV,be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone
421,ABBV,theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor
422,ABBV,administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work
423,ABBV,early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar
424,ABBV,today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement
425,ABBV,connect amy reeve ibd_areeve facebook halozyme therapeutic have be hotter biotech stock not exactly develop drug halozyme halo market product hylenex aids delivery injectable drug halozyme have also license enhanze same purpose such drug company pfizer pfe roche rhhby johnson johnson jnj janssen division abbvie abbv baxalta bxlt development injectable product san diego base halozyme be also testing product call pegph combination other drug treatment various cancer analyst don expect effort yield steady annual earning even recent biotech stock selloff halozyme be trading double be start year recent interview ibd halozyme ceo helen torley explain company business model catch wall street attention ibd have drug delivery product hylenex enhanze seem similar be difference torley market product be hylenex be basic rhuph enzyme degrade hyaluronan be sugar be present skin ve ever have subcutaneous injection re inject probably get sore re come resistance resistance be cause hyaluronan skin product be rhuph hylenex also enhanze temporarily break hyaluronan release water molecule be attach hyaluronan allow creation passage skin allow re inject have bigger surface area absorption bloodstream lymphatic hylenex be product halozyme go get approve promote small field force have basically be rhuph be used dispersion fluid be give skin also drug well be modest part business term generate revenue now also have part business call enhanze platform allow partner pfizer roche janssen abbvie baxalta license use enzyme most case combine molecule ll use roche herceptin mabthera rituxan example create new product be mixture herceptin enzyme go different regulatory path get approve so new product be call herceptin sc be inject enzyme work allow herceptin be absorb skin breaking hyaluronan barrier allow be bigger surface area absorption so instead herceptin have be give vein iv co administer drug give subcutaneous injection same base sugar just license call enhanze product call hylenex ibd drug re develop cancer treatment be also base same substance torley give hylenex marketplace today give subcutaneously be give vein be digest liver very rapidly so wouldn have big effect be give vein so pegylate pegylate be not uncommon approach take have drug have longer time circulate body get digest degraded liver pegph be basically pegylate version rhuph enzyme give vein last body several day so exert effect several day example be amgen amgn neupogen be give pretty frequently patient have low white blood cell receive chemotherapy peglyat create neulasta only have be inject couple week be obviously better convenience patient exactly re try do here have drug last longer so doesn have be give frequently ibd so be necessarily combine drug do do anything torley pegph have modest cancer effect type effect believe be important patient need be used therapy ll give example datum just present late study patient metastatic pancreatic cancer be patient generally have life expectancy month re diagnosed be look pegph addition current best available therapy be combination abraxane celgene celg drug gemcitabine be generic drug do be look pegph top abraxane gemcitabine vs abraxane gemcitabine alone theory pegph be work be patient be high level sugar hyaluronan tumor act barrier cancer therapy ability get tumor need work do bound water molecule create high pressure tumor compress blood vessel so get injection abraxane example theory be abraxane get tumor need work low blood flow tumor administer peg break hyaluronan open blood vessel open blood flow so give pegph give abraxane gemcitabine much higher concentration chemotherapy get tumor need work early datum phase study show patient receive pegph get gemcitabine abraxane have double progression free survival double response rate see interesting early trend improvement survival patient have high level hyaluronan estimate pancreatic cancer patient have high level sugar today abraxane gemcitabine be best standard care median survival be just month re hope do patient high level hyaluronan be get good improvement connect amy reeve ibd_areeve facebook
426,ABBV,drugmaker medivation mdvn agree acquire late stage breast cancer drug candidate biomarin pharmaceutical bmrn monday deal worth
427,ABBV,medivation be pay upfront talazoparib be currently phase testing advanced metastatic breast cancer involve germline mutation brca gene drug succeed biomarin be due milestone payment midsingle digit royalty sale
428,ABBV,talazoparib be parp inhibitor new class cancer drug include astrazeneca azn recently approve lynparza abbvie abbv late stage candidate veliparib medivation be still ride successful launch prostate cancer drug xtandi acquisition give chance diversify write rbc capital market analyst simo simeonidis
429,ABBV,medivation be essentially trick pony eye most investor promise license pd inhibitor mdv notwithstanding think move make sense simeonidis write research note monday astrazeneca lynparza recently approve ovarian cancer currently phase breast cancer brca germline mutation tesaro tsro niraparib currently phase breast cancer brca germline mutation provide competition space view reasonable bet medivation look late stage oncology asset
430,ABBV,part biomarin have be increasingly focuse rare disease drug so sale divest asset be outside core strategy
431,ABBV,biomarin offload expense enrolling pivotal program talazoparib bring nondilutive capital maintain royalty economic interest drug become much bigger expect road write rbc biotech analyst michael yee biomarin be not highly focuse cancer right now parp market be competitive so be develop enrolled commercialize cancer company
432,ABBV,drug stock be get hammer rest market monday morning medivation be exception early trading stock market today medivation plunge week low quickly bounce back loss biomarin stock follow similar pattern drop early recover loss
433,ABBV,astrazeneca abbvie fall tesaro be
434,ABBV,connect amy reeve ibd_areeve facebook drugmaker medivation mdvn agree acquire late stage breast cancer drug candidate biomarin pharmaceutical bmrn monday deal worth medivation be pay upfront talazoparib be currently phase testing advanced metastatic breast cancer involve germline mutation brca gene drug succeed biomarin be due milestone payment midsingle digit royalty sale talazoparib be parp inhibitor new class cancer drug include astrazeneca azn recently approve lynparza abbvie abbv late stage candidate veliparib medivation be still ride successful launch prostate cancer drug xtandi acquisition give chance diversify write rbc capital market analyst simo simeonidis medivation be essentially trick pony eye most investor promise license pd inhibitor mdv notwithstanding think move make sense simeonidis write research note monday astrazeneca lynparza recently approve ovarian cancer currently phase breast cancer brca germline mutation tesaro tsro niraparib currently phase breast cancer brca germline mutation provide competition space view reasonable bet medivation look late stage oncology asset part biomarin have be increasingly focuse rare disease drug so sale divest asset be outside core strategy biomarin offload expense enrolling pivotal program talazoparib bring nondilutive capital maintain royalty economic interest drug become much bigger expect road write rbc biotech analyst michael yee biomarin be not highly focuse cancer right now parp market be competitive so be develop enrolled commercialize cancer company drug stock be get hammer rest market monday morning medivation be exception early trading stock market today medivation plunge week low quickly bounce back loss biomarin stock follow similar pattern drop early recover loss astrazeneca abbvie fall tesaro be connect amy reeve ibd_areeve facebook
435,ABBV,big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug
436,ABBV,unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month
437,ABBV,go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month
438,ABBV,november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx
439,ABBV,abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future
440,ABBV,abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other
441,ABBV,drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction
442,ABBV,connect amy reeve ibd_areeve facebook big biotech unite therapeutic uthr agree sell priority review voucher abbvie abbv give unite infusion cash abbvie chance speed fda approval drug unite gain rare pediatric disease priority review voucher pprv march approval unituxin treatment rare childhood cancer call neuroblastoma fda start pprv program encourage development such drug cut standard review time new drug month go price pprv have rise sharply last year july regeneron pharmaceutical regn sanofi sny paid just buy biomarin pharmaceutical bmrn used get cholesterol drug praluent market last month november gilead science gild paid get pprv knight therapeutic used last month filing new combination therapy hiv price have rise sanofi acquire pprv retrophin rtrx abbvie didn say drug go use voucher have several late stage possibility company have be work expand cancer leukemia drug venetoclax breast cancer drug veliparib be review future abbvie be also work next generation hepatitis treatment race market be intense face gilead merck mrk other drug stock general be rest market early stock market today late morning unite therapeutic be wednesday midweek update ibd be abbvie stock also be fraction connect amy reeve ibd_areeve facebook
443,ABBV,big pharma pfizer pfe be reportedly deal acquire ireland base allergan agn thursday even treasury department say put new guidance cut economic benefit such deal pfizer allergan confirm rumor be such talk late last month detail such price be left wall street speculation late wednesday however bloomberg reuter report price have be set range share total bloomberg say deal be announce soon monday cnbc say thursday announcement be expect follow monday come just hour treasury secretary jacob lew send letter senate finance committee criticize tax inversion deal company acquire smaller company lower tax domicile sort reverse acquisition allow company relocate cut tax bill pfizer already try do last year acquire british drug giant astrazeneca azn be rebuff so pursuit dublin base allergan be generally see alternative inversion deal lew say letter later week treasury issue target guidance reduce further economic benefit corporate inversion treasury have previously issue guideline effect back september evercore isi policy analyst terry haine point never result actual change rule guidance say treasury never do propose new regulation combat hopscotch loan prevent restructure foreign subsidiary prevent inverted company transfer cash property controlled foreign corporation avoid tax strengthen interpretation ownership rule haine write email client treasury also say intend take comment earning strip also be not do just treasury do letter lew boast guideline do slow previously torrid rate tax inversion deal indeed torpedo abbvie abbv plan takeover shire shpg abbvie decide pay hefty termination fee rather take risk rule materializing haine evercore colleague specialty drug analyst umer raffat write separate email lew follow actual guideline time address issue earning strip inverted company foreign hq issue intercompany loan subsidiary charge tax deductible interest prior conversation legal expert treasury not have mandate change cap interest expense deduction raffat write be very interesting see treasury come change threshold guidance let concern party litigate hope timeline litigation be long enough prevent inversion transaction raffat add treasury also propose modify definition debt exclude such intercompany loan guideline come allergan ceo brent saunder say seem most plausible avenue attack worst case scenario hit company tax rate tune basis point allergan then call actavis be product tax inversion have large presence credit suisse analyst vamil divan write hard tell much tax pfizer save current inversion rule deal price now table still yield accretion pfizer modeled conservative tax benefit go forward anticipate tax rate subsequently drop divan write research note initial cost synergy assumption be also relatively conservative assumption cost synergy realize be possible pfizer be able extract greater cost synergy deal incremental synergy represent additional cent yearly ep midmorning trading stock market today allergan stock be pfizer be more follow amy reeve twitter ibd_areeve facebook
444,ABBV,expect treasury department late thursday issue tougher rule govern tax inversion company buy overseas firm then move headquarters country get more favorable tax treatment wasn clear immediately new rule impact possible pfizer pfe acquisition ireland base allergan agn deal value
445,ABBV,cvs health cvs announcement monday cover amgen amgn cholesterol drug repatha exclusively regeneron regn sanofi sny rival version praluent put pressure praluent maker deliver same say analyst repatha be only pcsk inhibitor cvs caremark commercial formulary say nation drugstore chain
446,ABBV,pfizer pfe be massive deal buy allergan agn redomicile ireland multiple report say even treasury department plan impose new restriction tax inversion pfizer be discuss deal pay share botox maker allergan bloomberg reuter report late wednesday allergan rise wednesday retreat hour follow news inversion rule allergan trade low oct pfizer allergan deal buzz picked pfizer rise wednesday be little change late wednesday share be takeover largest health care deal ever biggest takeover kind year bloomberg say company want announce deal soon monday reuter say announcement be not necessarily imminent say treasury wednesday announcement issue target tax inversion guidance later week affect timing agreement acquire irish drugmaker pfizer be able limit exposure punitive corporate tax system america corporate rate be highest industrial world country taxe company overseas profit be repatriate treasury issue restriction tax inversion september stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead unclear new limit treasury impose obama administration ban inversion addition inversion benefit pfizer beef brand name drug boost pipeline treatment mid late stage trial pfizer use allergan deal lead pfizer breakup company follow ed carson twitter ibd_ecarson facebook
447,ABBV,wednesday morning annual liver meeting wrapped san francisco wall street analyst sift implication datum rolled vast hepatitis market analyst see continue dominance gilead science gild genotype hepatitis virus hcv account majority case gilead harvoni
448,ABBV,treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation
449,ABBV,later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable
450,ABBV,be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home
451,ABBV,share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin
452,ABBV,treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead
453,ABBV,tax inversion company seek move be technically be acquire practice relocate company run combine business
454,ABBV,many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here
455,ABBV,follow bill peter twitter ibd_bpeter treasury department say wednesday announce target guidance intend discourage so call tax inversion deal used business relocate lower tax nation later week intend issue additional target guidance reduce further economic benefit corporate inversion treasury secretary jack lew say letter senior lawmaker further detail be unavailable be important emphasize however treasury stop inversion new statutory authority lew say congress act creative accountant lawyer continue find new way company move tax residence overseas avoid pay taxe here home share allergan agn ireland base drugmaker have be mull inversion deal pfizer pfe pfizer be little change hour allergan fall late trade nearly wipe regular session gain allergan be still sharply late october level pfizer buzz begin treasury department first begin attempt crack tax inversion september follow series inversion attempt particularly pharmaceutical business rule stop abbvie abbv acquisition deal involve burger king now restaurant brand qsr medtronic mdt mylan myl go ahead tax inversion company seek move be technically be acquire practice relocate company run combine business many say deal deplete tax revenue allow company much operation dodge taxe many business community say inversion wouldn be need corporate tax rate be lower have world highest tax rate industrial world taxe overseas profit be repatriate here follow bill peter twitter ibd_bpeter
456,ABBV,beleaguered drug giant valeant pharmaceutical international vrx say friday sever ty specialty pharmacy philidor say be shut completely criticism mount business practice philidor first hit headline oct new york time mentioned article specialty pharmacy few day later short seller citron
457,ABBV,big biotech amgen beat wall street estimate offer mixed guidance late wednesday send stock modestly hour trading
458,ABBV,amgen amgn report adjust earning share year earlier beating analyst consensus cent accord thomson reuter
459,ABBV,revenue climb consensus best gain several year
460,ABBV,amgen lift full year guidance compare beat imply underperform add revenue guidance now raise ep guidance cent now be wall street estimate
461,ABBV,amgen also provide preliminary guidance be line revenue estimate consensus ep amgen guide sale ep range
462,ABBV,rbc capital market analyst michael yee note issue preliminary target be surprise move perhaps imply management confidence business amgen usually doesn give such guidance report
463,ABBV,yee add experience show company start annual guidance conservatively then raise year ve do year now
464,ABBV,enbrel sale unsustainable
465,ABBV,half revenue beat come amgen top seller rheumatoid arthritis drug enbrel sale rise year earlier vs consensus amgen say sale be drive net selling price low inventory level prior year period offset partially impact competition
466,ABBV,neulasta drug beat consensus rise only
467,ABBV,evercore isi analyst mark schoenebaum note amgen indicated abnormally large purchase enbrel neulasta explain guidance doesn call continuation outperformance
468,ABBV,enbrel beat be drive mostly price increase product continue lose share grow market unit be quarter quarter share decline write email client
469,ABBV,enbrel have grow list rival rheumatoid arthritis include abbvie abbv humira johnson johnson jnj stelara newer product pfizer pfe xeljanz
470,ABBV,conference call analyst ceo robert bradway talk newer drug amgen be track meet goal new drug approval year fda approve melanoma drug imlygic day earning report potential blockbuster cholesterol drug repatha august
471,ABBV,amgen stock rise regular trade share be late big biotech amgen beat wall street estimate offer mixed guidance late wednesday send stock modestly hour trading amgen amgn report adjust earning share year earlier beating analyst consensus cent accord thomson reuter revenue climb consensus best gain several year amgen lift full year guidance compare beat imply underperform add revenue guidance now raise ep guidance cent now be wall street estimate amgen also provide preliminary guidance be line revenue estimate consensus ep amgen guide sale ep range rbc capital market analyst michael yee note issue preliminary target be surprise move perhaps imply management confidence business amgen usually doesn give such guidance report yee add experience show company start annual guidance conservatively then raise year ve do year now enbrel sale unsustainable half revenue beat come amgen top seller rheumatoid arthritis drug enbrel sale rise year earlier vs consensus amgen say sale be drive net selling price low inventory level prior year period offset partially impact competition neulasta drug beat consensus rise only evercore isi analyst mark schoenebaum note amgen indicated abnormally large purchase enbrel neulasta explain guidance doesn call continuation outperformance enbrel beat be drive mostly price increase product continue lose share grow market unit be quarter quarter share decline write email client enbrel have grow list rival rheumatoid arthritis include abbvie abbv humira johnson johnson jnj stelara newer product pfizer pfe xeljanz conference call analyst ceo robert bradway talk newer drug amgen be track meet goal new drug approval year fda approve melanoma drug imlygic day earning report potential blockbuster cholesterol drug repatha august amgen stock rise regular trade share be late
472,ABBV,big pharma abbvie abbv beat analyst estimate issue year guidance be expectation friday morning send stock sharply early trading abbvie adjust earning rise year earlier quarter share beating analyst consensus cent accord thomson reuter sale climb estimate
473,ABBV,company head record year share repurchase expert be split buyback be logical result excess capital come expense growth initiative
474,ABBV,number high profile company have implement aggressive buyback program recent quarters span sector economy
475,ABBV,include tech giant such apple aapl microsoft msft health care leader express script esrx abbvie abbv manufacturer boee ba general motor gm financial leader well fargo wfc consumer stock such nike nke wendy wen
476,ABBV,nike announce buyback program thursday dividend hike
477,ABBV,apple buy back share fiscal buy stock
478,ABBV,not surprisingly buyback have become focus intense medium coverage recent week
479,ABBV,critic say more money be reinvest research development initiative well new product technology service contribute long term growth feed economic expansion say critic also say executive use buyback flatter financial result
480,ABBV,defender say return money shareholder be good use money left capital have already be allocate normal business expense
481,ABBV,today environment many company be still left large amount excess capital even investing growth initiative say michael arone chief investment strategist state street global advisor intermediary business group
482,ABBV,be choose redeploy money investor tell ibd do right way buyback be good capital allocation be lot misperception share buyback
483,ABBV,record buyback pace
484,ABBV,certain be whole lot money be go buyback dividend lately
485,ABBV,total dollar amount dividend stock buyback be track reach new high year soar first time accord industry estimate
486,ABBV,percentage operate cash flow used buy back share be highest level arone say call watersh year buyback be also just fall sharp recession bear market
487,ABBV,look kind peak year say year percentage operate cash flow used buyback be still be largest year time absolute dollar term
488,ABBV,recent investigative report reuter note nearly publicly trade financial company examine have buy back share
489,ABBV,fiscal spending buyback dividend surpass company combine net income first time outside recessionary period reuter say spending keep climb higher company have already report fiscal suggest corporation be rely more heavily cheap interest rate use debt fund buyback dividend
490,ABBV,factset research report company buy back share paid dividend trail month end second quarter most recent datum available be spend firm share repurchase same period
491,ABBV,information technology sector spend most money buyback second quarter factset say lead apple microsoft qualcomm qcom oracle orcl
492,ABBV,meanwhile company issue dividend be establish new record accord datum henderson global investor
493,ABBV,be money go buyback dividend
494,ABBV,most basic answer be money be something have be do
495,ABBV,have low interest rate record profit arone say have result corporation peak level term have lot cash hand
496,ABBV,case activist investor be pressure company reward investor money analyst say other executive be simply gun shy investing product service not pay long term
497,ABBV,reason company be buy back outstanding share be do so fatten share earning
498,ABBV,innovation shortchange
499,ABBV,worry quarters be buyback come expense product development innovation long term growth
500,ABBV,be production everything flat panel tvs semiconductor solar photovoltaic cell gary pisano professor harvard business school tell reuter also author produce prosperity america need manufacturing renaissance
501,ABBV,reuter report so firm track buy back share report spending share net income spend innovation have averaged less com pare
502,ABBV,not datum show such grim view arone say bunch datum show grow fastest level year misperception company be not reinvest spending business growth many company do continue reinvest business
503,ABBV,also say buyback boost company ep research dow jone index show weight basis recent ep gain be build profit not buyback
504,ABBV,recent report deutsche bank find share profit have rise annually average just percentage point be buyback fall point
505,ABBV,misperception buyback be due couple factor arone say
506,ABBV,global economic growth have be sluggish therefore folk equate sluggishness lack business investment say also be lack meaningful wage growth view be accelerate much more quickly have business be investing more not convince accurate
507,ABBV,economic growth be sluggish return capital be low so return cash shareholder be sound decision
508,ABBV,not say aren case company issue buyback dividend detriment
509,ABBV,company be borrow aggressively levering balance sheet buy back stock be not necessarily good strategy arone say company buy back stock offset dilutive effect stock base compensation employee not good strategy
510,ABBV,be exception rather rule say say happen broadly be mind exaggeration company head record year share repurchase expert be split buyback be logical result excess capital come expense growth initiative number high profile company have implement aggressive buyback program recent quarters span sector economy include tech giant such apple aapl microsoft msft health care leader express script esrx abbvie abbv manufacturer boee ba general motor gm financial leader well fargo wfc consumer stock such nike nke wendy wen nike announce buyback program thursday dividend hike apple buy back share fiscal buy stock not surprisingly buyback have become focus intense medium coverage recent week critic say more money be reinvest research development initiative well new product technology service contribute long term growth feed economic expansion say critic also say executive use buyback flatter financial result defender say return money shareholder be good use money left capital have already be allocate normal business expense today environment many company be still left large amount excess capital even investing growth initiative say michael arone chief investment strategist state street global advisor intermediary business group be choose redeploy money investor tell ibd do right way buyback be good capital allocation be lot misperception share buyback record buyback pacewhat certain be whole lot money be go buyback dividend lately total dollar amount dividend stock buyback be track reach new high year soar first time accord industry estimate percentage operate cash flow used buy back share be highest level arone say call watersh year buyback be also just fall sharp recession bear market look kind peak year say year percentage operate cash flow used buyback be still be largest year time absolute dollar term recent investigative report reuter note nearly publicly trade financial company examine have buy back share fiscal spending buyback dividend surpass company combine net income first time outside recessionary period reuter say spending keep climb higher company have already report fiscal suggest corporation be rely more heavily cheap interest rate use debt fund buyback dividend factset research report company buy back share paid dividend trail month end second quarter most recent datum available be spend firm share repurchase same period information technology sector spend most money buyback second quarter factset say lead apple microsoft qualcomm qcom oracle orcl meanwhile company issue dividend be establish new record accord datum henderson global investor be money go buyback dividend most basic answer be money be something have be do have low interest rate record profit arone say have result corporation peak level term have lot cash hand case activist investor be pressure company reward investor money analyst say other executive be simply gun shy investing product service not pay long term reason company be buy back outstanding share be do so fatten share earning innovation shortchange worry quarters be buyback come expense product development innovation long term growth be production everything flat panel tvs semiconductor solar photovoltaic cell gary pisano professor harvard business school tell reuter also author produce prosperity america need manufacturing renaissance reuter report so firm track buy back share report spending share net income spend innovation have averaged less com pare not datum show such grim view arone say bunch datum show grow fastest level year misperception company be not reinvest spending business growth many company do continue reinvest business also say buyback boost company ep research dow jone index show weight basis recent ep gain be build profit not buyback recent report deutsche bank find share profit have rise annually average just percentage point be buyback fall point misperception buyback be due couple factor arone say global economic growth have be sluggish therefore folk equate sluggishness lack business investment say also be lack meaningful wage growth view be accelerate much more quickly have business be investing more not convince accurate economic growth be sluggish return capital be low so return cash shareholder be sound decision not say aren case company issue buyback dividend detriment company be borrow aggressively levering balance sheet buy back stock be not necessarily good strategy arone say company buy back stock offset dilutive effect stock base compensation employee not good strategy be exception rather rule say say happen broadly be mind exaggeration
511,ABBV,big biotech gilead science gild get price target increase tuesday big pharma merck mrk release new datum hepatitis regimen be rival gilead blockbuster franchise oppenheimer analyst wendy lam lift price target gilead writing stock considerable sell june high investor be due revisit gilead strong fundamental acknowledge investor be nervous launch merck grazoprevir elbasvir doublet therapy hepatitis result price war similar abbvie abbv release own rival therapy late last year maintain positive outlook hep franchise term expect continue growth patient volume payer continue lift restriction treatment lam write research note tuesday merck threat believe merck entry be less disruptive thought suspect merck be less incentivize abbvie instigate pricing war expect gilead defend share aggressively already have be maintain vast majority payer contract merck testing hepatitis drug combomerck meanwhile be testing next generation combo doublet mk drug same class gilead blockbuster sovaldi tuesday american association study liver disease aasld release late breaking abstract presentation next month annual liver meeting show triple therapy have achieve cure rate genotype hepatitis virus week treatment similarly high rate genotype week treatment gilead harvoni be approve only genotype sovaldi be also approve type lower rate success typically longer treatment duration week however last month gilead announce new drug combo have succeed treat genotype so field remain hotly competitive datum abstract efficacy datum week triple combo therapy gt gt lesser extent gt appear encourage potentially feasible await further detail include baseline patient characteristic actual presentation evercore isi analyst mark schoenebaum write email client neither stock be help much news early afternoon stock market today gilead stock be nearly merck stock be similar amount follow amy reeve twitter ibd_areeve facebook
512,ABBV,biotech halozyme therapeutic halo jump much tuesday morning nearly touch time high day company beat estimate provide update pipeline share reversed close lower late monday halozyme report revenue year earlier quarter more analyst expect more half revenue come milestone payment abbvie abbv june partnership firm announce june incorporate halozyme enhanze technology injectable drug abbvie be develop other revenue come sale injectable drug booster hylenex manufacturing agreement roche rhhby baxalta bxlt company turn profit cent share analyst expect loss cent however halozyme doesn expect make consistent quarterly profit launch lead drug candidate pegph be midstage testing pancreatic cancer early stage testing lung cancer phase study pegph pancreatic cancer remain track start follow feedback european medicine agency trial design continue progress companion diagnostic write ub analyst andrew peter research note monday other hand note enrollment phase lung cancer trial be schedule push potential stock catalyst still see initial efficacy datum overall response rate be secondary endpoint phase portion likely be report earlier give significant risk adjustment model still suggest meaningful upside peter add due abbvie deal halozyme lift full year revenue guidance more now operate expense guidance also go firm say add revenue cut cash burn halozyme expect have cash end year halozyme stock have be have quite good rise more new year day record high july halozyme high intraday stock market today close connect amy reeve ibd_areeve facebook
513,ABBV,ibd slim stock investment system be simple yet vital concept
514,ABBV,stand leader high growth stock greatest potential outstanding return
515,ABBV,true market leader be typically best performer top tier industry group sector boast strong profit revenue growth generate unique innovative product service receive solid institutional support
516,ABBV,top stock strong industry group have unbelievable growth other pack hardly stir write ibd chairman founder william neil best seller make money stock
517,ABBV,investing system emphasize buy stock have be beaten imply re undervalue therefore ready rebound slim investor focus stock be show strength break properly form basis hit new high
518,ABBV,overall stock market be trend higher buy proper buy point have strong chance make money quickly top stock volume stock break base be key heavy volume indicate stock be be drive higher mutual fund other high power investor
519,ABBV,top growth stock seemingly come nowhere break rack huge gain investor include computer networking king cisco system csco october apple aapl march search engine pioneer google googl september table accompany story show sample today lead stock include drugmaker abbvie abbv shoemaker nike nke medical device maker abiom abmd
520,ABBV,lead stock come top industry group ibd track see page partial list industry group have more leader investor restrict watch list more top
521,ABBV,leader have quarterly earning sale growth more annual profit be similar also have robust financial profile include solid margin profit estimate long term growth
522,ABBV,lead stock tend hold relative price strength rating least indicate stock price performance rank top stock past week stock share be fall usually indicate fundamental be deteriorate top mutual fund manager fact be exit stock
523,ABBV,easy way find outstanding leader be check sector leader table today page
524,ABBV,investing growth stock matter good fundamental chart pattern always come risk example market correction hit lead stock fall time more general market
525,ABBV,also lengthy uptrend leader maintain high rating ibd even re late stage price run prefer leader re breaking early stage basis breaking huge price run ibd slim stock investment system be simple yet vital concept stand leader high growth stock greatest potential outstanding return true market leader be typically best performer top tier industry group sector boast strong profit revenue growth generate unique innovative product service receive solid institutional support top stock strong industry group have unbelievable growth other pack hardly stir write ibd chairman founder william neil best seller make money stock investing system emphasize buy stock have be beaten imply re undervalue therefore ready rebound slim investor focus stock be show strength break properly form basis hit new high overall stock market be trend higher buy proper buy point have strong chance make money quickly top stock volume stock break base be key heavy volume indicate stock be be drive higher mutual fund other high power investor top growth stock seemingly come nowhere break rack huge gain investor include computer networking king cisco system csco october apple aapl march search engine pioneer google googl september table accompany story show sample today lead stock include drugmaker abbvie abbv shoemaker nike nke medical device maker abiom abmd lead stock come top industry group ibd track see page partial list industry group have more leader investor restrict watch list more top leader have quarterly earning sale growth more annual profit be similar also have robust financial profile include solid margin profit estimate long term growth lead stock tend hold relative price strength rating least indicate stock price performance rank top stock past week stock share be fall usually indicate fundamental be deteriorate top mutual fund manager fact be exit stock easy way find outstanding leader be check sector leader table today page investing growth stock matter good fundamental chart pattern always come risk example market correction hit lead stock fall time more general market also lengthy uptrend leader maintain high rating ibd even re late stage price run prefer leader re breaking early stage basis breaking huge price run
526,ABBV,come buyout drugmaker hard keep valeant pharmaceutical vrx rapid pace acquisition canadian drugmaker have already make flurry acquisition year lead stock ethical drug maker group composite rating other highly rate player group include horizon hznp eli lilly lly jazz pharmaceutical jazz nordisk nvo abbvie abbv
527,ABBV,group rank tuesday issue spot week
528,ABBV,outperform other drug group generic biotechs
529,ABBV,latest news valeant progenic tuesday say fda accept new drug application submission oral relistor
530,ABBV,last week valeant say buy synergetic usa deal value synergetic make surgical instrument used ophthalmology neurosurgery
531,ABBV,also last week valeant announce agreement pay astrazeneca azn licensing deal psoriasis drug candidate brodalumab amgen astrazeneca previous partner drug exit program several trial patient commit suicide valeant plan file fda approval
532,ABBV,august also strike deal buy pharmaceutical maker addyi libido pill woman fda reject drug twice approve august day valeant acquisition news first only drug market treat call hypoactive sexual desire disorder
533,ABBV,july valeant say acquire amoun pharmaceutical egypt biggest drugmaker
534,ABBV,major acquisition get away earlier year be botox maker allergan agn valeant offer target company go higher bid ireland base actavis then change name allergan
535,ABBV,many other health care stock valeant be attempt come back trigger multiple sell signal late august market take beating stock find support week move average have be find resistance week line
536,ABBV,also still flat base entry clear july point be best new pattern emerge
537,ABBV,valeant tuesday ibd have post double digit profit growth double digit better sale gain past quarters analyst expect earning gain higher revenue steady performance help earn earning share rating year earning stability factor scale most stable least stable however poor accumulation distribution rating volume ratio point weak recent demand share
538,ABBV,recent price performance weakness valeant be more year horizon nordisk have rally more respectively come buyout drugmaker hard keep valeant pharmaceutical vrx rapid pace acquisition canadian drugmaker have already make flurry acquisition year lead stock ethical drug maker group composite rating other highly rate player group include horizon hznp eli lilly lly jazz pharmaceutical jazz nordisk nvo abbvie abbv group rank tuesday issue spot week outperform other drug group generic biotechs latest news valeant progenic tuesday say fda accept new drug application submission oral relistor last week valeant say buy synergetic usa deal value synergetic make surgical instrument used ophthalmology neurosurgery also last week valeant announce agreement pay astrazeneca azn licensing deal psoriasis drug candidate brodalumab amgen astrazeneca previous partner drug exit program several trial patient commit suicide valeant plan file fda approval august also strike deal buy pharmaceutical maker addyi libido pill woman fda reject drug twice approve august day valeant acquisition news first only drug market treat call hypoactive sexual desire disorder july valeant say acquire amoun pharmaceutical egypt biggest drugmaker major acquisition get away earlier year be botox maker allergan agn valeant offer target company go higher bid ireland base actavis then change name allergan many other health care stock valeant be attempt come back trigger multiple sell signal late august market take beating stock find support week move average have be find resistance week line also still flat base entry clear july point be best new pattern emerge valeant tuesday ibd have post double digit profit growth double digit better sale gain past quarters analyst expect earning gain higher revenue steady performance help earn earning share rating year earning stability factor scale most stable least stable however poor accumulation distribution rating volume ratio point weak recent demand share recent price performance weakness valeant be more year horizon nordisk have rally more respectively
539,ABBV,big biotech gilead science gild get passel price target increase jump more stock market wednesday wake stellar report late tuesday
540,ABBV,analyst note strong sale hepatitis virus hcv drug increase guidance company know conservative forecasting piper jaffray analyst joshua schimmer raise price target gilead stock base news
541,ABBV,hcv franchise continue outperform expectation investor broadly expect company pull transaction improve long term growth outlook drive multiple expansion level more line peer say research note
542,ABBV,gilead earning conference call tuesday executive affirm re willing look deal large small say aren big hurry give company financial strength
543,ABBV,deutsche bank analyst robyn karnauskas ask specifically gilead acquisition strategy relation oncology field enter launch blood cancer drug zydelig last year zydelig be few drug underperform expectation vs consensus have vie market share new product celgene celg abbvie abbv amgen amgn other mix
544,ABBV,have be fascinating rate innovation ve see blood cancer space have get extremely crowd leave fewer opportunity think new product follow product make headway area chief operate officer john milligan say call so re broaden criterium thing be interested be look wide range thing
545,ABBV,karnauskas raise price target gilead stock
546,ABBV,maxim group analyst jason kolbert lift price target
547,ABBV,be see just tip iceberg hep write research note payer side equation payer restriction loosen ratio private public payer be expect move late
548,ABBV,midday stock market today gilead stock be
549,ABBV,follow amy reeve twitter ibd_areeve big biotech gilead science gild get passel price target increase jump more stock market wednesday wake stellar report late tuesday analyst note strong sale hepatitis virus hcv drug increase guidance company know conservative forecasting piper jaffray analyst joshua schimmer raise price target gilead stock base news hcv franchise continue outperform expectation investor broadly expect company pull transaction improve long term growth outlook drive multiple expansion level more line peer say research note gilead earning conference call tuesday executive affirm re willing look deal large small say aren big hurry give company financial strength deutsche bank analyst robyn karnauskas ask specifically gilead acquisition strategy relation oncology field enter launch blood cancer drug zydelig last year zydelig be few drug underperform expectation vs consensus have vie market share new product celgene celg abbvie abbv amgen amgn other mix have be fascinating rate innovation ve see blood cancer space have get extremely crowd leave fewer opportunity think new product follow product make headway area chief operate officer john milligan say call so re broaden criterium thing be interested be look wide range thing karnauskas raise price target gilead stock maxim group analyst jason kolbert lift price target be see just tip iceberg hep write research note payer side equation payer restriction loosen ratio private public payer be expect move late midday stock market today gilead stock be follow amy reeve twitter ibd_areeve
550,ABBV,google be veer deeper health care become involved everything investing range medical startup form joint venture major biotech firm
551,ABBV,google googl have come long way company shut google health say personal health care service wasn show broad impact
552,ABBV,company have regroup push health technology much bigger way
553,ABBV,google be not pursue term low hang fruit be very very ambitious say california life science association ceo sara radcliffe be really try advance health very way think deserve lot credit
554,ABBV,online search leader unveil most recent health tech effort june announce life science group have create health tracking design use clinical trial give researcher physician crystal clear view patient be experience
555,ABBV,experimental device await fda approval be develop company hush hush google division unit dedicate big technology breakthrough
556,ABBV,smart track pulse heart rhythm skin temperature other measurement
557,ABBV,product isn just fancy version google wear google consumer smartwatch health related apps measure wearer heart rate many step be take day
558,ABBV,instead health focuse be only be prescribe patient used person participate clinical research trial andy conrad head life science team google reportedly tell bloomberg automatically get health datum ensure researcher get most accurate information clinical trial participant conrad say
559,ABBV,other wearable include apple aapl watch fitbit fit fitness band have health apps be not rigorous enough research use
560,ABBV,google say collaborate academic researcher drug company test accuracy then seek approval regulator use europe clinical trial testing band expect start summer
561,ABBV,january google life science division part google announce have create glucose monitoring contact lens diabetic lens aim end need finger prick test glucose level continuously measure glucose level person tear used wireless chip miniaturize glucose sensor
562,ABBV,google be develop lens conjunction eye care company alcon fort worth texas base division novartis nvs switzerland
563,ABBV,vie piece worldwide glucose monitoring device market estimate reach accord research firm visiongain
564,ABBV,september google announce have buy lift lab san francisco base maker high tech swivel spoon counteract hand tremor make eating easier person parkinson disease similar neurological condition
565,ABBV,also september google announce life science spinoff calico have enter year collaboration chicago base pharmaceutical firm abbvie abbv research age related disease
566,ABBV,company pitch initially contribute additional
567,ABBV,investment side search firm google venture be look investment streamline health care system make health care delivery more efficient
568,ABBV,google decline comment story
569,ABBV,december google venture director bill maris tell wsj company allocate venture investing health focus area such mobile compute consumer internet
570,ABBV,more money be go digital health startup other sector
571,ABBV,google venture investment go health life science startup accord wsj report wsj say
572,ABBV,google venture identify life science health startup invest biggest health related investment be flatiron maker cloud base software aggregate ream cancer patient datum many source help doctor make treatment decision google venture lead financing deal flatiron say
573,ABBV,personal genetic firm andme be big life science investment google venture co founder ann wojcicki be ex wife google co founder sergey brin
574,ABBV,february fda say andme market test gene cause rare disorder call bloom syndrome cause short stature heighten risk cancer
575,ABBV,andme be force stop broadly marketing kit fda deem kit medical device hadn meet agency requirement
576,ABBV,foundation medicine develop personalize cancer treatment be google portfolio firm be funded google venture other go public be acquire roche january deal
577,ABBV,google venture company be impossible food be develop meat cheese make plant
578,ABBV,even rani therapeutic be develop robotic ingestible pill deliver drug include insulin body use needle first time
579,ABBV,follow michele chandler twitter ibd_mchandler google be veer deeper health care become involved everything investing range medical startup form joint venture major biotech firm google googl have come long way company shut google health say personal health care service wasn show broad impact company have regroup push health technology much bigger way google be not pursue term low hang fruit be very very ambitious say california life science association ceo sara radcliffe be really try advance health very way think deserve lot credit online search leader unveil most recent health tech effort june announce life science group have create health tracking design use clinical trial give researcher physician crystal clear view patient be experience experimental device await fda approval be develop company hush hush google division unit dedicate big technology breakthrough smart track pulse heart rhythm skin temperature other measurement product isn just fancy version google wear google consumer smartwatch health related apps measure wearer heart rate many step be take day instead health focuse be only be prescribe patient used person participate clinical research trial andy conrad head life science team google reportedly tell bloomberg automatically get health datum ensure researcher get most accurate information clinical trial participant conrad say other wearable include apple aapl watch fitbit fit fitness band have health apps be not rigorous enough research use google say collaborate academic researcher drug company test accuracy then seek approval regulator use europe clinical trial testing band expect start summer january google life science division part google announce have create glucose monitoring contact lens diabetic lens aim end need finger prick test glucose level continuously measure glucose level person tear used wireless chip miniaturize glucose sensor google be develop lens conjunction eye care company alcon fort worth texas base division novartis nvs switzerland vie piece worldwide glucose monitoring device market estimate reach accord research firm visiongain september google announce have buy lift lab san francisco base maker high tech swivel spoon counteract hand tremor make eating easier person parkinson disease similar neurological condition also september google announce life science spinoff calico have enter year collaboration chicago base pharmaceutical firm abbvie abbv research age related disease company pitch initially contribute additional investment side search firm google venture be look investment streamline health care system make health care delivery more efficient google decline comment story december google venture director bill maris tell wsj company allocate venture investing health focus area such mobile compute consumer internet more money be go digital health startup other sector google venture investment go health life science startup accord wsj report wsj say google venture identify life science health startup invest biggest health related investment be flatiron maker cloud base software aggregate ream cancer patient datum many source help doctor make treatment decision google venture lead financing deal flatiron say personal genetic firm andme be big life science investment google venture co founder ann wojcicki be ex wife google co founder sergey brin february fda say andme market test gene cause rare disorder call bloom syndrome cause short stature heighten risk cancer andme be force stop broadly marketing kit fda deem kit medical device hadn meet agency requirement foundation medicine develop personalize cancer treatment be google portfolio firm be funded google venture other go public be acquire roche january deal google venture company be impossible food be develop meat cheese make plant even rani therapeutic be develop robotic ingestible pill deliver drug include insulin body use needle first time follow michele chandler twitter ibd_mchandler
580,ABBV,big cap biotech biogen biib beat earning estimate friday lower guidance report failure clinical trial send stock plummet meanwhile big pharma abbvie abbv report steadier quarter affirm guidance stock be slide sale come short biogen earning exclude time item rise year earlier quarter
581,ABBV,biogen biib second quarter earning top view flagship drug tecfidera tysabri miss sale expectation cause biotech quarterly revenue growth come well consensus estimate company also cut full year revenue guidance
582,ABBV,share be plunge giant volume stock market today gapping lowest level nearly month stock be now trading more mid march high
583,ABBV,look weekly chart see biogen be breaking week week move average biggest weekly volume least year be long term sell signal mark end year run
584,ABBV,drugmaker abbvie abbv also report quarterly result today too top earning view miss sale estimate
585,ABBV,share gap quick turnover stock be look support day line currently buy range cup base buy point
586,ABBV,valeant pharmaceutical vrx celgene celg bristol myer bmy eli lilly lly also report earning week
587,ABBV,follow alissa william twitter ibd_awilliam biogen biib second quarter earning top view flagship drug tecfidera tysabri miss sale expectation cause biotech quarterly revenue growth come well consensus estimate company also cut full year revenue guidance share be plunge giant volume stock market today gapping lowest level nearly month stock be now trading more mid march high look weekly chart see biogen be breaking week week move average biggest weekly volume least year be long term sell signal mark end year run drugmaker abbvie abbv also report quarterly result today too top earning view miss sale estimate share gap quick turnover stock be look support day line currently buy range cup base buy point valeant pharmaceutical vrx celgene celg bristol myer bmy eli lilly lly also report earning week follow alissa william twitter ibd_awilliam
588,ABBV,big biotech gilead science handily beat analyst estimate raise full year guidance tuesday afternoon lead sale blockbuster hepatitis drug
589,ABBV,earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb street number
590,ABBV,gilead gild duly add guidance product sale now do not forecast ep do trim guidance sg expense well tax rate evercore isi analyst mark schoenebaum calculate imply full year ep guidance number be more dollar earlier guidance line consensus
591,ABBV,share rise hour
592,ABBV,sale gilead hepatitis virus hcv drug harvoni sovaldi beat analyst consensus accord evercore isi harvoni pull even just launch october together make more half revenue
593,ABBV,prescription downtrend
594,ABBV,legacy hiv franchise also do better time drug board miss consensus due new competition glaxosmithkline gsk time beat expectation atripla come bit light
595,ABBV,monday rbc capital market analyst michael yee write investor be look closely gilead report get overall sense hcv market be relevant rival such abbvie abbv bristol myer squibb bmy expect future player such merck mrk achillion pharmaceutical achn
596,ABBV,other analyst have be able track prescription datum sovaldi harvoni im health im tracking service
597,ABBV,weekly trx total prescription have be decline hit impressive peak march yee write research note time gilead commentary call be total treat patient usa be high possible april july trx have be decline peak weekly july
598,ABBV,still early day market
599,ABBV,conference call analyst tuesday paul carter gilead head commercial operation acknowledge prescription do decline march peak however say believe market be still early day many patient have be restrict payer get hcv drug due high price run day
600,ABBV,carter say believe restriction loosen real world benefit drug become apparent fact be cure week rather standard week course further lower cost
601,ABBV,gilead be also promote effort increase awareness diagnosis hcv many victim be infected year symptom appear big biotech gilead science handily beat analyst estimate raise full year guidance tuesday afternoon lead sale blockbuster hepatitis drug earning exclude time item rise year earlier quarter share beating analyst consensus cent accord thomson reuter revenue climb street number gilead gild duly add guidance product sale now do not forecast ep do trim guidance sg expense well tax rate evercore isi analyst mark schoenebaum calculate imply full year ep guidance number be more dollar earlier guidance line consensus share rise hour sale gilead hepatitis virus hcv drug harvoni sovaldi beat analyst consensus accord evercore isi harvoni pull even just launch october together make more half revenue prescription legacy hiv franchise also do better time drug board miss consensus due new competition glaxosmithkline gsk time beat expectation atripla come bit light monday rbc capital market analyst michael yee write investor be look closely gilead report get overall sense hcv market be relevant rival such abbvie abbv bristol myer squibb bmy expect future player such merck mrk achillion pharmaceutical achn other analyst have be able track prescription datum sovaldi harvoni im health im tracking service weekly trx total prescription have be decline hit impressive peak march yee write research note time gilead commentary call be total treat patient usa be high possible april july trx have be decline peak weekly july still early day marketon conference call analyst tuesday paul carter gilead head commercial operation acknowledge prescription do decline march peak however say believe market be still early day many patient have be restrict payer get hcv drug due high price run day carter say believe restriction loosen real world benefit drug become apparent fact be cure week rather standard week course further lower cost gilead be also promote effort increase awareness diagnosis hcv many victim be infected year symptom appear
602,ABBV,illumina ilmn surpass second quarter earning estimate late tuesday miss revenue first time year analyst expect beat raise maker gene sequence system so share suffer stock market today illumina stock gap huge volume wednesday breach day move average intraday stock be
603,ABBV,handful big cap stock be due report quarterly earning week only be expect post accelerate profit growth starbucks sbux report fiscal earning thursday profit be see rise cent share mark second straight quarter acceleration sale be forecast climb
604,ABBV,next week bring passel earning report large cap drugmaker biotech pharma stock be trading new high yet again novartis bristol myer squibb eli lilly valeant pharmaceutical abbvie biogen be tap busy earning week here quick rundown be especially big week news biogen biib
605,ABBV,just few week look biotech stock be way don count just yet most come time high few trigger sell signal many have stem decline biotech group have maintain top tier status come friday issue same week
606,ABBV,medical giant johnson johnson jnj beat wall street estimate lift guidance tuesday stock be fraction early trading revenue decline
607,ABBV,earning exclude special item shrank year earlier quarter share beating analyst consensus cent accord thomson reuter exclude impact foreign exchange rate profit rise
608,ABBV,revenue fall line consensus exclude fx impact sale fall
609,ABBV,lift full year guidance share previous
610,ABBV,sale decline come mixture divestiture hepatitis drug olysio sale have shrink dramatically compete product gilead science gild abbvie abbv come late last year say exclude factor fx sale rise
611,ABBV,view bode well ability medium term weather significant headwind olysio represent total sale contribute operate margin net incremental investment base estimate be likely face meaningful sale decline come quarters write leerink analyst danielle antalffy research note still strong performance other key drug notably xarelto imbruvica invokana name few be clearly help offset least part major headwind
612,ABBV,imbruvica new blood cancer drug be market profit sharing deal pharmacyclic abbvie acquire evercore isi analyst mark schoenebaum calculate take drug mean total abbvie hasn report yet
613,ABBV,number appear roughly line im im prescription appear be tracking well current consensus caveat don have clear consensus due abbvie pharmacyclic transaction schoenebaum write email client
614,ABBV,abbvie stock be more early trading stock market today
615,ABBV,other hand rbc capital market analyst glenn novarro note device business miss expectation continue trend past several quarters deduce company be lose market share spinal business upstart such globus medical gmed share atrial fibrillation market medtronic mdt st jude medical stj
616,ABBV,other hand seem be take share medtronic surgical product
617,ABBV,medtronic stock be early trading tuesday st jude stock be fraction
618,ABBV,follow amy reeve twitter ibd_areeve medical giant johnson johnson jnj beat wall street estimate lift guidance tuesday stock be fraction early trading revenue decline earning exclude special item shrank year earlier quarter share beating analyst consensus cent accord thomson reuter exclude impact foreign exchange rate profit rise revenue fall line consensus exclude fx impact sale fall lift full year guidance share previous sale decline come mixture divestiture hepatitis drug olysio sale have shrink dramatically compete product gilead science gild abbvie abbv come late last year say exclude factor fx sale rise view bode well ability medium term weather significant headwind olysio represent total sale contribute operate margin net incremental investment base estimate be likely face meaningful sale decline come quarters write leerink analyst danielle antalffy research note still strong performance other key drug notably xarelto imbruvica invokana name few be clearly help offset least part major headwind imbruvica new blood cancer drug be market profit sharing deal pharmacyclic abbvie acquire evercore isi analyst mark schoenebaum calculate take drug mean total abbvie hasn report yet number appear roughly line im im prescription appear be tracking well current consensus caveat don have clear consensus due abbvie pharmacyclic transaction schoenebaum write email client abbvie stock be more early trading stock market today other hand rbc capital market analyst glenn novarro note device business miss expectation continue trend past several quarters deduce company be lose market share spinal business upstart such globus medical gmed share atrial fibrillation market medtronic mdt st jude medical stj other hand seem be take share medtronic surgical product medtronic stock be early trading tuesday st jude stock be fraction follow amy reeve twitter ibd_areeve
619,ABBV,seller be stock market again thursday wall street digest avalanche second quarter earning report close dow jone industrial average have lose fall nasdaq have shed preliminary datum show nyse volume come higher wednesday level nasdaq volume edge lower decline stock outnumber advancer exchange more stock market today close amazon com amzn surge hour trading online retailer report unexpected profit cent share sale rise visa meanwhile also shot higher hour profit handily beat expectation regular session earning winner be valeant vrx armour ua valeant member ibd gap late stage base report strong earning open share jump canada base drugmaker report sale profit expectation raise full year guidance analyst consensus view armour surge sportswear company report better expect earning lift sale guidance top gainer ibd be software security name cyberark cybr ibd computer software security group be day top performer rise more help strong earning fortinet ftnt new york mercantile exchange september crude oil lose cent end barrel month low economic news weekly jobless claim slip year low economic indicator be also rosy conference board lead indicator index gain june be index downwardly revise advance well consensus forecast increase june new home sale datum be due friday et open watch earning report abbvie abbv biogen biib spirit airline save
620,ABBV,top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis
621,ABBV,share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move
622,ABBV,allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition
623,ABBV,also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average
624,ABBV,biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july
625,ABBV,regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break
626,ABBV,alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring
627,ABBV,ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open
628,ABBV,abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target
629,ABBV,analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early
630,ABBV,drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year
631,ABBV,celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder
632,ABBV,meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus
633,ABBV,other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say
634,ABBV,celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market
635,ABBV,next major mover
636,ABBV,piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock
637,ABBV,note celgene be return name top large cap pick share have climb year
638,ABBV,celgene have be especially active develop drug various cancer immune inflammatory disease
639,ABBV,drug fight least common disease multiple myeloma be fastest grow
640,ABBV,first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell
641,ABBV,sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june
642,ABBV,other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis
643,ABBV,sale second quarter prior year abraxane be celgene slower grow drug
644,ABBV,goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow
645,ABBV,analyst expect new indication geographic expansion keep abraxane peter
646,ABBV,sale otezla food drug administration approve march totale
647,ABBV,total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter
648,ABBV,lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start
649,ABBV,biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis
650,ABBV,biggest biotech merger
651,ABBV,higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva
652,ABBV,celgene offer receptos amount share expire august
653,ABBV,receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total
654,ABBV,phase datum ms be expect ulcerative colitis
655,ABBV,oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan
656,ABBV,have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say
657,ABBV,earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease
658,ABBV,celgene pay upfront buy share juno stock share also have right take stake juno
659,ABBV,not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected
660,ABBV,celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway
661,ABBV,yee expect side settle case go court drug treat cure hepatitis have make biotech company envy industry biotech celgene be poise break ahead peer pack next few year celgene celg sale profit growth be see rise double digit least multiple drug multiple disorder meanwhile gilead science gild biotech firm hepatitis drug harvoni predecessor sovaldi be expect see earning slow low single digit time start patient cure liver virus other big cap biotechs such amgen amgn biogen biib also fall far short celgene expect growth rate analyst say celgene have best top line growth large biotech right now have fastest revenue earning growth next year say michael yee manage director analyst rbc capital market next major mover piper jaffray analyst tell client recent research report celgene be position be next major mover large cap biotech stock note celgene be return name top large cap pick share have climb year celgene have be especially active develop drug various cancer immune inflammatory disease drug fight least common disease multiple myeloma be fastest grow first revlimid be celgene top selling drug sale second quarter higher year earlier oral drug be used treat anemia multiple myeloma cancer blood affect plasma cell sale pomalyst similar revlimid more potent increase last year make fastest grow company current lineup drug launch japan june other drug currently generate revenue celgene include abraxane treat advanced cancer breast lung pancreas vidaza help bone marrow produce healthier blood cell otezla pill treat psoriasis psoriasis arthritis sale second quarter prior year abraxane be celgene slower grow drug goldman sachs analyst terence flynn note continue face competition breast lung cancer share treat pancreatic cancer now have be grow analyst expect new indication geographic expansion keep abraxane peter sale otezla food drug administration approve march totale total revenue quarter rise analyst expect full year revenue rise earning be see grow share rise accord thomson reuter lot more come other drug percolate wing celgene report late july ceo bob hugin say new transaction astrazeneca azn juno therapeutic juno receptos rcpt likely speed earning growth start biggest deal announce mid july value be celgene pending acquisition receptos biotech firm lead drug ozanimod have show good result treat ulcerative colitis relapse multiple sclerosis biggest biotech mergersif higher bid doesn thwart deal be expect close third quarter be largest merger acquisition biotech drug industry year abbvie abbv bid pharmacyclic pcyc alexion alxn agreement merge synageva biopharma geva celgene offer receptos amount share expire august receptos oral pill ozanimod generate annual revenue ulcerative colitis alone ms yee say put peak sale total phase datum ms be expect ulcerative colitis oral drug celgene acquire last year licensing deal dublin ireland base nogra pharma generate well yee say know ged treat crohn disease phase trial be expect start later initially plan have very robust pipeline partnership new growth driver multiple dollar opportunity next year yee say earlier summer celgene announce year collaboration juno develop commercialize immunotherapy patient cancer autoimmune disease celgene pay upfront buy share juno stock share also have right take stake juno not full speed ahead overhang celgene stock note flynn remain potentially negative impact patent dispute shave year revlimid be patent protected celgene be litigation allergan agn revlimid patent extend key challenge be patent now expire pretrial hearing be underway yee expect side settle case go court
662,ABBV,exchange trade fund continue flounder friday earning major technology company disappoint investor doubt global growth grow gloom week amazon amzn blowout result buoy nternet consumer discretionary etfs
663,ABBV,online retail giant stunned market post profit give upbeat guidance current quarter
664,ABBV,be somewhat simplistic describe amazon just retailer now cloud compute juggernaut amazon web service generate more revenue june quarter year say unit be still small part company overall business
665,ABBV,amazon stock spiked nearly double average volume stock market today give market cap top rival wal mart wmt
666,ABBV,first trust dow jone internet fdn technology etf jump time high hold amazon lead advance
667,ABBV,don look amazon largest tech etfs technology select sector spdr xlk vanguard information technology vgt don consider tech stock grow cloud compute clout
668,ABBV,consumer discretionary select sector spdr xly pop amazon count hold etf nearly asset
669,ABBV,health care select sector spdr xlv ishare nasdaq biotechnology ibb shed nearly week see hefty slate drugmaker biotech earning abbvie abbv valeant pharmaceutical vrx biogen biib celgene celg eli lilly lly shire shpg bristol myer squibb bmy
670,ABBV,several stock beat analyst estimate guidance be more mixed key hold biogen plunge stock market today take bite xlv ibb
671,ABBV,big cap drugmaker beat ep forecast earning report today miss revenue also lower full year guidance come heel downbeat update week alzheimer drug clinical trial
672,ABBV,ibb have lose week set new high recently monday
673,ABBV,market vector gold miner gdx stumble more multiyear lows datum china show manufacturing contract sharply july china be world biggest metal consumer
674,ABBV,manufacturing datum also show business be struggle europe july hit greece debt crisis
675,ABBV,spdr gold share gld tracking physical gold have fall more week more year dollar rise economy show relative strength further pressure metal
676,ABBV,here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing
677,ABBV,bellwether etfs
678,ABBV,powershare db bullish uup rs
679,ABBV,ishare core aggregate bond agg rs
680,ABBV,powershare qqq qqq rs
681,ABBV,spdr gold trust gld rs
682,ABBV,ishare core mid cap ijh rs
683,ABBV,spdr spy rs
684,ABBV,spdr dow jone industrial average dium rs
685,ABBV,ishare russell iwm rs
686,ABBV,ishare msci eafe efa rs
687,ABBV,vanguard ftse emerge market vwo rs
688,ABBV,follow aparna narayanan twitter ibd_anarayanan exchange trade fund continue flounder friday earning major technology company disappoint investor doubt global growth grow gloom week amazon amzn blowout result buoy nternet consumer discretionary etfs online retail giant stunned market post profit give upbeat guidance current quarter be somewhat simplistic describe amazon just retailer now cloud compute juggernaut amazon web service generate more revenue june quarter year say unit be still small part company overall business amazon stock spiked nearly double average volume stock market today give market cap top rival wal mart wmt first trust dow jone internet fdn technology etf jump time high hold amazon lead advance don look amazon largest tech etfs technology select sector spdr xlk vanguard information technology vgt don consider tech stock grow cloud compute clout consumer discretionary select sector spdr xly pop amazon count hold etf nearly asset health care select sector spdr xlv ishare nasdaq biotechnology ibb shed nearly week see hefty slate drugmaker biotech earning abbvie abbv valeant pharmaceutical vrx biogen biib celgene celg eli lilly lly shire shpg bristol myer squibb bmy several stock beat analyst estimate guidance be more mixed key hold biogen plunge stock market today take bite xlv ibb big cap drugmaker beat ep forecast earning report today miss revenue also lower full year guidance come heel downbeat update week alzheimer drug clinical trial ibb have lose week set new high recently monday market vector gold miner gdx stumble more multiyear lows datum china show manufacturing contract sharply july china be world biggest metal consumer manufacturing datum also show business be struggle europe july hit greece debt crisis spdr gold share gld tracking physical gold have fall more week more year dollar rise economy show relative strength further pressure metal here look benchmark exchange trade fund tracking various asset class be perform today follow daily etf market action be key successful investing bellwether etfs powershare db bullish uup rs ishare core aggregate bond agg rs powershare qqq qqq rs spdr gold trust gld rs ishare core mid cap ijh rs spdr spy rs spdr dow jone industrial average dium rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs follow aparna narayanan twitter ibd_anarayanan
689,ABBV,jazz pharmaceutical get heavy border today sector leader chart see page buy point don let make give fellow drugmaker gilead science short shrift back week move average work flat base buy point share gilead gild gap
690,ABBV,gilead science have be winning streak recent year competition price pressure push biotech pace setter go acquisition continue momentum gilead gild revenue climb percent year earlier period company share earning more double foster city calif base gilead annual sale total more past year market value have rise more fivefold reach impressive stock earn best possible ibd composite rating mean stock have outperformed other stock combination factor include earning share relative strength rating gilead have flourished focuse treat hiv hepatitis patient hepatitis drug sovaldi harvoni have chalk more half company product sale backlash have be build sovaldi gilead have price drug pill week life treatment time get major move very hard person completely forget say michael holland head new york money management firm holland co management have task show person biotech boom isn ready end yet gilead continue be major player industry have show world have strong long last growth strategy just case kind bad news surface again consumerism be grow health care gilead surely feel pressure price charge say paul carroll partner devil advocate group consult firm ceo pressure take time build attempt deny use medicine base cost bring person woodwork shout death panel gilead need be prepare doomsday scenario imagine life be world longer charge pill not everyone agree rhetoric surround sovaldi gilead be very strong position strategically say dan mendelson ceo health business advisor avalere health strong position globally hep be big public health issue time dr barnett mennen physician long experience pharmaceutical industry have say sovaldi have change game many patient ve offer cure much be worth someone be suffering gilead be other price put pressure gilead company share plunge percent last dec reach month low fda approve rival abbvie abbv hepatitis product same time abbvie forge agreement express script esrx offer drug lower price become only hepatitis product big pharmacy benefit entity sanction industry observer say gilead handle pressure be look few acquisition target way lock continue solid growth brian skorney analyst baird milwaukee tell ibd jacob plieth senior editorial analyst epvantage also expect gilead pursue acquisition hard know else proceed have competitor come recent earning conference call gilead coo president john milligan say typically acquire company have impact phase drug trial accelerate product approval process integrator indication approval process tend think still re look thing feel catalyze development product have greater utility overall acquisition targetsin early gilead acquire danish drugmaker epitherapeutic other company gilead buy skorney be eyee such potential takeover target south boston mass base vertex pharmaceutical vrtx global biotech entity have draw praise work cystic fibrosis vertex fit nicely gilead skorney say point vertex have put stamp treat cystic fibrosis much gilead have focuse hepatitis also vertex have more dozen continue program target other life threaten disease acquisition be nothing new gilead company announce acquisition pharmasset give further range treat hepatitis sufferer acquisition turn be huge success not acquisition succeed remain dicey be long history bad acquisition pharmaceutical world note carroll devil advocate nevertheless epvantage plieth say gilead be very strong position right now have be most amazing biotech stock look back past year
691,ABBV,day teva pharmaceutical teva break base fellow drugmaker amgen amgn be clear buy point amgen report second quarter result close thursday earning be project rise slowdown first quarter growth
692,ABBV,stock climb big volume stock market today clear early buy point
693,ABBV,amgen be also near conventional buy point currently trading level
694,ABBV,monday teva gap new high giant volume breaking cup base buy point share be still trading buy range today be
695,ABBV,teva announce preliminary result top expectation raise guidance
696,ABBV,company also drop hostile bid mylan myl have agree buy allergan agn generic drug arm actavis
697,ABBV,analyst speculate amgen abbvie abbv biogen biib shire shpg be allergan next potential takeover target
698,ABBV,follow alissa william twitter ibd_awilliam day teva pharmaceutical teva break base fellow drugmaker amgen amgn be clear buy point amgen report second quarter result close thursday earning be project rise slowdown first quarter growth stock climb big volume stock market today clear early buy point amgen be also near conventional buy point currently trading level monday teva gap new high giant volume breaking cup base buy point share be still trading buy range today be teva announce preliminary result top expectation raise guidance company also drop hostile bid mylan myl have agree buy allergan agn generic drug arm actavis analyst speculate amgen abbvie abbv biogen biib shire shpg be allergan next potential takeover target follow alissa william twitter ibd_awilliam
699,ABBV,blockbuster hepatitis drug power sale profit gilead science have become drug industry hit stock gilead gild stock have soar nearly last year new run begin gilead market capitalization be now higher drug giant merck mrk even revenue
700,ABBV,face patent expiration blockbuster rheumatoid arthritis drug pharmaceutical powerhouse abbvie say defend humira generic challenger potentially year
701,ABBV,meantime abbvie abbv clinch acquisition say diversify bolster pipeline future prescription drug pipeline stand eventual decline humira sale
702,ABBV,north chicago ill base drugmaker be also ride wave strong earning most recently april report double digit advance sale post adjust first quarter earning share cent year earlier sale more
703,ABBV,sale humira climb make more overall revenue
704,ABBV,abbvie boast year ep growth rate be top rank company ibd medical ethical drug group composite rating valeant pharmaceutical international vrx have highest group best possible
705,ABBV,also april abbvie raise adjust ep estimate full year range previous guidance thank strong momentum humira sale gain other drug include higher sale cancer drug lupron thyroid disorder drug synthroid
706,ABBV,humira helm
707,ABBV,past year humira have grow product generate year abbvie say thank gain price sale volume humira sale be generate outside population age develop country demand drug treat common ailment such arthritis be steadily mount analyst say
708,ABBV,abbvie stock have rise past month be april dip ahead only year date hold check humira patent expiration worry analyst say
709,ABBV,key pressure stock morningstar analyst damien conover tell ibd
710,ABBV,abbvie be slate lose certain patent protection humira end make vulnerable generic challenger be eager introduce so call biosimilar lower cost version name brand drug
711,ABBV,morningstar estimate abbvie lose humira sale annually begin producer biosimilar be allow move take share conover say several competitor be work biosimilar version humira notably include rival amgen amgn have develop version have say start selling
712,ABBV,abbvie executive however say addition patent finished drug company have hundred other patent globally cover formulation manufacturing humira use legally challenge introduction biosimilar likely delay onset competitive pressure several year patent do not begin expire
713,ABBV,call analyst discuss first quarter result ceo richard gonzalez say have robust portfolio intellectual property protect humira intend enforce infringe biosimilar applicant company add expect humira drive strong growth significant cash flow generation many year
714,ABBV,gonzalez say abbvie be also braced worst case scenario competitor begin selling biosimilar early say abbvie trim cost keep expense line revenue protect bottom line sale humira decline
715,ABBV,acquisition expansion
716,ABBV,meanwhile abbvie have moved haste diversify offering buttress pipeline
717,ABBV,year example begin selling viekira pak treatment hepatitis pull sale more first quarter gonzalez say earning call expect viekira generate annualize run rate more global sale end
718,ABBV,company also jump path year close acquisition pharmacyclic deal give abbvie right imbruvica drug treat blood cancer abbvie say news release announce deal close treatment blood cancer be global market
719,ABBV,analyst say abbvie also have several drug make span area expertise virology immunology neurology oncology oncology alone gonzalez say abbvie have drug poise launch next few year complement imbruvica say help company grow share blood cancer treatment arena
720,ABBV,ve get great pipeline morningstar conover say mitigate patent headwind
721,ABBV,more dealmake too follow help add abbvie product lineup
722,ABBV,build buy case company important patent expire look buy growth order get ahead otherwise be decline revenue stream jack ablin chief investment officer bmo private bank observer prescription drug industry tell ibd
723,ABBV,abbvie spokeswoman do not respond ibd interview request speaking conference abbvie cfo bill chase tell investor deal range be not likely term say company continue look tuck deal help further complement exist pipeline
724,ABBV,abbvie chase say be not turn engine be much more likely pursue sort transaction have do onward be largely single asset addition pipeline face patent expiration blockbuster rheumatoid arthritis drug pharmaceutical powerhouse abbvie say defend humira generic challenger potentially year meantime abbvie abbv clinch acquisition say diversify bolster pipeline future prescription drug pipeline stand eventual decline humira sale north chicago ill base drugmaker be also ride wave strong earning most recently april report double digit advance sale post adjust first quarter earning share cent year earlier sale more sale humira climb make more overall revenue abbvie boast year ep growth rate be top rank company ibd medical ethical drug group composite rating valeant pharmaceutical international vrx have highest group best possible also april abbvie raise adjust ep estimate full year range previous guidance thank strong momentum humira sale gain other drug include higher sale cancer drug lupron thyroid disorder drug synthroid humira helmover past year humira have grow product generate year abbvie say thank gain price sale volume humira sale be generate outside population age develop country demand drug treat common ailment such arthritis be steadily mount analyst say abbvie stock have rise past month be april dip ahead only year date hold check humira patent expiration worry analyst say key pressure stock morningstar analyst damien conover tell ibd abbvie be slate lose certain patent protection humira end make vulnerable generic challenger be eager introduce so call biosimilar lower cost version name brand drug morningstar estimate abbvie lose humira sale annually begin producer biosimilar be allow move take share conover say several competitor be work biosimilar version humira notably include rival amgen amgn have develop version have say start selling abbvie executive however say addition patent finished drug company have hundred other patent globally cover formulation manufacturing humira use legally challenge introduction biosimilar likely delay onset competitive pressure several year patent do not begin expire call analyst discuss first quarter result ceo richard gonzalez say have robust portfolio intellectual property protect humira intend enforce infringe biosimilar applicant company add expect humira drive strong growth significant cash flow generation many year gonzalez say abbvie be also braced worst case scenario competitor begin selling biosimilar early say abbvie trim cost keep expense line revenue protect bottom line sale humira decline acquisition abbvie have moved haste diversify offering buttress pipeline year example begin selling viekira pak treatment hepatitis pull sale more first quarter gonzalez say earning call expect viekira generate annualize run rate more global sale end company also jump path year close acquisition pharmacyclic deal give abbvie right imbruvica drug treat blood cancer abbvie say news release announce deal close treatment blood cancer be global market analyst say abbvie also have several drug make span area expertise virology immunology neurology oncology oncology alone gonzalez say abbvie have drug poise launch next few year complement imbruvica say help company grow share blood cancer treatment arena ve get great pipeline morningstar conover say mitigate patent headwind more dealmake too follow help add abbvie product lineup build buy case company important patent expire look buy growth order get ahead otherwise be decline revenue stream jack ablin chief investment officer bmo private bank observer prescription drug industry tell ibd abbvie spokeswoman do not respond ibd interview request speaking conference abbvie cfo bill chase tell investor deal range be not likely term say company continue look tuck deal help further complement exist pipeline abbvie chase say be not turn engine be much more likely pursue sort transaction have do onward be largely single asset addition pipeline
725,ABBV,good idea scan chart ibd top world stock find right now be stock basis buy range just buy point resolution eurozone crisis greece quickly mood global market market thrive clarity dive
726,ABBV,new analyst coverage big celgene deal help give healthy boost hot new issue fitbit fit pair recent biotech ipos wednesday fitbit hit second straight new high continue hot streak june ipo run first day become biggest tech debut year jump much wednesday pull back soar tuesday share have rally offer price stock be well extend past buy point short ipo base clear july remain watch
727,ABBV,capital iq begin cover fitness tracking device maker hold rating price target cite growth potential also valuation concern deutsche bank stifel suntrust robinson humphrey start coverage monday buy piper jaffray overweight
728,ABBV,fitbit ceo james park tuesday tell fortune magazine plan integrate text messaging other feature tracking device researcher npd group estimate san francisco base company have share fitness activity tracking sale last year
729,ABBV,intrexon xon vault fast turnover extend gain cup handle buy point stock come public august have have volatile ride so far be more offer price synthetic biology firm hasn turn annual profit yet have year sale growth rate belong rate biotech group wednesday top gainer
730,ABBV,biotechs get lift celgene celg acquisition receptos rcpt developer treatment multiple sclerosis other immunological disorder celgene also announce preliminary earning analyst forecast
731,ABBV,enanta pharmaceutical enta rise early wednesday retreat mildly share clear cup handle buy point tuesday brisk trade correct steeper normal pattern reset base count result march ipo be nearly offer price share
732,ABBV,biotech be developer antiviral agent abbvie abbv hepatitis drug cocktail competitor gilead gild blockbuster drug sovaldi harvoni new analyst coverage big celgene deal help give healthy boost hot new issue fitbit fit pair recent biotech ipos wednesday fitbit hit second straight new high continue hot streak june ipo run first day become biggest tech debut year jump much wednesday pull back soar tuesday share have rally offer price stock be well extend past buy point short ipo base clear july remain watch capital iq begin cover fitness tracking device maker hold rating price target cite growth potential also valuation concern deutsche bank stifel suntrust robinson humphrey start coverage monday buy piper jaffray overweight fitbit ceo james park tuesday tell fortune magazine plan integrate text messaging other feature tracking device researcher npd group estimate san francisco base company have share fitness activity tracking sale last year intrexon xon vault fast turnover extend gain cup handle buy point stock come public august have have volatile ride so far be more offer price synthetic biology firm hasn turn annual profit yet have year sale growth rate belong rate biotech group wednesday top gainer biotechs get lift celgene celg acquisition receptos rcpt developer treatment multiple sclerosis other immunological disorder celgene also announce preliminary earning analyst forecast enanta pharmaceutical enta rise early wednesday retreat mildly share clear cup handle buy point tuesday brisk trade correct steeper normal pattern reset base count result march ipo be nearly offer price share biotech be developer antiviral agent abbvie abbv hepatitis drug cocktail competitor gilead gild blockbuster drug sovaldi harvoni
733,ABBV,biotechs continue rebound medical related stock remain center stage week big cap accounting half list edward lifescience ew gap past cup handle buy point initially clear tuesday rbc capital market upgrade heart valve maker outperform sector outperform lift price target friday
734,ABBV,be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain
735,ABBV,cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi
736,ABBV,abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point
737,ABBV,giant drugmaker report accelerate earning sale most recent quarter
738,ABBV,manage health care provider cigna be still buy range past flat base buy point clear heavy trade
739,ABBV,analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point
740,ABBV,be sell signal so far
741,ABBV,nike be testing support week line buy point latest pattern be part base base stretch back november
742,ABBV,nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb
743,ABBV,carmax break cup handle base friday light trade turn lower monday share remain just buy point
744,ABBV,carmax report fiscal result june market open analyst be look earning climb cent share revenue growth
745,ABBV,be used car dealer fifth straight quarter double digit earning sale growth
746,ABBV,decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average
747,ABBV,side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range
748,ABBV,stock still base include salesforce com crm facebook fb gilead gild illumina ilmn be frustrate environment growth stock investor recent breakout have be mixed bag best most big cap leader be hover just just recent buy point best way handle lackluster market be keep exposure modest more breakout prove show decent gain cut loss sell signal start appear keep good portion powder dry stock have be able hold recent entry include abbvie abbv cigna ci analog device adi abbvie break cup handle base heavy volume share have trade tight remain buy range past buy point giant drugmaker report accelerate earning sale most recent quarter manage health care provider cigna be still buy range past flat base buy point clear heavy trade analog device be pull back heavy volume share be still buy range many chip stock early gain be danger disappear other hand stock nike nke skywork solution swks cognizant technology solution ctsh carmax kmx have slip recent buy point be sell signal so far nike be testing support week line buy point latest pattern be part base base stretch back november nike be expect report profit growth release fiscal fourth quarter result end sale be expect climb carmax break cup handle base friday light trade turn lower monday share remain just buy point carmax report fiscal result june market open analyst be look earning climb cent share revenue growth be used car dealer fifth straight quarter double digit earning sale growth decent initial progress skywork solution have return flat base buy point volume have be mostly light stock pull back be positive sign watch see long time leader find support price week move average side regeneron regn be act well low volume base be late stage share have gain much buy point remain extend buy range stock still base include salesforce com crm facebook fb gilead gild illumina ilmn
749,ABBV,halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more
750,ABBV,abbvie agree pay upfront milestone payment target plan work used halozyme
751,ABBV,enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax
752,ABBV,halo rise stock market today late afternoon trading
753,ABBV,halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday
754,ABBV,halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue
755,ABBV,follow amy reeve twitter ibd_areeve halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more abbvie agree pay upfront milestone payment target plan work used halozyme enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax halo rise stock market today late afternoon trading halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue follow amy reeve twitter ibd_areeve
756,ABBV,medical sector continue show strength biotech stock illumina ilmn be get ready break san diego base firm be global leader genomic provide researcher tool conduct large scale analysis genetic variation big pharma leader valeant pharmaceutical vrx abbvie abbv be also recently featured ibd stock
757,ABBV,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
758,ABBV,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
759,ABBV,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
760,ABBV,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
761,ABBV,worst performer ibd be regeneron pharmaceutical regn more
762,ABBV,energy name be day best perform industry group push oil price be higher
763,ABBV,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
764,ABBV,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
765,ABBV,biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis
766,ABBV,tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock
767,ABBV,juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money
768,ABBV,celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating
769,ABBV,stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share
770,ABBV,celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma
771,ABBV,gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group
772,ABBV,gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi
773,ABBV,gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic
774,ABBV,enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually
775,ABBV,enanta have composite go public march have be profitable
776,ABBV,intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be
777,ABBV,other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually enanta have composite go public march have be profitable intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week
778,ABBV,new class hepatitis drug lead gilead science gild abbvie abbv have turn biggest success story biotech history yet hepatitis be only viruse cause viral hepatitis do other have such lucrative potential possibility be hepatitis existence
779,ABBV,initial public offering rev june slow start year etfs hold shiny new stock be beating broad market year date average first day ipo pop be year blockbuster year ipos accord renaissance capital manager renaissance ipo ipo exchange trade fund be year date comparison sdpr spy have gain
780,ABBV,ipo standout last couple week include fitbit fit maker wearable fitness tracker surge june debut
781,ABBV,steakhouse fogo chao fogo climb june debut opthalmic firm glaukos gkos rise june sere therapeutic mcrb gain june
782,ABBV,follow have be strong well average ipo have return offer price exclude first day pop
783,ABBV,positive aftermarket return etf overall ipo market be fuel drife ipo issurance say kathleen renaissance principal
784,ABBV,aftermarket return make ipos good bet successful investing unseasoned stock risk aftermarket return have scale back past month continue issuance slow hurt etf investor say
785,ABBV,industry outlook
786,ABBV,side say etf wrapper make investing stock less risky own individual name etfs also screen largest ipos be stock market winner long run rather speculate first day pop
787,ABBV,see rational pricing ipo market little sign overheat average ipo have price midpoint range
788,ABBV,biotech segment few consumer name such fitbit shake shack shak ipo market appear have appropriate tension issuer investor say
789,ABBV,ipo peer first trust ipo fpx benefit host private enterprise robust sale growth profit intend go public say
790,ABBV,many be leader emerge industry such subscription base software service small enterprise consumer health care technology organic pet food home automation healthy fast casual restaurant big datum car sharing apartment sharing
791,ABBV,be significant difference etfs fpx hold invest stock holding ipo have asset hold stock
792,ABBV,more important fpx hold company go public last year cap individual stock weighting facebook fb abbvie abbv launch respectively be top holding
793,ABBV,ipo remove company holding year trading generally start appear mainstream index hot new stock such top holding alibaba baba twitter twtr first buy soon day debut otherwise buy do quarterly rebalance
794,ABBV,ipo be more pure play etf accord fpx do not include split off such kraft food krft marathon petroleum mpc fiat chrysler fcau
795,ABBV,etf investment strategy ipo offer minimal holding overlap broad base peer such spy be slow include ipos initial public offering rev june slow start year etfs hold shiny new stock be beating broad market year date average first day ipo pop be year blockbuster year ipos accord renaissance capital manager renaissance ipo ipo exchange trade fund be year date comparison sdpr spy have gain ipo standout last couple week include fitbit fit maker wearable fitness tracker surge june debut steakhouse fogo chao fogo climb june debut opthalmic firm glaukos gkos rise june sere therapeutic mcrb gain june follow have be strong well average ipo have return offer price exclude first day pop positive aftermarket return etf overall ipo market be fuel drife ipo issurance say kathleen renaissance principal aftermarket return make ipos good bet successful investing unseasoned stock risk aftermarket return have scale back past month continue issuance slow hurt etf investor say industry outlookon side say etf wrapper make investing stock less risky own individual name etfs also screen largest ipos be stock market winner long run rather speculate first day pop see rational pricing ipo market little sign overheat average ipo have price midpoint range biotech segment few consumer name such fitbit shake shack shak ipo market appear have appropriate tension issuer investor say ipo peer first trust ipo fpx benefit host private enterprise robust sale growth profit intend go public say many be leader emerge industry such subscription base software service small enterprise consumer health care technology organic pet food home automation healthy fast casual restaurant big datum car sharing apartment sharing be significant difference etfs fpx hold invest stock holding ipo have asset hold stock more important fpx hold company go public last year cap individual stock weighting facebook fb abbvie abbv launch respectively be top holding ipo remove company holding year trading generally start appear mainstream index hot new stock such top holding alibaba baba twitter twtr first buy soon day debut otherwise buy do quarterly rebalance ipo be more pure play etf accord fpx do not include split off such kraft food krft marathon petroleum mpc fiat chrysler fcau etf investment strategy ipo offer minimal holding overlap broad base peer such spy be slow include ipos
796,ABBV,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
797,ABBV,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
798,ABBV,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
799,ABBV,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
800,ABBV,worst performer ibd be regeneron pharmaceutical regn more
801,ABBV,energy name be day best perform industry group push oil price be higher
802,ABBV,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
803,ABBV,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
804,ABBV,medical stock have be market top performer year drugmaker abbvie abbv be try add sector gain chicago base firm be leader ethical drug industry group also include valeant pharmaceutical vrx horizon pharma hznp jazz pharmaceutical jazz establish leadership position rapidly growth hematological oncology market
805,ABBV,stock rebound confidently wednesday index erase part previous session loss nasdaq jump dow jone industrial average skip higher tune respectively small cap russell gain volume stock market today run higher nasdaq lower nyse accord preliminary datum
806,ABBV,blue chip rally dozen stock stock dow gain more microsoft msft intel intc lead gain respectively microsoft intel have so so fundamental
807,ABBV,top rate stock also show strength breakout include chip designer technology avgo drug developer abbvie abbv
808,ABBV,new high top rate stock include bank ozark ozrk chip designer ambarella amba nxp semiconductor nxpi silicon motion technology simo hospital chain universal health service uhs drugmaker zoetis zts aerospace play spirit aerosystem spr tv station chain gray television gtn pizza restaurant papa john international pzza
809,ABBV,other leader show positive action retailer ulta beauty ulta retook day line strong volume illumina ilmn climb close buy point consolidation
810,ABBV,overall abundance top stock show good action be encourage development stock market uptrend
811,ABBV,company report quarterly result include apparel marketer michael kor kor gap earning miss weak outlook homebuilder toll bro tol skid revenue miss combine earning beat
812,ABBV,follow paul whitfield twitter ibd_pwhitfield stock rebound confidently wednesday index erase part previous session loss nasdaq jump dow jone industrial average skip higher tune respectively small cap russell gain volume stock market today run higher nasdaq lower nyse accord preliminary datum blue chip rally dozen stock stock dow gain more microsoft msft intel intc lead gain respectively microsoft intel have so so fundamental top rate stock also show strength breakout include chip designer technology avgo drug developer abbvie abbv new high top rate stock include bank ozark ozrk chip designer ambarella amba nxp semiconductor nxpi silicon motion technology simo hospital chain universal health service uhs drugmaker zoetis zts aerospace play spirit aerosystem spr tv station chain gray television gtn pizza restaurant papa john international pzza other leader show positive action retailer ulta beauty ulta retook day line strong volume illumina ilmn climb close buy point consolidation overall abundance top stock show good action be encourage development stock market uptrend company report quarterly result include apparel marketer michael kor kor gap earning miss weak outlook homebuilder toll bro tol skid revenue miss combine earning beat follow paul whitfield twitter ibd_pwhitfield
813,ABBV,market be bleed red today here be highly rate stock hold sell ambarella amba abbvie abbv vipshop vip gopro gpro chip supplier ambarella be trading time high reach last wednesday shortly find support day line tuesday volume be tracking average stock be
814,ABBV,stock wake foul mood tuesday partly due better expect economic datum put interest rate hike worry back front burner
815,ABBV,nasdaq lose dow jone industrial average fall give dollar index picked index have rise just
816,ABBV,nyse nasdaq volume be tracking higher friday level more so nyse
817,ABBV,investor have plenty housing datum ponder long weekend
818,ABBV,april new home sale come annualize rate unit slightly ahead consensus estimate nicely march read meanwhile home price rise sequentially year year march accord latest case shiller price index price gain come slightly consensus estimate sequential year year growth
819,ABBV,news charter communication chtr offer share time warner cable twc new offer be nearly premium charter offer company january share charter fall news time warner cable rise
820,ABBV,stock market today apple aapl lose raise price target cowen cowen cite positive iphone momentum
821,ABBV,elsewhere large cap drugmaker abbvie abbv try clear cup handle buy point share rise nearly heavy volume
822,ABBV,meanwhile workday wday not profitable yet be expect report quarter big sale growth report earning close share rise ahead result workday be close week high ahead result
823,ABBV,straight gain see stock rise new issue shake shack shak dive huge volume stock wake foul mood tuesday partly due better expect economic datum put interest rate hike worry back front burner nasdaq lose dow jone industrial average fall give dollar index picked index have rise just nyse nasdaq volume be tracking higher friday level more so nyse investor have plenty housing datum ponder long weekend april new home sale come annualize rate unit slightly ahead consensus estimate nicely march read meanwhile home price rise sequentially year year march accord latest case shiller price index price gain come slightly consensus estimate sequential year year growth news charter communication chtr offer share time warner cable twc new offer be nearly premium charter offer company january share charter fall news time warner cable rise stock market today apple aapl lose raise price target cowen cowen cite positive iphone momentum elsewhere large cap drugmaker abbvie abbv try clear cup handle buy point share rise nearly heavy volume meanwhile workday wday not profitable yet be expect report quarter big sale growth report earning close share rise ahead result workday be close week high ahead result straight gain see stock rise new issue shake shack shak dive huge volume
824,ABBV,small biotech achillion pharmaceutical achn announce late tuesday have enter collaboration johnson johnson jnj develop hepatitis drug potentially worth more agree invest achillion upfront promise development regulatory sale milestone payment company successfully launch pipeline
825,ABBV,biotechnology industry group remain year hottest have couple stock ipo leader screen be intrexon xon be trading buy point cup handle base
826,ABBV,company many new biotechs have be post loss be expect lose money again year next do earn profit past quarters sale growth be be most impressive
827,ABBV,revenue surge first quarter follow increase previous period part be payment various partner
828,ABBV,company also have operation food production energy such process convert natural gas fuel chemical lubricant
829,ABBV,germantown md base intrexon be lead company new field synthetic biology intrexon design build regulate gene cellular system
830,ABBV,partly acquisition intrexon have create suite technology handle drug development process engineering production
831,ABBV,enanta pharmaceutical enta be form right side cup shape base potential buy point be base be unusually deep chart reader tend frown
832,ABBV,company make hepatitis drug antibiotic bacterium resistant current treatment
833,ABBV,enanta develop antiviral agent abbvie abbv cocktail potential drug hepatitis virus analyst believe be advanced trial generate year mean milestone payment royalty enanta
834,ABBV,most development stage biotechs enanta have be profitable march end quarter earn share vs loss cent share year period
835,ABBV,revenue soar more be just year enanta result have be uneven be ep rating be just
836,ABBV,enanta recently get payment abbvie viekirax drug certain type hepatitis have win regulatory approval europe biotechnology industry group remain year hottest have couple stock ipo leader screen be intrexon xon be trading buy point cup handle base company many new biotechs have be post loss be expect lose money again year next do earn profit past quarters sale growth be be most impressive revenue surge first quarter follow increase previous period part be payment various partner company also have operation food production energy such process convert natural gas fuel chemical lubricant germantown md base intrexon be lead company new field synthetic biology intrexon design build regulate gene cellular system partly acquisition intrexon have create suite technology handle drug development process engineering production enanta pharmaceutical enta be form right side cup shape base potential buy point be base be unusually deep chart reader tend frown company make hepatitis drug antibiotic bacterium resistant current treatment enanta develop antiviral agent abbvie abbv cocktail potential drug hepatitis virus analyst believe be advanced trial generate year mean milestone payment royalty enanta most development stage biotechs enanta have be profitable march end quarter earn share vs loss cent share year period revenue soar more be just year enanta result have be uneven be ep rating be just enanta recently get payment abbvie viekirax drug certain type hepatitis have win regulatory approval europe
837,ABBV,new product introduction swipe trade secret chipmaker have steal spotlight so far week let not forget biotech stock be highlighted ibd screen day big cap leader semiconductor counterpart large cap biotechs include celgene celg regeneron pharmaceutical regn gilead science gild celgene have
838,ABBV,handful big cap stock be hover buy point regeneron pharmaceutical regn be try clear buy point cup handle base pattern be late stage make risky
839,ABBV,profit revenue growth have picked straight quarters earning latest quarter climb jump sale
840,ABBV,eylea treatment macular degeneration be drive company growth
841,ABBV,well regard fidelity contrafund add holding latest quarter columbia marsico st century fund open new position
842,ABBV,nike nke be approach buy point base base pattern stock accumulation distribution rating indicate rise demand share
843,ABBV,also stock relative strength line be hit new high bullish indicator
844,ABBV,president obama visit athletic apparel maker oregon headquarters friday promote tran pacific partnership trade deal country
845,ABBV,most nike sale currently come north america europe nike make most apparel overseas say pact create job
846,ABBV,abbvie abbv drugmaker have shape cup handle base buy point
847,ABBV,company be spun abbott laboratory be top stock highly rate prescription drug industry group
848,ABBV,profit year be expect rise share follow increase
849,ABBV,abbvie make drug treat rheumatoid arthritis psoriasis other ailment
850,ABBV,present new datum oncology drug pipeline meeting american society clinical oncology june
851,ABBV,anthem antm provider manage health care service be flat base buy point
852,ABBV,company have benefit growth enrollment business customer government program such medicaid
853,ABBV,anthem announce last month profit jump share easily beating wall street estimate revenue climb
854,ABBV,stock have triple past year late base be third stage pattern
855,ABBV,april oppenheimer raise price target anthem number other manage care stock cite continue improvement economy prospect federal reserve interest rate hike boost return investment portfolio
856,ABBV,manage care industry be rank ninth group track ibd monday handful big cap stock be hover buy point regeneron pharmaceutical regn be try clear buy point cup handle base pattern be late stage make risky profit revenue growth have picked straight quarters earning latest quarter climb jump sale eylea treatment macular degeneration be drive company growth well regard fidelity contrafund add holding latest quarter columbia marsico st century fund open new position nike nke be approach buy point base base pattern stock accumulation distribution rating indicate rise demand share also stock relative strength line be hit new high bullish indicator president obama visit athletic apparel maker oregon headquarters friday promote tran pacific partnership trade deal country most nike sale currently come north america europe nike make most apparel overseas say pact create job abbvie abbv drugmaker have shape cup handle base buy point company be spun abbott laboratory be top stock highly rate prescription drug industry group profit year be expect rise share follow increase abbvie make drug treat rheumatoid arthritis psoriasis other ailment present new datum oncology drug pipeline meeting american society clinical oncology june anthem antm provider manage health care service be flat base buy point company have benefit growth enrollment business customer government program such medicaid anthem announce last month profit jump share easily beating wall street estimate revenue climb stock have triple past year late base be third stage pattern april oppenheimer raise price target anthem number other manage care stock cite continue improvement economy prospect federal reserve interest rate hike boost return investment portfolio manage care industry be rank ninth group track ibd monday
857,ABBV,cross border merger boom be boost etfs hold catamaran ctrx dresser rand drc other pharma energy company be hot takeover target merger arbitrage exchange trade fund profit difference stock price deal be announce final purchase price typically upward move cross border merger acquisition have totale roughly
858,ABBV,medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more
859,ABBV,company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect
860,ABBV,sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth
861,ABBV,st jude say currency adjust sale growth continue rest year
862,ABBV,stock break flat base surge past buy point volume be heavy
863,ABBV,st jude composite rating be middling mainly company ep rating be unimpressive
864,ABBV,st jude be ibd medical product industry group rank group wednesday edition have be top group many week
865,ABBV,meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate
866,ABBV,abbott affirm previous full year profit guidance share vs last year
867,ABBV,continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january
868,ABBV,abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance
869,ABBV,abbott be diversify medical industry group rank have be trend lower
870,ABBV,ibd staff contribute report medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth st jude say currency adjust sale growth continue rest year stock break flat base surge past buy point volume be heavy st jude composite rating be middling mainly company ep rating be unimpressive st jude be ibd medical product industry group rank group wednesday edition have be top group many week meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate abbott affirm previous full year profit guidance share vs last year continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance abbott be diversify medical industry group rank have be trend lower ibd staff contribute report
871,ABBV,thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy
872,ABBV,abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst
873,ABBV,lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year
874,ABBV,viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end
875,ABBV,light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation
876,ABBV,abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur
877,ABBV,company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email
878,ABBV,swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point
879,ABBV,earning totale share cent consensus sale totale estimate
880,ABBV,novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth
881,ABBV,however company say strong dollar knock report sale report operate income
882,ABBV,foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point earning totale share cent consensus sale totale estimate novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth however company say strong dollar knock report sale report operate income foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance
883,ABBV,thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy
884,ABBV,abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst
885,ABBV,lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year
886,ABBV,viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end
887,ABBV,light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation
888,ABBV,abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur
889,ABBV,company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email
890,ABBV,swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point
891,ABBV,earning totale share cent consensus sale totale estimate
892,ABBV,novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth
893,ABBV,however company say strong dollar knock report sale report operate income
894,ABBV,foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance thursday bring passel earning report large cap drugmaker market greet mostly unenthusiastic response most anticipate report come abbvie abbv unveil first full quarter hepatitis treatment viekira pak address question buzz wall street spending strategy abbvie earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale climb consensus company raise full year ep guidance cent line analyst lead drug humira drive beat sale consensus last year conference call analyst cfo william chase say shipment timing help sale abbvie stick previous guidance midteen growth year viekira launch late december yielded analyst estimate call chase say abbvie contract provider start kick quarter so affirm previous guidance run rate year end light quarter do undergird recent analyst speculation rival gilead science gild be track beat expectation abbvie stock open higher be nearly midday trading thursday first question analyst earning conference call involved abbvie improve profit margin lower cost second analyst goldman sachs jami rubin say bluntly company seem be spending too much money marketing ceo rick gonzalez disagree say abbvie investment strategy be pay nonetheless allow firm be prepared cut unexpected downturn sale occur company do not however announce kind immediate restructure be absolutely line expectation perhaps be stock be now speculate evercore isi analyst mark schoenebaum email swiss pharma giant novartis nvs fared better hit new high mixed result share be slightly buy point earning totale share cent consensus sale totale estimate novartis affirm previous full year guidance constant currency basis midsingle digit sale growth high single digit operate income growth however company say strong dollar knock report sale report operate income foreign exchange headwind be also reason offer alexion pharmaceutical alxn miss profit estimate affirm full year guidance
895,ABBV,pharmaceutical company search new market energy business seek growth have fuel rate company buy overseas asset year high
896,ABBV,cross border merger acquisition worldwide year totale thursday year biggest year date total accord thomson reuter
897,ABBV,announce cross border deal comprise total so far largest annual share cross border transaction amount so far year have be announce transaction also most not deal have yet close
898,ABBV,megadeal have be full force deal value more make nearly half cross border total so far year
899,ABBV,company be lead charge have keen eye european target so far overseas deal have take place europe point last year company switzerland be most popular target value
900,ABBV,more attractive european
901,ABBV,europe rise popularity come continental value be damage great recession eurozone lurch crisis next persistent strength dollar make euro property more affordable american hope stronger economic growth indeed europe economy have grow faster recent month
902,ABBV,last year person begin feel more comfortable business model european company be solidify little bit say matthew toole thomson reuter director deal intelligence
903,ABBV,energy sector have be batter depress crude oil price translate fall earning revenue have be most active sector cross border year energy company have value deal year total more double year date energy sector value deal total
904,ABBV,royal dutch shell rdsa announce deal acquire read england base bg group be biggest announce cross border energy deal so far
905,ABBV,health care sector lead big pharma have generate deal ytd total year
906,ABBV,include reject megadeal offer st loui base agribusiness giant offer buy switzerland base syngenta syt offer reject purportedly undervalue company underestimate regulatory issue generic drug maker mylan myl reject offer rival teva pharmaceutical teva canonsburg pa base mylan currently be engineering hostile takeover bid irish drugmaker perrigo prgo
907,ABBV,obama administration last year crack tax inversion company buy foreign business relocate headquarters lower corporate tax rate hasn slow health care company desire expand new market
908,ABBV,pretty obvious inversion cross border piece have business rationale toole say be look new area business
909,ABBV,pfizer pfe valeant vrx abbvie abbv abandon attempt acquisition foreign target include astrazeneca azn have turn eye acquire domestic company just thursday pfizer say be ask federal trade commission more information propose merger hospira hsp pharmaceutical company search new market energy business seek growth have fuel rate company buy overseas asset year high cross border merger acquisition worldwide year totale thursday year biggest year date total accord thomson reuter announce cross border deal comprise total so far largest annual share cross border transaction amount so far year have be announce transaction also most not deal have yet close megadeal have be full force deal value more make nearly half cross border total so far year company be lead charge have keen eye european target so far overseas deal have take place europe point last year company switzerland be most popular target value more attractive europeanseurope rise popularity come continental value be damage great recession eurozone lurch crisis next persistent strength dollar make euro property more affordable american hope stronger economic growth indeed europe economy have grow faster recent month last year person begin feel more comfortable business model european company be solidify little bit say matthew toole thomson reuter director deal intelligence energy sector have be batter depress crude oil price translate fall earning revenue have be most active sector cross border year energy company have value deal year total more double year date energy sector value deal total royal dutch shell rdsa announce deal acquire read england base bg group be biggest announce cross border energy deal so far health care sector lead big pharma have generate deal ytd total year include reject megadeal offer st loui base agribusiness giant offer buy switzerland base syngenta syt offer reject purportedly undervalue company underestimate regulatory issue generic drug maker mylan myl reject offer rival teva pharmaceutical teva canonsburg pa base mylan currently be engineering hostile takeover bid irish drugmaker perrigo prgo obama administration last year crack tax inversion company buy foreign business relocate headquarters lower corporate tax rate hasn slow health care company desire expand new market pretty obvious inversion cross border piece have business rationale toole say be look new area business pfizer pfe valeant vrx abbvie abbv abandon attempt acquisition foreign target include astrazeneca azn have turn eye acquire domestic company just thursday pfizer say be ask federal trade commission more information propose merger hospira hsp
910,ABBV,medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more
911,ABBV,company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect
912,ABBV,sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth
913,ABBV,st jude say currency adjust sale growth continue rest year
914,ABBV,stock break flat base surge past buy point volume be heavy
915,ABBV,st jude composite rating be middling mainly company ep rating be unimpressive
916,ABBV,st jude be ibd medical product industry group rank group wednesday edition have be top group many week
917,ABBV,meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate
918,ABBV,abbott affirm previous full year profit guidance share vs last year
919,ABBV,continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january
920,ABBV,abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance
921,ABBV,abbott be diversify medical industry group rank have be trend lower
922,ABBV,ibd staff contribute report medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth st jude say currency adjust sale growth continue rest year stock break flat base surge past buy point volume be heavy st jude composite rating be middling mainly company ep rating be unimpressive st jude be ibd medical product industry group rank group wednesday edition have be top group many week meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate abbott affirm previous full year profit guidance share vs last year continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance abbott be diversify medical industry group rank have be trend lower ibd staff contribute report
923,ABBV,week bring first quarter earning report top rate large cap drug stock be expect report strong growth tuesday open unite therapeutic uthr be expect report revenue year earlier quarter accord thomson reuter earning be expect climb share give
924,ABBV,biogen biib friday morning be expect report earning share vs year earlier end quarter string accelerate growth sale show advance solid gain fourth straight quarter decelerate growth biogen rely heavily multiple sclerosis drug such tecfidera
925,ABBV,tech titan google googl make headline quarterly earning close thursday google growth be sluggish stock be lackluster check stock better performance search giant include drugmaker abbvie abbv coffee giant starbucks sbux
926,ABBV,alexion abbvie drug earning
927,ABBV,alexion pharmaceutical alxn be project see earning decline share report first quarter result open blip rather trend earning rise prior quarters rise more follow quarters
928,ABBV,revenue be estimate rise
929,ABBV,biotech have ibd composite rating only product currently shelve be rare disease drug soliris have see blockbuster success analyst estimate company alfa drug launch first half year alexion provide update
930,ABBV,alexion share rise stock market today stock be work price consolidation buy point
931,ABBV,abbvie abbv also release result open ethical drugmaker be expect increase earning cent share faster growth
932,ABBV,wall street have calculate rise revenue
933,ABBV,earlier month galapago belgian biotech partner abbvie report positive midstage datum rheumatoid arthritis drug filgotinib add standard treatment methotrexate abbvie have best selling treatment condition injectable drug humira
934,ABBV,be first full quarter sale hepatitis treatment viekira pak successful be abbvie grab market share first market gilead science gild sovaldi harvoni abbvie gilead science have make price discount top pharmacy benefit manager
935,ABBV,analyst also be interested abbvie plan deal pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica many wall street think abbvie be pay steep price
936,ABBV,abbvie share rise wednesday work right side cup base buy point drugmaker have ibd composite rating
937,ABBV,alaska southwest airline earning takeoff
938,ABBV,alaska air alk be expect report jump earning share report thursday morning mark second quarter faster growth revenue be see rise more modest
939,ABBV,domestic regional airline be benefit lower fuel price strong pricing power improve demand travel
940,ABBV,alaska share fall wednesday be work flat base buy point alaska have composite rating
941,ABBV,southwest airline luv have composite rating be set report result thursday morning earning be expect surge cent share huge acceleration last quarter growth revenue be see increase
942,ABBV,earlier month dalla base airline only have international flight mexico caribbean report jump march traffic increase capacity
943,ABBV,southwest share be build flat base buy point southwest stock fall wednesday
944,ABBV,starbucks sale growth perk
945,ABBV,starbucks report fiscal result close wall street expect earning grow cent share year year growth revenue be see rise mark starbucks fastest sale growth several year
946,ABBV,coffee giant have be forefront restaurant tech loyalty card mobile app starbucks say have active user company be also testing mobile order pay function delivery program
947,ABBV,starbucks have composite rating fall cent wednesday stock extend past flat base buy point initially clear late january investor buy stock buy range take profit gain
948,ABBV,other big name company release quarterly earning thursday include amazon com amzn microsoft msft altrium mo general motor gm procter gamble pg dow chemical dow
949,ABBV,follow alissa william twitter ibd_awilliam tech titan google googl make headline quarterly earning close thursday google growth be sluggish stock be lackluster check stock better performance search giant include drugmaker abbvie abbv coffee giant starbucks sbux alexion abbvie drug earningsalexion pharmaceutical alxn be project see earning decline share report first quarter result open blip rather trend earning rise prior quarters rise more follow quarters revenue be estimate rise biotech have ibd composite rating only product currently shelve be rare disease drug soliris have see blockbuster success analyst estimate company alfa drug launch first half year alexion provide update alexion share rise stock market today stock be work price consolidation buy point abbvie abbv also release result open ethical drugmaker be expect increase earning cent share faster growth wall street have calculate rise revenue earlier month galapago belgian biotech partner abbvie report positive midstage datum rheumatoid arthritis drug filgotinib add standard treatment methotrexate abbvie have best selling treatment condition injectable drug humira be first full quarter sale hepatitis treatment viekira pak successful be abbvie grab market share first market gilead science gild sovaldi harvoni abbvie gilead science have make price discount top pharmacy benefit manager analyst also be interested abbvie plan deal pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica many wall street think abbvie be pay steep price abbvie share rise wednesday work right side cup base buy point drugmaker have ibd composite rating alaska southwest airline earning takeoffalaska air alk be expect report jump earning share report thursday morning mark second quarter faster growth revenue be see rise more modest domestic regional airline be benefit lower fuel price strong pricing power improve demand travel alaska share fall wednesday be work flat base buy point alaska have composite rating southwest airline luv have composite rating be set report result thursday morning earning be expect surge cent share huge acceleration last quarter growth revenue be see increase earlier month dalla base airline only have international flight mexico caribbean report jump march traffic increase capacity southwest share be build flat base buy point southwest stock fall wednesday starbucks sale growth perk upstarbuck report fiscal result close wall street expect earning grow cent share year year growth revenue be see rise mark starbucks fastest sale growth several year coffee giant have be forefront restaurant tech loyalty card mobile app starbucks say have active user company be also testing mobile order pay function delivery program starbucks have composite rating fall cent wednesday stock extend past flat base buy point initially clear late january investor buy stock buy range take profit gain other big name company release quarterly earning thursday include amazon com amzn microsoft msft altrium mo general motor gm procter gamble pg dow chemical dow follow alissa william twitter ibd_awilliam
950,ABBV,american have unofficially make memorial day kickoff summer go be hot drug industry now labor day company be look fda decision launch blockbuster drug make big impact bottom line first be drug valeant pharmaceutical industry vrx
951,ABBV,johnson johnson kick health care earning season report point solid fundamental punish foreign exchange fx headwind report basis johnson johnson jnj sale drop year earlier quarter modestly beating analyst consensus earning decline share beating estimate
952,ABBV,big pharma abbvie abbv get upgrade monday bmo capital market warm potential pending acquisition analyst alex arfaei upgrade abbvie outperform market perform say grow awareness biosimilar competition flagship drug humira have drive stock reasonable level same time be overcome initial skepticism
953,ABBV,good clinical trial news rolled lead drugmaker wednesday help buoy group recovery stock market big pharma pfizer pfe say early wednesday have stop phase trial drug ibrance early have already hit endpoint patient metastatic breast cancer ibrance be fda approve february base similarly
954,ABBV,biotech receptos rcpt report positive midstage trial result lead drug candidate ulcerative colitis thursday send stock much early trading receptos say phase study call touchstone meet primary endpoint improve chronic bowel disease week maintenance ozanimod formerly know rpc
955,ABBV,big pharma merck release late stage datum wednesday hepatitis regime meet wall street expectation also disclose fda have award breakthrough therapy designation certain patient group merck mrk study be newly release abstract presentation annual meeting european association study liver easl vienna
956,ABBV,johnson johnson kick health care earning season report point solid fundamental punish foreign exchange fx headwind report basis johnson johnson jnj sale drop year earlier quarter modestly beating analyst consensus earning decline share beating estimate
957,ABBV,stock hold early gain noon hour monday chinese adrs continue show strength string breakout last week
958,ABBV,nasdaq rise dow jone industrial average gain volume be tracking slightly higher nasdaq lower nyse stock market today
959,ABBV,ishare china large cap fxi etf track index chinese stock rise nearly back gain last week
960,ABBV,china be ease monetary policy government have unveil ambitious transportation project design open trade other asian country middle east africa europe
961,ABBV,china mobile game entertainment cmge gain nearly
962,ABBV,several stock break basis last week continue upward thrust volume
963,ABBV,apogee enterprise apog gap flat base thursday gain third straight day share rise buy point noah holding noah chinese adr break undefined consolidation wednesday gain additional share soar last week
964,ABBV,abbvie abbv be little change upgrade bmo say be grow more confident company pending acquisition pharmacyclic pcyc stock hold early gain noon hour monday chinese adrs continue show strength string breakout last week nasdaq rise dow jone industrial average gain volume be tracking slightly higher nasdaq lower nyse stock market todayishare china large cap fxi etf track index chinese stock rise nearly back gain last week china be ease monetary policy government have unveil ambitious transportation project design open trade other asian country middle east africa europe china mobile game entertainment cmge gain nearly several stock break basis last week continue upward thrust volume apogee enterprise apog gap flat base thursday gain third straight day share rise buy point noah holding noah chinese adr break undefined consolidation wednesday gain additional share soar last week abbvie abbv be little change upgrade bmo say be grow more confident company pending acquisition pharmacyclic pcyc
965,ABBV,fda last month approve first biosimilar drug take first step lucrative potentially disruptive field medicine pfizer pfe be move big biosimilar hospira hsp acquisition have estimate global biosimilar sale hit year sale be just yearly now mainly european union march approval zarxio novartis nvs biosimilar version amgen amgn age blockbuster neupogen market crack open fda become more comfortable re go see biosimilar get lot more easily predict jitendra malik attorney alston bird specialize intellectual property drug approval issue first always hardest get fda be more cautious uncharted territory year biotech revolution not only bring life save new medicine also profit save protection competitor traditional pharmaceutical be assemble machine different chemical ingredient biologic drug be form biological process high tech version fermentation many process be trade secret patent have expiration date reverse engineeringas more company become familiar biotech manufacturing however be able reverse engineer process create biosimilar drug not identical original close enough novartis sandoz unit historically devote traditional generic drug have be pioneer field already selling biosimilar version neupogen sister drug epogen europe many other be line border own product hospira teva pharmaceutical teva have launch own version neupogen europe company be work biosimilar version abbvie abbv blockbuster immunology drug humira include sandoz hospira pfizer prior acquire hospira amgen german pharma giant boehringer ingelheim abbvie announce richly price acquisition pharmacyclic pcyc march analyst figured be drive need blockbuster face humira competitor key biologic face rivalsother drug biosimilar version late stage testing include biogen biib cancer drug rituxan roche rhhby breast cancer treatment herceptin johnson johnson jnj remicade merck mrk be develop biosimilar version sanofi sny popular diabetes drug lantus hospira biosimilar version remicade already have be approve europe be expect be february fda delay advisory panel meeting product due information request pending sponsor application analyst be closely watch biosimilar rollout europe remicade be approve variety ailment psoriasis inflammatory bowel disease ibd rheumatoid arthritis provide test case willing different specialist be use knockoff independent study iosimilar remicade be approve study account remicade sale write leerink analyst jason gerberry december research report specialist ve speak do not plan use remicade ibd indication clinical study report late europe biosimilar version neupogen have take market analyst generally expect same much depend drug be price generic pharmaceutical generally go fraction original drug price drive retail value so much original developer stop marketing product do keep manufacturing biosimilar be more difficult expensive develop so be fewer player less pricing competition novartis still hasn launch zarxio be keep mum price company spokeswoman geena wardaki tell investor business daily email biosimilar general typically expect discount be range reference biologic however depend therapeutic area market channel number competitor reimbursement situation cms vs fda biosimilarson tuesday center medicare medicaid service cms announce physician prescribe medicare part drug be reimburse biosimilar same way original drug average selling price pharmacy dispense part drug exclude original list prefer drug favor biosimilar wish so long provide transitional supply original patient already take imply cms be treat biosimilar effectively interchangeable original further muddy issue already unclear fda rule zarxio be used used approve neupogen boost blood cell various kind cancer patient not technically interchangeable mean doctor prescribe original drug pharmacy fill biosimilar doesn matter so much zarxio drug be administer hospital clinic rather retail pharmacy nonetheless drugmaker find worthwhile file separately approval likely involve study patient switch product say expert matter be deterrent second person come say malik show product be interchangeable doesn necessarily mean applicant road do same thing just piggybac lot case structure original drug be not perfectly know do have spend time convince person same yet question be aggressive payer pharmacy benefit manager pbms be push biosimilar ahead original drug save cost march report analyst gerberry write unnamed payer specialist have tell payer probably leave grace period month doctor get used biosimilar then start lean harder specialist expect policy grandfather stable patient receive tnf therapy remicade same reimbursement new patient new switch likely be require go prior authorization require patient use biosimilar first write gillian woollett senior vice president consult firm avalere health say issue be naming company develop new drug get generic also call nonproprietary name brand name generic name filgrastim case neupogen be used generic drugmaker patent expire name many biologic approve fda even have never be compare also share nonproprietary name be simply name active ingredient not name product biosimilar most other market share nonproprietary name reference product too first approval fda assign maker placeholder nonproprietary name case filgrastim sndz naming thing be important space watch woollett tell investor business daily think be go be brand product biosimilar most originator biologic have brand name again generic drug situation be totally different most generic do not have brand name
966,ABBV,best etfs april performance updatevalue stock gain ground etf investor past month market remain choppy growth oriented exchange trade fund continue lead year date tend hold more stock offer promise higher return present greater risk value oriented etfs focus safer more mature stock spdr spy track broad stock market rise last week so far investor bullishness stem part federal reserve hold interest rate lower longer news corporate acquisition be also help say russ blackrock blk global chief investment strategist positive side effect extraordinary low interest rate be continuation even acceleration merger activity write april note low rate make money cheap readily available financing large deal last week multinational announce acquisition expand internationally fedex fdx agree buy dutch delivery service tnt royal dutch shell rdsa offer buy bg group initial public offering be chug last year record pace ipos price thus far have raise accord ipo expert renaissance capital web host domain registrar godaddy gddy instance raise ipo march hit expectation such sign strength be help diversify stock etfs first trust ipo fpx grow trail month year date large cap growth fund hold largest most liquid ipos have asset more half be tech consumer sector currently favor top stock holding be facebook fb abbvie abbv kraft food krft investor bet growth stock cap size spectrum successful investing powershare dwa smallcap momentum dwa be thus far schwab mid cap schm gain sector etfs oil gas producer servicer come back strongly past month commodity price re-cover so do gold miner similar reason investor also consider stock extremely oversold ripe rebound year date health care biotech fund continue dominate alp medical breakthrough sbio new etf beat peer gain etf invest small midcap stock least drug phase phase clinical trial spdr biotech xbi be top sector so far be guggenheim solar tan ishare global clean energy icln benefit investor take note greater efficiency subindustry well apple aapl recent clean energy deal first solar fslr guggenheim solar have surge year date ishare global clean energy advanced foreign fundsemerge market notch huge gain fund hold foreign stock offer pocket relative value vs stock first trust emerge market alphadex fem spiked past month category leader vanguard ftse emerge market vwo asset grow first trust emerge allocate asset china stock have be tear recently vanguard ftse emerge assign investor be selective emerge market say analyst emerge global advisor look country better current account management be embrace reform write march most country be locate asia country mismanage current account have income flow abroad be rac debt foreign fund overall currency hedge continue hold sway europe hedge equity hedj peer be still year best performer etf rise past month take gain
967,ABBV,biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate
968,ABBV,gilead doesn give ep guidance add full year product sale target now
969,ABBV,essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast
970,ABBV,evercore isi analyst mark schoenebaum say guidance raise be especially significant
971,ABBV,company tend be conservative so raise revenue guidance early year speak volume write email client
972,ABBV,conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach
973,ABBV,bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash
974,ABBV,cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product
975,ABBV,gilead stock rise hour trading share have close
976,ABBV,abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week
977,ABBV,earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent
978,ABBV,sale dip beat estimate exclude currency headwind divestment sale rise
979,ABBV,teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september
980,ABBV,teva stock slide
981,ABBV,celgene sale miss
982,ABBV,celgene celg report mixed quarter ep rise penny view sale grow miss consensus more
983,ABBV,big biotech affirm full year guidance product sale ep last year make share revenue
984,ABBV,sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus
985,ABBV,celgene stock dive close
986,ABBV,danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus
987,ABBV,nordisk hike profit growth guidance add percentage point low end sale growth guidance
988,ABBV,president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen
989,ABBV,stock rise biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate gilead doesn give ep guidance add full year product sale target now essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast evercore isi analyst mark schoenebaum say guidance raise be especially significant company tend be conservative so raise revenue guidance early year speak volume write email client conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product gilead stock rise hour trading share have close abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent sale dip beat estimate exclude currency headwind divestment sale rise teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september teva stock slide celgene sale misscelgene celg report mixed quarter ep rise penny view sale grow miss consensus more big biotech affirm full year guidance product sale ep last year make share revenue sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus celgene stock dive close danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus nordisk hike profit growth guidance add percentage point low end sale growth guidance president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen stock rise
990,ABBV,banker lawyer shareholder accustomed hearing ka ching merger acquisition activity be instead get used sound deal be flush toilet apply material amat monday scrap takeover bid tokyo electron just day comcast cmcsa pull plug propose acquisition time warner cable twc apply material japan
991,ABBV,maybe bigger be better pharmacy benefit manager pbms unitedhealth group unh think catamaran ctrx be worth increase leverage bargaining pricey medicine pbms client include health insurer employer labor union health plan handle process medical prescription negotiate price drug company analyst say grow size benefit more
992,ABBV,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
993,ABBV,volume nasdaq nyse be tracking tuesday level
994,ABBV,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
995,ABBV,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
996,ABBV,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
997,ABBV,solar stock be day best performer lead first solar fslr jump new high heavy volume
998,ABBV,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
999,ABBV,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
1000,ABBV,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
1001,ABBV,swiss pharma novartis win first fda approval biosimilar drug friday agency clear knockoff amgen best seller neupogen fda approve drug call zarxio same indication have approve neupogen boost white blood cell count patient suffering cancer other disease neupogen patent expire
1002,ABBV,stock future blipped higher ahead thursday open market appear set build wednesday late day rally dow future trade point fair market value have come well earlier high nasdaq future be strong point future show point gain
1003,ABBV,stock market today head session nasdaq lower week ibd index be russell open loss rally late wednesday session follow release federal reserve september beige book report left nasdaq top day trading range positive sign little have change regard overall message correct market be send be patient build watch list watch follow day
1004,ABBV,investor attention be august nonfarm payroll report due friday thursday preliminary include august job cut report challenger gray christmas show number layoff slow sharply vs july year high compare year figure employer announce plan cut worker retail sector account nearly layoff most tie bankruptcy grocery chain report say
1005,ABBV,initial jobless claim rise week end aug labor department say economist consensus have project claim week move average edge
1006,ABBV,stock grifol grfs rise sunedison sune jump market continue be hard slip up late season earning report
1007,ABBV,be morning weak revenue guidance upended quarterly result verint system vrnt tumble better expect earning revenue do not offset full year earning guidance consensus view
1008,ABBV,generic drug maker lannett lci spiked premarket trade philadelphia base company say pay acquire kremer urban pharmaceutical generic drug unit belgium base ucb kremer own portfolio drug strong pipeline pending application candidate effectively double lannett revenue lannett end wednesday april high fall week line support early august
1009,ABBV,switzerland base syngenta syt rolled gain announce seek divest vegetable seed business launch share repurchase program syngenta see more revenue herbicide insecticide stock end wednesday june high
1010,ABBV,lead stock be unusually flat ahead open refinery operator tesoro tso post largest move ibd stock premarket trade stock have be work fashion bottom week consolidation hover week move average
1011,ABBV,overseas china market be close country celebrate anniversary end wwii europe market layer healthy gain lead index more board midday
1012,ABBV,dollar trade flat vs euro yen bond slip not much crude oil ease few penny west texas intermediate hold barrel week gold ease ounce less week stock future blipped higher ahead thursday open market appear set build wednesday late day rally dow future trade point fair market value have come well earlier high nasdaq future be strong point future show point gain stock market today head session nasdaq lower week ibd index be russell open loss rally late wednesday session follow release federal reserve september beige book report left nasdaq top day trading range positive sign little have change regard overall message correct market be send be patient build watch list watch follow day investor attention be august nonfarm payroll report due friday thursday preliminary include august job cut report challenger gray christmas show number layoff slow sharply vs july year high compare year figure employer announce plan cut worker retail sector account nearly layoff most tie bankruptcy grocery chain report say initial jobless claim rise week end aug labor department say economist consensus have project claim week move average edge stock grifol grfs rise sunedison sune jump market continue be hard slip up late season earning report be morning weak revenue guidance upended quarterly result verint system vrnt tumble better expect earning revenue do not offset full year earning guidance consensus view generic drug maker lannett lci spiked premarket trade philadelphia base company say pay acquire kremer urban pharmaceutical generic drug unit belgium base ucb kremer own portfolio drug strong pipeline pending application candidate effectively double lannett revenue lannett end wednesday april high fall week line support early august switzerland base syngenta syt rolled gain announce seek divest vegetable seed business launch share repurchase program syngenta see more revenue herbicide insecticide stock end wednesday june high lead stock be unusually flat ahead open refinery operator tesoro tso post largest move ibd stock premarket trade stock have be work fashion bottom week consolidation hover week move average overseas china market be close country celebrate anniversary end wwii europe market layer healthy gain lead index more board midday dollar trade flat vs euro yen bond slip not much crude oil ease few penny west texas intermediate hold barrel week gold ease ounce less week
1013,ABBV,pretty miserable day major index fail trigger sell signal ibd stock only stock elite list growth name manage gain gain be small dow jone industrial nasdaq lose more volume be average board
1014,ABBV,week ibd week rise vs decline
1015,ABBV,not say more misery come day week couldn result breakdown lead stock investor want consider lighten position due buildup day increase volume be few close call friday
1016,ABBV,papa john pzza break day move average close volume be average daily weekly chart not sufficient call sell signal however pizza chain have show sign distribution past few week reflect poor accumulation distribution rating
1017,ABBV,criteo crto french adr come public november fall close volume be heavy stock find support day line least now still fall list friday company target advertisement product help commerce company increase post click sale chinese firm be ibd worst performer trade volatile fashion operate automobile related website china bitauto bita drop nearly drop athm drop loss
1018,ABBV,ambarella amba drop second day light volume pullback buy point flat base pullback have bring back buy range base be light volume catalyst wednesday be better expect earning report company make chip used camera include hero line action sport wearable make gopro gpro
1019,ABBV,pharmacyclic pcyc hold own gain day gain more new time high
1020,ABBV,abbvie abbv announce thursday be buy pharmacyclic cash equity deal abbvie drop nearly thursday friday pierce day line heavy volume
1021,ABBV,monster beverage mnst drop gap time high feb favorable earning report
1022,ABBV,click here view full list week new high lows pretty miserable day major index fail trigger sell signal ibd stock only stock elite list growth name manage gain gain be small dow jone industrial nasdaq lose more volume be average board week ibd week rise vs decline not say more misery come day week couldn result breakdown lead stock investor want consider lighten position due buildup day increase volume be few close call friday papa john pzza break day move average close volume be average daily weekly chart not sufficient call sell signal however pizza chain have show sign distribution past few week reflect poor accumulation distribution rating criteo crto french adr come public november fall close volume be heavy stock find support day line least now still fall list friday company target advertisement product help commerce company increase post click sale chinese firm be ibd worst performer trade volatile fashion operate automobile related website china bitauto bita drop nearly drop athm drop loss ambarella amba drop second day light volume pullback buy point flat base pullback have bring back buy range base be light volume catalyst wednesday be better expect earning report company make chip used camera include hero line action sport wearable make gopro gpro pharmacyclic pcyc hold own gain day gain more new time high abbvie abbv announce thursday be buy pharmacyclic cash equity deal abbvie drop nearly thursday friday pierce day line heavy volume monster beverage mnst drop gap time high feb favorable earning report click here view full list week new high lows
1023,ABBV,come stock often size speed quote trading place have ibd screen day be big cap leader include liquid large cap stock strong record earning growth let meet top boast robust share gain recent month be
1024,ABBV,share shire shpg moved higher early thursday irish drugmaker better expect quarterly revenue upbeat outlook offset earning miss report open shire logged fourth quarter earning american depositary share year earlier period nickel consensus estimate analyst poll thomson reuter revenue climb
1025,ABBV,gilead science beat analyst fourth quarter expectation tuesday give weak sale guidance biotech suffer pricing pressure blockbuster hepatitis drug earning leap share cent consensus revenue jump more wall street view however gilead gild see full year net product sale
1026,ABBV,merger mania be heating again ethical drug firm rush acquire other expand portfolio salix pharmaceutical slxp be target latest potential bidding war stock surge heavy trade feb report valeant pharmaceutical vrx be talk buy drug maker rise thursday
1027,ABBV,earning report start roll next month likely biggest mover biotech pharma stock be release clinical trial datum here be such report expect month street expect probably most anticipate be biogen idec biib presentation phase result alzheimer disease drug
1028,ABBV,world biggest drugmaker issue mixture report friday continue be tough earning season abbvie abbv say profit exclude time item rise year earlier quarter cent beating analyst consensus cent accord thomson reuter sale climb ahead consensus full year profit increase share sale gain abbvie affirm guidance issue earlier month call earning didn set revenue range however conference call analyst ceo richard gonzalez say expect newly launch hepatitis combo viekira pak achieve run rate end year midst abbvie hepatitis battle gilead science gild land exclusive deal payer gonzalez say expect insure patient have access viekira pak rbc capital market analyst michael yee calculate mean year be consensus positive abbv announce generation regimen improve possible single pill booster ribavirin have datum soon plan go phase iii later year be way maintain share alternative gild yee write research note friday still abbvie share fall afternoon trading stock market today stock fall month low intraday eli lilly lly still shadow patent cliff report sale shrank miss consensus nearly earning rise cent share beating street average estimate cent full year profit drop share sale slide lilly also affirm earlier profit guidance share shave revenue guidance be now singing familiar tune earning season lilly blame lower guidance solely reflect recent strengthen dollar compare several other currency however capital iq analyst jeffrey loo be hearten ep guidance stay same point better expect gross margin raise price target say be low point sale see improve growth next few year lilly stock rise afternoon trading follow amy reeve twitter ibd_areeve
1029,ABBV,specialty drugmaker mallinckrodt mnk announce deal thursday acquire privately hold ikarium be greet enthusiasm stock market ikarium make inomax inhaled nitric oxide used treat newborn respiratory problem mallinckrodt say deal expand hospital business add cent share financial
1030,ABBV,pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb
1031,ABBV,report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi
1032,ABBV,express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year
1033,ABBV,not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately
1034,ABBV,gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise
1035,ABBV,express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny
1036,ABBV,drug trend report didn specifically mention do drug end cost year
1037,ABBV,follow amy reeve twitter ibd_areeve pharmacy benefit manager express script esrx say prescription drug spending rise more last year have accord annual review accord drug trend report spending drug commercially insure rise member last year medicare spending rise member medicaid spending climb report say spending hepatitis drug account more half increase be not big surprise disease be still treat mainly generic drug gilead science gild premium price sovaldi often prescribe tandem johnson johnson jnj also pricey olysio take market october gilead launch harvoni render olysio obsolete cost more sovaldi express script pharmacy benefit management leader be earliest loudest critic sovaldi price amount standard week treatment press release accompany report pbm brag have take bite gilead make exclusive deal abbvie abbv come gilead first serious competitor form viekira pak year end express claim save client year not clear however well be work abbvie analyst tracking prescription datum estimate only have market share datum be incomplete win be fully know abbvie report caveat be express price datum do not include rebate be significant part picture especially hepatitis market lately gilead report last month investor have minor freak company executive guide gross net adjustment rebate level hepatitis franchise express script release also echo comment make ceo january jpmorgan healthcare conference indicated next price war target be pcsk inhibitor new class cholesterol drug expect come market year offering amgen amgn team regeneron pharmaceutical regn sanofi sny drug trend report didn specifically mention do drug end cost year follow amy reeve twitter ibd_areeve
1038,ABBV,hca holding bump full year guidance preview first quarter result beat expectation strong admission growth strong growth admission pressured insurer stock fear increase patient utilization rate hospital operator now project earning share revenue prior guidance
1039,ABBV,drugmaker seize market headline thursday pharmacyclic pcyc spiked word be acquire abbvie abbv cash stock deal news send abbvie heavy trade also launch mild rally pharmaceutical stock
1040,ABBV,dublin ireland mallinckrodt mnk jump twice normal trade announce own acquisition mallinckrodt say buy washington base ikarium privately hold maker respiratory treatment delivery system ikarium inomax treat half case hypoxic respiratory failure afflict infant year
1041,ABBV,mallinckrodt acquire blockbuster multiple sclerosis medicine acthar purchase questcor last april acquire pain medication ofirmev purchase cadence pharmaceutical march
1042,ABBV,flush portfolio drive sale past quarters double triple digit earning gain analyst consensus call ep gain year revenue jump year analyst expect earning rise sale grow
1043,ABBV,thursday gain send stock ibd top world stock new time high stock remain well extend late january rebound week support
1044,ABBV,drugmaker other medical stock have be run strong time make difficult find stock buy point
1045,ABBV,dublin base medical play icon iclr be hover high knock gain february provider contract clinical research service announce march have complete acquisition medimedium pharma solution stock clear cup handle buy point mid february end thursday buy point buy range
1046,ABBV,other smaller play show promise include ireland horizon pharma hznp maker osetoarthritis pain treatment duexis have be tick new high follow triple digit sale growth first profitable year horizon sport composite rating average daily volume share
1047,ABBV,israel thinly trade generic firm taro pharmaceutical taro be expect see ep rise year share drugmaker seize market headline thursday pharmacyclic pcyc spiked word be acquire abbvie abbv cash stock deal news send abbvie heavy trade also launch mild rally pharmaceutical stock dublin ireland mallinckrodt mnk jump twice normal trade announce own acquisition mallinckrodt say buy washington base ikarium privately hold maker respiratory treatment delivery system ikarium inomax treat half case hypoxic respiratory failure afflict infant year mallinckrodt acquire blockbuster multiple sclerosis medicine acthar purchase questcor last april acquire pain medication ofirmev purchase cadence pharmaceutical march flush portfolio drive sale past quarters double triple digit earning gain analyst consensus call ep gain year revenue jump year analyst expect earning rise sale grow thursday gain send stock ibd top world stock new time high stock remain well extend late january rebound week support drugmaker other medical stock have be run strong time make difficult find stock buy point dublin base medical play icon iclr be hover high knock gain february provider contract clinical research service announce march have complete acquisition medimedium pharma solution stock clear cup handle buy point mid february end thursday buy point buy range other smaller play show promise include ireland horizon pharma hznp maker osetoarthritis pain treatment duexis have be tick new high follow triple digit sale growth first profitable year horizon sport composite rating average daily volume share israel thinly trade generic firm taro pharmaceutical taro be expect see ep rise year share
1048,ABBV,medical sector have most noteworthy new high thursday sector continue be capable market leader buyout have spur sector thursday pharmacyclic pcyc surge news chicago base abbvie abbv agree acquire company deal pharmacyclic jump huge volume
1049,ABBV,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
1050,ABBV,volume nasdaq nyse be tracking tuesday level
1051,ABBV,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
1052,ABBV,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
1053,ABBV,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
1054,ABBV,solar stock be day best performer lead first solar fslr jump new high heavy volume
1055,ABBV,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
1056,ABBV,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
1057,ABBV,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
1058,ABBV,stock quietly step solid gain early trade thursday company report dip unemployment claim focal point early action
1059,ABBV,dow jone industrial average rise nasdaq climb apiece volume be soft nasdaq lower nyse compare trade same time wednesday
1060,ABBV,stock market today earning beat forecast management say sale accelerate march april stock have be work regain week move average shallow week consolidation
1061,ABBV,more ibd stock moved higher start trade gain be moderate many evaporate quickly newlink genetic nlnk drop almost slip week line support
1062,ABBV,close el pollo dd jwn symantec symc be long list company expect post quarterly result stock quietly step solid gain early trade thursday company report dip unemployment claim focal point early action dow jone industrial average rise nasdaq climb apiece volume be soft nasdaq lower nyse compare trade same time wednesday stock market today earning beat forecast management say sale accelerate march april stock have be work regain week move average shallow week consolidation more ibd stock moved higher start trade gain be moderate many evaporate quickly newlink genetic nlnk drop almost slip week line support close el pollo dd jwn symantec symc be long list company expect post quarterly result
1063,ABBV,price war new hepatitis drug heat consensus estimate be too high accord deutsche bank separate note tuesday wednesday analyst robyn karnauskas calculate prospect abbvie abbv viekira pak gilead science gild harvoni sovaldi company announce series exclusive agreement payer pharmacy benefit manager abbv have so far nail life express script esrx national formulary gild have be choose prefer life cvs cvs anthem antm write be assume market share abbv exclusive prefer life see overall share abbv sale add revenue europe drug viekira pak be expect launch year set separate product karnauskas arrived total hcv sale vs consensus however also expect gilead be go low ball consensus due price discount have negotiate compete abbvie worst case expect discount commercial channel be harvoni sovaldi couple government discount harvoni sovaldi calculate overall discount hcv franchise write explain result revenue guidance lower present consensus guidance come lower validate pbms pharmacy benefit manager be telegraph regard discount abbvie be due report guidance jan gilead hasn yet set date report lower estimate karnauskas maintain buy rating stock due pipeline full other promising drug candidate stock didn react much stock market today afternoon trading gilead be abbvie be gilead moved back day move average tuesday abbvie continue slide key level follow amy reeve twitter ibd_areeve related aetna side gilead hepatitis drug battle
1064,ABBV,gilead science gild be well position grow hepatitis drug market vs rival abbvie abbv say analyst upgrading gilead stock rating matthew harrison analyst morgan stanley raise gilead rating overweight equal weight also raise price target gilead stock gilead science stock be more
1065,ABBV,anglo irish drugmaker shire shpg announce monday have agree acquire nps pharmaceutical cash deal dublin base shire say sunday pay share nps pharmaceutical npsp be base new jersey specialize drug disorder represent premium nps pharmaceutical share price dec rumor deal emerge deal come month propose sale shire illinois base pharmaceutical company abbvie abbv fall follow unfavorable tax rule change issue department treasury industry speculation have shire remain takeover target shire do buy acquisition nps pharma be significant step advance shire strategy become lead biotechnology company say shire ceo flem ornskov company press release look forward accelerate growth nps pharmaceutical portfolio base proven track record maximize value acquire asset commercial execution leerink analyst jason gerberry however say transaction offer limit cost synergy deal be consistent shire merger acquisition strategy benefit very low cost funding gerberry write monday report add not be buyer shire approval launch nps pharmaceutical hormone replacement therapy natpara leerink maintain market perform rating shire stock shire stock be afternoon trading stock market today shire stock be brush time high late september nps pharmaceutical stock be afternoon trading stock market today year high also monday swiss pharmaceutical giant roche say acquire majority stakein tumor testing company foundation medicine more deal drive personalize cancer treatment drug development
1066,ABBV,stock future point strong open tuesday strength most overseas market nasdaq future rally point vs fair value future climb point future dow jone industrial average jump point
1067,ABBV,stock reversed higher monday solid gain volume be lower
1068,ABBV,equity market overseas be mostly higher european bourse lead charge france cac bolt germany dax rally meanwhile london ftse gain
1069,ABBV,asia hong kong hang seng climb japan nikkei gain shanghai composite be fractionally lower
1070,ABBV,gain monday rise tension friday terrorist attack paris crude oil pull back december crude lose cent barrel
1071,ABBV,economic front consumer price rise october be first gain month match view
1072,ABBV,datum industrial production nahb housing market index be et et respectively fed governor jerome powell daniel tarullo be speaking later today
1073,ABBV,stock home depot hd rally premarket trading stock market today beating view home improvement retailer post earning share sale view be ep revenue also peg full year earning share nickel view
1074,ABBV,rival lowe low be also premarket trading report quarterly result wednesday
1075,ABBV,wal mart wmt rise premarket post mixed quarterly result world biggest retailer report fiscal earning share exclude gain lease earning be cent share sale come analyst poll thomson reuter have expect ep cent revenue
1076,ABBV,fitbit fit gain more premarket activity be upgrade buy neutral bank america lynch share maker fitness tracker bounce back monday hit record low friday
1077,ABBV,dick sporting good dks plunge premarket trade follow disappointing earning weak outlook retailer post adjust earning cent share revenue view be ep cent sale retailer guide earning share vs view monday share fall lowest level january
1078,ABBV,follow vincent mao twitter ibd_vmao stock future point strong open tuesday strength most overseas market nasdaq future rally point vs fair value future climb point future dow jone industrial average jump point stock reversed higher monday solid gain volume be lower equity market overseas be mostly higher european bourse lead charge france cac bolt germany dax rally meanwhile london ftse gain asia hong kong hang seng climb japan nikkei gain shanghai composite be fractionally lower gain monday rise tension friday terrorist attack paris crude oil pull back december crude lose cent barrel economic front consumer price rise october be first gain month match view datum industrial production nahb housing market index be et et respectively fed governor jerome powell daniel tarullo be speaking later today stock home depot hd rally premarket trading stock market today beating view home improvement retailer post earning share sale view be ep revenue also peg full year earning share nickel view rival lowe low be also premarket trading report quarterly result wednesday wal mart wmt rise premarket post mixed quarterly result world biggest retailer report fiscal earning share exclude gain lease earning be cent share sale come analyst poll thomson reuter have expect ep cent revenue fitbit fit gain more premarket activity be upgrade buy neutral bank america lynch share maker fitness tracker bounce back monday hit record low friday dick sporting good dks plunge premarket trade follow disappointing earning weak outlook retailer post adjust earning cent share revenue view be ep cent sale retailer guide earning share vs view monday share fall lowest level january follow vincent mao twitter ibd_vmao
1079,ABBV,goldman sachs upgrade eli lilly lly neutral thursday say big pharma have turn corner fall hard patent cliff investment bank downgrade johnson johnson cite increase drug competition believe lly have turn corner improve margin new product launch drive company earning trough
1080,ABBV,monday bring surprising turn twist story hepatitis treatment pharmacy giant cvs health say offer exclusive coverage gilead science hep drug
1081,ABBV,key issue price remain unanswered deal seem counterattack cut week pharmacy benefit manager express script esrx abbvie abbv day fda abbvie drug viekira pak genotype hepatitis virus hcv express script say start cover only viekira pak genotype patient already start course drug firm be tight lip detail cvs cvs deal appear mirror express script start wednesday cvs also operate pharmacy benefit manager cover gilead gild sovaldi harvoni exclusively cvs caremark standard commercial exchange marketplace medicare part medicaid formulary viekira pak be cover only patient get exception prior approval didn say be much cvs pay drug price be big motive express script deal have objected cost new hepatitis drug ever sovaldi launch december week round therapy harvoni most patient eliminate need companion drug launch october week however wasn much anyone do long be competitor equal quality market viekira pak be approve dec price war seem have be avert treatment price modest discount harvoni week most analyst thought account fact more complicate take pill day harvoni equally effective price subject hagglingas evercore isi analyst mark schoenebaum have observed official list price drug be lot sticker price car just start point haggle abbvie acknowledge express get viekira pak discount decline reveal much analyst think have be gilead stock fall more day express disclose deal analyst cut rating lower target monday news help gilead stock rally abbvie fall gilead be not biotech start maxim group analyst jason kolbert say monday be savvy marketing drive company understand launch manage product life cycle don underestimate gilead ability manage competitive environment own research note monday rbc capital market analyst michael yee point most street have already assume gilead price cut once viekira pak come already have steep gross net move follow few quarters yee write so not think average price cvs be go be drastically different discount
1082,ABBV,stock be flat thursday afternoon investor weigh mixed economic datum new stimulus effort european central bank
1083,ABBV,nasdaq dow jone industrial average be flat slip index be modestly higher early session volume be run lower board compare same time wednesday
1084,ABBV,stock market today get early boost ecb announce launch bond buy stimulus monday help offset generally weak economic datum include unexpected dip january factory order
1085,ABBV,pharmacyclic pcyc jump new high illinois base abbvie abbv say buy maker blood cancer drug imbruvica abbvie drop
1086,ABBV,qualys qlys provider cloud security software be nearly new high volume be heavy stock be profit take zone climb more past flat base buy point
1087,ABBV,ceo philippe courtot be due speak thursday morgan stanley technology medium telecom conference
1088,ABBV,sprout farmer market sfm rise heavy volume be hit resistance day move average
1089,ABBV,joy global joy maker mining machinery drop heavy turnover lower full year earning outlook depress commodity price see follow story more detail stock be flat thursday afternoon investor weigh mixed economic datum new stimulus effort european central bank nasdaq dow jone industrial average be flat slip index be modestly higher early session volume be run lower board compare same time wednesday stock market today get early boost ecb announce launch bond buy stimulus monday help offset generally weak economic datum include unexpected dip january factory order pharmacyclic pcyc jump new high illinois base abbvie abbv say buy maker blood cancer drug imbruvica abbvie drop qualys qlys provider cloud security software be nearly new high volume be heavy stock be profit take zone climb more past flat base buy point ceo philippe courtot be due speak thursday morgan stanley technology medium telecom conference sprout farmer market sfm rise heavy volume be hit resistance day move average joy global joy maker mining machinery drop heavy turnover lower full year earning outlook depress commodity price see follow story more detail
1090,ABBV,abbvie be make major oncology push agree late wednesday pay acquire pharmacyclic pcyc maker blockbuster blood cancer drug imbruvica abbvie pay share cash stock pharmacyclic close price wednesday biotech close record high wednesday buyout buzz
1091,ABBV,regulus therapeutic rgls stock leap tuesday night astrazeneca azn take nash fatty liver disease candidate testing part microrna alliance join crowd field drugmaker develop treatment make investment get part nash form liver damage cause accumulation fat regulus say rg compound treat nonalcoholic
1092,ABBV,big pharma abbvie deal acquire hot biotech pharmacyclic be meet widespread skepticism abbvie investor thursday send abbvie stock fall thursday abbvie abbv announce cash stock acquisition late wednesday rumor have be swirl afternoon novartis nvs johnson johnson jnj be engage bidding war pharmacyclic pcyc surprised wall street abbvie turn be buyer especially already have partnership pharmacyclic market blood cancer drug imbruvica doesn really make sense be abbvie prevailing pcyc partner natural buyer jnj secure pcyc pay price do asset bernstein analyst geoffrey porge write research note thursday believe jnj be only buyer able secure operational advantage full control buy partner jnj more other buyer have be able maximize synergy reduce product support single commercial organization cash stock deal value pharmacyclic share stock rise thursday stock trade start year conference call analyst early thursday abbvie ceo richard gonzalez affirm bidding war have come contestant didn name justified price cite enormous market potential imbruvica launch late bring pharmacyclic last year abbvie reckon imbruvica bring firm year peak change exist deal split profit evercore isi say assume total worldwide sale make imbruvica biggest selling cancer drug history say analyst mark schoenebaum analyst consensus sale estimate be bullish not bullish latest year available average estimate be call gonzalez break assumption number growth come expansion imbruvica currently approve used second line treatment chronic lymphocytic leukemia cll mantle cell lymphoma well anytime treatment less common condition cll deletion macroglobulemia additional come expansion first line treatment cll lymphoma gonzalez say have very high probability success give clinical trial datum rest come unspecified amount accounting approval other cancer cell more speculative assumption product also work solid tumor do see datum solid tumor be impressed gonzalez say many analyst view abbvie late stage blood cancer candidate potential competitor imbruvica chief scientific officer michael severino say drug potentially work combination expect launch clinical trial prove general executive say acquisition boost abbvie entire cancer business much be change focus abbvie make fortune immunology blockbuster drug humira however humira likely get biosimilar competition amgen amgn pfizer pfe other patent expire call gonzalez affirm abbvie commitment humira defend patent court develop new improve version drug say have nothing do price paid pharmacyclic analyst porge however say premium here be explain abbvie desperation
1093,ABBV,stock end solid gain friday battle back weakness spur disappointing job report nasdaq end respectively be friday low dow jone industrial average climb accord preliminary datum volume end higher board stock market today lead stock dave buster entertainment play reversed higher gain stock have already rise thursday follow pricing share offer dave buster be recently featured stock spotlight verisk analytic vrsk stretched streak straight session rebound loss rise stock nearly reach buy point flat base verisk provide datum insurance underwriter bank be add wednesday close tyler technology tyl add second straight new high now past buy point flat base clear thursday company announce buy privately hold new world system cash stock domino pizza dpz climb buck morning weakness fail retake day move average domino report earning thursday analyst poll thomson reuter see pizza chain profit rise cent share
1094,ABBV,share cyberonic cybx gap record high thursday company report better expect earning growth say be merge italy sorin move headquarters europe new treasury rule intend curb tax inversion deal stock transaction create global contender start annual revenue
1095,ABBV,big pharma merck mrk be nearly stock market today latest datum hepatitis pipeline underwhelm street sunday annual conference american association study liver disease merck report much anticipate interim datum swift trial analyst thought challenge market leader gilead
1096,ABBV,biotech industry be set hit ground run january alone bring passel potentially stock move event biggest player second full week month bring annual jpmorgan healthcare conference san francisco many company release product financial news first thing morning
1097,ABBV,mylan myl be early trading stock market today drugmaker beat estimate late thursday earlier stock be more nearly month high
1098,ABBV,earning come high end raise guidance range mylan offer oct share be year earlier quarter cent higher analyst consensus accord thomson reuter sale rise ahead street consensus
1099,ABBV,mylan also raise narrow full year ep guidance give oct now lower revenue guidance however range
1100,ABBV,leerink analyst jason gerberry write beat be drive sale epipen adrenaline self injection device treat anaphylaxis help push specialty pharma revenue larger generic drug business be line expectation bit light europe
1101,ABBV,many question conference call analyst be mylan pending deal buy develop market segment abbott laboratory establish product business be base netherlands mylan say go ahead deal treasury department propose new rule limit ability company lower taxe buy overseas firm
1102,ABBV,company reiterate pro tax rate low cfo expect tax rate step high teen next few year gerberry say research note thursday abbvie abbv board walk away shire shpg transaction concern relate treasury notice generally agree myl management notice remain recommendation ultimately not pass law
1103,ABBV,mylan be largest highest rate company ibd generic drug group composite rating have be consolidation pattern hit time high march
1104,ABBV,follow amy reeve twitter ibd_areeve mylan myl be early trading stock market today drugmaker beat estimate late thursday earlier stock be more nearly month high earning come high end raise guidance range mylan offer oct share be year earlier quarter cent higher analyst consensus accord thomson reuter sale rise ahead street consensus mylan also raise narrow full year ep guidance give oct now lower revenue guidance however range leerink analyst jason gerberry write beat be drive sale epipen adrenaline self injection device treat anaphylaxis help push specialty pharma revenue larger generic drug business be line expectation bit light europe many question conference call analyst be mylan pending deal buy develop market segment abbott laboratory establish product business be base netherlands mylan say go ahead deal treasury department propose new rule limit ability company lower taxe buy overseas firm company reiterate pro tax rate low cfo expect tax rate step high teen next few year gerberry say research note thursday abbvie abbv board walk away shire shpg transaction concern relate treasury notice generally agree myl management notice remain recommendation ultimately not pass law mylan be largest highest rate company ibd generic drug group composite rating have be consolidation pattern hit time high march follow amy reeve twitter ibd_areeve
1105,ABBV,flem ornskov have be shire only month term have be quite adventure already
1106,ABBV,january close anglo irish drugmaker biggest acquisition buy biotech viropharma
1107,ABBV,bring shire shpg deeper grow field rare disease drug help diversify core business attention deficit treatment have also make number smaller buyout
1108,ABBV,year shire biggest drama be role have be biggest tax inversion deal drug industry
1109,ABBV,north chicago base big pharma abbvie abbv successfully woo shire back july nearly offer abbvie plan cut taxe relocate headquarters britain
1110,ABBV,treasury department propose new rule september limit benefit such deal abbvie be legally unable renegotiate term big pharma backed leave shire breakup fee
1111,ABBV,undaunted oct shire report result beat expectation
1112,ABBV,ornskov recently speak ibd abbvie adventure shire strategy
1113,ABBV,ibd abbvie first make bid initially resist apart issue price be become part big pharma ever plan be now
1114,ABBV,ornskov situation abbvie make bid be go put strong case investor stay independent layer plan call achieve annual sale abbvie increase offer number time eventually think board shire feel number be offer be such magnitude have recommend also feedback get investor
1115,ABBV,deal do not happen be lot speculation tax deal importance think right now most important thing be have strong opportunity independent company
1116,ABBV,have very strong growth grow third quarter compare similar quarter think progressed profitability very strongly progressed pipeline think now have focus be independent company
1117,ABBV,long term think ve make really good progress business development ve make least deal period time lumena fibrotech company call bikam ophthalmic area quickly put abbvie situation think so team
1118,ABBV,ibd speaking tax issue shire be domicile dublin even lot operation be elsewhere do see propose change irish law political pressure be affect business
1119,ABBV,ornskov shire be base ireland quite time think ve see tax be complex issue now company treasury notice person be interpret try figure mean
1120,ABBV,think end tax be thing have manage complex environment high demand growth efficiency really key thing be focus innovation growth person pipeline
1121,ABBV,ibd ve be diversify away core add business do wind mix therapeutic area re be most focuse point
1122,ABBV,ornskov ve come board ve shift strategy be more focuse become biotech company have aspirational peer celgene celg gilead gild biogen idec biib find company be characterize innovative pipeline high growth high profitability very strong research focus patient focus
1123,ABBV,put strategy take direction have plan achieve be ambitious think achievable goal even exclude business development
1124,ABBV,more more business be rare disease be now largest fastest grow business true historically ve be more adhd now rare disease be focal point go forward investment business development acquisition
1125,ABBV,ibd size acquisition expect
1126,ABBV,ornskov well shire have always be acquisitive company ve make quite number come board largest make be acquisition viropharma think be incredibly successful
1127,ABBV,not only do acquire product cinryze used prevent attack angioedema swell face body excellent growth also ve significantly increase growth ve take product same disease area firazyr already have picked growth significantly good pattern build domain expertise have make target acquisition perform very well acquire asset spillover effect exist asset
1128,ABBV,ll look opportunity do other area flem ornskov have be shire only month term have be quite adventure already january close anglo irish drugmaker biggest acquisition buy biotech viropharma bring shire shpg deeper grow field rare disease drug help diversify core business attention deficit treatment have also make number smaller buyout year shire biggest drama be role have be biggest tax inversion deal drug industry north chicago base big pharma abbvie abbv successfully woo shire back july nearly offer abbvie plan cut taxe relocate headquarters britain treasury department propose new rule september limit benefit such deal abbvie be legally unable renegotiate term big pharma backed leave shire breakup fee undaunted oct shire report result beat expectation ornskov recently speak ibd abbvie adventure shire strategy ibd abbvie first make bid initially resist apart issue price be become part big pharma ever plan be now ornskov situation abbvie make bid be go put strong case investor stay independent layer plan call achieve annual sale abbvie increase offer number time eventually think board shire feel number be offer be such magnitude have recommend also feedback get investor deal do not happen be lot speculation tax deal importance think right now most important thing be have strong opportunity independent company have very strong growth grow third quarter compare similar quarter think progressed profitability very strongly progressed pipeline think now have focus be independent company long term think ve make really good progress business development ve make least deal period time lumena fibrotech company call bikam ophthalmic area quickly put abbvie situation think so team ibd speaking tax issue shire be domicile dublin even lot operation be elsewhere do see propose change irish law political pressure be affect business ornskov shire be base ireland quite time think ve see tax be complex issue now company treasury notice person be interpret try figure mean think end tax be thing have manage complex environment high demand growth efficiency really key thing be focus innovation growth person pipeline ibd ve be diversify away core add business do wind mix therapeutic area re be most focuse point ornskov ve come board ve shift strategy be more focuse become biotech company have aspirational peer celgene celg gilead gild biogen idec biib find company be characterize innovative pipeline high growth high profitability very strong research focus patient focus put strategy take direction have plan achieve be ambitious think achievable goal even exclude business development more more business be rare disease be now largest fastest grow business true historically ve be more adhd now rare disease be focal point go forward investment business development acquisition ibd size acquisition expect ornskov well shire have always be acquisitive company ve make quite number come board largest make be acquisition viropharma think be incredibly successful not only do acquire product cinryze used prevent attack angioedema swell face body excellent growth also ve significantly increase growth ve take product same disease area firazyr already have picked growth significantly good pattern build domain expertise have make target acquisition perform very well acquire asset spillover effect exist asset ll look opportunity do other area
1129,ABBV,special report best mutual fund february performance report stock mutual fund manager andrew acheson paul cloonan have be kick higher gear pioneer fundamental growth fund average annual return fund rank top large cap growth rival track morningstar inc year end
1130,ABBV,stock hepatitis field be wednesday wake gilead science gild cautious forecast potential competitor merck hit fda setback gilead stock plunge more early trading multiple analyst cut price target wake guidance comment point high rate
1131,ABBV,nothing competition help lower price market abbvie abbv enter hepatitis arena december gilead science gild have be discounting price sovaldi harvoni drug foster city calif base biotech jan sign health insurer aetna aet provider sovaldi cost week
1132,ABBV,wednesday report fastest quarterly earning growth more year revenue gain continue slow
1133,ABBV,drug health supply distributor fiscal earning share leap fourth straight quarter accelerate growth beating view cent
1134,ABBV,revenue rise help boot alliance wba contract inked last year provide pharmaceutical product top view sale growth slow more prior quarters
1135,ABBV,abc stock end have rise intraday record high
1136,ABBV,re cycling onboard expect revenue growth come evercore isi analyst ross muken tell ibd growth come be still medical distributor market overall
1137,ABBV,be impressive quarter board notably revenue side think have solid result overall say
1138,ABBV,also lift earning outlook share prior view
1139,ABBV,midpoint be roughly line consensus revision be help cent ep beat acquisition mwi veterinary supply company expect add cent ep latter half year
1140,ABBV,only thing investor question be magnitude earning guidance muken say give be not surprised magnitude earning guidance revision
1141,ABBV,company expect revenue wall street consensus
1142,ABBV,fiscal drug unit sale rise specialty sale jump say drug sale gain be due largely pact demand hepatitis drug
1143,ABBV,market hep drug be increasingly competitive gilead gild sovaldi debut december rival treatment johnson johnson jnj abbvie abbv have launch
1144,ABBV,cvs health cvs month say select gilead sovaldi harvoni exclusive hepatitis treatment express script esrx picked abbvie viekira december wednesday report fastest quarterly earning growth more year revenue gain continue slow drug health supply distributor fiscal earning share leap fourth straight quarter accelerate growth beating view cent revenue rise help boot alliance wba contract inked last year provide pharmaceutical product top view sale growth slow more prior quarters abc stock end have rise intraday record high re cycling onboard expect revenue growth come evercore isi analyst ross muken tell ibd growth come be still medical distributor market overall be impressive quarter board notably revenue side think have solid result overall say also lift earning outlook share prior view midpoint be roughly line consensus revision be help cent ep beat acquisition mwi veterinary supply company expect add cent ep latter half year only thing investor question be magnitude earning guidance muken say give be not surprised magnitude earning guidance revision company expect revenue wall street consensus fiscal drug unit sale rise specialty sale jump say drug sale gain be due largely pact demand hepatitis drug market hep drug be increasingly competitive gilead gild sovaldi debut december rival treatment johnson johnson jnj abbvie abbv have launch cvs health cvs month say select gilead sovaldi harvoni exclusive hepatitis treatment express script esrx picked abbvie viekira december
1145,ABBV,recent flurry deal make drug sector have put spotlight other top rate drugmaker have grow help savvy merger acquisition just past week abbvie abbv agree buy pharmacyclic pcyc beating johnson johnson jnj mallinckrodt mnk announce deal acquire privately
1146,ABBV,euphoria third quarter gdp growth evaporate tuesday morning leave stock trading mixed midday nasdaq lead other index best level
1147,ABBV,nasdaq be rise dow jone industrial average gain volume be trend lower exchange
1148,ABBV,befit holiday spirit best perform industry group be leisure toy department store worst perform group be health care field biotech stock show biggest loss morning
1149,ABBV,department store operator dd trouble jcpenney jcp rise macy gain mattel mat hasbro have rise stock market today
1150,ABBV,biotechs have be lead bull market show age tuesday morning celgene celg shed be try find support day move average recent biogen biib fizzle share lose
1151,ABBV,gilead science gild fall punch day move average week monday pharmacy benefit manager express script esrx picked abbvie abbv hepatitis drug gilead sovaldi
1152,ABBV,alexion pharmaceutical alxn fall also fall day line
1153,ABBV,ibd stock be be worst performer be biotech pharmacyclic pcyc fall day line buy point cup base euphoria third quarter gdp growth evaporate tuesday morning leave stock trading mixed midday nasdaq lead other index best level nasdaq be rise dow jone industrial average gain volume be trend lower exchange befit holiday spirit best perform industry group be leisure toy department store worst perform group be health care field biotech stock show biggest loss morning department store operator dd trouble jcpenney jcp rise macy gain mattel mat hasbro have rise stock market today biotechs have be lead bull market show age tuesday morning celgene celg shed be try find support day move average recent biogen biib fizzle share lose gilead science gild fall punch day move average week monday pharmacy benefit manager express script esrx picked abbvie abbv hepatitis drug gilead sovaldi alexion pharmaceutical alxn fall also fall day line ibd stock be be worst performer be biotech pharmacyclic pcyc fall day line buy point cup base
1154,ABBV,receptos rcpt stock jump more new high morning trading stock market today company get multiple price target increase bowel disease drug succeed midstage trial receptos announce late monday drug rpc have proven significantly better placebo patient ulcerative colitis uc disease
1155,ABBV,broader index be mostly tread water monday afternoon blue chip continue outshine
1156,ABBV,lift intel intc boee ba ibm ibm dow jone industrial average rally nasdaq edge be fractionally higher volume be tracking sharply lower board stock market today friday turnover be boost expiration option future contract
1157,ABBV,lead stock facebook fb rise time high fast trade ibd stock clear buy point first stage flat base facebook reset base count october breach low prior base
1158,ABBV,wagework wage be still more pare gain earlier stock clear buy point flat base also be view giant cup handle pattern same buy point last month provider health other employee benefit report jump earning gain sale be best several quarters
1159,ABBV,downside gilead science gild come slightly session low be still share slump monday low news express script esrx drop coverage hepatitis drug favor new treatment abbvie abbv share abbvie be reverse early gain
1160,ABBV,other biotechs celgene celg biogen idec biib be session lows still broader index be mostly tread water monday afternoon blue chip continue outshine lift intel intc boee ba ibm ibm dow jone industrial average rally nasdaq edge be fractionally higher volume be tracking sharply lower board stock market today friday turnover be boost expiration option future contract lead stock facebook fb rise time high fast trade ibd stock clear buy point first stage flat base facebook reset base count october breach low prior base wagework wage be still more pare gain earlier stock clear buy point flat base also be view giant cup handle pattern same buy point last month provider health other employee benefit report jump earning gain sale be best several quarters downside gilead science gild come slightly session low be still share slump monday low news express script esrx drop coverage hepatitis drug favor new treatment abbvie abbv share abbvie be reverse early gain other biotechs celgene celg biogen idec biib be session lows still
1161,ABBV,biotechs monday sector leader screen have rough go early session most re-cover well session lows overall ibd biotech group hold relatively well consider fall nearly early end loss soundest biotech sector leader point be biogen idec biib
1162,ABBV,stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open
1163,ABBV,dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain
1164,ABBV,volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading
1165,ABBV,start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action
1166,ABBV,drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss
1167,ABBV,leader leane generally higher gain be limit
1168,ABBV,airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october
1169,ABBV,drugmaker post list worst decline early trade
1170,ABBV,gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction
1171,ABBV,celgene biogen also ibd list drop amgen amgn slip lower
1172,ABBV,economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale stock get mixed start quickly turn positive shorten holiday week drugmaker show particular weakness monday open dow jone industrial average lead nasdaq backed early loss gain struggle hold fractional gain volume be sharply lower nasdaq nyse contrast friday heavy option expiration trading start last week stock market today feel little pressure overseas market oil price reversed early gain oil sector stock put damper early market action drugmaker be be hit hard market merck mrk post heaviest loss dow gilead science gild biogen idec biib regeneron pharmaceutical regn celgene celg hold low ground nasdaq stock energy issue hold worst loss leader leane generally higher gain be limit airline buck head list spirit airline save alaska air group alk ahead more spirit be recover harsh sell week end dec alaska have pull back test week support breaking double bottom base october drugmaker post list worst decline early trade gilead topple prescription benefit manager express script esrx announce support drug combination market abbvie abbv gilead sovaldi prefer treatment patient hepatitis express script rise abbvie share gain fraction celgene biogen also ibd list drop amgen amgn slip lower economic news exist home sale slip november annualize rate accord national association realtor be pace slight downward revision original estimate economist have forecast more moderate slowdown sale
1173,ABBV,decade charlotte stewart be carry virus be houseguest refuse leave hepatitis
1174,ABBV,stewart be first diagnosed hcv believe contract much year earlier receive blood transfusion injection blood related product
1175,ABBV,time virus be detected liver be already show scarring know cirrhosis appear more advanced case disease
1176,ABBV,fortunately didn get much do do treatment stewart now tell ibd do round treatment sixth be harvoni
1177,ABBV,harvoni be new pill just launch month gilead science gild stewart get early participate clinical trial harvoni be combination novel drug ledipasvir sofosbuvir nearly year have be sell alone brand name sovaldi
1178,ABBV,high hope
1179,ABBV,sovaldi launch smash previous new drug launch come december have rac nearly sale gilead third quarter report be due oct harvoni be new improve sovaldi analyst expect treat even more patient
1180,ABBV,stewart previous treatment experience show just gilead be roll money right now
1181,ABBV,first treatment be variation combination interferon ribavirin be standard time credit treatment slow liver damage didn get rid hcv do make feel sick
1182,ABBV,fact third treatment round involved daily injection interferon drive blood cell count so low nearly land hospital
1183,ABBV,be very difficult go treatment say always develop anemia fever chill energy
1184,ABBV,contrast be harvoni trial take pill day week suffer side effect week viral load be undetectable still be more year later
1185,ABBV,physically have more energy just overall better health stewart say mentally emotionally have huge weight take
1186,ABBV,more patient trial respond way yet gilead stock fall day harvoni be approve keep fall next day
1187,ABBV,way be story gilead life sovaldi launch company score high ibd metric perfect composite rating price earning multiple be more big pharma boom biotech say drug analyst just hint bad news seem trigger sell
1188,ABBV,biggest cause concern have be price sovaldi price pill add week course come fire advocacy group insurer pharmacy benefit manager even member congress however nobody really do anything so long sovaldi be so clearly superior everything else market
1189,ABBV,gilead price harvoni basically parity sovaldi most patient still have take interferon ribavirin sovaldi drug be generic therefore cheaper gilead marked harvoni sovaldi cover cost absent drug
1190,ABBV,however harvoni official label allow week treatment be consider patient cirrhosis haven be treat gilead estimate patient be eligible
1191,ABBV,give fbr analyst andrew beren estimate average cost harvoni treatment be
1192,ABBV,however also point cirrhotic patient previous treatment have fail patient charlotte stewart be recommend take harvoni week also say patient sovaldi treatment have fail represent underrate opportunity
1193,ABBV,used hcv patient flow model calculate total patient need re treatment sovaldi viable patent life alone beren write oct note raise estimate harvoni sale
1194,ABBV,longer term threat gilead pricing power be competition next few month bring lot more clarity competition look
1195,ABBV,first real peer harvoni be expect be abbvie abbv regimen fda be due make approval decision dec
1196,ABBV,clinical trial regimen have be comparable harvoni safety effectiveness do involve different drug make easier patient mess
1197,ABBV,discount price
1198,ABBV,abbvie management have be tight lip price drug leave wall street speculate much be willing undercut harvoni
1199,ABBV,isi group analyst mark schoenebaum expect probably price comparably perhaps offer rebate certain customer estimate chance abbvie price significant discount
1200,ABBV,happen second weekend november be precise merck mrk report mid stage trial datum own hcv program potentially cut treatment time week
1201,ABBV,wouldn launch few more year drug industry tend think long time frame gilead acquire sofosbuvir buyout pharmasset nov be already think fact legacy hiv franchise such blockbuster viread truvada atripla start go patent
1202,ABBV,hcv franchise be fill space now gilead hasn exactly give hiv gilead report positive late stage trial result drug analyst have dub son viread similar compound fewer side effect
1203,ABBV,long term future hold gilead term success be expect roll analyst poll thomson reuter expect gilead report earning share prior year sale be see more double just less decade charlotte stewart be carry virus be houseguest refuse leave hepatitis stewart be first diagnosed hcv believe contract much year earlier receive blood transfusion injection blood related product time virus be detected liver be already show scarring know cirrhosis appear more advanced case disease fortunately didn get much do do treatment stewart now tell ibd do round treatment sixth be harvoni harvoni be new pill just launch month gilead science gild stewart get early participate clinical trial harvoni be combination novel drug ledipasvir sofosbuvir nearly year have be sell alone brand name sovaldi high hopessovaldi launch smash previous new drug launch come december have rac nearly sale gilead third quarter report be due oct harvoni be new improve sovaldi analyst expect treat even more patient stewart previous treatment experience show just gilead be roll money right now first treatment be variation combination interferon ribavirin be standard time credit treatment slow liver damage didn get rid hcv do make feel sick fact third treatment round involved daily injection interferon drive blood cell count so low nearly land hospital be very difficult go treatment say always develop anemia fever chill energy contrast be harvoni trial take pill day week suffer side effect week viral load be undetectable still be more year later physically have more energy just overall better health stewart say mentally emotionally have huge weight take more patient trial respond way yet gilead stock fall day harvoni be approve keep fall next day way be story gilead life sovaldi launch company score high ibd metric perfect composite rating price earning multiple be more big pharma boom biotech say drug analyst just hint bad news seem trigger sell biggest cause concern have be price sovaldi price pill add week course come fire advocacy group insurer pharmacy benefit manager even member congress however nobody really do anything so long sovaldi be so clearly superior everything else market gilead price harvoni basically parity sovaldi most patient still have take interferon ribavirin sovaldi drug be generic therefore cheaper gilead marked harvoni sovaldi cover cost absent drug however harvoni official label allow week treatment be consider patient cirrhosis haven be treat gilead estimate patient be eligible give fbr analyst andrew beren estimate average cost harvoni treatment be however also point cirrhotic patient previous treatment have fail patient charlotte stewart be recommend take harvoni week also say patient sovaldi treatment have fail represent underrate opportunity used hcv patient flow model calculate total patient need re treatment sovaldi viable patent life alone beren write oct note raise estimate harvoni sale longer term threat gilead pricing power be competition next few month bring lot more clarity competition look first real peer harvoni be expect be abbvie abbv regimen fda be due make approval decision dec clinical trial regimen have be comparable harvoni safety effectiveness do involve different drug make easier patient mess discount price abbvie management have be tight lip price drug leave wall street speculate much be willing undercut harvoni isi group analyst mark schoenebaum expect probably price comparably perhaps offer rebate certain customer estimate chance abbvie price significant discount happen second weekend november be precise merck mrk report mid stage trial datum own hcv program potentially cut treatment time week wouldn launch few more year drug industry tend think long time frame gilead acquire sofosbuvir buyout pharmasset nov be already think fact legacy hiv franchise such blockbuster viread truvada atripla start go patent hcv franchise be fill space now gilead hasn exactly give hiv gilead report positive late stage trial result drug analyst have dub son viread similar compound fewer side effect long term future hold gilead term success be expect roll analyst poll thomson reuter expect gilead report earning share prior year sale be see more double just less
1204,ABBV,big pharma abbvie beat analyst estimate raise guidance friday send stock time high abbvie abbv earning rise year earlier quarter cent share cent analyst consensus accord thomson reuter sale increase just beating estimate nearly
1205,ABBV,big biotech celgene celg announce monday present datum crohn disease drug ged conference tuesday post abstract top line result high side expectation celgene stock be morning trading stock market today drug be potential blockbuster phase trial compare different dose
1206,ABBV,celgene rolled more upbeat datum new crohn disease drug send biotech giant share higher tuesday monday celgene celg release abstract phase trial ged also call mongersen show good result patient week take drug share rise monday news tuesday present
1207,ABBV,specialty drugmaker allergan agn report solid result raise guidance monday hostile suitor valeant pharmaceutical international vrx say raise bid company again allergan earning rise year earlier quarter share exclude time item result be high end guidance
1208,ABBV,specialty drugmaker shire face future stand alone company thursday abbvie director late wednesday vote plan acquisition
1209,ABBV,investor analyst seem optimistic shire shpg stock be early trading stock market today
1210,ABBV,leerink analyst jason gerberry write research note thursday shire be unlikely attract buyer point pfizer pfe allergan agn have be rumore be interested firm same potential change tax inversion rule kill abbvie abbv interest likely do same say
1211,ABBV,additional cash likely break fee view shpg more likely buyer market expect ceo flem ornskov resume orphan asset roll gerberry write shire look buy drug treat rare medical condition
1212,ABBV,add upcoming event boost stock price include potential approval next year drug lifitegrast dry eye disease potential blockbuster indication
1213,ABBV,gerberry cut price target shire stock give stock be trading wednesday plunge see buy opportunity
1214,ABBV,bank america graham parry echo point upgrade stock buy wednesday base price drop thursday note re emphasize buy opportunity give attractive entry price fundamental compelling stand alone investment case
1215,ABBV,shire be already high rate stock abbvie deal jacked ibd relative strength rating be likely abbvie have raise offer time finally clinch deal summer even wednesday hit stock boast highest possible ibd composite rating
1216,ABBV,follow amy reeve twitter ibd_areeve specialty drugmaker shire face future stand alone company thursday abbvie director late wednesday vote plan acquisition investor analyst seem optimistic shire shpg stock be early trading stock market today leerink analyst jason gerberry write research note thursday shire be unlikely attract buyer point pfizer pfe allergan agn have be rumore be interested firm same potential change tax inversion rule kill abbvie abbv interest likely do same say additional cash likely break fee view shpg more likely buyer market expect ceo flem ornskov resume orphan asset roll gerberry write shire look buy drug treat rare medical condition add upcoming event boost stock price include potential approval next year drug lifitegrast dry eye disease potential blockbuster indication gerberry cut price target shire stock give stock be trading wednesday plunge see buy opportunity bank america graham parry echo point upgrade stock buy wednesday base price drop thursday note re emphasize buy opportunity give attractive entry price fundamental compelling stand alone investment case shire be already high rate stock abbvie deal jacked ibd relative strength rating be likely abbvie have raise offer time finally clinch deal summer even wednesday hit stock boast highest possible ibd composite rating follow amy reeve twitter ibd_areeve
1217,ABBV,ibd medical biom biotech group be big gainer group be show sign let
1218,ABBV,head thursday be rank group ibd database base month price performance
1219,ABBV,thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock
1220,ABBV,look group be ready roll early february lose straight session find support day move average resume uptrend
1221,ABBV,pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month
1222,ABBV,stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline
1223,ABBV,isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note
1224,ABBV,isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer
1225,ABBV,january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform
1226,ABBV,last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease
1227,ABBV,isis be eighth week consolidation show buy point point thursday be only week high
1228,ABBV,elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone
1229,ABBV,infectious disease newlink be work merck mrk ebola vaccine candidate
1230,ABBV,newlink recently clear base buy point close time high
1231,ABBV,meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn ibd medical biom biotech group be big gainer group be show sign let head thursday be rank group ibd database base month price performance thursday be top perform group abbvie abbv announce plan buy pharmacyclic pcyc cash stock look group be ready roll early february lose straight session find support day move average resume uptrend pharmacyclic be several biotechs have show big sale growth recent quarters blood cancer drug imbruvica be blockbuster food drug administration first approve imbruvica november treat mantle cell lymphoma drug have be approve other indication recent month stock biotech group recently have composite rating higher good bet group see more activity come month big player scoop smaller one compelling pipeline isis pharmaceutical isis isn profitable yet straight quarters accelerate sale growth solid mutual fund sponsorship market capitalization be worth note isis pipeline consist drug treat wide variety disease emphasis cardiovascular metabolic severe rare disease include neurological disorder cancer january company inked potentially lucrative licensing deal johnson johnson jnj janssen biotech unit agree pay front milestone payment develop drug autoimmune disorder tract used isis rna target platform last month isis receive milestone payment biogen idec biib isis be multiyear collaboration biogen advance treatment neurological disease isis be eighth week consolidation show buy point point thursday be only week high elsewhere group small cap newlink genetic nlnk have be busy partnership front newlink partner roche rhhby subsidiary genentech early stage cancer program newlink receive upfront payment genentech more potential milestone infectious disease newlink be work merck mrk ebola vaccine candidate newlink recently clear base buy point close time high meanwhile few large cap name group be back week move average consolidate gain include amgen amgn gilead science gild alexion alxn
1232,ABBV,medical giant johnson johnson jnj beat analyst profit estimate tuesday miss topline offer weak guidance send stock more morning trading say earning exclude time item rise year earlier quarter share beating analyst consensus penny accord thomson reuter
1233,ABBV,cvs health cvs monday say select gilead science gild sovaldi harvoni exclusive treatment hepatitis patient use benefit plan latest development become price war hepatitis drugmaker decision take hold wednesday come express script esrx move last month dump gilead drug prefer formulary list genotype hepatitis patient favor abbvie abbv rival drug viekira pak abbvie agree discount drug get list concern hep drug abbvie gilead be too expensive many low income patient harvoni cost week treatment compare viekira pak sovaldi cost week treatment goal be create lowest net cost solution entire population patient genotype hepatitis cvs say accord bloomberg be unclear gilead cvs agree kind discount express script announce decision add abbvie drug prefer list cite concern lack sufficient price competition hepatitis drug space company client have also warn cost specialty drug trend continue increase double digit percentage payer be force implement even more narrow management tool thus limit number patient afford receive drug therapy paula jakub ceo american foreign service protective association say last month only make sense manufacturer work payer pricing decision gilead share tumble dec day express script announcement be stock market today abbvie share fall day line first time october cvs say sovaldi harvoni be exclusive treatment list standard commercial drug well medicaid medicare part health exchange formulary wall street journal report patient get abbvie viekira pak only obtain approval medical exception advance rbc capital market react favorably cvs decision analyst note view positive remove term uncertainty many investor fear cvs also strike deal abbv further put more pressure gild rbc say
1234,ABBV,gilead science gild picked provider hepatitis drug friday ongoing battle market share disease giant health insurer aetna announce harvoni sovaldi now be prefer therapy aetna commercial customer company negotiate unspecified discount drug price officially sovaldi be
1235,ABBV,share big pharma abbvie abbv drop more friday morning company issue ep guidance get downgrade bank america abbvie say expect full year earning midpoint just average estimate analyst poll thomson reuter company say further refine guidance
1236,ABBV,regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm
1237,ABBV,jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak
1238,ABBV,ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market
1239,ABBV,pre emptive drug price war
1240,ABBV,everyone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline
1241,ABBV,be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter
1242,ABBV,paz comment seem allude widespread perception street pcsk be basically similar
1243,ABBV,regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just
1244,ABBV,schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not
1245,ABBV,regeneron eylea sale bright
1246,ABBV,presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus
1247,ABBV,also guide expense item tend do lieu earning be heavily affected option expense
1248,ABBV,range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation
1249,ABBV,regeneron stock rise nearly intraday reversed overall market close day move average
1250,ABBV,separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation
1251,ABBV,expect isrg share move higher morning continue believe worst be isrg henry write note market open
1252,ABBV,be right first part intuitive surgical rise intraday stock retreat afternoon close regeneron pharmaceutical report solid sale big cap biotech stock reversed lower tuesday potentially huge new cholesterol fighter be crosshair lead pharmacy benefit manager pbm jpmorgan healthcare conference san francisco express script esrx ceo george paz chat session company recent success drive discount pricey new hepatitis drug exclude gilead science gild sovaldi harvoni national prefer formulary favor abbvie abbv viekira pak pbm drug store giant cvs health cvs have opted sovaldi harvoni viekira pak ask sort drug be next list sort action paz say big course be cholesterol lower drug be come market pre emptive drug price wareveryone take be refer pcsk inhibitor new class ldl lower drug first be expect launch third quarter year regeneron regn praluent alirocumab develop partnership sanofi sny amgen amgn evolocumab be expect bring multibillion dollar annual sale eventually pfizer pfe also have farther pipeline be powerful drug re also very expensive paz say be several chain re talk drugmaker see show promise re talk market share position pricing more be too more need understand competitive nature re enter paz comment seem allude widespread perception street pcsk be basically similar regeneron ceo len schleifer dispute session own presentation same conference later tuesday point praluent likely be approve different dose evolocumab be set be available just schleifer be diplomatic express say have exact same goal downplay impact market share end day not sure turn much differently be exclusive formulary negotiation not regeneron eylea sale brightat presentation schleifer give preliminary sale figure regeneron lead product eye drug eylea be high side firm prior guidance factset consensus also guide expense item tend do lieu earning be heavily affected option expense range be set sg capital spending tax rate figure be gaap analyst estimate available ibd used gaap so wasn clear compare expectation regeneron stock rise nearly intraday reversed overall market close day move average separately conference robotic surgery system maker former star stock intuitive surgical isrg release preliminary sale year earlier more consensus firm also see procedure growth rbc capital market analyst brandon henry write be line expectation expect isrg share move higher morning continue believe worst be isrg henry write note market open be right first part intuitive surgical rise intraday stock retreat afternoon close
1253,ABBV,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
1254,ABBV,google be expect show robust growth core business post earning late wednesday analyst say heavy spending slam google margin analyst expect google googl ep ex item rise vs year earlier quarter accord thomson reuter figure reflect google stock split
1255,ABBV,big cap biotech celgene make name cancer fighter now branch disease immune system biggest test new strategy come weekend unite european week vienna run saturday oct celgene celg be set present phase datum ged treatment crohn disease inflammatory disease gi tract celgene license drug april privately hold nogra pharma upfront payment regulatory development milestone payment sale milestone payment drug launch price raise eyebrow wall street few have hear nogra pharma be most celgene have ever paid upfront licensing deal only information have be publicly release be phase trial have only subject be not placebo controlled celgene however say already know phase datum be worth price ged be potentially therapy demonstrated striking clinical activity phase trial crohn disease scott celgene global head inflammation immunology say press release time date ged release near wall street curiosity optimism have be build accord rbc capital market analyst michael yee combine sale world lead immunology drug abbvie abbv humira johnson johnson jnj remicade come treatment crohn disease cause disease be still mysterious treatment be more management cure accord yee third patient don respond drug do relapse be frequent so potentially huge opportunity celgene drug work still drug have take get much attention recently aug deutsche bank analyst robyn karnauskas assert ged be not modeled wall street consensus number therefore bring huge potential upside then bandwagon have get more crowd nomura security analyst ian somaiya report interview investigator participate clinical trial study be double blind so didn know patient get ged get placebo investigator report patient go clinical remission response time be less half usual week humira take somaiya also observed safety problem strong efficacy expect believe full phase datum reflect clinical site finding confirm strong efficacy see phase trial rapid benefit durable remission clean safety profile somaiya write research note estimate ged reach peak worldwide sale drive upside celg share anticipation drug have boost celgene stock be trading record high week market crash evidence ged be drive celgene rise come stock drop trading day wasn apparent reason short note put late isi group analyst mark schoenebaum report meeting have celgene management new crohn disease drug be unlikely be once daily product schoenebaum write be due theoretical risk fibrotic change long term exposure however company very interested study re treatment intermittent dose month month fibrosis harden thicken bowel wall be common symptom crohn disease idea long term exposure ged make seem have spook investor schoenebaum apparently blame stock drop next day put clarification emphasize word theoretical note note such problem have be report trial go well ged be expect launch be celgene second immunology drug first otezla hit market march psoriatic arthritis be also approve psoriasis larger market street estimate peak annual sale otezla pass
1256,ABBV,think sizzling new stock alibaba baba pole vault mind
1257,ABBV,etf investor win find chinese commerce behemoth most broad base product so most likely miss alibaba gain door bust ipo new york just month
1258,ABBV,broad mainstream index tend be conservative be slow include debut stock say kathleen principal renaissance capital ipo research investment management firm
1259,ABBV,ipo etfs aim fix sluggishness renaissance ipo ipo snap largest most liquid newly list company little day initial trading quarterly review
1260,ABBV,handful etfs now have stake alibaba top hold ipo well kraneshare csi china internet kweb weighting first trust ipo fpx allocate stock top hold
1261,ABBV,re disruptor sort say company ipo etfs be grow faster overall economy
1262,ABBV,investor seem shot outperform core broad base portfolio more seasoned stock year launch ipo have gather asset fpx seem gather dust first year existence zoetis zts debut begin potent string highflying ipos fpx asset have balloon roughly
1263,ABBV,etfs be ideal way capture return security aren include be underinclude core portfolio expert say
1264,ABBV,diversify less risky approach pick next hot ipo stock stock basis say ryan issakainen etf strategist first trust advisor
1265,ABBV,high profile name
1266,ABBV,more half recent ipos be red first year average return tend beat broader stock market add etfs allow get exposure average performance issakainen say
1267,ABBV,so far fpx have rise strength abbvie abbv facebook fb hca holding hca alibaba tesla tsla account portfolio combine return lag spdr spy year average annual year average beat average annual period
1268,ABBV,tesla terrific performer last few year be not even large cap issakainen note marsh mclennan mmc be
1269,ABBV,investor have take note fpx recent track record uptick demand financial adviser lead debut first trust international ipo fpxi november issakainen say renaissance launch own international ipo ipos october fpxi ipos have rake respectively then
1270,ABBV,more ipo etfs wing renaissance have regulatory approval product tracking ipo market asia pacific region europe consumer technology sector plan launch soon
1271,ABBV,stoyan bojinov analyst etf database advise investor study methodology different ipo etfs be aware nuance say note fpx keep holding year ipo hold year
1272,ABBV,accord renaissance company have come public so far last year amount ipos raise investor rise average ipos gain offer price so far year company have file ipo think sizzling new stock alibaba baba pole vault mind etf investor win find chinese commerce behemoth most broad base product so most likely miss alibaba gain door bust ipo new york just month broad mainstream index tend be conservative be slow include debut stock say kathleen principal renaissance capital ipo research investment management firm ipo etfs aim fix sluggishness renaissance ipo ipo snap largest most liquid newly list company little day initial trading quarterly review handful etfs now have stake alibaba top hold ipo well kraneshare csi china internet kweb weighting first trust ipo fpx allocate stock top hold re disruptor sort say company ipo etfs be grow faster overall economy investor seem shot outperform core broad base portfolio more seasoned stock year launch ipo have gather asset fpx seem gather dust first year existence zoetis zts debut begin potent string highflying ipos fpx asset have balloon roughly etfs be ideal way capture return security aren include be underinclude core portfolio expert say diversify less risky approach pick next hot ipo stock stock basis say ryan issakainen etf strategist first trust advisor high profile namesalthough more half recent ipos be red first year average return tend beat broader stock market add etfs allow get exposure average performance issakainen say so far fpx have rise strength abbvie abbv facebook fb hca holding hca alibaba tesla tsla account portfolio combine return lag spdr spy year average annual year average beat average annual period tesla terrific performer last few year be not even large cap issakainen note marsh mclennan mmc be investor have take note fpx recent track record uptick demand financial adviser lead debut first trust international ipo fpxi november issakainen say renaissance launch own international ipo ipos october fpxi ipos have rake respectively then more ipo etfs wing renaissance have regulatory approval product tracking ipo market asia pacific region europe consumer technology sector plan launch soon stoyan bojinov analyst etf database advise investor study methodology different ipo etfs be aware nuance say note fpx keep holding year ipo hold year accord renaissance company have come public so far last year amount ipos raise investor rise average ipos gain offer price so far year company have file ipo
1273,ABBV,fda approve gilead science gild hepatitis combo pill harvoni friday afternoon widely expect still crucial step drug expect be megablockbuster gilead also disclose drug price first time week course harvoni be combination ledipasvir sofosbuvir latter already be sell solo
1274,ABBV,investor turn bit skittish medical stock monday gilead science gild plunge express script esrx announce support hepatitis drug abbvie abbv rather gilead sovaldi ibd stock spotlight pharmaceutical actavis act valeant pharmaceutical vrx take comparatively mild hit ireland base actavis ease weak trade stock be look
1275,ABBV,stock hold small gain midday monday shake dalla fed manufacturing datum badly miss expectation
1276,ABBV,nasdaq add be dow inched fraction volume stock market today be tracking significantly higher friday exchange
1277,ABBV,chipotle grill cmg add nearly heavy trading be approach time high stock recently clear buy point shallow consolidation earning sale growth have accelerate last quarters huge same store sale growth burrito chain
1278,ABBV,identity theft protection firm lifelock lock rise heavy volume clear buy point flat base pattern stock be show sign institutional accumulation have highest possible composite rating
1279,ABBV,gilead science gild climb active trading continue bounce support day move average stock come heavy selling pressure last week news express script esrx shun gilead sovaldi drug lower cost alternative abbvie abbv stock hold small gain midday monday shake dalla fed manufacturing datum badly miss expectation nasdaq add be dow inched fraction volume stock market today be tracking significantly higher friday exchange chipotle grill cmg add nearly heavy trading be approach time high stock recently clear buy point shallow consolidation earning sale growth have accelerate last quarters huge same store sale growth burrito chain identity theft protection firm lifelock lock rise heavy volume clear buy point flat base pattern stock be show sign institutional accumulation have highest possible composite rating gilead science gild climb active trading continue bounce support day move average stock come heavy selling pressure last week news express script esrx shun gilead sovaldi drug lower cost alternative abbvie abbv
1280,ABBV,massive ep gain year mean company top next ibd stock today screen be set show ep growth leave dust year not be bountiful share gilead science gild have launch upward hepatitis drug sovaldi debut last year company full year ep be expect grow year year partly sovaldi harvoni combine sovaldi interferon treatment harvoni win fda approval october however drug have face headwind year effectiveness concern government patient advocacy group drug steep cost have persist many have argue drug be far too costly low income hepatitis patient more express script esrx cite concern cost hep drug say monday dump sovaldi harvoni prefer formulary list favor abbvie abbv viekira pak treatment genotype hepatitis gilead stock plunge day fall entire week gilead share have rise begin year have struggle find support day line october relative strength measure have fall well massive ep growth be expect analyst project growth shrivel low double single digit year follow stock close stock market today generic drug maker akorn akrx maintain top shelf ibd composite relative strength rating company be poise see ep gain year however price hike drug clobetasol topical rash treatment weigh result report november gilead analyst forecast akorn earning growth slow dramatically next few year share drop earning result continue consolidation stock begin october have remain facebook fb full year ep be expect grow share drive facebook still cool teen instagram photo sharing app social medium site have snap variety company year attempt anticipate shift online social landscape many forecast company gain big online mobile advertising part effort strengthen position online advertising facebook recently announce deal show nfl video clip verizon vz ad site facebook have warn cost rise step spending analyst currently expect facebook full year ep growth dip then reaccelerate year share hit time intraday high dec clear cup base day earlier share close cent friday bitauto bita auto information advertising base china have benefit be world largest auto market china expand car culture analyst expect company grow ep year november company beat view strength ad gain ever crucial mobile space best ibd fundamental stock have dip day line month cool rise company report result still share close friday more double value begin year analyst expect company ep growth decelerate remain solidly double digit finally alexion pharmaceutical alxn be forecast full year ep growth strength only market drug soliris treat rare blood disease company have year double digit quarterly sale ep growth belt share clear month consolidation october jump strong report stock have see more seller enter picture bring accumulation distribution rating analyst expect only ep growth stronger growth stock have rattle day line past week close friday just line potential sign support come
1281,ABBV,brutal correction several lead biotech member ibd find support day move average correction kick monday express script esrx nation largest health benefit manager announce exclusively use abbvie abbv hepatitis drug left gilead science gild recent growth have be fuel hepatitis
1282,ABBV,approval abbvie abbv hepatitis regimen viekira pak hogged most headline past week fda have approve whole passel medicine be blockbuster maker
1283,ABBV,here short list most significant
1284,ABBV,bristol myer bmy win approval opdivo melanoma monday be something surprise fda deadline be march opdivo be pd inhibitor hot new class cancer drug short circuit cancer cell ability fight immune system be widely expect eventually make billion dollar treat multiple cancer
1285,ABBV,sped opdivo approval dilute first mover advantage merck mrk keytruda be approve melanoma september opdivo be also review squamous cell lung cancer definitely boost sale current consensus forecast sale opdivo vs just keytruda
1286,ABBV,speaking merck dec buyout target cubist pharmaceutical cbst win approval zerbaxa antibiotic treat drug resistant intra abdominal urinary tract infection zerbaxa be key component cubist strategy survive patent expiration flagship drug cubicin approval become lot more urgent month cubist lose patent case bring generic competitor cubicin early cubist have couple more drug near fda filing zerbaxa be biggest rbc capital market analyst adnan butt estimate peak sale hit
1287,ABBV,also dec astrazeneca azn win approval lynparza treatment ovarian cancer company believe achieve peak annual sale follow notable trend cancer treatment be approve companion diagnostic test myriad genetic mygn call bracanalysis cdx design identify woman brca gene mutation indicate re most likely benefit drug
1288,ABBV,lynparza approval be far sure thing june fda advisory panel vote grant accelerate approval astrazeneca have request base phase datum firm still hasn finished phase study do bring more datum fda apparently find convince
1289,ABBV,tuesday nordisk nvo obesity drug saxenda win fda nod saxenda be brand name liraglutide sell lower dose blockbuster diabetes drug victoza
1290,ABBV,morgan stanley recently estimate annual sale hit bullish assessment give underwhelm launch ofvivus vvus qsymia late arena pharmaceutical arna belviq earlier year still too early make call orexigen orex contrave be approve september
1291,ABBV,market successful obesity treatment be potentially enormous also have very large overlap diabetes market nordisk be well establish approval abbvie abbv hepatitis regimen viekira pak hogged most headline past week fda have approve whole passel medicine be blockbuster maker here short list most significant bristol myer bmy win approval opdivo melanoma monday be something surprise fda deadline be march opdivo be pd inhibitor hot new class cancer drug short circuit cancer cell ability fight immune system be widely expect eventually make billion dollar treat multiple cancer sped opdivo approval dilute first mover advantage merck mrk keytruda be approve melanoma september opdivo be also review squamous cell lung cancer definitely boost sale current consensus forecast sale opdivo vs just keytruda speaking merck dec buyout target cubist pharmaceutical cbst win approval zerbaxa antibiotic treat drug resistant intra abdominal urinary tract infection zerbaxa be key component cubist strategy survive patent expiration flagship drug cubicin approval become lot more urgent month cubist lose patent case bring generic competitor cubicin early cubist have couple more drug near fda filing zerbaxa be biggest rbc capital market analyst adnan butt estimate peak sale hit also dec astrazeneca azn win approval lynparza treatment ovarian cancer company believe achieve peak annual sale follow notable trend cancer treatment be approve companion diagnostic test myriad genetic mygn call bracanalysis cdx design identify woman brca gene mutation indicate re most likely benefit drug lynparza approval be far sure thing june fda advisory panel vote grant accelerate approval astrazeneca have request base phase datum firm still hasn finished phase study do bring more datum fda apparently find convince tuesday nordisk nvo obesity drug saxenda win fda nod saxenda be brand name liraglutide sell lower dose blockbuster diabetes drug victoza morgan stanley recently estimate annual sale hit bullish assessment give underwhelm launch ofvivus vvus qsymia late arena pharmaceutical arna belviq earlier year still too early make call orexigen orex contrave be approve september market successful obesity treatment be potentially enormous also have very large overlap diabetes market nordisk be well establish
1292,ABBV,pharmacy benefit manager express script announce monday putt abbvie newly approve hepatitis treatment prefer formulary list knock rival treatment gilead science gilead gild stock plunge abbvie abbv fall late friday food drug administration approve abbvie viekira pak combination novel drug older
1293,ABBV,abbvie hepatitis regimen win fda approval friday become second entrant be already huge market interferon free hcv treatment viekira pak cost week line forecast undercut gilead science gild same treatment length abbvie abbv regimen consist drug ombitasvir paritaprevir first develop
1294,ABBV,biotech stock take bath holiday shorten week catalyst be announcement express script esrx nation largest benefit manager use abbvie abbv hepatitis drug exclusively hurt gilead science gild stock have soar sale own ground breaking hepatitis treatment gilead be hammer loss week so far
1295,ABBV,stock future hold early gain global market spark optimistically higher caution eurozone official bailout agreement greece be not likely today
1296,ABBV,dow future be point fair market value only slightly earlier high nasdaq future be also high still strong point future hung strong point gain small cap be less enthusiastic russell future ahead point
1297,ABBV,rundown stock market today begin overseas market monday give sense pressure place global stock eurozone greek financial crisis
1298,ABBV,lead index paris frankfurt have jump nearly midday tokyo hong kong gain more apiece shanghai exchange be close day holiday
1299,ABBV,greek prime minister alexis tsipra early monday proffer new plan resolve budget problem news report quote finance official say plan first time concede country tightly protected pension arrangement move least crack door hope agreement
1300,ABBV,eurozone official exit summit aim work greece related issue announce caution agreement
1301,ABBV,support extend weekend european central bank prop greece bank depositor confidence monday stall last week run saving withdrawal athen exchange bank stock lead index
1302,ABBV,week steady economic calendar begin exist home sale national association realtor et run university michigan final read june consumer sentiment friday durable good order final read gdp personal income spending way
1303,ABBV,stock thwart merger activity weigh early trade
1304,ABBV,natural gas process transport giant william co wmb spiked open tulsa okla base firm reject unsolicited bid energy transfer equity ete dalla base master limit partnership stock deal be value william be process re absorb master limit partnership william partner wpz say share bid undervalue company william co share have be correct september william partner share fall premarket trade
1305,ABBV,manage care provider cigna ci spiked reject inadequate bid anthem antm value share offer be premium cigna close price friday stock punch new high last week anthem share be fraction higher pre open trade monday
1306,ABBV,stock be generally flat higher ibd list biggest gain go vasco datum security vdsi nearly stock end friday buy point cup handle base
1307,ABBV,currency market dollar be euro yen commodity be mixed oil gold less stock future hold early gain global market spark optimistically higher caution eurozone official bailout agreement greece be not likely today dow future be point fair market value only slightly earlier high nasdaq future be also high still strong point future hung strong point gain small cap be less enthusiastic russell future ahead point rundown stock market today begin overseas market monday give sense pressure place global stock eurozone greek financial crisis lead index paris frankfurt have jump nearly midday tokyo hong kong gain more apiece shanghai exchange be close day holiday greek prime minister alexis tsipra early monday proffer new plan resolve budget problem news report quote finance official say plan first time concede country tightly protected pension arrangement move least crack door hope agreement eurozone official exit summit aim work greece related issue announce caution agreement support extend weekend european central bank prop greece bank depositor confidence monday stall last week run saving withdrawal athen exchange bank stock lead index week steady economic calendar begin exist home sale national association realtor et run university michigan final read june consumer sentiment friday durable good order final read gdp personal income spending way stock thwart merger activity weigh early trade natural gas process transport giant william co wmb spiked open tulsa okla base firm reject unsolicited bid energy transfer equity ete dalla base master limit partnership stock deal be value william be process re absorb master limit partnership william partner wpz say share bid undervalue company william co share have be correct september william partner share fall premarket trade manage care provider cigna ci spiked reject inadequate bid anthem antm value share offer be premium cigna close price friday stock punch new high last week anthem share be fraction higher pre open trade monday stock be generally flat higher ibd list biggest gain go vasco datum security vdsi nearly stock end friday buy point cup handle base currency market dollar be euro yen commodity be mixed oil gold less
1308,ABBV,stock be filled christmas cheer little more hour remain wednesday shorten session dow jone industrial average be trading time high
1309,ABBV,nasdaq lead charge dow jone industrial average gain stock market today not surprisingly volume be light
1310,ABBV,best worst industry group swap place day biotechs weak tuesday be best wednesday oil stock strongest prior day be weakest oil price drop again
1311,ABBV,fall oil price help airline become top perform group day new issue virgin america va be top stock group be poise clear first stage ipo base
1312,ABBV,gilead science gild pummeled earlier week express script esrx announcement exclusively use competitor abbvie abbv hepatitis drug rise more try retake day move average celgene celg rise nearly
1313,ABBV,time leader sanchez energy sn fall report first earning decline more year november stock have relative price strength rating meaning be be outperformed stock market
1314,ABBV,dow component financial giant visa bank america bac rise stock be filled christmas cheer little more hour remain wednesday shorten session dow jone industrial average be trading time high nasdaq lead charge dow jone industrial average gain stock market today not surprisingly volume be light best worst industry group swap place day biotechs weak tuesday be best wednesday oil stock strongest prior day be weakest oil price drop again fall oil price help airline become top perform group day new issue virgin america va be top stock group be poise clear first stage ipo base gilead science gild pummeled earlier week express script esrx announcement exclusively use competitor abbvie abbv hepatitis drug rise more try retake day move average celgene celg rise nearly time leader sanchez energy sn fall report first earning decline more year november stock have relative price strength rating meaning be be outperformed stock market dow component financial giant visa bank america bac rise
1315,ABBV,stock edge higher fourth straight session monday bring positive start holiday shorten trading week rise new close high just point away dec time high help strength chip stock nasdaq climb philadelphia semiconductor index rally dow jone industrial
1316,ABBV,early gain stock market today nearly evaporate midday monday general lack interest go christmas week
1317,ABBV,dow jone industrial average outperformed gain nasdaq add be mostly flat volume be significantly lighter shorten week trading swollen volume friday option expiration
1318,ABBV,dow be hold aloft part tech giant intel intc cisco system csco bank america bac be nearly
1319,ABBV,ibd stock be higher be lower ambarella amba be best performer worst performer be gilead science gild nearly
1320,ABBV,express script esrx largest manager prescription drug benefit say abbvie abbv drug be exclusive option treatment hepatitis instead gilead drug have be gilead growth engine recent quarters
1321,ABBV,abbvie abbv be less express script rise
1322,ABBV,oil resume plunge barrel go noon hour trading
1323,ABBV,energy issue be generally weak exploration production firm chesapeake energy chk crumble early gain stock market today nearly evaporate midday monday general lack interest go christmas week dow jone industrial average outperformed gain nasdaq add be mostly flat volume be significantly lighter shorten week trading swollen volume friday option expiration dow be hold aloft part tech giant intel intc cisco system csco bank america bac be nearly ibd stock be higher be lower ambarella amba be best performer worst performer be gilead science gild nearly express script esrx largest manager prescription drug benefit say abbvie abbv drug be exclusive option treatment hepatitis instead gilead drug have be gilead growth engine recent quarters abbvie abbv be less express script rise oil resume plunge barrel go noon hour trading energy issue be generally weak exploration production firm chesapeake energy chk crumble
1324,ABBV,big pharma bristol myer squibb bmy say monday drop effort get drug treatment hepatitis approve continue pursue other aspect hep strategy bristol myer stock be morning trading stock market today bristol press release cite rapidly evolve hepatitis treatment
1325,ABBV,abbvie abbv late wednesday say board director recommendation shareholder reject plan buy shire pharmaceutical board cite new treasury rule issue make tax inversion deal less attractive abbvie say statement breadth scope change include unexpected nature exercise administrative authority
1326,ABBV,stock future cut sharply lower ahead wednesday open global market react second day currency policy decision make china
1327,ABBV,dow future bob loss point fair market value nasdaq future hung point red future be point
1328,ABBV,stock market today once again open eye china currency slip nearly second straight day central bank hold new policy let yuan adjust accord market force
1329,ABBV,day contraction raise question much adjustment be store impact currency shift be china domestic demand import good suddenly become more expensive currency shift also cloud view possible federal reserve rate hike
1330,ABBV,global market show dread uncertainty europe lead index hard midday lead decline dax frankfurt cac paris china hong kong hang seng drop shanghai composite shed tokyo nikkei fall
1331,ABBV,fear spread premarket session loss be moderate approach open bell still apple aapl be more diving tuesday alcoa aa be more caterpillar cat exxon mobil xom general electric ge trim loss less prior hour
1332,ABBV,backdrop earning report continue roll
1333,ABBV,watch maker fossil fosl tank report weak revenue guidance internet retailer wayfair surge trample analyst earning revenue expectation
1334,ABBV,china alibaba baba swoon ahead open bell earning narrowly beat revenue gain stop short analyst consensus view
1335,ABBV,gross merchandise volume measure good sell alibaba online channel rise slowest rate year management also launch year share buyback program alibaba end tuesday november high september ipo price
1336,ABBV,cdk global cdk punch apparently news report company be explore possibility sale private equity group
1337,ABBV,bloomberg report provider software auto dealership manufacturer spun last year automatic datum process adp be work morgan stanley neither cdk morgan stanley comment
1338,ABBV,head capital management elliott management be cdk largest shareholder stock end tuesday test support day move average june high more october ipo
1339,ABBV,economic news new york federal reserve chief william dudley be schedule speak et labor department report job opening labor turnover survey energy information administration release weekly petroleum status report
1340,ABBV,dollar dip vs euro yen year yield drop basis point commodity be generally higher oil bounce not nearly enough lift west texas intermediate back barrel gold add ounce copper silver be narrowly higher stock future cut sharply lower ahead wednesday open global market react second day currency policy decision make china dow future bob loss point fair market value nasdaq future hung point red future be point stock market today once again open eye china currency slip nearly second straight day central bank hold new policy let yuan adjust accord market force day contraction raise question much adjustment be store impact currency shift be china domestic demand import good suddenly become more expensive currency shift also cloud view possible federal reserve rate hike global market show dread uncertainty europe lead index hard midday lead decline dax frankfurt cac paris china hong kong hang seng drop shanghai composite shed tokyo nikkei fall fear spread premarket session loss be moderate approach open bell still apple aapl be more diving tuesday alcoa aa be more caterpillar cat exxon mobil xom general electric ge trim loss less prior hour backdrop earning report continue roll watch maker fossil fosl tank report weak revenue guidance internet retailer wayfair surge trample analyst earning revenue expectation china alibaba baba swoon ahead open bell earning narrowly beat revenue gain stop short analyst consensus view gross merchandise volume measure good sell alibaba online channel rise slowest rate year management also launch year share buyback program alibaba end tuesday november high september ipo price cdk global cdk punch apparently news report company be explore possibility sale private equity group bloomberg report provider software auto dealership manufacturer spun last year automatic datum process adp be work morgan stanley neither cdk morgan stanley comment head capital management elliott management be cdk largest shareholder stock end tuesday test support day move average june high more october ipo economic news new york federal reserve chief william dudley be schedule speak et labor department report job opening labor turnover survey energy information administration release weekly petroleum status report dollar dip vs euro yen year yield drop basis point commodity be generally higher oil bounce not nearly enough lift west texas intermediate back barrel gold add ounce copper silver be narrowly higher
1341,ABBV,stock shave early loss remain hard wednesday weak economic datum hammer away investor confidence
1342,ABBV,show loss more dive early trade dow jone industrial average re-cover decline nasdaq narrow decline
1343,ABBV,volume rise sharply nasdaq nyse
1344,ABBV,stock market today open wave disappointing economic news begin september producer price datum top sharp manufacturing slowdown new york region
1345,ABBV,disappointing piece datum business inventory eke august commerce department report be half july increase estimate gain
1346,ABBV,oil future rise slightly barrel remain enough multus year lows continue pressure energy sector stock
1347,ABBV,drugmaker shire shpg open loss statement larger suitor abbvie abbv late tuesday say chicago base company be reconsider offer merge relocate headquarters overseas shire dublin base abbvie cite recent shift treasury rule affect benefit such strategy abbvie open
1348,ABBV,online travel issue expedia expe tripadvisor trip slump more worst loss nasdaq intel intc drop more drag dow
1349,ABBV,regional bank keycorp key narrow less gap loss start trade cleveland base lender report weaker forecast revenue earning
1350,ABBV,essentially ibd stock open lower wednesday salix pharmaceutical slxp expedia notch heaviest loss
1351,ABBV,salix be week move average appear head test support week move average fourth week steep pullback
1352,ABBV,expedia punch week line heavy trade tuesday be high
1353,ABBV,federal reserve release october beige book et busy hour report schedule include report american express axp ebay ebay netflix nflx kinder morgan complex company stock shave early loss remain hard wednesday weak economic datum hammer away investor confidence show loss more dive early trade dow jone industrial average re-cover decline nasdaq narrow decline volume rise sharply nasdaq nyse stock market today open wave disappointing economic news begin september producer price datum top sharp manufacturing slowdown new york region disappointing piece datum business inventory eke august commerce department report be half july increase estimate gain oil future rise slightly barrel remain enough multus year lows continue pressure energy sector stock drugmaker shire shpg open loss statement larger suitor abbvie abbv late tuesday say chicago base company be reconsider offer merge relocate headquarters overseas shire dublin base abbvie cite recent shift treasury rule affect benefit such strategy abbvie open online travel issue expedia expe tripadvisor trip slump more worst loss nasdaq intel intc drop more drag dow regional bank keycorp key narrow less gap loss start trade cleveland base lender report weaker forecast revenue earning essentially ibd stock open lower wednesday salix pharmaceutical slxp expedia notch heaviest loss salix be week move average appear head test support week move average fourth week steep pullback expedia punch week line heavy trade tuesday be high federal reserve release october beige book et busy hour report schedule include report american express axp ebay ebay netflix nflx kinder morgan complex company
1354,ABBV,gilead science gild stock be rebound afternoon trading stock market today analyst lift forecast sale blockbuster hepatitis drug sovaldi fbr analyst andrew beren raise estimate examine august prescription datum health industry research firm symphony health solution record breaking launch follow approval last december sovaldi sale have slow summer have be generally interpreted doctor warehousing patient ahead launch gilead hep drug expect october well possible price competition abbvie abbv therapy expect launch december beren however say find less warehousing expect analysis first month projection remain month show sovaldi prescription tracking previous estimate suggest formation second warehouse ahead anticipate launch oral therapy be slower anticipate write research note tuesday report help arrest decline gilead stock fall monday news allow generic sovaldi poor country gilead stock open lower tuesday mid afternoon be gilead stock touch time high
1355,ABBV,part solid approach investing be become aware factor work stock gilead science gild have several thing go current earning growth be huge compare year earlier earning rise revenue rise street expect ep
1356,ABBV,big pharma merck affirm wednesday ll present much anticipate datum hepatitis program next month american association study liver disease liver meeting investor have meeting find actual datum bristol myer squibb bmy be more forthcoming result fail ignite stock merck mrk
1357,ABBV,share gilead science gild be news drugmaker be reportedly near licensing deal bring blockbuster hepatitis drug sovaldi develop country such india pakistan generic drugmaker be able manufacture best selling hepatitis therapy well experimental sovaldi hybrid accord bloomberg pricing be sore spot gilead much have be make drug pill price tag be probably cause chatter bellwether biotech today fbr capital market andrew beren tell ibd so much gilead value drug say beren person be really really scared anything cause volatility lot discounting go already say sovaldi likely have discount already apply retail value week course prison governmental health program gilead intend retail sovaldi less affluent country only same course report bloomberg investor be worry government be go say be go give away india re pay patient say beren make more foil re charge recent medium attention regard sovaldi be cause share dip say rbc capital market analyst michael yee note make pharmaceutical available lower income country discount be nothing new be something already do hiv pill be already expect say yee be worth look say fbr beren be abbvie abbv anticipate hepatitis treatment investor be keep eye drug pricing be go become very interesting market once abbvie launch drug say follow elaine low twitter ibd_elow
1358,ABBV,share specialty drugmaker shire plummet stock market today word get late tuesday big pharma abbvie be reconsider buyout company shire shpg confirm report wednesday morning statement say abbvie abbv board intend consider withdraw modify recommendation light
1359,ABBV,surge stock robust economic growth strengthen job market have lift business confidence result thirst deal year continue analyst say target merger acquisition totale comprise global deal total accord datum provide
1360,ABBV,biotech company enanta pharmaceutical have be year fiscal year enter now be surely most important life dec food drug administration be expect approve abbvie abbv viekirax hepatitis treatment combine enanta enta drug paritaprevir abbvie develop drug enanta partnership
1361,ABBV,celgene amgen be highly rate company ibd screen day bolt rs line relative strength line measure stock perform compare index rs line hit new high actual stock be bullish sign today screen feature drugmaker relative strength line be bolt higher
1362,ABBV,top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal
1363,ABBV,ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record
1364,ABBV,illumina outlook cautious
1365,ABBV,gene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say
1366,ABBV,monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average
1367,ABBV,biogen buy convergence
1368,ABBV,cambridge mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease
1369,ABBV,sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain
1370,ABBV,biogen rise high tuesday whisker time high set dec close
1371,ABBV,shire buy nps pharma
1372,ABBV,january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease
1373,ABBV,shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate
1374,ABBV,shire have partly re-cover stock fall monday stock close tuesday day line
1375,ABBV,actavis see exceptional sale
1376,ABBV,actavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter
1377,ABBV,actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close
1378,ABBV,celgene bullish revlimid
1379,ABBV,monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale
1380,ABBV,celgene expect overall sale climb
1381,ABBV,term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer
1382,ABBV,celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average
1383,ABBV,follow james detar twitter ibd_jdetar top rate medical stock such illumina ilmn be bullish jpmorgan healthcare conference san francisco week several talk earning sale prospect announce new takeover deal ibd screen day be big cap leader top rate stock generally price market capitalization least today screen include large drug other medical stock proven track record illumina outlook cautiousgene sequence equipment maker illumina monday say collaborate lockheed martin lmt develop next generation gene sequence gear envision advantage early national adoption country globe lower health care cost lockheed health life science vice president horace blackman say monday jpmorgan conference illumina report preliminary revenue beating estimate full year guidance be conservative ibd leaderboard stock just clear flat base last week hit intraday peak friday stock fall monday tuesday fall close day move average biogen buy mass base biogen idec biib develop treatment variety ailment include multiple sclerosis cancer autoimmune disease sunday biogen agree buy privately hold base drugmaker convergence pharmaceutical milestone be meet expand biogen presence pain management drug convergence be develop drug treat chronic nerve pain biogen rise high tuesday whisker time high set dec close shire buy nps pharmain january ireland base shire shpg buy biotech viropharma specialize rare disease drug shire begin buyout bid nps pharmaceutical npsp biopharma focuse rare disease shire share plunge more oct abbvie abbv withdraw buyout offer treasury department tighten rule limit tax inversion tax inversion be maneuver company buy company base country shift own headquarters country get lower tax rate shire have partly re-cover stock fall monday stock close tuesday day line actavis see exceptional salesactavis act irish drugmaker recently agree buy botox maker allergan agn top hostile bid valeant pharmaceutical vrx pairing create global top drugmaker combine annual revenue more deal be expect close second quarter actavis say monday jpmorgan conference expect ep top wall street estimate strong sale actavis consolidated late november monday rise time high touch intraday high tuesday pull back close celgene bullish revlimidon monday conference summit base drugmaker celgene celg give generally bullish forecast flagship cancer fight drug revlimid account estimate sale celgene expect overall sale climb term celgene guide sale view partly negative currency effect preliminary ep top wall street target sale revlimid climb drug gain approval treat more type cancer celgene stock form cup handle base january mid june buy point gap have rise tuesday stock rise hit new high rise monday celgene stock clear month consolidation too short be proper base be extend day day average follow james detar twitter ibd_jdetar
1384,ABBV,market confirm uptrend many ipo leader be extend buy point few include whitewave food wwav enanta pharmaceutical enta be still striking distance
1385,ABBV,whitewave have be trading buy point double bottom base initially clear late last month downward reversal nov send share much buy point close week move average find support line be entry
1386,ABBV,base company last week report earning rise cent share match view revenue increase top forecast profit guidance cent fall short consensus estimate cent cause nov slump
1387,ABBV,profit sale growth have hold double digit past quarters analyst expect streak continue ep gain jump revenue
1388,ABBV,maker almond milk other food beverage horizon organic international delight silk other brand have be grow acquisition buy dairy free dessert company so delicious september organic produce grower earthbound farm january
1389,ABBV,whitewave come public little year have more double price oct debut most recent base be second stage
1390,ABBV,enanta pharmaceutical also clear buy point second stage base oct brisk trade reversed next session close entry have remain level whitewave continue find support week line
1391,ABBV,stock make nasdaq debut march have rally offer price trigger week hold rule december be buy point prior run
1392,ABBV,watertown mass base biotech be schedule announce fiscal result nov open analyst expect loss cent share jump revenue
1393,ABBV,enanta developer inhibitor used combination therapy fight hepatitis virus have team drugmaker abbvie abbv novartis nvs market confirm uptrend many ipo leader be extend buy point few include whitewave food wwav enanta pharmaceutical enta be still striking distance whitewave have be trading buy point double bottom base initially clear late last month downward reversal nov send share much buy point close week move average find support line be entry base company last week report earning rise cent share match view revenue increase top forecast profit guidance cent fall short consensus estimate cent cause nov slump profit sale growth have hold double digit past quarters analyst expect streak continue ep gain jump revenue maker almond milk other food beverage horizon organic international delight silk other brand have be grow acquisition buy dairy free dessert company so delicious september organic produce grower earthbound farm january whitewave come public little year have more double price oct debut most recent base be second stage enanta pharmaceutical also clear buy point second stage base oct brisk trade reversed next session close entry have remain level whitewave continue find support week line stock make nasdaq debut march have rally offer price trigger week hold rule december be buy point prior run watertown mass base biotech be schedule announce fiscal result nov open analyst expect loss cent share jump revenue enanta developer inhibitor used combination therapy fight hepatitis virus have team drugmaker abbvie abbv novartis nvs
1394,ABBV,selling picked pace major average late afternoon trading tuesday dow jone industrial average fall give nasdaq lose nyse nasdaq volume be tracking lower monday level stock market today base astrazeneca azn lose government release new rule fight tax inversion company avoid taxation move headquarters overseas pfizer pfe be talk acquire astrazeneca ireland base shire shpg meanwhile lose be well session lows agree deal illinois base abbvie abbv earlier year china name bounce back recent weakness cheer better expect manufacturing datum china vipshop vip jump nearly try reclaim day move average day line have be resistance level stock drop heavy volume ibd polaris industry pii outperformed rise nearly surge week end july polaris have show positive technical action trading tightly week move average several week polaris be leaderboard name investor comrailroad operator kansa city southern ksu extend loss fall stock be still buy range hold buy point merger news salix pharmaceutical slxp jump report drugmaker be advanced talk be acquire allergan agn potential union have be rumore time allergan be try fend hostile bid valeant pharmaceutical vrx elsewhere cf industry cf clear base rise news news investor com business cf industry yara talk form fertilizer giant htmthat be be court norwegian firm yara international
1395,ABBV,stock remain lower early afternoon trading tuesday analyst warning new apple iphone hurt share company supplier nasdaq be dow jone industrial average be volume be tracking lower nyse higher nasdaq decline stock have small edge advancer nyse loser lead nasdaq solar energy automaker staffing dairy product company be poorest performer stock market today tesla tsla skid more sink deeper day day move average metal retail utility real estate investment trust industry group be best tuesday supplier apple aapl iphone be lower credit suisse warn company be cut back component order iphone model apple share gap loss average volume cirrus logic crus slide busy trading fall day move average skywork solution swks gap day move average shed heavy trading side ruth hospitality ruth better know ruth chris steak house clear buy point double bottom base active trading company beat earning expectation couple week ep jump restaurant industry group have be trend lower ibd group ranking
1396,ABBV,stock market fall again tuesday leave outlook less murky have be other day lately nasdaq slip selling picked final minute index close session lows ibd fall only be third straight drop lead stock have
1397,ABBV,stock future muscle higher ahead friday open aim build be play be strong week dow future be point fair market value rise nasdaq future be point future climb point
1398,ABBV,stock market today set nasdaq sit gain week be back day move average nasdaq open nearly day line index hold psychologically important day line support weigh heavy load distribution day be key factor current rally
1399,ABBV,economic calendar be relatively quiet kansa city federal reserve regional manufacturing survey be due et
1400,ABBV,st loui federal reserve president james bullard new york federal reserve president william dudley be schedule speak morning crude future continue struggle trading more flat week just barrel price see effect result weekly rig count baker hughe bhi
1401,ABBV,nike nke hoist dow gain announce late thursday year share buyback program top current buyback be complete end
1402,ABBV,management also increase quarterly dividend cent announce stock split effective dec market close ibd stock end thursday test support day move average cup base buy point
1403,ABBV,retail industry group have take serious beating past week continue make splashy move
1404,ABBV,abercrombie fitch anf spirale higher earning soar past consensus expectation revenue fall less forecast
1405,ABBV,ross store rost surge dublin calif base chain report solid third quarter result thursday close stock close thursday nov low aug high double dip consolidation
1406,ABBV,foot locker fl hop sale earning clear analyst expectation shoe retailer close ty nike finished thursday week september high
1407,ABBV,william sonoma wsm slip nearly beating sale earning expectation guide result estimate
1408,ABBV,intuit intu rally nearly open developer quickbook turbotax report thursday close fiscal profit cent share vs consensus projection share loss cent revenue growth trounce expectation management raise ep guidance estimate share end thursday buy point cup handle base
1409,ABBV,morning heaviest loss mentor graphic ment unspooled report late thursday revenue earning be shade shy consensus view kicker be earning management say come less half current consensus projection developer automate design software finished thursday session just cup base buy point stock future muscle higher ahead friday open aim build be play be strong week dow future be point fair market value rise nasdaq future be point future climb point stock market today set nasdaq sit gain week be back day move average nasdaq open nearly day line index hold psychologically important day line support weigh heavy load distribution day be key factor current rally economic calendar be relatively quiet kansa city federal reserve regional manufacturing survey be due et st loui federal reserve president james bullard new york federal reserve president william dudley be schedule speak morning crude future continue struggle trading more flat week just barrel price see effect result weekly rig count baker hughe bhi nike nke hoist dow gain announce late thursday year share buyback program top current buyback be complete end management also increase quarterly dividend cent announce stock split effective dec market close ibd stock end thursday test support day move average cup base buy point retail industry group have take serious beating past week continue make splashy move abercrombie fitch anf spirale higher earning soar past consensus expectation revenue fall less forecast ross store rost surge dublin calif base chain report solid third quarter result thursday close stock close thursday nov low aug high double dip consolidation foot locker fl hop sale earning clear analyst expectation shoe retailer close ty nike finished thursday week september high william sonoma wsm slip nearly beating sale earning expectation guide result estimate intuit intu rally nearly open developer quickbook turbotax report thursday close fiscal profit cent share vs consensus projection share loss cent revenue growth trounce expectation management raise ep guidance estimate share end thursday buy point cup handle base morning heaviest loss mentor graphic ment unspooled report late thursday revenue earning be shade shy consensus view kicker be earning management say come less half current consensus projection developer automate design software finished thursday session just cup base buy point
1410,ABBV,ireland have become hot spot global company locate corporate headquarters
1411,ABBV,reason be taxe re lower emerald isle
1412,ABBV,successful ipo be game maker king digital entertainment king headquarter ireland game studio stockholm barcelona berlin bucharest malmo london office san francisco malta company have more casual game include flagship smartphone tablet pc game candy crush saga
1413,ABBV,company go public march break deep base july drop buy point stock need build new base ep soar cent
1414,ABBV,ireland be popular health care company drug company be try merge irish company way lower tax bill
1415,ABBV,chicago base abbvie abbv be try buy dublin base shire shpg make drug treat rare disease shire have reject numerous offer too low headquarter dublin most work be do britain merged firm be domicile taxe be not low ireland lower
1416,ABBV,shire break base april be then
1417,ABBV,icon iclr irish company be set cup handle base stock be buy point
1418,ABBV,company do clinical research drug biotech medical supply industry customer provide majority revenue
1419,ABBV,company have year annualize growth rate have straight quarters earning growth better analyst be forecasting increase come quarter
1420,ABBV,ibd rank icon company composite rating stock medical research equipment service industry group be rank industry group
1421,ABBV,irish company jazz pharmaceutical jazz break base july have fall buy point cup handle base be build new handle
1422,ABBV,firm have year ep growth rate earning most recent quarter be analyst be forecasting increase next report ireland have become hot spot global company locate corporate headquarters reason be taxe re lower emerald isle successful ipo be game maker king digital entertainment king headquarter ireland game studio stockholm barcelona berlin bucharest malmo london office san francisco malta company have more casual game include flagship smartphone tablet pc game candy crush saga company go public march break deep base july drop buy point stock need build new base ep soar cent ireland be popular health care company drug company be try merge irish company way lower tax bill chicago base abbvie abbv be try buy dublin base shire shpg make drug treat rare disease shire have reject numerous offer too low headquarter dublin most work be do britain merged firm be domicile taxe be not low ireland lower shire break base april be then icon iclr irish company be set cup handle base stock be buy point company do clinical research drug biotech medical supply industry customer provide majority revenue company have year annualize growth rate have straight quarters earning growth better analyst be forecasting increase come quarter ibd rank icon company composite rating stock medical research equipment service industry group be rank industry group irish company jazz pharmaceutical jazz break base july have fall buy point cup handle base be build new handle firm have year ep growth rate earning most recent quarter be analyst be forecasting increase next report
1423,ABBV,dropout rate patient gilead science hepatitis treatment sovaldi be quadruple be see clinical trial datum show wednesday
1424,ABBV,cvs health cvs research institute researcher find real world use gilead gild blockbuster drug reflect discontinuation rate vs approximate rate trial
1425,ABBV,study also find patient new hepatitis treatment be less likely complete course treatment overall sovaldi use have plateau decline august
1426,ABBV,share fall be high
1427,ABBV,cvs datum add concern sovaldi sale be slow doctor patient be wait gilead next version hepatitis fighter hit market fall well treatment abbvie abbv year end
1428,ABBV,such warehousing patient be not high anticipate sovaldi prescription so far tracking estimate fbr analyst andrew beren say tuesday also lift sovaldi sale forecast
1429,ABBV,meantime gilead be try expand access drug develop country announce monday license sovaldi indian generic drug manufacturer
1430,ABBV,also wednesday gilead release result study explore simtuzumab combine gemcitabine benefit untreated advanced pancreatic cancer researcher find treatment do not do not significantly increase progression free survival compare placebo combination dropout rate patient gilead science hepatitis treatment sovaldi be quadruple be see clinical trial datum show wednesday cvs health cvs research institute researcher find real world use gilead gild blockbuster drug reflect discontinuation rate vs approximate rate trial study also find patient new hepatitis treatment be less likely complete course treatment overall sovaldi use have plateau decline august share fall be high cvs datum add concern sovaldi sale be slow doctor patient be wait gilead next version hepatitis fighter hit market fall well treatment abbvie abbv year end such warehousing patient be not high anticipate sovaldi prescription so far tracking estimate fbr analyst andrew beren say tuesday also lift sovaldi sale forecast meantime gilead be try expand access drug develop country announce monday license sovaldi indian generic drug manufacturer also wednesday gilead release result study explore simtuzumab combine gemcitabine benefit untreated advanced pancreatic cancer researcher find treatment do not do not significantly increase progression free survival compare placebo combination
1431,ABBV,big cap biotech ibd stock gilead science put important brick fortress competition wednesday report positive trial datum latest hiv drug stock rise news drug call tenofovir alafenamide taf have be nickname son viread wall street new improve version
1432,ABBV,just few year drug generate small slice revenue jazz pharmaceutical drug xyrem target small patient population narcolepsy sufferer person prone fall suddenly asleep middle day high price make sale effort worthwhile jazz pharmaceutical jazz keep raise price
1433,ABBV,specialty drug giant valeant pharmaceutical international vrx agree drop litigation hostile takeover target allergan exchange allergan allow originally schedule dec special shareholder meeting speed potential merger
1434,ABBV,meeting go ahead make merger likelier bmo capital market analyst david maris report visit allergan agn executive still sound confident stay independent
1435,ABBV,allergan mentioned not be surprised shareholder be elect participate special meeting actually vote favor allergan maris write research report tuesday base discussion several holder believe have independently confirm be holder participate meeting state intend vote valeant measure
1436,ABBV,allergan be fraction morning trading stock market today valeant stock be fraction
1437,ABBV,allergan shareholder william ackman persh square capital be collaborate valeant bid have be fight make meeting happen hope rally shareholder replace most allergan exist board have steadfastly resist valeant overture allergan part sue valeant ackman august say involvement amount abuse insider information
1438,ABBV,analyst maris say allergan executive also discuss persistent rumor allergan evade buyout make large acquisition own preferably take lower tax locale reportedly try fail british drugmaker shire shpg eventually go abbvie abbv rumor mill have lately focuse jazz pharmaceutical jazz salix pharmaceutical slxp latter be subject fresh round twitter chatter tuesday be mentioned cnbc david faber salix stock be morning trading tuesday jazz stock be fraction
1439,ABBV,maris write allergan executive didn discuss specific name potential buyout do say large tax arbitrage be likely not sustainable
1440,ABBV,think comment mean inversion deal be table not have read rather believe comment be meant tell investor strategic deal be drive less so opportunity lower tax maris say add company seem be rush get deal do dec meeting
1441,ABBV,related
1442,ABBV,allergan seek salix deal avoid valeant
1443,ABBV,follow amy reeve twitter ibd_areeve specialty drug giant valeant pharmaceutical international vrx agree drop litigation hostile takeover target allergan exchange allergan allow originally schedule dec special shareholder meeting speed potential merger meeting go ahead make merger likelier bmo capital market analyst david maris report visit allergan agn executive still sound confident stay independent allergan mentioned not be surprised shareholder be elect participate special meeting actually vote favor allergan maris write research report tuesday base discussion several holder believe have independently confirm be holder participate meeting state intend vote valeant measure allergan be fraction morning trading stock market today valeant stock be fraction allergan shareholder william ackman persh square capital be collaborate valeant bid have be fight make meeting happen hope rally shareholder replace most allergan exist board have steadfastly resist valeant overture allergan part sue valeant ackman august say involvement amount abuse insider information analyst maris say allergan executive also discuss persistent rumor allergan evade buyout make large acquisition own preferably take lower tax locale reportedly try fail british drugmaker shire shpg eventually go abbvie abbv rumor mill have lately focuse jazz pharmaceutical jazz salix pharmaceutical slxp latter be subject fresh round twitter chatter tuesday be mentioned cnbc david faber salix stock be morning trading tuesday jazz stock be fraction maris write allergan executive didn discuss specific name potential buyout do say large tax arbitrage be likely not sustainable think comment mean inversion deal be table not have read rather believe comment be meant tell investor strategic deal be drive less so opportunity lower tax maris say add company seem be rush get deal do dec meeting related allergan seek salix deal avoid valeantfollow amy reeve twitter ibd_areeve
1444,ABBV,treasury department new rule crack tax inversion company move headquarters overseas take advantage lower corporate tax rate have immediate impact investor trade business so engage
1445,ABBV,medtronic mdt share drop late morning trade stock market today minneapoli base medical device maker currently propose inversion deal irish health care product company covidien cov north chicago ill base abbvie abbv see stock fall propose acquisition ireland base firm shire be catch rule crosshair
1446,ABBV,late monday treasury secretary jack lew announce rule change effective immediately make more difficult business invert use cash generate overseas treasury make change wave inversion deal threaten reduce tax revenue significantly deal have prompt criticism be legal
1447,ABBV,critic have argue various tax exemption business use corporate tax rate federal level push average factor state taxe be highest industrialize world motivate company look deal overseas move comprehensive tax reform have stall capitol hill
1448,ABBV,other propose deal potentially affected treasury department action include burger king worldwide bkw have negotiate inversion deal canadian coffee donut chain tim horton thi company see share fall morning trading burger king tim horton chiquita brand international cqb stock drop morning trading later rise rule change affect chiquita propose merger ireland base fruit firm fyffes
1449,ABBV,treasury move prompt differ partisan reaction
1450,ABBV,senate finance committee chairman ron wyden ore say lew move reinforce urgency action grow wave inversion erode nation tax base
1451,ABBV,house way mean committee chairman dave camp mich say few campaign style speech stopgap measure treasury win do hasn work past even secretary lew admit only real solution be tax reform fear administration be only interested do bare minimum just enough say care
1452,ABBV,man urge congress take action neither call new rule be abolish treasury department new rule crack tax inversion company move headquarters overseas take advantage lower corporate tax rate have immediate impact investor trade business so engage medtronic mdt share drop late morning trade stock market today minneapoli base medical device maker currently propose inversion deal irish health care product company covidien cov north chicago ill base abbvie abbv see stock fall propose acquisition ireland base firm shire be catch rule crosshair late monday treasury secretary jack lew announce rule change effective immediately make more difficult business invert use cash generate overseas treasury make change wave inversion deal threaten reduce tax revenue significantly deal have prompt criticism be legal critic have argue various tax exemption business use corporate tax rate federal level push average factor state taxe be highest industrialize world motivate company look deal overseas move comprehensive tax reform have stall capitol hill other propose deal potentially affected treasury department action include burger king worldwide bkw have negotiate inversion deal canadian coffee donut chain tim horton thi company see share fall morning trading burger king tim horton chiquita brand international cqb stock drop morning trading later rise rule change affect chiquita propose merger ireland base fruit firm fyffes treasury move prompt differ partisan reaction senate finance committee chairman ron wyden ore say lew move reinforce urgency action grow wave inversion erode nation tax base house way mean committee chairman dave camp mich say few campaign style speech stopgap measure treasury win do hasn work past even secretary lew admit only real solution be tax reform fear administration be only interested do bare minimum just enough say care man urge congress take action neither call new rule be abolish
1453,ABBV,big cap biotech amgen amgn offer guidance set target resist pressure split business review meeting tuesday heel monday earning beat amgen action help drive stock more afternoon trading stock market today new high amgen guide revenue
1454,ABBV,european union medical advisory committee endorse approve key product major drugmaker friday expect be blockbuster
1455,ABBV,abbvie abbv get thumb oral hepatitis combo now have brand name committee medical product human use go french acronym chmp endorse viekirax exviera genotype hepatitis virus generic drug ribavirin chmp also endorse combo ribavirin genotype patient
1456,ABBV,viekirax be combination drug include enanta pharmaceutical enta protease inhibitor paritaprevir exviera be nonnucleoside polymerase inhibitor dasabuvir
1457,ABBV,abbvie say expect european commission make final decision first quarter next year start negotiating price country country
1458,ABBV,pricing environment be tough france announce thursday have negotiate lowest price europe gilead science gild sovaldi almost price week course much speculation have abound abbvie price combo expect fda approval next month
1459,ABBV,analyst expect abbvie take minority share market gilead dominate still amount several dollar year
1460,ABBV,abbvie be midday trading stock market today new high
1461,ABBV,chmp also backed celgene celg first immunology drug otezla treat psoriasis psoriatic arthritis news come day celgene present datum psoriatic arthritis patient be otezla year third show least improvement symptom accord standard arthritis score system
1462,ABBV,otezla be approve psoriatic arthritis march psoriasis september celgene have guide peak annual sale least analyst have be skeptical
1463,ABBV,celgene stock be midday trading friday
1464,ABBV,sanofi sny drug cerdelga be also endorse gaucher disease rare genetic disorder cause buildup fat organ sanofi already sell injectable cerezyme disease cerdelga bring oral option
1465,ABBV,leerink analyst seamus fernandez model slow liftoff drug expect annual sale
1466,ABBV,sanofi stock be more midday friday
1467,ABBV,follow amy reeve twitter ibd_areeve
1468,ABBV,related sanofi bullish pipeline forecast underwhelm european union medical advisory committee endorse approve key product major drugmaker friday expect be blockbuster abbvie abbv get thumb oral hepatitis combo now have brand name committee medical product human use go french acronym chmp endorse viekirax exviera genotype hepatitis virus generic drug ribavirin chmp also endorse combo ribavirin genotype patient viekirax be combination drug include enanta pharmaceutical enta protease inhibitor paritaprevir exviera be nonnucleoside polymerase inhibitor dasabuvir abbvie say expect european commission make final decision first quarter next year start negotiating price country country pricing environment be tough france announce thursday have negotiate lowest price europe gilead science gild sovaldi almost price week course much speculation have abound abbvie price combo expect fda approval next month analyst expect abbvie take minority share market gilead dominate still amount several dollar year abbvie be midday trading stock market today new high chmp also backed celgene celg first immunology drug otezla treat psoriasis psoriatic arthritis news come day celgene present datum psoriatic arthritis patient be otezla year third show least improvement symptom accord standard arthritis score system otezla be approve psoriatic arthritis march psoriasis september celgene have guide peak annual sale least analyst have be skeptical celgene stock be midday trading friday sanofi sny drug cerdelga be also endorse gaucher disease rare genetic disorder cause buildup fat organ sanofi already sell injectable cerezyme disease cerdelga bring oral option leerink analyst seamus fernandez model slow liftoff drug expect annual sale sanofi stock be more midday friday follow amy reeve twitter ibd_areeve related sanofi bullish pipeline forecast underwhelm street
1469,ABBV,stock slide fresh session lows late monday oil price continue weigh west texas intermediate close barrel
1470,ABBV,dow jone industrial average slump respectively nasdaq drop volume spiked higher major exchange stock market today
1471,ABBV,lead stock virgin america va stretched loss more airline stock be weak monday plunge oil price alaska air group alk delta air line dal southwest airline luv fall delta even boost margin outlook again
1472,ABBV,elsewhere unite rental uri tumble be cut sell buy evercore
1473,ABBV,upside gilead science gild rise reverse high cvs caremark cvs announce cover gilead solvaldi harvoni hepatitis drug several plan gilead tumble last month news express script esrx drop coverage hepatitis treatment favor abbvie abbv
1474,ABBV,fellow biotech akorn akrx be session high still nearly stock slide fresh session lows late monday oil price continue weigh west texas intermediate close barrel dow jone industrial average slump respectively nasdaq drop volume spiked higher major exchange stock market today lead stock virgin america va stretched loss more airline stock be weak monday plunge oil price alaska air group alk delta air line dal southwest airline luv fall delta even boost margin outlook again elsewhere unite rental uri tumble be cut sell buy evercore upside gilead science gild rise reverse high cvs caremark cvs announce cover gilead solvaldi harvoni hepatitis drug several plan gilead tumble last month news express script esrx drop coverage hepatitis treatment favor abbvie abbv fellow biotech akorn akrx be session high still nearly
1475,ABBV,december be usually quiet month medical tech news year bring few potentially stock move event worth keep eye digest thanksgiving turkey here be top chronological order dec biotech incyte incy be look get important expansion label sole market drug jakafi explain recent incyte profile new america incyte partner novartis nvs have be pull respectable income jakafi treatment rare bone marrow cancer call myelofibrosis fda be ponder add indication polycythemia vera milder more common condition uptake condition be expect be fairly slow expect help push incyte more consistently profitable territory next year day later hot medical device company edward lifescience ew hold annual investor day be expect give guidance first time company impressed street last month strong report guidance strong launch latest sapien artificial heart valve currently analyst be forecasting sale year estimate earning share be expect rise then sometime dec likely mean dec fda be due issue verdict abbvie abbv hepatitis combo viekirax exviera clinical trial datum be so good street probably be less surprised meteor hit manhattan fda reject drug have analyst pin needle be price be price significantly lower gilead science gild recently launch harvoni cost week treatment help abbvie gain market share certainly please pharmacy benefit manager express script esrx have be hope start price war drive suddenly high cost hepatitis treatment however most analyst be expect abbvie price only little bit lower also affected be enanta pharmaceutical enta license component viekirax abbvie speaking hepatitis sometime end year street be expect hear phase clinical trial datum achillion pharmaceutical achn drug belong coveted nucleoside inhibitor class gilead mega blockbuster sovaldi also component harvoni belong have otherwise show enough safety issue be few left development especially merck mrk acquire idenix pharmaceutical nuc speculation achillion be next target have drive stock price street have see little real datum safety effectiveness datum help analyst determine just much company be worth speculation exist abort takeover attempt earlier year be re up street seem have mostly give possibility pfizer pfe make bid astrazeneca azn month cool period mandate takeover rule expire wednesday astra ceo pascal soriot throw more cold water appear cnbc thursday say deal have fall apart even have be make propose restriction tax inversion deal however rbc capital market analyst glenn novarro be still hold hope union orthopedic firm stryker syk nephew snn stryker didn bid company news report leak be work get slap month cool period anyway expire nov believe syk snn deal provide more recon reconstructive surgery scale particularly international market expand syk presence trauma sport medicine bring cost synergy novarro write note friday
1476,ABBV,anglo irish drugmaker shire beat estimate raise guidance friday add weight assertion do fine own buyout deal abbvie fall apart
1477,ABBV,shire shpg stock rise
1478,ABBV,earning exclude time item rise year earlier quarter share cent analyst consensus accord thomson reuter revenue increase more street expect
1479,ABBV,be fifth straight quarter accelerate earning growth fourth straight quarter faster sale growth
1480,ABBV,shire raise full year guidance product sale growth low range previous guidance high teen also guide gaap earning growth high range earlier low mid guidance figure be bit higher consensus
1481,ABBV,leerink analyst jason gerberry write flash note friday sale cinryze hereditary angioedema drug shire acquire buy viropharma last year partly drive beat shire major drug beat expectation board add timing large order contribute beat time milestone payment appear boost guidance however say result also suggest longer term improvement
1482,ABBV,operate margin be strong shpg spend be low end be imply full year guidance view reflect ceo flem ornskov focus deliver margin expansion cost cut initiative announce write moderate high risk associate shpg term pipeline catalyst believe shpg ability drive operate leverage be critical story street already forecast operate margin expand basis point
1483,ABBV,friday stock gain continue recovery shire share dive oct abbvie abbv backed away buyout cite treasury department recent move tax inversion deal abbvie say propose rule destroy value deal takeover rule don allow renegotiation price
1484,ABBV,however shire always seem feel do fine own give hard initially resist abbvie overture fundamental be strong enough keep composite rating even share still peak
1485,ABBV,abbvie be now buy back more stock rise friday hit new high intraday gain week anglo irish drugmaker shire beat estimate raise guidance friday add weight assertion do fine own buyout deal abbvie fall apart shire shpg stock rise earning exclude time item rise year earlier quarter share cent analyst consensus accord thomson reuter revenue increase more street expect be fifth straight quarter accelerate earning growth fourth straight quarter faster sale growth shire raise full year guidance product sale growth low range previous guidance high teen also guide gaap earning growth high range earlier low mid guidance figure be bit higher consensus leerink analyst jason gerberry write flash note friday sale cinryze hereditary angioedema drug shire acquire buy viropharma last year partly drive beat shire major drug beat expectation board add timing large order contribute beat time milestone payment appear boost guidance however say result also suggest longer term improvement operate margin be strong shpg spend be low end be imply full year guidance view reflect ceo flem ornskov focus deliver margin expansion cost cut initiative announce write moderate high risk associate shpg term pipeline catalyst believe shpg ability drive operate leverage be critical story street already forecast operate margin expand basis point friday stock gain continue recovery shire share dive oct abbvie abbv backed away buyout cite treasury department recent move tax inversion deal abbvie say propose rule destroy value deal takeover rule don allow renegotiation price however shire always seem feel do fine own give hard initially resist abbvie overture fundamental be strong enough keep composite rating even share still peak abbvie be now buy back more stock rise friday hit new high intraday gain week
1486,ABBV,american company such abbvie abbv mylan myl edge closer merger firm base overseas obama administration be push end inversion practice company reincorporate abroad reduce taxe letter member house way mean committee treasury secretary jacob lew urge lawmaker immediately
1487,ABBV,stock be hold session high pace second straight gain recent rocky market action
1488,ABBV,blue chip dow jone industrial outperformed gain meanwhile broader nasdaq be respectively turnover be tracking higher major exchange stock market today trade be barely higher nyse
1489,ABBV,kandi technology kndi stretched gain chinese automaker announce kandi electric vehicle group joint venture shanghai maple guorun automobile sell electric vehicle first quarter kandi lose money past quarters sale growth accelerate straight period kandi be quickly build right side new base
1490,ABBV,perrigo prgo be session high still hefty trading drugmaker be say be seek buyer accord theflyonthewall com cite globe hebrew financial newspaper
1491,ABBV,shire shpg add fresh record high stock be now past buy point cup base clear last month stock have trigger ibd week rule handle fast mover late last week suitor abbvie abbv raise buyoutoffer irish drugmaker fourth time
1492,ABBV,leader volume be few michael kor kor extend loss slice day move average long term support level stock have be trading line april stock be hold session high pace second straight gain recent rocky market action blue chip dow jone industrial outperformed gain meanwhile broader nasdaq be respectively turnover be tracking higher major exchange stock market today trade be barely higher nyse kandi technology kndi stretched gain chinese automaker announce kandi electric vehicle group joint venture shanghai maple guorun automobile sell electric vehicle first quarter kandi lose money past quarters sale growth accelerate straight period kandi be quickly build right side new base perrigo prgo be session high still hefty trading drugmaker be say be seek buyer accord theflyonthewall com cite globe hebrew financial newspaper shire shpg add fresh record high stock be now past buy point cup base clear last month stock have trigger ibd week rule handle fast mover late last week suitor abbvie abbv raise buyoutoffer irish drugmaker fourth time leader volume be few michael kor kor extend loss slice day move average long term support level stock have be trading line april
1493,ABBV,country worldwide have cut corporate tax rate past decade germany lower top rate canada go ireland average top rate country go
1494,ABBV,unite state have buck trend stubbornly cling top rate slightly more federal level average state
1495,ABBV,tax foundation scour country find only top corporate tax burden higher unite arab emirate chad
1496,ABBV,adopt global norm
1497,ABBV,lower corporate tax rate global norm further politically feasible doubt benefit company investor move global mainstream corporate taxe even hold carrot political class more corporate tax revenue
1498,ABBV,high corporate tax rate make sense increasingly global economy high rate don raise revenue once do estimate receipt fiscal year even high rate encourage tax drive tactic strategy economy
1499,ABBV,ve see company move job operation country lower tax rate ve see american company stash nearly profit overseas avoid tax bite
1500,ABBV,ve see company such burger king worldwide bkw chiquita brand international cqb medtronic mdt abbvie abbv mylan myl announce corporate inversion merger acquisition transfer headquarters overseas just year first month more be likely follow
1501,ABBV,political class harrumph howl perfectly legal tax avoidance brand company unpatriotic
1502,ABBV,catcall divert attention politician already have hand fiscally sound economically sensible way keep company america lower country punish corporate tax rate
1503,ABBV,other country cut corporate rate weren merely kowtow corporate power politician understood lower taxe help keep company home bolster nation economy pay faster growth higher employment add tax revenue
1504,ABBV,apply laffer curve
1505,ABBV,unite state doesn necessarily have choose larger budget deficit fix onerous corporate tax system step rest world
1506,ABBV,economist arthur laffer famously put forward proposition tax rate be so high choke economic activity actually reduce revenue so lower rate raise tax receipt very well be case corporate taxe
1507,ABBV,american enterprise institute economist kevin hassett alex brill determine tax revenue maximize top corporate rate go late
1508,ABBV,reason decline increase international mobility capital other country cut corporate tax rate
1509,ABBV,other country have keep cut corporate tax rate so revenue maximize rate have probably come few percentage point then ll stick hassett brill see take
1510,ABBV,go revenue maximize rate add third corporate tax receipt lower taxe reduce incentive move abroad stash profit overseas
1511,ABBV,more important encourage american foreign company expand invest unite state raise overall economic growth corporate earning tax receipt
1512,ABBV,sound too good be true tax foundation william mcbride take look canada top rate corporate tax revenue averaged gdp
1513,ABBV,country reduce rate corporate tax revenue rise gdp comparison high corporate tax rate have yielded average revenue just gdp
1514,ABBV,cut corporate tax rate raise tax earning good news company shareholder
1515,ABBV,tax kick come greater incentive do business so see more company stay home more transplant overseas more new business more investment domestic foreign source more economic growth lead higher corporate revenue profit
1516,ABBV,tax gain be more direct profit firm now keep rather stock price gain depend several factor include much actual tax relief company get other country respond more tax cut back envelope calculation suggest market gain be substantial go today high rate even lower
1517,ABBV,corporate tax rate closer worldwide norm find easier change flaw corporate tax system be handful country tax worldwide revenue force american company pay high rate overseas earning most other country use territorial approach tax only profit earn country
1518,ABBV,england switch territorial system so british company make profit ireland pay country multinational pay ireland still owe taxe irish earning difference ireland low rate much higher rate
1519,ABBV,year now democrat republican have call cut corporate tax rate nothing be do sign paralysis grip nation capital
1520,ABBV,hubbub burger king propose move canada wasn encourage member congress administration seem more interested chastising corporate escapee lower tax penalty ve impose do business here
1521,ABBV,cox be director neil center global market freedom smu cox school business former chief economist dalla federal reserve
1522,ABBV,alm be writer residence center country worldwide have cut corporate tax rate past decade germany lower top rate canada go ireland average top rate country go unite state have buck trend stubbornly cling top rate slightly more federal level average state tax foundation scour country find only top corporate tax burden higher unite arab emirate chad adopt global normslowering corporate tax rate global norm further politically feasible doubt benefit company investor move global mainstream corporate taxe even hold carrot political class more corporate tax revenue high corporate tax rate make sense increasingly global economy high rate don raise revenue once do estimate receipt fiscal year even high rate encourage tax drive tactic strategy economy ve see company move job operation country lower tax rate ve see american company stash nearly profit overseas avoid tax bite ve see company such burger king worldwide bkw chiquita brand international cqb medtronic mdt abbvie abbv mylan myl announce corporate inversion merger acquisition transfer headquarters overseas just year first month more be likely follow political class harrumph howl perfectly legal tax avoidance brand company unpatriotic catcall divert attention politician already have hand fiscally sound economically sensible way keep company america lower country punish corporate tax rate other country cut corporate rate weren merely kowtow corporate power politician understood lower taxe help keep company home bolster nation economy pay faster growth higher employment add tax revenue apply laffer unite state doesn necessarily have choose larger budget deficit fix onerous corporate tax system step rest world economist arthur laffer famously put forward proposition tax rate be so high choke economic activity actually reduce revenue so lower rate raise tax receipt very well be case corporate taxe american enterprise institute economist kevin hassett alex brill determine tax revenue maximize top corporate rate go late reason decline increase international mobility capital other country cut corporate tax rate other country have keep cut corporate tax rate so revenue maximize rate have probably come few percentage point then ll stick hassett brill see take go revenue maximize rate add third corporate tax receipt lower taxe reduce incentive move abroad stash profit overseas more important encourage american foreign company expand invest unite state raise overall economic growth corporate earning tax receipt sound too good be true tax foundation william mcbride take look canada top rate corporate tax revenue averaged gdp country reduce rate corporate tax revenue rise gdp comparison high corporate tax rate have yielded average revenue just gdp cut corporate tax rate raise tax earning good news company shareholder tax kick come greater incentive do business so see more company stay home more transplant overseas more new business more investment domestic foreign source more economic growth lead higher corporate revenue profit tax gain be more direct profit firm now keep rather stock price gain depend several factor include much actual tax relief company get other country respond more tax cut back envelope calculation suggest market gain be substantial go today high rate even lower corporate tax rate closer worldwide norm find easier change flaw corporate tax system be handful country tax worldwide revenue force american company pay high rate overseas earning most other country use territorial approach tax only profit earn country england switch territorial system so british company make profit ireland pay country multinational pay ireland still owe taxe irish earning difference ireland low rate much higher rate year now democrat republican have call cut corporate tax rate nothing be do sign paralysis grip nation capital hubbub burger king propose move canada wasn encourage member congress administration seem more interested chastising corporate escapee lower tax penalty ve impose do business here cox be director neil center global market freedom smu cox school business former chief economist dalla federal reserve alm be writer residence center
1523,ABBV,biotech pharmacyclic pcyc get price target cut nomura monday investment bank maintain buy rating pharmacyclic stock say company competitive position remain strong
1524,ABBV,pharmacyclic stock be flat midday trading stock market today
1525,ABBV,nomura analyst ian somaiya write research note meeting management be raise forecast company expense due higher spending international launch blood cancer drug imbruvica clinical trial other product higher tax rate thus lower price target
1526,ABBV,somaiya however say survey competition find still potential upside imbruvica go im health im weekly prescription tracker launch gilead science gild rival zydelig be go slower imbruvica launch write citi analyst last month also be negative zydelig
1527,ABBV,somaiya add abbvie abbv succeed shortening development time potential rival just half year still give imbruvica time get establish note however abbvie new partnership infinity pharmaceutical infi put lead develop combination novel drug infinity duvelisib be expect be test together
1528,ABBV,follow amy reeve twitter ibd_areeve biotech pharmacyclic pcyc get price target cut nomura monday investment bank maintain buy rating pharmacyclic stock say company competitive position remain strong pharmacyclic stock be flat midday trading stock market today nomura analyst ian somaiya write research note meeting management be raise forecast company expense due higher spending international launch blood cancer drug imbruvica clinical trial other product higher tax rate thus lower price target somaiya however say survey competition find still potential upside imbruvica go im health im weekly prescription tracker launch gilead science gild rival zydelig be go slower imbruvica launch write citi analyst last month also be negative zydelig somaiya add abbvie abbv succeed shortening development time potential rival just half year still give imbruvica time get establish note however abbvie new partnership infinity pharmaceutical infi put lead develop combination novel drug infinity duvelisib be expect be test together follow amy reeve twitter ibd_areeve
1529,ABBV,bristol myer squibb bmy win approval oral hepatitis virus hcv drug daklinza european union wednesday company continue carve niche increasingly competitive hcv space
1530,ABBV,eu approve daklinza sofosbuvir also know gilead science gild sovaldi genotype disease
1531,ABBV,combo perform outstandingly clinical trial achieve cure rate group gilead elect not pursue combo instead combine sofosbuvir own drug ledipasvir be similar daklinza combo be expect be approve october
1532,ABBV,bristol myer have own dual regimen daklinza asunaprevir have already be approve japan be await approval nov however cure rate isn good sofosbuvir combo so company ultimate goal be approval triple therapy daklinza asunaprevir drug dub bms combo be late stage clinical testing
1533,ABBV,meanwhile fact consumer buy sovaldi daklinza separately potentially put pressure daklinza price price sovaldi be infamously high typical week treatment
1534,ABBV,bristol myer didn announce price wednesday release have say european price be set individual country level different country have different reimbursement scheme be separately negotiate
1535,ABBV,potential arrival pricing daklinza market also influence pricing decision abbvie abbv highly efficacious drug hcv therapy be expect be approve december
1536,ABBV,bristol myer stock be fraction morning trading stock market today perhaps influenced fact deutsche bank initiate coverage hold rating
1537,ABBV,gilead stock rebound dip tuesday be
1538,ABBV,follow amy reeve twitter ibd_areeve bristol myer squibb bmy win approval oral hepatitis virus hcv drug daklinza european union wednesday company continue carve niche increasingly competitive hcv space eu approve daklinza sofosbuvir also know gilead science gild sovaldi genotype disease combo perform outstandingly clinical trial achieve cure rate group gilead elect not pursue combo instead combine sofosbuvir own drug ledipasvir be similar daklinza combo be expect be approve october bristol myer have own dual regimen daklinza asunaprevir have already be approve japan be await approval nov however cure rate isn good sofosbuvir combo so company ultimate goal be approval triple therapy daklinza asunaprevir drug dub bms combo be late stage clinical testing meanwhile fact consumer buy sovaldi daklinza separately potentially put pressure daklinza price price sovaldi be infamously high typical week treatment bristol myer didn announce price wednesday release have say european price be set individual country level different country have different reimbursement scheme be separately negotiate potential arrival pricing daklinza market also influence pricing decision abbvie abbv highly efficacious drug hcv therapy be expect be approve december bristol myer stock be fraction morning trading stock market today perhaps influenced fact deutsche bank initiate coverage hold rating gilead stock rebound dip tuesday be follow amy reeve twitter ibd_areeve
1539,ABBV,stock future show strong gain ahead wednesday open global market rally word ukraine russia cease fire dow future be point fair market value lean higher nasdaq future be strong point also uptick future be ahead point small cap russell future be point climb stock market today be rattle awake stock future bolt higher world ukraine president petro poroshenko claim permanent cease fire have be agree russian president vladimir putin russia have deny agreement however say be not party conflict ukraine presidential office update initial statement declare agreement permanent cease fire regime have be reach stock moonshot smaller pharmaceutical play continue infinity pharmaceutical infi rocket ahead open cambridge mass base biotech announce partner abbvie abbv develop commercialize oral cancer treatment duvelisib abbvie share rise fraction leader broad swathe china base stock moved higher tracking wednesday gain asian market athm pop premarket action volatile stock reversed sharp dive tuesday back attempt last week baidu bidu rise ahead bell search engine heavy surge strong trade tuesday clear buy point vipshop holding vip also climb online clothing retailer retook day move average tuesday day cut line very heavy trade friday overseas russia market leap initial news possible cease fire agreement pare gain back asia market close sharply higher hong kong hang seng index lead gain europe major index be also significantly cac paris frankfurt dax show gain midday euro rise dollar buoy ukraine cease fire talk dollar be flat yen start bank japan day policy meeting commodity edge higher take back ground lose tuesday week economic calendar begin pick today july factory order expect commerce department et follow fed september beige book report challenger job cut adp national employment report be due thursday wrapping august payroll number labor department friday
1540,ABBV,stock put rebound tuesday continue drama greece debt ride nation be expect miss payment international monetary fund have midnight deadline less hour now
1541,ABBV,nasdaq composite climb nearly rise meanwhile dow jone industrial average edge
1542,ABBV,volume end lower board stock market today accord preliminary volume
1543,ABBV,lead stock noah holding noah bolt first gain session stock be still day line breach earlier month
1544,ABBV,athm jump nearly regain day move average stock be build right side new base latest correction be much less prior pattern
1545,ABBV,boot barn holding boot step more new high positive action analyst riley start coverage retailer buy recommendation place price target jeffery lift stock price target
1546,ABBV,taser international tasr rally retook day line volume run slightly normal level stock fall more buy point flat base monday trigger sell signal earlier tuesday company announce win order body camera fresno calif polouse department stock put rebound tuesday continue drama greece debt ride nation be expect miss payment international monetary fund have midnight deadline less hour now nasdaq composite climb nearly rise meanwhile dow jone industrial average edge volume end lower board stock market today accord preliminary volume lead stock noah holding noah bolt first gain session stock be still day line breach earlier month athm jump nearly regain day move average stock be build right side new base latest correction be much less prior pattern boot barn holding boot step more new high positive action analyst riley start coverage retailer buy recommendation place price target jeffery lift stock price target taser international tasr rally retook day line volume run slightly normal level stock fall more buy point flat base monday trigger sell signal earlier tuesday company announce win order body camera fresno calif polouse department
1547,ABBV,biotech pharmaceutical company be rise life save promise add hope stock also be healthy investment industry be friday general market weakness concern growth stock continue dominate week ibd list company base superior earning strong price performance leadership industry here
1548,ABBV,big pharma abbvie abbv raise earning guidance monday send company stock morning trading stock market meanwhile abbvie buyout target shire shpg detailed own bullish guidance explain investor be worth more abbvie offer last week abbvie add cent full year ep range
1549,ABBV,burger king bkw be apparently unfazed pressure wag face drugstore giant decide used foreign acquisition move headquarters low tax country fast food chain sunday confirm report be talk ontario canada base tim horton thi purchasing company burger king say move
1550,ABBV,development stage biotech infinity pharmaceutical infi land key deal develop blood cancer drug duvelisib partnership big pharma abbvie abbv send infinity stock month high stock market today abbvie infinity collaboration include upfront payment milestone payment duvelisib pass
1551,ABBV,daunting headline technology sector didn stop nasdaq turn solid performance monday nasdaq jump nearly fourth day rally attempt normally be strong enough gain qualify follow day nyse nasdaq volume be well friday level volume be unusually
1552,ABBV,persistence paid big pharma abbvie friday announce takeover shire fifth attempt same time shire report earning ahead schedule earning beat analyst estimate
1553,ABBV,abbvie abbv agree pay british pound share combine company shire shpg share more base abbvie thursday close price
1554,ABBV,abbvie expect close deal year say be immediately accretive earning accretion rise share
1555,ABBV,new firm be domicile
1556,ABBV,abbvie say move firm efficient tax structure cut tax rate now
1557,ABBV,conference call discuss merger analyst pressed abbvie ceo richard gonzalez detail include tax projection be instead takeover rule restrict say
1558,ABBV,gonzalez stress taxe weren only reason abbvie be so determine get shire cite shire strong portfolio neurological rare disease drug
1559,ABBV,abbvie fact plan create rare disease division
1560,ABBV,transaction have significant strategic financial rationale gonzalez say tax be clearly benefit not primary rationale
1561,ABBV,reason brushed concern government recent attack tax inversion deal include call retroactively forbid such move firm have announce such deal do remark see more discussion tax reform try stop company go abroad
1562,ABBV,call bmo capital market analyst alex arfaei say be surprised gonzalez assertion deal wasn tax drive not perception
1563,ABBV,just last month shire be still spurn abbvie bid shire ceo flem ornskov tell wall street journal think main strategic rationale here be tax inversion
1564,ABBV,ornskov wasn friday call gonzalez say shire boss stay deal close help integrate company wasn clear ornskov have permanent role
1565,ABBV,shire director join abbvie board
1566,ABBV,shire release financial result have be set july earning leap vs year earlier share beating analyst estimate cent sale rise top view
1567,ABBV,shire press release didn change recent guidance estimate sale
1568,ABBV,leerink analyst jason gerberry cut shire stock market perform say do not expect rival bid pfizer pfe allergan agn pfizer be rumore be interested astrazeneca azn reject tax inversion attempt allergan reportedly mulled shire escape hatch valeant pharmaceutical vrx hostile takeover bid
1569,ABBV,shire stock jump june company reveal abbvie takeover bid have rise then include friday rise abbvie rise friday persistence paid big pharma abbvie friday announce takeover shire fifth attempt same time shire report earning ahead schedule earning beat analyst estimate abbvie abbv agree pay british pound share combine company shire shpg share more base abbvie thursday close price abbvie expect close deal year say be immediately accretive earning accretion rise share new firm be domicile abbvie say move firm efficient tax structure cut tax rate now conference call discuss merger analyst pressed abbvie ceo richard gonzalez detail include tax projection be instead takeover rule restrict say gonzalez stress taxe weren only reason abbvie be so determine get shire cite shire strong portfolio neurological rare disease drug abbvie fact plan create rare disease division transaction have significant strategic financial rationale gonzalez say tax be clearly benefit not primary rationale reason brushed concern government recent attack tax inversion deal include call retroactively forbid such move firm have announce such deal do remark see more discussion tax reform try stop company go abroad call bmo capital market analyst alex arfaei say be surprised gonzalez assertion deal wasn tax drive not perception just last month shire be still spurn abbvie bid shire ceo flem ornskov tell wall street journal think main strategic rationale here be tax inversion ornskov wasn friday call gonzalez say shire boss stay deal close help integrate company wasn clear ornskov have permanent role shire director join abbvie board shire release financial result have be set july earning leap vs year earlier share beating analyst estimate cent sale rise top view shire press release didn change recent guidance estimate sale leerink analyst jason gerberry cut shire stock market perform say do not expect rival bid pfizer pfe allergan agn pfizer be rumore be interested astrazeneca azn reject tax inversion attempt allergan reportedly mulled shire escape hatch valeant pharmaceutical vrx hostile takeover bid shire stock jump june company reveal abbvie takeover bid have rise then include friday rise abbvie rise friday
1570,ABBV,wag reportedly remain domicile company political backlash american company used foreign acquisition lower taxe share company be more stock market today sky news report soon wednesday drugstore giant announce plan take rest swiss base alliance boot
1571,ABBV,big cap biotech gilead science gild rise stock market today hit new time high friday win dispute roche right blockbuster hepatitis drug separately be endorse cost benefit authority roche rhhby have claim right drug sovaldi last year due partnership
1572,ABBV,second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering
1573,ABBV,get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month
1574,ABBV,give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate
1575,ABBV,be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price
1576,ABBV,believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis
1577,ABBV,amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating
1578,ABBV,aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival
1579,ABBV,july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug
1580,ABBV,market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write
1581,ABBV,get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas
1582,ABBV,seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable
1583,ABBV,fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better
1584,ABBV,aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty
1585,ABBV,model aristada sale write july research note
1586,ABBV,aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter
1587,ABBV,stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon
1588,ABBV,connect amy reeve ibd_areeve facebook second half august be usually desert business news fda schedule be year round several important drug be approval decision month provide upside biotech stock have recently be suffering get most attention likely be repatha amgen amgn cholesterol drug expect be approve aug repatha be pcsk inhibitor similar praluent drug regeneron pharmaceutical regn sanofi sny be approve much fanfare last month give resemblance drug repatha be widely expect be approve july research note nomura analyst ian somaiya write amgen drug probably also get similar label doesn cover quite many patient have hope be sufficiently broad support peak sale estimate be especially interesting investor be pricing dynamic come drug appear market pharmacy benefit manager express script esrx have say hope start price war similar happened abbvie abbv launch rival hepatitis regimen gilead science gild harvoni late last year gilead have maintain dominant market share only rebate half drug list price believe rebate drive access sanofi regeneron amgen be directly compete formulary position somaiya write repatha net price month estimate imply discount praluent gross price believe competition result average discounting similar have be see hepatitis amgen stock hit new high report have shed larger biotech selloff retain excellent ibd composite rating aug fda be due decide label expansion adcetris sole market drug seattle genetic sgen adcetris market partner takeda be already approve patient hodgkin lymphoma ve relapse receive stem cell transplant chemotherapy treatment current filing follow study patient receive transplant hadn relapse find significant improvement progression free survival july research note rbc capital market analyst adnan butt write chance approval look good fda didn convene advisory committee approval date normally do have issue drug market opportunity post transplant hodgkin lymphoma set take adcetris year higher sale potentially butt write get new indication adcetris be key part seattle genetic strategy even drug launch year still hasn make company profitable adcetris be also be test cell lymphoma front line set kind lymphoma january company also announce collaboration bristol myer squibb bmy test bristol hot new cancer drug opdivo adcetris various kind lymphomas seattle genetic stock be july high retain good relative strength rating analyst expect turn profitable fda have aug deadline decide aristada schizophrenia drug alk create drug take aripiprazole brand name abilify be best seller otsuka bristol myer go patent year add own technology turn dose regimen daily pill monthly injection patient compliance be biggest problem face psychotic medicine generally less frequent dose better aristada win be alone long act psychotic market leerink analyst michael schmidt say do nearly well johnson johnson jnj invega sustenna also used technology be therefore provide royalty model aristada sale write july research note aristada be important component strategy return growth be lead stock last year sacrifice profit growth invest marketing new drug vivitrol most recent quarter revenue also flatlined analyst expect sale growth next year rise profitability be not see return accord thomson reuter stock hit high march go form cup handle base fail break slump sector last week be trading fraction wednesday afternoon connect amy reeve ibd_areeve facebook
1589,ABBV,wag miss third quarter earning forecast share pare loss tuesday drug store giant confirm first time be mull move overseas cut taxe drug retailer earn cent share exclude certain item analyst consensus estimate cent vs year
1590,ABBV,big cap stock continue trade time high early afternoon trading friday dovish federal reserve continue fuel rally be carry sixth day
1591,ABBV,volume be run higher due option expiration
1592,ABBV,dow jone industrial average rise gain nasdaq rise fractionally dow be trading just time high set earlier day
1593,ABBV,little economic news energize trader earning news takeover talk take spotlight oracle orcl gap be trading lower heavy volume report earning cent share increase year estimate revenue also miss
1594,ABBV,big winner be carmax kmx share vault company report ep cent share increase year estimate sale rise
1595,ABBV,irish drugmaker shire shpg gap be trading higher reject bid rival abbvie abbv abbvie be trading volatile morning
1596,ABBV,shire be best perform stock ibd kapstone paper packaging ks be second best volume well average stock break cup handle base buy point big cap stock continue trade time high early afternoon trading friday dovish federal reserve continue fuel rally be carry sixth day volume be run higher due option expiration dow jone industrial average rise gain nasdaq rise fractionally dow be trading just time high set earlier day little economic news energize trader earning news takeover talk take spotlight oracle orcl gap be trading lower heavy volume report earning cent share increase year estimate revenue also miss big winner be carmax kmx share vault company report ep cent share increase year estimate sale rise irish drugmaker shire shpg gap be trading higher reject bid rival abbvie abbv abbvie be trading volatile morning shire be best perform stock ibd kapstone paper packaging ks be second best volume well average stock break cup handle base buy point
1597,ABBV,stock future ladle moderate loss ahead friday open uptick producer price add inflation pressure federal reserve
1598,ABBV,dow future slip point fair market value nasdaq future drop point future be point
1599,ABBV,stock market today head friday nasdaq week ahead nasdaq continue find support day move average slip level late last week retook support wednesday significant change eurozone debt standoff greece clarity regard possible rate increase federal reserve help urge index month long limit market challenge high lows recent range investor stay prepared shift direction
1600,ABBV,economic news price paid producer rise labor department report largest increase least december gain reversed april decline top analyst expectation increase core producer price index energy food edge vs slip april line expectation
1601,ABBV,university michigan be slate release initial june consumer sentiment estimate et
1602,ABBV,stock action showedtwitter twtr perk announce chief executive dick costolo step july twitter co founder chairman jack dorsey serve interim ceo search new ceo dorsey say take compensation position later year stock have be unable exit consolidation begin shortly november ipo end thursday dec high
1603,ABBV,connecticut base biotech alexion pharmaceutical alxn drop more premarket action stock have be deepen consolidation december have be struggle regain week move average early
1604,ABBV,ibd stock synaptic syna rise open company announce thursday have reach milestone shipment fingerprint sensor now top unit sensor be used smartphone tablet notebook computer stock have be hover just june high end thursday almost buy point
1605,ABBV,overseas market asia end higher lead jump hong kong hang seng index shanghai composite rise end week hang seng end fraction week japan tokyo nikkei rise friday end week effectively flat
1606,ABBV,europe top index be also tracking flat finish week ftse london frankfurt dax cac paris show moderate loss midday
1607,ABBV,dollar continue gain ground keep downward pressure stock commodity price oil gold trade lower west texas intermediate future hold just barrel august gold contract trading ounce week oil be not quite gold be higher last friday settle price stock future ladle moderate loss ahead friday open uptick producer price add inflation pressure federal reserve dow future slip point fair market value nasdaq future drop point future be point stock market today head friday nasdaq week ahead nasdaq continue find support day move average slip level late last week retook support wednesday significant change eurozone debt standoff greece clarity regard possible rate increase federal reserve help urge index month long limit market challenge high lows recent range investor stay prepared shift direction economic news price paid producer rise labor department report largest increase least december gain reversed april decline top analyst expectation increase core producer price index energy food edge vs slip april line expectation university michigan be slate release initial june consumer sentiment estimate et stock action showedtwitter twtr perk announce chief executive dick costolo step july twitter co founder chairman jack dorsey serve interim ceo search new ceo dorsey say take compensation position later year stock have be unable exit consolidation begin shortly november ipo end thursday dec high connecticut base biotech alexion pharmaceutical alxn drop more premarket action stock have be deepen consolidation december have be struggle regain week move average early ibd stock synaptic syna rise open company announce thursday have reach milestone shipment fingerprint sensor now top unit sensor be used smartphone tablet notebook computer stock have be hover just june high end thursday almost buy point overseas market asia end higher lead jump hong kong hang seng index shanghai composite rise end week hang seng end fraction week japan tokyo nikkei rise friday end week effectively flat europe top index be also tracking flat finish week ftse london frankfurt dax cac paris show moderate loss midday dollar continue gain ground keep downward pressure stock commodity price oil gold trade lower west texas intermediate future hold just barrel august gold contract trading ounce week oil be not quite gold be higher last friday settle price
1608,ABBV,listless session friday see nasdaq outperform early afternoon trading
1609,ABBV,nasdaq add dow jone industrial average slip less volume nyse nasdaq be tracking lower thursday level
1610,ABBV,stock market today audio product firm harman international industry har rise clear buy point volume be tad average not so bad low volume day broad market
1611,ABBV,elsewhere drugmaker shire shpg surge bloomberg report abbvie abbv raise offer shire fourth time
1612,ABBV,meanwhile tobacco firm lorillard jump news discussion rival reynold american rai possible merger just announcement base imperial tobacco say talk buy asset lorillard reynold
1613,ABBV,volume be heavy early facebook fb stock moved closer reclaim cup handle buy point share rise volume be tracking higher average
1614,ABBV,china base stock ibd outperformed include vipshop vip qihoo qihu bitauto bita vipshop be hold well recent late stage base
1615,ABBV,downside oil gas producer come pressure again only leader group be danger fall day line sanchez energy sn anadarko petroleum apc listless session friday see nasdaq outperform early afternoon trading nasdaq add dow jone industrial average slip less volume nyse nasdaq be tracking lower thursday level stock market today audio product firm harman international industry har rise clear buy point volume be tad average not so bad low volume day broad market elsewhere drugmaker shire shpg surge bloomberg report abbvie abbv raise offer shire fourth time meanwhile tobacco firm lorillard jump news discussion rival reynold american rai possible merger just announcement base imperial tobacco say talk buy asset lorillard reynold volume be heavy early facebook fb stock moved closer reclaim cup handle buy point share rise volume be tracking higher average china base stock ibd outperformed include vipshop vip qihoo qihu bitauto bita vipshop be hold well recent late stage base downside oil gas producer come pressure again only leader group be danger fall day line sanchez energy sn anadarko petroleum apc
1616,ABBV,medical product giant abbott laboratory agree friday buy chilean drugmaker cfr pharmaceutical abbott stock dip fraction heavy trading stock market today
1617,ABBV,deal also involve abbott assumption debt add abbott revenue make top pharmaceutical company latin america accord press release announce deal abbott get business develop new drug spun abbvie abbv last year outside already have strong presence brand generic drug company say cfr buyout double brand generic presence latin america
1618,ABBV,abbott also say cfr portfolio include more product be well align abbott current pharmaceutical therapeutic area focus woman health central nervous system cardiovascular respiratory disease
1619,ABBV,abbott say expect double digit sale growth business useful boost company sale have be flat last couple quarters company management have be say time now re look emerge market growth develop market have be subject pricing pressure general market saturation
1620,ABBV,follow amy reeve twitter product giant abbott laboratory agree friday buy chilean drugmaker cfr pharmaceutical abbott stock dip fraction heavy trading stock market today deal also involve abbott assumption debt add abbott revenue make top pharmaceutical company latin america accord press release announce deal abbott get business develop new drug spun abbvie abbv last year outside already have strong presence brand generic drug company say cfr buyout double brand generic presence latin america abbott also say cfr portfolio include more product be well align abbott current pharmaceutical therapeutic area focus woman health central nervous system cardiovascular respiratory disease abbott say expect double digit sale growth business useful boost company sale have be flat last couple quarters company management have be say time now re look emerge market growth develop market have be subject pricing pressure general market saturation follow amy reeve twitter ibd_areeve
1621,ABBV,stock continue hold modest gain wednesday afternoon shake early loss cause disappointing economic datum nasdaq be respectively meanwhile dow jone industrial average be volume continue be mixed stock market today volume nyse be sharply higher possibly due active trading oil stock nasdaq trade be run lower barne noble bks trim gain be still huge trade share be nearly news company plan separate entity focus retail business other nook reader stock gap buy point cup handle base be trading entry shire shpg rally new high win favorable ruling concern vyvanse treatment attention deficit hyperactivity disorder adhd shire be midst defend takeover abbvie abbv diamondback energy fang rise fast trade recoup most tuesday loss stock have be tear rise past session diamondback blow past buy point flat base june downside omnivision technology ovti slump heavy trading already fall nearly tuesday stock be still past buy point
1622,ABBV,specialty drugmaker ibd stock shire shpg have reject takeover offer big pharma abbvie abbv most recent value company announce friday shire stock vault nearly early trading stock market today time high abbvie stock be fraction company
1623,ABBV,have noticed growth stock be back favor major stock index sit high ibd have come back life recent week mid april low index be compare gain solid price action several ibd growth name recent week have occasionally be
1624,ABBV,big pharma abbvie abbv beat estimate friday get street talk company executive imply win discount new hepatitis regimen stock be morning trading stock market today
1625,ABBV,abbvie earning rise year earlier quarter cent share beating analyst consensus cent sale rise estimate
1626,ABBV,company do not raise full year guidance however still expect ep vs last year sale fraction exclude impact company new hepatitis regimen await fda approval
1627,ABBV,analyst have many question regimen hepatitis particularly abbvie pricing strategy compete gilead science gild recently launch blockbuster sovaldi pharmacy benefit manager express script esrx have be say hope reduce sovaldi price play competitor other ask abbvie plan compete price ceo richard gonzalez say not strategy go forward
1628,ABBV,sound abbvie wouldn engage significant price war gain share hep morningstar analyst damien conover write email ibd abbvie hold very strong treatment hep think compete efficacy relatively good side effect profile treatment
1629,ABBV,research note friday rbc capital market analyst michael yee agree abbvie executive sound very bullish competitive potential
1630,ABBV,consistently comment allude drug be competitive stand nicely market profile be strong convenience be lower totem pole patient need think long large market never suggest pricing be key lever share write further support gild long term view hcv market be billlion global market gild earn share least mean gild stock be reasonably cheap
1631,ABBV,gilead investor didn seem entirely assuage gilead stock be flat late morning trading
1632,ABBV,yee also note abbvie candidate chronic lymphocytic leukemia cll be move nicely late stage testing potentially create more competition pharmacyclic pcyc recently launch imbruvica however model be likely best sicker patient probably not optimal community docs want less aggressive tolerable pcyc regimen
1633,ABBV,pharmacyclic stock be nearly morning trading
1634,ABBV,follow amy reeve twitter ibd_areeve
1635,ABBV,related gilead illumina earning wall street lovebig pharma abbvie abbv beat estimate friday get street talk company executive imply win discount new hepatitis regimen stock be morning trading stock market today abbvie earning rise year earlier quarter cent share beating analyst consensus cent sale rise estimate company do not raise full year guidance however still expect ep vs last year sale fraction exclude impact company new hepatitis regimen await fda approval analyst have many question regimen hepatitis particularly abbvie pricing strategy compete gilead science gild recently launch blockbuster sovaldi pharmacy benefit manager express script esrx have be say hope reduce sovaldi price play competitor other ask abbvie plan compete price ceo richard gonzalez say not strategy go forward sound abbvie wouldn engage significant price war gain share hep morningstar analyst damien conover write email ibd abbvie hold very strong treatment hep think compete efficacy relatively good side effect profile treatment research note friday rbc capital market analyst michael yee agree abbvie executive sound very bullish competitive potential consistently comment allude drug be competitive stand nicely market profile be strong convenience be lower totem pole patient need think long large market never suggest pricing be key lever share write further support gild long term view hcv market be billlion global market gild earn share least mean gild stock be reasonably cheap gilead investor didn seem entirely assuage gilead stock be flat late morning trading yee also note abbvie candidate chronic lymphocytic leukemia cll be move nicely late stage testing potentially create more competition pharmacyclic pcyc recently launch imbruvica however model be likely best sicker patient probably not optimal community docs want less aggressive tolerable pcyc regimen pharmacyclic stock be nearly morning trading follow amy reeve twitter gilead illumina earning wall street love
1636,ABBV,week filled earning report big cap biotechs gilead science gild be most watch reveal first full quarter sale blockbuster hepatitis drug sovaldi gilead report market close tuesday overall analyst poll thomson reuter estimate gilead make cent share
1637,ABBV,allergan report accelerate earning growth bullish guidance monday specialty drugmaker set plan cut workforce face hostile takeover bid share rise earning rise vs year earlier share beating analyst consensus cent be fourth straight quarter
1638,ABBV,analyst be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today
1639,ABBV,gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday
1640,ABBV,rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach
1641,ABBV,nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk
1642,ABBV,cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price
1643,ABBV,gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early
1644,ABBV,meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent
1645,ABBV,company now expect full year sale growth ep range be consensus
1646,ABBV,leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target
1647,ABBV,isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth
1648,ABBV,follow amy reeve twitter be singing praise life science giant gilead science gild illumina ilmn wednesday morning surge estimate late tuesday share company be stock market today gilead sale new hepatitis drug sovaldi be call most impressive beat biopharma history piper jaffray joshua schimmer increase price target only dollar gilead be morning trading wednesday rbc capital market analyst michael yee lift sale estimate previous add full year ep estimate now expect sovaldi sale hit next year ep reach nomura ian somaiya lift price target write gilead position hcv market be sustainable say sovaldi new sovaldi base combo pill expect launch later year be superior compete product abbvie abbv merck mrk cowen phil nadeau be also impressed note lengthy discussion payor pushback tuesday earning call provide probably not nearly enough resolution satisfy investor pharmacy benefit manager express script esrx insurer unite health unh have criticize sovaldi price gilead do discuss argument support price sovaldi such value cure health care system cost treat patient end stage liver disease yr nadeau write find gilead discussion datapoint encourage suspect investor concern payor ability limit access sovaldi shuttle patient compete regimen linger abbv pricing strategy be know presumably approval payor strategy be defined early meanwhile gene testing company illumina be wednesday morning beat estimate raise guidance sale rise year earlier quarter nearly consensus earning climb cent share top estimate cent company now expect full year sale growth ep range be consensus leerink analyst dan leonard write note tuesday report exceed even have consider best case scenario face multiple new instrument launch lift price target write launch new hiseq miseq gene sequence system do not appear be cannibalize older version add order hiseq system illumina announce january fanfare due claim sequence genome apiece be double initial target isi group ross muken note demand be illumina entire sequence portfolio raise price target reflect increase ep forecast however maintain neutral rating stock say current price already reflect annual revenue growth follow amy reeve twitter ibd_areeve
1649,ABBV,gilead science gild newly approve hepatitis drug sovaldi come fire price pharmacy benefit manager express script esrx tuesday rival abbvie abbv report good datum compete drug candidate gilead stock drop abbvie rise stock market today bloomberg reporter draw say twitter express script chief medical officer
1650,ABBV,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
1651,ABBV,hot biotech stock achillion pharmaceutical achn be midday trading stock market today analyst find more support prospect buyout candidate baird brian skorney note merck mrk official tender offer statement friday indicated be bidder idenix pharmaceutical idix accept merck bid last week skorney view mean somebody still prowl nucleoside hepatitis drug achillion have company draw many similarity idenix asset perspective have only unpartnered nuc left development make attractive target write research note friday skorney also write achillion prospect develop oral hep cure be dim pipeline have be slow various issue even gilead science gild abbvie abbv steam ahead own regimen maintain outperform rating set price target reflect more modest expectation maxim target set earlier week average price target stock be accord thomson follow amy reeve twitter ibd_areeve
1652,ABBV,merck mrk seek add potential new blockbuster drug disease fight arsenal take cancer hepatitis monday drugmaker present result phase trial pembrolizumab cancer treatment american society clinical oncology meeting chicago study show patient advanced melanoma have spread elsewhere
1653,ABBV,stock give early gain go lunch hour wednesday nasdaq fall dow jone industrial average give volume be tracking higher same time tuesday exchange stock market today
1654,ABBV,dollar be steady oil future be barrel shanghai composite lose overnight
1655,ABBV,ibd stock be higher be lower best performer mile be webmd wbmd company say close tuesday expect sale be slightly higher high end previous guidance
1656,ABBV,auto part maker be have rough day borgwarner bwa make engine drive train component fall company say be be hit higher taxe stronger dollar
1657,ABBV,american axle axl fall say backlog decline loss gm gm business company be boost capital spending sale stock be trading lowest level
1658,ABBV,company present detroit conference
1659,ABBV,stock have show recent strength relative strength line have go nearly vertical bullish development
1660,ABBV,share lendingtree tree sank stock open higher company raise full year fiscal revenue range range stock have find resistance day move average
1661,ABBV,oil refiner be worst perform industry group valero energy vlo tesoro tso be stock give early gain go lunch hour wednesday nasdaq fall dow jone industrial average give volume be tracking higher same time tuesday exchange stock market today dollar be steady oil future be barrel shanghai composite lose overnight ibd stock be higher be lower best performer mile be webmd wbmd company say close tuesday expect sale be slightly higher high end previous guidance auto part maker be have rough day borgwarner bwa make engine drive train component fall company say be be hit higher taxe stronger dollar american axle axl fall say backlog decline loss gm gm business company be boost capital spending sale stock be trading lowest level company present detroit conference stock have show recent strength relative strength line have go nearly vertical bullish development share lendingtree tree sank stock open higher company raise full year fiscal revenue range range stock have find resistance day move average oil refiner be worst perform industry group valero energy vlo tesoro tso be
1662,ABBV,even re not biotech pharma investor ve probably catch earful news lately virus call hepatitis last december record breaking launch gilead science gild wonder drug sovaldi controversy price tag merck mrk recent buyout formerly neglected biotech idenix pharmaceutical idix
1663,ABBV,past year state have legalize marijuana medical used lead past few year rush startup pop well weed cater new market june new york become latest state medical marijuana many observer mention gw pharmaceutical gwph pot
1664,ABBV,salix pharmaceutical slxp announce tax inversion merger last month be several ibd drug stock report earning week july salix announce plan merge italy cosmo pharmaceutical irish subsidiary cosmo technology new headquarters be ireland boast lower taxe drug company focus find treatment
1665,ABBV,big pharma merck mrk report stellar result phase hepatitis hcv drug trial thursday spark debate analyst potential take market share leader gilead science
1666,ABBV,international liver congress london merck report cure rate patient hepatitis genotype take combination drug candidate mk mk
1667,ABBV,potentially combine pill take once day pairing rival convenience effectiveness gilead gild combo sofosbuvir ledipasvir be currently await fda approval expect october
1668,ABBV,gilead launch sofosbuvir alone sovaldi december be still recommend be combine interferon genotype account hcv infection be already enjoy biggest launch drug history
1669,ABBV,now however wall street attention be turn rival
1670,ABBV,face competiton
1671,ABBV,isi group analyst mark schoenebaum write email client consensus peak sale estimate merck regimen almost certainly go current nonetheless write rise present real danger gilead
1672,ABBV,most analyst include have assume gild capture perhaps genotype share peak write open question however have be company grab other market propose perhaps mrk be now lead contender position
1673,ABBV,merck still have way go clinical trial file approval win have first compete regimen expect be abbvie abbv enanta enta cocktail also expect launch late year
1674,ABBV,however research note thursday nomura analyst ian somaiya write symposium hepatologist stefan zeuzam bring gilead higher efficacy abbvie certain patient well risk drug interaction patient also have hiv
1675,ABBV,zeuzam also raise issue higher alanine level small percentage patient merck regimen point acute liver injury motivate many physician avoid regimen somaiya raise estimate gilead total hcv franchise year next year
1676,ABBV,defense
1677,ABBV,well fargo financial adviser brian abraham rise abbvie defense
1678,ABBV,thesis regard hep competitive dynamic be abbvie regimen be competitor gild give efficacy multiple patient type clean safety still have disadvantage versus gild merck regimen be hyped potential competitive threat write research note thursday
1679,ABBV,gilead share tumble more thursday lowest close mid october biotechs other growth stock lead sharp market sell abbvie lose even merck initially rise year intraday high close
1680,ABBV,gilead worry express script esrx officer say pharmacy benefit manager try drive sovaldi price goldman sachs analyst terence flynn wednesday trim gilead price target physician survey imply hcv market be price sensitive big pharma merck mrk report stellar result phase hepatitis hcv drug trial thursday spark debate analyst potential take market share leader gilead science international liver congress london merck report cure rate patient hepatitis genotype take combination drug candidate mk mk potentially combine pill take once day pairing rival convenience effectiveness gilead gild combo sofosbuvir ledipasvir be currently await fda approval expect october gilead launch sofosbuvir alone sovaldi december be still recommend be combine interferon genotype account hcv infection be already enjoy biggest launch drug history now however wall street attention be turn rival face competitonisi group analyst mark schoenebaum write email client consensus peak sale estimate merck regimen almost certainly go current nonetheless write rise present real danger gilead most analyst include have assume gild capture perhaps genotype share peak write open question however have be company grab other market propose perhaps mrk be now lead contender position merck still have way go clinical trial file approval win have first compete regimen expect be abbvie abbv enanta enta cocktail also expect launch late year however research note thursday nomura analyst ian somaiya write symposium hepatologist stefan zeuzam bring gilead higher efficacy abbvie certain patient well risk drug interaction patient also have hiv zeuzam also raise issue higher alanine level small percentage patient merck regimen point acute liver injury motivate many physician avoid regimen somaiya raise estimate gilead total hcv franchise year next year defensewell fargo financial adviser brian abraham rise abbvie defense thesis regard hep competitive dynamic be abbvie regimen be competitor gild give efficacy multiple patient type clean safety still have disadvantage versus gild merck regimen be hyped potential competitive threat write research note thursday gilead share tumble more thursday lowest close mid october biotechs other growth stock lead sharp market sell abbvie lose even merck initially rise year intraday high close gilead worry express script esrx officer say pharmacy benefit manager try drive sovaldi price goldman sachs analyst terence flynn wednesday trim gilead price target physician survey imply hcv market be price sensitive
1681,ABBV,stock put second straight gain monday extend recovery effort last week loss help apple aapl win upgrade barclay price target hike morgan stanley nasdaq climb gain amazon com amzn google googl also boost tech heavy index rise have already recoup more
1682,ABBV,fourth july be time backyard grill relax earning season be right corner so now time look ibd stock be expect post strongest earning gain ibd list company base superior earning strong price performance leadership industry salix pharmaceutical slxp be slate
1683,ABBV,big pharma abbvie abbv release first set result phase trial new hepatitis regimen monday send abbvie stock stock market today study find week treatment abbvie drug candidate standard oral drug ribavirin patient show sustain viral
1684,ABBV,baxter international bax announce thursday split biopharma medical product business separate company mid jump start lag stock move seem surprise wall street many investor have always view separation attractive prospect have mostly discount idea term give management
1685,ABBV,alibaba world largest online retailer have enthralled investor be largest tech initial public offer history eye pop market value make china online shopping sale eclipse amazon com amzn ebay ebay combine chinese medium report here
1686,ABBV,big cap name lead way stock be higher noon hour approach friday dow jone industrial average hit time high
1687,ABBV,volume swell quadruple witching simultaneous quarterly expiration single stock index future single stock index option
1688,ABBV,dow be top performer major index rise nasdaq gain just year high
1689,ABBV,stock market today dow stock merck mrk caterpillar cat be nearly dupont dd johnson johnson jnj exxonmobil xom be more
1690,ABBV,ibd stock irish drugmaker shire shpg be top performer reject buyout offer abbvie abbv be little change volatile morning
1691,ABBV,worst performer be emerge energy service emes announce secondary offer share discount thursday close price company mine silica hydraulic fracture used oil gas drill
1692,ABBV,auto dealer carmax kmx vault report earning cent share increase year quarter analyst be forecasting cent big cap name lead way stock be higher noon hour approach friday dow jone industrial average hit time high volume swell quadruple witching simultaneous quarterly expiration single stock index future single stock index option dow be top performer major index rise nasdaq gain just year high stock market today dow stock merck mrk caterpillar cat be nearly dupont dd johnson johnson jnj exxonmobil xom be more ibd stock irish drugmaker shire shpg be top performer reject buyout offer abbvie abbv be little change volatile morning worst performer be emerge energy service emes announce secondary offer share discount thursday close price company mine silica hydraulic fracture used oil gas drill auto dealer carmax kmx vault report earning cent share increase year quarter analyst be forecasting cent
1693,ABBV,biotech stock be selling hard friday consensus wall street seem pin blame letter send several house democrat gilead science gild ask briefing price hepatitis blockbuster sovaldi letter sign rep henry waxman frank pallone diana degete date thursday expressed concern
1694,ABBV,stock open higher quickly begin trim gain friday dollar edge higher oil price hold steady dow jone industrial average add apiece nasdaq hold advance
1695,ABBV,volume be soft nasdaq lower nyse compare trade same time thursday
1696,ABBV,stock market today be rebound still correct nasdaq deep hole week market receive early assist today china rule change federally engineer buy help lift market first healthy close week
1697,ABBV,december hire be also factor labor department report payroll jump month far expectation
1698,ABBV,wholesale inventory drop november commerce department say be even october slip expectation change
1699,ABBV,market have ear post payroll comment san francisco federal reserve bank president john william speak et richmond federal reserve bank president jeffrey lacker docket speech
1700,ABBV,apple aapl dupont dd race head dow nearly wynn resort wynn head gain
1701,ABBV,gap gps crater announce late thursday december same store sale slip vs consensus view decline
1702,ABBV,chipmaker apple supplier qorvo qrvo drop greensboro company late thursday lower revenue guidance well consensus expectation company also say repurchase share quarter leave share repurchase program cash balance more share trade week june high
1703,ABBV,ibd list universal display oled flash ahead nearly open maker organic light emit diode chip used high definition tv computer screen be trading buy point cup base trigger automatic sell signal diving more mark
1704,ABBV,hawaiian jump more report total number passenger rise load factor fourth quarter stock remain well day move average be attempt build right side deep consolidation
1705,ABBV,aircraft carrier mechanic huntington ingall industry hii sail ahead nearly cowen co upgrade stock outperform market perform huntington be trading buy point long cup handle base stock open higher quickly begin trim gain friday dollar edge higher oil price hold steady dow jone industrial average add apiece nasdaq hold advance volume be soft nasdaq lower nyse compare trade same time thursday stock market today be rebound still correct nasdaq deep hole week market receive early assist today china rule change federally engineer buy help lift market first healthy close week december hire be also factor labor department report payroll jump month far expectation wholesale inventory drop november commerce department say be even october slip expectation change market have ear post payroll comment san francisco federal reserve bank president john william speak et richmond federal reserve bank president jeffrey lacker docket speech apple aapl dupont dd race head dow nearly wynn resort wynn head gain gap gps crater announce late thursday december same store sale slip vs consensus view decline chipmaker apple supplier qorvo qrvo drop greensboro company late thursday lower revenue guidance well consensus expectation company also say repurchase share quarter leave share repurchase program cash balance more share trade week june high ibd list universal display oled flash ahead nearly open maker organic light emit diode chip used high definition tv computer screen be trading buy point cup base trigger automatic sell signal diving more mark hawaiian jump more report total number passenger rise load factor fourth quarter stock remain well day move average be attempt build right side deep consolidation aircraft carrier mechanic huntington ingall industry hii sail ahead nearly cowen co upgrade stock outperform market perform huntington be trading buy point long cup handle base
1706,ABBV,biotech stock sell hard friday wall street blame letter several house democrat ask gilead science justify price hepatitis blockbuster sovaldi
1707,ABBV,letter date thursday be sign rep henry waxman frank pallone diana degete ranking member committee energy commerce call sovaldi breakthrough hcv treatment expressed concern treatment not cure patient afford
1708,ABBV,due sovaldi price tag letter go say colorado pennsylvania medicaid program have already announce re funding sovaldi only sickest patient california be still figure reimbursement policy letter also note pharmacy benefit manager express script esrx be encourage doctor network delay prescribe sovaldi
1709,ABBV,meanwhile hepatitis be disease find poor result lawmaker tell gilead provide explanation pricing april
1710,ABBV,health insurer wellpoint wlp chime friday concern new hepatitis drug cost say executive ken goulet
1711,ABBV,biotech stock cheaper
1712,ABBV,gilead gild fall nearly month close low biotechs selling expensive drug fall even harder perhaps fear larger change national mood drug pricing
1713,ABBV,alexion pharmaceutical alxn sole drug soliris go upward year tumble vertex pharmaceutical vrtx also sell expensive hepatitis drug call incivek retreat
1714,ABBV,biogen idec biib have costly multiple sclerosis treatment tecfidera lose
1715,ABBV,ibd top rate medical biom biotech group fall
1716,ABBV,abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rally friday close fraction
1717,ABBV,gilead catch cold rest market catch pneumonia say tom vandeventer portfolio manager tocqueville opportunity fund
1718,ABBV,sovaldi bargain
1719,ABBV,analyst most part advise stay calm michael yee rbc capital market write email client friday pricing discussion generate headline concern view underscore drug be go be huge re cure patient improve society hcv be important public health issue hiv be validate significance market
1720,ABBV,deutsche bank analyst robyn karnauskas write client note speak gilead official be already make case sovaldi be actually bargain
1721,ABBV,liver transplant related hcv cost year med so person do not reject liver write gilead have co pay program place pocket cost be low
1722,ABBV,isi group analyst mark schoenebaum point sovaldi compare favorably older hepatitis drug especially vertex incivek go year sovaldi cure rate be also much higher incivek so cost cure be even better say webinar friday
1723,ABBV,dem seek public shaming
1724,ABBV,schoenebaum also query terry haine longtime washington lawyer lobbyist once serve senior republican counsel same congre sional committee send letter haine respond government actually have little power address drug price view waxman et al hope accomplish be public shaming not waxman deliver tobacco industry year
1725,ABBV,letter be bank shot get thing go goal get gilead significantly lower price sovaldi haine write
1726,ABBV,such move be politically popular add discontent high price sovaldi new drug general have be swell payer general public time now aids healthcare foundation large nonprofit history criticize gilead hiv drug pricing recently turn fire sovaldi
1727,ABBV,gilead latest display touch greed come heel company january pricing new hepatitis treatment sovaldi sofosbuvir pill more gilead most expensive aids drug stribild ahf say feb press release
1728,ABBV,have play biotech stock have hit lull last few week bull run not see lead fear party be vandeventer say biotechs be high beta group be probably just correction point drug price have be political football early
1729,ABBV,shouldn be completely unexpected kind issue come fore periodically say just part investing health care biotech stock sell hard friday wall street blame letter several house democrat ask gilead science justify price hepatitis blockbuster sovaldi letter date thursday be sign rep henry waxman frank pallone diana degete ranking member committee energy commerce call sovaldi breakthrough hcv treatment expressed concern treatment not cure patient afford due sovaldi price tag letter go say colorado pennsylvania medicaid program have already announce re funding sovaldi only sickest patient california be still figure reimbursement policy letter also note pharmacy benefit manager express script esrx be encourage doctor network delay prescribe sovaldi meanwhile hepatitis be disease find poor result lawmaker tell gilead provide explanation pricing april health insurer wellpoint wlp chime friday concern new hepatitis drug cost say executive ken goulet biotech stock cheapergilead gild fall nearly month close low biotechs selling expensive drug fall even harder perhaps fear larger change national mood drug pricing alexion pharmaceutical alxn sole drug soliris go upward year tumble vertex pharmaceutical vrtx also sell expensive hepatitis drug call incivek retreat biogen idec biib have costly multiple sclerosis treatment tecfidera lose ibd top rate medical biom biotech group fall abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rally friday close fraction gilead catch cold rest market catch pneumonia say tom vandeventer portfolio manager tocqueville opportunity fund sovaldi bargain analyst most part advise stay calm michael yee rbc capital market write email client friday pricing discussion generate headline concern view underscore drug be go be huge re cure patient improve society hcv be important public health issue hiv be validate significance market deutsche bank analyst robyn karnauskas write client note speak gilead official be already make case sovaldi be actually bargain liver transplant related hcv cost year med so person do not reject liver write gilead have co pay program place pocket cost be low isi group analyst mark schoenebaum point sovaldi compare favorably older hepatitis drug especially vertex incivek go year sovaldi cure rate be also much higher incivek so cost cure be even better say webinar friday dem seek public shaming schoenebaum also query terry haine longtime washington lawyer lobbyist once serve senior republican counsel same congre sional committee send letter haine respond government actually have little power address drug price view waxman et al hope accomplish be public shaming not waxman deliver tobacco industry year letter be bank shot get thing go goal get gilead significantly lower price sovaldi haine write such move be politically popular add discontent high price sovaldi new drug general have be swell payer general public time now aids healthcare foundation large nonprofit history criticize gilead hiv drug pricing recently turn fire sovaldi gilead latest display touch greed come heel company january pricing new hepatitis treatment sovaldi sofosbuvir pill more gilead most expensive aids drug stribild ahf say feb press release have play biotech stock have hit lull last few week bull run not see lead fear party be vandeventer say biotechs be high beta group be probably just correction point drug price have be political football early shouldn be completely unexpected kind issue come fore periodically say just part investing health care
1730,ABBV,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
1731,ABBV,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
1732,ABBV,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
1733,ABBV,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
1734,ABBV,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
1735,ABBV,sovaldi set new standard
1736,ABBV,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
1737,ABBV,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
1738,ABBV,ultimately however do not expect single regimen conquer other not patient be same
1739,ABBV,treat toughest patient
1740,ABBV,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
1741,ABBV,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
1742,ABBV,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
1743,ABBV,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
1744,ABBV,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
1745,ABBV,believe regimen provide option genotype infected patient bernstein tell ibd
1746,ABBV,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
1747,ABBV,next generation regime
1748,ABBV,further road even more drug be way
1749,ABBV,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
1750,ABBV,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
1751,ABBV,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
1752,ABBV,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
1753,ABBV,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
1754,ABBV,still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher
1755,ABBV,doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow
1756,ABBV,bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate
1757,ABBV,gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market
1758,ABBV,bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon
1759,ABBV,sovaldi set new standard
1760,ABBV,october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply
1761,ABBV,dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing
1762,ABBV,ultimately however do not expect single regimen conquer other not patient be same
1763,ABBV,treat toughest patient
1764,ABBV,daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation
1765,ABBV,decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death
1766,ABBV,decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year
1767,ABBV,respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing
1768,ABBV,barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis
1769,ABBV,believe regimen provide option genotype infected patient bernstein tell ibd
1770,ABBV,abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum
1771,ABBV,next generation regime
1772,ABBV,further road even more drug be way
1773,ABBV,abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine
1774,ABBV,earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen
1775,ABBV,sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink
1776,ABBV,still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future
1777,ABBV,think ll have gilead represent hep market tell ibd abbvie take lion share remain still early day dec approval gilead science hepatitis drug sovaldi be enjoy most massive drug launch time current consensus call sale year whisper number be run even higher doesn surprise wall street sovaldi provide faster safer stronger alternative punish yearlong regimen interferon analyst obsessively watch weekly prescription number grow re also eyee datum sovaldi potential challenger market estimate year grow bristol myer squibb bmy daclatasvir grab headline last april phase trial combine sovaldi score cure rate gilead gild elect not pursue combo further instead study sovaldi combination similar drug ledipasvir so co formulate single pill not share market bristol however file european union approval daclatasvir use combination other agent include sofosbuvir generic name sovaldi be grant accelerate review early january firm plan submit similar filing food drug administration soon sovaldi set new standardin october bristol file approve combo daclatasvir drug asunaprevir japan have unusually high rate hepatitis virus hcv infection due formerly taint blood supply dougla manion bristol vice president development virology japan say dual regimen score good result week duration be look yesterday news now sovaldi have set week standard hope be resolve triple therapy involve daclatasvir asunaprevir drug dub bms co formulate pill be take twice day now phase testing ultimately however do not expect single regimen conquer other not patient be same treat toughest patient daclatasvir have be study so many different drug used genotype hepatitis virus patient population especially toughest treat population manion say be go be liver transplant patient genotype patient patient cirrhosis ultimately patient decompensation decompensate cirrhosis worst form liver damage result hcv usually result liver transplant death decompensate group be population not include abbvie abbv phase trial regimen combine antiviral agent abbvie also stick most common genotype genotype do very well trial cure rate range company plan file second quarter hit market late year respect have nearly catch gilead current fda guideline sovaldi recommend be used interferon genotype patient tolerate interferon gilead be banking sofosbuvir ledipasvir combo be first official interferon free genotype treatment also expect launch later year feb filing barry bernstein abbvie vice president infectious disease development tout strong safety profile fact cure upward patient compensate cirrhosis believe regimen provide option genotype infected patient bernstein tell ibd abbvie bristol myer gilead be expect report final study detail international liver congress meeting london april company official be keep mum study be present abstract go online march late breaking abstract appear right conference often have hottest datum next generation regimesfurther road even more drug be way abbvie partner enanta pharmaceutical enta be already work next generation regime treat more genotype also be simpler take common criticism be more complicate gilead promise pill day routine earlier month merck mrk also report very strong phase result drug combo genotype patient be co infected hiv johnson johnson jnj last october acquire hcv drug glaxosmithkline gsk hope combine already approve olysio oral regimen sovaldi meanwhile have lately be pressure pill price tag concern sustainability outcome find curative drug be patient population eventually shrink still morningstar analyst damien conover say gilead have first mover advantage such strong trial datum likely be biggest player indefinite future think ll have gilead represent hep market tell ibd abbvie take lion share remain
1778,ABBV,specialty drug company horizon pharma hznp be roll arthritis drug duexis vimovo treat arthritis pain protect ulcer bang most other drug treat arthritis don provide most arthritis drug use nonsteroidal inflammatory drug nsaid add roll layer ulcer protect compound
1779,ABBV,biotech stock take beating friday lead gilead science concern grow blockbuster drug sovaldi gilead gild tumble close month low stock be already hit previous friday word congressional inquiry high price sovaldi launch december revolutionary treatment hepatitis
1780,ABBV,medical product giant abbott laboratory miss sale estimate meeting profit expectation wednesday send abbott stock morning trading stock market today earlier have be much
1781,ABBV,abbott say revenue totale quarter year earlier quarter short analyst consensus earning rise cent share match estimate company say ep be bracketing consensus vs last year
1782,ABBV,leerink analyst danielle antalffy write email client abbott operate leverage allow meet profit goal have miss sale estimate quarters row
1783,ABBV,trend top line miss highlight continue head wind key business primarily nutritional establish product brand generic drug write business be key accelerate long term sale growth profile think investor likely look sign stable improve fundamental here share move meaningfully higher current level
1784,ABBV,bright spot establish product business be key emerge market segment include sale china brazil russia
1785,ABBV,abbott quarter be weaker fellow diversify medical giant johnson johnson jnj report tuesday beat estimate drive strong performance proprietary drug abbott longer have proprietary drug business spun abbvie abbv start last year ep guidance nonetheless miss consensus drive stock tuesday several analyst rise company defense however point early guidance be usually conservative midmorning wednesday jnj stock be flat
1786,ABBV,follow amy reeve twitter ibd_areeve medical product giant abbott laboratory miss sale estimate meeting profit expectation wednesday send abbott stock morning trading stock market today earlier have be much abbott say revenue totale quarter year earlier quarter short analyst consensus earning rise cent share match estimate company say ep be bracketing consensus vs last year leerink analyst danielle antalffy write email client abbott operate leverage allow meet profit goal have miss sale estimate quarters row trend top line miss highlight continue head wind key business primarily nutritional establish product brand generic drug write business be key accelerate long term sale growth profile think investor likely look sign stable improve fundamental here share move meaningfully higher current level bright spot establish product business be key emerge market segment include sale china brazil russia abbott quarter be weaker fellow diversify medical giant johnson johnson jnj report tuesday beat estimate drive strong performance proprietary drug abbott longer have proprietary drug business spun abbvie abbv start last year ep guidance nonetheless miss consensus drive stock tuesday several analyst rise company defense however point early guidance be usually conservative midmorning wednesday jnj stock be flat follow amy reeve twitter ibd_areeve
1787,ABBV,gilead science gild hepatitis drug sofosbuvir win european advisory panel vote earlier wall street expect friday send stock more time high stock market today eu committee medicinal product human use chmp recommend approve sofosbuvir now brand sovaldi follow accelerate review procedure drug
1788,ABBV,big pharma abbvie abbv beat analyst expectation friday send share highest point stock market spinoff abbott laboratory start year company sale rise beating analyst consensus profit be cent share best estimate cent
1789,ABBV,recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale
1790,ABBV,now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor
1791,ABBV,american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial
1792,ABBV,pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease
1793,ABBV,pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug
1794,ABBV,monthly injection
1795,ABBV,drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate
1796,ABBV,majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease
1797,ABBV,then be patient tolerate statin
1798,ABBV,morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate
1799,ABBV,regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone
1800,ABBV,company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab
1801,ABBV,amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal
1802,ABBV,pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc
1803,ABBV,analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville
1804,ABBV,look safety issue
1805,ABBV,think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety
1806,ABBV,think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug
1807,ABBV,safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report
1808,ABBV,turn other pcsk player have get same letter deny have find significant safety issue
1809,ABBV,analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia
1810,ABBV,isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame
1811,ABBV,safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve
1812,ABBV,pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point recent decade high cholesterol have be big pharma gravy train statin oral drug lower bad cholesterol turn best selling drug history pfizer lipitor peak nearly sale now however statin have go patent be so pfizer pfe passel other company lead amgen amgn regeneron regn regeneron partner sanofi sny be turn new class cholesterol buster call pcsk inhibitor american cardiology conference acc washington saturday monday investor get chance see new drug be do clinical trial pcsk be short proprotein convertase subtilisin kexin type enzyme bound liver receptor ldl bad cholesterol target degredation block pcsk company aim boost liver ability eliminate ldl cholesterol blood thus reduce chance heart disease pcsk inhibitor mid late stage testing be monoclonal antibody biotechnology already be used best selling cancer immunology drug monthly injectionsall drug also have be inject once twice month make somewhat more unpleasant take statin partly reason drugmaker be gun subgroup high cholesterol sufferer statin aren adequate majority patient program be treat statin normally highest tolerable dose say jay edelberg head sanofi pcsk development launch unit be primarily patient be familial genetic disorder ve have cardiovascular event be diabetic be high risk cardiovascular disease then be patient tolerate statin morningstar analyst stefan quenneville estimate description cover person expect grow roughly equivalent number potential patient also live abroad estimate regeneron sanofi drug alirocumab take most stage time acc meeting presentation detail datum clinical trial be conduct product include study patient genetic high cholesterol patient be take merck mrk zetia abbvie abbv tricor aren well comparison patient zetia alone vs alirocumab alone company expect file approval alirocumab early so do amgen be also conduct different late stage clinical trial candidate evolocumab amgen be give presentation evolocumab compare zetia statin well effectiveness statin intolerant subject patient kind genetic heterozygous march report study homozygous patient have meet endpoint didn say further detail be reveal pfizer be bit regeneron amgen bococizumab just launch phase program october schedule present dose range study patient statin acc analyst have be pleased trial result drug so far haven converge favorite way do recent hepatitis race instance hasn be much datum differentiate other say quenneville look safety issue think trial present acc be go be interesting point drug have be pretty similar quenneville tell ibd look more difference efficacy be anything do safety think go be major concern safety signal appear didn see smaller trial waylay specific drug even entire class drug safety pcsk come particular scrutiny earlier month word get twitter food drug administration have become aware neurocognitive adverse event pcsk inhibitor class have ask sanofi regeneron make assessment potential neurocognitive adverse event global development program alirocumab especially longer term study accord sanofi annual report turn other pcsk player have get same letter deny have find significant safety issue analyst however seem have settle evolocumab culprit member cohort osler trial include person report memory impairment amnesia isi group analyst mark schoenebaum however point most patient be also statin memory loss have be connect statin so not clear evolocumab be blame safety turn be problem quenneville estimate pcsk drug collectively sell more assume alirocumab evolocumab split most market due be first say pfizer yet have something sleeve pfizer have imply conference call have more potent pcsk phase discontinue patient person have dramatic lower say ll see not really enough datum tease point
1813,ABBV,slew downgrade hit achillion pharmaceutical achn monday wake weekend bad news hepatitis pipeline achillion stock plunge nearly stock market midday trading monday almost year low late friday achillion announce fda have decide not lift clinical hold drug candidate
1814,ABBV,share small biotechs kythera kyth repro therapeutic rprx jump stock market tuesday good clinical trial report drug candidate
1815,ABBV,kythera be late afternoon trading highest point go public last october company report late monday late stage trial atx injection reduce double chin meet primary secondary endpoint only patient drop point highlighted leerink analyst seamus fernandez raise price target stock
1816,ABBV,tolerability atx reflect report low single digit dropout rate look extremely manageable write fernandez maintain outperform rating add price target now
1817,ABBV,goldman sachs launch coverage kythera tuesday morning raft other health care stock rating neutral valuation reason share already have rise more mid august even tuesday move lead goldman conclude good study result already be factor price
1818,ABBV,cowen ken cacciatore however write ultimate value be higher kythera become buyout target
1819,ABBV,give lack viable aesthetic product not be surprising strategic buyer make wealth create decision acquire asset relieve kythera significant sg spend give strategic buyer already place sale infrastructure write escalate stand alone base case dcf discount cash flow analysis
1820,ABBV,also late monday repro report positive result study efficacy safety testosterone replacement drug androxal reprose say subject hypogonadism achieve testosterone level normal range safety profile compare favorably androgel standard treatment sell abbvie abbv risk profile be especially note brean capital analyst raise price target also cite possibility buyout management have say sell
1821,ABBV,repro stock open monday close price late afternoon trading be enthusiasm have be dampen cautionary column thestreet com point significant datum have yet be release share small biotechs kythera kyth repro therapeutic rprx jump stock market tuesday good clinical trial report drug candidate kythera be late afternoon trading highest point go public last october company report late monday late stage trial atx injection reduce double chin meet primary secondary endpoint only patient drop point highlighted leerink analyst seamus fernandez raise price target stock tolerability atx reflect report low single digit dropout rate look extremely manageable write fernandez maintain outperform rating add price target now goldman sachs launch coverage kythera tuesday morning raft other health care stock rating neutral valuation reason share already have rise more mid august even tuesday move lead goldman conclude good study result already be factor price cowen ken cacciatore however write ultimate value be higher kythera become buyout target give lack viable aesthetic product not be surprising strategic buyer make wealth create decision acquire asset relieve kythera significant sg spend give strategic buyer already place sale infrastructure write escalate stand alone base case dcf discount cash flow analysis also late monday repro report positive result study efficacy safety testosterone replacement drug androxal reprose say subject hypogonadism achieve testosterone level normal range safety profile compare favorably androgel standard treatment sell abbvie abbv risk profile be especially note brean capital analyst raise price target also cite possibility buyout management have say sell repro stock open monday close price late afternoon trading be enthusiasm have be dampen cautionary column thestreet com point significant datum have yet be release
1822,ABBV,share big pharma merck mrk gap stock market tuesday morning company announce restructure say save merck say news release cut job global workforce top job cut have already be
1823,ABBV,share neurocrine bioscience nbix gap year high stock market midday trading wednesday get upgrade outperform cowen co base dyskinesia drug cowen analyst phil nadeau write research note talk physician consultant prospect nbi be currently phase
1824,ABBV,tesla motor investor take foot brake late wednesday company report earning outlook top expectation record high normal session trading tesla stock zoom much close see story here analyst believe electric car maker share have race ahead too far
1825,ABBV,wall street newest big pharma abbvie abbv beat analyst expectation friday raise guidance send share morning trading stock market
1826,ABBV,company spun abbott laboratory start year say sale rise year earlier quarter analyst consensus profit special item come cent share beating estimate cent do not offer year comparison figure presumably due complication be part abbott time do say operate earning rise
1827,ABBV,abbvie lift low end full year ep guidance range be now
1828,ABBV,immunology drug humira continue drive sale growth revenue rise drug continue compile new indication originally approve rheumatoid arthritis humira have be labele psoriasis psoriatic arthritis crohn disease ulcerative colitis earlier week advisory panel fda vote approve humira axial stock take only bit ding
1829,ABBV,abbvie beat raise continue be pretty good earning season drugmaker thursday most big biotechs beat estimate day earlier eli lilly lly jump own beat raise main downer have be bristol myer squibb bmy thursday lower outlook report surprisingly weak launch stroke prevention drug eliquis stock fall thursday be early trading friday wall street newest big pharma abbvie abbv beat analyst expectation friday raise guidance send share morning trading stock market company spun abbott laboratory start year say sale rise year earlier quarter analyst consensus profit special item come cent share beating estimate cent do not offer year comparison figure presumably due complication be part abbott time do say operate earning rise abbvie lift low end full year ep guidance range be now immunology drug humira continue drive sale growth revenue rise drug continue compile new indication originally approve rheumatoid arthritis humira have be labele psoriasis psoriatic arthritis crohn disease ulcerative colitis earlier week advisory panel fda vote approve humira axial stock take only bit ding abbvie beat raise continue be pretty good earning season drugmaker thursday most big biotechs beat estimate day earlier eli lilly lly jump own beat raise main downer have be bristol myer squibb bmy thursday lower outlook report surprisingly weak launch stroke prevention drug eliquis stock fall thursday be early trading friday
1830,ABBV,gilead science gild report more positive datum hepatitis drug pipeline wednesday send share stock market today datum come phase study used recently approve drug sofosbuvir candidate ledipasvir patient genotype virus most common type sustain response rate be well
1831,ABBV,go public march little biotech enanta pharmaceutical have be middle clash giant enanta enta be developer protease inhibitor antiviral agent abbvie abbv cocktail drug testing treat hepatitis virus hcv abbvie be consider be nearest contender
1832,ABBV,share gilead science gild hit time high vertex pharmaceutical vrtx plunge morning trading stock market friday gilead seem stretch lead race make oral hepatitis treatment gilead be passel big biotech report earning thursday beat sale estimate be merely
1833,ABBV,share incyte pharmaceutical incy vault year high morning trading stock market wednesday company release encourage datum clinical trial pancreatic cancer drug incyte say drug jakafi improve overall survival patient phase trial live month more vs just
1834,ABBV,new issue be not typically know pay juicy dividend abbvie abbv be exception former pharmaceutical arm abbott laboratory declare inaugural dividend last month abbvie pay cent share feb shareholder jan annualize basis abbvie pay share work
1835,ABBV,gilead science gild late thursday post earning revenue miss wall street estimate report be overshadowed round powerful datum earlier day biotech ongoing hepatitis drug trial miss least analyst say be expect gilead share be fraction hour trading
1836,ABBV,specialty drugmaker santarus snt blow past analyst estimate late monday send share hour trading
1837,ABBV,santarus report earning share cent just penny year earlier quarter top analyst consensus cent sale rise estimate
1838,ABBV,company also raise guidance year add sale range now vs last year add dime ep forecast now cent cent vs cent last year
1839,ABBV,diabetes drug glumetza provide nearly half revenue report growth bigger growth come acid reflux treatment zegerid sale triple
1840,ABBV,zegerid be santarus first commercialize drug launch back however generic competition come scene santarus stop actively promote
1841,ABBV,september company win ruling protect patent court so february re launch product
1842,ABBV,santarus also report revenue uceris treatment inflammatory bowel disease food drug administration approve mid january be launch month later analyst scott henry roth capital partner have be issue weekly tracking report uceris prescription launch recently raise full year estimate drug last week be still modele less uceris revenue first quarter however
1843,ABBV,believe uceris prescription trend be encourage ceo gerald proehl say statement monday
1844,ABBV,proehl have previously guide peak annual uceris sale be few year company be still await reimbursement determination medicare leerink swann analyst jason gerberry say come late year sometime next year april research note gerberry write manage care specialist tell uceris be view unlikely target reimbursement pushback due small patient population low price vs such biologic treatment abb vie abbv humira johnson johnson jnj remicade
1845,ABBV,analyst henry tell ibd january uceris peak best case scenario
1846,ABBV,santarus stock close monday regular session fraction time high touch april drive positive buzz uceris other good news april win new patent cycloset diabetes drug base enhancement formulation new patent be set last note gerberry say cycloset previous patent technically last analyst consensus assume generic competition
1847,ABBV,cycloset sale totale less first quarter do gain endorsement thursday american association clinical endocrinologist include comprehensive diabetes management algorithm guide physician battery different treatment
1848,ABBV,cycloset be interesting useful therapy beneficial impact hba hemoglobin fact clinical testing be not associate increase risk adverse cardiovascular event dr alan garber head association algorithm task force say statement last week specialty drugmaker santarus snt blow past analyst estimate late monday send share hour trading santarus report earning share cent just penny year earlier quarter top analyst consensus cent sale rise estimate company also raise guidance year add sale range now vs last year add dime ep forecast now cent cent vs cent last year diabetes drug glumetza provide nearly half revenue report growth bigger growth come acid reflux treatment zegerid sale triple zegerid be santarus first commercialize drug launch back however generic competition come scene santarus stop actively promote september company win ruling protect patent court so february re launch product santarus also report revenue uceris treatment inflammatory bowel disease food drug administration approve mid january be launch month later analyst scott henry roth capital partner have be issue weekly tracking report uceris prescription launch recently raise full year estimate drug last week be still modele less uceris revenue first quarter however believe uceris prescription trend be encourage ceo gerald proehl say statement monday proehl have previously guide peak annual uceris sale be few year company be still await reimbursement determination medicare leerink swann analyst jason gerberry say come late year sometime next year april research note gerberry write manage care specialist tell uceris be view unlikely target reimbursement pushback due small patient population low price vs such biologic treatment abb vie abbv humira johnson johnson jnj remicade analyst henry tell ibd january uceris peak best case scenario santarus stock close monday regular session fraction time high touch april drive positive buzz uceris other good news april win new patent cycloset diabetes drug base enhancement formulation new patent be set last note gerberry say cycloset previous patent technically last analyst consensus assume generic competition cycloset sale totale less first quarter do gain endorsement thursday american association clinical endocrinologist include comprehensive diabetes management algorithm guide physician battery different treatment cycloset be interesting useful therapy beneficial impact hba hemoglobin fact clinical testing be not associate increase risk adverse cardiovascular event dr alan garber head association algorithm task force say statement last week
1849,ABBV,gilead science gild newly approve hepatitis drug sovaldi come fire price pharmacy benefit manager express script esrx tuesday rival abbvie abbv report good datum compete drug candidate gilead stock drop abbvie rise stock market today bloomberg reporter draw say twitter express script chief medical officer
1850,ABBV,drugmaker aptalis holding file go public thursday ipo expect raise half dollar company formerly trade axcan pharma return new incarnation private equity firm tpg capital acquire axcan have merged several other company notably pharmaceutical acquire company have
1851,ABBV,big pharma abbvie abbv raise offer british drugmaker shire shpg tuesday morning wall street seem pessimistic stock fall stock market today abbvie offer british pound abbvie share share shire work more abbvie fourth attempt
1852,ABBV,wednesday confirm keep headquarters america win pursue inversion lower taxe purchase pharmacy alliance boot
1853,ABBV,pharmacy say remain headquarter deerfield ill chicago alliance boot keep current headquarters nottingham england
1854,ABBV,however wag do exercise option purchase alliance boot doesn already own
1855,ABBV,ceo greg wasson say consider then rule idea move headquarters more favorable taxe
1856,ABBV,take account factor include not arrive structure provide company board requisite level confidence transaction significance need withstand extensive ir review scrutiny say release
1857,ABBV,wasson add company also be mindful ongoing public reaction potential inversion unique role iconic american consumer retail company major portion revenue derive government funded reimbursement program
1858,ABBV,also see earning share vs wall street forecast ep
1859,ABBV,share plunge hit month low investor be surprised win pursue inversion
1860,ABBV,inversion have be come fire washington company look move only headquarters abroad more favorable tax rate keep most operation america have highest corporate tax rate develop world gap be grow
1861,ABBV,share fall tuesday medium report company eschew tax inversion report also come say treasury department be look unilateral action try stem tax inversion congress
1862,ABBV,investor absorb new inversion climate several other stock fall abbvie abbv retreat shire shpg nearly concern abbvie takeover plan not go forward plan base astrazeneca azn recently rebuff pfizer pfe megamerger offer slide
1863,ABBV,drugstore also retreat ep guidance cvs caremark cvs fall just fraction rite aid rad plunge wednesday confirm keep headquarters america win pursue inversion lower taxe purchase pharmacy alliance boot pharmacy say remain headquarter deerfield ill chicago alliance boot keep current headquarters nottingham england however wag do exercise option purchase alliance boot doesn already own ceo greg wasson say consider then rule idea move headquarters more favorable taxe take account factor include not arrive structure provide company board requisite level confidence transaction significance need withstand extensive ir review scrutiny say release wasson add company also be mindful ongoing public reaction potential inversion unique role iconic american consumer retail company major portion revenue derive government funded reimbursement program also see earning share vs wall street forecast ep share plunge hit month low investor be surprised win pursue inversion inversion have be come fire washington company look move only headquarters abroad more favorable tax rate keep most operation america have highest corporate tax rate develop world gap be grow share fall tuesday medium report company eschew tax inversion report also come say treasury department be look unilateral action try stem tax inversion congress investor absorb new inversion climate several other stock fall abbvie abbv retreat shire shpg nearly concern abbvie takeover plan not go forward plan base astrazeneca azn recently rebuff pfizer pfe megamerger offer slide drugstore also retreat ep guidance cvs caremark cvs fall just fraction rite aid rad plunge
1864,ABBV,big pharma abbvie abbv beat analyst estimate lead drug humira grow sharply company say slow affirm full year guidance stock fall fractionally morning trading stock market today abbvie make cent share quarter same year earlier quarter cent analyst
1865,ABBV,newly mint big pharma abbvie abbv narrowly beat estimate first quarter independent company rival biggest drug get surprise setback abbvie share be stock market
1866,ABBV,abbvie be spun abbott laboratory start year early friday say sale rise year quarter hair analyst estimate compile bloomberg net income rise cent share cent time item penny consensus company affirm previous full year ep guidance share
1867,ABBV,humira blockbuster treatment rheumatoid arthritis psoriasis other immunological condition continue grow nicely year year now provide more half abbvie revenue abbvie also get good news competition front late thursday european medicine agency surprised observer reject pfizer pfe xeljanz xeljanz be already approve rheumatoid arthritis earlier year injectable humira come oral form pfizer stock be nearly early trading friday
1868,ABBV,abbvie meanwhile be also present datum late stage hepatitis trial international liver congress run weekend amsterdam company release abstract datum earlier week support claim lead contender gilead science gild prize best interferon free treatment provider
1869,ABBV,related abbott lab earning steady abbvie spinoff newly mint big pharma abbvie abbv narrowly beat estimate first quarter independent company rival biggest drug get surprise setback abbvie share be stock market abbvie be spun abbott laboratory start year early friday say sale rise year quarter hair analyst estimate compile bloomberg net income rise cent share cent time item penny consensus company affirm previous full year ep guidance share humira blockbuster treatment rheumatoid arthritis psoriasis other immunological condition continue grow nicely year year now provide more half abbvie revenue abbvie also get good news competition front late thursday european medicine agency surprised observer reject pfizer pfe xeljanz xeljanz be already approve rheumatoid arthritis earlier year injectable humira come oral form pfizer stock be nearly early trading friday abbvie meanwhile be also present datum late stage hepatitis trial international liver congress run weekend amsterdam company release abstract datum earlier week support claim lead contender gilead science gild prize best interferon free treatment provider related abbott lab earning steady abbvie spinoff
1870,ABBV,big pharma pfizer pfe partly own veterinary business zoetis zts be set report earning open tuesday stock struggle recent setback pfizer be still shrink mode loss patent exclusivity major drug analyst poll thomson reuter expect sale decline
1871,ABBV,medical product maker abbott laboratory early wednesday meet expectation first quarterly financial report proprietary drug business sharply differ result emerge develop market share be early trading abbott report earning cent share penny analyst consensus cent year earlier quarter exclude pharma business
1872,ABBV,medical giant johnson johnson jnj deliver modest beat earning expectation early tuesday offer key insight first quarter health care industry share be stock market today company share profit exclude special item climb year quarter top analyst consensus cent
1873,ABBV,tango have turn full hoedown several major pharmaceutical company continue change partner floor valeant pharmaceutical vrx persh square capital management reportedly up bid tuesday allergan agn share accord wall street journal new bid raise valeant bid
1874,ABBV,name former kraft krft cfo timothy mclevish new evp cfo ahead national drugstore chain decision acquire rest alliance boot share wag rise stock market today buy alliance boot have be mull move europe
1875,ABBV,big biotech amgen amgn early monday report positive interim result crucial late stage trial blood cancer drug kyproli monday help justify acquisition onyx last year amgen be more early trading stock market today modest rise investor await result important second trial first trial call
1876,ABBV,biotech pharmacyclic pcyc be seesaw stock market today sale beat consensus late thursday company decline update guidance pharmacyclic sale more double year earlier quarter higher consensus loss cent share be well consensus cent analyst
1877,ABBV,medical product maker abbott laboratory wednesday meet expectation first quarterly report proprietary drug business sharply differ result emerge develop market share rise
1878,ABBV,abbott report earning cent share penny analyst consensus cent year quarter exclude pharma business spun abbvie abbv start year sale rise bit shy analyst sale figure include negative impact foreign exchange rate company say
1879,ABBV,abbott also affirm previous ep guidance full year last year offer guidance cent vs cent year line analyst estimate also guide mid single digit revenue growth quarter year
1880,ABBV,conference call discuss result abbott ceo mile white emphasize gap develop emerge market overall slow sale growth revenue emerge country rise double digit most product category white echo johnson johnson jnj executive comment tuesday continue sluggish demand medical product north america europe japan
1881,ABBV,be underlie economic malaise weakness pretty consistent develop market say not unique not unique europe conversely emerge market just opposite re pretty robust
1882,ABBV,be differ growth rate abbott major business unit however analyst expect nutritional business be key driver increase operate revenue be largest segment total sale business benefit launch new product include new version similac formula most growth be formula infant toddler have see explode demand china other emerge market
1883,ABBV,call white say company hope persuade chinese adult need nutritional formula also introduce ensure product line company plan boost capacity asian plant
1884,ABBV,market demographically culture use standpoint be perfect ensure white say
1885,ABBV,diagnostic rise again lopsided growth certain market core lab sale make majority revenue jump china russia company have also be add product portfolio particularly architect family immunoassay chemistry instrument detect disease
1886,ABBV,patent pharmaceutical abbott sell only overseas rise just new product launch have fight pricing pressure europe japan medical device come worst sale shrink year abbott stent business have be especially weak lose royalty promus stent japan face new competition medtronic mdt resolute integrity white note however latest addition xience line new absorb stent only just launch so business see improve sale medical product maker abbott laboratory wednesday meet expectation first quarterly report proprietary drug business sharply differ result emerge develop market share rise abbott report earning cent share penny analyst consensus cent year quarter exclude pharma business spun abbvie abbv start year sale rise bit shy analyst sale figure include negative impact foreign exchange rate company say abbott also affirm previous ep guidance full year last year offer guidance cent vs cent year line analyst estimate also guide mid single digit revenue growth quarter year conference call discuss result abbott ceo mile white emphasize gap develop emerge market overall slow sale growth revenue emerge country rise double digit most product category white echo johnson johnson jnj executive comment tuesday continue sluggish demand medical product north america europe japan be underlie economic malaise weakness pretty consistent develop market say not unique not unique europe conversely emerge market just opposite re pretty robust be differ growth rate abbott major business unit however analyst expect nutritional business be key driver increase operate revenue be largest segment total sale business benefit launch new product include new version similac formula most growth be formula infant toddler have see explode demand china other emerge market call white say company hope persuade chinese adult need nutritional formula also introduce ensure product line company plan boost capacity asian plant market demographically culture use standpoint be perfect ensure white say diagnostic rise again lopsided growth certain market core lab sale make majority revenue jump china russia company have also be add product portfolio particularly architect family immunoassay chemistry instrument detect disease patent pharmaceutical abbott sell only overseas rise just new product launch have fight pricing pressure europe japan medical device come worst sale shrink year abbott stent business have be especially weak lose royalty promus stent japan face new competition medtronic mdt resolute integrity white note however latest addition xience line new absorb stent only just launch so business see improve sale
1887,ABBV,celgene celg friday get upgrade deutsche bank analyst robyn karnauskas defy conventional wisdom predict biotech new psoriasis drug really be blockbuster ibd report recently late stage trial result drug show good safety profile efficacy be similar amgen amgn already market enbrel lower abbvie
1888,ABBV,drugmaker abbvie abbv offer nice dividend yield stock march higher abbvie be spun abbott laboratory earlier year be highest level go public jan climb ipo meanwhile company feb declare quarterly cash dividend cent share
1889,ABBV,key measure stock strength measure benchmark be relative strength line
1890,ABBV,rs line hit fresh high especially ahead stock price signal worth watch
1891,ABBV,today screen day be bolt rs line list top rate stock rs line hit new high prior session have average daily trading volume least share
1892,ABBV,today screen feature several medical company health care firm typically enjoy steady demand good bad economic time so often lead general market be bumpy
1893,ABBV,obamacare roll medical be see benefit other be shrink higher cost related regulatory obligation
1894,ABBV,here be medical company bolt rs line screen rs line have strike new high stock recent week
1895,ABBV,team health holding tmh provide outsourced staffing service hospital state tennessee base company go public mid december share revenue have rise double digit clip more year profit growth also take last year rise last quarters last quarter
1896,ABBV,trade relatively flat early begin climb low april have rise then rise monday stock market trading new close high
1897,ABBV,cigna ci offer variety way attain maintain insurance coverage include hmo ppos point service plan
1898,ABBV,cigna report higher earning share last quarters row consensus analyst poll thomson reuter be more modest gain announce first quarter earning share advanced monday new close high jump last week obama administration hike final medicare advantage reimbursement rate
1899,ABBV,abbvie abbv highest rate company most person have never hear be spun abbott laboratory jan sell testosterone boost androgel flagship product be humira rheumatoid arthritis also develop hepatitis treatment analyst expect come market
1900,ABBV,abbvie begin trading just month have rise close share rise monday hit new high
1901,ABBV,abc distribute brand name generic drug well counter health care product equipment
1902,ABBV,take care laundry list job medical community need get do include medicine packaging pharmacy automation drug distribution recently inked deal wag drugstore giant look offload distribution trading well day day line share rise
1903,ABBV,cvs caremark cvs be drugstore giant well lead pharmacy benefit manager boast annual revenue top mid november example stock have climb slightly outpace market upturn
1904,ABBV,be note period sale profit growth decelerate ep rise slim last quarter sale rise still sport ibd composite rating meaning outperformed stock recently key metric such sale profit growth share climb new high
1905,ABBV,related
1906,ABBV,oil related company mutual fund be buy
1907,ABBV,top stock long term earning sale growth key measure stock strength measure benchmark be relative strength line rs line hit fresh high especially ahead stock price signal worth watch today screen day be bolt rs line list top rate stock rs line hit new high prior session have average daily trading volume least share today screen feature several medical company health care firm typically enjoy steady demand good bad economic time so often lead general market be bumpy obamacare roll medical be see benefit other be shrink higher cost related regulatory obligation here be medical company bolt rs line screen rs line have strike new high stock recent week team health holding tmh provide outsourced staffing service hospital state tennessee base company go public mid december share revenue have rise double digit clip more year profit growth also take last year rise last quarters last quarter trade relatively flat early begin climb low april have rise then rise monday stock market trading new close high cigna ci offer variety way attain maintain insurance coverage include hmo ppos point service plan cigna report higher earning share last quarters row consensus analyst poll thomson reuter be more modest gain announce first quarter earning share advanced monday new close high jump last week obama administration hike final medicare advantage reimbursement rate abbvie abbv highest rate company most person have never hear be spun abbott laboratory jan sell testosterone boost androgel flagship product be humira rheumatoid arthritis also develop hepatitis treatment analyst expect come market abbvie begin trading just month have rise close share rise monday hit new high abc distribute brand name generic drug well counter health care product equipment take care laundry list job medical community need get do include medicine packaging pharmacy automation drug distribution recently inked deal wag drugstore giant look offload distribution trading well day day line share rise cvs caremark cvs be drugstore giant well lead pharmacy benefit manager boast annual revenue top mid november example stock have climb slightly outpace market upturn be note period sale profit growth decelerate ep rise slim last quarter sale rise still sport ibd composite rating meaning outperformed stock recently key metric such sale profit growth share climb new high related oil related company mutual fund be buy top stock long term earning sale growth
1908,ABBV,biotech stock bounce back recently last month medical biom biotech group be rank ibd industry be dead last last week plunge partly reflect growth stock overall fall hard current market correction specific concern sky high drug price notably gilead science blockbuster hepatitis
1909,ABBV,last month democrat congress send now famous letter gilead science gild question price new blockbuster hepatitis medicine sovaldi reason raise suspicion price didn need be high speed sovaldi be approve food drug administration gilead file receive
1910,ABBV,wag mull use loophole tax law save million dollar move headquarters europe former treasury official argue white house close loophole congressional approval article publish monday tax note journal accountant tax lawyer stephen shay former treasury
1911,ABBV,push company move overseas keep investor busy monday mylan agree buy part abbott laboratory generic drug business relocate netherlands mean abbott former proprietary drug unit abbvie close deal anglo irish shire pharmaceutical fifth offer abbott keep brand generic business emerge market
1912,ABBV,push company move overseas keep investor busy monday mylan agree buy part abbott laboratory generic drug business relocate netherlands mean abbott former proprietary drug unit abbvie close deal anglo irish shire pharmaceutical fifth offer abbott keep brand generic business emerge market
1913,ABBV,share celgene celg slide stock market today biotech release drug trial datum weekend disappoint investor
1914,ABBV,dermatology meeting saturday celgene report phase result experimental oral treatment psoriasis drug work many patient efficacy be biologic treatment already market include amgen amgn enbrel johnson johnson jnj stelara abbvie abbv humira
1915,ABBV,email client isi group analyst mark schoenebaum write still think drug be approve used doctor give good safety profile have be price discount biologic nonetheless say celgene sale guidance be too high analyst have fact be doubt figure ever phase datum come current consensus call sale
1916,ABBV,perhaps anticipation better news celgene stock hit new time high friday drive stock highest possible ibd composite rating celgene be monday ibd ranking top stock
1917,ABBV,related celgene earning meet raise guidance share celgene celg slide stock market today biotech release drug trial datum weekend disappoint investor dermatology meeting saturday celgene report phase result experimental oral treatment psoriasis drug work many patient efficacy be biologic treatment already market include amgen amgn enbrel johnson johnson jnj stelara abbvie abbv humira email client isi group analyst mark schoenebaum write still think drug be approve used doctor give good safety profile have be price discount biologic nonetheless say celgene sale guidance be too high analyst have fact be doubt figure ever phase datum come current consensus call sale perhaps anticipation better news celgene stock hit new time high friday drive stock highest possible ibd composite rating celgene be monday ibd ranking top stock related celgene earning meet raise guidance
1918,ABBV,share drug giant pfizer pfe animal health affiliate zoetis zts moved opposite direction tuesday company report sharply different first quarters
1919,ABBV,zoetis bring good news adjust net income reach cent share year earlier top analyst estimate cent sale rise slightly view
1920,ABBV,full year guidance be line consensus estimate ep sale last year company make cent share revenue
1921,ABBV,ipo month
1922,ABBV,zoetis partly spun pfizer ipo month perform best sale rise grow less europe do better have fear french competitor virbac report earlier april
1923,ABBV,be obvious weakness europe fact region include europe report revenue growth year year be excellent opinion write analyst mark schoenebaum isi group email client
1924,ABBV,conference call analyst discuss result ceo juan ramon alaix admit livestock portion zoetis business have hit head wind especially recent drought say sale pet market make difference be help partly now resolve supply issue rival
1925,ABBV,say company be optimistic pet market think have have right strategy right program also interaction customer direct interaction customer
1926,ABBV,zoetis share spiked much early fall back bit close
1927,ABBV,pfizer meanwhile issue much gloomier report sale shrank miss estimate profit fall cent share penny consensus
1928,ABBV,pfizer also shave full year revenue forecast be now vs last year also cut cent ep guidance be now vs last year
1929,ABBV,revenue miss revenue guidance cut be due unfavorable foreign exchange rate
1930,ABBV,be also timing issue center disease control purchase pneumococcal vaccine prevnar sale come consensus
1931,ABBV,ep guidance be hit foreign exchange rate zoetis divestment latter peel cent conference call pfizer ceo ian read say executive be still make mind divest zoetis pfizer still own also address prospect rest pfizer eventually split company much abbott laboratory abbvie abbv do earlier year already company be be organized core business read say win be ready separate earliest
1932,ABBV,potential blockbuster
1933,ABBV,research note morningstar analyst damien conover call quarter minor disappointment say didn affect longer term positive view say sale have be shrink due patent loss quarter bring launch potential blockbuster anticoagulant eliquis jointly own bristol myer squibb bmy oral rheumatoid arthritis drug xeljanz xeljanz be reject european union authority last week conover say pfizer succeed refile
1934,ABBV,other analyst have call eliquis launch weak read characterize line expectation xeljanz wasn fully launch march read say re encourage early indication indicator re see
1935,ABBV,pfizer stock fall tuesday close share drug giant pfizer pfe animal health affiliate zoetis zts moved opposite direction tuesday company report sharply different first quarters zoetis bring good news adjust net income reach cent share year earlier top analyst estimate cent sale rise slightly view full year guidance be line consensus estimate ep sale last year company make cent share revenue ipo month agozoetis partly spun pfizer ipo month perform best sale rise grow less europe do better have fear french competitor virbac report earlier april be obvious weakness europe fact region include europe report revenue growth year year be excellent opinion write analyst mark schoenebaum isi group email client conference call analyst discuss result ceo juan ramon alaix admit livestock portion zoetis business have hit head wind especially recent drought say sale pet market make difference be help partly now resolve supply issue rival say company be optimistic pet market think have have right strategy right program also interaction customer direct interaction customer zoetis share spiked much early fall back bit close pfizer meanwhile issue much gloomier report sale shrank miss estimate profit fall cent share penny consensus pfizer also shave full year revenue forecast be now vs last year also cut cent ep guidance be now vs last year revenue miss revenue guidance cut be due unfavorable foreign exchange rate be also timing issue center disease control purchase pneumococcal vaccine prevnar sale come consensus ep guidance be hit foreign exchange rate zoetis divestment latter peel cent conference call pfizer ceo ian read say executive be still make mind divest zoetis pfizer still own also address prospect rest pfizer eventually split company much abbott laboratory abbvie abbv do earlier year already company be be organized core business read say win be ready separate earliest potential blockbustersin research note morningstar analyst damien conover call quarter minor disappointment say didn affect longer term positive view say sale have be shrink due patent loss quarter bring launch potential blockbuster anticoagulant eliquis jointly own bristol myer squibb bmy oral rheumatoid arthritis drug xeljanz xeljanz be reject european union authority last week conover say pfizer succeed refile other analyst have call eliquis launch weak read characterize line expectation xeljanz wasn fully launch march read say re encourage early indication indicator re see pfizer stock fall tuesday close
1936,ABBV,oral rheumatoid arthritis treatment develop rigel pharmaceutical rigl astrazeneca azn yielded mixed result late stage trial send rigel share tumble early trading friday drug fostamatinib meet primary endpoint show statistically significant improvement patient acr score denote least fewer tender joint fewer swollen joint however
1937,ABBV,early wednesday abbott laboratory be set report first quarter half company used be spin proprietary drug business new year day
1938,ABBV,result year year comparison be bit deceptive current consensus accord thomson reuter call drop sale last year earning fall cent share year number however include company now know abbvie abbv own blockbuster arthritis drug humira other popular drug accord analyst remain division see mixed result
1939,ABBV,nutritional now make largest division abbott revenue earlier month william blair morgan stanley offer bullish outlook business especially mead johnson mjn ceo peter jakobsen say march crucial chinese market be improve gain further support tuesday french competitor danone danoy report record growth asian sale especially infant formula danone mead johnson share rise more
1940,ABBV,william blair analyst ben andrew be modele growth abbott nutrition business also modele similar growth diagnostic division again due growth emerge market well new product however expect sale patent drug shrink due austerity measure europe reimbursement cut japan sale stent business be also expect shrink company face rollout medtronic mdt resolute integrity stent
1941,ABBV,related johnson johnson earning beat expectation early wednesday abbott laboratory be set report first quarter half company used be spin proprietary drug business new year day result year year comparison be bit deceptive current consensus accord thomson reuter call drop sale last year earning fall cent share year number however include company now know abbvie abbv own blockbuster arthritis drug humira other popular drug accord analyst remain division see mixed result nutritional now make largest division abbott revenue earlier month william blair morgan stanley offer bullish outlook business especially mead johnson mjn ceo peter jakobsen say march crucial chinese market be improve gain further support tuesday french competitor danone danoy report record growth asian sale especially infant formula danone mead johnson share rise more william blair analyst ben andrew be modele growth abbott nutrition business also modele similar growth diagnostic division again due growth emerge market well new product however expect sale patent drug shrink due austerity measure europe reimbursement cut japan sale stent business be also expect shrink company face rollout medtronic mdt resolute integrity stent related johnson johnson earning beat expectation
1942,ABBV,big cap biotech celgene celg report wednesday drug otezla fail trial inflammatory spinal disease stock rebound early drop analyst say news wasn surprise phase study look otezla ankylose spondylitis immunological disease cause pain sometimes fusion spinal cord be not
1943,ABBV,chairman senior member senate finance committee friday issue battery question gilead science gild price blockbuster hepatitis drug sovaldi add chorus objection product pill price market be unfazed however gilead stock fraction morning trading
1944,ABBV,exchange trade fund create track basket initial public offering renaissance ipo etf ipo have own ipo new york stock exchange wednesday aptly trading ticker ipo etf create renaissance capital greenwich conn pound gorilla ipo research investment management start trading
1945,ABBV,share celgene celg be trading time high early tuesday slew analyst upgrade follow investor presentation monday jpmorgan healthcare conference san francisco biotech issue financial guidance way predict annual revenue have more double also say psoriasis
1946,ABBV,big pharma astrazeneca azn pull plug rheumatoid arthritis pill be develop rigel pharmaceutical rigl send latter share plunge stock market tuesday astrazeneca make decision see late stage result fostamatinib be less impressed rheumatoid arthritis be extremely competitive market give already dominate world
1947,ABBV,big pharma club gain newest member wednesday abbvie abbv begin trading nyse separate abbott laboratory
1948,ABBV,spinoff execute abbott longtime plan separate call research base drug business other branch devote generic drug device nutritional product
1949,ABBV,abbvie take abbott biggest revenue draw immunology drug humira account more abbvie sale abbvie total revenue first month last year be year earlier period net earning rise
1950,ABBV,today abbvie launch outstanding portfolio solid pipeline enthusiastic person serve patient deliver growth abbvie ceo richard gonzalez say company press release asset relentless focus innovation intend create significant value shareholder
1951,ABBV,abbvie be spun distribution rather ipo so do not start fix price however early trading be open price
1952,ABBV,market cap more standard poor announce few week abbvie replace dell dell latter price decline have push megacap threshold
1953,ABBV,analyst already start issue initiation report jpmorgan launch coverage neutral bmo capital market outperform big pharma club gain newest member wednesday abbvie abbv begin trading nyse separate abbott laboratory spinoff execute abbott longtime plan separate call research base drug business other branch devote generic drug device nutritional product abbvie take abbott biggest revenue draw immunology drug humira account more abbvie sale abbvie total revenue first month last year be year earlier period net earning rise today abbvie launch outstanding portfolio solid pipeline enthusiastic person serve patient deliver growth abbvie ceo richard gonzalez say company press release asset relentless focus innovation intend create significant value shareholder abbvie be spun distribution rather ipo so do not start fix price however early trading be open price market cap more standard poor announce few week abbvie replace dell dell latter price decline have push megacap threshold analyst already start issue initiation report jpmorgan launch coverage neutral bmo capital market outperform
1954,ABBV,many say drug industry be enter post blockbuster era mega seller such lipitor lose patent be drug pipeline expect pass traditional blockbuster benchmark global annual sale here preview expect launch next month have attract much interest
1955,ABBV,biotech gilead science gild keep roll good news hepatitis pipeline tuesday analyst upgrade drive stock new time high gilead say combination drug candidate sofosbuvir establish oral treatment ribavirin beat back hc virus more half especially difficult population patient
1956,ABBV,medical giant johnson johnson deliver modest beat first quarter earning expectation tuesday offer key insight new year health care industry share rise jnj share profit exclude special item climb year quarter top analyst consensus cent sale slightly beat expectation rise
1957,ABBV,giant pharma pfizer pfe stock hit year high tuesday firm beat analyst expectation offer guidance line estimate real stock driver have be heighten rumor major divestment revenue fall year earlier quarter drop reflect pfizer loss patent exclusivity blockbuster
1958,ABBV,news be come thick fast medical sector wednesday send stock move direction swiss pharma giant novartis nvs be nearly early trading result beat expectation top bottom line profit share be prior year analyst have expect
1959,ABBV,share biotech santarus snt pop nearly early trading tuesday hit year high fda approve bowel disease drug uceris be fifth commercial product market santarus already sell drug zegerid well diabetes drug cholesterol lower fenoglide uceris other product be enter
1960,ABBV,big drugmaker look place grow generally look disease have certain characteristic have fair size patient population re chronic re inadequately treat current medicine psoriasis meet qualification not surprisingly then biggest name pharma have late stage candidate work include amgen amgn eli lilly lly pfizer pfe novartis ticker
1961,ABBV,company segment health care debut stock market thursday meet friendly reception biotech enanta pharmaceutical enta price low end expect range wednesday night midmorning trading thursday be already past top range enanta create molecular technology
1962,ABBV,big boy wall street mostly stay ipo market february only handful offering come mostly backed second tier underwriter thursday successful debut artisan partner apam stock market today backed citi goldman model announcement term signale possible change
1963,ABBV,stock rally thursday thank better expect jobless claim round earning report equity pare gain final hour
1964,ABBV,nasdaq end rise much intraday trim gain rise fifth straight session thursday duo nearly touch april high intraday meanwhile dow jone industrial average rise volume climb board stock market today
1965,ABBV,hour expedia expe jump post profit cent share cent view sale also beat view grow year stock be double bottom base buy point
1966,ABBV,amazon com amzn share be also higher late trading commerce giant mixed result company post earning cent share cent year period still dime view sale rise miss view
1967,ABBV,regular session cabela cab gap sky-rocket record high even marked fade late cabela close session high open outdoor equipment retailer deliver earning jump cent share beat cent thank strong demand gun ammo sale rise top bottom line growth be best year stock clear buy point irregular flat base
1968,ABBV,assignment asgn rally heavy trading regain day move average stock close almost smack session high share staffing firm be much intraday erase gain power news assigment earning sale more double result be lift last year buyout staffing company apex system assignment also guide profit revenue expectation
1969,ABBV,pultegroup phm climb report mixed result earlier thursday stock be double bottom base buy point pattern be third stage base generally first second stage pattern be prefer
1970,ABBV,downside proto lab prlb shave earlier loss also climb back day move average breaking line intraday maker custom part sell warning profit margin offset better expect result proto lab recently have fail find support level
1971,ABBV,abbvie abbv burger king worldwide bkw chevron cvx saia saia weyerhauser wy report earning friday
1972,ABBV,datum first quarter gross domestic product university michigan consumer sentiment index also be friday stock rally thursday thank better expect jobless claim round earning report equity pare gain final hour nasdaq end rise much intraday trim gain rise fifth straight session thursday duo nearly touch april high intraday meanwhile dow jone industrial average rise volume climb board stock market today hour expedia expe jump post profit cent share cent view sale also beat view grow year stock be double bottom base buy point amazon com amzn share be also higher late trading commerce giant mixed result company post earning cent share cent year period still dime view sale rise miss view regular session cabela cab gap sky-rocket record high even marked fade late cabela close session high open outdoor equipment retailer deliver earning jump cent share beat cent thank strong demand gun ammo sale rise top bottom line growth be best year stock clear buy point irregular flat base assignment asgn rally heavy trading regain day move average stock close almost smack session high share staffing firm be much intraday erase gain power news assigment earning sale more double result be lift last year buyout staffing company apex system assignment also guide profit revenue expectation pultegroup phm climb report mixed result earlier thursday stock be double bottom base buy point pattern be third stage base generally first second stage pattern be prefer downside proto lab prlb shave earlier loss also climb back day move average breaking line intraday maker custom part sell warning profit margin offset better expect result proto lab recently have fail find support level abbvie abbv burger king worldwide bkw chevron cvx saia saia weyerhauser wy report earning friday datum first quarter gross domestic product university michigan consumer sentiment index also be friday
1973,ABBV,april notch month gain stock market straight month so far year
1974,ABBV,market rally be get long tooth top fund manager have be cautious buy
1975,ABBV,nation top perform fund past month have be add medical stock portfolio such big biotech firm celgene celg biogen idec biib amgen amgn regeneron pharmaceutical regn latest report period drugmaker abbvie abbv draw heavy buy top fund
1976,ABBV,medium giant time warner twx news corp nwsa have be solid performer lead fund invest estimate news corp latest report period
1977,ABBV,housing market start recover build supply retailer home depot hd self storage facility reit extra space storage exr have garner buy interest lead fund
1978,ABBV,ibd spot best perform fund buy pulte group phm dws core equity fund add stock holding
1979,ABBV,bloomfield hill mich base pulte build single family home townhouse condo duplex first time homebuyer well repeat buyer financial service segment handle mortgage banking title operation
1980,ABBV,pulte be back track housing rebound inventory home sale be still tight well buildable land low mortgage rate have also fuel buy
1981,ABBV,stock have be consolidate run week high
1982,ABBV,analyst see earning rise
1983,ABBV,sell side
1984,ABBV,country lead fund have be unload handful drug giant such pfizer pfe bristol myer squibb bmy latest report period
1985,ABBV,stock have have strong run up so far year notch fresh week high ve hit wall recent week
1986,ABBV,pfizer report disappointing first quarter earning result miss analyst expectation earning revenue
1987,ABBV,cite lose sale generic version best selling cholesterol lower drug lipitor overseas revenue be also hurt strong dollar april notch month gain stock market straight month so far year market rally be get long tooth top fund manager have be cautious buy nation top perform fund past month have be add medical stock portfolio such big biotech firm celgene celg biogen idec biib amgen amgn regeneron pharmaceutical regn latest report period drugmaker abbvie abbv draw heavy buy top fund medium giant time warner twx news corp nwsa have be solid performer lead fund invest estimate news corp latest report period housing market start recover build supply retailer home depot hd self storage facility reit extra space storage exr have garner buy interest lead fund ibd spot best perform fund buy pulte group phm dws core equity fund add stock holding bloomfield hill mich base pulte build single family home townhouse condo duplex first time homebuyer well repeat buyer financial service segment handle mortgage banking title operation pulte be back track housing rebound inventory home sale be still tight well buildable land low mortgage rate have also fuel buy stock have be consolidate run week high analyst see earning rise sell country lead fund have be unload handful drug giant such pfizer pfe bristol myer squibb bmy latest report period stock have have strong run up so far year notch fresh week high ve hit wall recent week pfizer report disappointing first quarter earning result miss analyst expectation earning revenue cite lose sale generic version best selling cholesterol lower drug lipitor overseas revenue be also hurt strong dollar
1988,ABBV,stock remain mixed narrowing tighter range quiet trade midday friday market track healthy gain week
1989,ABBV,dow jone industrial average trade be nasdaq improve loss volume be nasdaq lower nyse
1990,ABBV,stock market today receive mixed send first quarter gdp growth improve much less expect final read april consumer sentiment improve sharply initial estimate industry group track ibd be trading lower midday
1991,ABBV,stock penney jcp horton dhi lead morning session respectively medical scientific equipment maker perkinelmer pki drop score index worst loss deliver weak first quarter report
1992,ABBV,ibd list rental car competitor avis budget group car hertz global holding htz catch fire avis more hertz grab gain
1993,ABBV,move drive avis just april high thick trade rebound support day move average hertz be also just april high hasn come day line february
1994,ABBV,new issue drugmaker abbvie abbv jump new high putt share january open price spinoff abbott laboratory narrowly top sale earning expectation quarter reiterate full year guidance be low end analyst consensus view
1995,ABBV,baidu bidu stumble loss result miss analyst consensus forecast
1996,ABBV,chipmaker maxim integrate product mxim shed report fiscal third quarter result late thursday earning rise better expect sale growth top projection fourth quarter sale earning guidance be line consensus estimate
1997,ABBV,stock have be shallow consolidation struggle hold week support mid march stock remain mixed narrowing tighter range quiet trade midday friday market track healthy gain week dow jone industrial average trade be nasdaq improve loss volume be nasdaq lower nyse stock market today receive mixed send first quarter gdp growth improve much less expect final read april consumer sentiment improve sharply initial estimate industry group track ibd be trading lower midday stock penney jcp horton dhi lead morning session respectively medical scientific equipment maker perkinelmer pki drop score index worst loss deliver weak first quarter report ibd list rental car competitor avis budget group car hertz global holding htz catch fire avis more hertz grab gain move drive avis just april high thick trade rebound support day move average hertz be also just april high hasn come day line february new issue drugmaker abbvie abbv jump new high putt share january open price spinoff abbott laboratory narrowly top sale earning expectation quarter reiterate full year guidance be low end analyst consensus view baidu bidu stumble loss result miss analyst consensus forecast chipmaker maxim integrate product mxim shed report fiscal third quarter result late thursday earning rise better expect sale growth top projection fourth quarter sale earning guidance be line consensus estimate stock have be shallow consolidation struggle hold week support mid march
1998,ABBV,bristol myer squibb company bmy free report announce positive result phase ii study eloquent oncology drug empliciti study be evaluate addition empliciti pomalyst low dose dexamethasone epd patient relapse refractory multiple myeloma rrmm international study be evaluate pomalyst base triplet combination patient rrmm receive least prior therapy include revlimid proteasome inhibitor study achieve primary endpoint result show statistically significant clinically meaningful improvement progression free survival pfs patient treat epd compare only pomalyst dexamethasone pd datum be also present rd congress european hematology association datum study show patient randomize epd experience reduction risk disease progression compare patient randomize pd alone median pfs month compare month pd patient additionally pfs benefit experience patient randomize epd be consistent patient have receive prior line therapy more prior line therapy combination therapy approve provide important treatment option patient relapse refractory multiple myeloma disease have progressed treatment lenalidomide proteasome inhibitor bristol myer be co develop empliciti abbvie abbv free report bristol myer share have decline year date compare industry decline earlier company announce china national drug administration have approve blockbuster immuno oncology drug opdivo treatment locally advanced metastatic small cell lung cancer nsclc prior platinum base chemotherapy adult patient egfr alk genomic tumor aberration company be first only pd inhibitor approve china approval be base datum pivotal phase iii study checkmate trial patient enrolled be china note opdivo become first pd immune checkpoint inhibitor gain regulatory approval be currently approve several country include unite state eu japan several cancer indication opdivo become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november drug have be perform impressively due demand result rapid commercial acceptance several indication include melanoma renal cell carcinoma second line nsclc label expansion additional indication give product access higher patient population increase commercial potential drug significantly however opdivo face stiff competition merck mrk free report keytruda roche rhhby free report tecentriq limit market share gain zack rank stock considerbristol myer carry zack rank hold see complete list today zack strong buy rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1999,ABBV,alzheimer candidate fail clinical study week independent datum monitoring committee idmc recommend lilly lly free report astrazeneca azn free report discontinue study lanabecestat share israel base small biotech galm pharmaceutical ltd glmd free report rise announce positive datum mid stage study nash candidate aramchol merck mrk free report gain fda approval new indication blockbuster pd therapy keytruda glaxo gsk free report late stage hiv study meet primary endpoint abbvie abbv free report roche rhhby free report astrazeneca gain regulatory nod label expansion key cancer drug recap week most important storieslilly astrazeneca alzheimer candidate fail lilly astrazeneca be discontinue late stage study alzheimer disease candidate lanabecestat recommendation idmc idmc say study early alzheimer disease other mild alzheimer disease dementia be unlikely meet primary endpoint completion lead decision discontinue study oral beta secretase cleave enzyme bace inhibitor latest setback add long list fail treatment option deadly brain disease read more lilly astrazeneca scrap study alzheimer candidate merck keytruda get fda nod new indication merck gain fda accelerate approval new indication blockbuster pd therapy keytruda week include third line treatment adult well pediatric patient primary mediastinal cell lymphoma pmbcl type hodgkin lymphoma second line treatment recurrent metastatic cervical cancer label expansion approval drive sale keytruda future quarters also merck regulatory application seek approval expand age indication hpv vaccine gardasil be grant priority review fda merck be look get gardasil approve woman man age hpv vaccine be presently approve man woman age read more merck keytruda get fda nod lymphoma indication glaxo gemini study drug hiv regimen succeed glaxo late stage study testing drug hiv regimen dolutegravir tivicay lamivudine show inferiority hiv control standard drug regimen regimen dolutegravir tenofovir alafenamide fumarate emtricitabine study be conduct treatment naïve hiv infected adult have not receive prior antiviral therapy regulatory application get drug regimen dolutegravir lamivudine approve be expect be file later year positive news glaxo mylan generic version glaxo blockbuster respiratory drug advair be delay again second complete response letter fda galm share hit roof nash candidate succeed study galm announce positive top line result mid stage study lead candidate aramchol treatment alcoholic steatohepatitis nash study demonstrated aramchol be effective reach primary endpoint importantly reduction liver fat measure magnetic resonance spectroscopy be demonstrated patient have complete week treatment aramchol mg compare placebo result strongly support advancement aramchol pivotal phase iii study share company sky-rocket news be announce read more galm soar positive nash datum aramchol allergan cgrp drug meet goal study allergan announce second cgrp candidate atogepant meet primary endpoint mid stage study cgp md study evaluate dose atogepant prevention episodic migraine week atogepant achieve reduction statistical significance monthly migraine probable migraine mpm headache day baseline dose allergan oral cgrp acute migraine treatment ubrogepant have already show positive result phase iii study separately allergan announce positive top line datum phase iii study pipeline candidate bimatoprost sr investigational implant develop first sustain release drop free treatment option lower intraocular pressure iop patient open angle glaucoma ocular hypertension datum study show bimatoprost sr reduce iop approximately week primary efficacy period thereby demonstrate inferiority study comparator timolol eye drop abbvie roche cancer drug get fda nod combo use abbvie roche announce fda approval combination use cancer drug venclexta rituxan previously treat chronic lymphocytic leukemia cll fda approval be base positive datum phase iii murano study venclexta rituxan relapse refractory cll venclexta be jointly market abbvie roche subsidiary genentech unite state abbvie outside unite state separately roche announce fda approval cancer drug avastin combination chemotherapy carboplatin paclitaxel treatment woman advanced ovarian cancer follow initial surgery latest approval avastin be now approve different type cancer unite state tagrisso get eu approval first line set astrazeneca azn free report lung cancer drug tagrisso gain eu approval first line treatment adult patient metastatic nsclc tumor have egfr mutation similar label expansion application be approve unite state april now tagrisso be approve unite state european union japan china second line treatment option patient egfr mutation positive nsclc label expansion first line set drive sale tagrisso higher future quarters read more astrazeneca tagrisso win eu nod first line lung cancer accept offer sell diabetes unit formally accept bound offer receive march approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year transaction be expect be close end year read more accept platinum equity offer lifescan unit nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session last week pfizer decline most glaxo generate highest return past month too glaxo have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup mrk impress asco lly get fda nod olumiant next pharma world watch fda decision several pipeline drug line extension market product month wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2000,ABBV,abbvie inc abbv free report announce fda have grant approval combination use cancer drug venclexta roche rhhby free report rituxan treatment patient relapse refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma sll deletion have receive least prior therapy venclexta be jointly market abbvie roche pharma arm genentech unite state abbvie outside unite state fda approval combination use be base positive datum phase iii murano study venclexta rituxan relapse refractory clldata study present september last year show combination lead profound improvement progression free survival compare teva pharmaceutical teva free report treanda rituxan br result study show fix duration treatment venclexta rituxan significantly reduce risk disease progression death compare br overall response rate orr be venclexta rituxan arm compare br concurrently fda also approve venclexta monotherapy cll sll patient deletion now monotherapy venclexta be approve treat patient cll deletion detected fda approve test fda approval label expansion venclexta indication expand patient population venclexta significantly boost commercial potential latest approval venclexta rituxan become first oral chemotherapy free fix duration treatment option cll patient also summer abbvie file regulatory application unite state venclexta acute myeloid leukemia aml phase iii program multiple myeloma be also progress well abbvie share have gain year so far industry decline abbvie currently carry zack rank hold better rank large cap pharma stock be eli lilly company lly free report zack rank buy see complete list today zack rank strong buy stock here lilly earning estimate increase past day company deliver positive earning surprise trail quarters average beat share lilly have gain year so far hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2001,ABBV,be approve therapy completely cure autoimmune inflammatory disease development new treatment technology be ongoing meanwhile be difficult control autoimmune disease majority patient newest class medication treat disease be janus kinase jak inhibitor be provide patient better treatment option class therapy have generate significant interest due better efficacy compare tumor necrosis factor tnf inhibitor therapy autoimmune diseasesin patient autoimmune disease body immune system mistakenly attack healthy cell scientist be yet find reason abnormality however incidence autoimmune disease be rise be multiple type autoimmune disease include rheumatoid arthritis ra psoriasis multiple sclerosis ms inflammatory bowel disease ibd etc several company be dedicate bring better drug treatment disease symptom include fatigue muscle ach swell redness affected body part most common first line treatment autoimmune disease be disease modify rheumatic drug dmard especially methotrexate apart methotrexate be several class dmard include tnf inhibitor therapy approve disease be perform well abbvie abbv free report humira amgen amgn free report enbrel be blockbuster tnf inhibitor drug other however treatment have serious safety issue include increase risk tuberculosis lymphoma other jak pharma company be develop jak inhibitor work block particular signal body immune response cytokine instead suppress immune system do dmard patient treat jak inhibitor clinical study have show faster better response disease however safety concern still loom large segment be attractive company be only jak inhibitor presently approve treatment autoimmune disease especially ra however several company be develop candidate be likely increase competition go forward segment be news recently eli lilly lly free report olumiant jak inhibitor receive approval unite state abbvie abbv free report announce top line datum late stage study evaluate jak inhibitor candidate upadacitinib pharma biotech company grow interest jak inhibitor let take look pharma biotech company be look change way autoimmune disease be treat pfizer pfe free report xeljanz tofacitinib be first approve jak inhibitor unite state treatment ra have be available market drug be also approve psoriatic arthritis generate sale first quarter year year regulatory application seek line extension drug ulcerative colitis be approve late last month unite state regulatory application seek approval indication be review europe company currently carry zack rank hold see complete list today zack rank strong buy stock here eli lilly jak inhibitor olumiant baricitinib be second drug receive approval treat ra unite state drug be approve early month however be launch certain european country note fda reject company new drug application seek approval olumiant april cite safety concern lilly develop commercialize drug partnership incyte corporation drug generate sale first quarter sequentially lilly be currently evaluate drug autoimmune indication atopic dermatitis eczema late stage study company currently carry zack rank buy abbvie be company be focuse develop jak inhibitor base treatment company jak inhibitor upadacitinib show promising result late stage study evaluate candidate ra patient be also be develop atopic dermatitis late stage study enjoy breakthrough therapy status unite state late stage study be evaluate candidate crohn disease company currently carry zack rank galapago nv glpg free report be develop jak inhibitor candidate filgotinib collaboration gilead science inc gild free report separate late stage study be evaluate candidate ra crohn disease ulcerative colitis moreover several mid stage study be evaluate candidate multiple autoimmune indication include ankylose spondylitis psoriatic arthritis cutaneous lupus erythematosus other datum mid stagei study evaluate filgotinib psoriatic arthritis show significant improvement patient company currently carry zack rank prospect jak inhibitor several blockbuster dmard near patent expiration new class drug hold potential replace exist treatment boost prospect company have drug candidate pipeline commercial portfolio however jak inhibitor also have several side effect delay approval note lower dose lilly olumiant be approve box warning state risk serious infection malignancy thrombosis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2002,ABBV,week be rule cancer datum presentation annual meeting american society clinical oncology asco chicago pharma bigwig bristol myer bmy free report merck mrk free report roche rhhby free report other jak inhibitor be news week lilly lly free report finally gain fda approval rheumatoid arthritis ra candidate olumiant baricitinib unite state abbvie abbv free report present positive top line datum fifth late stage study upadacitinib ra recap week most important storiesupdate asco merck steal show asco present datum several cancer study pd inhibitor keytruda key presentation be pivotal lung cancer trial keynote study evaluate keytruda monotherapy newly diagnosed lung cancer patient keynote study evaluate keytruda combination chemotherapy difficult treat squamous small cell lung cancer nsclc study show treatment keytruda lead improve survival particularly datum keynote study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be consider practice change investor year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc bristol myer nektar therapeutic nktr present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result drop nektar stock monday read more nektar bristol myer present datum cancer study bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression novartis nvs announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna roche present datum late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone abbvie present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer pfe free report astrazeneca also make cancer datum presentation meeting lilly get fda nod lower dose olumiant eli lilly partner incyte gain fda approval lower dose mg company jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan generate sale first quarter unite state lilly face significant trouble get fda nod olumiant april last year fda have issue complete response letter new drug application seek approval olumiant request additional information determine most appropriate dose year april fda advisory committee have recommend approval lower dose drug not recommend higher dose mg inadequate safety profile support approval relative benefit read more eli lilly olumiant get fda nod rheumatoid arthritis abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program top line datum study show thata significantly higher proportion patient treat upadacitinib mg dose achieve superior response compare chemotherapy agent methotrexate abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year read more abbvie upadacitinib fifth ra study datum positive allergan activist pressure split ceo chairman role allergan agn free report be pressure week hedge fund firm senator investment group appaloosa disclose letter urge company engage management board overhaul firm ask pharmaceutical company split chairman chief executive role presently hold brent saunder other management change appaloosa run david tepper senator investment group run dougla silverman suggest outsider be hire role letter come heel allergan strategic plan announce last week divest woman health infectious disease unit allergan respond say board have be refreshed addition member last month read more allergan request shareholder veto management change glaxo complete buyout novartis stake consumer healthcare jv glaxo announce have complete previously announce deal buy novartis stake consumer healthcare joint venture acquisition novartis stake glaxo now have ownership consumer healthcare unit include product such sensodyne flonase glaxo novartis create jv part part transaction company combine consumer division pfizer invest more venture capital arm pfizer plan invest venture capital arm pfizer venture be invest small biotechs other emerge growth company be earmark company involved promising early stage neuroscience research read more pfizer boost venture capital effort neuroscience focus meanwhile pfizer regulatory application orally available parp inhibitor talazoparib metastatic breast cancer patient inherited brca mutation be accept review fda european medicine agency unite state new drug application nda be grant priority review fda decision accept december year top line result talazoparib registrational study embraca germline brca mutate breast cancer present december demonstrated superiority talazoparib chemotherapy improve progression free survival roche haemophilium candidate get priority review roche sbla look label expansion drug hemlibra person haemophilium factor viii inhibitor be grant priority review fda hemlibra be presently market routine prophylaxis prevent reduce frequency bleed episode haemophilium patient factor viii inhibitor fda grant priority review decision be expect oct separately roche cancer drug rituxan gain fda approval new indication moderate severe pemphigus vulgaris pv potentially life threaten nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock be green last week astrazeneca decline merck rise most asco strength past month glaxo gsk have be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup zoetis buy abaxis nvs get fda nod migraine drug next pharma world watch fda decision many pipeline drug line extension market product month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2003,ABBV,value investing be easily most popular way find great stock market environment wouldn want find stock be fly radar be compelling buy offer tantalize discount compare fair value way find company be look several key metric financial ratio many be crucial value stock selection process let put abbvie inc abbv free report stock equation find be good choice value oriented investor right now investor subscribe methodology look elsewhere top pick pe ratioa key metric value investor always look be price earning ratio pe short show much investor be willing pay dollar earning give stock be easily most popular financial ratio world best use pe ratio be compare stock current pe ratio ratio have be past compare average industry sector compare market whole front abbvie have trail month pe ratio nearly see chart level actually compare pretty favorably market large pe stand focus long term pe trend abbvie current pe level put slightly midpoint past year moreover current level be fairly high stock suggest be good entry point further stock pe also compare favorably sector trail month pe ratio stand very least indicate stock be relatively undervalue right now compare peer also point abbvie have forward pe ratio price relative year earning just so be fair say slightly more value oriented path be ahead abbvie stock term too ratioanother key metric note be price sale ratio approach compare give stock price total sale lower read be generally consider better person metric more other value focuse one look sale something be far harder manipulate accounting trick earning right now abbvie have ratio be higher average come right now nonetheless see chart be well high stock particular past few year broad value outlookin aggregate abbvie currently have zack value style score putt top stock cover look make abbvie solid choice value investor other key metric make pretty clear too example peg ratio abbvie be just level be lower industry average peg ratio be modify pe ratio take account stock earning growth rate stock overall abbvie be good choice value investor be plenty other factor consider investing name particular be worth note company have growth grade momentum score give abbv zack vgm score overarch fundamental grade read more zack style score here meanwhile company recent earning estimate have be trend higher current quarter have see estimate go higher past day compare none lower full year estimate have see upward downward revision same time period result current quarter consensus estimate have rise past month full year estimate have inched see consensus estimate trend recent price action stock chart abbvie inc price consensus abbvie inc price consensus abbvie inc favorable trend be stock have zack rank buy be look outperformance company term bottom lineabbvie be inspire choice value investor be hard beat incredible lineup statistic front strong zack rank also indicate robust growth potential future however company prospect be constrain due adverse broader factor have sluggish industry rank bottom more industry fact past year industry have clearly underperform broader market see so value investor want broader factor turn name first once happen stock be compelling pick wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2004,ABBV,gilead science gild free report enter research collaboration license agreement hookipa biotech ag agreement gilead own exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv research work be carry hookipa manufacture arenavirus base vector clinical development gilead exchange gilead provide upfront payment addition hookipa be eligible receive payment total more base achievement specify development regulatory commercial milestone moreover gilead fund research development activity hookipa also be eligible receive tiered royalty net sale agreement further expand relationship hookipa gilead follow gilead participation hookipa series financing dec hookipa unique therapeutic vaccine technology demonstrated excellent safety immunogenicity phase study gilead be banking hiv franchise drive growth future give persistent decline hcv sale gilead stock have lose last month industry loss gilead hcv franchise witness slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other meanwhile gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib first quarter gilead announce agreement sangamo therapeutic inc sgmo free report use sangamo zinc finger nuclease technology platform development next generation ex vivo cell therapy oncology zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2005,ABBV,abbvie inc abbv free report announce investigational oral jak inhibitor upadacitinib meet primary well secondary endpoint fifth phase iii study select program phase iii study select early evaluate candidate moderate severe rheumatoid arthritis ra patient have not be previously treat chemotherapy agent methotrexate mtx versus mtx monotherapy select program evaluate more patient study ra week treatment acr response primary endpoint be achieve patient receive mg oral once daily dose upadacitinib patient take mg dose versus patient receive mtx second primary endpoint clinical remission be achieve patient mg dose arm mg dose arm week versus only mtx meanwhile patient mg mg dose arm respectively achieve acr response week versus mtx result clearly show significantly higher proportion patient treat upadacitinib dose achieve superior response compare mtx suggest upadacitinib monotherapy have potential control progression ra reduce risk permanent bone joint damage mtx naive patient abbvie plan submit regulatory application upadacitinib rheumatoid arthritis second half year other rheumatoid arthritis upadacitinib be also be evaluate late stage study crohn disease psoriatic arthritis mid stage study atopic dermatitis giant cell arteritis ulcerative colitis jak inhibitor also know janus kinase inhibitor be emerge potential treatment option ra eczema other inflammatory disease medicine work inhibit activity more janus kinase family enzymeslast week eli lilly lly free report partner incyte corporation incy free report gain fda approval lower dose mg oral jak inhibitor olumiant fda do not approve higher dose mg drug label be approve box warning state risk serious infection malignancy thrombosis olumiant be already market europe japan jak inhibitor available market treat ra be pfizer pfe free report xeljanz successful development upadacitinib boost abbvie ra portfolio especially biosimilar competition loom blockbuster ra drug humira humira account abbvie sale amgen samsung bioepis biogen humira biosimilar be launch unite state eu abbvie share have gain year so far industry decline abbvie currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2006,ABBV,ever president trump imposition tariff steel aluminum import china market large have suffer dearly have be number meeting trade representative country vain further escalate trade war tension report have surface treasury department have be draft policy prohibit firm have more chinese ownership benefit emerge technology unite state such policy have negative ramification industry healthcare biotech pharmaceutical be tech heavy need acquire industrially efficient technology growth sustenance so trade war china turn be nightmare healthcare sector let have look trump protectionism dampen healthcare fortunesearly stage pharmaceutical startup biotech company have historically benefit increase access chinese investment resource intellectual property right protection be go hamper grow entrepreneurial spirit biotech space long run brunt be bear more relatively small scale startup american vcs focus more larger startup top notch university further china have not include medical product retaliatory tariff impose unite state be not likely do so future well however case such scenario occur not be too good healthcare industry norm china refrain used copy drug american biotech company expert fear china get violate patent right due escalation trade war start copy drug company have significant exposure asian country such circumstance company pharmaceutical drug industry have pay dearly such turn event also result dwindle global share healthcare industry market leader zack large cap pharmaceutical industry such abbvie abbv free report glaxosmithkline gsk free report eli lilly lly free report merck mrk free report pifzer pfe free report end be biggest loser such company not only have significant chinese exposure be highly vulnerable instance right infringement see complete list today zack rank stock here chinese investment be oxygen biotech pharma chinese venture capital fund have invest whopping biotech drug company period january march surpass investment chinese vcs whole part such increase be attribute china effort become leader healthcare investment globe china increasingly want make use manufacturing intensive nature economy reason typically increase investment biotech firm be china want access novel therapy make use high return such investment however restriction trump administration chinese involvement biotech spell doomsday industry big reason be be relatively cheaper drug pharmaceutical company perform clinical trial china china drug administration cda chinese fda take less third time take fda approve result consequently cost involved be also lower pharmaceutical industry have suffer recent past due rise cost associate raw material trump act tariff imposition china have prove be rather several industry large turn be nightmarish healthcare industry be know fact chinese investment breathe life small mid scale healthcare company america finally event china infringe drug patent right american company have significant operation chinese shore bloodbath healthcare industry be inevitable wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2007,ABBV,amgen inc amgn free report announce positive top line result late stage study evaluate safety efficacy abp biosimilar version jnj free report merck mrk free report remicade compare reference product treatment moderate severe rheumatoid arthritis ra abp be tnf monoclonal antibody datum phase iii study show abp be inferior compare remicade base primary endpoint be assessment acr week acr american college rheumatology criterium be used measure effectiveness various arthritis medicine clinical study acr score mean person ra have improve datum show be clinically meaningful difference abp remicade amgen share have gain so far year decrease register industry amgen have biosimilar product portfolio amgen biosimilar version abbvie abbv free report ra drug humira amjevita be approve fda september eu march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve amgen begin selling amjevita most country eu year unite state january amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine biosimilar version roche avastin mvasi be already approve unite state eu biosimilar version herceptin kanjinti be review unite state eu biosimilar version rituxan abp be late stage development several amgen own drug be face biosimilar competition biosimilar be already have negative impact key product neupogen neulasta eu unite state neupogen be already face biosimilar competition other key drug neulasta epogen start face biosimilar competition year entry additional biosimilar unite state have negative impact company top line sensipar also lose patent exclusivity march generic be launch soon amgen currently carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2008,ABBV,abbvie inc abbv free report announce extension research development agreement calico life science jointly develop candidate treat age related disease include cancer calico be san francisco bay area base biotech company backed alphabet inc googl free report company first enter deal partnership have produce more dozen early stage program latest agreement collaboration have be extend year calico be responsible early program continue advance program phase iia abbvie continue support calico early stage have option manage late stage development commercial activity company be sharing cost profit equally contribute additionally collaboration deal strengthen abbvie grip oncology segment be abbvie have strong position oncology market drug imbruvica market partnership jnj free report imbruvica currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease several study imbruvica be ongoing evaluate drug alone combination different patient segment abbvie expect imbruvica peak sale more revenue abbvie be also study chronic lymphocytic leukemia cll drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy other hematologic malignancy multiple myeloma aml datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll present last september show combination lead profound improvement progression free survival compare treanda rituxan regulatory application seek approval combination use broader patient population be approve unite state earlier month label expansion indication expand patient population venclexta significantly boost commercial potential abbvie share have decline year so far compare industry decline abbvie currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2009,ABBV,world cancer research be change fast space be see huge development company be take great stride treat variety cancer cancer research be definitely exciting area investor keep close watch come year be disease be lead cause morbidity mortality world precede only heart disease day asco conference chicago be basically most important annual cancer research event conclude yesterday conference featured clinical update several company latest development treat disease merck mrk free report steal limelight asco present datum several cancer study pd inhibitor keytruda datum presentation merck garner most attention physician investor be second interim analysis pivotal lung cancer study keytruda phase iii keynote study study evaluate keytruda combination chemotherapy first line treatment metastatic squamous nsclc be difficult treat lung cancer patient population datum study show combination keytruda chemotherapy lead significant improvement overall survival os progression free survival regardless pd expression pd be protein present surface cell risk death os be reduce compare chemotherapy alone pfs improvement be nearly half patient keytruda combination group compare chemotherapy alone datum be term practice change cnbc change way doctor look prescribe drug cancer patient further cement merck position lung cancer market be most lucrative oncology sector context mention roche rhhby free report also present datum similar late stage study show tecentriq atezolizumab chemotherapy reduce risk disease worsening death pfs advanced squamous nsclc patient versus chemotherapy alone come back merck company also present datum pivotal lung cancer study keynote evaluate keytruda monotherapy first line nsclc patient pd expression least study also show treatment keytruda lead improve survival meanwhile year follow datum present advanced melanoma study show treatment keytruda lead long term survival benefit interim datum cohort phase ii study keynote evaluate keytruda monotherapy patient previously treat advanced small cell lung cancer sclc demonstrated encourage response rate overall population sclc patient well patient tumor express pd meanwhile keytruda also demonstrated encourage orr study evaluate lenvima keytruda combination different tumor type keytruda monotherapy first line treatment advanced clear cell rcc merck partner astrazeneca also present positive lynparza combo datum breast cancer share merck have go more friday jun asco strength nektar therapeutic nktr free report be biggest loser asco nektar partner bristol myer bmy free report present preliminary datum mid stage study evaluate nktr combination bristol myer pd inhibitor opdivo several tumor type response rate melanoma kidney cancer patient do not impress investor result fall nektar stock jun be probably worst performance index member last year read more nektar bristol myer present datum cancer study merck bristol myer nektar currently have zack rank hold see complete list today zack rank strong buy stock here bristol myer also present datum opdivo asco late stage study evaluate opdivo versus yervoy broad range patient resect stage iii iv melanoma opdivo demonstrated sustain superior recurrence free survival versus yervoy study opdivo chemotherapy show improve pfs versus chemotherapy first line lung cancer patient pd expression celgene celg free report partner bluebird bio present early stage datum car cell therapy bb patient late stage relapse refractory multiple myeloma study show median pfs month heavily pre treat patient population datum do not impress investor celgene also present datum car therapy liso ce jcar acquire acquisition juno earlier year datum show month patient relapse refractory aggressive cell hodgkin lymphoma nhl remain remission maintain complete response read more celgene present datum car therapy revlimid pomalyst novartis nvs free report announce positive datum combination study breast cancer drug kisqali long term leukemia study tasigna read more novartis announce positive datum kisqali tasigna abbvie abbv free report present early datum phase ii study evaluate combination cancer drug imbruvica venclexta venetoclax first line treatment patient chronic lymphocytic leukemia cll datum demonstrated high rate response such patient also interim datum late stage study evaluate imbruvica roche rituxan waldenström rare form hodgkin lymphoma show combination significantly reduce risk disease progression death compare placebo rituxan pfizer amgen astrazeneca also make cancer datum presentation meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2010,ABBV,abbvie inc abbv free report announce fda have grant priority review lymphoma drug imbruvica ibrutinib snda treatment waldenström wm combination rituxan rituximab market genentech subsidiary roche group rhhby free report snda be base positive datum phase iii study innovate evaluate imbruvica combination rituxan show positive outcome line wm treatment include patient untreated relapse refractory wm phase iii study enrolled patient relapse refractory treatment naive wm patient receive intravenous rituxan mg once weekly consecutive week follow second weekly rituxan course post month interval receive imbruvica mg placebo once daily permanently discontinue treatment primary endpoint be progression free survival measure safety tolerability treatment line base datum approve snda expand drug label indication wm first chemotherapy free combination treatment option notably imbruvica be first class bruton tyrosine kinase inhibitor drug be already approve unite state follow indication such chronic lymphocytic leukemia small lymphocytic lymphoma waldenström previously treat mantle cell lymphoma previously treat marginal zone lymphoma previously treat chronic graft versus host disease drug be be jointly develop market pharmacyclic llc get acquire abbvie janssen biotech unit johnson johnson jnj free report also mark abbvie humira drug be key growth driver revenue base imbruvica also appear have great potential blockbuster drug first quarter drug net revenue be year year end year global revenue exceed sale unite state likely cross share abbvie have decrease year date compare industry decline abbvie currently carry zack rank hold better rank stock same sector be lundbeck hluyy free report sporting zack rank strong buy see complete list today zack rank stock hereh lundbeck earning estimate have be revise upward past day stock have soar year date more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2011,ABBV,gilead science inc gild free report announce european commission have grant marketing authorization hiv combination therapy biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf biktarvy be approve once daily single tablet regimen str treatment hiv infection adult present past evidence viral resistance integrase class emtricitabine tenofovir approval be support positive datum ongoing phase iii study namely study treatment naïve hiv infected adult study virologically suppress adult approval bic ftc taf become gilead third ftc taf base str approve european union past year bic ftc taf meet primary objective week study regimen be earlier approve fda february approval europe further strengthen company hiv franchise gilead be dominant player hiv market impressive portfolio same hiv be primary area focus gilead company be work bring new hiv treatment market further boost sale franchise company be first bring market single tablet regimen str treatment hiv atripla taf base product genvoya odefsey descovy be perform well strong adoption unite state europe biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone smallest insti base triple therapy str be produce approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq meanwhile gilead be banking hiv franchise drive growth future give persistent decline hcv sale gilead stock have gain last month industry decline gilead hcv franchise be experience slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start pricing have largely stabilize market share stabilize mid patient start be expect decline further note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other meanwhile gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta be also encourage gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2012,ABBV,eli lilly company lly free report partner incyte corporation incy free report announce fda have approve mg dose olumiant baricitinib treat moderately severely active rheumatoid arthritis ra once daily oral jak inhibitor be approve monotherapy combination methotrexate treat adult patient inadequate response tumor necrosis factor tnf inhibitor therapy approval unite state be not much surprise consider fda advisory committee have recommend approval lower dose drug april however mg dose drug be not approve moreover drug label include box warning state risk serious infection malignancy thrombosis company expect launch drug end second quarter be available price lower lead tnf inhibitor approve ra include abbvie abbv free report humira amgen amgn free report enbrel other remind investor fda have issue complete response letter april new drug application seek approval olumiant request additional information determine most appropriate dose olumiant be already approve europe japan generate sale first quarter approval further boost sale drug lilly share price have increase year date compare industry decline approval be base datum ra beacon study evaluate olumiant combination disease modify rheumatic drug versus placebo datum show patient treat olumiant achieve improvement sign symptom ra compare placebo company conduct long term safety study olumiant ra patient part approval follow approval unite state incyte be now eligible receive milestone payment lilly expect record full second quarter olumiant be also be evaluate late stage study treatment atopic dermatitis eli lilly company price eli lilly company price eli lilly company quotelilly currently carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2013,ABBV,pfizer inc pfe free report announce fda have approve label expansion jak inhibitor xeljanz tofacitinib include new indication moderately severely active ulcerative colitis uc drug be approve treatment adult patient recommend dose mg twice daily least week approval be expect fda drug advisory committee have adopt positive vote meeting march recommend approval supplemental new drug application snda file july last year seek label expansion xeljanz uc xeljanz be already market treatment rheumatoid arthritis active psoriatic arthritis first quarter xeljanz sale be year period label expansion uc indication be likely boost sale further share pfizer have lose so far year compare decrease industry belong approval be base datum pivotal study octave induction octave induction octave sustain demonstrated statistically significant greater proportion patient achieve remission treat xeljanz compare placebo pfizer be currently evaluate xeljanz open label long term extension study octave open however be several blockbuster drug inflammatory segment approve uc include johnson johnson jnj free report remicade simponi abbvie abbv free report humira shire shpg free report lialda moreover many biotech company be develop candidate treatment uc hence competition be likely increase segment pfizer inc price pfizer inc price pfizer inc quotepfizer currently have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2014,ABBV,share astrazeneca plc azn free report have rise so far year large cap pharma industry decline drug sector be strong start have struggle thereafter probably market instability few negative update pipeline regulatory front only large cap drug stock have rise year include astrazeneca merck mrk free report abbvie inc abbv free report glaxo gsk free report factor drive astrazeneca announce quite few positive development regulatory pipeline front year lead share outperform industry astrazeneca record good progress oncology first quarter lynparza receive eu approval broad second line ovarian cancer indication tablet formulation breast cancer unite state tagrisso receive important approval first line egfr mutate small cell lung cancer nsclc pd inhibitor imfinzi be approve immediately launch second indication unite state early stage lung cancer drive sale higher first quarter hematology moxetumomab submission be accept fda grant priority review intend indication third line hairy cell leukemia cvrm astrazeneca receive eu approval lokelma treat hyperkalemia respiratory biologic medicine fasenra be approve eu japan january be however few negative pipeline update fasenra do not meet primary endpoint first copd trial galathea arctic trial imfinzi tremelimumab third line small cell lung cancer do not meet primary endpoint progression free survival pfs overall survival os meanwhile core product nexium crestor seroquel be face generic competition be hurt sale growth diabetes franchise also face stiff competition pricing pressure be hurt sale astrazeneca respiratory franchise nonetheless astrazeneca newer drug brilinta cardiovascular lynparza ovarian cancer farxiga forxiga type ii diabetes tagrisso lung cancer be do well brilinta farxiga achieve blockbuster status exceed sale imfinzi fasenra launch early be strong start give highly competitive clinical profile astrazeneca be also look further label expansion drug newer medicine register sale growth first quarter new drug keep contribute top line several launch be underway therapeutic area oncology cv metabolism respiratory astrazeneca be look return growth back newer drug meanwhile cost cut initiative drive bottom line positive development be likely keep stock momentum alive year astrazeneca currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2015,ABBV,cooper company coo free report second quarter fiscal result be schedule release jun market close core coopervision cvi division be likely put stellar performance growth other major segment also act catalyst fiscal first quarter cooper company post strong result adjust earning share beating zack consensus estimate increase year year moreover revenue first quarter increase constant currency cc also outpace zack consensus estimate notably second quarter zack consensus estimate revenue be peg reflect year year growth same adjust earning share be pin show year year growth furthermore trail quarters cooper company have positive earning surprise cooper company inc price ep surprise cooper company inc price ep surprise cooper company inc quotelet delve deeper coopervision manufacture sell wide range contact lense last report quarter segment account whopping cooper company revenue revenue segment come cc robust performance toric cvi revenue multifocal single use sphere lense single use sphere lense drive solid growth segment notably second quarter zack consensus estimate cvi revenue be pin show year year increase multifocal revenue rise year year cc zack consensus estimate second quarter revenue be peg reflect rise year toric revenue increase consensus estimate second quarter revenue be peg indicate year year upside single use sphere lense sale climb cc zack consensus estimate second quarter revenue stand show year year rise sale single use sphere lense rise zack consensus estimate second quarter revenue be pin show year year growth other factor csi coopersurgical offer variety medical device surgical instrument be primarily utilize gynecologist obstetrician first quarter fiscal segment account total revenue meanwhile zack consensus estimate segment second quarter revenue be peg indicate growth prior year quarter management be also optimistic recently close acquisition paragard fertility category post revenue cc however zack consensus estimate segment be peg record prior year quarter recently cooper company acquire asset lifeglobal group affiliate be likely augment fertility business guidance fiscal total revenue be project band compare previous revenue cvi segment be now estimate range higher earlier adjust earning share be now anticipate band versus earlier intense company operate highly competitive industry company business segment face considerable competition peer coopervision primarily face competition spherical toric multifocal lens category like johnson johnson vision care ciba vision own novartis ag valeant pharmaceutical bausch lomb model predictsour quantitative model do not conclusively predict beat cooper company earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cooper company be uncover best stock buy sell re report earning esp filter zack rank cooper company carry zack rank stock worth lookhere be few stock worth consider have right combination element post beat earning season abbvie inc abbv free report have earning esp zack rank see complete list today zack rank stock here ally financial inc ally free report have earning esp zack rank american tower corporation amt free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2016,ABBV,first quarter result pharma bigwig pfizer pfe free report merck mrk free report allergan agn free report steal limelight week other novartis nvs free report gain fda approval second indication car therapy kymriah abbvie abbv free report submit regulatory application eu psoriasis candidate risankizumab merck pd inhibitor keytruda gain fda priority review status yet label expansion application recap week most important storiesmixed result merck pfizer pharma giant beat estimate earning miss same sale pfizer re affirm previously issue guidance merck raise outlook earning sale company witness relatively weaker top line performance quarter merck strong sale keytruda gardasil bridion be partially offset lower sale other key therapy rotateq zepatier zostavax meanwhile loss market exclusivity several drug also hurt top line pfizer top line be hurt decline sale key drug lyrica prevnar prevenar enbrel loss exclusivity product viagra pristiq continue supply shortage legacy hospira product allergan beat estimate earning revenue first quarter raise guidance earning sale novartis kymriah get fda approval second indication novartis supplemental biologic license application sbla look get car therapy kymriah approve second indication be grant approval fda latest approval kymriah suspension have be approve intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma more line systemic therapy include diffuse large cell lymphoma dlbcl high grade cell lymphoma dlbcl arise follicular lymphoma kymriah be first car therapy obtain fda approval august treatment patient year age cell precursor be refractory second later relapse separately novartis announce fda have give complete response letter bla propose biosimilar version roche cancer drug rituxan merck keytruda news merck supplemental biologic license application sbla look get overall survival datum phase iii keynote study include label pd inhibitor keytruda be grant priority review fda fda give decision sep study evaluate keytruda combination lilly alimta pemetrexed platinum chemotherapy cisplatin carboplatin first line treatment patient metastatic squamous nsclc regardless pd expression combination treatment improve overall survival regardless pd expression include patient tumor test negative pd notably combination therapy be grant accelerate approval fda aforementioned indication approval be base tumor response rate pfs datum keynote study hence positive readout keynote confirmatory study help company gain continue approval combo therapy support uptake sale merck also announce interim datum pivotal lung cancer study keytruda meet pre specify secondary endpoint overall response rate orr early cohort participant phase keynote study evaluate keytruda combination carboplatin paclitaxel nab paclitaxel first line treatment metastatic squamous nsclc abbvie submit application psoriasis candidate eu abbvie submit marketing application european regulatory authority investigational interleukin il inhibitor risankizumab treatment moderate severe plaque psoriasis marketing authorization application maa be support datum pivotal phase iii study datum study have show more half patient receive risankizumab achieve complete skin clearance year meanwhile abbvie also announce commencement self tender offer common stock price not less share not more share unite therapeutic acquire steadyme unite therapeutic corporation uthr free report announce definitive merger agreement steadyme ltd unite therapeutic acquire latter include contingent payment deal unite therapeutic add steadyme drug device pipeline product trevyent pulmonary arterial hypertension pah patient portfolio product have pose competition unite therapeutic remosynch implantable pump be review unite state trevyent be single use pre filled pump have be develop steadyme deliver day supply treprostinil subcutaneously used steadyme patchpump technology treat pah steadyme receive refuse file letter fda want further information steadyme intend resubmit nda end allergan ubrogepant succeed phase iii study allergan announce second pivotal phase iii study evaluate oral cgrp acute migraine treatment ubrogepant meet co primary endpoint phase iii datum show ubrogepant display strong efficacy clean side effect profile achieve ii study evaluate efficacy safety orally administer ubrogepant mg mg treat single migraine attack moderate severe headache intensity study datum demonstrated significant greater percentage patient treat ubrogepant dose be free pain hour initial dose compare treat placebo also statistically significant greater percentage ubrogepant patient take mg dose experience absence most bothersome migraine associate symptom photophobia phonophobia nausea hour initial dose compare treat placebo however mg dose fail demonstrate statistical significance endpoint seek label expansion pah drug jnj free report actelion submit supplemental new drug application snda fda seek approval label expansion pah drug opsumit macitentan include treatment patient chronic thromboembolic pulmonary hypertension cteph also announce definitive agreement acquire private biotech benevir biopharm benevir make oncolytic immunotherapy utilize proprietary stealth oncolytic virus platform have potential treatment solid nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock decline last week astrazeneca rise pfizer decline most last month glaxo be biggest gainer bristol myer decline most see last pharma stock roundup here pharma stock roundup nvs jnj sale earning top mrk bmy active aacr next pharma world watch pipeline regulatory update today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2017,ABBV,gilead science inc gild free report report dismal result first quarter earning revenue miss expectation due wider expect decline hepatitis virus hcv franchise consequently stock decline market hour trading be expect open red give expectation further decline hcv franchise gilead stock have lose last month industry gain company first quarter earning share miss zack consensus estimate earning be also year quarter figure share gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quote moreover total revenue also miss zack consensus estimate further revenue decline year year harvoni sovaldi plunge furtherproduct sale come year year due accelerate decline hcv sale antiviral product sale include gilead hiv liver disease portfolio come quarter year quarter research development expense decline selling general administrative sg expense increase hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly due lower sale harvoni sovaldi major market lower sale epclusa unite state result increase competition sale harvoni plunge year year quarter epclusa garner sale quarter year period figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale entry generic greater inventory drawdown prior year quarter somewhat impact sale however hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively adjust product gross margin be compare year period guidance continue expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company also acquire cell design lab expand further car space yescarta sale come quarter dividend share declare cash dividend cent share common stock second quarter dividend be payable jun stockholder record close business jun quarter company paid cash dividend repurchase share takegilead first quarter result be disappointing company earning sale miss estimate magnitude decline hcv sale be wider expect hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr merck mrk free report zepatier pricing have largely stabilize market share stabilize mid patient start be expect decline further meanwhile hiv franchise maintain momentum drive rapid adoption descovy base regimen approval biktarvy feb fda have further widen portfolio biktarvy sale come quarter march biktarvy be add dhhs guideline use antiretroviral agent adult adolescent live hiv recommend initial regimen chmp have also adopt positive opinion marketing authorization application biktarvy eu gilead expect obtain approval same third quarter further solidify portfolio truvada use pre exposure prophylaxis set continue maintain momentum estimate patient used truvada end first quarter give persistent decline hcv sale company be look newer avenue help top line gilead be look solidify presence gene therapy space initial uptake yescarta be also encourage first quarter gilead announce agreement sangamo therapeutic inc sgmo free report use sangamo zinc finger nuclease technology platform development next generation ex vivo cell therapy oncology gilead be also intend foray nash market pipeline candidate selonsertib filgotinib candidate be be evaluate late stage study tentative approval diversify gilead portfolio zack rankgilead currently carry zack rank buy see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2018,ABBV,latest earning preview earning season have already crossed half way mark be gain strength earning revenue growth track reach highest level year total earning member have already report result be same period last year higher revenue beating top line estimate beating revenue estimate proportion company beating earning revenue estimate be ongoing earning season seem have start solid note drug biotech sector major large cap player have report result bristol myer squibb bmy free report abbvie abbv free report beat zack consensus estimate earning well sale amgen inc amgn free report also surpass earning revenue expectation quarter higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor be expect keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue witness rise earning quarter review pharma biotech giant be schedule report earning result let see thing be shape company upcoming release pfizer inc pfe free report be slate releaseresult market open company deliver positive earning surprise last report quarter company performance have be impressive recent past earning surpass expectation trail quarters average beat accord zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp combination company zack rank earning esp make reasonably confident earning beat zack consensus estimate company earning quarter review be peg cent share innovative health segment new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be expect drive top line essential health biosimilar emerge market be expect support sale bottom line be expect be drive cost saving share buyback read more pfizer earning beat estimate again pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotemerck co inc mrk free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise model do not conclusively show merck beat estimate quarter be stockha earning esp zack rank zack consensus estimate quarterly earning be peg cent share see complete list today zack rank strong buy stock here merck new product cancer drug keytruda lynparza bridion injection be likely drive top line however loss market exclusivity several drug softness diabetes januvia janumet franchise lower sale key product zostavax zepatier due competitive pressure hurt sale read more card merck earning season merck co inc price ep surprise merck co inc price ep surprise merck co inc quotegilead science inc gild free report be slate report result market close company deliver positive earning surprise trail quarters average beat last report quarter gilead deliver positive earning surprise model show gilead be likely beat estimate quarter combination gilead zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg share company strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost read more be beat card gilead earning gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteincyte corporation incy free report be slate report result market open incyte track record have be impressive so far company deliver positive earning surprise trail quarters average beat last report quarter incyte deliver positive earning surprise model show incyte be likely beat estimate quarter combination incyte zack rank earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter incyte continue gain traction lead drug jakafi performance incyte jakafi performance be strong drive patient demand sale guidance be also impressive october fda approve label update drug include addition new patient report outcome datum comfort study well update warning related progressive multifocal pivotal reach trial evaluate jakafi patient steroid refractory acute graft versus host disease have complete enrollment result be expect first half assume successful result incyte expect submit snda seek approval jakafi indication jakafi sale be expect get boost update label read more jafaki help incyte beat earning estimate incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2019,ABBV,month have go last earning report abbvie inc abbv free report share have add time frame recent positive trend continue lead next earning release be abbv due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver abbvie top earning revenue estimate up guidanceabbvie report better expect earning sale first quarter importantly raise earning expectation base strong performance optimistic outlook future quarters abbvie report first quarter earning share beating zack consensus estimate ahead guide range earning grow year year strong sale performance higher operate profit lead bottom line beat revenue report quarter marginally beat zack consensus estimate sale increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue rise backed continue strong performance humira imbruvica solid uptake new hcv medicine mavyret operational revenue growth be line management expectation growth mid range currency tailwind be also better expect company quarter detailshumira record sale growth operational basis revenue come reflect continue strong demand trend sale unite state increase drive strong prescription volume growth major market category humira sale ex market be operational basis report basis drive primarily market growth indication humira hold lead market position front line therapy major market category stiffer competition new class drug well indirect biosimilar competition international marketshowever call abbvie say retail specialty pharmacy destock hurt sale humira somewhat quarter humira sale unite state be expect be approximately be lower prior expectation humira sale expectation be softer previous outlook due impact retail specialty pharmacy destock first quarter conservative stance co pay cost associate co pay accumulator program internationally humira sale be expect approach previously include expect impact biosimilar entrant europe fourth quarter first quarter net revenue imbruvica be year year include sale international profit sharing johnson johnson continue uptake front line cll market steady gain other indication lead strong performance imbruvica imbruvica global revenue be expect exceed sale unite state likely cross other product perform well include lupron year year duodopa year year creon competitive dynamic hcv market abbvie hcv sale include viekira mavyret be quarter sequential basis mavyret alone account nearly quarter drive better expect launch uptake unite state international market mavyret command market share unite state less year market medicine have also establish strong position other major country well such japan germany spain italy viekira sale decline quarter global hcv sale be expect be approximately higher expect previously adjust gross margin rise bps quarter adjust sg expense increase percentage sale sg expense rise bps quarter reflect new product launch cost expense escalate quarter due greater investment pipeline adjust operate margin be sale report quarter bps year year outlookabbvie raise adjust ep guidance range compare predict earlier strong first quarter performance couple optimistic outlook stronger underlie business performance rest year benefit plan share buyback dutch tender offer propel increase earning guidance earning guidance reflect year year surge mid point versus previously revenue be expect approach previous expectation currency impact be expect benefit revenue compare expect previously expense be expect be slightly more revise sale outlook sg be expect be sale operate margin be expect be roughly basis point level previously abbvie expect operate margin be approximately sale abbvie decrease project operate margin expectation plan increase investment upcoming product launch adjust tax rate be expect be approximately normalize tax rate expectation next year be second quarter outlooksecond quarter earning be expect revenue be estimate grow approximately operational basis foreign exchange be expect have approximately favorable impact sale second quarter humira sale be expect grow approximately year year internationally sale be expect be approximately imbruvica sale be expect be approximately global hcv sale be expect be approximately approximately sale come sale have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter abbvie inc price consensus abbvie inc price consensus abbvie inc quotevgm scoresat time abbv have nice growth score however momentum be do bit better stock be also allocate grade value side putt second quintile investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable momentum investor look value growth outlookestimate have be trend upward stock magnitude revision look promising notably abbv have zack rank hold expect line return stock next few month
2020,ABBV,abbvie abbv free report announce top line result phase iii illuminate pcyc study meet primary endpoint improvement progression free survival pfs study evaluate cancer drug imbruvica ibrutinib combination gazyva obinutuzumab previously untreated chronic lymphocytic leukemia small lymphocytic lymphoma cll sll patient compare chlorambucil obinutuzumab year date share abbvie have increase industry decline imbruvica be jointly develop market abbvie subsidiary pharmacyclic llc johnson johnson jnj free report subsidiary janssen biotech be currently approve unite state treat patient mantle cell lymphoma mcl have receive least therapy earlier cll patient deletion be also approve european union treatment mcl significantly january imbruvica be approve patient marginal zone lymphoma mzl require systemic therapy have receive least prior cd base therapy illuminate study meet primary endpoint clinically statistically significant difference pfs patient treat imbruvica obinutuzumab versus receive chlorambucil obinutuzumab assessed independent review committee irc pharmacyclic janssen be sharing primary analysis datum study regulatory authority plan present datum future publication medical congress base datum approve fda imbruvica obinutuzumab be first chemotherapy free cd combination first line cll treatment zack rank stock considerabbvie have zack rank hold better rank stock same space be illumina inc ilmn free report ligand pharmaceutical lgnd free report illumina sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here illumina earning share estimate have moved past day company deliver positive earning surprise trail quarters average beat stock have rally so far year ligand earning share estimate have be revise upward past day company come positive earning surprise trail quarters average beat company share have rally year date abbvie inc price abbvie inc price abbvie inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2021,ABBV,biotech bigwig gilead science inc gild free report develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease hcv franchise boast drug sovaldi harvoni recently launch epclusa however hcv franchise continue grapple competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak merck mrk free report zepatier other gilead be dominant player hiv market impressive portfolio same company be first bring market single tablet regimen str treatment hiv atripla strs hiv market include complera eviplera stribild other newly launch tenofovir alafenamide taf base product genvoya odefsey descovy be perform well strong adoption unite state europe genvoya have already become most prescribe regimen treatment naïve switch patient launch november also genvoya have be list prefer regimen several hiv treatment guideline taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy zack consensus estimate sale genvoya be truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage approximately patient used truvada end note hiv be primary area focus gilead company be work bring new hiv treatment market further boost sale franchise company receive major boost fda approve company once daily str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection approval provide major boost gilead hiv franchise biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone be smallest insti base triple therapy str available approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq gilead stock have return last month compare industry loss gilead have decent track record company earning beating estimate last miss last report quarter company earning beat expectation overall company record average positive earning surprise expect strength hiv franchise offset hcv franchise weakness make highly likely company beat earning first quarter read more be beat card gilead earning zack rankgilead currently carry zack rank buy see complete list today zack strong buy rank stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2022,ABBV,davita inc dva free report first quarter result be schedule release market close davita dialysis related lab service business segment have be consistent driver revenue company surge acquisition dialysis center also add positive notably fourth quarter company report adjust operate earning cent share beating zack consensus estimate cent however earning decline year year basis meanwhile revenue last report quarter increase year year miss zack consensus estimate quarter review zack consensus estimate revenue be peg reflect year year decline same earning share be project cent indicate year year growth company deliver average negative earning surprise trail quarters davita inc price ep surprise davita inc price ep surprise davita inc quotelet delve other factor be likely impact davita first quarter result kidney care business dialysis center drive davita medical group kidney care also know dmg provide integrate care management operate division company focus deliver healthcare broad range service kidney care business witness several prospect adjust operate income segment be adjust guidance lately company collaboration texas base methodist specialty transplant hospital announce launch transplant waitlist support program aim be help keep waitlist patient transplant ready deploy technology enabled solution development be likely help davita register solid quarterly result fourth quarter davita acquire dialysis center open new center close unite state davita also acquire dialysis center open center close center outside unite state however zack consensus estimate number dialysis center current quarter be peg sequentially other factor company project kidney care consolidated operate income range operate cash flow continue operation be estimate band effective tax rate be expect range solid guidance such raise optimism company upcoming quarterly result drug used treat mineral bone disease just moved dialysis reimbursement introduction injectable drug call presibib be early understand full picture management be optimistic probable contribution quarterly result acquisition surge labor cost inflation davita be likely witness solid margin pressure traditional medicare fee service business series acquisition dialysis center davita affect operation debt capital ratio capital expenditure other aspect business further joint venture minority investment inherently involve lesser degree control business operation thereby potentially increase financial legal operational compliance risk associate joint venture minority investment quantitative model predict earning beat davita upcoming quarterly result be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack espearning esp davita be uncover best stock buy sell re report earning esp filter zack rankdavita carry zack rank here be few other medical stock worth consider also have right combination element post earning beat cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here teleflex incorporate tfx free report have earning esp zack rank abbvie inc abbv free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2023,ABBV,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however many peer be face generic competition pricing pressure product pharmaceutical segment stock have depreciate year so far compare unfavorably decline record industry pharma segment sale picked second half be soft first half be likely see positive impact trend second quarter result zack consensus estimate pharma segment sale be believe new product continue share gain key product label expansion drug imbruvica xarelto stelara darzalex meaningful contribution acquisition support top line continue share gain drive sale imbruvica cancer indication xarelto blood thinner zytiga prostate cancer stelara psoriasis please note market imbruvica partnership abbvie abbv free report zack consensus estimate total imbruvica sale be strong adoption witness newer indication crohn disease continue contribute stelara growth zytiga be approve first line set february contribute strong performance drug first quarter trend expect continue second quarter also strong adoption outside market accelerate adoption unite state line therapy be likely drive sale darzalex importantly darzalex be approve first line set add significantly sale second quarter positive offset loss sale drug invokana due higher manage care discounting market share decline due competitive pressure meanwhile biosimilar competition be expect hurt sale key arthritis drug remicade outside unite state please note market remicade partnership merck mrk free report zack consensus estimate total remicade sale be note inventory build seasonality issue hurt sale xarelto first quarter remain be see issue persist second quarter well regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter meanwhile expect discuss initial sale number erleada newly approve next generation oral androgen receptor ar inhibitor prostate cancer second quarter conference call overall second quarter sale pharmaceutical segment be expect remain strong consumer medical device segment continue improve read more set pharma earning motion currently carry zack rank hold better rank large cap pharma stock be lundbeck hluyy free report sport zack rank strong buy see complete list today zack rank stock here share lundbeck have gain year so far earning estimate have go past day medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2024,ABBV,biggest news week be pfizer pfe free report announcement plan re organize business new segment effective next year jnj free report be order st loui jury pay approximately nearly dozen woman lawsuit related talc base product merck mrk free report abbvie abbv free report bristol myer bmy free report provide update cancer drug pfizer re organize business unit pfizer be re organize business business segment separate consumer healthcare business standalone unit begin pfizer report new business unit innovative medicine establish medicine consumer healthcare presently pfizer have report segment namely innovative health essential health present innovative health unit be call innovative medicine unit now include biosimilar new hospital business unit infective sterile injectable be presently report essential health essential health unit now be rename establish medicine unit include pfizer legacy brand have lose lose market exclusivity read more pfizer reorganize business new unit pay talc lawsuit be order jury st loui court pay damage woman allege talc base product include baby powder contain asbestos cause develop ovarian cancer damage comprise compensatory damage punitive damage official statement say verdict be unfair appeal also say talc product neither contain asbestos cause cancer face more case talc product trump slam pfizer price hike pfizer defer increase tweet president donald trump slam pfizer raise price several prescription drug effective jul trump say pfizer other drugmaker be ashamed have raise drug price reason tweet also say raise drug price unite state drug company be offer bargain basement price overseas warn administration respond day tweet be publish pfizer issue statement say defer price increase president drug pricing blueprint go effect end year be earlier abbvie imbruvica lymphoma study fail abbvie announce late stage study evaluate cancer drug imbruvica first line treatment diffuse large cell lymphoma dlbcl fail meet primary endpoint study evaluate addition imbruvica chop combination rituximab doxorubicin vincristine prednisone be exist standard care dlbcl aggressive form hodgkin lymphoma nhl versus chop placebo however study datum show add imbruvica chop do not improve event free survival ef target patient population imbruvica be presently fda approve indication include cell blood cancer well chronic graft versus host disease drug abbvie market partnership record sale first quarter include sale international profit sharing abbvie also file supplemental new drug application snda fda label expansion venclexta venetoclax first line treatment acute myeloid leukemia aml abbvie be look get venclexta approve combination hypomethylating agent hma low dose cytarabine ldac aml patient be ineligible intensive chemotherapy read more abbvie imbruvica fail phase iii blood cancer study merck keytruda sbla get priority review merck supplemental biologic license application sbla look expand label keytruda previously treat patient advanced hepatocellular carcinoma hcc most common type liver cancer be grant priority review fda fda decision be expect nov sbla filing be base datum phase ii keynote study read more merck keytruda get fda priority review liver cancer bristol myer opdivo yervoy combo get fda nod colorectal cancer bristol myer announce accelerate approval combination immuno oncology drug opdivo yervoy type colorectal cancer combination be now approve previously treat patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer opdivo yervoy combination be also approve other tumor type first line treatment intermediate poor risk advanced renal cell carcinoma unresectable metastatic melanoma read more bristol myer combo drug get fda nod colorectal cancer cti biopharma slump study failure share cti biopharma ctic free report slump monday pivotal study evaluate combination regimen cancer drug pixuvri hodgkin lymphoma fail improve progression free survival pixuvri have conditional approval europe monotherapy treatment multiply relapse refractory aggressive cell nhl however be yet receive approval unite state read more cti biopharma fall failure pivotal lymphoma study nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record increase last week astrazeneca azn free report gain most past month glaxo have be biggest gainer jnj free report decline most see last pharma stock roundup here pharma stock roundup nvs divest eye care unit chmp give nod several drug next pharma world watch earning bigwig pharma world later month begin jul medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2025,ABBV,investor abbvie inc abbv free report need pay close attention stock base move option market lately be put have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move abbvie share be fundamental picture company currently abbvie be zack rank hold large cap pharmaceutical industry rank top zack industry rank last day analyst have increase earning estimate current quarter analyst have drop estimate net effect have take zack consensus estimate current quarter share period give way analyst feel abbvie right now huge imply volatility mean trade develop often time option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
2026,ABBV,eli lilly company lly free report announce fda have approve inclusion additional datum label psoriasis injection taltz latest approval taltz label now include datum psoriasis involve genital area impact roughly psoriasis patient course disease taltz be already market treatment adult patient moderate severe plaque psoriasis be candidate systemic therapy phototherapy well active psoriatic arthritis taltz work specifically target il protein play role drive underlie inflammation psoriasis drug record sale first quarter label expansion expand eligible patient population drug drive sale go forward approval genital psoriasis be base datum study evaluate patient moderate severe psoriasis involve genital area study taltz demonstrated significant improvement compare placebo week severity psoriasis affect genital area overall psoriasis genital itch impact genital psoriasis sexual activity such patient many other drug novartis nvs free report cosentyx jnj free report tremfya abbvie abbv free report humira be approve treat plaque psoriasis lilly claim taltz be now first only fda approve treatment genital psoriasistaltz be also be study late stage study axial year date lilly share have decline compare industry decline lilly currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2027,ABBV,roche rhhby free report announce full result phase iii study haven evaluate haemophilium drug hemlibra emicizumab randomize multicenter open label phase iii study evaluate efficacy safety pharmacokinetic hemlibra prophylaxis versus prophylaxis episodic demand factor viii treatment patient hemophilia factor viii inhibitor trial result show hemlibra reduce treat bleed compare prophylaxis haven study haemophilium factor viii inhibitor moreover subset patient include study previously receive factor viii prophylaxis be standard care hemlibra reduce bleed compare prior therapy almost patient treat hemlibra week patient treat hemlibra week experience treat bleed compare none patient treat prophylaxis additionally result phase iii study haven show hemlibra administer week provide clinically meaningful control bleed person factor viii inhibitor remind investor fda grant breakthrough therapy designation hemlibra april patient hemophilia factor viii inhibitor base datum haven study drug be already approve fda routine prophylaxis prevent reduce frequency bleed episode adult child haemophilium factor viii inhibitor hemlibra be also approve european commission february routine prophylaxis bleed episode person haemophilium factor viii inhibitor roche hematology portfolio include approve drug mabthera rituxan gazyva gazyvaro tecentriq venclexta note roche be develop venclexta collaboration abbvie abbv free report company be jointly commercialize drug unite state abbvie be commercialize drug outside unite state well approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar roche stock have lose last month compare industry gain novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2028,ABBV,corporation abc free report second quarter fiscal result schedule release be expect show steady growth pharmaceutical distribution segment significant contributor revenue last report quarter company post adjust earning share beating zack consensus estimate improve year year upside be attribute strong growth company pharmaceutical distribution segment world courier business revenue improve almost previous quarter beat zack consensus estimate quarter be report zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg indicate increase year year let dig deeper analyze thing be shape earning announcement pharmaceutical distribution boost distribution account total revenue last quarter revenue segment be year year basis operate income be year year upcoming quarterly result zack consensus estimate pharmaceutical distribution segment be peg figure reflect increase year figure strong organic growth rate pharmaceutical market improve patient access medical care improve economic condition population demographic introduction new innovative drug hepatitis drug consistent good brand pricing environment drive growth quarter be report corporation price ep surprise corporation price ep surprise corporation quotemoreover company focus specialty drug bode well im pharmaceutical sale be estimate grow approximately annually year period courtesy strong demand favorable pricing new product introduction deal sign look encourage be likely boost top line company enter strategic agreement boot alliance deal include year pharmaceutical distribution contract company distribute brand generic pharmaceutical product walgreen however segment be likely be affected lower expect production pharmedium outsource facility notably operation facility be voluntarily suspend company last quarter follow few inspection fda other factor considergeneric product launch drive growth believe benefit generic growth long run last quarter marked consecutive quarter greater revenue growth business management confirm strategic focuse effort be drive generic product volume growth offset historic deflation rate however important highlight have increase quarterly interest expense begin second quarter operational efficiency recent tax legislation have enhance ability invest business innovate deliver value shareholder long term enable boost business recently company make strategic investment system realize greater operational efficiency increase operate leverage be likely boost company result second quarter fact also announce plan roll new system new commerce platform mwi enhance company result quarter be report guidance base expectation recently legislate tax reform raise guidance fiscal notably strong guidance fiscal indicate company expect deliver solid result second quarter company expect adjust earning share range previously range revenue growth fiscal be expect range previous band pharmedium slow recently receive grand jury subpoena attorney office western district tennessee document lab testing certain type syringe make pharmedium lab be company largest highly automate production facility result subpoena suspend operation recall product have yet expire fact fda also visit facility same reason sluggishness unit be likely hamper company specialty distribution segment quarter be report last report quarter segment result be negatively impact pharmedium company have lower expect revenue profit contribution management time certain ongoing incremental expense require perform remedial measure pharmedium contribution adjust ebit ep second quarter be lower anticipate earning whispersour proven model do not show earning beat second quarter be stock need have positive earning zack rank strong buy buy hold happen be not case here see zack esp have earning esp uncover best stock buy sell re report earning esp filter zack rank carry zack rank here be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here teleflex incorporate tfx free report have earning esp zack rank abbvie inc abbv free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2029,ABBV,abbvie abbv free report announce combination regimen blockbuster cancer drug imbruvica ibrutinib fail phase iii study dbl evaluate first line treatment diffuse large cell lymphoma dlbcl drug fail improve event free survival ef compare current standard care dlbcl be aggressive form hodgkin lymphoma nhl type blood cancer new therapy have be approve decade treatment naive patient chop combination rituximab doxorubicin vincristine prednisone chemotherapy be standard care patient share abbvie slide jul follow news company share have decrease year date compare industry decline phase iii study be conduct collaboration johnson johnson jnj free report evaluate imbruvica combination chop versus chop placebo together primary endpoint study be superiority ef combination regimen be investigate treatment dlbcl patient have germinal center cell gcb activate cell abc subtype patient subtype commonly have poorer treatment outcome greater unmet medical need however datum study demonstrated improvement certain patient sub population be clinically meaningful be analyze further company present detailed analysis study future scientific conference publish peer review medical journal separate press release abbvie partner roche rhhby free report announce submission supplemental new drug application snda label expansion leukemia drug venclexta venetoclax snda be seek approval venclexta combination hypomethylating agent hma low dose cytarabine ldac treat newly diagnosed patient acute myeloid leukemia aml be ineligible intensive chemotherapy snda be file base datum separate early stage study evaluate venclexta combination mha ldac venclexta label be expand last month monotherapy combination roche biogen biib free report rituxan treatment relapse refractory chronic lymphocytic leukemia small lymphocytic lymphoma second later line setting abbvie inc price abbvie inc price abbvie inc quoteabbvie currently carry zack rank buy see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2030,ABBV,expect johnson johnson jnj free report healthcare bellwether beat expectation report second quarter result jul market open last report quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson stock have depreciate year so far compare unfavorably decline record industry factor considerj sale improve first quarter be pharmaceutical segment continue positive momentum see second half consumer segment sale improve positive sale trend be expect continue second quarter fact be quite confident pharma segment continue perform better market year impact biosimilar sale key arthritis drug remicade sale consumer medical device segment be expect improve believe new product segment successful label expansion cancer drug imbruvica darzalex contribution recent acquisition continue drive top line growth core product stelara zytiga simponi simponi aria invega sustenna be expect contribute growth however past quarters revenue pulmonary arterial hypertension pah product add june acquisition actelion decline sequentially due lower sale tracleer outside unite state due generic competition be less likely pah revenue improve second competition be expect hurt sale remicade outside unite state please note market remicade partnership merck mrk free report however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state however full year guidance include impact generic procrit tracleer well remicade biosimilar regard newly launch tremfya say first quarter conference call uptake product have be strong drug record sale first quarter be expect be higher be report quarter expect discuss initial sale number erleada newly approve prostate cancerdrug second quarter conference call medical device segment sale be expect rise consistently vision care cardiovascular unit diabetes care unit however continue remain weakin consumer segment beauty counter product be expect do well domestic baby care product sale likely remain weak recent acquisition well new product be likely provide support however higher investment new product launch continue hurt profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp be zack consensus estimate stand share uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock also have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result jul see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result jul hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2031,ABBV,time celebrate president trump second year office time second year presidential term have favore stock investor wall street way have show enough confidence even concern trade war loom large matter fact solid job addition last month economy poise growth come teasingly close milestone achieve have instilled confidence investor give bullishness investing stock solid growth potential doesn seem be bad proposition wall street usually rise year presidential termsthere be always chance stock market scale north second year presidential term dow jone industrial average inception have rise time average say period stock market rise less first half be assured do deal needless say broader index rise less first half year even market be fraught concern geopolitical tension pending mid term election pin hope success second year presidential term not stock market be always forward look have already discount such issue further odd win get hampered even be age bull market be be say bull market don die old age time djia rise year presidential term datum underlie fundamental point way higherstock way have remain resilient potential threat such china trade skirmish white house impose tariff worth chinese good compelling beij retaliate read more think small china trade war break top pick bull also have solid faith underlie strength economy perhaps point way higher unite state have be able create job june healthy sign show corporate be find way fill open job lack skilled worker such hire figure easily top analyst estimate job addition job gain be pretty broad base white collar job lead way job addition manufacturer health care provider construction company hire worker clear sign burgeon economy unemployment rate rise last month good reason jobless rate go mostly person enter labor force show more american be search job be easier find company meanwhile be raise pay benefit hourly wage rise cent yearly rate pay hike remain unchanged ramp business investment way be expect help economy gain traction economy be project expand second quarter annual pace nearly gain first month year economist say put economy solid position year meet even beat growth gross domestic product gdp primary aim government read more gdp hit elusive annual growth year pick pundit remain sanguine equity outlooka number market pundit remain upbeat outlook equity have look potential headwind have be hurt market so far year fact analyst jpmorgan chase co jpm free report have say upbeat economic datum couple pro business policy help company register double digit growth accelerate buyback term dubravko lakos bujas firm head equity strategy raise year end target upside potential current level tobias levkovich citigroup free report chief strategist be also upbeat upgrading rating overweight neutral set price price target upside potential current level andrew adam strategist raymond james meantime say even year have see more torrid run last year be yet see red flag indicate bull run be end fact have urge investor look long term trend remain bullish stock solid upside potential second halfwall street be gain traction headline flash warning trade war same time statistical evidence show trump second year office be fruitful stock market thus investing stock make most bullish trend seem judicious have hence select stock flaunt zack rank strong buy buy growth score offer best investment opportunity growth investing space apache corporation apa free report be independent energy company stock currently have zack rank growth score last day earning estimate moved north moved south current year zack consensus estimate earning rise same period company expect earning growth rate current year be compare oil gas exploration production unite state industry project rally continental resource inc clr free report explore develop produce crude oil natural gas property north south east region unite state stock currently have zack rank growth score last day earning estimate moved north none moved south current year zack consensus estimate earning increase same period company expect earning growth rate current year be compare oil gas exploration production unite state industry expect gain kmg chemical inc kmg free report manufacture formulate distribute specialty chemical performance material worldwide stock currently have zack rank growth score last day earning estimate moved none moved current year zack consensus estimate earning increase nearly same period company expect earning growth rate current year be compare chemical specialty industry estimate rally see complete list today zack rank stock here zagg inc zagg free report design manufacture distribute mobile tech accessory smartphone tablet unite state internationally stock currently have zack rank growth score last day earning estimate moved north none moved south current year zack consensus estimate earning advanced same period company expect earning growth rate current year be compare electronic miscellaneous component industry project rally abbvie inc abbv free report discover develop manufacture sell pharmaceutical product worldwide stock currently have zack rank growth score last day earning estimate moved north none moved south current year zack consensus estimate earning rise same period company expect earning growth rate current year be compare large cap pharmaceutical industry estimate growth look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2032,ABBV,large cap pharmaceutical sector comprise biggest drugmaker world be strong start however sector take backseat due reason market instability few negative update pipeline well regulatory front also older drug company be not perform mark induce drop revenue zack large cap pharma industry have decline so far year zack composite gain overall sector be expect rebound second half year believe new product sale be ramp back rise demand successful innovation product line expansion strong clinical study result frequent fda approval upside turn bring sector back track year also many company have accelerate cost save initiative enable investment new product well defend exist product portfolio optimize long short term growth cost saving drive earning performance importantly merger acquisition activity be gain momentum tax reform place new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be spur merger activity year optimistic outlook rest year here highlight stock prove be good buy stock sport zack rank strong buy buy have see share price earning estimate rise term see complete list today zack rank stock here large cap pharma stocksh lundbeck hluyy free report share danish drugmaker have rally past month zack consensus estimate current year ep have be revise upward respectively last day lundbeck have zack rank company witness solid revenue growth first quarter headwind exchange rate generic erosion also strengthen pipeline inclusion parkinson disease candidate foliglurax acquisition prexton therapeutic currently mid stage development pfizer inc pfe free report zack rank stock have be work strengthen suite product buyout licensing deal company new product ibrance contribution acquisition cost cut effort lower tax rate share buyback help company achieve guidance pfizer also boast strong pipeline expect approximately drug approval include product blockbuster potential pfizer grow immuno oncology portfolio offer strong growth prospect share company have increase past month earning estimate have also moved north respectively past day abbvie inc abbv free report abbvie key arthritis drug humira be perform well strong demand trend new competition moreover drug imbruvica market partnership johnson johnson jnj free report be approve hematological cancer have multibillion dollar potential company be explore possibility label expansion solid tumor autoimmune disease mavyret hepatitis virus have become major growth driver abbvie short span market moreover abbvie boast impressive late stage pipeline label expansion new exist product expect next few year several pivotal datum readout regulatory milestone be also anticipate additionally company carry zack rank share price have also gain past month consensus estimate company current next year bottom line have also be raise respectively past day make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2033,ABBV,abbvie inc abbv free report post impressive result first quarter better expect earning revenue moreover company raise expectation bottom line response share too climb almost pre market trading share abbvie have surge year time significantly outperform industry rise company report earning share first quarter beating zack consensus estimate also figure grow year year earning also surpass previous expect range company post revenue quarter review marginally trumping zack consensus estimate top line also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue rise revenue show higher growth compare previous projection mid range operational basis quarter detailkey drug humira record sale growth operational basis revenue come sale unite state increase humira sale ex market be operational basis report basis growth major market category drive upside stiffer competition new class drug well indirect biosimilar contest international market first quarter net revenue imbruvica be year year sale imbruvica gross compare year figure abbvie logged international profit sharing johnson johnson jnj free report other product have deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness ascent revenue operational report basis hcv chronic hepatitis virus product record sale significantly compare last report adjust sg expense increase expense escalate first quarter adjust operate margin be sale notably first quarter earning abbvie announce intention commence tender offer purchase share common stock cash value company expect initiate same early outlookabbvie raise adjust ep range compare predict earlier earning guidance reflect year year surge mid point zack consensus estimate metric current year be peg share abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quote zack rank key picksabbvie carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have surge year infinity loss share estimate have narrow cent cent cent last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2034,ABBV,bristol myer squibb company bmy free report announce european commission ec have approve label expansion oncology drug sprycel consequently drug be now approve treatment child adolescent age year year philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp also include powder oral suspension formulation approval be card european medicine agency committee medicinal product human use chmp have give positive opinion same april approval be base positive datum nct study evaluate safety efficacy sprycel pediatric patient newly diagnosed cp cml be resistant intolerant gleevec note sprycel be already approve unite state treatment adult philadelphia chromosome positive ph chronic myeloid leukemia cml chronic phase cp drug also receive fda approval adult ph acute lymphoblastic leukemia be resistant intolerant prior therapy fda also approve sprycel treatment pediatric patient ph cml cp november label expansion exist drug bode well bristol myer bristol myer share have decline year date compare industry decline blockbuster drug opdivo continue perform well label expansion drug further boost top line pricing concern stiff competition immuno oncology space be major cause concern particular merck mrk free report keytruda roche rhhby free report tecentriq stiff competition hence label expansion other drug company maintain top line momentum cancer portfolio also get major boost launch immuno oncology drug empliciti treatment multiple myeloma december bristol myer be co develop empliciti abbvie abbv free report zack rankbristol myer have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2035,ABBV,abbvie inc abbv free report share have outperformed large cap pharma industry past month stock have return timeframe industry decline abbvie outperformance be backed decent quarterly result optimistic outlook stronger underlie business performance rest year positive pipeline news flow regulatory update be repute name pharmaceutical sector abbvie come existence jan abbott laboratory free report divest pharmaceutical divisionhere be reason invest stock favorable rank earning surprise record abbvie have zack rank buy see complete list today zack rank strong buy stock here have be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate increase respectively past day valuation look reasonable outperformance abbvie valuation look fairly reasonable currently abbvie currently have forward month price earning ratio be lowest level past year compare highest level median level past year be apparently upside left space also look inexpensive compare industry current well median ratio industry be respectively price earning forward month chart key drug humira go strong abbvie flagship product humira be approve several inflammatory indication rheumatoid arthritis humira continue witness strong demand trend launch drug new mechanism action competition indirect biosimilar currently approve indication humira sale have increase consistently backed robust demand trend product continue see strong growth dermatology market company expect humira sale approach biosimilar version humira be already approve fda settlement amgen amgn free report samsung bioepis biosimilar entry unite state be set thus delay direct biosimilar competition country strong oncology portfolio abbvie work rigorously expand accelerate presence oncology key drug oncology portfolio be imbruvica be currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease several study imbruvica be ongoing evaluate drug alone combination different patient segment abbvie expect imbruvica peak sale more revenue abbvie have develop imbruvica partnership jnj free report abbvie be also study cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy multiple myeloma acute myeloid leukemia june regulatory application seek approval combination venclexta roche rhhby rituxan relapse refractory cll be approve unite state label expansion include broader patient population boost venclexta commercial potential meanwhile acquisition drugmaker stemcentrx add key late stage candidate rovalpituzumab tesirine rova abbvie portfolio rova be currently registrational study first second line small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing promising pipeline abbvie have deep pipeline consist several interesting late stage candidate promising candidate include elagolix endometriosis risankizumab inflammatory disease depatux glioblastoma multiforme abbv early alzheimer disease progressive supranuclear palsy psp upadacitinib inflammatory disease company expect move tumor candidate clinical development several pivotal datum readout regulatory milestone be expect second half year include fda decision risankizumab elagolix regulatory application mavyret perform expectation abbvie week pan genotypic ribavirin free once daily hepatitis hcv treatment mavyret gain approval unite state eu canada japan mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor mavyret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history mavyret perform expectation first year launch record sale almost positive sale trend continue drug record sale first quarter less year market mavyret already command share unite state conclusion abbvie face share challenge form slower sale hcv drug potential biosimilar competition humira regular pipeline setback rise competition however believe abbvie be well position overcome headwind today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2036,ABBV,pfizer inc pfe free report be reportedly raise price almost drug effective july be second time drug giant have raise price drug year scrutiny drug price have increase trump assume office however softer drug pricing policy form last month expect other company follow suit increase price be nearly majority drug agree limit price rise year however price few drug xalatan viagra chanix have already increase double digit include price hike january trump announce plan control drug price unite state however group investor believe plan be not likely have major impact profit large pharma company instead include provision direct negotiation medicare pharma company trump target intermediary certain small pharma company foreign country thus medicare be major customer drug pay nearly dollar value prescription filled medicare have negotiate lower price directly manufacturer president also expect increase competition streamline approval related regulatory process promote faster approval generic biosimilar plan allow more substitution addition medicare drug list single source generic contain price rise give sponsor more negotiation power manufacturer also instruct company display list price advertising plan also focus more transparency related pricing availability generic moreover announcement price hike pfizer come week trump claim pharma company take massive price cut voluntarily soon pfizer have defend price rise state list price do not reflect actual price include discount also mentioned have hike price only tenth drug portfolio also reduce price drug meanwhile price hike company soon trigger market wide increase drug price thus pfizer move again stir opposition related drug price rise especially large pharma company pfizer stock price several other large cap pharma company moved north jul include johnson johnson jnj free report eli lilly company lly free report abbvie inc abbv free report rise drug price certainly help company boost profit so far year large cap pharma industry have decline rise expect investor remain focuse other pharma company announcement related drug price subsequent move government restrict further hike look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2037,ABBV,express script hold company esrx free report be schedule report first quarter result market close solid performance pharmacy benefit management segment pbm be likely drive company top line however company be get acquire cigna corporation end last report quarter express script deliver adjust earning share beat zack consensus estimate further adjust earning improve year quarter revenue also beat zack consensus estimate first quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg indicate increase year year let dig deeper analyze thing be shape earning announcement pbm focusexpress script be largest pbm north america company have be consistently try expand core pbm business meanwhile zack consensus estimate pbm revenue be peg believe company unique offering home delivery pharmacy care specialty pharmacy care specialty benefit management medical drug datum analysis service buoy optimism express script also distribute full range product provide extensive cost management patient care service company inked agreement acquire privately hold evicore healthcare october transaction be close fourth quarter evicore provide evidence base integrate medical benefit management service mbm solution drive cost reduction quality care outcome acquisition be expect prove accretive express script adjust diluted earning share first full year operation first quarter be exception express script hold company price ep surprise express script hold company price ep surprise express script hold company quoteexpress script pbm service couple evicore complementary medical benefit management be likely build solution strong demand company solution continue quarter review company expect solid demand safeguardrx day supply chronic medication exclusive accredo specialty pharmacy advanced opioid solution program well many other express script deliver superior care patient affordable cost company latest offer multiple sclerosis care value program have be launch jan program extend company differentiate payment model shielding payer cost associate discontinue therapy express script already enrolled life yet management claim most successful launch date other factor adjust claim first quarter be expect range adjust earning share first quarter be estimate range represent growth year year basis full year adjust earning be estimate band reflect growth year year revenue be expect band adjust ebitda be expect come guidance express script core business total adjust claim be expect range first quarter client retention rate positive express script enter strong market momentum continue witness success retain key client end previous quarter company create trust client relationship deliver exceptional care patient control cost favorable drug trend result be clearly indicative fact buoy strong prospect express script expect provide retention rate guidance express script get acquire declare express script be lose biggest customer lead health insurer anthem inc company recently announce be get acquire cigna global health insurance company acquisition be expect be complete dec definitive agreement cigna take express script cash stock transaction worth notably include cigna assumption approximately debt express script fact moody investor service rating service arm moody corporation be worry express script high customer concentration pricing pressure moody express script be likely experience decline script volume higher typical customer loss day come other challenge include fewer generic drug introduction softening mail order growth trend client focus cost saving transparency earning whispersour proven model do not show earning beat express script quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp express script have earning esp uncover best stock buy sell re report earning esp filter zack rank express script carry zack rank here be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here teleflex incorporate tfx free report have earning esp zack rank abbvie inc abbv free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2038,ABBV,gilead science inc gild free report be schedule report first quarter result market close gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quote gilead leader hepatitis virus hcv space have decent track record company earning beating estimate last miss last report quarter company earning beat expectation overall company record average positive earning surprise gilead stock have rally year outperform industry decline likely positive surprise proven model indicate gilead be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be case be here see zack esp earning esp gilead be uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combine positive esp make reasonably confident earning beat quarter conversely caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision factor playconcurrent fourth quarter earning call gilead provide guidance gilead now expect net product sale range strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue first quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch taf base regimen now represent total gilead hiv prescription volume truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage approximately patient used truvada end moreover franchise receive further boost fda approval once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection february hence sale get further boost zack consensus estimate sale genvoya be however gilead lose exclusivity viread country outside unite state impact sale other hand hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr other franchise suffer significant plunge sale due new competition fewer patient start pricing market share be expect stabilize mid patient start be expect decline further hcv revenue be project decline further constitute smaller portion top line go forward zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range meanwhile kite acquisition be step right direction fda approval chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma however management state yescarta launch be controlled launch ensure patient safety car therapy be complicate sometimes be associate severe side effect gilead be also look build nonalcoholic steatohepatitis franchise expect management throw more light same first quarter call investor be also likely keep eye other pipeline update other stock considerhere be other health care stock want consider model show too have right combination element post earning beat quarter gw pharmaceutical plc gwph free report be expect report earning company have earning esp zack rank see complete list today zack rank stock here celgene corporation celg free report be schedule release first quarter result company have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2039,ABBV,vice etfs primarily target company deal product see vice such alcohol tobacco marijuana etfs be attractive option seek diversification portfolio investing so call sin stock need form such category be primarily investor inclination sustainable investing mainly seek avoid sin stock however investor choose such stock attractive return potential add sin stock portfolio investor have multiple way gain exposure space depend preference investor choose pure play alcohol stock tobacco marijuana stock form diversify portfolio entire space however owing high volatility space stringent regulation be advisable go etf way gain exposure sector experience manager handle money investor be good spot sector perform well advisorshare vice etf be launch last september fund portfolio manager dan ahren say re not make kind moral judgment statement person want consume focus strong economic argument look sector positive segment investor be product be somewhat staple even economy be not perform well person drink smoke result even sector take beating time recession outperform other segment market owing demand interdependency alcohol industry have be look growth surpass expectation volume spirit grow last year accord datum provide distill spirit council supplier revenue be moreover cannabis legal marijuana industry be see strong growth tobacco sale be see slight decline let now discuss few etfs provide exposure space spirite fund etfmg whiskey spirit etf fund focus provide exposure company world involved production sale whiskey spirit have aum charge fee basis point year geographical perspective fund have high allocation unite kingdom france unite state exposure respectively have allocation diageo pernod ricard radico khaitan fund have garner inflow so far year have return year etfmg alternative harvest etf mj free report fund seek provide exposure company involved cannabis business have aum charge fee basis point year fund top holding be gw pharmaceutical plc gwph free report hydropothecary corp medreleaf corp allocation respectively fund have garner inflow so far year have return year advisorshare vice etf act free report fund be popular etf focuse provide exposure company involved alcohol tobacco cannabis business have aum charge fee basis point year sector perspective fund have allocation alcohol business tobacco business cannabis business fund top holding be abbvie inc abbv free report constellation brand inc stz free report mgp ingredient inc mgpi free report allocation respectively fund have garner inflow so far year have lose year want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2040,ABBV,alexion pharmaceutical inc alxn free report be schedule report first quarter result apr open bell last quarter company earning surpass zack consensus estimate also alexion track record be excellent have consistently top estimate last quarters average positive earning surprise alexion share have underperform industry past year stock have lose compare industry decline do zack model unveil proven model show alexion be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold have significantly higher chance beating estimate zack esp alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank stock here note sell rate stock zack rank never be consider go earning announcement let see thing be shape announcement factor likely impact resultsalexion blockbuster drug soliris continue perform well alexion continue identify treat consistently high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be work expand soliris label additional indication fda recently approve drug treatment refractory generalized myasthenia gravis gmg patient be acetylcholine receptor antibody positive drug be approve europe indication approximately patient be expect have gmg unite state additionally phase iii study prevent soliris patient relapse neuromyelitis optica spectrum disorder be ongoing enrollment be complete datum expect mid label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly zack consensus estimate soliris hint drug sale increase year quarter alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate company plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity alexion reduce spending headcount associate previously announce prioritize pipeline program well optimize additional expense company plan relocate headquarters boston mid approximately position result restructure plan company reduce global workforce approximately company expect increase financial flexibility allow reinvest approximately annually alexion expect pretax saving approximately meantime company effort develop pipeline be impressive particularly case alxn currently be evaluate alxn longer act antibody inhibit terminal complement phase iii study pnh ahus tentative approval pnh be expect patient be also be dose phase iii trial alxn administer intravenously week complement inhibitor treatment naive adolescent adult patient ahus company be expect complete enrollment second quarter announce result fourth quarter alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quoteother stock warrant lookhere be biotech stock want consider model show too have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2041,ABBV,astrazeneca azn free report announce japanese regulatory authority have grant approval parp inhibitor lynparza tablet treatment patient unresectable recurrent brca mutate metastatic breast cancer patient have receive prior chemotherapy approval lynparza become first only parp inhibitor approve use ovarian cancer japan be second indication lynparza be now approve japan lynparza be approve first indication advanced ovarian cancer regardless brca mutation status country earlier year astrazeneca share have rise so far year contrast industry have decline unite state lynparza be approve breast cancer indication january lynparza be also presently market advanced ovarian cancer later setting lynparza be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer first quarter lynparza sale rise sale unite state surge gain recent label expansion approval ovarian cancer tablet breast cancer indication europe sale rise push higher number successful launch high brca testing rate encourage level reimbursement astrazeneca have joint development collaboration agreement merck mrk free report lynparza astrazeneca cancer drug imfinzi be also approve japan early stage lung cancer indication pd inhibitor be approve patient locally advanced unresectable stage iii small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt approval be base positive progression free survival datum phase iii pacific study imfinzi be already approve unite state canada switzerland india indication application eu be review decision expect second half meanwhile imfinzi durvalumab be be evaluate multiple cancer alone combination other regimen include late stage study combination tremelimumab hepatocellular carcinoma hcc liver cancer nsclc small cell lung cancer metastatic urothelial cancer head neck squamous cell carcinoma hnscc other imfinzi be launch unite state first indication second line advanced bladder cancer last year thereafter imfinzi be approve immediately launch early stage lung cancer unite state february year contribute significantly drug sale first quarter astrazeneca have zack rank sell better rank large cap pharma stock include pfizer inc pfe free report abbvie inc abbv free report zack rank buy see complete list today zack rank strong buy stock here pfizer stock have gain past year earning estimate well rise last day abbvie stock have rally past year earning estimate increase rise last day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2042,ABBV,volatility uncertainty stock market have raise appeal dividend growth stock history dividend growth year year lead healthy portfolio greater scope capital appreciation opposed simple dividend pay stock high yield dividend growth stock have strong history dividend growth mature company be less susceptible large swing market thus act hedge economic political uncertainty well stock market volatility same time offer downside protection consistent increase payout additionally stock have superior fundamental make dividend growth quality promising investment long term include sustainable business model long track profitability rise cash flow good liquidity strong balance sheet value characteristic further history strong dividend growth indicate dividend increase be likely future stock do not necessarily have highest yield have outperformed longer period broader stock market other dividend pay stock result pick dividend growth stock appear winning strategy other parameter be also include year historical dividend growth greater select stock solid dividend growth history year historical sale growth greater represent stock strong record grow revenue year historical ep growth greater represent stock solid earning growth history next year ep growth rate greater represent rate company earning be expect grow improve earning help company sustain dividend payment price cash flow less industry ratio less industry indicate stock be undervalue industry investor need pay less better cash flow generate company week price change greater market weight ensure stock appreciate more past year top zack rank stock have zack rank strong buy buy generally outperform peer type market environment growth score better research show stock growth score combine zack rank offer best upside potential here be stock fit bill ohio base progressive corporation pgr free report provide personal commercial auto insurance residential property insurance other specialty property casualty insurance related service primarily unite state company have see positive earning estimate revision cent past day year have expect earning growth rate sport zack rank growth score see complete list today zack rank stock here texas base brinker international inc eat free report be world lead casual dine restaurant company brinker international own operate franchise be involved ownership restaurant name chili grill bar maggiano little italy deliver average positive earning surprise past quarters have expect earning growth rate fiscal end june have zack rank growth score illinois base abbvie inc abbv free report be global research base company discover develop manufacture sell pharmaceutical product worldwide company deliver average positive earning surprise last quarters have expect earning growth rate year have zack rank growth score pennsylvania base vishay intertechnology inc vsh free report be global manufacturer supplier discrete semiconductor passive component see positive earning estimate revision penny past day year expect earning growth stock have zack rank growth score hawaii base matson inc matx free report operate ocean transportation logistic company offer shipping service hawaii guam micronesia island expedite service china southern california stock see positive earning estimate revision couple cent past day year have expect earning growth rate have zack rank growth score get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
2043,ABBV,vertex pharmaceutical incorporate vrtx free report share rally more jun follow announcement lower expect top line result galapago nv glpg free report phase ii study cystic fibrosis cf candidate glpg galapago be evaluate candidate top vertex cf drug orkambi lumacaftor ivacaftor phase ii pelican study cf patient be homozygous class ii del mutation patient treat glpg be treat orkambi least week study continue receive study company be develop glpg triple combination regimen treat cf patient datum study show glpg combination orkambi improve ppfev measure lung function reduce sweat chloride mmol baseline versus placebo however investor have find datum disappointing lead decline galapago share price last friday vertex be also develop triple combo regimen candidate vx vx combination tezacaftor ivacaftor have improve ppfev respectively early mid stage study reduction sweat chloride patient be also materially higher glpg moreover candidate be phase iii stage development number stage show vertex be clear leader development process triple combo regimen cf patient study result be also significantly higher probably competition longer term so far year vertex share have gain decrease register industry galapago be also develop triple combination regimen own cf potentiator corrector glpg glpg glpg phase study interim datum expect third quarter cf study be be conduct partnership abbvie abbv free report however abbvie have opted not proceed development previously contemplated second triple combination therapy comprise glpg glpg glpg meanwhile vertex announce press release third cf drug be approve treatment patient age older copy del mutation cftr gene canada drug available brand name prsymdeko corbus pharmaceutical holding inc crbp free report base clinical stage pharmaceutical company be also develop cf candidate lenabasum mid stage study vertex pharmaceutical incorporate price vertex pharmaceutical incorporate price vertex pharmaceutical incorporate quotevertex currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2044,ABBV,gilead science inc gild free report announce european medicine agency ema committee medicinal product human use chmp have issue positive opinion company marketing authorization application maa car therapy axicabtagene ciloleucel treatment adult patient relapse refractory diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl more line systemic therapy axicabtagene ciloleucel chimeric antigen receptor cell car therapy modify patient own cell recognize attack cancer cell agency have earlier grant prime status axicabtagene ciloleucel tentative approval be card ema generally take chmp recommendation account review maa note axicabtagene ciloleucel be approve fda october yescarta approval europe boost growth prospect therapy give market potential information provide company be estimate patient dlbcl be refractory have relapse more line therapy be eligible car therapy europe concurrently novartis nvs free report also obtain positive opinion chmp car therapy kymriah cell malignancy cell acute lymphoblastic leukemia dlbcl gilead stock have gain year so far industry decline note gilead be look newer avenue help top line solidify presence gene therapy space initial uptake yescarta unite state be also encourage gilead be also intend foray nash market gilead hcv franchise be experience slowdown key market include unite state europe reflect lower sale harvoni sovaldi result competitive pricing pressure franchise see significant plunge sale due new competition fewer patient start note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak mayret merck mrk free report zepatier other nevertheless hiv franchise continue maintain momentum zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2045,ABBV,north chicago il base abbvie inc abbv free report be best know autoimmune disease drug humira abbvie flagship product humira be approve several indication rheumatoid arthritis moderate severe moderately severely active polyarticular juvenile idiopathic arthritis active psoriatic arthritis active ankylose spondylitis crohn disease moderate severe ulcerative colitis moderate severe axial pediatric crohn disease chronic plaque psoriasis moderate severe hidradenitis suppurativa moderate severe other key product include imbruvica cancer viekira pak hepatitis virus hcv treatment humira be major contributor abbvie top line humira remain key growth driver abbvie come quarters see investor focus remain primarily pipeline update meanwhile pharmacyclic acquisition have diversify abbvie product portfolio addition imbruvica abbvie performance have be impressive pharmaceutical company deliver positive surprise past quarter average earning beat last quarters be currently abbvie have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning abbvie first quarter earning come share beating zack consensus estimate revenue abbvie post revenue marginally beat zack consensus estimate key stat humira sale come year year exclude currency impact first quarter imbruvica net revenue be year year outlook abbvie update outlook company raise adjust ep range compare expect previously zack consensus estimate be currently peg share share price impact share rise more pre market trading check back later full abbvie earning report abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quotemore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2046,ABBV,inogen inc ingn free report first quarter result be schedule release apr market close broaden long term oxygen therapy ltot market inherent benefit portable oxygen concentrator poc traditional delivery model direct customer business model underpenetrated international market expand product portfolio be key growth catalyst notably last quarter inogen report adjust earning cent share beating zack consensus estimate earning increase year year basis total revenue report quarter rise year year basis figure beat zack consensus estimate current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg cent let delve other factor be likely impact inogen first quarter result european sale boost top lineinogen have be lead provider pocs europe last report quarter sale europe represent international sale year quarter expect trend continue upcoming quarterly result fact management expect long term opportunity ahead market transition tank liquid oxygen system delivery solution further support european customer inogen begin production inogen concentrator fourth quarter used contract manufacturer foxconn locate czech republic company expect foxconn produce huge number inogen concentrator require support massive european demand first quarter be exception inogen be just first leg collaboration foxconn company have be already deliver improve service level lower cost expect company deliver solid first quarter performance back inogen concentrator inogen home concentrator inogen inc price ep surprise inogen inc price ep surprise inogen inc quote other factor inogen expect revenue range previously issue range notably represent growth year year upbeat trend be expect continue quarter be report well direct consumer modelinogen expect direct consumer sale be fastest grow channel domestic business business sale have significant growth rate international business business sale have modest growth rate strategy still focus european market inogen direct customer business model have lend lead position oxygen therapy market direct consumer model give company opportunity build unique brand relationship directly customer recently company sign lease expansion site ohio accelerate growth domestic direct consumer sale channel grow direct customer sale marketing effort help increase awareness patient growth physician referral segment be expect boost top line long term fourth quarter direct consumer sale domestic international increase year year basis company sale team consist sale representative dec represent increase rep year end total company announce plan execute direct consumer pricing trial ensure product be optimally price unique direct consumer business model be likely boost company first quarter bottom line dull rental revenuesinogen derive significant portion revenue medicare service reimbursement program company expect rental revenue patient decline upcoming quarters due lower reimbursement rate connection nationalization competitive bidding continue reimbursement decline rental revenue represent total revenue fourth quarter lower net revenue year quarter rental revenue fourth quarter be compare fourth quarter year year management decline be cause rental benefit year quarter model predictsour quantitative model do not predict earning beat inogen upcoming quarterly result be stock need have positive earning zack rank strong buy buy hold be able beat estimate be illustrated zack espearning esp inogen be uncover best stock buy sell re report earning esp filter zack rankinogen carry zack rank here be few medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here teleflex incorporate tfx free report have earning esp zack rank abbvie inc abbv free report have earning esp zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2047,ABBV,earning season have start gather steam latest earning preview member accounting index have already release financial figure apr total earning member have report result already be same period last year higher revenue beating ep estimate beating revenue estimate proportion company beating ep revenue estimate be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strong note beating zack consensus estimate earning well sale large cap player report earning last week be novartis nvs free report also surpass earning revenue expectation quarter also biogen inc biib free report release result week surpass earning miss sale expectation higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning quarter review pharma biotech giant be schedule report earning result apr let see thing be shape company upcoming release abbvie inc abbv free report be slate releaseresult market open company deliver positive earning surprise last report quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive earning surprise proven model show abbvie be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank hold zack consensus estimate company earning quarter review be peg share company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally other drug namely duopa creon be also likely maintain encourage performance soon be report quarter read more be beat card abbvie earning abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote alexion alxn free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise alexion be likely beat earning be report quarter have positive earning esp zack rank buy zack consensus estimate quarterly earning be peg share see complete list today zack rank strong buy stock here alexion blockbuster drug soliris continue perform well company be work expand soliris label additional indication alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quote bristol myer squibb bmy free report be slate report result open bell company deliver positive earning surprise last quarter company deliver positive earning surprise trail quarters average beat model show bristol myer be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quote vertex pharmaceutical incorporate vrtx free report be slate report result market close vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex deliver positive earning surprise model show vertex be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter vertex cystic fibrosis cf drug kalydeco orkambi perform well sale rise almost expect positive trend continue soon be report quarter also boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february expect company provide update symdeko plan initial uptake company be also likely provide full year revenue guidance include symdeko sale call read more be beat store vertex earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quote investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2048,ABBV,expect abbvie inc abbv free report beat expectation report first quarter result apr market open last quarter company deliver positive earning surprise share abbvie have marginally outperformed industry so far year stock have decline industry have decrease notably abbvie earning history be quite impressive pharmaceutical company have outpaced estimate last quarters average beat let see thing be shape company quarter factor considerabbvie expect first quarter earning range share revenue be estimate grow mid range operational basis foreign exchange be anticipate gain favorable impact sale period be report company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally zack consensus estimate humira be peg significantly first quarter conference call investor focus also be performance level well label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica stand other drug namely duopa creon be also likely maintain encourage performance soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale affected intense pricing competitive pressure hcv market moreover march abbvie rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line therapy later small cell lung cancer sclc first quarter conference call expect management provide update same notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret secure approval unite state eu canada well japan second half importantly mavyret record global sale last year initial uptake drug have be commendable expect higher sale first quarter well earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp zack consensus estimate be share positive esp indicate likely earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvieha zack rank increase predictive power esp together positive esp chance stock beating estimate upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision other stock warrant lookhere be couple other health care stock worth consider right combination element also surpass estimate time pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here bristol myer squibb company bmy free report be schedule report earning apr company have earning esp zack rank celgene corporation celg free report be slate announce financial figure company have earning esp be zack rank player abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2049,ABBV,healthcare space have be tough journey year popular etf health care select sector spdr fund xlv free report have shed so farwhile vanguard health care etf vht free report fidelity msci health care index etf fhlc free report have gain least meanwhile ishare healthcare etf iyh free report have add mixed trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read healthy earning unitedhealth etfs watch let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate higher chance beating estimate quarter stock have see positive earning estimate revision cent be report quarter deliver average positive earning surprise past quarters have vgm score pfizer be schedule report earning open bell merck be expect report result market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness positive earning estimate revision cent past day be report quarter merck have vgm score amgen carry zack rank have earning esp indicate reasonable chance beating estimate time earning surprise track past quarters be strong average positive surprise addition amgen witness positive earning estimate revision cent past day quarter be report stock have solid vgm score amgen report earning apr market close read small cap biotech etfs be soar abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see solid earning estimate revision cent past month be report quarter stock have solid vgm score company be schedule report apr open bell gilead be expect release earning market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision penny past month be report quarter have vgm score bristol myer likely report earning apr open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have vgm score sum earning surprise well card healthcare sector be expect witness earning growth first quarter suggest upside healthcare etfs particular etfs have zack etf rank see healthcare etfs here want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2050,ABBV,ecolab inc ecl free report be schedule report first quarter result market open solid performance global industrial segment be likely drive top line further expect improvement revenue other segment be likely help company generate solid result season last quarter ecolab report adjust earning share miss zack consensus estimate penny earning improve year quarter adjust quarterly net sale be year quarter also net sale miss zack consensus estimate current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg cent indicate increase year year let delve deeper ecolab inc price ep surprise ecolab inc price ep surprise ecolab inc quoteglobal industrial drive global total revenue last quarter sale segment grow year year almost upside be drive major gain water food beverage life science unit europe north america latin america lead global industrial regional growth upcoming quarterly result zack consensus estimate global industrial segment be peg figure reflect increase year figure ecolab global industrial segment primarily provide water treatment process application operate unit global industrial reportable segment include nalco water food beverage paper textile care life science ecolab acquire new york base cascade water service inc privately hold company provide water treatment program service institutional market notably acquisition broaden service improve opportunity strategic water treatment market global industrial unit mar ecolab divest phosphonate component business china italmatch chemical spa lead global specialty chemical group phosphonate supplier management divestment be likely enhance ecolab strategic focus core business allow drive profit china term other factor first quarter ecolab expect adjust earning range cent share previous range cent current outlook reflect increase year year adjust gross margin first quarter be expect be net revenue ecolab project adjust earning range share year year percentage revenue adjust gross margin be expect range global energy boost top lineglobal energy account total revenue last quarter sale segment rise owing strong growth well stimulation business modest gain downstream business segment operate nalco champion name global energy cater process chemical water treatment need global petroleum petrochemical industry upstream downstream application management ecolab announce margin improvement operate income growth energy business last report quarter solid estimate revision trend ecolab global energy segment buoy optimism zack consensus estimate global energy segment be peg reflect nominal improvement year year basis global institutional focusglobal total revenue last quarter sale increase lead strong growth specialty business line segment witness solid growth north america asia pacific segment provide specialize clean sanitizing product foodservice hospitality lodging healthcare government education retail industry operate unit global institutional segment include institutional specialty healthcare management expect first quarter result surpass fourth quarter number solid growth business further china business global institutional unit have be grow very steadily double digit high single digit be expect maintain pace be reflect be report quarter zack consensus estimate global institutional segment be peg reflect rise year year basis thus ecolab be confident improve growth trajectory be visible upcoming quarterly result model predictsour quantitative model show earning beat ecolab quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp ecolab be uncover best stock buy sell re report earning esp filter zack rank ecolab carry zack rank other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here teleflex incorporate tfx free report have earning esp zack rank abbvie inc abbv free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2051,ABBV,biogen inc biib free report report first quarter earning share beat zack consensus estimate moreover bottom line rise year year sale come year period however metric marginally miss zack consensus estimate top line exclude hemophilia revenue grow year year remind investor last year biogen spun hemophilia business new company call bioverativ earlier january sanofi sny free report announce have enter agreement bioverativ buy latter share biogen be more pre market trading stock have decline year so far underperform industry decrease quarter detailbiogen multiple sclerosis ms revenue be year year reporter quarter include approximately royalty sale roche rhhby free report ms drug ocrevus deal roche biogen be entitle receive royalty sale ocrevus oral ms drug tecfidera sale increase year year decrease sequentiallyto other ms drug tysabri sale decline year year be flat sequentially combine interferon revenue avonex plegridy first quarter be year year sequentially avonex revenue decline year period plegridy contribute revenue decrease year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well due higher discount allowance zinbryta launch collaboration abbvie abbv free report contribute revenue first quarter compare fourth quarter notably march biogen announce decision withdraw zinbryta market less year fda approval due grow safety concern limit commercial adoption drug restrictive label company decide discontinue drug marketing ground complex evolve benefit risk profile biogen newest drug spinraza spinal muscular atrophy logged revenue first quarter almost line previous spinraza sale be first quarter decrease sequentially however ex market spinraza record sale sequentially significantly number patient receive spinraza grow unite state outside unite state quarter review compare precede period company say spinraza international revenue be mainly gross germany turkey japan first quarter biogen record biosimilar revenue compare fourth quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period spend increase year year decrease sequentially other hand sg spend be year year decrease sequentially biogen inc price consensus ep surprise biogen inc price consensus ep surprise biogen inc quotezack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2052,ABBV,pharma giant eli lilly company lly free report announce positive top line result second phase iii study arthritis drug taltz ixekizumab treatment ankylose spondylitis also know radiographic axial axspa phase iii study coast evaluate safety efficacy taltz treatment be first trial patient population inadequate response tumor necrosis factor tnf inhibitor intolerance tnf inhibitor result show taltz demonstrated statistically significant improvement sign symptom measure proportion patient have achieve assessment international society asas response week compare placebo study meet primary major secondary endpoint be type affect pelvic joint spine notably company have earlier report positive result phase iii coast study taltz therapy lilly plan submit detailed datum coast study scientific meeting peer review journal later base positive result coast coast study company plan submit same approval unite state later year remind investor apart psoriatic arthritis taltz be approve treat moderate severe plaque psoriasis adult eligible systemic therapy phototherapy well active psoriatic arthritis many other drug novartis nvs free report cosentyx abbvie abbv free report humira be approve treat plaque psoriasis lilly claim taltz be now first only fda approve treatment genital psoriasis taltz logged sale first quarter label expansion turn expand eligible patient population drug drive sale go forward drug record sale share lilly have inched year date industry decline lilly currently carry zack rank hold top rank stock same sector be lundbeck hluyy free report carry zack rank strong buy see complete list today zack rank stock here lundbeck earning estimate have be revise upward past day stock have surge year date wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2053,ABBV,expect bristol myer squibb company bmy free report beat expectation report first quarter result apr market open bristol myer share have decrease so far year compare industry decline bristol myer track record have be mixed so far company deliver positive earning surprise last quarters miss expectation once average positive earning surprise last quarters be last report quarter bristol myer deliver positive surprise let see thing be shape quarter drive growth bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer opdivo combination yervoy significantly improve progression free survival patient compare chemotherapy potential approval indication be significant boost drug give immense scope lung cancer market zack consensus estimate drug sale first quarter be peg january european commission approve label expansion yervoy injection pediatric patient year age older unresectable metastatic melanoma fda approve drug indication july zack consensus estimate drug sale quarter be november fda approve line extension sprycel pediatric patient ph chronic myeloid leukemia chronic phase drug register growth previous quarter be expect receive boost quarter due expand label zack consensus estimate sprycel sale stand cardiovascular drug eliquis come strong performance sale grow year year sale be expect remain robust first quarter too zack consensus estimate eliquis sale be peg other hand decline hepatitis franchise be expect continue due intense competition multiple drug include epclusa label be expand include hiv co infection august moreover hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise zack consensus estimate hepatitis franchise sale be peg quarter year quarter actual figure label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively likely positive surprise proven model indicate bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank bristol myer have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter pfizer inc pfe free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here abbvie inc abbv free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2054,ABBV,invest pot stock stock pick update acbff gwph smg iipr top pick abbv cron stz insy cara risk reward buy pot stock episode roundup podcast zack comit be get easier buy stock do business emerge cannibis industry tracey dave explore option description welcome episode zack market edge podcast week host zack stock strategist tracey ryniec be joined guest discuss hottest investing topic stock bond etfs impact life episode tracey be joined david bartosiak editor zack surprise trader momentum trader blockchain innovator newsletter discuss favorite topic marijuana stock jan tracey dave first explore marijuana investment option podcast title get rich marijuana stock back early investment picking be slim have thing change mature pot stock industrydemand remain high pot stock reason several marijuana etfs have now launch more business be look way get foothold industry addition stock talk last year tracey dave also find several more investing option focuse be trade exchange have soon have zack rank mean stock trade pink sheet aurora cannabis acbff example be not high list even have market cap stock get marijuana trade scott miracle gro company smg free report make pot soil specifically grow marijuana be stock mentioned podcast performance hasn be great share have fall time gw pharmaceutical gwph free report be british company be develop cannabis medicine lead product be development treat rare catastrophic form childhood set epilepsy expect lose share fiscal fiscal share be just january podcast innovative industrial property iipr free report be reit manage free standing property grow license medical use cannabis facility be operated state license grower have building new york minnesota just acquire site arizona have long term lease earning be expect be have paid distribution share be jan podcast abbvie abbv free report be large cap company just happen be first fda approve cannabis base drug marinol market marinol be approve chemotherapy induced nausea vomit anorexia abbvie be expect grow earning yet trade forward just crono group cron free report list nasdaq exchange feb canadian base company cultivate medical marijuana company own peace natural original whistler medical marijuana company doesn yet have zack rank stay tune be other be development stage cannabis base therapy treatment additionally large food beverage company be look way invest cannabis food drink product other stock be marijuana investment listen podcast find don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2055,ABBV,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2056,ABBV,pass new tax bill corporate tax rate have come be likely boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location time tax rate leave company extra spending power most big pharma company discuss plan use extra cash save new tax bill fourth quarter conference call extra cash mostly be invest capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback however majority company do not mention effort regard lower prescription drug cost last week senator tina letter big pharma company expressed concern big pharma company plan used billion dollar save tax cut offer tax bill pass december be concern fact company be favore investor instead used saving bring prescription drug cost major life save drug be protected patent be steeply price thus make drug affordable help consumer lower medical cost senator have send letter ceo pfizer inc pfe free report merck co inc mrk free report johnson johnson jnj free report abbvie inc abbv free report abbott laboratory free report provide detail intend utilize major saving tax overhaul price major prescription drug have sky-rocket past year pinch hard citizen medical bill have soar moreover government also have pay higher cost drug be cover medicare concern senator be thus justified move restrict use tax saving boost shareholder be welcome move consumer moreover large player other industry have similar plan have undercut president donald trump plan create job boost wage senator be also work make cheaper generic drug available market faster introduce new legislation report kdal large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returndon even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2057,ABBV,buy hold value investing example successful long term retail investor buy hold strategy tracey top stock pick episode roundup deo myl sne abbv wbawelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick do want be buy hold investor just don know start buy hold investing be toughest type investing do call go human nature instant big payout do play lottery love idea become millionaire overnight buy hold investing be slow slog payout not come several decade have gut stick long investor do have gut buy hold investing pay big return strategy buy hold investing start young longer have invest more ll reap reward compound diversify don just buy stock even be bear stearn spread risk don get fancy don need latest fad stock biotech wonder stick basic buy company have solid fundamental strong brand stock buy buy hold portfolio todaywhen read successful buy hold investor re almost always invest company ve hear therefore tracey screen big cap company zack rank strong buy buy hold also have value component average be diageo plc deo free report isn technically value stock have forward expect grow earning fiscal maker guinness bailey johnnie walker also pay dividend currently yielding healthy mylan myl free report be dirt cheap drug company trade forward just also have earning growth be expect be sony sne free report be big entertainment be also move self drive car market work sensor value stock forward sony also pay dividend currently yielding abbvie abbv free report be rare growth value stock have forward yet be expect grow earning extra bonus shareholder also get dividend yielding walgreen boot wba free report have pull back high so cheaper january trade forward close rite aid deal add store earning be expect rise fiscal else know be buy hold investor find week podcast breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2058,ABBV,johnson johnson jnj free report kick pharma earning season strong note beating zack consensus estimate earning sale first quarter performance be drive continue positive momentum second half improvement consumer segment sale do perform earning share beat zack consensus estimate quarterly revenue be also beat consensus mark buoy strong performance company up previously issue sale outlook read more top earning estimate raise sale guidance pharmaceutical segment sale grow year year first quarter due strong sale domestic international market favorable currency impact sale market rise quarter international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well oncology sale increase quarter constitute almost quarter pharmaceutical sale core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth imbruvica sale rise drug be market partnership abbvie inc abbv free report edurant sale rise prezista sale increase however concerta sale continue decline due generic competition sale risperdal consta also fall sale invokana invokamet decline due higher manage care discounting blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report fall pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set certainly boost sale now expect revenue range higher expect previously overall expect pharmaceutical segment remain strong consumer medical device segment continue improve expect other company merck amgen inc amgn free report pfizer lilly follow suit novartis report encourage resultsnovartis ag nvs free report also report week swiss pharma giant beat earning revenue estimate drive strong performance key drug cosentyx entresto novartis report core earning share beating zack consensus estimate record year quarter revenue increase beating zack consensus estimate read more novartis beat earning revenue estimate sale innovative medicine division grow drive volume growth cosentyx entresto however entry generic gleevec unite state europe impact sale unfavorably cosentyx sale increase drive strong growth indication expand access entresto sale increase drive increase uptake oncology franchise exclude gleevec grow drive promacta revolade tafinlar mekinist jakavi recent launch however sale sandoz division be due price erosion unite state however year so far share have lose novartis share be decrease witness industry other pharma bigwig report solid result too pfizerpfizer top line be expect be favorably impact new product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner soon be report quarter moreover line extension xeljanz sutent bosulif receive fourth quarter be also expect bring more sale however loss exclusivity associate generic competition pristiq unite state lyrica europe product shortage legacy hospira likely affect sale negatively blockbuster drug enbrel sale continue decline quarter due biosimilar competition company sale be expect increase low single digit level zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale currently stand represent year year growth pfizer carry zack rank buy merckmerck blockbuster drug keytruda lynparza bridion injection be expect boost revenue first quarter keytruda sale be gain momentum approval launch keytruda new indication especially first line lung cancer however rise competitive pricing pressure be expect hurt sale zostavax zepatier januvia isentress animal health franchise sale be likely remain strong first quarter merck carry zack rank see complete list today zack rank strong buy stock here zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be represent year year increase eli lilly lly sale lilly diabetes drug trulicity jardiance be expect grow drive market share gain other new drug such cyramza taltz lartruvo be also expect boost top line due continue strong demand verzenio be also expect generate higher sale first quarter however patent expiry country cymbalta strattera effient axiron zyprexa evista competitive pressure mainly immuno oncology agent alimta hurt sale drug expect strong uptake new product offset decline sale establish product quarter too zack consensus estimate sale earning be peg respectively zack consensus estimate sale stand represent rise year year lilly carry zack rank bristol myer squibb company bmy several label expansion bristol myer blockbuster cancer drug opdivo drive company sale last year be expect do so year well moreover cardiovascular drug eliquis also demonstrated strong performance expect trend continue quarter label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact however genericization plavix avapro avalide baraclude unite state due loss exclusivity be significantly hurt company top line company also face stiff competition immuno oncology space hiv business continue face competitive pressure zack consensus estimate sale earning be peg cent respectively zack consensus estimate sale be peg represent rise year year bristol myer carry zack rank new product majority company be do well be expect offset decline sale legacy drug due loss exclusivity moreover most company boast deep promising pipeline also new tax law boost prospect strategic merger acquisition licensing deal collaboration smaller company strengthen company product portfolio wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2059,ABBV,roche hold ag rhhby free report member genentech announce fda have grant breakthrough therapy designation hemophilia drug hemlibra emicizumab kxwh designation be grant hemlibra treatment person hemophilia factor viii inhibitor designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible designation be base datum phase iii haven study person year older hemophilia inhibitor study hemlibra prophylaxis dose subcutaneously week week show statistically significant clinically meaningful reduction treat bleed compare prophylaxis study meet primary endpoint well key secondary endpoint hemlibra significantly reduce bleed roche stock have lose year compare industry gain note fda approve hemlibra routine prophylaxis event reduce frequency bleed episode adult child haemophilium factor viii inhibitor november hemlibra be review fda priority review grant breakthrough therapy designation september january eu committee medicinal product human use chmp adopt positive opinion hemlibra emicizumab routine prophylaxis bleed episode patient suffering hemophilia factor viii inhibitor chmp have recommend drug use age group marketing authorisation application be be review accelerate assessment potential approval further boost roche hematology portfolio include approve drug mabthera rituxan gazyva gazyvaro tecentriq venclexta note roche be develop venclexta collaboration abbvie abbv free report company be jointly commercialize drug unite state abbvie be commercialize drug outside unite state approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer roche hold ag price roche hold ag price roche hold ag quotezack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2060,ABBV,first quarter earning season have just kick latest earning preview bottom line company be expect increase highly impressive rate year year basis prospective upside mark maximum quarterly earning growth pace year report further predict zack sector be project exhibit double digit earning growth be report quarter total revenue same set company be project grow however focuse attention large cap pharma medical drug sector note sector have decrease respectively february year due broader market pressure further index have register decline second month remind investor stock market be face severe volatility last couple month strong start year downside mainly be attributable potentially damage trade war world largest economy unite state china february president donald trump announce plan impose tariff annual chinese import china retaliate notify intention levy tariff product such aggressive exchange have trigger tension possible trade dispute country moreover sluggish large cap tech stock be cite reason plummet market recent market unrest optimistic sentiment revolve remain year notably biotech sector be likely improve year advance expect new product sale thrive tandem rise demand apart successful innovation host product launch strong clinical study outcome more frequent fda nod solid performance key product grow demand drug especially deal rare treat disease agee population escalate healthcare expenditure be factor keep sector stable see complete list today zack rank stock here be important note outlook upcoming first quarter result look bright earning preview broader medical sector inclusive drug biotech well medical device company be expect record year year growth revenue rise earning pick potential winnersgiven enormity healthcare space task select stock possibility beat estimate appear quite daunting zack proprietary methodology make job fairly simple way carve top choice report cycle be look stock combination favorable zack rank zack rank strong buy buy hold positive earning esp be observed positive earning surprise deliver company mostly lead stock price appreciation well research quantitative model earning esp be used identify stock higher chance pull positive surprise impending earning announcement show percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter proven methodology cull stock large cap pharma medical drug sector poise surpass estimate be report quarter large cap stock be follow first pick be abbvie inc abbv free report north chicago il base company have earning esp zack rank stock have see zack consensus estimate first quarter earning be peg share company boast encourage earning track record exceed expectation last quarters average beat abbvie be schedule report earning number apr next choice be eli lilly company lly free report stock have earning esp zack rank consensus mark first quarter earning stand share headquarter indianapoli lilly have excellent positive earning surprise history company average beat trail quarters be lilly be slate announce result apr pfizer inc pfe free report too have please earning profile company have consistently outpaced expectation last quarters average beat look perfectly poise repeat winning streak time well new york base player be zack rank have earning esp consensus mark first quarter bottom line be peg cent share pfizer be schedule release financial figure give be medical drug stock first pick medical drug sector be catalent inc ctlt free report new jersey base company have earning esp zack rank zack consensus estimate first quarter earning be peg cent share company flaunt positive earning surprise record outshine expectation last quarters average beat catalent be expect report earning next choice be aratana therapeutic inc petx free report stock have earning esp be rank player consensus mark first quarter loss stand cent share base kansa aratana have outstanding earning history consecutive estimate beat trail quarters average be company be slate announce result investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2061,ABBV,buy hold value investing example successful long term retail investor buy hold strategy tracey top stock pick episode roundup deo myl sne abbv wbawelcome episode value investor podcastevery week tracey ryniec editor zack value investor portfolio service share top value investing tip stock pick do want be buy hold investor just don know start buy hold investing be toughest type investing do call go human nature instant big payout do play lottery love idea become millionaire overnight buy hold investing be slow slog payout not come several decade have gut stick long investor do have gut buy hold investing pay big return strategy buy hold investing start young longer have invest more ll reap reward compound diversify don just buy stock even be bear stearn spread risk don get fancy don need latest fad stock biotech wonder stick basic buy company have solid fundamental strong brand stock buy buy hold portfolio todaywhen read successful buy hold investor re almost always invest company ve hear therefore tracey screen big cap company zack rank strong buy buy hold also have value component average be diageo plc deo free report isn technically value stock have forward expect grow earning fiscal maker guinness bailey johnnie walker also pay dividend currently yielding healthy mylan myl free report be dirt cheap drug company trade forward just also have earning growth be expect be sony sne free report be big entertainment be also move self drive car market work sensor value stock forward sony also pay dividend currently yielding abbvie abbv free report be rare growth value stock have forward yet be expect grow earning extra bonus shareholder also get dividend yielding walgreen boot wba free report have pull back high so cheaper january trade forward close rite aid deal add store earning be expect rise fiscal else know be buy hold investor find week podcast breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2062,ABBV,key highlight week include fda acceptance regeneron sanofi dupixent sbla asthma biogen abbvie decision withdraw multiple sclerosis drug zinbryta due risk liver failure celgene completion juno acquisition recap week most important sanofi dupixent sbla asthma accept fda regeneron regn free report partner sanofi sny free report announce fda have accept review supplemental biologic license application sbla dupixent dupilumab add maintenance treatment adult adolescent year age older moderate severe asthma fda have set target action date oct prescription drug user fee act sbla be support result pivotal trial liberty asthma clinical development program sanofi regeneron be study dupilumab broad range clinical development program disease drive type inflammation include pediatric atopic dermatitis phase iii nasal polyp phase iii eosinophilic esophagitis phase iii read more fda accept regeneron sanofi dupixent sbla asthma regeneron be zack rank strong buy stock see complete list today zack rank stock here biogen abbvie withdraw zinbryta biogen biib free report partner abbvie abbv free report announce company withdraw multiple sclerosis drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient be treat drug be currently available europe unite state switzerland canada australia abbvie distribute zinbryta unite state biogen distribute drug ex market european regulatory authority provisionally restrict use zinbryta adult patient highly active relapse disease full adequate course treatment least dmt rapidly evolve severe relapse ms be unsuitable treatment other dmts follow report case fatal fulminant liver failure well case serious liver injury gilead report new datum biktarvy gilead gild free report announce encourage result week phase iii study study virologically suppress adult woman hiv infection international workshop hiv woman conference retroviruse opportunistic infection croi boston poster biktarvy be find be statistically inferior regimen contain bpi boost elvitegravir demonstrated treatment emergent resistance week ongoing study biktarvy gilead latest triple therapy be approve fda february complete regimen treatment hiv infection adult have antiretroviral treatment history read more gilead announce positive datum new hiv therapy biktarvy celgene complete juno acquisition celgene corporation celg free report announce have complete previously announce acquisition juno therapeutic inc juno focus development car chimeric antigen receptor tcr cell receptor therapeutic promising pipeline evaluate multiple target cancer indication acquisition add jcar lisocabtagene maraleucel liso cel celgene lymphoma pipeline jcar be best class cd direct car currently pivotal program relapse refractory diffuse large cell lymphoma dlbcl candidate be expect obtain regulatory approval unite state potential global peak sale approximately biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron gain last month celgene lose vertex gain see last biotech stock roundup here biotech stock round celgene suffer setback gilead team sangamo next biotech world stay tune more regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2063,ABBV,president donald trump biggest tax overhaul decade have raise appeal buyback etfs be especially true massive tax cut repatriation policy have prompt company almost sector boost multus dollar share buyback program year notably approximately american corporate profit be sit overseas bank account half be cash new tax law encourage company bring cash back home much reduce rate read tax reform affect buyback dividend etfs company have announce worth share buyback begin year accord latest report senate democrat california base research firm trimtab state pace buyback have explode february record january largest share repurchase so far cisco csco free report have be forefront additional buyback plan be follow well fargo wfc free report pepsico pep free report abbvie abbv free report amgen amgn free report give optimism be expect be second busiest year buyback bull market begin company be track return record shareholder analyst morgan jpm free report expect company index buy back much share own stock year represent whopping jump repurchase last year additional buyback be result tax saving stronger earning be generate repatriation bonanza analyst goldman sachs gs free report project buyback rise year read top rank sector etfs stock top industry result investor take advantage ongoing boom share buyback follow etfs spdr buyback etf spyb free report fund focus top company highest buyback ratio last month follow buyback index charge investor bps annual fee sector look financial consumer discretionary take largest share allocation respectively information technology healthcare round next spot product have lower aum trade paltry volume share day average read buyback etf hit new week high powershare buyback achiever portfolio pkw free report etf track nasdaq buyback achiever index comprise company have repurchase more common stock trail month hold stock basket charge higher annual fee bps here also financial consumer discretionary be top sector least share closely follow consumer staple pkw be popular fund buyback space manage asset base nearly trading average daily volume share advisorshare wilshire buyback etf ttfs free report be actively manage fund seek generate long term capital appreciation investing stock liquidity fundamental characteristic be historically associate superior long term performance approach result basket security financial consumer discretionary top sector accounting asset be follow industrial information technology healthcare product have amassed asset base see low volume nearly share day fund charge bps annual fee ishare dividend buyback etf divb free report fund offer exposure broad basket company return capital shareholder pay dividend buy back stock information technology financial consumer discretionary health care industrial be top sector double digit exposure etf have newly debut space accumulate month trade paltry volume share day average charge bps annual fee read make ishare dividend buyback etf launch timely want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2064,ABBV,gilead science inc gild free report announce encourage week result phase iii study study virologically suppress adult woman hiv infection international workshop hiv woman conference retroviruse opportunistic infection croi boston poster study evaluate efficacy safety switch boost protease inhibitor bpi boost elvitegravir contain regimen biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg once daily single tablet regimen str biktarvy be find be statistically inferior regimen contain bpi boost elvitegravir demonstrated treatment emergent resistance week ongoing study study datum show woman switch biktarvy maintain high level viral suppression comparable remain baseline regimen genvoya stribild atv rtv ftc tdf moreover none participant biktarvy develop treatment emergent resistance biktarvy gilead latest triple therapy be approve fda february complete regimen treatment hiv infection adult have antiretroviral treatment history replace current antiretroviral regimen be virologically suppress hiv rna ml stable antiretroviral regimen least month history treatment failure know substitution associate resistance individual component biktarvy meanwhile hiv franchise continue gain traction back rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy marketing authorization application biktarvy be review european union meanwhile additional clinical trial biktarvy be ongoing include study adolescent child hiv approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq gilead stock have lose last month compare industry decline gilead be banking hiv franchise have be tremendous pressure due lower patient start increase competition abbvie abbv free report therapy zack rank key pickgilead currently carry zack rank hold better rank stock health care sector be regeneron pharmaceutical inc regn free report sport zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2065,ABBV,johnson johnson jnj free report kick pharma earning strong note beating zack consensus estimate count first quarter drug consumer product giant up previously issue sale outlook share be pre market trading year so far share have decline compare unfavorably decline witness industry earning beatj first quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include item report first quarter earning share compare earning year period sale beat slightlysale come beating zack consensus estimate sale also increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better increase see be pharmaceutical segment continue positive momentum see second half consumer segment sale improve first quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow operational increase new product imbruvica cancer darzalex multiple myeloma continue perform well core product xarelto stelara zytiga simponi simponi aria invega sustenna also contribute growth please note market imbruvica partnership abbvie inc abbv free report organically exclude impact acquisition divestiture sale increase operational basis slightly less growth see previous quarter quarter record pulmonary arterial hypertension pah revenue less previous quarter acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth first quarter however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report be quarter sale decline however international sale rise biosimilar competition pharma segment achieve clinical milestone quarter include fda approval prostate cancer drug erleada treatment man metastatic castration resistant prostate cancer line extension already market prostate cancer drug zytiga combination prednisone first line set medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market rise year period meanwhile international segment record increase reflect operational increase positive currency impact outlook maintain previously issue earning guidance increase sale range still expect adjust earning share range reflect operational growth rate however now expect revenue range higher reflect operational constant currency sale growth rate range previously quite few key product portfolio remicade concerta face generic competition believe new product plaque psoriasis drug tremfya guselkumab cancer drug darzalex imbruvica zytiga currency tailwind contribution acquisition help deliver strong sale profit first quarter year lead raise sale outlook whole year fact be quite confident pharma segment continue perform better market year impact biosimilar remicade sale tell chief financial officer dominic caruso bloomberg meanwhile announce global supply chain initiative annually save approximately pre tax cost meanwhile alex gorsky chairman chief executive officer say company invest more capital investment unite state next year new tax law leave extra cash hand large pharma company allow invest innovation capital build zack rank stock considerj carry zack rank hold johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotea better rank stock be pfizer inc pfe free report have zack rank buy see complete list today zack rank strong buy stock here share pfizer have gain year so far breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2066,ABBV,rise last year large cap pharmaceutical industry have rise year so far have however underperform gain same time frame sector be strong start struggle little thereafter probably broader market correction also mention high drug price president donald trump state union address hurt investor sentiment however sector be largely expect rebound year progress be good year pharma biotech stock sector witness positive development lead much await recovery nyse arca pharmaceutical index gain sharp contrast decline witness be tough year pharma stock give furor rise drug price key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy remain headline risk investor appear more comfortable issue moreover significantly higher number fda approval restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector come back believe new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep sector track faster drug approval process propose removal outdated regulation drive cost slow innovation also provide benefit possibility more merger acquisition be also high now tax reform be place big player be lookout company innovative pipeline technology have already be quite bit buzz year potential deal sanofi sny free report celgene celg free report have already announce deal meanwhile large cap pharma industry be top zack rank industry make sense look buy rank stock space investing stock large market cap be much more reliable investment fact control large portion give industry also company larger market cap have perform well look well poise earn higher profit here be look large cap pharma company sport favorable zack rank strong buy buy lundbeck hluyy free report denmark base lundbeck specialize psychiatric neurological disorder company key area focus include depression schizophrenia parkinson disease alzheimer disease accord lundbeck person world suffer psychiatric neurological disorder many receive inadequate treatment ytd lundbeck have outperformed large cap pharmaceutical industry share gain addition deliver revenue growth local currency lundbeck issue upbeat outlook estimate earning growth current year be meanwhile earning estimate be past day abbvie inc abbv free report abbvie beat estimate earning sale fourth quarter also raise earning expectation base continue strong operational performance abbvie key drug humira have be perform well base strong demand trend new competition abbvie share have outperformed industry past year support series positive news include promising datum several pivotal study regulatory nod include approval competitive hcv medicine mavyret approval imbruvica settlement humira patent dispute biotech major amgen amgn free report abbvie share be impressive year so far outperform industry estimate earning growth current year be meanwhile estimate be respectively past day pfizer inc pfe free report new york base pfizer be most well know name pharmaceutical sector not just medicine vaccine also consumer healthcare product pfizer report better expect fourth quarter result beat estimate earning well sale provide upbeat outlook believe pfizer snew product ibrance contribution acquisition cost cut share buyback help company earn profit future quarters pfizer share have rise year so far estimate earning growth current year be meanwhile estimate be respectively past day nordisk nvo free report year be eventful denmark base pharma giant gain regulatory approval key pipeline drug candidate include fast act insulin aspart fiasp once daily pre filled pen ozempic hemophilia treatment rebinyn meanwhile strong performance victoza be drive top line growth believe new product solid pipeline pave way growth year company past day earning estimate have rise respectively estimate earning growth current year be pfizer abbvie nordisk be zack rank buy stock lundbeck be zack rank strong buy stock see complete list today zack rank stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2067,ABBV,shire plc shpg free report announce have enter definitive agreement french company servier sell oncology business deal be value include global right leukemia drug oncaspar ex right pancreatic cancer drug onivyde servier also add leukemia drug calaspargase pegol portfolio be review unite state shire oncology segment also include immuno oncology pipeline collaboration comprise multiple early stage study oncology segment have deliver high growth profitability contribute lower product sale company have initiate sale segment part long term strategy focus rare disease leadership shire plan return proceed sale shareholder share buyback however buyback program be initiate takeda pharmaceutical potential offer acquire shire be expect apr term recent agreement servier acquire segment cash deal be value attractive revenue multiple time revenue deal be not subject shareholder approval be expect close second third quarter shire be also look dispose other strategic asset part strategy shire share have decrease so far year compare favorably industry decline period investor cheer news potential buyout shire takeda sale oncology segment takeda be expect reconsider decision make offer oncology be core therapeutic area takeda be look strengthen shire acquisition however deal takeda shire be still expect bring strategic synergy takeda acquire ariad pharmaceutical last year bid strengthen diversify oncology business sale shire oncology segment bring acquisition cost takeda investor community also believe formal takeover offer takeda also trigger bid other company previously show interest shire include abbvie abbv free report pfizer pfe free report demand company rare disease drug portfolio pipeline candidate be rise be evident dollar deal sign year novartis be acquire avexis sanofi have spend nearly boost rare blood disorder pipeline shire plc price shire plc price shire plc quoteshire carry zack rank sell see complete list today zack rank strong buy stock here breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2068,ABBV,last week have be eventful pharma stock novartis nvs free report announce be acquire gene therapy company avexis merck mrk free report abbvie abbv free report announce successful study result other news pfizer pfe free report kidney cancer drug inlyta miss primary endpoint phase iii study recap week most important storiesnovartis buy avexis big news early week be novartis deal buy avexis lead product candidate avxs be time gene replacement therapy spinal muscular atrophy sma regulatory filing avxs unite state be expect second half year avxs have potential generate million dollar novartis approve company agree pay share avexis represent whooping premium avexis close price friday board company have approve deal buyout be anticipate close second half year read more novartis inks gene therapy deal buy avexis merck keytruda succeed key lung cancer study pivotal lung cancer study keynote merck blockbuster pd inhibitor keytruda meet primary endpoint keynote study evaluate patient locally advanced metastatic nonsquamous squamous small cell lung cancer nsclc tumor express pd protein level percent greater tps percent such patient keytruda show significant survival benefit compare platinum base chemotherapy notably keytruda monotherapy be already market first line treatment patient metastatic nsclc tumor express pd protein level percent greater tps percent os datum keynote study be approve be include keytruda label drug be prescribe treat expand lung cancer patient population further reinforce position lung cancer market read more merck keytruda offer survival benefit lung cancer study abbvie late stage upadacitinib study succeed abbvie oral jak selective inhibitor upadacitinib meet primary well secondary endpoint phase iii study select program phase iii study select compare evaluate candidate moderate severe rheumatoid arthritis patient be stable background methotrexate elicit inadequate response week treatment acr response first primary endpoint be achieve patient receive mg dose upadacitinib versus placebo second primary endpoint clinical remission be achieve patient upadacitinib arm versus only placebo arm read more abbvie ra candidate meet primary endpoint phase iii meanwhile fda have extend review period abbvie pipeline candidate elagolix month fda decision previously expect second quarter now come third quarter read more fda prolong review date abbvie endometriosis candidate pfizer inlyta miss primary endpoint phase iii study pfizer kidney cancer drug inlyta axitinib fail demonstrate clear improvement primary endpoint extend disease free survival dfs compare placebo phase iii atla study accordingly independent datum monitoring committee recommend study be stop plan interim analysis read more pfizer kidney cancer drug miss endpoint phase iii pfizer also announce initiation dose early stage study evaluate mini gene therapy candidate pf treatment boy duchenne muscular dystrophy dmd most common type muscular dystrophy early datum study be expect first half pacira exparel get fda nod expand label pacira pharmaceutical inc pcrx free report supplemental new drug application snda label expansion exparel nerve block set patient undergo upper extremity surgery get fda nod fda approval come surprise fda committee vote approval expand indication february read more fda okay label expansion pacira exparel stock exparel generate sale represent increase latest label expansion sale be expect go glaxo divest rare disease gene therapy drug private biotech glaxo gsk free report be divest rare disease gene therapy portfolio private biotech orchard therapeutic exchange stake company well seat board divesture be part strategic review glaxo announce july last year divest preclinical clinical program allocate capital priority program current area respiratory hiv infectious potential area oncology immuno inflammation read more glaxo sell rare disease gene therapy private biotech nyse arca pharmaceutical index rise last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session stock record gain bristol myer bmy free report merck astrazeneca be biggest gainer rise respectively bristol myer decline last month astrazeneca have be biggest gainer merck decline most see last pharma stock roundup here pharma stock roundup lly cyramza shine cancer study pfe azn focus next pharma world watch novartis first quarter earning result other pipeline regulatory update make fortune shift electric carshere stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2069,ABBV,johnson johnson jnj free report have most diverse revenue stream industry pharmaceutical division account almost half revenue company have several multus dollar drug cover broad range area such neuroscience cardiovascular metabolism immunology oncology pulmonary hypertension infectious disease vaccine however several product segment be face generic competition stock have depreciate year so far compare unfavorably decline record industry domestic pharma segment sale witness positive trend second half be soft first half year be likely see positive impact trend first quarter result zack consensus estimate pharmaceutical segment be last quarter segment sale beat consensus estimate believe new product continue share gain key product label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june support top line continue share gain drive sale imbruvica cancer indication xarelto blood thinner zytiga prostate cancer stelara psoriasis meanwhile strong adoption newer indication crohn disease continue contribute stelara growth also gain fda approval zytiga first line set february drive sale drug higher first quarter please note market imbruvica partnership abbvie inc abbv free report also strong adoption outside market accelerate adoption unite state line therapy drive sale darzalex positive likely offset loss sale drug invokana due higher manage care discounting meanwhile biosimilar competition be expect continue hurt key arthritis drug remicade sale outside unite state market remicade partnership merck mrk free report regard newly launch tremfya say fourth quarter conference call uptake product have be decent drug record sale last quarter be expect be higher be report quarter also discuss initial sale uptake juluca call first dual treatment hiv develop partnership glaxosmithkline gsk free report gain fda approval last november juluca be review eu meanwhile expect discuss plan erleada newly approve prostate cancer drug first quarter conference call overall expect pharmaceutical segment remain strong consumer medical device segment continue improve read more begin pharma earning store carry zack rank buy see complete list today zack rank strong buy stock here johnson johnson price ep surprise johnson johnson price ep surprise johnson johnson quotewill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2070,ABBV,pfizer inc pfe free report announce committee medicinal product human use chmp european medicine agency ema have recommend hematology medicine be grant marketing authorization eu however committee give negative opinion recommend label expansion pfizer kidney cancer medication sutent chmp recommend approval mylotarg combination standard chemotherapy treatment patient age year newly diagnosed cd positive acute myeloid leukemia aml acute promyelocytic leukemia apl mylotarg be approve unite state september last year chmp also grant positive opinion label expansion leukemia drug bosulif first line treatment patient suffering chronic phase philadelphia chromosome positive ph chronic myelogenous leukemia cml bosulif be approve first line set ph cml unite state december last year however chmp recommend approve label expansion sutent adjuvant treatment patient high risk recurrent advanced renal cell carcinoma rcc follow nephrectomy surgical removal cancer contain kidney please note sutent be approve use same patient population unite state november last year be only adjuvant therapy approve recurrent rcc most common type kidney cancer european commission ec be not bound follow chmp opinion usually do so bosulif record sale develop europe region record growth year year sutent sale same region decline share pfizer be so far year compare favorably increase industry zack rank other stock considerpfizer carry zack rank buy see complete list today zack rank strong buy stock here other large cap pharma stock worth consider be lundbeck hluyy free report abbvie abbv free report nordisk nvo free report lundbeck sport zack rank strong buy abbvie nordisk have same zack rank pfizer share lundbeck be year so far estimate be past day abbvie share be year so far past day earning estimate have rise respectively nordisk share be year so far past day earning estimate have rise respectively zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2071,ABBV,month have go last earning report abbvie inc abbv free report share have add time frame outperform market recent positive trend continue lead next earning release be abbv due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst abbvie top earning revenue up guidanceabbvie report better expect result fourth quarter importantly raise earning expectation base continue strong operational performance lower tax rate abbvie report fourth quarter earning share beating zack consensus estimate come ahead guide range earning grow year year strong sale performance higher operate profit lead bottom line beat include charge related recent tax law change other time special item earning be cent share compare cent year quarter revenue report quarter marginally beat zack consensus estimate sale increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue rise backed continue strong performance humira imbruvica solid initial uptake mavyret operational revenue growth also surpass management expectation approximately growth quarter detailshumira record sale growth operational basis revenue come reflect continue strong demand trend sale unite state increase humira sale ex market be operational basis report basis humira sale growth unite state be expect be approximately internationally humira sale be expect peak approximately fourth quarter net revenue imbruvica be year year include imbruvica sale international profit sharing continue uptake front line cll market steady gain other indication lead strong performance imbruvica abbvie meet expectation record imbruvica global revenue more sale unite state cross imbruvica global revenue be expect exceed sale unite state likely cross other product perform well include lupron year year duodopa year year creon competitive dynamic hcv market abbvie hcv sale include viekira mavyret be quarter operational basis strong uptake mavyret unite state international market lead increase call management mentioned mavyret have witness strong uptake unite state internationally global hcv sale be expect exceed roughly equal split outside market adjust sg expense inched however percentage sale sg expense decline bps drive sale leverage operational efficiency expense escalate quarter due greater investment pipeline adjust operate margin be sale report quarter bps year year resultsfull year sale jump year year operational basis sale outpaced zack consensus estimate revenue growth be line expectation growth operational basis adjust earning share full year exceed zack consensus estimate well guide range earning rise year year outlookabbvie raise adjust ep guidance range predict earlier consistently strong organic growth couple tax rate reduction result recent tax reform propel increase earning guidance guidance reflect year year increase mid point revenue be expect approach reflect year year growth approximately currency impact be expect benefit revenue expense be expect be roughly sale sg be expect be just sale operate margin be expect be approximately roughly basis point level adjust tax rate be expect be approximately normalize tax rate expectation next year be call company say plan invest approximately capital project unite state next year increase access foreign cash follow tax reform addition company accelerate pension funding also plan contribute select not profit organization first quarter outlookfirst quarter earning be expect revenue be estimate grow mid range operational basis foreign exchange be expect have favorable impact sale first quarter humira sale be expect grow low teen range year year internationally operational sale growth be expect mid single digit range imbruvica sale be expect grow mid single digit range sequentially fourth quarter have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter past month consensus estimate have shift due change abbvie inc price consensus abbvie inc price consensus abbvie inc quotevgm scoresat time abbv have average growth score be do lot better momentum front stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable growth value momentum investor outlookestimate have be trend upward stock magnitude revision look promising come little surprise abbv have zack rank buy expect average return stock next few month
2072,ABBV,mylan myl free report be partner fujifilm kyowa kirin biologic co ltd commercialize biosimilar abbvie abbv free report blockbuster arthritis drug humira adalimumab adalimumab be develop fujifilm kyowa kirin biologic mylan intend seek approval commercialize product europe european medicine agency ema accept marketing authorization application review propose biosimilar humira company expect receive ema decision second half agreement mylan have exclusive license commercialize biosimilar europe receive upfront fee fujifilm kyowa kirin company also be responsible sale activity product european country other hand fujifilm kyowa kirin biologic be eligible receive subsequent milestone payment sale royalty year share mylan increase compare industry fall humira be tnf inhibitor aim treat multiple chronic inflammatory condition be approve europe treatment rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis ankylose spondylitis crohn disease ulcerative colitis plaque psoriasis hidradenitis suppurativa uveitis note few day biogen inc biib free report partner samsung bioepis announce resolution ongoing patent dispute abbvie regard biogen biosimilar version imraldi abbvie humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn free report be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan mylan price mylan price mylan quote zack rankmylan carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2073,ABBV,expect johnson johnson jnj free report healthcare bellwether beat expectation report first quarter result april market open last quarter company deliver positive earning surprise performance have be pretty impressive company exceed earning expectation trail quarters average positive earning surprise last quarters be stock have depreciate year so far compare unfavorably decline record industry factor considerj sale growth accelerate second half backed higher sale pharmaceutical segment improve performance medical device expect pharmaceutical segment remain strong consumer medical device segment likely continue improve believe new product segment label expansion drug imbruvica xarelto stelara darzalex meaningful contribution swiss biotech actelion buy june last year support top line zack consensus estimate sale pharmaceutical segment be however fourth quarter revenue pulmonary arterial hypertension pah product add actelion acquistion decline sequentially be be see pah revenue improve meanwhile biosimilar competition be expect continue hurt sale key arthritis drug remicade outside unite state however do not expect biosimilar entrant zytiga prezista risperdal consta invega sustenna unite state year regard newly launch tremfya note conference call uptake product have be decent drug record sale be expect be higher be report quarter meanwhile expect discuss plan erleada newly approve prostate cancer drug conference call also discuss initial sale uptake juluca first dual treatment hiv develop partnership glaxosmithkline gsk free report receive fda approval november last year juluca be review eu medical device segment sale be expect continue rise vision care cardiovascular unit diabetes care unit continue remain weak zack consensus estimate sale medical device segment be consumer segment global consumer category slowdown many company market continue hurt sale however recent acquisition well new product likely provide support zack consensus estimate sale consumer segment be meanwhile higher investment new product launch continue thwart profit earning whispersour proven model show be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold likely positive surprise zack esp earning esp represent difference most accurate estimate share zack consensus estimate share be uncover best stock buy sell re report earning esp filter zack rank have zack rank combination zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other large drug biotech stock have right combination element beat earning time amgen inc amgn free report earning esp zack rank company be schedule release result apr see complete list today zack rank stock here abbvie inc abbv free report have earning esp zack rank company be slate release result apr today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2074,ABBV,amgen inc amgn free report partner allergan agn free report announce european commission have grant marketing approval biosimilar version roche rhhby free report blockbuster cancer drug avastin bevacizumab mvasi drug be approve unite state september mvasi be approve eu treatment multiple type cancer note mvasi be first bevacizumab biosimilar be approve european union approval be line expectation consider committee medicinal product human use chmp european medicine agency ema have render positive opinion approval mvasi november approval be support comprehensive datum package demonstrated similarity mvasi bevacizumab amgen have collaborate allergan worldwide development oncology antibody biosimilar medicine other mvasi amgen allergan portfolio also include biosimilar version herceptin review unite state eu rituxan late stage study overall amgen have biosimilar pipeline include biosimilar version johnson johnson merck remicade alexion soliris amgen biosimilar version abbvie abbv free report blockbuster rheumatoid arthritis drug humira amjevita be approve fda september eu trade name amgevita march same indication humira amjevita be first biosimilar version humira be approve fda well amgen first biosimilar medicine be approve settlement agreement abbvie amgen begin selling amjevita most country eu year unite state january amgen biosimilar opportunity be likely translate annual revenue more amgen have also partner daiichi sankyo biosimilar japan past year amgen share have return compare increase register industry amgen carry zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2075,ABBV,investing sound large cap pharma stock seem judicious be fundamentally lucrative ensure steady stream cash inflow investor drug sector have good run bounce back drug pricing issue dampen performance importantly sector see considerable increase new drug approval last year fda approve novel drug last year more double tally large cap pharma industry witness impressive rally decline run be propel encourage quarterly result increase demand new product sale successful innovation product line expansion strong clinical study result continue strong performance legacy product also boost sector factor be expect play instrumental role well take large cap drug sector new high industry be already so far year notably large cap pharma industry carry zack industry rank place top zack industry back testing show top zack rank industry outperform bottom half factor more pass tax overhaul bill congress be cherry top slash corporate tax rate be likely further boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location leave company extra cash hand lead strategic deal merger acquisition year be relatively fewer most drug company large market cap have see share price rise so far here present company johnson johnson jnj free report abbvie inc abbv free report zoetis inc zts free report nordisk nvo free report outperformed industry last year have potential repeat same performance johnson company stock be compare favorably gain record industry company have zack rank hold see complete list today zack rank strong buy stock here company share be boost approval drug tremfya plaque psoriasis juluca hiv several line extension major drug include xarelto simponi aria stelara imbruvicain trend be expect continue have several regulatory application label expansion key drug review potential approval line extension certainly boost company growth prospect meanwhile be several pivotal datum readout regulatory milestone line moreover pharma segment growth accelerate third quarter slow first half due number factor include competition key drug remicade concerta upside be expect continue stock company be company hold zack rank buy company report series positive news include promising datum several pivotal study regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication imbruvica settlement humira patent dispute amgen inc amgn free report abbvie also expect several pivotal datum readout regulatory milestone be expect further aid company datum readout pivotal phase iii trinity study rova third line later small cell lung cancer be important catalyst stock moreover fda decision be expect new drug application nda elagolix endometriosis be grant priority review october last year abbvie blockbuster drug humira have be perform well competitive pressure company expect drug performance continue boost topline imbruvica be also do consistently well multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease nordiskshare company increase company carry zack rank company be grant approval expand label diabetes drug victoza include treatment major adverse cardiovascular event adult type ii diabetes august moreover new diabetes drug fiasp receive approval september treat adult diabetes december fda approve ozempic semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient also receive approval rebinyn hemophilia unite state refixia treatment adolescent adult same indication europe company expect launch ozempic approval same europe certainly boost company revenue moreover company serve almost half insulin market quarter diabetes market grow diabetes market certainly boost topline company share rise company sport zack rank strong buy company have diversify portfolio livestock companion animal product company increase share dermatology product dog market companion animal business have be perform well launch apoquel cytopoint company acquire nexvet biopharma last year boost pipeline solution chronic pain management dog cat company also expand reach poultry diagnostic product major european market zoetis topline be expect benefit cytopoint be launch europe fourth quarter company expect cattle herd size increase drive growth strong product portfolio consistently successful pipeline development anticipate growth demand drug company likely attract investor attention year well zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2076,ABBV,share johnson johnson jnj free report hit new week high jan eventually close day stock hit new high probably reuter news state chinese bidder be plan buy diabetes care unit country deal be worth billiona be stock have have great run past year share have rally year industry have register increase promising datum several pivotal study rapid progress pipeline line extension year keep stock growth trajectory positive trend be likely continue well company receive approval new drug last year guselkumab tremfyain unite statesas well eu plaque thefirst dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also receive fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene corporation celg free report multiple myeloma drug pomalyst sixth indication imbruvica other investor note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale sale company pharma segment accelerate third quarter trend be likely continue fourth quarter well asin believe new product segment label expansion drug imbruvica xarelto darzalex contribution recent acquisition mainly actelion support top line growth year expect file approval depression candidate esketaminewhile pre metastatic prostate cancerand symtuza darunavir base once daily single tablet regimen be approve fda several pivotal datum readout regulatory milestone expect bullish run stock be likely continue johnson johnson price johnson johnson price johnson johnson quote zack rank have zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2077,ABBV,abbvie inc abbv free report partner neurocrine bioscience announce fda have extend review period marketing application company pipeline candidate elagolix month result regulatory body now announce decision third quarter instead previously anticipate second quarter timeline abbvie be look get elagolix approve oral medicine pain management associate endometriosis last september fda accept abbvie new drug application nda elagolix subsequently grant priority review status october however regulatory body request extend time frame review additional information provide abbvie nda pertain liver function test result notably management show confidence company datum provide fda continue work regulatory body bring elagolix market remind investor nda filing be support positive result replicate pivotal phase iii trial evaluate elagolix aforementioned indication detailed datum study present last october show treatment elagolix result statistically significant reduction menstrual menstrual pelvic pain associate endometriosis compare placebo datum study also demonstrated superiority compare placebo alleviate pelvic pain menstrual pelvic pain painful intercourse associate endometriosis endometriosis affect estimate woman reproductive age be associate pain symptom present be cure disease pain associate be currently manage oral contraceptive progestin danazol nsaid opioid gnrh agonist many medicine be not specifically indicated treat endometriosis approve elagolix be first option patient need additional treatment apprehend disease abbvie share price have surge year compare favorably industry gain meanwhile elagolix be also be evaluate phase iii program prevent heavy menstrual bleed premenopausal woman uterine fibroid importantly pharma company allergan agn free report also have pipeline candidate ulipristal acetate portfolio be currently evaluation treatment uterine fibroid here too fda february request extend review period company nda candidate august abbvie inc price abbvie inc price abbvie inc quote zack rank key picksabbvie carry zack rank hold better rank stock health care sector be ligand pharmaceutical incorporate lgnd free report infinity pharmaceutical inc infi free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have soar year infinity loss share estimate narrow cent cent cent last day company deliver positive surprise trail quarters average beat medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2078,ABBV,biotech sector be bumpy ride week share spectrum surge positive datum phase ii study incyte plunge failure melanoma study effort bolster presence gene therapy space swiss giant novartis announce acquisition avexis inc spectrum surge lung cancer datum share spectrum pharmaceutical inc sppi free report surge company report encourage result phase ii study poziotinib egfr exon mutant small cell lung cancer patient result show confirm objective response rate be first patient better expectation early datum suggest poziotinib have meaningful impact outcome patient have limit treatment option median progression free survival rate have still not be reach median follow period month meanwhile original cohort egfr patient be fully enrolled expand cohort patient be near completion enrollment avexis skyrocket novartis deal avexis inc share sky-rocket news merger swiss pharma giant novartis nvs free report agreement novartis pay clinical stage gene therapy company avexis lead product candidate avxs be be evaluate time gene replacement therapy spinal muscular atrophy disease result early death life long disability considerable healthcare cost acquisition poise novartis promising gene therapy space acquisition be complete mid candidate enjoy breakthrough therapy designation unite state prime designation europe fda also grant avxs fast track status treatment sma type regulatory filing unite state be expect second half year launch anticipate read more novartis inks gene therapy deal buy avexis incyte plunge study failure share incyte corporation incy free report plunge external datum monitoring committee review phase iii study echo keynote evaluate incyte epacadostat combination merck keytruda patient unresectable metastatic melanoma determine study do not meet primary endpoint improve progression free survival overall population compare keytruda monotherapy moreover second primary endpoint overall survival be not expect reach statistical significance hence study be stop failure late stage candidate disappoint investor incyte have pin hope success give improve response rate mid stage study read more incyte epacadostat fail melanoma study share plunge conatus pharmaceutical sink study failure conatus pharmaceutical cnat free report plummet report pipeline candidate emricasan fail phase iib study polt hcv svr candidate do not achieve primary endpoint study evaluate patient fibrosis cirrhosis undergo liver transplant datum polt hcv svr study show emricasan do not achieve better overall response rate compare placebo overall patient population however patient subset advanced fibrosis early cirrhosis emricasan provide evidence fibrotic treatment effect patient compare placebo company evaluate emricasan further particular subset read more conatus emricasan fail phase ii study share sink biogen settle litigation abbvie humira biosimilar biogen inc biib free report partner samsung bioepis announce agreement abbvie abbv free report imraldi biosimilar humira term abbvie grant patent license use sale imraldi europe country country basis biogen samsung bioepis make royalty payment abbvie company have agree dismiss pending patent litigation biogen plan launch biosimilar europe october samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan read more biogen crack case abbvie humira biosimilar biogen carry zack rank hold see complete list today zack rank strong buy stock here performance nasdaq biotechnology index lose last trading session major biotech stock alexion fall last month celgene lose vertex gain see last biotech stock roundup here biotech stock roundup edge fall alk fda amgn drug label expansion medical biomedical genetic industry yr return medical biomedical genetic industry yr return next biotech world stay tune more regulatory pipeline update medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2079,ABBV,abbvie inc abbv free report have announce pipeline candidate upadacitinib meet primary endpoint phase iii study select program evaluate candidate treatment patient rheumatoid arthritis ra upadacitinib be investigational oral jak selective inhibitor be be study once day oral therapy phase iii select compare study be design evaluate efficacy safety upadacitinib mg compare placebo abbvie market drug humira adalimumab week patient moderate severe ra be stable background methotrexate have inadequate response study upadacitinib meet primary well secondary endpoint compare placebo show superiority compare humira primary endpoint study register acr response clinical remission datum trial demonstrated patient receive oral once daily dose upadacitinib mg achieve acr response compare patient receive placebo week moreover subject treat upadacitinib achieve complete remission comparison placebo additionally datum study also show patient experience low disease activity secondary endpoint treat upadacitinib compare receive humira receive placebo week notably select compare be fourth ongoing phase iii study select ra clinical trial program conduct upadacitinib remind investor last december abbvie announce upadacitinib meet primary endpoint rd phase iii study select trial other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis share abbvie have rally past year outperform industry rise notably abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be approve eu ra last february pfizer pfe free report xeljanz be market unite state same indication strong competition upadacitinib approval also late biogen biib free report have announce resolution ongoing patent dispute abbvie regard biogen biosimilar version humira eu settlement agreement biogen plan launch humira biosimilar europe october however upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc price abbvie inc price abbvie inc quotezack rankabbvie carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2080,ABBV,biogen inc biib free report partner samsung bioepis have announce resolution ongoing patent dispute abbvie abbv free report regard biogen biosimilar version imraldi abbvie blockbuster arthritis drug humira eu settlement agreement biogen samsung bioepis plan launch imraldi europe oct also unite state samsung bioepis enter settlement agreement abbvie allow former bring humira biosimilar market jan imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis notably imraldi be second biosimilar version humira be launch eu biotechnology company amgen amgn be also expect launch biosimilar version humira eu come october year amjevita settlement abbvie notably amjevita be approve eu last march approve unite state september unite state settlement abbvie amjevita be likely be launch jan share biogen have underperform industry year so far stock have lose compare industry decrease remind investor biogen have joint venture samsung biologic biosimilar call samsung bioepis already market couple biosimilar eu namely flixabi biosimilar reference merck mrk free report remicade benepali biosimilar reference amgen pfizer pfe free report enbrel development turn make imraldi third tnf biosimilar biogen receive marketing authorization eu biogen be also work samsung biologic introduce new biosimilar market importantly biogen gross biosimilar revenue month period end december compare logged upside be primarily drive benepali record revenue compare year figure increase market share biogen inc price biogen inc price biogen inc quote zack rankbiogen carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2081,ABBV,aeglea biotherapeutic inc agle free report announce have initiate dose patient study evaluate lung cancer candidate pegzilarginase small cell lung cancer sclc cohort expansion phase study be evaluate pegzilarginase monotherapy sclc patient other be phase ii study evaluate candidate combination merck mrk free report pd therapy keytruda similar indication top line datum study be expect fourth quarter aeglea share have rise so far year industry loss period sclc expansion cohort be arm phase study be evaluate pegzilarginase cancer tumor stop produce certain amino acid arginine depletion arginine level tumor cause cell death promote tumor immune response phase ii study be evaluate combination pegzilarginase keytruda overall response rate patient extensive disease sclc disease have relapse progressed receive platinum base chemotherapy press release only sclc patient survive year treatment show significant unmet need several pharma company be develop therapy treat sclc astrazeneca azn free report be develop combination parp inhibitor lynparza chemotherapy temodar phase ii study abbvie abbv free report bristol myer have collaborate develop rovalpituzumab tesirine combination opdivo yervoy phase study therapeutic be also develop therapy combination chemotherapy sclc apart sclc aeglea be also develop pegzilarginase phase ii study patient deficiency rare genetic disease company report positive preliminary datum study earlier month aeglea biotherapeutic inc price aeglea biotherapeutic inc price aeglea biotherapeutic inc quotezack rankaeglea currently have zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2082,ABBV,discourage result phase ii study evaluate abbvie abbv free report promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc grab headline week other news include purchase offer jnj free report diabetes device unit successful study result announce heron therapeutic hrtx free report roche rhhby free report recap week most important storiesabbvie rova fall short key lung cancer study abbvie promising cancer candidate rovalpituzumab tesirine rova fall short expectation phase ii trinity study evaluate third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line set consult fda rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential failure trinity have raise skepticism rova potential have bring question viability stemcentrx deal read more abbvie stock fall weak lung cancer study outcome get offer lifescan unit say have receive bound offer private equity firm platinum equity lifescan diabetes device unit have time jun offer fail expire have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year read more get offer lifescan diabetes device unit pfizer get fda priority review expand label xtandi pfizer pfe free report japanese partner astella gain fda priority review regulatory filing be look expand label prostate cancer drug xtandi include early stage patient population regulatory application add metastatic castration resistant prostate cancer crpc indication drug label be base result prosper study xtandi fda grant priority review decision be expect july read more pfizer xtandi label expansion filing get priority review meanwhile british company reckitt benckiser group pull discussion pfizer buy latter consumer health segment last october pfizer have say be explore strategic alternative consumer healthcare segment include partial full separation spin sale other transaction decision regard same be expect be make year ultimately opt retain business glaxo also say have withdraw race buy pfizer unit heron htx succeed phase iii heron therapeutic pipeline candidate htx meet primary endpoint pivotal phase iii study evaluate post operative pain control follow bunionectomy hernia repair respectively top line datum study show treatment htx lead statistically significant reduction pain intensity opoid use hour follow surgery candidate be also superior bupivacaine solution be current standard care local anesthetic postoperative pain control read more heron pain candidate meet endpoint pivotal studiesroche tecentriq succeed lung cancer combo study roche tecentriq meet co primary endpoint progression free survival phase iii study evaluate pd inhibitor combination chemotherapy carboplatin abraxane first line treatment advanced squamous small cell lung cancer nsclc tecentriq be already market treatment second line metastatic nsclc label expansion first line set boost drug sale further however roche await overall survival datum study continue read more roche tecentriq phase iii combo study meet primary endpoint novartis tasigna get fda nod label expansion novartis nvs free report leukemia drug tasigna be grant fda approval use pediatric year age older population first second line treatment philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp glaxo begin new combo study benlysta glaxo gsk free report have initiate late stage study bliss believe evaluate systemic lupus erythematosus medicine benlysta combination roche rituxan benlysta previous late stage study have demonstrated consistent efficacy reduce disease activity sle aim new combination study be achieve clinical remission sle patient apart demonstrate low disease activity read more glaxosmithkline initiate phase iii combo study nyse arca pharmaceutical index decline last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform week astrazeneca azn free report be only stock record gain last trading session decline bristol myer bmy free report be last month astrazeneca be biggest gainer merck mrk free report be biggest loser decline see last pharma stock roundup here abbv elagolix meet study goal mrk keytruda focus next pharma world watch regulatory pipeline news pharma stock look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2083,ABBV,key announcement week include fda approval second indication astrazeneca azn free report imfinzi acquisition offer merck mrk free report abbvie abbv free report present new datum pipeline candidate announce alzheimer deal small biotech recap week most important imfinzi gain fda nod second indication astrazeneca pd inhibitor imfinzi gain fda approval early stage lung cancer indication make drug second fda approval latest approval imfinzi now be prescribe treat unresectable stage iii small cell lung cancer nsclc patient disease have not progressed follow chemoradiation therapy imfinzi be launch unite state first indication second line advanced bladder cancer be also be develop several other cancer indication read more astrazeneca imfinzi get fda nod label expansion meanwhile astrazeneca license new antisense drug kidney disease ionis az rx ionis pharmaceutical inc ion free report go forward astrazeneca be responsible develop commercialize ionis az rx read more ionis license second candidate astrazeneca earn merck look buy innovative immuno oncology candidate merck propose buy australian oncolytic immunotherapy maker viralytic limit australian dollar believe deal get strengthen merck presence fast grow immuno oncology market deal merck gain viralytic lead pipeline candidate cavatak oncolytic virus engage innate immune system attack cancer cell transaction be expect be complete second quarter contingent viralytic shareholder approval read more merck buy australian firm boost immunotherapy pipeline abbvie report new mid stage datum upadacitinib abbvie announce new datum phase ii celest study evaluate multiple dose regimen jak inhibitor upadacitinib crohn disease week datum study show patient clinically respond upadacitinib treatment week induction phase maintain response week extension phase study please note result week induction phase celest study be previously announce last year read more abbvie present new datum upadacitinib crohn disease separately abbvie neurocrine bioscience first pivotal phase iii study pipeline candidate elagolix meet primary endpoint elaris uf study be evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid datum study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed compare placebo read more abbvie uterine fibrosis candidate meet goal study elagolix be already review unite state management endometriosis associate pain abbvie also announce global strategic collaboration small biotech voyager therapeutic inc vygr free report develop potential new treatment alzheimer disease other tau related disease nordisk oral ozempic succeed study nordisk nvo free report announce phase iii study pioneer evaluate tablet oral formulation newly approve diabetes treatment ozempic semaglutide achieve primary objective datum study show person type ii diabetes be treat once weekly oral semaglutide glp receptor agonist experience significant superior blood glucose control compare placebo dose mg evaluate meanwhile significant superior weight loss versus placebo be observed patient be give highest dose mg nordisk expect file approval oral formulation ozempic pending datum remain pioneer study ozempic semaglutide be approve last year december once daily pre filled pen improve glycaemic control type ii diabetes patient approval ozempic be base result phase iii sustain study fda accept acorda inbrija nda accorda therapeutic inc acor free report nda parkinson disease candidate inbrija be accept fda marked resubmission nda inbrija fda have issue refusal file letter inbrija august last year declare nda application be incomplete preliminary review fda be expect give decision candidate oct read more fda accept acorda nda parkinson disease candidate large cap pharmaceutical industry yr return large cap pharmaceutical industry yr nyse arca pharmaceutical index decline last trading session here be major stock perform last trading session major stock decline astrazeneca decline bristol myer squibb bmy free report go last month astrazeneca have gain merck decline see last pharma stock roundup here merck keytruda shine study priority review kymriah label expansion next pharma world watch regulatory pipeline news pharma stock zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2084,ABBV,abbvie inc abbv free report partner neurocrine bioscience announce phase iii study late stage meet primary endpoint woman uterine fibroid top line result first pivotal phase iii study elagolix elaris uf reveal month elagolix combination low dose add back hormone therapy reduce heavy menstrual bleed compare placebo woman uterine fibroid achieve clinical response study also meet rank secondary endpoint month hypoestrogenic effect such hot flush reduction bone mineral density elagolix treatment be observed study however overall safety profile elagolix be consistent be observed phase ii study uterine fibroid datum phase iii study support regulatory submission elagolix be present upcoming medical conference elagolix be review unite state management endometriosis associate pain so far year abbvie share price have return compare favorably gain record industry note be many other company have pipeline candidate be evaluate uterine fibroid bayer bayry free report be evaluate vilaprisan woman suffering uterine fibroid phase iii asteroid studyallergan agn free report pipeline candidate ulipristal acetate be regulatory review unite state company expect fda give decision first half separate press release abbvie also announce have inked anexclusive strategic collaboration option agreement clinical stage gene therapy company voyager therapeutic vygr free report develop commercialize vectorized antibody treatment alzheimer disease other disease deal voyager receive upfront cash payment well potential preclinical phase option payment follow announcement deal share voyager rise almost abbvie inc price abbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2085,ABBV,novartis ag nvs free report generic arm sandoz announce fda accept biologic license application bla propose biosimilar abbvie inc abbv free report humira biosimilar be submit pathway drug be already approve treatment number inflammatory disease include rheumatoid arthritis plaque psoriasis crohn disease ulcerative colitis datum package submit fda comprise analytical preclinical clinical datum be expect demonstrate sandoz propose biosimilar adalimumab match reference biologic term safety efficacy quality also include pharmacokinetic study healthy volunteer phase iii confirmatory safety efficacy study patient moderate severe chronic plaque type psoriasis novartis stock have rally past year compare industry gain biosimilar version humira be also review eu note sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version rituximab rixathon be approve european commission june be currently review unite state meanwhile sandoz witness strong growth outside unite state buoy launch rixathon erelzi biosimilar amgen inc amgn free report enbrel europe however pricing pressure intensified unite state company expect low single digit sale decline sandoz fourth quarter mainly due seasonal shipment phase continue pricing pressure unite state meanwhile novartis be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive well now even separation capital market create value shareholder other hand novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2086,ABBV,cancer space see label expansion major drug week seattle genetic inc sgen free report adcetris label be expand include treatment naive patient advanced hodgkin lymphoma chl novartis nvs free report tasigna receive approval use pediatric patient year age older meanwhile fda grant priority review pfizer pfe free report regulatory application seek label expansion xtandi include early stage patient population roche hold ag rhhby free report pd inhibitor tecentriq meet primary endpoint phase iii lung cancer combination study however abbvie abbv free report announce disappointing result mid stage study evaluate lung cancer candidate rovalpituzumab tesirine rova let see news detail seattle genetic adcetris label expansion fda approve supplemental biologic license application sbla seek label expansion seattle genetic adcetris treatment naive stage iii iv chl patient drug be approve combination chemotherapy regimen avd adriamycin vinblastine dacarbazine base statistically significant improvement progression free survival datum phase iii echelon study study compare adcetris combination regimen current standard care read more seattle genetic adcetris get fda nod label expansion seattle genetic inc price seattle genetic inc price seattle genetic inc quotenovartis tasigna label expand pediatric patient novartis announce fda have approve line extension leukemia drug tasigna pediatric patient year age older philadelphia chromosome positive chronic myeloid leukemia chronic phase drug receive approval first second line set patient population drug be already available adult indication approval be base datum study evaluate tasigna patient age group year year datum show major molecular response mmr rate be newly diagnosed patient patient resistant prior therapy respectively novartis ag price novartis ag price novartis ag quotepfizer sbla xtandi get priority review fda grant priority review sbla pfizer prostate cancer drug xtandi pfizer be look include metastatic castration resistant prostate cancer indication drug label regulatory status be grant base datum phase iii prosper study decision fda be expect july year read more pfizer xtandi label expansion filing get priority review pfizer inc price pfizer inc price pfizer inc quoteroche tecentriq meet primary endpoint roche subsidiary genentech announce tecentriq combination chemotherapy carboplatin abraxane reduce risk disease worsening death compare chemotherapy alone phase iii impower study study be evaluate combo regimen patient advanced squamous small cell lung cancer however study be continue statistically significant overall survival benefit be not achieve read more roche tecentriq phase iii combo study meet primary endpoint roche hold ag price roche hold ag price roche hold ag quoteabbvie rova fail phase ii study abbvie share crash thursday follow announcement disappointing result pivotal phase ii study evaluate rova third line later small cell lung cancer study evaluate candidate sclc patient high expression protein dll have receive least previous treatment regimen include least platinum base regimen result do not meet expectation be not significant enough candidate be prioritize accelerate approval however phase iii study evaluate rova first second line setting sclc be ongoing read more abbvie stock fall weak lung cancer study outcome week abbvie collaborate international myeloma foundation conduct landmark retrospective chart review study study evaluate overall survival patient multiple myeloma abbvie inc price abbvie inc price abbvie inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2087,ABBV,abbvie inc abbv free report announce disappointing result pivotal phase ii study evaluate promising cancer candidate rovalpituzumab tesirine rova third line later small cell lung cancer sclc abbvie say not seek accelerate approval rova third line sclc set consult fda abbvie stock crash more thursday response news stock have return year so far compare favorably decrease record industry trinity study be single arm study comparator be evaluate efficacy rova treatment patient relapse refractory sclc high expression protein dll have receive least previous treatment regimen include least platinum base regimen sclc be characterize poor outcome very few treatment choice available study best overall response rate be objective response rate be only median duration response be month median overall survival rate be month probability survival month be result be much lower company have hope not significant enough be prioritize accelerate approval however phase iii study rova first second line setting meru tahoe respectively be ongoing however investor concern success remain study increase failure trinity rova be add abbvie portfolio follow acquisition stemcentrx june abbvie have significant confidence rova potential believe candidate have blockbuster potential abbvie have past guide peak sale rova failure trinity have raise scepticism rova potential have bring question viability stemcentrx deal rova be also be evaluate early stage arm basket study neuroendocrine tumor rova be key candidate abbvie oncology pipeline abbvie key cancer drug present be imbruvica market partnership jnj free report imbruvica currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be also conduct study cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy multiple myeloma aml datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll present september last year show combination lead profound improvement progression free survival compare teva pharma teva free report treanda rituxan regulatory application seek approval combination use be review unite state abbvie carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2088,ABBV,share pharmaceutical behemoth abbvie inc abbv free report drop more early morning trading thursday company rova program report disappointing mid stage result force drugmaker abandon plan seek accelerate approval treatment abbvie be hopeful rova rovalpituzumab tesirine therapy qualify accelerate approval treat third line refractory small cell lung cancer company have shift focus base phase trial result magnitude effect multiple parameter decision be make consult food drug administration company say nevertheless abbvie say do still believe drug have potential small cell lung cancer other cancer dll protein rova continue be test phase trial first line second line small cell lung cancer investor appear be disappoint today news base scale abbvie investment rova abbvie acquire drug deal stemcentrix back rova be purchase firm lead asset time today selloff add recent headach abbvie have see share price slump nearly reach new high late january however pharmaceutical stock be still past year analyst sentiment have also be relatively solid abbvie recently company have witness positive revision full year earning estimate past day lift zack consensus estimate cent time still pair negative revision have keep stock zack rank hold regardless be expect be year aggressive top bottom line growth north chicago illinois base company base current consensus projection abbvie be track witness ep growth revenue growth year want more market analysis author make sure follow ryan_mcqueeney twitter zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2089,ABBV,johnson johnson jnj free report announce have receive bound offer approximately private equity firm platinum equity lifescan diabetes device unit lifescan unit make blood glucose monitoring product generate revenue last year stock have decline year so far compare unfavorably gain record industry have time jun offer fail expire accept offer transaction be expect close end year sale diabetes care franchise decline due price decline competitive pressure have be evaluate potential strategic option diabetes care unit specifically lifescan corporation calibra medical early last year fact october announce close operation corporation diabetes care unit exit insulin pump business stop manufacturing vibe onetouch ping insulin pump say deal medical device maker medtronic inc mdt free report patient used insulin pump be offer option transfer medtronic pump carry zack rank hold better rank large cap pharma stock include abbvie inc abbv free report pfizer inc pfe free report zack rank buy see complete list today zack rank strong buy stock here abbvie earning share estimate have moved almost last day share company have shot year pfizer earning share estimate have moved last day share price company have increase past year more stock news be bigger iphoneit become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2090,ABBV,multiple sclerosis ms space hit headline once again follow biotech bigwig biogen biib free report partner abbvie abbv free report decision withdraw jointly own ms drug zinbryta voluntarily worldwide basis due risk liver injury company decide withdraw drug ground complex evolve benefit risk profile zinbryta give limit number patient treat november european medicine agency ema conclude review zinbryta review find unpredictable potentially fatal immune mediate liver injury occur treatment zinbryta month stopping treatment clinical trial patient receive zinbryta have serious liver reaction give complexity market ms drug have long history serious side effect make risky therapeutic area autoimmune inflammatory disease centrol nervous system ms disrupt normal function brain optic nerve spinal cord inflammation tissue loss be type ms widely know affect adult relapse remit ms rrm secondary progressive ms spms primary progressive ms ppms market ms change drastically introduction oral formulation be mostly prefer injection variety drug available ms come own set risk mostly biogen be dominant player ms market drug avonex tysabri tecfidera plegridy zinbryta however company have be scrutiny pricing ms drug earlier emergence progressive multifocal pml case type brain infection associate use tysabri tecfidera have mar prospect ms drug fda thereafter update label tecfidera nevertheless company be name reckon ms market earlier fda also issue warning novartis nvs free report gilenya pml drug be recently grant breakthrough therapy designation gilenya treatment child adolescent year age older relapse ms drug be already approve same adult novartis have ms drug portfolio glatopa generic version copaxone mg sandoz company generic arm recently win fda approval generic version copaxone mg israel base teva pharmceutical teva free report have long be ms market widely used drug copaxone be face stiff competition last few year meanwhile past seizure be know side effect ms drug ampyra seizure risk be see increase higher blood level drug result fda have update ampyra label clarify recommendation kidney function be checked patient start ampyra monitored least annually ampyra treatment continue nevertheless risk associate drug have not deter newer entrant claim better formulation lesser side effect consequently market have become too crowd march fda approve roche rhhby ocrevus treat adult relapse form ms primary progressive multiple sclerosis however be question ocrevus be new innovation reformulation roche older drug rituxan drug sale aren impressive yet fda recently issue refusal file letter celgene celg free report new drug application nda ozanimod be development treatment patient relapse form multiple sclerosis fda determine nonclinical clinical pharmacology section nda be insufficient permit complete review hence company be now gear meet fda determine future course action haven be safety issue report delay definitely open avenue competition give so much be happen space expect investor remain glue further update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2091,ABBV,novartis ag nvs free report end positive note courtesy strong performance psoriasis drug cosentyx cosentyx achieve multus blockbuster drug status back strong growth approve indication psoriasis ankylose spondylitis psoriatic arthritis drug have grab market share rival abbvie abbv free report humira amgen amgn free report enbrel drug have be evaluate more patient study have be prescribe more patient global basis indication novartis recently report new encourage datum cosentyx datum phase iii study scalp american academy dermatology aad annual meeting san diego randomize double blind placebo controlled phase iii study be be conduct evaluate efficacy safety cosentyx patient moderate severe scalp psoriasis eligible patient be equally randomize subcutaneous cosentyx mg placebo week then week week patient placebo group do not achieve least improvement baseline psoriasis scalp severity index pssi score week be re randomize cosentyx mg completion study primary endpoint be proportion patient achieve pssi response rate week majority patient scalp psoriasis cosentyx achieve clear skin pssi week improve quality life study show pssi response rate be achieve significantly higher proportion patient receive cosentyx vs placebo week vs further improvement take cosentyx week estimate scalp psoriasis affect person worldwide earlier month fda approve line extension cosentyx moderate severe scalp psoriasis fda approval come back positive efficacy safety outcome dedicate phase iii study scalp patient scalp psoriasis novartis share have gain year par industry gain label expansion drug be likely boost sale further zack rank key picknovartis carry zack rank hold better rank stock health care space be exelixis exel free report carry zack rank buy see complete list today zack rank strong buy stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2092,ABBV,week be relatively light far development pharma sector be concern key highlight be priority review merck mrk free report keytruda advanced cervical cancer delay final datum astrazeneca azn free report key lung cancer study success abbvie abbv free report late stage study breakthrough therapy designation jnj free report cancer candidate recap week most important delay final datum mystic study final overall survival datum astrazeneca pivotal phase iii mystic study imfinzi first line lung cancer indication have be delay second half year datum be previously expect be present first half july last year study fail meet primary endpoint progression free survival read more astrazeneca final datum key lung cancer study delay merck keytruda get priority review indication merck supplemental filing look expand label pd therapy keytruda treat advanced cervical cancer have be accept priority review fda decision be expect jun be regulatory submission keytruda accept fda read more merck keytruda get priority review cervical cancer abbvie second late stage study elagolix meet endpoint abbvie neurocrine bioscience second pivotal phase iii study pipeline candidate elagolix meet primary endpoint elaris uf ii study be evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid datum study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed woman uterine fibroid compare placebo month read more abbvie uterine fibroid candidate succeed phase iii top line datum first study elagolix uterine fibroid be announce february study also meet primary endpoint read more abbvie uterine fibrosis candidate meet goal study cancer candidate get breakthrough therapy designation late stage pipeline candidate erdafitinib gain breakthrough therapy designation fda treatment urothelial cancer type bladder cancer read more erdafitinib get breakthrough therapy status nyse arca pharmaceutical index be marginal last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returnhere be major stock perform merck emerge biggest gainer last trading session glaxo gsk free report share decline most last month astrazeneca have gain merck decline see last pharma stock roundup here mrk sign new cancer deal derm acne candidate fail next pharma world watch regulatory pipeline news pharma stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2093,ABBV,biosimilar space be focus key fda approval biosimilar contain version active substance already approve original biological drug development biosimilar be technically more challenge development generic drug former require clinical study patient be engineer match reference drug quality safety efficacy due complex nature product development regulatory pathway biosimilar differ significantly generic biosimilar be usually less expensive brand drug thus market same be highly lucrative acceleration approval biosimilar market have thus attract lot many player be witness rapid growth here go progress report merck co inc mrk free report launch reneflexis biosimilar version remicade infliximab unite state july approval april fda also grant tentative approval lusduna nexvue biosimilar version lantus basal insulin pre filled dose device merck currently carry zack rank hold see complete list today zack rank strong buy stock here remicade have be see intense competition biosimilar space late note pfizer inc pfe free report supply inflectra biosimilar version remicade pfizer be strong player biosimilar market december pfizer get fda approval remicade biosimilar ixifi treatment rheumatoid arthritis crohn disease pediatric crohn disease ulcerative colitis ankylose spondylitis psoriatic arthritis plaque psoriasis company have portfolio market biosimilar medicine outside unite state include inflectra retacrit epoetin zeta nivestim filgrastim strong pipeline distinct biosimilar molecule various stage development pfizer currently carry zack rank generic leader mylan nv myl free report be also explore biosimilar market have potential grow early last december mylan partner biocon ltd announce fda approval ogivri trastuzumab dkst biosimilar version herceptin trastuzumab ogivri have be approve indication include label reference product herceptin include treatment overexpressing breast cancer metastatic stomach cancer ogivri be first fda approve biosimilar herceptin first biosimilar mylan biocon joint portfolio mylan currently carry zack rank meanwhile amgen inc amgn free report allergan plc agn free report win fda approval biosimilar version avastin september treatment multiple type cancer note mvasi be first biosimilar approve unite state treatment cancer amgen biosimilar version humir amjevita be already approve fda be launch unite state jan company resolve litigation abbvie inc abbv free report company have also submit bla fda abp biosimilar candidate herceptin july note company be collaborate oncology biosimilar include abp be second be submit fda approval company also submit marketing authorization application european medicine agency candidate note amgen have total biosimilar pipeline have be approve fda amgen currently carry zack rank boehringer ingelheim cyltezo adalimumab adbm biosimilar humira be also approve fda august medical generic drug industry yr return medical generic drug industry yr slew fda approval expect investor remain focuse space future zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2094,ABBV,abbvie inc abbv free report announce new datum phase ii study investigational jak inhibitor upadacitinib week celest study evaluate upadacitinib multiple dose regimen week adult patient crohn disease be intolerant have inadequate response immunomodulator tumor necrosis factor alpha antagonist tnf patient clinically respond treatment week induction phase maintain response week extension phaseof study evaluate multiple dose regimen upadacitinib week please note result week induction phase celest study be previously announce last year improvement see patient be give higher dose mg mg twice daily be numerically greater compare mg twice daily week result also show patient respond upadacitinib induction treatment week achieve numerically higher rate clinical remission endoscopic response patient receive mg dose extension phase compare other other lower dose week study show overall safety profile upadacitinib be consistent observed other upadacitinib study new safety signal detected datum be present congress european crohn colitis organisation ecco vienna austria abbvie share have rally year outperform industry growth separately american academy dermatology aad annual meeting san diego company presentedresult phase iib study evaluate upadacitinib adult patient moderate severe atopic dermatitis upadacitinib also be mainly be investigate phase iii study rheumatoid arthritis other study be also underway treatment ulcerative colitis psoriatic arthritis abbvie inc price abbvie inc price abbvie inc quote zack rank other stock considerabbvie carry zack rank buy other top rank stock health care space be exelixis exel free report xoma corp xoma free report enanta pharma enta free report exelixis sport zack rank strong buy xoma enanta pharma carry zack rank see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat share price company moved year xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company sky-rocket year enanta pharma deliver positive earning surprise last quarters average beat share price company surge year breaking news cryptocurrency now bigger visa total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2095,ABBV,abbvie abbv free report partner neurocrine bioscience announce second pivotal phase iii study evaluate pipeline candidate elagolix uterine fibroid meet primary endpoint abbvie be look get elagolix approve oral medicine reduce heavy menstrual bleed premenopausal woman uterine fibroid elagolix be already review unite state management endometriosis associate pain abbvie share have increase more mar follow news release moreover so far year abbvie share price have increase compare favorably gain record industry come back latest release datum phase iii elaris uf ii study demonstrated elagolix combination low dose add back therapy reduce heavy menstrual bleed woman uterine fibroid compare placebo month safety profile candidate be also find be consistent first phase iii study elaris uf result study meet secondary endpoint well datum elaris uf ii study support regulatory submission elagolix aforementioned indication note positive top line datum first phase iii elaris uf study be announce february study also meet primary endpoint company press release uterine fibroid affect woman age experience symptom such heavy menstrual bleed painful period vaginal bleed time other menstruation anemia present be limit surgical treatment option woman suffering disease uterine fibroid be currently manage oral contraceptive progestin gnrh agonist many medicine be not specifically indicated treatment uterine fibroid hence approval candidate provide company access patient be need additional treatment option apprehend disease meanwhile pharma company allergan agn free report also have pipeline candidate ulipristal acetate portfolio be be evaluate treatment uterine fibroid be first oral treatment hit market be review unite state response expect regulatory agency august abbvie inc price abbvie inc price abbvie inc quotezack rank key picksabbvie carry zack rank buy other top rank stock health care sector be regeneron pharmaceutical inc regn free report ligand pharmaceutical incorporate lgnd free report regeneron sport zack rank strong buy ligand hold zack rank buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company pull positive earning surprise last quarters average beat ligand earning share estimate have moved last day company deliver positive surprise trail quarters average beat share price company have surge year breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2096,ABBV,pharma biotech industry be plague drug pricing issue last year however bounce back make considerable headway year courtesy slew fda approval particularly large cap player industry rake stellar return not forget same space post decline year earlier upbeat quarterly result rise demand new product sale successful innovation product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector new high year moreover encourage factor be expect drive sector growth meanwhile jubilant republican pass tax overhaul bill first time year bill slash corporate tax rate such tax reduction be likely further boost profit margin company large cap pharma sector more cash left hand turn also be used striking strategic deal be be remember merger acquisition activity lag previous year notably large cap pharma sub industry carry zack industry rank place top zack industry backtesting show top zack rank industry outperform bottom half factor more banking such positive trend investing sound large cap pharma stock seem judicious top such stock be fundamentally lucrative ensure steady stream cash inflow have hence select such company have outperformed broader index year be also poise continue winning streak head new year johnson johnson inc jnj free report new jersey base biotech giant johnson johnson have outperformed year share company have rally broader market have increase stock earning be further expect grow company track record product launch have be impressive year be make fast progress achieve goal more approval new blockbuster product moreover company be target more line extension exist well new drug october receive fda approval line extension simponi aria psoriatic arthritis ankylose spondylitis additionally contribution recent acquisition mainly actelion generate positive sentiment investor continuous development have lead consistent rise share company carry zack rank hold abbvie inc abbv free report illinois base company also outperformed so far year share company have surge period rally price movement be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen stock earning be further estimate increase next year abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret secure approval unite state eu canada third quarter additionally august abbvie clinch nod regulatory agency imbruvica address sixth indication other meanwhile company announce positive datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll september later october too abbvie announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson stelara humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint several pivotal datum readout regulatory milestone be expect mentioned factor bode well stock company be zack rank player astrazeneca plc azn free report uk base giant outperformed year company share increase period have announce quite few progression regulatory pipeline front year drive steady appreciation share price astrazeneca also have promising late stage pipeline include immuno oncology candidate imfinzi approve bladder cancer currently be evaluate multiple cancer be key drug pipeline company have new molecular entity phase iii trial regulatory review apart several lifecycle management program last month fasenra benralizumab have be approve unite state treatment asthma be review eu chronic obstructive pulmonary disease copd month fda have accept application label expansion market drug tagrisso osimertinib first line treatment adult patient metastatic nsclc additionally regulatory filing tagrisso label expansion be accept eu november similar indication december astrazeneca also announce positive top line datum phase iv study evaluate market drug tudorza pressair expand indication copd cardiovascular risk factor company carry zack rank nordisk nvo free report nordisk have be news past few month base encourage progress diabetes pipeline constant improvement corresponding approval have lead regular surge share company be rank player share company have soar so far year outpace index stock earning be further project rise october endocrinologic metabolic drug advisory committee fda vote ratio favor approval semaglutide improve glycaemic control adult type ii diabetes meanwhile late last year company also file semaglutide eu give indication moreover september fda approve fiasp fast act insulin aspart treat adult diabetes august fda approve label expansion company diabetes drug victoza drug be now approve reduce risk major adverse cardiovascular event adult type ii diabetes same month label expansion lessen risk severe hypoglycaemia tresiba be endorse committee medicinal product human use eu tresiba label update boost company sale conclusiona series datum readout upside regulatory pipeline front stock year be likely help continue bullish run next year surpass broader market well more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2097,ABBV,novartis ag nvs free report initiate head head trial surpass psoriasis drug cosentyx drug be compare propose biosimilar treatment ankylose spondylitis trial be first head head clinical trial investigate superiority cosentyx slow spinal bone damage compare propose biosimilar adalimumab note surpass exceed be part larger rheumatology program cosentyx head head exceed trial cosentyx be be compare abbvie inc abbv free report humira psoriatic arthritis psa trial be currently recruit patient trial be first large double blind head head clinical trial versus humira psa investigate superiority cosentyx acr week primary endpoint novartis stock have rally year compare industry gain cosentyx be first target biologic specifically inhibit il cornerstone cytokine involved inflammation enthesis play major role psa drug be approve treatment active psa drug be approve treatment moderate severe plaque psoriasis uptake cosentyx have be strong company have grab market share rival humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale novartis expect sale cosentyx note novartis have strong oncology portfolio company breast cancer portfolio include drug afinitor kisqali tykerb approval new drug label expansion exist drug further enhance portfolio march novartis acquire certain oncology product pipeline compound glaxosmithkline plc gsk free report exchange company sell influenza vaccine business glaxo meanwhile sandoz generic arm novartis continue advance portfolio biosimilar generic zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2098,ABBV,week focus be annual morgan healthcare conference several biotech pharma company provide preliminary look result have also provide pipeline update well outlook meanwhile celgene celg free report be news company announce intention acquire impact biomedicine recap week most important storiescelgene buy impact celgene have start year acquisition announcement company be acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera deal term include upfront payment approximately contingent payment base achievement regulatory approval milestone myelofibrosis celgene make additional payment base approval label expansion achievement sale base milestone plan be submit new drug application fda mid celgene be look boost pipeline acquisition company have rough share decline last year issue pipeline setback well weak performance otezla have be weigh stock read more celgene acquire impact biomedicine boost pipeline key takeaway morgan healthcare conference several biotech company be present annual morgan healthcare conference most company provide preliminary look fourth quarter result outlook key update acorda acor free report start face generic competition flagship drug ampyra time jul company be currently seek fda approval inbrija response be february read more acorda share disappointing ampyra view vertex vrtx free report hold strong position cystic fibrosis cf market be look strengthen position further potential approval tezacaftor ivacaftor unite state decision fda be expect feb vertex also be company pursue acquisition deal year celgene also provide preliminary result outlook read more celgene provide preliminary result view vertex be zack rank strong buy stock see complete list today zack rank stock here axovant plunge intepirdine discontinuation axovant science axon free report share lose more value company announce disappointing result lead pipeline candidate intepirdine candidate fail meet primary efficacy endpoint study be conduct patient dementia lewy body dlb patient dementia gait impairment base axovant have decide discontinue development intepirdine be not first time axovant have face setback development effort intepirdine last year september company have say intepirdine fail meet co primary efficacy endpoint late stage study be conduct mild moderate alzheimer disease ad patient be receive background donepezil therapy time too company share have plunge significantly axovant share be last year compare decline record industry belong regeneron sanofi boost investment dupixent cemiplimab regeneron pharmaceutical regn free report partner sanofi have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential indication include atopic dermatitis asthma chronic obstructive pulmonary disease abbvie eczema drug get btd abbvie abbv free report investigational once daily oral jak selective inhibitor upadacitinib have be grant breakthrough therapy designation btd fda use adult patient moderate severe atopic dermatitis be candidate systemic therapy breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint upadacitinib be schedule move late stage program atopic dermatitis first half year read more abbvie upadacitinib gain breakthrough therapy designation biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here gwph submit epidiolex eu sangamo inks deal pfizer next biotech world watch usual regulatory pipeline update well preliminary result announcement outlook ahead release fourth quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2099,ABBV,johnson johnson jnj free report stock be compare favorably gain record industry last year share price surge be support series positive news include promising datum several pivotal study rapid progress pipeline line extension positive trend be likely continue year well drive stock new drug be approve last year guselkumab tremfya unite state well eu plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also gain fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other please note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale higher future quarters also submit regulatory application label expansion key drug include darzalex first line set multiple myeloma xarelto chronic coronary artery disease peripheral artery disease invokana include cardiovascular indication zytiga earlier stage metastatic prostate cancer get fda nod line extension year factor likely support rally several pivotal datum readout regulatory milestone expect bullish run stock be likely continue year expect file approval depression candidate esketamine apalutamide pre metastatic prostate cancer symtuza darunavir base once daily single tablet regimen hiv be approve fda domestic pharma segment sale decelerate first half number key growth driver remicade concerta face competition however sale growth accelerate third quarter be likely see positive impact trend fourth quarter result probably believe new product segment label expansion drug imbruvica xarelto stelara darzalex contribution recent acquisition mainly actelion support top line growth factor bode well stock carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2100,ABBV,year have turn be pretty impressive pharma biotech stock industry be hampered drug pricing issue bounce back make considerable headway courtesy slew fda approval regulatory body approve novel drug last year easily surpass total tally particularly large cap player industry rake stellar return last month nonetheless same space also post decline upbeat quarterly result rise demand new product sale successful innovation product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector scale new high moreover tailwind be expect drive sector growth meanwhile jubilant republican have late pass tax overhaul bill first time year bill slash corporate tax rate such tax reduction be likely further boost profit margin company more cash left hand turn also be used striking strategic deal year be relatively fewer notably large cap pharma sub industry carry zack industry rank place top zack industry backtesting show top zack rank industry outperform bottom half factor more banking such positive trend investing sound large cap pharma stock year seem judicious have therefore identify large cap stock base favorable combination solid zack rank strong buy buy strong vgm score stock be backed sound fundamental ensure steady stream cash inflow back test result show only stock impressive vgm style score combine bullish zack rank offer best upside potential be select company poise continue winning streak year abbvie inc abbv free report illinois base company be lucrative option stock have zack rank buy vgm score share company have soar year time moreover stock earning sale be further estimate increase respectively positive trend be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen amgn free report several pivotal datum readout regulatory milestone expect bullish run stock be expect continue year nordisk nvo free report also recommend nordisk denmark base global healthcare company leader worldwide diabetes market share company have surge year time moreover stock earning sale be further estimate increase respectively currently stock vgm score carry zack rank see complete list today zack rank strong buy stock here nordisk have be news past few month base encourage progress diabetes pipeline december nordisk announce fda have approve semaglutide once daily pre filled pen improve glycaemic control type ii diabetes patient be market trade name ozempic company expect launch ozempic unite state begin meanwhile september fda have approve fiasp fast act insulin aspart treat adult diabetes august fda have approve label expansion company diabetes drug victoza now approve reduce risk major adverse cardiovascular event adult type ii diabetes company label expansion effort corresponding approval bode well growth roche hold ag rhhby free report investor count switzerland base roche hold vgm score company be zack rank player share have gain last month roche dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla company also have dominant position lung cancer market company be look label expansion drug namely actemra be approve treatment giant cell arteritis last be sixth fda approval actemra medicine be launch moreover recent fda approval hemlibra routine prophylaxis prevent reduce frequency bleed episode patient haemophilium be encourage also potential acquisition ignyta announce couple week earlier be likely strengthen roche pipeline integration add mid stage cancer candidate entrectinib portfolio continuous label expansion key drug regular approval robust pipeline be expect drive stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2101,ABBV,abbvie inc abbv free report announce investigational oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study select program evaluate candidate treatment patient rheumatoid arthritis ra abbvie share have outperformed industry so far year stock have surge compare industry rally phase iii study select monotherapy evaluate upadacitinib monotherapy moderate severe ra patient be not responsive methotrexate period week once daily dose mg mg evaluate study demonstrated superiority acr response low disease activity lda compare methotrexate acr response be achieve patient receive mg dose response rate be mg dose versus methotrexate lda be achieve patient receive mg mg methotrexate respectively upadacitinib be be evaluate large program include study ra patient abbvie be also develop candidate psoriatic arthritis crohn disease ulcerative colitis ankylose spondylitis atopic dermatitis candidate have also meet endpoint phase iii study select program select monotherapy study support potential candidate treat ra patient background methotrexate therapy successful development upadacitinib boost abbvie ra portfolio already include blockbuster drug humira sale humira account net revenue first month approval incyte corporation incy free report eli lilly company lly free report olumiant europe february have not have significant impact humira sale be approve patient be unresponsive tnf inhibitor humira moreover olumiant new drug application receive complete response letter fda april year meanwhile upadacitinib be direct line competition olumiant be jak inhibitor abbvie inc price abbvie inc price abbvie inc quotezack rank stock considerabbvie carry zack rank hold celldex therapeutic inc cldx free report be better rank stock pharma sector carry zack rank buy see complete list today zack rank strong buy stock here celldex loss estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2102,ABBV,bristol myer squibb company bmy free report announce committee medicinal product human use chmp european medicine agency have recommend approval yervoy pediatric patient year older unresectable metastatic melanoma note european commission take chmp recommendation account consider application be not bound fda have approve drug same indication july remind investor yervoy mg kg monotherapy be approve so far year bristol myer share have rally compare industry gain last week company announce fda have accept supplemental biologic license application priority review opdivo yervoy treatment intermediate poor risk patient advanced renal cell carcinoma rcc application be base datum phase iii study checkmate study be stop ahead schedule base recommendation independent datum monitoring committee follow plan interim analysis overall survival study evaluate combination opdivo yervoy versus sutent previously untreated advanced metastatic rcc fda make decision apr meanwhile company continue evaluate blockbuster immune oncology drug opdivo alone combination therapy yervoy other cancer agent label expansion combination additional indication give product access higher patient population increase commercial potential however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank bristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2103,ABBV,roche holding ag rhhby free report announce positive result pivotal phase iii study murano evaluate venclexta rituxan compare bendamustine rituxan br treatment relapse refractory chronic lymphocytic leukemia cll result study show fix duration treatment venclexta rituxan significantly reduce risk disease progression death compare br result be present american society hematology annual meeting primary endpoint study be investigator assessed progression free survival note roche be develop venclexta collaboration abbvie inc abbv free report company be jointly commercialize unite state abbvie be commercialize drug outside unite state company expect submit datum murano study fda remind investor fda grant accelerate approval venclexta april treatment cll deletion detected fda approve test have receive least prior therapy murano study be be conduct aim convert current accelerate approval venclexta full approval meanwhile venclexta have be grant breakthrough therapy designation fda combination rituxan person relapse refractory cll monotherapy relapse refractory cll deletion combination hypomethylating agent azacitidine decitabine untreated acute myeloid leukaemia aml ineligible intensive chemotherapy combination low dose cytarabine patient untreated aml ineligible intensive chemotherapy roche hematology portfolio have approve drug include mabthera rituxan gazyva gazyvaro tecentriq venclexta well encourage pipeline comprise candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg company also obtain fda approval hemlibra emicizumab kxwh routine prophylaxis prevent reduce frequency bleed episode adult child haemophilium factor viii inhibitor so far year share company have moved compare industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be already face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2104,ABBV,abbvie inc abbv free report partner janssen johnson johnson jnj free report pharmaceutical subsidiary announce combination study evaluate key cancer drug imbruvica waldenström wm rare form hodgkin lymphoma meet primary endpoint interim datum phase iii innovate study show combination imbruvica roche rhhby free report rituxan lead improve progression free survival pfs treatment naive previously treat patient wm compare rituxan alone base early positive result independent datum monitoring committee idmc recommend unblinded study abbvie plan discuss positive interim datum regulatory be already approve monotherapy treatment wm fact include wm imbruvica be presently approve distinct patient population include mantle cell lymphoma mcl small lymphocytic lymphoma sll chronic lymphocytic leukemia cll marginal zone lymphoma mzl chronic graft versus host disease gvhd imbruvica be add abbvie pipeline acquisition pharmacyclic have become key revenue driver abbvie abbvie expect record imbruvica global revenue more sale unite state expect cross first month imbruvica have record sale represent growth year year fact abbvie expect imbruvica peak sale more revenue present cll segment be largest revenue contributor imbruvica growth expansion hodgkin lymphoma nhl other indication be major growth driver future imbruvica have multus dollar potential abbvie be explore potential expand label solid tumor autoimmune disease imbruvica be phase iii study diffuse large cell lymphoma follicular lymphoma abbvie be position imbruvica pipeline molecule treatment feature several company sponsored study abbvie share have gain so far year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain regulatory approval unite state europe japan competitive hcv medicine mavyret receive fda approval sixth indication imbruvicaand settle humira patent dispute amgen inc amgn free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2105,ABBV,week company amgen amgn free report revance therapeutic inc rvnc free report abbvie abbv free report be news amgen get fda approval inclusion cardiovascular outcome datum pcsk inhibitor abbvie revance provide datum pipeline candidate recap week most important storiesrevance soar rt datum revance share shot positive top line datum late stage study evaluate company next generation neuromodulator rt rt meet primary well secondary endpoint study be conduct reduction moderate severe glabellar line frown line wrinkle brow long term safety study be currently ongoing study schedule complete second half successful completion study allow revance file fda approval first half potentially launch product company believe fda approval make rt first neuromodulator long act duration month currently market neuromodulator have show duration month treat glabellar line rt approval well change neuromodulator treatment landscape be need only twice year accord information provide company treatment glabellar line be most popular aesthetic procedure injectable neuromodulator almost third global neuromodulator sale come area currently approve treatment include botox dysport amgen pcsk inhibitor label approve cardiovascular outcome datum amgen pcsk inhibitor repatha get bit boost fda grant approval company request add cardiovascular outcome datum drug label make repatha first pcsk inhibitor prevent heart attack stroke coronary adult establish cardiovascular disease repatha be also approve use adjunct diet alone combination other lipid lower therapy statin treatment adult primary hyperlipidemia reduce low density lipoprotein cholesterol ldl update label provide physician new treatment option prevent cardiovascular event dramatically lower ldl cholesterol repatha especially case patient be already maximally tolerate statin therapy need lower ldl cholesterol level further cardiovascular outcome datum help drive repatha sale be yet take expect factor strict utilization management criterium process employ insurer pharmacy benefit manager pbms impact sale however amgen have be work payer improve access appropriate patient repatha remain growth brand company read more amgen pcsk inhibitor get fda nod stroke prevention amgen be zack rank hold stock see complete list today zack rank strong buy stock here positive datum abbvie risankizumab imbruvica abbvie risankizumab meet primary endpoint fourth pivotal phase iii study conduct treatment patient moderate severe plaque psoriasis week treatment almost half risankizumab patient achieve complete skin clearance pasi compare patient placebo risankizumab be be develop collaboration boehringer ingelheim read more abbvie psoriasis candidate succeed phase iii study abbvie also present datum combination btk inhibitor imbruvica rituxan treatment newly previously treat patient waldenström wm primary endpoint progression free survival pfs be achieve late stage study imbruvica be approve different indication include chronic lymphocytic leukemia previously treat mantle cell lymphoma wm well chronic graft versus host disease abbvie expect imbruvica revenue priority review clovis snda clovis oncology clvs free report supplemental new drug application snda use parp inhibitor rubraca rucaparib have be grant priority review status fda company be look get rubraca approve use maintenance treatment woman recurrent ovarian cancer be platinum sensitive complete partial response platinum chemotherapy requirement diagnostic testing fda grant priority review response be apr clovis share be year date compare gain record industry belong galectin nash datum galectin therapeutic inc share fall datum phase iib study gr md candidate show statistically significant clinically meaningful result sub group alcoholic steatohepatitis nash cirrhosis patient fail achieve statistical significance total group patient positive week datum ultragenyx drug ultragenyx pharmaceutical inc rare free report partner kyowa kirin announce positive week datum late stage study burosumab krn adult link xlh company say further improvement disease symptom fracture heal be observed week treatment burosumab burosumab be currently priority review treatment pediatric adult patient xlh response fda expect apr biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline slightly last trading session major biotech stock amgen be vertex decline last month biogen biib free report be regeneron regn free report lose see last biotech stock roundup here regeneron eylea datum biogen ms deal next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2106,ABBV,abbvie abbv free report announce hike quarterly dividend authorization new share buyback program board abbvie stock rise more thursday response news dividend be increase cent share cent share cash dividend be payable shareholder record apr new quarterly dividend amount annual dividend share imply dividend yield please note be second dividend hike abbvie less month october last year abbvie announce hike quarterly dividend cent share cent share abbvie hike quarterly dividend fact inception abbvie have hike dividend fourth quarter conference call hold last month management hint shareholder return be likely go company cash position have improve follow recent tax reform fact abbvie have perform exceptionally well past year support series positive news stock have return past year compare favorably gain record industry abbvie meet primary endpoint several pivotal study key phase iii murano study venclexta roche rhhby free report rituxan relapse refractory chronic lymphocytic leukemia phase iii study evaluate oral jak selective inhibitor upadacitinib rheumatoid arthritis also phase iib study atopic dermatitis pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira moderate severe chronic plaque psoriasis meanwhile abbvie gain regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication cancer drug imbruvica fact mavyret launch have be stronger expect inform company fourth quarter conference call abbvie also settle patent dispute amgen amgn free report delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market several pivotal datum readout regulatory milestone expect bullish run stock continue importantly humira have be generate solid sale base strong demand trend drug trend expect continue year imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock abbvie carry zack rank buy see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2107,ABBV,eli lilly company lly free report announce positive top line datum phase iii label expansion study evaluate psoriasis drug taltz ixekizumab patient ankylose spondylitis drug meet primary endpoint improvement sign symptom secondary endpoint well taltz il antagonist be currently approve treatment adult moderate severe plaque psoriasis active psoriatic arthritis psa share company be past year underperform industry gain period phase iii study coast evaluate drug patient have not receive prior treatment biologic disease modify rheumatic drug study consist placebo arm active control arm abbvie abbv free report arthritis drug humira datum study show treatment taltz lead statistically significant improvement measure proportion patient achieve assessment international society week additional datum study be expect be present later year ankylose spondylitis be type affect pelvic joint spine be characterize chronic inflammatory back pain stiffness impair function mobility taltz sale increase quarter quarter last quarter back strong uptake january drug receive approval europe psa be expect boost sale drug first quarter however several drug be approve treatment include humira novartis nvs free report cosentyx other company be develop therapy treat include galapago glpg free report filgotinib eli lilly company price eli lilly company price eli lilly company quote zack ranklilly carry zack rank hold see complete list today zack rank strong buy stock here don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2108,ABBV,rise yield have dampen appeal dividend stock high dividend stock be eye soar current environment dividend growth one strong fundamental be lucrative especially give new tax legislation unite state heighten volatility dividend growth stock have strong history dividend growth mature company be less susceptible large swing market thus act hedge economic political uncertainty well stock market volatility same time offer downside protection consistent increase payout additionally stock have superior fundamental make dividend growth quality promising investment long term include sustainable business model long track profitability rise cash flow good liquidity strong balance sheet value characteristic further history strong dividend growth indicate dividend increase be likely future moreover history dividend growth year year lead healthy portfolio greater scope capital appreciation opposed simple dividend pay stock high yield stock do not necessarily have highest yield have outperformed longer period broader stock market other dividend pay stock result pick dividend growth stock appear winning strategy other parameter be also include year historical dividend growth greater select stock solid dividend growth history year historical sale growth greater represent stock strong record grow revenue year historical ep growth greater represent stock solid earning growth history next year ep growth rate greater represent rate company earning be expect grow improve earning help company sustain dividend payment price cash flow less industry ratio less industry indicate stock be undervalue industry investor need pay less better cash flow generate company week price change greater market weight ensure stock appreciate more past year top zack rank stock have zack rank strong buy buy generally outperform peer type market environment growth score better research show stock growth score combine zack rank offer best upside potential ratio less industry ratio less industry indicate stock be cheap undervalue industry here be stock fit bill illinois base jone lang lasalle inc jll free report be full service real estate firm provide management service corporate financial service investment management service corporation other real estate owner user investor worldwide have ratio versus industry average expect earning growth rate year stock have zack rank growth score see complete list today zack rank stock here california base intel intc free report be world largest semiconductor chip maker be expect see earning growth year have ratio versus industry average stock have zack rank growth score tennessee base dollar general corporation dg free report be discount retailer provide various merchandise product southern southwestern midwestern eastern unite state be expect see earning growth fiscal year end jan have ratio versus industry average stock have zack rank growth score illinois base abbvie inc abbv free report be global research base company discover develop manufacture sell pharmaceutical product worldwide company have ratio compare industry average expect earning growth rate year have zack rank growth score ohio base owen corning inc oc free report be world leader build material system composite solution be expect see earning growth year have ratio versus industry average owen corning have zack rank growth score get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
2109,ABBV,abbvie inc abbv free report share have gain so far second half year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain key regulatory approval settle humira patent dispute amgen resolution amgen lawsuitabbvie announce resolution patent dispute amgen inc amgn free report september have delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market key regulatory approvalsabbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada third quarter mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history august abbvie gain approval sixth indication imbruvica drug be approve chronic graft versus host disease gvhd serious potentially life threaten condition high unmet medical need cgvhd be first indication imbruvica outside cancer also imbruvica be first treatment specifically approve cgvhd positive datum studiesabbvie announce positive datum phase iii murano study venclexta roche rhhby free report rituxan relapse refractory cll last month datum show venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll label expansion indication expand patient population venclexta significantly boost commercial potential abbvie oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra highly statistically significant clinically meaningful result dose mg mg upadacitinib compare placebo upadacitinib also meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year datum upadacitinib study be announce september october abbvie announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint several pivotal datum readout regulatory milestone expect bullish run stock continue next year importantly humira have be generate strong sale new competition abbvie raise long term target humira sale october base strong demand trend drug imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock abbvie carry zack rank hold seethe complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2110,ABBV,johnson johnson jnj free report partner glaxosmithkline gsk free report recently announce fda approval juluca combination glaxo tivicay rilpivirine edurant dolutegravir single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen reduce number medicine hiv patient take compromise efficacy conventional drug regimen approval juluca have shift investor focus hiv disease space let see company be try tap huge market note hivhiv stand human virus weaken immune system destroy cell fight disease infection eventually lead aids acquire syndrome medicine treatment hiv be call antiretroviral therapy art slow put check progression virus globally person be live hiv aids end total be child less year old improve medical understand hiv prevention treatment well significant effort make lead government medical body hiv aids still have cure notably person die aids related illness reach total number start epidemic company develop hiv drugsmarkete therapy hivseveral pharmaceutical company be marketing drug therapy treat hiv gilead gild free report be dominant player hiv market impressive portfolio company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya be bestseller surpass truvada atripla fourth quarter company glaxosmithkline have long standing commitment hiv infectious disease company have develop widely used antibiotic amoxycillin year develop first medicine approve treat hiv azt company other market hiv drug include triumeq tivicay other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress pharmaceutical company mylan myl free report have receive tentative approval fda combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate treat hiv pipeline company be work develop new drug treat prevent possibly cure hiv scientist be explore new treatment paradigm drug regimen make therapy drug improve safety profile new mechanism action gilead str bictegravir hiv treatment be priority review unite state fda be expect announce decision next february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone merck be develop investigational nucleoside reverse transcriptase inhibitor mk doravirine hiv infection plan tofile regulatory application fix dose combination same single entity tablet fix dose combination tabletconsist fix dose combination doravirine dor lamivudine tc tenofovir disoproxil fumarate tdf late glaxo be also develop drug regimen be dolutegravir cabotegravir rilpivirine increase number company be develop drug treat life threaten disease competition have intensified manifold space meanwhile be be see juluca fare market be reissue article correct mistake original article issue tuesday nov longer be rely
2111,ABBV,very few option be available treat ovarian cancer primarily include chemotherapy radiation surgery effective treatment have many side effect chemotherapy destroy patient immune system radiation kill normal cell cancerous cell surgical process be ineffective cancer spread approval astrazeneca azn free report merck mrk free report lynparza december new target therapy treat ovarian cancer come market drug inhibit enzyme cell parp help repair dna cell thus destroy cell other parp inhibitor be approve fda tesaro inc tsro free report zejula clovis oncology inc clvs free report rubraca parp inhibitor have show more tolerability effectiveness clinical study however none market parp inhibitor rubraca zejula lynparza have be approve first line set date be many other company develop parp inhibitor include pfizer inc pfe free report abbvie inc abbv free report other let see market drug be perform have better prospect lynparza recent label expansion august be indicated maintenance treatment patient suffering platinum sensitive recurrent psr ovarian cancer regardless brca mutation status be also approve brca mutate ovarian cancer third line set drug be available capsule tablet formulation drug record sale first month grow annually drug be also be develop first line maintenance treatment brca mutate ovarian cancer astrazeneca merck expect file label expansion mid however lynparza sale have fall lately unite state launch zejula april year label expansion august include ovarian cancer patient regardless brca mutation have bring par zejula moreover potential approval first line set next year give edge other drug also astrazeneca have collaborate merck co develop lynparza combination immunotherapy successful development be boon patient rubraca receive accelerate approval fda late last year monotherapy advanced ovarian cancer patient deleterious brca mutation treat more chemotherapy clovis be conduct confirmatory study convert approval full approval meanwhile company file supplemental new drug application last month seek label expansion maintenance treatment patient psr ovarian cancer rubraca be review eu drug report sale first month however drug lag other drug be approve treat ovarian cancer irrespective brca mutation meanwhile clovis be evaluate drug phase iii study combination bristol myer bmy free report opdivo first line maintenance therapy stage iii iv high grade ovarian cancer patient be treat platinum base chemotherapy zejula be first parp inhibitor be approve maintenance treatment recurrent ovarian cancer regardless brca mutation be launch april drug be used patient do not have brca mutation be prescribe broader patient population moreover also remove requirement diagnosis brca mutation thereby reduce treatment cost time due competitive advantage zejula have register impressive growth launch have also encroach lynparza rubraca market share drug have generate sale launch company have also claim be most frequently prescribe parp inhibitor ovarian cancer further boost prospect drug european commission grant marketing authorization earlier week tesaro be also develop zejula combination merck pd drug keytruda patient platinum resistant ovarian cancer discussion be evident zejula have edge due requirement brca mutation status have fared better thus far however expand label lynparza be set get back lose share believe rubraca be relatively weaker position drug be uncertainty perform europe lynparza zejula be already approve however have end see actual performance drug few label expansion be expect next year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2112,ABBV,novartis ag nvs free report be currently go transitional stage company blockbuster drug diovan be face stiff generic competition unite state eu japan loss patent protection top selling drug continue hurt sale exforge be also face generic competition unite state eu oncology drug be face new competition immuno oncology therapy moreover certain patent extension cover afinitor gilenya expire negative impact generic competition impact sale ceo joseph jimenez step position vasant global head drug development chief medical officer replace effective feb nevertheless believe approval new drug label expansion exist drug boost company top line psoriasis drug cosentyx be approve treatment new indication ankylose spondylitis psoriatic arthritis psa uptake cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale novartis expect garner sale cosentyx entresto respectively other approval include farydak odomzo combination tafinlar mekinist novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu improve formulation exjade oncology portfolio receive further boost approval new drug recent fda approval kisqali use combination inhibitor first line treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced metastatic breast cancer boost sale drug be also approve europe meanwhile fda also approve label expansion zykadia include first line treatment patient metastatic small cell lung cancer european commission ec have recently approve tasigna treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include imatinib fda recently approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah formerly ctl be first chimeric antigen receptor cell car therapy approve approval provide major boost novartis approval open new frontier treatment cancer advance immune cellular therapy child young adult cell comprise approximately cancer diagnosis child year be most common form childhood cancer unite state kymriah have be launch unite state moreover sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version roche holding rhhby free report rituxan rituximab rixathon be approve european commission june be currently review unite state biosimilar version humira be also review eu novartis stock have rally year date compare industry gain first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive hence decision possible spin be take zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2113,ABBV,galapago nv glpg free report announce positive top line datum phase ii study albatross evaluate cystic fibrosis transmembrane conductance cftr corrector candidate glpg cystic fibrosis cf patient lead improvement lung function so far year galapago share have outperformed industry stock have gain compare increase register industry phase ii study evaluate once daily dose mg mg candidate cf patient have gate mutation del mutation be long term stable treatment vertex pharmaceutical incorporate vrtx free report cf drug kalydeco treatment kalydeco be continue course study study achieve primary objective safety be well tolerate patient population datum also show improvement mean percent predict fev measure lung function compare baseline mg arm study meanwhile vertex be also develop combination therapy tezacaftor kalydeco similar indication apart glpg galapago be also develop glpg cftr regulator phase study glpg cftr potentiator phase ii study cf patient candidate be be develop partnership abbvie inc abbv free report company have diverse pipeline candidate be develop several other indication include atopic dermatitis psoriatic arthritis uveitis lupus membranous nephropathy other galapago nv price galapago nv price galapago nv quotezack rank stock carry zack rank hold sucampo pharmaceutical inc be better rank health care stock sporting zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2114,ABBV,pfizer inc pfe free report announce fda have approve label expansion janus kinase jak inhibitor xeljanz tofacitinib dose mg twice daily mg once daily extend release xr formulation latest approval xeljanz now be administer treat adult patient active psoriatic arthritis psa have inadequate response conventional synthetic disease modify antirheumatic drug csdmard tumor necrosis factor inhibitor respectively notably xeljanz mg twice daily be approve unite state second line treatment option patient moderate severely active rheumatoid arthritis ra have have inadequate response tolerate methotrexate mtx drug be approve europe china march ra significantly be first only jak inhibitor approve unite state moderate severe ra active psa share pfizer have gain so far year underperform industry rally supplemental new drug application snda xeljanz be file fda year aforementioned indication approval be base encourage datum phase iii opal oral psoriatic arthritis trial study broaden xeljanz opal broaden opal trial evaluate efficacy safety xeljanz adult patient psa program achieve primary efficacy endpoint statistically significant improvement twice daily xeljanz mg compare placebo month measurement american college rheumatology response change baseline health assessment questionnaire disability index score overall safety result study be find be consistent observed broader rheumatology development program xeljanz remind investor company be also look get drug label expand include treatment adult patient suffering moderate severe active ulcerative colitis response fda be expect march next year additionally pfizer be conduct phase iiib iv head head study compare xeljanz abbvie abbv free report humira february company announce top line result assessment outcome trial demonstrated inferiority combo therapy comprise xeljanz mtx compare other combo agent humira mtx thus meeting primary endpoint be encourage pfizer label expansion effort xeljanz sale surge year year first month drug label expansion boost further sale blockbuster drug approve treat psa ra include johnson johnson jnj free report remicade amgen inc amgn free report enbrel pfizer market outside unite state canada pfizer press release company announce have start phase iii study evaluate efficacy safety once daily janus kinase jak inhibitor pf treatment moderate severe atopic dermatitis initiation surface first trial jak atopic dermatitis efficacy safety global development program pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2115,ABBV,bristol myer squibb company bmy free report announce fda have accept supplemental biologic license application sbla priority review opdivo yervoy ipilimumab treatment intermediate poor risk patient advanced renal cell carcinoma rcc note fda have grant breakthrough therapy designation application expedite development review same fda make decision apr application be base datum phase iii study checkmate study study be stop ahead schedule base recommendation independent datum monitoring committee follow plan interim analysis overall survival study evaluate combination opdivo yervoy versus sutent previously untreated advanced metastatic rcc study meet co primary endpoint improve overall survival objective response rate compare sutent intermediate poor risk patient combination demonstrated improvement progression free survival relative sutent co primary endpoint do not reach statistical significance so far year bristol myer share have rally compare industry gain note opdivo be already approve number indication include classical hodgkin lymphoma recurrent metastatic squamous cell carcinoma head neck disease progression platinum base therapy additionally be approve monotherapy treatment squamous cell carcinoma head neck adult progress platinum base therapy opdivo be also approve intravenous use patient hepatocellular carcinoma have be previously treat nexavar drug receive approval liver colorectal cancer meanwhile company continue evaluate opdivo alone combination therapy yervoy other cancer agent label expansion drug additional indication give product access higher patient population increase commercial potential however opdivo be face competitive challenge unite state fda approve merck mrk free report keytruda first line treatment metastatic squamous nsclc company be expect suffer further loss market share virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank stock considerbristol myer currently carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2116,ABBV,bristol myer squibb company bmy free report announce positive datum phase ii study sprycel patient receive sprycel mg tablet powder oral suspension once daily addition chemotherapy regimen modelled berlin frankfurt munster high risk backbone year occurrence unacceptable toxicity ongoing nct study study evaluate sprycel pediatric patient newly diagnosed philadelphia chromosome positive ph acute lymphoblastic leukemia add chemotherapy regimen combination demonstrated event free survival rate study primary endpoint overall survival rate year meanwhile patient have minimal residual disease mrd end first block treatment mrd remain mrd positive detectable level additional high risk chemotherapy block be eligible hematopoietic stem cell transplantation hsct first remission remind investor sprycel be approve unite state treatment adult ph chronic myeloid leukemia cml chronic phase cp be resistant intolerant prior therapy include imatinib sprycel be also approve adult ph be resistant intolerant prior therapy drug be also approve treatment adult newly diagnosed cp ph cml sprycel receive fda approval expand indication treatment pediatric patient cp ph cml november label expansion improve sale further so far year bristol myer share have rally compare industry gain bristol myer immuno oncology opdivo continue perform well eliquis orencia company be look expand opdivo label further recently obtain fda approval liver colorectal cancer however opdivo be currently face competitive challenge unite state virology business be also pressure company be also look counter generic threat key drug deal acquisition company recently enter deal abbvie inc abbv free report halozyme therapeutic inc halo free report zack rank stock considerbristol myer currently carry zack rank hold better rank health care stock be sucampo pharmaceutical zack rank strong buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2117,ABBV,novartis ag nvs free report announce positive result post subgroup analysis phase ii study sustain pipeline candidate crizanlizumab multicenter multinational randomize placebo controlled double blind month study be conduct evaluate safety efficacy selectin antibody crizanlizumab concomitant use hydroxyurea therapy patient sickle cell related pain crisis result study show crizanlizumab defer time first sickle cell pain crisis scpc patient compare placebo key subgroup adult patient sickle cell crizanlizumab mg kg month increase estimate median time first scpc versus placebo approximately fold more result be publish new england journal medicine datum study enable company conduct discussion regulatory agency filing unite state be expect end believe approval new drug label expansion exist drug boost company top line novartis stock have rally last month compare industry gain novartis be currently go transitional stage company blockbuster drug diovan be face stiff generic competition unite state eu japan loss patent protection top selling drug continue hurt sale exforge be also face generic competition unite state eu oncology drug be face new competition immuno oncology therapy moreover certain patent extension cover afinitor gilenya expire negative impact generic competition impact sale moreover sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version roche holding rhhby free report rituxan rituximab be rixathon be approve european commission june be currently review unite state biosimilar version abbvie inc abbv free report humira be also review eu zack rank key picknovartis currently carry zack rank hold better rank health care stock be sucampo pharmaceutical zack rank buy see complete list today zack rank strong buy stock here sucampo earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2118,ABBV,eli lilly company lly free report announce fda have approve label expansion psoriasis drug taltz include treatment active psoriatic arthritis psa adult note taltz be presently approve treat moderate severe plaque psoriasis adult have systemic therapy phototherapy drug have grow more first month contribute significantly revenue volume approval expand label unite state be expect further boost growth lilly stock price have increase past year outperform industry gain come back news fda approval taltz label expansion be base datum phase iii study spirit spirit evaluate drug active psa patient have not receive antirheumatic drug therapy have fail tumor necrosis factor tnf inhibitor respectively drug achieve reduction more composite measure disease activity acr more half patient population study week drug mg ml be inject single agent combination disease modify antirheumatic drug methotrexate however taltz face competition several drug especially novartis nvs free report cosentyx drug work target il cosentyx be also approve psa plaque psoriasis psa be chronic form inflammatory arthritis be painful progressive well press release approximately person unite state be affected disease apart cosentyx johnson johnson jnj free report stelara abbvie inc abbv free report humira other be fight market share eli lilly company price eli lilly company price eli lilly company quotelilly carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2119,ABBV,amgen inc amgn free report announce launch enbrel mini autotouch new auto injector device enbrel unite state enbrel mini single dose prefil cartridge used autotouch reusable autoinjector device provide additional administration option rheumatoid arthritis drug enbrel enbrel mini autotouch device be approve fda september amgen share have rally year so far better industry growth sale amgen largest product enbrel have be soft quite time now pricing pressure stiff competition be hurt sale enbrel main driver amgen revenue enbrel have record sale so far decline year year ra market be extremity crowd give presence treatment abbvie abbv free report humira pfizer pfe free report xeljanz other remain be see new device enbrel lead improvement sale however conference call amgen have say decline trend price market share continue europe biosimilar version enbrel be available unite state sandoz generic arm novartis nvs free report have receive fda approval biosimilar version enbrel erelzi notably erelzi be yet be launch unite state currently amgen have zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2120,ABBV,novartis nvs free report announce fda have approve line extension il inhibitor drug cosentyx moderate severe scalp psoriasis fda approval come back positive efficacy safety outcome dedicate phase iii study scalp patient scalp psoriasis note drug be approve similar indication europe june be already approve treatment plaque psoriasis psoriatic arthritis psa ankylose spondylitis press release scalp psoriasis be difficult treat form psoriasis affect half approximately patient disease line extension drug be important achievement treatment scalp psoriasis topical agent phototherapy be challenge due presence hair other factor novartis share have return past year compare industry gain same period scalp study evaluate subcutaneous administration cosentyx mg week datum show significant improvement patient compare placebo cosentyx performance be impressive achieve multus blockbuster drug status back strong growth approve indication sale drug increase surpass mark drug have show superiority clinical study johnson johnson jnj free report stelara amgen amgn free report enbrel treat psoriasis novartis be also conduct head head clinical trial exceed surpass evaluate superiority cosentyx versus abbvie abbv free report humira psa propose biosimilar humira respectively superiority drug stelara enbrel have help gain market share potential superiority humira biosimilar line extension scalp psoriasis certainly boost prospect drug novartis ag price novartis ag price novartis ag quotezack ranknovartis carry zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2121,ABBV,gilead science inc gild free report receive major boost fda approve company once daily single tablet regimen str biktarvy bictegravir mg emtricitabine mg tenofovir alafenamide mg bic ftc taf hiv infection approval come ahead pdufa date feb provide major boost gilead hiv franchise company top earning revenue estimate fourth quarter magnitude decline hcv sale be wider expect hcv franchise have be pressure due lower patient start increase competition form abbvie abbv free report company guidance also lack lustre expect sale same decline further such scenario approval latest triple hiv therapy be likely provide impetus stock gilead be now banking hiv franchise newer avenue car therapy post kite acquisition promising nash candidate growth follow news approval share company moved gilead stock have gain last month industry decline biktarvy gilead latest triple therapy be approve complete regimen treatment hiv infection adult have antiretroviral treatment history replace current antiretroviral regimen be virologically suppress hiv rna ml stable antiretroviral regimen least month history treatment failure know substitution associate resistance individual component biktarvy meanwhile hiv franchise continue gain traction back rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy biktarvy combine novel unboosted integrase strand transfer inhibitor insti bictegravir demonstrated safety efficacy profile descovy ftc taf dual nucleoside reverse transcriptase inhibitor nrti backbone be smallest insti base triple therapy str available approval biktarvy be support encourage datum ongoing study study treatment naïve hiv infected adult study virologically suppress adult biktarvy meet primary objective inferiority week study however biktarvy have box warning product label regard risk post treatment acute exacerbation hepatitis approval new hiv therapy stiff competition glaxosmith gsk free report exist therapy tivicay triumeq other hand report reuter viiv healthcare joint venture majority own glaxosmith pfizer pfe free report shionogi ltd have file lawsuit gilead allege patent infringement viiv dolutegravir component venture triple drug hiv treatment triumeq zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2122,ABBV,growth reasonable price garp be excellent way investor make quick gain strategy help investor gain exposure stock have impressive prospect be trading discount garp approach lead identification stock be price market reasonable target determine fundamental analysis stock also have solid prospect term cash flow revenue earning share ep so mean portfolio create basis garp strategy be expect have stock offer best value growth investing growth metricsstrong earning growth solid prospect be main concept garp investor borrow growth investing strategy however instead super normal growth rate pick stock more stable reasonable growth rate be prefer tactic garp investor hence growth rate be consider ideal strategy growth metric be consider growth garp investor be return equity roe garp investor look strong higher roe compare industry average identify superior stock moreover stock positive cash flow find precedence garp plan value metricsgarp investing give priority popular value metric price earning ratio investing style pick stock higher ratio compare value investor avoid company extremely high ratio moreover price book value ratio be value metric be consider used garp principle have run screen identify stock be likely offer solid return term screening parametersalong criterium discuss section have consider favorable zack rank strong buy buy last year ep project year ep growth rate strong ep growth history prospect ensure improve business roe past month greater industry average higher roe compare industry average indicate superior stock ratio less industry average ratio less industry indicate stock be undervalue few criterium have narrow universe stock only here be stock make screen msci inc msci free report be independent provider research drive insight tool institutional investor company have average quarter positive earning surprise carry zack rank american financial group inc afg free report be hold company subsidiary be engage primarily private passenger automobile specialty property casualty insurance business sale tax defer annuity certain life supplemental health insurance product stock have average quarter positive earning surprise carry zack rank home depot inc hd free report be world largest home improvement retailer company have average quarter positive earning surprise carry zack rank abbvie inc abbv free report be global research base company stock have average quarter positive earning surprise carry zack rank lazard ltd laz free report be preeminent international financial advisory asset management firm have long specialize craft solution take care complex financial strategic challenge face client company have average quarter positive earning surprise carry zack rank carter inc cri free report be lead provider apparel related product exclusively baby young child stock have average quarter positive earning surprise carry zack rank first american financial corporation faf free report provide financial service title insurance service segment specialty insurance segment stock have average quarter positive earning surprise carry zack rank get rest stock list start putt other idea test be do research wizard stock pick back testing software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
2123,ABBV,gilead science inc gild free report report fourth quarter result earning revenue surpass expectation however management issue bleak view consequently stock decline market hour trading be expect open red give expectation further decline hepatitis virus hcv franchise nevertheless gilead stock have gain last month industry decline company fourth quarter earning share beat zack consensus estimate however earning be year quarter figure share moreover total revenue top zack consensus estimate however revenue decline year year gilead science inc price consensus gilead science inc price consensus gilead science inc quote harvoni sovaldi plunge furtherproduct sale come year year decline be due lower hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market sale harvoni decline year year quarter further sovaldi sale record steep year year decline epclusa garner sale quarter year figure meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due impact ongoing milestone payment selling general administrative sg expense decrease adjust product gross margin be compare year period resultsrevenue come surpass zack consensus estimate earning share come beat zack consensus estimate guidancegilead now expect net product sale range adjust expense adjust sg expense be project range respectively adjust product gross margin be expect range company acquire kite pharma fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy gilead prospect company recently acquire cell design lab expand further car space dividend share gilead declare cash dividend cent share common stock first quarter increase dividend be payable mar stockholder record close business mar company paid cash dividend repurchase share company top earning revenue estimate fourth quarter magnitude decline hcv sale be larger expect hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report merck mrk free report zepatier pricing market share be expect stabilize mid patient start be expect decline further meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy truvada use pre exposure prophylaxis set also put strong performance company see significant uptick prep usage estimate patient used truvada end approval yescarta also bode well gilead expect decline hcv franchise offset positive momentum hiv franchise gilead be also intend foray nash market pipeline candidate selonsertib filgotinib zack rankgilead currently carry zack rank sell see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2124,ABBV,arena pharmaceutical inc arna free report announce have complete full enrollment patient phase ii study evaluate pipeline candidate etrasimod ulcerative colitis uc etrasimod apd be orally available next generation sphingosine phosphate receptor modulator primary endpoint study be improvement uc symptom measure mayo clinic score week compare placebo top line result be expect be available first quarter meanwhile arena continue progress pipeline target different therapeutic area include ralinepag pulmonary arterial hypertension apd pain fibrotic disease company report positive result phase ii study ralinepag july be prepare initiate phase iii study discussion fdaarena share have outperformed industry so far year share company have soar industry have register increase several other company be also evaluate candidate uc include pfizer pfe free report be conduct study expand label rheumatoid arthritis drug xeljanz include uc indication company abbvie inc abbv free report be also look get flagship product humira approve uc company have candidate upadacitinib be be evaluate uc zack rank stock considerarena carry zack rank hold better rank health care stock same space be ligand pharmaceutical incorporate lgnd free report sporting zack rank strong buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2125,ABBV,abbvie inc abbv free report report mixed result third quarter company surpass earning estimate post line revenue period importantly company raise long term sale expectation blockbuster rheumatoid arthritis drug humira rise competition market response share nudge almost pre market trading year so far abbvie share have surge significantly outperform industry rally company report third quarter earning share beating zack consensus estimate bottom line grow year year company post revenue report quarter have meet zack consensus estimate revenue also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue climb quarter detailkey drug humira record sale growth operational basis revenue come sale unite state rally humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market third quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness increase revenue operational report basis hcv chronic hepatitis virus product record sale operational report basis respectively downside be attributable intense pricing competitive pressure hcv market adjust sg expense be expense escalate quarter adjust operate margin be sale report quarter abbvie announce hike quarterly dividend cent share cent share increase payment begin dividend payable february next year outlookabbvie raise adjust earning range compare expect previously earning guidance reflect year year growth mid point zack consensus estimate be currently peg share long term guidanceabbvie project adjust ep range show approximate rally mid point revise range outlook abbvie estimate humira generate global sale higher predict previously several company be work biosimilar version humira amgen amgn free report humira biosimilar receive fda approval september launch be delay due settlement patent dispute abbvie make humira free competition few more year also abbvie have robust intellectual property be expect generate positive sentiment investor zack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report carry zack rank buy see complete list today zack rank strong buy stock here eli lilly earning share estimate increase last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2126,ABBV,centene inc cnc free report report fourth quarter adjust net income share cent beat zack consensus estimate earning however decline year year higher expense fourth quarter total revenue grow year quarter primarily drive growth health insurance marketplace business expansion new program many state revenue surpass zack consensus estimate full year company report adjust earning year year figure also surpass zack consensus estimate centene report total revenue year year rise be primarily drive health net result year impact growth health insurance marketplace business expansion new program many state end year manage care membership totale quarterly operational updatehealth benefit ratio hbr fourth quarter be compare prior year quarter reflect year year improvement basis point bps quarter adjust selling general administrative sg ratio be bps year year deteriorationis result increase business expansion cost prior year quarter notably revenue recognize fourth quarter relate minimum mlr amendment california have reduce quarter adjust sg expense ratio hence expense ratio fourth quarter appear higher compare year quarter total operate expense end fourth quarter increase nearly prior year quarter centene corporation price consensus ep surprise centene corporation price consensus ep surprise centene corporation quotefinancial updatea dec centene have cash cash equivalent end total asset grow dec centene long term debt totale cash inflow operation be compare end guidancecentene expect adjust earning share be range previously guide range total revenue be expect be range earlier guidance hbr be expect range compare previous guidance adjust sg expense ratio be expect range previous guidance share outstanding be expect be previous guidance zack rank performance other peerscentene sport zack rank strong buy see complete list today zack rank stock here other player medical sector have report fourth quarter earning so far abbvie inc abbv free report unitedhealth group incorporate unh free report abbott laboratory free report have surpass respective zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2127,ABBV,bristol myer squibb company bmy free report fourth quarter earning cent share beat zack consensus estimate cent come ahead year quarter earning cent moreover total revenue surpass zack consensus estimate increase record year period strong sale opdivo eliquis contribute top line report quarter share company be almost pre market trading presumably better expect earning bristol myer share have increase past year compare favorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue increase unite state outside country ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year november fda approve label expansion drug include treatment pediatric patient ph chronic myeloid leukemia chronic phase rheumatoid arthritis drug orencia be fourth quarter melanoma drug yervoy contribute top line report quarter january label expansion drug pediatric patient advanced melanoma be approve europe opdivo be approve multiple cancer indication generate revenue year period drug receive approval intravenous administration melanoma patient adjuvant treatment however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively sale eliquis be report quarter year year multiple myeloma drug empliciti record sale year year research development expense quarter increase mainly due charge related license asset acquisition marketing selling administrative expense decline gross margin be quarter compare year quarter due change product mix december bristol myer privately hold taris biomedical llc announce clinical collaboration evaluate combination bristol myer opdivo taris investigational product tar patient muscle invasive bladder cancer moreover bristol myer also enter agreement japan base ono pharmaceutical same month agreement grant bristol myer right develop commercialize ono selective prostaglandin receptor antagonist ono sale increase primarily drive strong sale opdico follow several line extension opdivo sale rise eliquis sale increase adjust earning share full year come pipeline updatein february bristol myer announce datum phase iii study checkmate show superior progression free survival first line small cell lung cancer nsclc treat opdivo yervoy combination compare chemotherapy moreover january bristol myer announce positive datum phase ii checkmate study evaluate combination opdivo yervoy patient dna mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer mcrc december fda lift partial clinical hold phase study phase ii study evaluate opdivo combination regimen relapse refractory multiple myeloma november phase iii study checkmate be stop early opdivo achieve superior overall survival previously treat patient nsclc compare docetaxel earning guidancebristol myer provide adjust earning expectation company project earning range share zack consensus estimate earning be peg company expect revenue increase low mid single digit takebristol myer beat earning expectation primarily robust sale drug opdivo eliquis yervoy quarter guidance be also encourage meanwhile be positive bristol myer effort develop pipeline especially opdivo several label expansion application opdivo be review unite state europe potential approval prospect drug bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here better rank company large cap pharma industry be abbvie inc abbv free report pfizer inc pfe free report lundbeck hluyy free report carry zack rank buy share abbvie have gain past year earning estimate have go past day share pfizer have return past year earning estimate have go past day share lundbeck have gain past year earning estimate have go past day today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2128,ABBV,biotech major amgen inc amgn free report report fourth quarter earning share miss zack consensus estimate earning be flat year year lower sale higher operate cost offset benefit lower tax rate include charge related tax reform fourth quarter loss share be earning share fourth quarter total revenue quarter miss zack consensus estimate revenue decline year year quarter detailtotal product revenue decline year quarter ex increase demand newer product prolium kyproli xgeva blincyto be not enough make lower sale amgen largest product enbrel aranesp epogen neulasta neupogen due competitive pressure revenue amgen erythropoiesis stimulating agent esa aranesp decline year quarter due lower demand unfavorable change currency rate revenue other esa epogen decline due lower selling price owing newly negotiate contract davita inc neulasta revenue be flat year period lower demand be offset change accounting estimate increase competition pd other new cancer therapy be hurt demand neulasta however neulasta onpro kit body injector continue perform well command market share unite state neulasta sale please note neulasta epogen start face biosimilar competition unite state year hurt sale further neupogen record decline sale due biosimilar competition unite state zarxio sandoz novartis nvs free report generic arm biosimilar version neupogen be launch unite state september be hurt sale enbrel deliver revenue year quarter due lower selling price increase competition hurt demand amgen launch enbrel autotouch autoinjector device november last year prolium revenue come year quarter due higher demand osteoporosis drug witness continue growth new patient start strong repeat injection rate drive year year growth meanwhile xgeva deliver revenue year quarter mainly due higher demand favorable change inventory level earlier year amgen gain fda approval expand label xgeva include prevention ofskeletal related event sre inpatient multiple myeloma now xgeva be only approve prevention sre solid tumor patient bone metastase approval expand patient population drive sale xgeva future quarters sensipar mimpara revenue be flat higher price increase be offset unfavorable inventory change vectibix revenue come drive higher demand kyproli record sale year year drive higher demand robust uptake outside market amgen regulatory application unite state include overall survival datum endeavor study label kyproli be grant approval fda earlier month also earlier week amgen announce committee medicinal product human use chmp have give positive opinion recommend addition endeavor kyproli label eu study demonstrated combination kyproli dexamethasone lead superior overall survival compare takeda velcade dexamethasone overall survival datum approve help drive usage boost sale kyproli blincyto sale surge year period reflect higher demand amgen pcsk inhibitor repatha generate revenue compare third quarter uptake drug gain fda approval august have not be very encourage so far due pricing re imbursement issue payer restriction sanofi sny free report partner regeneron pharmaceutical also face similar issue pcsk inhibitor praluent priority amgen right now be improve patient access repatha december amgen gain fda approval include new indication risk reduction major cardiovascular event datum repatha label base datum phase iii cardiovascular outcome study fourier make repatha first pcsk inhibitor prevent heart attack stroke coronary adult establish cardiovascular disease cardiovascular indication approve be include repatha label patient access repatha be expect improve operate margin decreaseadjust operate margin decline basis point bps due higher operate cost expense related hurricane marium recovery effort expense decline quarter due lower late stage pipeline related cost lower payment licensing transaction sg spend increase due higher investment support new product launch partially offset impact october expiration enbrel residual royalty payment month amgen board director approve new share buyback plan bring total exist share repurchase authorization resultsfull year sale miss zack consensus estimate revenue be guidance range sale decline year year adjust earning be share also miss zack consensus estimate share earning be guidance range earning rise year year company expect total revenue range fall short zack consensus estimate adjust earning be now expect range zack consensus estimate be peg share adjust tax rate be expect be approximately much lower reflect impact tax reform expectation improve cash position follow tax reform amgen plan invest approximately next year capital expenditure approximately investment be make unite state include set new drug substance manufacturing plant country takeamgen have rather poor quarter miss expectation earning sale also issue lower expect sale guidance share lose market trading response however past year amgen share have return better increase register industry amgen newer product prolium xgeva vectibix nplate sensipar be perform well volume growth be not enough offset decline mature brand enbrel due competitive pressure however amgen be also progress pipeline expect approval launch migraine candidate aimovig year also amgevita amgen biosimilar version abbvie abbv free report blockbuster rheumatoid arthritis drug humira be expect be launch europe later year parsabiv specialty product kidney disease be launch unite state last month also management seem quite confident repatha become important growth driver company inclusion outcome datum label nonetheless other continue competitive dynamic enbrel possible generic competition sensipar new competition neulasta aranesp be new challenge amgen carry zack rank hold see complete list today zack rank strong buy stock here amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quotebreaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2129,ABBV,astrazeneca plc azn free report report fourth quarter core earning cent american depositary share ad beat zack consensus estimate cent core earning rise year year constant exchange rate cer higher product sale boost profit quarter total revenue rise cer report quarter revenue also beat zack consensus estimate revenue growth however be partially offset decrease externalization revenue meanwhile product sale rise cer quarter due better performance new product partially offset lower sale legacy product key growth platform represent total revenue be quarter cer key growth platform emerge market new cardiovascular metabolic disease cvmd new oncology japan perform well quarter growth rate mentioned be year year basis cer product sale impresscrestor sale decline sale europe due entry multiple generic version drug market negative impact be expect continue europe seroquel xr sale decline due competition generic launch quarter onglyza sale rise drive growth emerge market symbicort sale remain flat quarter higher sale emerge market be offset lower sale unite state sale decline due continue pricing pressure manage care access ics laba class also competition other class lama laba combination medicine nexium record sale other crestor seroquel xr other legacy product record decline quarter include zoladex seloken toprol xl casodex however older drug grow quarter include iressa pulmicort faslodex daliresp daxas newer medicine lynparza sale rise sale unite state gain label expansion approval august treatment second line ovarian cancer europe sale be push higher number successful launch please note astrazeneca share lynparza development cost profit equally merck co inc mrk free report brilinta brilique sale be report quarter year year brilinta maintain leadership position brand oral platelet market unite state europe china brilinta continue display impressive performance tagrisso launch record sale year year new medicine movantik moventig record sale quarter bevespi lama laba pressurize meter dose inhaler launch commercially unite state january record sale quarter higher third quarter slower anticipate growth lama laba class pd inhibitor imfinzi launch second line bladder cancer unite state generate sale fourth quarter regulatory application seek label expansion imfinzi treat earlier stage lung cancer be grant priority review fda imfinzi be key candidate company immuno oncology pipeline candidate be be evaluate multiple cancer alone combination other regimen october astrazeneca expand clinical trial collaboration incyte incy free report evaluate latter investigational selective ido enzyme inhibitor epacadostat combination imfinzi compare imfinzi alone early lung cancer sale decline primarily due generic competition crestor seroquel xr pricing pressure symbicort unite state european market witness decline sale revenue emerge market be primarily back strong growth china establish row market sale be flat other core gross margin decline basis point bps core selling general administrative sg expense rise quarter core research development expense decline provide ep guidance be expect range adr zack consensus estimate stand adr company also expect revenue grow low single digit percentage base average exchange rate january currency movement be expect favorably impact top line low single digit percentage minimally impact core ep takeastrazeneca fourth quarter performance be impressive beat estimate earning sale also provide encourage outlook revenue improve company expect trend continue astrazeneca announce quite few positive development regulatory pipeline front past year several readout be expect backed positive news flow past year astrazeneca share have gain compare favorably industry growth astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here astrazeneca plc price consensus ep surprise astrazeneca plc price consensus ep surprise astrazeneca plc quotea better rank company large cap pharma industry be abbvie inc abbv free report carry zack rank share abbvie be earning estimate have go past day breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2130,ABBV,have enter report cycle look stock unswerving earning growth be highest priority astute investor not company doesn make money win last long haul consider company revenue give period time subtract cost production have earning metric be also consider be most noteworthy variable influence share price better expect earning performance normally lead rally share price however addition actual earning expectation earning play significant role influence price stock earning estimate shape share priceswe have often see decline stock price earning growth rally price follow earning decline be largely result company earning fail meet market expectation earning estimate embody analyst opinion factor such sale growth product demand competitive industry environment profit margin cost control thus earning estimate serve valuable tool take investment decision earning estimate also help analyst assess cash flow determine fair value firm earning season pick pace investor be lookout stock be ready make big move hence be important investor invest stock have historical earning growth be also see rise quarterly annual earning estimate winning strategyin order shortlist stock have striking earning growth positive estimate revision have add follow parameter zack rank equal only zack strong buy be allow zack rank prove be best rating system be great way start thing see complete list today zack rank stock here year historical ep growth greater industry stock possess strong ep growth history change ep greater equal company witness year year earning growth rate more last report fiscal change estimate last week greater stock have see current quarter earning estimate revise higher last week change estimate last week greater stock have see annual earning estimate revise higher last week change estimate last week greater stock have see annual earning estimate revise higher last week criterium narrow universe stock only here be top stock best buy co bby free report operate retailer technology product service solution unite state canada mexico company estimate growth rate year be higher industry gain zack consensus estimate current year earning increase last day abbvie abbv free report discover develop manufacture sell pharmaceutical product worldwide company estimate growth rate year be higher industry gain zack consensus estimate current year earning increase last day neogen neog free report develop manufacture market various product food animal safety worldwide company estimate growth rate year be higher industry gain zack consensus estimate current year earning increase last day horton dhi free report operate homebuilding company east midwest southeast south central southwest west america company estimate growth rate year be higher industry gain zack consensus estimate current year earning increase last day state bank financial stbz free report operate bank hold company state bank trust company provide various community banking service individual business company estimate growth rate year be higher industry gain zack consensus estimate current year earning increase last day get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
2131,ABBV,amgen inc amgn free report announce committee medicinal product human use chmp european medicine agency ema have give positive opinion expand label nplate include pediatric population nplate be presently market treatment chronic immune purpura itp autoimmune disease characterize low platelet count adult amgen be look get nplate approve use pediatric patient year age older be refractory other treatment corticosteroid immunoglobulin positive opinion be base study demonstrate nplate reduce rate bleed child rare blood disorder amgen share have rally year so far better industry growth separate press release amgen partner allergan agn free report announce chmp have render positive opinion marketing application biosimilar version roche rhhby free report cancer drug avastin abp accord company be first bevacizumab biosimilar have be recommend approval avastin biosimlar be approve unite state september be market trade name mvasi remind investor amgen allergan have collaborate worldwide development oncology antibody biosimilar medicine include roche avastin herceptin ritixan fact amgen have biosimilar pipeline biosimilar version abbvie abbv free report rheumatoid arthritis drug humira amjevita be approve fda last year eu march year same indication however settlement abbvie amgen begin selling amjevita most country eu next year unite state january currently amgen have zack rank hold see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2132,ABBV,major biotech company report earning result last trading day company amgen amgn free report vertex vrtx free report top expectation be mixed quarter company celgene celg free report alexion read more alexion top earning lag sale view biomarin read more biomarin loss narrow profit guidance raise recap week most important storiesa look earning result be earning week several key name report third quarter result amgen top expectation witness year year decline revenue company also announce not be develop oral cetp inhibitor amg be explore licensing opportunity candidate read more amgen earning top sale decline stock fall meanwhile celgene plunge follow release third quarter result celgene top earning estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook reflect impact discontinuation ged crohn disease market dynamic impact otezla opportunity risk associate late stage datum read out schedule read more celgene top earning sale miss update view vertex have strong presence cystic fibrosis cf market report strong quarter earning revenue surpass expectation company also raise guidance cf franchise sale read more vertex beat earning sale raise view vertex have gain year date outperform industry rally abbvie abbv free report top earning estimate revenue be line read more abbvie earning top revenue line view gilead surpass expectation company hepatitis virus hcv franchise remain immense pressure read more gilead weak hcv sale earning beat incyte epacadostat be study early lung cancer imfinzi incyte corporation incy free report report strong third quarter result also announce expansion clinical trial collaboration astrazeneca company say evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone company conduct late stage study patient locally advanced stage iii unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt study be co funded company be conduct astrazeneca patient enrolment schedule commence first half note incyte have clinical trial collaboration merck well bristol myer squibb epacadostat incyte be zack rank hold stock see complete list today zack strong buy rank stock here voyager sanofi exit parkinson disease program voyager therapeutic inc vygr free report share be sanofi exit company vy aadc program advanced parkinson disease deal sign february sanofi have exclusive option ex development commercial right vy aadc deal term include upfront payment well future potential development sale milestone payment tiered royalty product sale accord voyager sanofi decide exit deal option do not include right unite state voyager gain global right vy aadc program advanced parkinson disease company say remain track dose first patient second quarter gw finish roll drug submission epilepsy drug gw pharmaceutical plc gwph free report announce have complete roll submission new drug application nda unite state epidiolex cannabidiol adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy gw have rare pediatric disease orphan drug designation indication unite state dravet syndrome indication have fast track status well fda timely approval allow company launch product biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow release third quarter result alexion be last month vertex be celgene be see last biotech stock roundup here biogen top earning gilead car drug get fda nod next biotech world focus remain earning result several mid small cap biotech company more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2133,ABBV,hca healthcare inc hca free report report third quarter adjust earning share come line zack consensus estimate bottom line decline nearly year year hca holding inc price consensus ep surprise hca holding inc price consensus ep surprise hca holding inc revenue be offset increase expense share be pre market trading hca healthcare post revenue almost line zack consensus estimate report figure be year quarter provision doubtful account surge year year quarterly detailsadjust ebitda totale year year same facility equivalent admission inched year year same facility admission nudge same facility revenue equivalent admission increase salary benefit supply other operate expense increase year year sep hca healthcare run hospital free standing surgery center financial updatea sep company have cash cash equivalent total debt total asset report quarter capital expenditure totale exclude acquisition cash flow provide operate activity totale year year sep company total debt adjust ebitda be compare dec quarter review company spend buy back share board director approve additional share repurchase program follow latest authorization company have remain exist repurchase authorization oct company expect revenue range adjust ebidta ep capital expenditure zack rank performance other company medical sectorhca healthcare presently carry zack rank strong sell see complete list today zack rank stock here abbvie inc abbv free report abiom inc abmd free report abbott laboratory free report have surpass respective zack consensus estimate last quarter wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2134,ABBV,attempt get arm deluge earning report ahead final open bell trading week get first look gdp consensus estimate second consecutive handle follow final read mark first time economy have gdp number particularly noteworthy number be do see negative impact gdp quarter hurricane harvey irma marium most notably consumer spending have ratchete previous quarter time gdp take basis point hit still reach illustrate economic strength power consumer inventory be be normal come do ahead holiday season perhaps surprisingly federal government spend more maybe most importantly zack chief strategist john blank point last week major economy world be currently experience recession growth be now global synchronize be very rare occurrence see geopolitical headwind americas europe asia pacific earning roll onaside big blowout beat yesterday close amazon amzn free report alphabet googl free report microsoft msft free report have already add additional market see more earning tonnage generally oil gas pharma bio sector exxonmobil xom free report share be modestly today pre market follow result surpass estimate top bottom line earning cent share top zack consensus cent revenue really outperformed expectation far exceed have be look mark fourth beat past quarters largest oil gas supermajor energy sector have struggle xom look be improve chevron cvx free report also beat estimate earning sale morning share surpass cent consensus revenue ahead expect outgoing ceo john watson retire early next year cite continue improvement earning cash flow supermajor refine company phillip psx free report post mixed today pre market earning share beating consensus estimate cent revenue fall short estimate company refine business more triple quarter offset quarter quarter midstream chemical marketing pharmaceutical major merck co mrk free report post share ahead zack consensus estimate however quarterly sale be short have be expect say merck up fiscal year earning guidance share last time morning follow initial bump pre market share be now trading more ahead bell also biopharma firm abbvie abbv free report have branch abbott lab beat earning estimate cent share revenue come basically line estimate lymphoma treatment imbruvica rise year year rheumatoid arthritis drug humira improve year quarter
2135,ABBV,abbvie abbv free report announce fda have grant breakthrough therapy designation btd investigational jak inhibitor upadacitinib treatment severe atopic designation aim expedite development review drug intend treat serious life threaten condition provide patient access soon possible abbvie share have increase past year outperform industry gain period fda have grant btd designation upadacitinib base positive datum phase iib study announce september study primary outcome be mean percentage change eczema area severity index easi score tool used measure extent disease severity study upadacitinib show greater mean percentage change baseline easi score compare placebo week also patient receive mg once daily dose upadacitinib show almost clear skin additionally study meet secondary endpoint demonstrate significant reduction skin itch upadacitinib be also be investigate phase iii study rheumatoid arthritis other study be also underway treatment crohn disease ulcerative colitis psoriatic arthritis national eczema association person unite state be affected atopic dermatitis remind investor regeneron pharmaceutical inc regn free report partner sanofi sny free report have launch dupixent injection treat atopic dermatitis early thus upadacitinib have contend competitive pressure market once approve abbvie inc price abbvie inc price abbvie inc quotezack rank stock considerabbvie carry zack rank hold better rank stock pharma sector be celldex therapeutic inc cldx free report carry zack rank buy see complete list today zack rank strong buy stock here celldex loss estimate remain stable cent cent last day company deliver positive earning surprise trail quarters average beat zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2136,ABBV,eating gooey chocolatey brownie take few hit freshly rolled joint common knowledge lot person get high many investor however have yet light hesitate add marijuana stock portfolio apprehension pot company be involved scam still deem illegal federal government let not forget market have turn big money maker not only be fastest grow industry also receive major boost election marijuana be declare legal recreational medical purpose additional state marijuana sale have potential greatly add government treasury well be immensely helpful medical field nowadays be also easier bank provide service legal marijuana business banking optimism have select largest most stable legal cannabis related company rake high return focus american head poll last presidential election state arizona california maine massachusett nevada arkansa florida north dakota be set vote medical recreational cannabis initiative gallup poll ahead election show voter back full legalization soar meager recent time result come maine california massachusett nevada pass measure legalize recreational marijuana use arizona highly contest proposition recreational marijuana measure fail florida north dakota arkansa vote legalize medical marijuana usage montana vote expand state medical marijuana law fact number state legalize marijuana have be rise steady pace prior year only state california maine oregon have make medical cannabis legal last year however state have officially authorize medical marijuana state have adopt medical marijuana program include district columbia just last year medical marijuana be legalize ohio pennsylvania tax revenue improvesale legalize marijuana help significantly boost government tax revenue state colorado washington government collect roughly tax revenue recreational marijuana sale back accord cnn time magazine legal marijuana industry be grow rapid pace gain make fastest pace industry accord arcview group market research firm add industry be expect grow last year financial behemoth bank american bac free report even say marijuana market reach net worth annually almost time yearly revenue national football league marijuana stock considergiven such bullish trend movement legalize marijuana have definitely picked steam be cannabis link stock be poise benefit legalization abbvie inc abbv free report be company already have cannabis base drug approve fda call marinol drug relieve nausea vomit patient undergo chemotherapy be also used aids patient have lose appetite corbus pharmaceutical inc crbp free report company focus development therapeutic treat life threaten inflammatory fibrotic disease key product oral endocannabinoid memetic drug resunab help treat systemic sclerosis chronic autoimmune rheumatic disease leader industry be insys therapeutic inc insy free report know develop commercialize pharmaceutical product target unmet need cancer patient first synthetic cannabinoid candidate syndro be approve fda treatment anorexia associate weight loss aids patient nausea vomit associate cancer chemotherapy patient have fail respond adequately conventional treatment zynerba pharmaceutical be specialty pharmaceutical company focus develop commercialize proprietary synthetic cannabinoid therapeutic have develop candidate temporarily name zyn be clinical trial treatment refractory epilepsy fragile syndrome osteoarthritis investor also consider look industry first etf horizon etfs management inc be base canada horizon medical marijuana life science etf trade toronto stock exchange ticker hmmj provide exposure north american list stock be involved medical marijuana bioengineering production hmmj have surge past year bottom linethere be doubt profit potential weed industry be move rapid pace new development grow technology medical treatment pop quickly consistently important recognize many cannabis base treatment be still trial stage have yet translate financial success many company list therapy show great promise future marijuana medical biopharma industry depend course legalization marijuana be ever reschedule check unite state schedule classify controlled substance here deem have medical benefit company finally see synthetic organic cannabis base treatment enter market most importantly bottom line benefit zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum etfs stock stock corporate insider be buy company be report positive earning surprise even look portfolio so exclusive be normally close new investor click here zack private trade
2137,ABBV,biotech bigwig gilead science inc gild free report develop drug treatment human virus hiv liver disease such chronic hepatitis virus hcv infection chronic hepatitis virus hbv infection cardiovascular hematology oncology inflammation respiratory disease apart blockbuster hcv drug sovaldi harvoni recently launch epclusa primary product gilead include stribild viread atripla complera eviplera emtriva other tenofovir alafenamide taf base product genvoya odefsey descovy newly approve hbv drug vemlidy gilead have solid presence hcv market however hcv franchise continue grapple competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr merck mrk free report zepatier nevertheless hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult sovaldi recently obtain approval china approval new drug somewhat offset decline legacy drug gilead stock have gain last month compare industry gain company suffer decline hcv sale third quarter same be expect fourth quarter well hcv product sale be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset higher sale epclusa launch sale vosevi approve unite state europe july patient start have exceed expectation competition have start erode gilead hcv market share net pricing company see impact third quarter most be due be experience fourth quarter hence expect older hcv product continue witness decline sale company expect hcv product sale zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively fourth quarter hence weakness hcv franchise adversely impact gilead performance fourth quarter gilead have mixed track record company beating estimate last miss earning beat look highly unlikely fourth quarter give competitive pressure read more gilead disappoint investor earning zack rank key pickgilead currently carry zack rank sell see complete list today zack strong buy rank stock here better rank stock healthcare sector be exelixis exel free report zack rank strong buy exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
2138,ABBV,market start new year strong note post fresh record multiple occasion newly instituted tax cut have beneficial impact stock dow breach mark same month economic datum remain strong even fourth quarter earning promise be most bullish recent time meanwhile fed refrain raise rate indicated hike be more less certain march january month january dow nasdaq increase respectively passage tax cut job act permanently slash corporate tax rate last december contribute january gain additionally beige book fed provide encourage outlook economy turn also boost investor sentiment moreover month senate give consent pass short term spending bill end recent government shutdown additionally upbeat fourth quarter earning season include very strong revenue momentum average proportion positive surprise unusually positive revision trend current come quarters also contribute strong market performance benchmark breach multiple recordskey index achieve multiple milestone last month jan nasdaq close mark first time very next trading day moved past first time optimism strong market performance contribute gain jan dow touch psychological level first time be blue chip index fastest point rise inception jan gain point close record sixth straight session mark best start year jan dow finished first time additionally dow post best trading day start first time year follow bond yield dollar increase benchmark hit record level again jan senate give consent bill finally jan benchmark close record level follow better expect earning finished record level trading day best such feat month june index also post best day rise mar additionally dow post rise more point nasdaq register biggest day gain jan bullish domestic dataeconomic datum release november be largely encourage nature ism manufacturing index rise december reach highest settlement last year construction increase downwardly revise october figure highest level record factory order surge month november cpi core cpi gain respectively december additionally retail sale increase december increase fourth straight month end high industrial production december surge surpass consensus estimate consumer spending increase october line consensus estimate period core pce inflation december come higher previous month figure however ism service index december decline point trade deficit increase november settle be highest level deficit january meanwhile ppi month december decrease be index first decline month however core ppi shot housing sector softensa certain degree softness afflict housing sector january confidence level nation homebuilder slip slightly first month reach year high december accord national association home builder nahb housing market index january read be point december level also housing start decline december largest percentage drop record november however industry watcher believe downturn experience december be likely be temporary further housing possibly feel december brutally low temperature read amazing housing stock buy ahead earning meanwhile exist home sale slip december seasonally adjust annual rate unit downwardly revise november straight month strong increase read housing stock soar brave weak december home sale also new home sale come unit december lower consensus estimate only pending home sale increase last month housing supply hit record low gdp slip growth stretch best gdp increase seasonally adjust annual rate final month follow gain more previous quarters advance estimate release bureau economic analysis fact marked economy strongest stretch growth expansion start mid economy be boost solid consumer spending increase quarter gain third quarter consumer outlay register fastest pace growth fourth quarter almost year company also ramp spending fourth quarter other bright spot government spending also increase clip job addition fall unemployment stay flatnonfarm payroll addition month december come lower consensus estimate moreover unemployment rate december remain stagnant line consensus estimate jobless rate have remain same level consecutive month average hourly earning december surge also line consensus estimate average workweek last month come hour remain constant figure last month earning reflect round strengtha slew earning result major bank kick fourth quarter earning season jpmorgan chase co jpm free report goldman sachs group inc gs free report bank america corporation bac free report bancorp usb free report post impressive performance intel corporation intc free report abbvie inc abbv free report honeywell international inc hon free report also post encourage earning number total earning member have report result be same period last year higher revenue beating ep estimate beating revenue estimate jan earning growth energy be highest sector total earning space expect be same period last year higher revenue exclude energy sector total earning rest index be earning growth be expect be strong technology sector total earning sector expect be higher revenue finance sector earning be expect be year year growth revenue read very strong earning picture fed leave rate unchanged hike likely marchon jan federal reserve opted leave benchmark rate unchanged range nevertheless fed policymaker reckon rate hike year set stage imminent increase march jerome powell day policy meeting conclude yesterday be last oversee janet yellen post be set be take powell day federal open market committee fomc policy statement follow meeting end jan fed indicated economic activity have increase solid rate continue grow moderate pace additionally statement labor market remain strong inflation likely move reach desire rate medium term fomc also say federal fund rate be likely increase gradual pace come month star performer januaryi run screen research wizard company follow parameter click here sign free trial research wizard today percentage price change last week greater equal forward price earning ratio current financial year less equal pick stock be good value choicesexpect earning growth current financial year greater equal zack rank less equal ascertain stock have show average return last year see performance zack portfolio strategy here zack performance here be top stock make screen have zack rank buy see complete list today zack rank strong buy stock here kemet corporation kem free report subsidiary be manufacturer seller passive electronic component price gain last week kemet expect earning growth current year be more stock have onemain holding inc omf free report be consumer financial service hold company price gain last week expect earning growth current year onemain holding have ichor holding ltd ichr free report be engage design engineering manufacturing critical fluid delivery subsystem semiconductor capital equipment price gain last week expect earning growth current year ichor holding have petroleo brasileiro pbr free report petrobra be largest integrate energy firm brazil largest latin america price gain last week expect earning growth current year petrobra have amtrust financial service inc afsi free report be largest specialty property casualty insurer unite state provide insurance coverage small business product high volume price gain last week expect earning growth current year amtrust financial service have benchmark breach more record february investor have have little worry recent specter rise bond yield situation have be exacerbate grow prospect rate hike march higher rate environment optimism steady economic growth higher inflation have weigh bond price send yield higher however effective signale part fed be likely result investor pricing decision well hike actually take place ultimately strong fourth quarter earning season steady economic growth be likely propel market new milestone week ahead wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2139,ABBV,gilead science inc gild free report be schedule report fourth quarter result feb market close gilead leader hepatitis virus hcv space have mixed track record company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quote gilead stock have rally year compare industry gain factor playconcurrent third quarter earning call gilead update annual guidance gilead expect net product sale range provide earlier hcv product sale be project earlier projection strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue fourth quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy strong uptake truvada use pre exposure prophylaxis set be also expect boost sale zack consensus estimate sale genvoya be however gilead lose exclusivity viread country outside unite state impact sale hcv product sale be project earlier projection hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie inc abbv free report viekira pak viekira xr other patient start have exceed expectation competition have start erode gilead market share net pricing company see impact third quarter most be due be experience fourth quarter zack consensus estimate sale lead hcv drug sovaldi harvoni be respectively hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent meanwhile kite acquisition be step right direction fda approval chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma however management state yescarta launch be controlled launch ensure patient safety car therapy be complicate sometimes be associate severe side effect expect management throw more light same fourth quarter call investor be also likely keep eye other pipeline update earning whispersour proven model do not conclusively show gilead beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp gilead be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank sell be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be health care stock want consider model show have right combination element post earning beat quarter alexion pharmaceutical inc alxn free report be schedule release fourth quarter result feb company have earning esp zack rank see complete list today zack rank stock here anthera pharmaceutical inc anth free report be expect release fourth quarter result feb company have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2140,ABBV,acquisition once again remain focus week ablynx agree be acquire sanofi sny free report deal worth approximately seattle genetic sgen free report also announce intention acquire cascadian therapeutic meanwhile earning result be focus abbvie abbv free report report strong quarter provide upbeat outlook recap week most important storiesa look earning result company celgene celg free report abbvie biogen vertex vrtx free report report fourth quarter result last trading session celgene read more celgene earning sale beat solid revlimid vertex top earning well revenue estimate biogen top revenue miss earning read more biogen earning miss sale top view upbeat vertex also announce have select next generation corrector vx vx move late stage development part different triple combination regimen person cystic fibrosis cf last year vertex share be compare gain record industry belong abbvie share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret read more abbvie soar result key takeaway earning call abbvie be zack rank buy stock see complete list today zack rank strong buy stock here ablynx be acquire sanofi belgium base biopharma company ablynx have agree be acquire french pharma giant sanofi price share cash approximately announcement come just few week nordisk have announce interest acquire ablynx deal value approximately ablynx have reject nordisk offer company board say proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity company have more program pipeline nanobody clinical development acquisition be expect close end second quarter read more sanofi buyout spree month buy ablynx bellicum fda clinical hold bellicum pharmaceutical share be almost follow company announcement fda have place clinical hold study be conduct bpx hold be place case encephalopathy be deem possibly connect bpx company say case be complex certain factor prior fail transplant prior history concurrent infection administration rimiducid combination other medication bellicum be now wait receive formal notice fda step need be take resumption study clinical hold not impact ongoing registration study europe seattle genetic boost pipeline cascadian acquisition seattle genetic announce be acquire cascadian therapeutic share cash acquisition slate close first quarter seattle be add tucatinib pipeline tucatinib be investigational oral small molecule tyrosine kinase inhibitor tki be highly selective growth factor receptor be overexpressed several cancer include breast colorectal ovarian gastric candidate be currently pivotal phase ii program metastatic breast cancer complement seattle exist pipeline biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion decline gilead gild free report gain last month biogen be regeneron lose next biotech world watch amgen amgn free report fourth quarter result be market close today read more amgen benefit growth drug earning meanwhile fda be expect issue decision regard label expansion amag pharmaceutical feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2141,ABBV,galapago nv glpg free report announce positive top line datum phase ib study evaluate osteoarthritis oa candidate glpg candidate reduce level args neoepitope cartilage breakdown biomarker more half highest dosage share company have rise past year outperform industry decline period phase ib study evaluate dose glpg versus placebo period week glpg reduce level args neoepitope low medium high dose respectively compare placebo glpg work target adamts cartilage degrading enzyme meanwhile galapago be work design phase ii program further evaluate candidate oa study be expect start end year apart glpg galapago be also develop candidate filgotinib sjogren syndrome infectious uveitis ankylose spondylitis psoriatic arthritis company have global collaboration gilead science inc gild free report development filgotinib inflammatory indication moreover galapago be develop glpg cystic fibrosis cf patient be long term stable treatment vertex pharmaceutical incorporate vrtx free report cf drug kalydeco november last year galapago announce positive top line datum phase ii study demonstrate improvement lung function compare baseline company have cf candidate include glpg be be develop partnership abbvie inc abbv free report galapago nv price galapago nv price galapago nv quotegalapago carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
2142,ABBV,abbvie inc abbv free report share be expect be northbound carry momentum achieve last year stock be compare favorably gain record industry abbvie carry zack rank buy see complete list today zack rank strong buy stock here last year share price surge be support series positive news abbvie meet primary endpoint several pivotal study key phase iii murano study venclexta roche rhhby free report rituxan relapse refractory chronic lymphocytic leukemia phase iii study evaluate oral jak selective inhibitor upadacitinib rheumatoid arthritis also phase iib study atopic dermatitis pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara humira moderate severe chronic plaque psoriasis meanwhile abbvie gain regulatory approval unite state europe japan competitive hcv medicine mavyret fda approval sixth indication cancer drug imbruvica abbvie also settle patent dispute amgen amgn free report delay launch latter biosimilar version abbvie blockbuster arthritis drug humira unite state most country eu october agreement have remove major overhang abbvie share moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market factor likely support rally several pivotal datum readout regulatory milestone expect bullish run stock continue important catalyst stock be datum pivotal phase iii trinity study rova third line later small cell lung cancer sclc first half year important regulatory milestone be fda decision elagolixin second quarter please note new drug application nda elagolix endometriosis be grant priority review fda october last year importantly humira have be generate strong sale new competition abbvie raise long term target humira sale october base strong demand trend drug imbruvica abbvie second most important drug be also do consistently well have multibillion dollar potential abbvie be explore possibility label expansion solid tumor autoimmune disease factor bode well stock wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2143,ABBV,abbvie inc abbv free report be big mover last session company see share nearly day move come solid volume too far more share change hand normal session continue recent uptrend company stock be now past month time frame move come company report better expect fourth quarter result company have see change come estimate revision past few week zack consensus estimate current quarter have also remain unchanged recent price action be encourage so make sure keep close watch firm future abbvie currently have zack rank buy earning esp be positive abbvie inc price abbvie inc price abbvie inc quoteinvestor interested large cap pharmaceutical industry consider lundbeck hluyy free report have zack rank strong buy see complete list today zack rank stock here be abbv go predict see other think downzack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2144,ABBV,abbvie abbv free report share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret imbruvica continue witness strong uptake chronic lymphocytic leukemia cll indication humira performance be drive robust demand introduction new mechanism action competition indirect biosimilar meanwhile mavyret hepatitis virus hcv have be witness strong uptake unite state international market mavyret exit market share unite state be expect become major growth driver company rosy outlook company provide upbeat outlook reflect mavyret strong uptake continue robust underlie performance other product lower tax rate thank passage tax reform abbvie expect earning share range revenue almost mid point earning guidance range reflect year year growth improvement company previously provide guidance growth mid point provide third quarter result humira sale be expect grow approximately unite state ex sale be expect be company expect record imbruvica revenue more mavyret sale be expect cross other product venclexta androgel duodopa be expect record sale respectively creon sale be expect grow synagis lupron synthroid sale be expect remain flat zinbryta sale be expect come reflect impact competition label change cash repatriation capital deployment tax reform allow abbvie more efficient access foreign cash ability use unite state company intend invest capital unite state next year be currently evaluate additional expansion facility abbvie also intend accelerate pension funding enhance executive employee compensation company be also plan time shareable contribution select not profit organization support initiative such puerto rico rebuild effort child healthcare access program certain charity abbvie also say be increase shareholder return be combination acceleration dividend growth more share buyback detail be provide later company deal far deal be concern company key focus be opportunity drive growth timeframe abbvie say be look early stage asset catalyst rich abbvie spend be expect be sale reflect higher spending support late stage pipeline mid stage program addition work expand label approve product imbruvica venclexta abbvie late stage pipeline include candidate upadacitinib rheumatoid arthritis ra crohn disease risankizumab psoriasis crohn disease abbvie be look file regulatory approval risankizumab psoriasis indication first half year regulatory filing upadacitinib ra indication be expect second half meanwhile elagolix be priority review endometriosis response fda expect second quarter abbvie share be last year compare rally industry belong abbvie be zack rank buy stock see complete list today zack rank strong buy stock here week pharma company pfizer pfe free report eli lilly company lly free report nordisk nvo free report be report fourth quarter result pfizer have earning esp fourth quarter lilly nordisk have earning esp respectively earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time pfizer lilly be zack rank hold stock nordisk be zack rank stock uncover best stock buy sell re report earning esp filter zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2145,ABBV,friday october attempt get arm deluge earning report ahead final open bell trading week get first look gdp consensus estimate second consecutive handle follow final read mark first time economy have gdp number back back quarters particularly noteworthy number be do see negative impact gdp quarter hurricane harvey irma marium most notably consumer spending have ratchete previous quarter time gdp take basis point hit still reach illustrate economic strength power consumer inventory be be normal come do ahead holiday season perhaps surprisingly federal government spend more maybe most importantly zack chief strategist john blank point last week major economy world be currently experience recession growth be now global synchronize be very rare occurrence see geopolitical headwind americas europe asia pacific earning roll onaside big blowout beat yesterday close amazon amzn free report alphabet googl free report microsoft msft free report have already add additional market see more earning tonnage generally oil gas pharma bio sector exxonmobil xom free report share be modestly today pre market follow result surpass estimate top bottom line earning cent share top zack consensus cent revenue really outperformed expectation far exceed have be look mark fourth beat past quarters largest oil gas supermajor energy sector have struggle xom look be improve chevron cvx free report also beat estimate earning sale morning share surpass cent consensus revenue ahead expect outgoing ceo john watson retire early next year cite continue improvement earning cash flow supermajor refine company phillip psx free report post mixed today pre market earning share beating consensus estimate cent revenue fall short estimate company refine business more triple quarter offset quarter quarter midstream chemical marketing pharmaceutical major merck co mrk free report post share ahead zack consensus estimate however quarterly sale be short have be expect say merck up fiscal year earning guidance share last time morning follow initial bump pre market share be now trading more ahead bell also biopharma firm abbvie abbv free report have branch abbott lab beat earning estimate cent share revenue come basically line estimate lymphoma treatment imbruvica rise year year rheumatoid arthritis drug humira improve year quarter mark vickerysenior editorquestion comment article author click here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2146,ABBV,third quarter report cycle be witness revenue acceleration positive revision trend result third company member be already revenue beat ratio company be slightly precede quarter be unusually high compare historically total earning member have report already be same period last year higher revenue beating ep estimate accord latest earning preview report company account index total market capitalization report total earning company be expect grow year year higher revenue biotech pharma bigwig eli lilly company lly free report biogen inc biib free report amgen inc amgn free report have report third quarter result week company beat expectation earning sale lilly also raise earning sale outlook amgen slightly raise lower end previously issue sale outlook raise earning guidance back effective cost management however share biogen amgen decline follow result announcement concern regard biogen multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza hurt investor sentiment amgen year year decline sale lead share price fall here have large pharma company be set report third quarter result oct let see thing be shape quarter abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter lilly earning performance have be mixed earning breaking even last quarters beating same other bring average surprise quarter abbvie have earning esp almost zack rank hold zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter company key drug humira be likely remain main growth driver backed higher demand quarter abbvie expect humira sale rise high teen range internationally same be estimate increase mid single digit range operational basis other drug duopa creon be also expect continue perform well soon be report quarter read more abbvie spring surprise earning season abbvie inc price consensus abbvie inc price consensus abbvie inc quotemerck co inc mrk free report merck be schedule release earning market open merckhad deliver positive earning surprise last quarter company earning performance have be pretty impressive so far have deliver positive surprise last quarters average earning beat last quarters be company also have earning esp almost zack rank zack consensus estimate be peg share see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection be likely drive top line quarter keytruda sale unite state be gain particularly back strong momentum new indication first line lung cancer read more merck keep earning streak alive previous article show merck be likely beat earning quarter however estimate change thereafter be not certain beat earning season merck company inc price consensus merck company inc price consensus merck company inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2147,ABBV,biogen biib free report third quarter result surpass top bottom line expectation meanwhile gilead gild free report car therapy gain earlier expect fda approval alexion alxn free report also get regulatory boost fda expand label company flagship product soliris recap week most important storiesbiogen beat front biogen third quarter result be better expect company surpass earning revenue expectation share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza spinraza sale be third quarter more less flat second quarter sale company report increase number patient therapy unite state compare end second quarter however second quarter sale include inventory buildup read more biogen top earning sale spinraza sale biogen have gain year date outperform industry rally gilead car therapy yescarta approve gilead yescarta become part company portfolio follow kite pharma acquisition gain fda approval treatment adult patient relapse refractory large cell lymphoma more line systemic therapy make yescarta first chimeric antigen receptor cell car therapy gain approval use patient population yescarta be second gene therapy gain approval unite state first be novartis kymriah treatment come box warning regard risk cytokine release syndrome crs neurologic toxicity yescarta approval be major boost gilead be currently face decline sale hepatitis virus hcv franchise accord information provide company diffuse large cell lymphoma dlbcl be most common aggressive hodgkin lymphoma nhl patient refractory dlbcl be eligible car therapy year yescarta represent new treatment option patient have run treatment option face poor prognosis yescarta be launch list price unite state be currently review eu response be expect first half read more gilead car therapy yescarta clinch fda approval gilead also announce phase ii result investigational treatment nonalcoholic steatohepatitis nash company say higher dose mg gs oral acc inhibitor achieve significant reduction buildup fat liver noninvasive marker fibrosis timp compare placebo however statistical significance be not achieve other parameter liver stiffness fibroscan mre serum alt piii np serum marker fibrogenesis meanwhile difference lower dose mg gs placebo be not statistically significant celgene hit crohn disease study discontinuation celgene celg free report share be news company be discontinue study phase iii revolve study extension study sustain be conduct investigational crohn disease drug ged mongersen decision be base recommendation datum monitoring committee october follow interim futility analysis meaningful safety imbalance be observed analysis celgene also say review full dataset phase ii ulcerative colitis study ged decide path forward company not be initiate phase iii define study crohn disease read more celgene discontinue crohn disease drug study abbvie announce immuno therapy focuse deal abbvie abbv free report announce couple deal week deal be focuse immuno neurology other be focuse immuno oncology immuno neurology deal see abbvie collaborate alector use latter immuno neurology discovery platform innovative new therapy alzheimer disease other neurological disorder immuno neurology rapidly evolve scientific area be focuse harness power immune system attack disorder alzheimer disease development cost well profit be share equally company alector get upfront payment potential future equity investment meanwhile immuno oncology deal see abbvie team harpoon therapeutic use harpoon tri specific cell activate construct tritac platform abbvie research stage immuno oncology target develop cancer therapeutic read more abbvie inks immuno oncology deal harpoon therapeutic label expansion alexion soliris fda grant approval alexion use flagship product soliris eculizumab adult patient generalized myasthenia gravis gmg be achr antibody positive soliris already approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year gmg indication represent incremental growth opportunity soliris alexion be zack rank hold stock see complete list today zack strong buy rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow crohn disease update biogen be last month vertex vrtx free report be celgene be see last biotech stock roundup here exelixis soar priority review fda panel support spark drug next biotech world week company amgen amgn free report vertex alexion gilead celgene abbvie be report third quarter result zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
2148,ABBV,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale third quarter company revenue be drive continue strong performance newest drug spinraza spinal muscular atrophy better expect result biogen share be almost pre market trading be probably due fact sale multiple sclerosis franchise be expectation increasingly competitive market however note biogen share have gain so far year compare unfavorably industry increase third quarter earning share be comfortably beat zack consensus estimate earning also rally year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february year quarter detail biogen ms revenue be quarter include approximately royalty sale roche ms drug ocrevus tecfidera sale increase year period however drug record sequential drop revenue include sale ex sale unite state tecfidera inventory level third quarter be relatively flat compare year level hurt sale report quarter third quarter tysabri revenue be ex decrease year year sequentially believe ocrevus launch have put pressure tysabri sale quarter combine interferon revenue avonex plegridy third quarter be ex year period avonex revenue decline year period plegridy contribute third quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue third quarter sequentially newly launch spinraza bring revenue revenue third quarter register growth sequentially drug witness strong demand unite state company be work expand access patient quarter biogen record biosimilar revenue compare second quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare second quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period third quarter spend decrease report quarter sg spend decline year year collaboration month biogen announce restructure collaboration arrangement eisai neurimmune improve long term value alzheimer candidate aducanumab be presently phase iii study concurrent earning release biogen announce renegotiation agreement neurimmune make time payment exchange reduction neurimmune royalty rate potential sale aducanumab re negotiate deal thus increase aducanumab profit potential oct biogen partner eisai refine exist alzheimer collaboration biogen already have agreement eisai develop phase iii bace inhibitor phase ii amyloid beta antibody ban alzheimer disease however biogen have announce eisai have exercise option jointly develop commercialize aducanumab company now receive aducanumab potential profit unite state europe japan biogen inc price consensus ep surprise biogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2149,ABBV,abbvie inc abbv free report be schedule release third quarter earning oct open bell abbvie share have soar so far year industry have record increase last quarter company deliver positive surprise notably abbvie earning history be mixed bag pharmaceutical company beat estimate last quarters record line earning other quarter average beat be abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quotelet see thing be shape company quarter factor considerabbvie expect third quarter earning range share revenue be estimate grow approximately operational basis foreign exchange be not expect impact sale third quarter company key drug humira be likely remain main growth driver third quarter backed higher demand quarter abbvie expect humira sale rise high teen range internationally sale be estimate increase mid single digit range operational basis zack consensus estimate humira be third quarter significantly cancer drug imbruvica record strong sale past few quarters trend expect continue quarter be report imbruvica be approve fda treat adult patient chronic graft versus host disease cgvhd disease failure more line systemic therapy imbruvica expand label also contribute sale growth company expect drug sale growth approach third quarter zack consensus estimate imbruvica be quarter other drug duopa creon be also expect continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue be adversely impact intense pricing competitive pressure hcv market notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada earlier july august company believe maviret have potential rejuvenate growth hcv franchisea compare competitive dynamic hcv market expect management update plan maviret conference call maviret be expect contribute considerably revenue only onward company have make significant progress pipeline quarter be focus investor keep tab abbvie partner roche rhhby free report announce positive datum phase iii murano study venclexta rituxan september expand label address broader relapse refractory cll chronic lymphocytic leukemia patient population label expansion indication increase patient population venclexta significantly boost commercial potential also same month company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra rheumatoid arthritis additionally abbvie partner neurocrine bioscience announce new drug application nda elagolix have be submit fda september abbvie be look get elagolix approve oral medicine pain management associate endometriosis earning whispersour proven model do not conclusively show abbvie be likely beat earning quarter be stock need have positive earning esp bullish zack rank strong buy buy hold happen be not case here see zack esp abbvie have earning esp most accurate estimate zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter zack rank abbvie zack rank increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model have right combination element beat earning quarter merck company inc mrk free report be schedule release result oct zack rank company have earning esp see complete list today zack rank stock here pfizer inc pfe free report be schedule release result oct company have earning esp also carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2150,ABBV,novartis ag nvs free report report encourage result third quarter earning revenue beat estimate drive strong performance cosentyx entresto third quarter core earning share beat zack consensus estimate be record year quarter revenue increase volume growth drive cosentyx entresto be partially offset negative impact generic competition pricing revenue also beat zack consensus estimate novartis stock have rally year date compare industry gain growth rate mentioned be year year basis constant exchange rate quarter detailnovartis operate segment innovative medicine pharmaceutical alcon ophthalmology unit sandoz generic innovative medicine division record sale generic competition impact sale segment primarily due entry generic gleevec unite state europe nevertheless growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya boost sale psoriasis cosentyx sale surge back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state oncology franchise exclude gleevec grow drive mainly promacta revolade jakavi tafinlar mekinist sale sandoz division be volume growth be offset price erosion unite state sale unite state decline due pricing pressure sale grow mainly drive zarxio unite state launch rixathon biosimilar version roche holding inc rhhby free report rituxan rituximab erelzi biosimilar amgen inc amgn free report enbrel eu sale alcon division be surgical sale increase drive broad recovery most market segment include strong growth vitreoretinal product vision care sale be fuel continue double digit growth daily total earlier novartis announce be mull strategic option lag eye care unit alcon include retain business separation capital market transaction such spin initial public offer company update strategic plan announce have potential grow sale market deliver profitability line industry company also make significant progress develop potential capital market solution include financial carve out tax legal entity structuring identify list incorporation location final decision be take depend alcon sale performance be not likely happen first half meanwhile novartis move ophthalmic otc product alcon division effective jan allow innovative medicine division focus pharmaceutical pipeline however ophthalmic prescription business remain innovative medicine division outlook expect net sale be broadly line level include impact continue genericization gleevec glivec unite state europe management have earlier estimate impact generic competition sale be approximately novartis ag price ep surprise novartis ag price ep surprise novartis ag quotepipeline updatenovartis pipeline candidate progress have be encourage oncology portfolio continue gain traction significant boost fda approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah have be launch unite state breast cancer drug kisqali be approve europe first line option hr advanced metastatic breast cancer combination inhibitor drug be already approve unite state company also receive approval rydapt europe treatment newly diagnosed flt mutate acute myeloid leukemia type systemic mastocytosis meanwhile fda accept novartis regulatory application amg erenumab filing prevention migraine patient experience more migraine day month fda also accept supplemental new drug application tasigna grant priority review snda seek addition attempt treatment free remission drug label other hand tafinlar mekinist receive breakthrough therapy designation adjuvant melanoma sandoz propose biosimilar roche rituxan be accept regulatory review fda propose biosimilar version abbvie inc abbv free report humira adalimumab match reference drug term efficacy safety week clinical study biosimilar be currently review eu treatment several immunological disease takenovartis third quarter result beat earning sale estimate strong performance cosentyx entresto generic division sandoz also combat pricing pressure strongly buoy biosimilar launch rixathin erelzi first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2151,ABBV,gilead science inc gild free report report third quarter result earning revenue surpass expectation however stock be expect open red give decline hepatitis virus hcv franchise nevertheless gilead stock have gain year date industry decline company third quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue top zack consensus estimate however revenue decline year year hiv impress yet again harvoni sovaldi plungesproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi epclusa vosevi be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch sale vosevi approve unite state europe july sale harvoni decline year year report quarter further sovaldi sale record steep year year decline epclusa garner sale report quarter year figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline respectively viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline other hand selling general administrative sg expense increase adjust product gross margin be compare year period guidance updatedgilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project earlier projection cent kite company recently acquire kite pharma last week company receive fda approval yescarta car therapy treatment adult patient relapse refractory large cell lymphoma more line systemic therapy dividend share gilead declare cash dividend cent share common stock fourth quarter dividend be payable dec stockholder record close business dec quarter company paid cash dividend repurchase share company top earning revenue estimate third quarter witness decline hcv sale hcv franchise be tremendous pressure due lower patient start increase competition expect sale decline further go forward note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other competition well pricing pressure have intensified further launch merck co inc mrk free report zepatier only patient begin treatment gilead regimen quarter prior quarter meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen unite state eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set further boost sale company see significant uptick prep usage estimate patient used truvada end third quarter approval yescarta also bode well gilead however gilead have lose exclusivity viread truva further impact performance expect decline hcv franchise offset positive momentum hiv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2152,ABBV,north chicago il base abbvie inc abbv free report be best know autoimmune disease drug humira abbvie flagship product humira be approve several indication rheumatoid arthritis moderate severe moderately severely active polyarticular juvenile idiopathic arthritis active psoriatic arthritis active ankylose spondylitis crohn disease moderate severe ulcerative colitis moderate severe axial pediatric crohn disease chronic plaque psoriasis moderate severe hidradenitis suppurativa moderate severe other key product include imbruvica cancer viekira pak hepatitis virus hcv treatment humira be major contributor abbvie top line humira remain key growth driver abbvie come quarters see investor focus remain primarily viekira performance well pipeline update meanwhile pharmacyclic acquisition have diversify abbvie product portfolio addition imbruvica abbvie performance have be mixed pharmaceutical company deliver positive surprise past quarter record line earning other average earning beat last quarters be currently abbvie have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning abbvie third quarter earning come share beating zack consensus estimate revenue abbvie post revenue line zack consensus estimate key stat humira sale come year year exclude currency impact third quarter imbruvica net revenue be year year outlook abbvie update outlook company raise adjust ep range compare expect previously zack consensus estimate be currently peg share share price impact share be more pre market trading check back later full abbvie earning report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2153,ABBV,be big week earning company expect report include many dow industrial company addition top technology titan be also handful other company keep eye company be everyone list be breaking be widely hold just have fantastic earning track record not easy beat earning consensus quarter year company be do just earning report watch baidu bidu free report hasn miss share have be stick narrow trading range have recently bust new year high build even more momentum earning beat abbvie abbv free report have miss only once spin abbott lab share have soar healthcare stock be favor continue hit new high expedia expe free report have miss quarters row share be still trading year high do miss beat matter company colgate palmolive cl free report have only miss once last year share aren go anywhere consumer product company remain favor columbia sportswear colm free report be dread retail sector so share have be stick have great earning track record just miss last year want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2154,ABBV,vertex pharmaceutical incorporate vrtx free report report third quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter vertex report revenue third quarter almost year year drive strong product revenue revenue also beat zack consensus estimate cf franchise sale strongvertex third quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be third quarter year year kalydeco sale rise follow approval treat expand population kalydeco be approve use cf patient year older have residual function mutation cftr gene more person unite state have mutation expand indication boost sale drug future quarters august kalydeco be approve cf patient year older have residual function mutation result splice defect cftr gene occur more patient orkambi lumacaftor ivacaftor deliver sale year year growth be support continue uptake pediatric patient unite state additional revenue european country vertex have sign reimbursement agreement cost riseadjust research development expense increase third quarter due higher cost related development triple combination cf regimen adjust selling general administrative sg expense increase due increase investment support global orkambi kalydeco guidance raisedvertex increase guidance orkambi kalydeco sale however maintain guidance combine operate cost orkambi revenue be expect range previously kalydeco revenue be estimate range previously total cf product revenue be expect range note increase orkambi sale projection be base strong demand see so far year projection kalydeco be increase follow strong demand newly approve indication combine adjust research development selling general administrative sg expense be still anticipate range focus next generation cf regimensvertex tezacaftor ivacaftor combination treat cf patient be review unite state europe company be seek approval person cf age older have copy del mutation del mutation residual function mutation decision be expect february next year unite state approval europe be expect second half concurrent press release company announce datum phase iii study evaluate combination cf patient copy del mutation copy gate mutation study have fail meet primary endpoint absolute change percent predict force expiratory volume second ppfev measure lung function vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination vx tezacaftor ivacaftor follow discussion regulatory agency vertex initiate pivotal phase iii study triple combination regimen first half other cf pipeline updatevertex epithelial sodium channel enac inhibitor candidate vx be be evaluate phase ii study cf patient be be treat orkambi press release study do not meet primary endpoint change ppfev phase ii study be develop vx treat patient primary ciliary dyskinesia takevertex third quarter result be encourage company beat estimate count sale cf drug rise share decline slightly hour trading probably due failure pivotal tezacaftor ivacaftor study however so far year vertex share price be massive compare favorably increase industry vertex cf pipeline be quite strong broad portfolio next generation cf corrector triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient future however competition be increase several major company be develop interest cf belgian company galapago nv glpg free report abbvie inc abbv free report be also develop triple cftr combination therapy cf threat vertex triple combo regimen vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotevertex carry zack rank hold better rank stock health care sector be adaptimmune therapeutic plc adap free report carry zack rank buy see complete list today zack rank strong buy stock here adaptimmune loss estimate narrow cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2155,ABBV,bristol myer squibb company bmy free report third quarter earning cent share fall short zack consensus estimate well year quarter earning cent however total revenue come ahead zack consensus estimate well record year period strong sale opdivo eliquis contribute top line report quarter share company be pre market trading presumably due lower expect earning bristol myer share have increase so far year compare unfavorably industry increase quarterly detailsrevenue be year year adjust foreign exchange impact revenue unite state increase increase outside unite state ex revenue be adjust foreign exchange impact leukemia drug sprycel rake sale year year melanoma drug yervoy contribute top line report quarter opdivo be approve multiple cancer indication generate revenue year period drug receive approval label expansion more indication include hepatocellular carcinoma metastatic colorectal cancer recurrent gastric cancer however performance key drug virology unit continue disappoint sale baraclude decline reyataz sustiva franchise deteriorate year year respectively nevertheless sale eliquis be report quarter year year multiple myeloma drug empliciti record sale year year research development expense quarter increase mainly due charge related acquisition ifm therapeutic marketing selling administrative expense remain flat gross margin be quarter compare year quarter due change product mix recognition inventory charge september bristol myer complete acquisition outstanding capital stock ifm gain full right ifm preclinical sting nlrp agonist program enhance body immune response treat cancer moreover company sign global collaboration license agreement halozyme therapeutic develop subcutaneous administration immuno oncology medicine used halozyme enhanze drug delivery technology quarter bristol myer enter multiple collaboration develop opdivo combination antibody drug conjugate parp inhibitor tyrosine kinase inhibitor several tumor type include daiichi sankyo investigational candidate ds abbvie inc abbv free report abbv exelixis inc exel free report cabometyx clovis oncology inc clvs free report rubraca pipeline updatein september bristol myer announce datum phase iii study checkmate show significant improvement recurrence free survival stage iiib stage iv melanoma treat opdivo yervoy combination compare yervoy alone meanwhile phase iii study checkmate be stop early opdivo yervoy achieve superior overall survival compare current standard care sunitinib study be conduct previously untreated patient advanced metastatic renal cell carcinoma however study be place partial clinical hold evaluate opdivo base combination patient relapse refractory multiple myeloma hold be place base risk observed study evaluate pd agent pembrolizumab multiple myeloma patient earning guidance revisedbristol myer have raise adjust earning expectation company now project earning range share old guidance zack consensus estimate earning be peg takebristol myer miss earning expectation primarily due increase expense however robust sale drug opdivo eliquis yervoy quarter drive top line revise guidance be also encourage meanwhile be positive bristol myer effort develop pipeline especially opdivo bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotebristol myer carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2156,ABBV,leader hepatitis virus hcv space gilead science inc gild free report be expect beat expectation report third quarter result oct market close gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead stock have gain year date industry strong performance third quarter boost share price performance further likely positive surprise proven model show gilead be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg penny lower uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quote factor playconcurrent second quarter earning call gilead update annual guidance base better expect performance first half specifically unite state company raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project cent earlier projection cent strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment naïve patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale however gilead lose exclusivity viread country outside unite state impact sale meanwhile hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie inc abbv free report viekira pak viekira xr other higher discount payer mix continue impact sale adversely company increase guidance hcv franchise zack consensus estimate lead hcv drug sovaldi harvoni currently stand third quarter hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult other hand expect company increase guidance further incremental contribution recent kite pharma acquisition fda recently approve chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma expect management throw more light same third quarter call investor be also likely keep eye other pipeline update other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release third quarter result oct see complete list today zack rank stock here glaxosmithkline plc gsk free report have earning esp zack rank company be schedule release third quarter result oct make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2157,ABBV,eli lilly company lly free report report fourth quarter adjust earning share beat zack consensus estimate share earning rise year quarter backed higher operate profit revenue beatquarterly revenue also beat zack consensus estimate sale grow year year backed strong performance new drug favorable currency movement lesser extent partially offset lower sale establish product strattera humalog ciali effient lilly establish product portfolio record decline worldwide revenue volume rise strong performance new product trulicity taltz basaglar jardiance lartruvo offset decline sale establish product higher realize price several drug also contribute sale growth quarter foreign exchange rate also hada favorable impact segment revenue rise quarter backed volume growth new product revenue grow ex revenue rise establish product record growth quarter include forteo humulin cymbalta erbitux sale other establish product decline quarter humalog sale decline due lower realize price unite state moreover december fda approve sanofi sny free report admelog biosimilar version humalog approval certainly increase competition alimta sale decline reflect lower demand ex market due competitive pressure loss exclusivity certain country however sale alimta increase unite state due increase volume partially offset lower realize price zyprexa sale decline due loss exclusivity japan ciali sale decline hurt worldwide lower demand strattera sale decline effient sale decline quarter drug see lower demand due loss exclusivity new product trulicity generate revenue year year revenue benefit growth glp market market share gain cyramza revenue be year year backed strong demand cyramza ex revenue increase benefit strong volume japan partially offset lower realize price revenue increase drive increase volume jardiance sale be drive increase market share grow sglt class unite state increase volume outside unite state basaglar record revenue compare previous quarter basaglar lilly partner boehringer ingelheim follow insulin sanofi blockbuster drug lantus be launch unite state mid december taltz bring sale compare previous quarter reflect strong uptake december drug be approve psoriatic arthritis launch unite state european commission also approve drug last week lartruvo olaratumab generate revenue fourth quarter compare previous quarter lartruvo be launch unite state eu soft tissue sarcoma fourth quarter lilly partner incyte corporation incy free report rheumatoid arthritis drug olumiant baricitinib have be launch select european country japan drug generate sale fourth quarter compare previous quarter backed strong launch uptake germany however unite state lilly receive complete response letter fda baricitinib april want additional datum company have re submit application late verzenio be launch unite state fourth quarter generate sale lilly elanco animal health segment sale decline due decrease food animal revenue however companion animal revenue increase include revenue acquisition boehringer ingelheim vetmedica feline canine rabies vaccine portfolio acquire january be offset competitive pressure lower demand unite state gross margin operate income risesadjust gross margin quarter decrease basis point manufacturing efficiency be offset negative product mix effect foreign exchange rate international inventory sell operate income increase year year total operate expense percent revenue decline basis point quarter ep guidance uppedlilly raise previously issue adjust earning outlook adjust earning share be now expect range compare expect previously reflect positive impact tax reform however revenue be still expect range gross margin be expect be approximately same previously expect adjust tax rate be expect be approximately previously approximately marketing selling administrative expense be still expect range research development expense be project be takelilly fourth quarter result be strong company beating estimate count meanwhile expectation lower tax rate due new tax law propel company raise earning outlook share be pre market trading lilly share price have rise past year compare increase industry go forward new product trulicity taltz basaglar cyramza jardiance lartruvo be expect see higher revenue lilly be also progress well pipeline fda approval taltz line extension also boost lilly product revenue october lilly have announce be look sell spin elanco animal health business potential sale underperform animal health segment help improve margin however alimta continue be impact competition other headwind include competition immuno oncology agent well loss exclusivity many drug emerge market eli lilly company price consensus ep surprise eli lilly company price consensus ep surprise eli lilly company quote zack rank stock considerlilly carry zack rank hold better rank stock pharma sector be abbvie inc abbv free report carry zack rank buy see complete list today zack rank strong buy stock here abbvie earning estimate increase last day company come positive surprise trail quarters average beat stock be past year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2158,ABBV,anthem inc antm free report fourth quarter adjust net income share surpass zack consensus estimate bottom line however decline year year company adjust net income come share last year operate revenue surpass zack consensus estimate top line also grow year year due premium rate increase well higher enrollment medicaid medicare local group insure self funded business upside be partially offset impact year waiver health insurance tax operate revenue come year year quarterly operational updatemedical enrollment increase year year member rise be primarily drive commercial specialty business enrollment growth government business also contribute appreciation upside be partially offset decline membership national account individual business total expense increase nearly report quarter mainly due rise benefitexpense increase selling general administrative sg expense year year basis anthem benefit expense ratio deteriorate basis point bps prior year quarter be largely due year waiver health insurance tax however deterioration be partially offset improve medical cost performance individual local group business sg expense ratio improve bps year quarter be due year waiver health insurance tax impact fix cost leverage operate revenue growth however decline be partially offset increase spend support growth initiative quarter segment specialty businessoperate revenue be fourth quarter year year operate gain totale year year due increase spend support growth initiative impact year waiver health insurance tax decrease be partially offset improve medical cost performance local group individual business operate margin be bps year year government businessoperate revenue be fourth quarter prior year quarter operate gain be year year downside reflect increase spend support growth initiative quarter impact year waiver health insurance tax however deterioration be partially offset improve medical cost performance medicaid business operate margin be decline bps year year other operate revenue be fourth quarter prior year quarter segment report operate loss narrower operate loss prior year quarter improvement be primarily drive lower expense related terminate cigna acquisition operate margin be bps year year anthem inc price consensus ep surprise anthem inc price consensus ep surprise anthem inc quotefinancial updatea dec anthem have cash cash equivalent year end dec long term debt increase year end dec shareholder equity be year end operate cash outflow be fourth quarter bring full year operate cash flow time net income also reflect year year growth fourth quarter anthem record time cash defer tax benefit corporate tax reform reduce total income tax expense share repurchase dividend updatedure quarter anthem repurchase share common stock repurchase share common stock dec have approximately share repurchase authorization remain fourth quarter anthem paid quarterly dividend cent share jan board declare dividend cent share first quarter reflect hike dividend be paid mar shareholder record mar guidance anthem expect adjust net income be greater share medical membership be now expect range operate revenue be project range benefit expense ratio be expect be adjustment bps sg ratio be expect be adjustment expect operate cash flow be more zack rank performance other sport zack rank strong buy see complete list today zack rank stock here other player medical sector have report fourth quarter earning so far abbvie inc abbv free report unitedhealth group incorporate unh free report abbott laboratory free report have surpass respective zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2159,ABBV,abbvie inc abbv free report report impressive result fourth quarter company surpass earning revenue estimate period importantly raise earning expectation response share climb almost pre market trading abbvie share have soar year time significantly outperform industry rally company report fourth quarter earning share beating zack consensus estimate bottom line grow year year earning also surpass previous expectation company post revenue report quarter marginally beating zack consensus estimate top line also increase year year exclude favorable impact foreign exchange rate fluctuation operational revenue jump revenue report higher growth compare previously expect rise operational basis quarter detailkey drug humira record sale growth operational basis revenue come sale unite state increase humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market fourth quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product have deliver impressive performance include duodopa show revenue growth operational report basis product call creon witness ascent revenue operational report basis hcv chronic hepatitis virus product record sale significantly operational report basis respectively adjust sg expense inched expense escalate quarter adjust operate margin be sale report quarter resultsfull year sale jump year year sale outpaced zack consensus estimate revenue growth be slightly higher previous expectation earning share exceed zack consensus estimate full year bottom line reflect growth compare year figure moreover report earning be slightly higher past projection outlookabbvie raise adjust ep range compare predict earlier earning guidance reflect year year surge mid point zack consensus estimate current year earning be peg share abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quote zack rank key picksabbvie carry zack rank hold better rank stock health care sector be nordisk nvo free report sucampo pharmaceutical inc carry zack rank buy see complete list today zack rank strong buy stock here nordisk earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat company share price have surge year sucampo earning share estimate have moved north last day company pull positive earning surprise last quarters average beat company share price have soar year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2160,ABBV,abbvie inc abbv free report announce have enter immuno oncology research collaboration small biotech harpoon therapeutic inking immuno oncology research collaboration deal aim generate novel cell engager treatment cancer base combination harpoon tri specific cell activate construct tritac molecule abbvie research stage immuno oncology target agreement harpoon provide abbvie right pursue further development tritac molecule abbvie share have outperformed industry year date stock have surge compare industry gain last week abbvie enter research option license agreement clinical stage immuno oncology company turnstone biologic abbvie obtain exclusive option license turnstone next generation oncolytic viral immunotherapy agreement abbvie have option obtain global development right turnstone biologic ad mg magea therapy turnstone ad mg magea therapy be couple phase ii study different solid tumor indication alone well combination approve pd checkpoint inhibitor abbvie continue work expand accelerate presence oncology build grow position hematological oncology acquistion cancer drugmaker stemcentrx april abbvy gain late stage candidate rovalpituzumab tesirine rova additional early stage compound solid tumor indication significant portfolio pre clinical asset rova be currently registrational study small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing datum pivotal phase iii trinity study rova third line later sclc be expect year accord abbvie candidate have blockbuster potential be launch abbvie intend study candidate additional indication estimate peak sale close abbvie be also study market cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy abbvie inc price abbvie inc price abbvie inc quotezack rank other stock considerabbvie sport zack rank hold better rank stock health care sector include ligand pharmaceutical inc lgnd free report adaptimmune therapeutic plc adap free report nordisk nvo free report ligand hold zack rank adaptimmune nordisk carry zack rank buy see complete list today zack rank stock here ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date adaptimmune loss share estimate have narrow cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date nordisk earning share estimate have moved last day company come positive earning surprise trail quarters average beat share price company have increase year date wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2161,ABBV,pfizer inc pfe free report announce fda have approve ixifi second biosimilar version johnson johnson jnj free report blockbuster rheumatoid arthritis ra drug remicade infliximab notably ixifi be chimeric human murine monoclonal antibody tumor necrosis factor ixifi receive nod approve indication remicade include ra ulcerative colitis plaque psoriasis psoriatic arthritis ankylose spondylitis crohn disease share pfizer have rise so far year underperform industry rally approval be base encourage datum phase iii study reflection biologic license application be file fda april notably february pfizer have divest right development manufacturing ixifi european economic area eea novartis generic arm sandoz however pfizer retain manufacturing right ixifi country outside eea remind investor pfizer first biosimilar product remicade inflectra be launch last november unite state company have exclusive right inflectra unite state certain other territory september pfizer file lawsuit district court allege be resort unfair practice prevent sale inflectra available wholesale acquisition cost be lower reference product pfizer allege complaint file district court eastern district pennsylvania have enter biosimilar exclusion contract insurer contract boost insurer not cover inflectra thus make difficult access patient protect reference product pfizer also claim anticompetitive contract discount be offer hospital purchase remicade condition do not buy biosimilar version pfizer claim unfair practice benefit sale reference product key revenue generator latter pfizer be evaluate biosimilar molecule various stage development biosimilar product late stage development include biosimilar version roche rhhby free report rituxan avastin abbvie abbv free report humira biosimilar version herceptin be review unite state eu europe pfizer market nivestim biosimilar version amgen neupogen retacrit well biosimilar version amgen epogen pfizer inc price pfizer inc price pfizer inc quotezack rankpfizer carry zack rank hold see complete list today zack rank strong buy stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
2162,ABBV,abbvie inc abbv free report announce fourth pivotal phase iii study evaluate investigational il inhibitor risankizumab treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint top line datum immhance study show significant portion patient treat risankizumab achieve high level skin clearance nearly half patient treat risankizumab achieve complete skin clearance versus placebo week treatment continuous treatment risankizumab week risankizumab patient maintain response year datum show patient achieve better disease improvement time continuous treatment risankizumab rather withdraw therapy initial response result study support regulatory filing candidate week result study be present international congress psoriasis gene clinic meeting london abbvie have license risankizumab boehringer ingelheim abbvie be responsible future development candidate remind investor october abbvie have announce pivotal head head phase iii study evaluate risankizumab versus johnson johnson jnj free report stelara abbvie humira treatment moderate severe chronic plaque psoriasis meet co primary secondary endpoint top line datum present study show risankizumab achieve significantly greater response clear almost clear skin versus stelara humira placebo week treatment risankizumab be also be evaluate phase ii study other immunological disorder crohn disease psoriatic arthritis abbvie share have gain so far year compare favorably gain only record industry share price surge be support series positive news past few month abbvie present promising datum several pivotal study gain regulatory approval unite state europe japan competitive hcv medicine mavyret receive fda approval sixth indication imbrivicaand settle humira patent dispute amgen inc amgn free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here better rank large cap pharma stock be lundbeck hluyy free report carry zack rank buy share lundbeck have rise so far year earning estimate have go past day look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2163,ABBV,year world aids day be celebrate dec raise public awareness acquire immuno deficiency syndrome popularly know aids day be observed make person aware proper cure prevention disease regard year theme day year be right health day also commemorate have die aids related illness world aids day be official global public health campaign marked world health organization accord globally person be suffering hiv aids end total be child less year old aids be pandemic disease cause due infection human virus hiv virus weaken immune system destroy cell fight disease infection eventually lead aids medicine treatment hiv be call antiretroviral therapy art slow put check progression virus currently company be investigate new medicine treat prevent ultimately cure hiv scientist also be explore new treatment paradigm drug regimen make therapy drug drug improve long term safety profile new mechanism action improve medical understand hiv significant effort make lead government medical body prevent treat hiv aids disease still have limit treatment option person die aids related illness totale start epidemic base statistic be not surprising several healthcare company be investing significant amount expenditure develop treatment device hiv aids stock watch world aids day here be key pharma company hiv market investor rely glaxosmithkline gsk free report have long standing commitment hiv aids company have develop widely used antibiotic amoxycillin year be first medicine approve treat hiv sale older hiv product epzicom selzentry have be decline however newer hiv drug triumeq tivicay be witness consistent increase sale gain market share meanwhile significant portion expenditure be be used develop hiv medicine treat prevent hiv last week glaxo partner johnson johnson announce fda approval juluca combination glaxo edurant dolutegravir tivicay rilpivirine single tablet treatment hiv most medicine hiv treatment be make more antiretroviral drug juluca be first drug regimen be approve reduce number medicine hiv patient take compromise efficacy conventional drug regimen week viiv healthcare hiv company majorly own glaxo pfizer pfe free report announce start large late stage african study evaluate long act prevention hiv sexually active woman approve cabotegravir injection be administer month opposed presently available oral retroviral medication need be take day already viiv healthcare have start conduct hptn study cabotegravirin hiv uninfected man transgender woman have sex man co funding national institute allergy infectious disease niaid meanwhile cabotegraviris also be evaluate late stage study drug regimen withedurant third study initiation announce earlier week furthermore glaxo be develop drug regimen ofdolutegravir lamivudine gilead gild free report be dominant player hiv market impressive portfolio fact gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera company be first introduce single tablet regimen str treatment hiv atripla gilead other strs hiv include complera eviplera stribild taf base product genvoya happen be bestseller surpass truvada atripla fourth quarter currently gilead bictegravir single table regimen str hiv treatment be priority review unite state fda be expect announce decision february str be fix dose combination bictegravir insti emtricitabine tenofovir alafenamide ftc taf dual nrti backbone combination be also review eu company work develop hiv drug be johnson johnson jnj free report company partner glaxo recently receive fda approval first drug regimen juluca discuss further company bill melinda gate foundation national institutes health be conduct efficacy study investigational mosaic hiv preventive vaccine study evaluate vaccine be safe be able reduce incidence hiv infection woman sub saharan africa hiv have significant unmet need woman girl account person live hiv eastern southern africa otherssome other popular market hiv drug be abbvie abbv free report kaletra merck mrk free report isentress mylan myl free report also recently receive tentative fda approval combination tablet comprise efavirenz lamivudine tenofovir disoproxil fumarate meanwhile merck be develop investigational nucleoside reverse transcriptase inhibitor doravirine single entity tablet combination fix dose tablet other antiretroviral agent lamivudine tenofovir disoproxil fumarate tdf company plan file regulatory application same end conclusionaid hiv be life threaten disease have limit medical cure however be numerous company be develop drug treatment care person suffering hiv be risk become infected hiv thereby make space competitive johnson johnson sport zack rank strong buy glaxo gilead carry zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
2164,ABBV,roche holding rhhby free report announce fda have approve hemlibra emicizumab kxwh routine prophylaxis prevent reduce frequency bleed episode adult child haemophilium factor viii inhibitor approval come month ahead assign pdufa date feb drug be review fda priority review meanwhile datum haven haven be be review accelerate assessment european medicine agency ema roche legacy drug herceptin mabthera be already face competition biosimilar approval new drug certainly boost roche portfolio be note hemlibra carry box warning thrombotic microangiopathy tma blood clot limit sale potential moreover competition be intense haemophilium market too shire plc shpg free report hemophila drug advate hemophilia rixubis hemophilia stiff competition roche also presence nordisk nvo free report same space be concern meanwhile hemlibra be currently be evaluate clinical development program include additional phase iii study haven be evaluate hemlibra prophylaxis dose once weekly once other week person year age older haemophilium inhibitor factor viii haven be evaluate hemlibra prophylaxis dose week person year age older haemophilium inhibitor roche stock have gain only year date compare industry growth roche also obtain fda approval gazyva combination chemotherapy follow gazyva alone respond previously untreated advanced follicular lymphoma stage ii bulky iii iv drug be already approve combination chlorambucil treat chronic lymphocytic leukemia cll adult have not have previous cll treatment roche hematology portfolio consist approve drug mabthera rituxan rituximab gazyva gazyvara venclexta venclyxto venetoclax collaboration abbvie inc abbv free report zack rank roche carry zack rank hold see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2165,ABBV,look latest economic datum
2166,ABBV,ahead open bell final trading day week new gross domestic product gdp figure be release not exactly disappointing come short many analyst have be expect first read gdp reach lower consensus estimate figure remain unchanged future revision second read be expect february amount domestic economic growth roughly be nothing sneeze fact be almost exactly average gdp growth rate previous year level have bring edge abyss great recession way current time high major stock market index say basis point miss do come bit surprise especially consider very strong retail industry holiday shopping season well recovery oil gas construction manufacturing serve albatross previous year indeed analyst be expect positive surprise gdp have push december quarter growth time row first time decade yet happen course future gdp read have benefit more datum point time information break more positive indeed see most robust economy recession particular look adjustment private inventory investment shake personal consumption expenditure be highest ve see couple year earning roll onwe finish week begin new batch earning result overall ve enjoy very strong earning season positive surprise far outweigh negative one even better earning revision future quarters company already have report be currently double digit first time many quarters accord zack director research sheraz mian industrial giant honeywell hon free report beat earning estimate penny share revenue outpaced zack consensus fiscal year earning guidance be ratchete range previous guide more hon earning click here defense contractor rockwell collin col free report post fiscal earning share ahead expect revenue also outperformed estimate estimate be also year year tax reform add time cent share company bottom line more col earning click here biotech company abbvie abbv free report be today pre market earning beat share expect quarterly sale eke positive surprise zack consensus drug title imbruvica humira lead way gain company guidance be way share zack consensus have be share more abbv earning click here
2167,ABBV,friday january ahead open bell final trading day week new gross domestic product gdp figure be release not exactly disappointing come short many analyst have be expect first read gdp reach lower consensus estimate figure remain unchanged future revision second read be expect february amount domestic economic growth roughly be nothing sneeze fact be almost exactly average gdp growth rate previous year level have bring edge abyss great recession way current time high major stock market index say basis point miss do come bit surprise especially consider very strong retail industry holiday shopping season well recovery oil gas construction manufacturing serve albatross previous year indeed analyst be expect positive surprise gdp have push december quarter growth time row first time decade yet happen course future gdp read have benefit more datum point time information break more positive indeed see most robust economy recession particular look adjustment private inventory investment shake personal consumption expenditure be highest ve see couple year earning roll onwe finish week begin new batch earning result overall ve enjoy very strong earning season positive surprise far outweigh negative one even better earning revision future quarters company already have report be currently double digit first time many quarters accord zack director research sheraz mian industrial giant honeywell hon free report beat earning estimate penny share revenue outpaced zack consensus fiscal year earning guidance be ratchete range previous guide more hon earning click here defense contractor rockwell collin col free report post fiscal earning share ahead expect revenue also outperformed estimate estimate be also year year tax reform add time cent share company bottom line more col earning click here biotech company abbvie abbv free report be today pre market earning beat share expect quarterly sale eke positive surprise zack consensus drug title imbruvica humira lead way gain company guidance be way share zack consensus have be share more abbv earning click here mark vickerysenior editorquestion comment article author click here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
2168,ABBV,north chicago il base abbvie inc abbv free report be best know autoimmune disease drug humira abbvie flagship product humira be approve several indication rheumatoid arthritis moderate severe moderately severely active polyarticular juvenile idiopathic arthritis active psoriatic arthritis active ankylose spondylitis crohn disease moderate severe ulcerative colitis moderate severe axial pediatric crohn disease chronic plaque psoriasis moderate severe hidradenitis suppurativa moderate severe other key product include imbruvica cancer viekira pak hepatitis virus hcv treatment humira be major contributor abbvie top line humira remain key growth driver abbvie come quarters see investor focus remain primarily pipeline update meanwhile pharmacyclic acquisition have diversify abbvie product portfolio addition imbruvica abbvie performance have be impressive pharmaceutical company deliver positive surprise past quarter record line earning other average earning beat last quarters be currently abbvie have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning abbvie fourth quarter earning come share beating zack consensus estimate revenue abbvie post revenue marginally beat zack consensus estimate key stat humira sale come year year exclude currency impact fourth quarter imbruvica net revenue be year year outlook abbvie update outlook company raise adjust ep range compare expect previously zack consensus estimate be currently peg share share price impact share rise more pre market trading check back later full abbvie earning report abbvie inc price consensus abbvie inc price consensus abbvie inc quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2169,ABBV,novartis ag nvs free report enter licensing agreement spark therapeutic develop register commercialize luxturna voretigene neparvovec market outside unite state note luxturna be approve unite state dec time gene therapy restore functional vision child adult patient biallelic mutation rpe retinal pigment epithelial kda protein gene market authorization application be file european medicine agency july novartis make upfront payment well pay milestone royalty spark therapeutic meanwhile spark therapeutic retain exclusive right luxturna unite state retain responsibility obtain approval europe spark therapeutic also be responsible supply luxturna separate manufacturing supply agreement novartis remind investor fda approve novartis breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah have be launch unite state earlier week novartis report encourage result fourth quarter result beat earning sale estimate strong performance cosentyx entresto psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state generic division sandoz also combat pricing pressure strongly buoy launch rixathon biosimilar version roche holding inc rhhby free report rituxan rituximab erelzi biosimilar amgen inc amgn free report enbrel eu propose biosimilar version abbvie inc abbv free report humira adalimumab have also be accept review fda meanwhile strategic decision alcon retain business separation capital market transaction such spin initial public offer have be postpone company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2170,ABBV,fourth quarter earning season be full swing financial figure member index already jan latest earning preview total earning index member jump year quarter drive improvement revenue beat ratio be bottom line top line positive note ongoing earning phase seem have begin well drug biotech sector major large cap player johnson johnson jnj free report kick season earning beating estimate sale slightly miss same few other large pharma company release earning result last week picture look quite encourage pharma bigwig have report last week be novartis nvs free report abbvie abbv free report surpass earning sale estimate quarter review novartis raise sale guidance abbvie increase previously issue earning expectation year major player biotech sector biogen biib free report announce mixed performance report period earning lag estimate sale exceed same however celgene corp celg free report outpaced metric expectation fourth quarter drug biotech stock remain growth trajectory courtesy slew fda approval rise demand new product sale successful innovation product line expansion strong clinical report well continue robust performance legacy product moreover impressive factor regular acquisition be expect drive sector growth well also earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number jan let see thing be shape company upcoming release eli lilly company lly free report lilly be schedule release fourth quarter earning market open company deliver positive surprise last quarter lilly earning performance have be modest earning miss expectation last quarters beating same remain thus bring average beat proven model show lilly be likely beat earning quarter combination lilly zack rank increase predictive power esp solid zack rank positive earning esp make confident earning beat impending report zack consensus estimate quarter be report be peg share uncover best stock buy sell re report earning esp filter expect sturdy uptake new product trulicity taltz basaglar cyramza jardiance lartruvo upside be likely make decline sale establish product zyprexa alimta ciali strattera effient fourth quarter read more lilly report earning card vertex pharmaceutical inc vrtx free report vertex be slate release fourth quarter earning market close company track record have also be impressive so far deliver positive surprise trail quarters average beat third quarter vertex come positive surprise however proven model do not conclusively show vertex be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here vertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect uptrend be reflect result soon be report quarter read more vertex report earning card don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
2171,ABBV,hca healthcare inc hca free report report fourth quarter adjust earning share surpass zack consensus estimate bottom line also rise nearly year year company report net income share fourth quarter include cash increase company provision income taxe cent share stem impact tax cut job act reflect year year decline company report net income share year year hca healthcare generate revenue fourth quarter surpass zack consensus estimate report figure be year quarter upside be primarily drive increase same facility equivalent admission increase same facility revenue equivalent admission compare year quarter company report revenue year year quarterly detailsadjust ebitda totale year year same facility equivalent admission inched year year same facility admission jump same facility revenue equivalent admission increase total operate expense increase year year dec hca healthcare run hospital free standing surgery center hca holding inc price consensus ep surprise hca holding inc price consensus ep surprise hca holding inc quotefinancial updatea dec company have cash cash equivalent total long term debt total asset report quarter capital expenditure totale exclude acquisition cash flow provide operate activity totale year year share repurchase company repurchase share common stock fourth quarter company repurchase share common stock company plan increase year capital expenditure program pursue growth opportunity exist market new capital investment program be expect be roughly previous year spend nearly dividend updatehca healthcare have declare quarterly cash dividend cent share company common stock dividend be paid mar stockholder record close business mar initiation quarterly dividend reflect company financial strength company expect revenue range adjust ebidta ep capital expenditure zack rank performance other stockshca healthcare carry zack rank hold see complete list today zack rank strong buy stock here other player medical sector have report fourth quarter earning so far abbvie inc abbv free report unitedhealth group inc unh free report abbott laboratory free report have surpass respective zack consensus estimate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now be reissue article correct mistake original article issue jan longer be rely
2172,ABBV,novartis ag nvs free report subsidiary advanced accelerator application obtain fda approval new drug application nda lutathera lutetium lu dotatate treatment somatostatin receptor positive neuroendocrine tumor gep net include foregut midgut hindgut neuroendocrine tumor adult remind investor last week novartis complete successful tender offer advanced accelerator application lutathera be first class drug first available fda approve peptide receptor radionuclide therapy form treatment comprise target molecule carry radioactive component approval be base encourage phase iii study result demonstrated reduction risk disease progression death lutathera best standard care arm octreotide lar mg week compare mg octreotide lar alone hazard ratio ci approval luthera expand novartis neuroendocrine tumor portfolio approval new drug boost novartis portfolio be face generic competition blockbuster drug gleevec last week novartis report encourage result fourth quarter result beat earning sale estimate strong performance cosentyx entresto psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state novartis stock have rally last month compare industry gain generic division sandoz also combat pricing pressure strongly buoy launch rixathon biosimilar version roche holding rhhby free report rituxan rituximab erelzi biosimilar amgen amgn free report enbrel eu propose biosimilar version abbvie abbv free report humira adalimumab have also be accept review fda meanwhile strategic decision alcon retain business separation capital market transaction such spin initial public offer have be postpone company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2173,ABBV,biotech industry turn year drug pricing issue cripple performance last year have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring sector track year however rise first month year january september medical biotech genetic industry have decline so far fourth quarter oct date macro industry specific factor result sudden downfall uncertain macro picturea big component sell be confusion pass tax reform reform aim bring corporate tax stimulate economic well employment growth propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast shadow future biotech sector october president trump once again criticize high drug price come time investor have start expect trump action drug price not be onerous previously fear send health care stock lower tepid resultscome industry specific factor most big biotechs beat estimate earning sale however share most company decline post earning release various reason gilead gild free report top earning revenue estimate third quarter witness continue decline sale hcv drug harvoni sovaldi result competitive pricing pressure amgen amgn free report also beat expectation earning sale raise earning guidance however sale decline year year result share price decline post earning call sale pcsk inhibitor repatha be also disappointing celgene celg free report share plunge follow release third quarter result celgene earning top estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook biogen biib free report third quarter result be better expect share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza alexion alxn free report top earning estimate miss revenue third quarter vertex vrtx free report abbvie abbv free report be only outperformer conclusionwe believe biotech space be back track be more certainty regard timing tax reform be fundamental sector remain strong meanwhile earning season now stock start pick positive datum key clinical study drive sector share price biotechs be correlated success key study major biotech player need infusion new growth driver pipeline product portfolio internal development buy asset outside strategic deal sign biotechs also push stock higher look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2174,ABBV,novartis ag nvs free report generic arm sandoz report datum clinical study study compare propose biosimilar adalimumab biosimilar rituximab reference drug abbvie inc abbv free report humira roche holding rhhby free report mabthera respectively study include innovative trial involve switch pharmacokinetic pk pharmacodynamic pd study phase iii confirmatory efficacy safety study meet primary endpoint proportion patient achieve improvement week study confirm be meaningful clinical difference efficacy safety immunogenicity patient continuously receive adalimumab continuously receive reference drug switch biosimilar adalimumab reference drug multiple occasion addition phase iii study evaluate rituximab retreatment patient rheumatoid arthritis ra have already receive reference rituximab treatment ra past study evaluate biosimilar reference drug term safety immunogenicity patient switch reference drug biosimilar rituximab continue treatment reference drug addition pk pd datum demonstrated equivalence phase pk study meet primary endpoint be demonstrated biosimilar adalimumab reference drug note sandoz hold lead position biosimilar space portfolio market biosimilar currently deep pipeline biosimilar version rituximab rixathon be approve european commission june be currently review unite state biosimilar version humira be also review eu meanwhile sandoz witness strong growth outside unite state buoy biosimilar launch rixathon erelzi biosimilar amgen inc amgn free report enbrel europe however pricing pressure intensified unite state company expect low single digit sale decline sandoz fourth quarter mainly due seasonal shipment phase continue pricing pressure unite state novartis stock have rally year date compare industry gain first half novartis announce be mull strategic option alcon include retain business separation capital market transaction such spin initial public offer company believe alcon division have revive hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2175,ABBV,approval gilead science inc gild free report yescarta week see approval second car therapy treat cancer be regard most advanced immune oncology treatment option moreover fda have grant priority review label expansion application major cancer drug include astrazeneca plc azn free report lynparza advanced breast cancer imfinzi earlier stage lung cancer bristol myer squibb company bmy free report opdivo melanoma patient high risk recurrence exelixis inc exel free report cabometyx advanced renal cell carcinoma rcc meanwhile ipsen partner exelixis announce positive result phase iii study hepatocellular carcinoma candidate moreover abbvie abbv free report enter immuno oncology research collaboration harpoon therapeutic focuse novel cell recruit biologic therapy abbvie use harpoon tri specific cell activate construct platform develop immuno oncology pipeline let see news detail key newsgilead acquisition kite pharma nearly have finally paid approval yescarta axicabtagene ciloleucel latter chimeric antigen receptor cell car therapy candidate fda approve therapy treat relapse refractory large cell lymphoma rlbcl adult have receive more line systemic therapy various form rlbcl yescarta be approve include diffuse large cell lymphoma dlbcl primary mediastinal large cell lymphoma pmbcl high grade cell lymphoma be second gene therapy be approve unite state novartis ag nvs free report kymriah receive approval august acute lymphoblastic leukemia car therapy be most advanced form treat cancer be do modify patient cell part body immune system fight cancerous cell therapy be manufacture specifically single patient gilead science inc price consensus gilead science inc price consensus gilead science inc partner merck mrk free report market advanced ovarian cancer drug lynparza receive priority review supplemental new drug application snda seek approval previously treat chemotherapy patient negative metastatic breast cancer fda be expect give decision first quarter lynparza be different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer meanwhile fda have also grant priority review astrazeneca snda key cancer drug imfinzi unresectable small cell lung cancer read more astrazeneca snda cancer drug get priority review astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quotebristol myer announce fda have grant priority review supplemental biologic license application sbla label expansion opdivo company be look get drug approve treat patient melanoma be high risk disease recurrence follow complete surgical resection drug be already approve treatment patient braf mutation positive unresectable metastatic melanoma moreover company announce opdivo alone combination yervoy achieve encourage result previously treat small cell lung cancer patient phase ii checkmate study opdivo monotherapy combo therapy achieve objective response rate respectively read more bristol myer get priority review opdivo label expansion bristol myer squibb company price consensus bristol myer squibb company price consensus bristol myer squibb company quoteother newsexelixis renal carcinoma drug cabometyx be also grant priority review fda snda snda seek approval cabometyx patient treatment naive advanced rcc fda deem snda be sufficiently complete decision expect feb moreover company advanced hepatocellular carcinoma candidate cabozantinib achieve statistically significant clinically meaningful improvement median overall survival rate placebo phase iii celestial study exelixis be develop candidate partnership ipsen meanwhile inovio pharmaceutical inc ino free report initiate phase ib ii study evaluate combination ino cell activate immunotherapy ino immune activator roche pdl inhibitor tecentriq advanced bladder cancer immune design also initiate pivotal phase iii study support regulatory application cmb treat patient synovial sarcoma wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2176,ABBV,swiss pharmaceutical company novartis ag nvs free report be schedule report third quarter result oct novartis stock have rally year date compare industry gain last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent second quarter result novartis reiterate guidance net sale be expect be broadly line level include impact continue genericization gleevec glivec unite state europe novartis operate segment innovative medicine pharmaceutical alcon sandoz generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu recently approve kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space meanwhile fda have recently approve label expansion zykadia first line treatment patient metastatic small cell lung cancer new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale entresto be expect record revenue sale cosentyx be project reach additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure be expect impact third quarter result also loss exclusivity key drug novartis portfolio be hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu furthermore oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale company ophthalmologic division alcon continue face challenge due lower surgical equipment sale stiff competition face intraocular lens slowdown demand equipment purchase continue act dampener earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company negative esp make highly unlikely earning beat quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price ep surprise novartis ag price ep surprise novartis ag quote stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result oct see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2177,ABBV,emerge biotech market be time invest be large cap biotech value trap gilead biogen bluebird generic drug company teva valeant abbvie manage healthcare sector effect obamacare growth stock healthcare healthcare value stock screener episode roundup podcast zack comwelcome episode zack market edge podcast week host zack stock strategist tracey ryniec be joined guest discuss hottest investing topic stock bond etfs impact life episode tracey be joined zack senior strategist kevin cook be also editor zack healthcare innovator portfolio hold healthcare medical stock long term tracey have be get question listener wonder be value healthcare stock right now be cheap biotechs biotechs be hot again biotech etf xbi have soar year ishare nasdaq biotechnology etf ibb have gain value still be find biotechs other healthcare industry zack medical sector have company include drug company hospital manage care insurer medical device company dental company other re not create equal tracey kevin run screen quickly find basic value stock sector look only medical sector choose current year forward less next year forward didn screen zack rank return stock tracey kevin discuss dozen week podcast include big name cheap healthcare stock gilead gild free report have be cheap year trade forward just earning be decline company make last year expect just make year recently buy kite be enough give earning boost be value trap biogen biib free report be big biotech be cheap trade forward just analyst just raise price target stock gilead expect see earning growth year next year teva teva free report be cheapest group trade forward investor have be concern fall earning estimate make be expect make just be value trap abbvie abbv free report have rare combination attractive just rise earning estimate earning be expect jump abbv be short list aetna aet free report be manage care group be most difficult area be right now due obamacare uncertainty aetna have be reduce exposure exchange trade forward just be other industry be also cone uncertainty due unknown surround obamacare include hospital tracey kevin discuss hospital group especially tenet healthcare thc additionally valeant vrx appear be cheap tracey fear value trap medical device company ve be hot year be just too expensive make list find answer question more week podcast look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2178,ABBV,roche rhhby free report announce eu committee medicinal product human use chmp have adopt positive opinion hemlibra emicizumab routine prophylaxis bleed episode patient suffering hemophilia factor viii inhibitor chmp have recommend drug use age group marketing authorisation application be be review accelerate assessment final decision be expect european commission shortly chmp recommendation be base positive result pivotal clinical study person haemophilium inhibitor phase iii haven haven study note fda approve hemlibra routine prophylaxis event reduce frequency bleed episode adult child haemophilium factor viii inhibitor november hemlibra be review fda priority review grant breakthrough therapy designation fda person age year older haemophilium inhibitor september meanwhile hemlibra be be evaluate clinical development program include additional phase iii study haven haven result haven show statistically significant clinically meaningful reduction number treat bleed time adult adolescent year age older haemophilium inhibitor receive hemlibra prophylaxis week week compare receive prophylaxis interim result haven show clinically meaningful control bleed adult adolescent year age older haemophilium inhibitor receive hemlibra prophylaxis once week potential approval europe further boost roche hematology portfolio include approve drug mabthera rituxan gazyva gazyvaro tecentriq venclexta well encourage pipeline comprise candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg note roche be develop venclexta collaboration abbvie abbv free report company be jointly commercialize unite state abbvie be commercialize drug outside unite state earlier month european commission grant marketing authorization multiple sclerosis ms drug ocrevus drug be approve active relapse form ms defined clinical imaging feature well early primary progressive ms term disease duration level disability imaging feature characteristic inflammatory activity roche stock have lose year compare industry gain approval new drug potential label expansion exist drug bode well roche legacy drug herceptin mabthera be face competition biosimilar novartis ag nvs free report have already launch biosimilar version rituxan mabthera europe amgen amgn free report have also obtain fda approval biosimilar version avastin treatment type cancer include lung cancer colorectal cancer glioblastoma renal cell carcinoma cervix cancer zack rankroche currently carry zack rank hold see complete list today zack rank strong buy stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2179,ABBV,astrazeneca plc azn free report announce positive top line result phase iii study evaluate investigational triple combination therapy pt treatment chronic obstructive pulmonary disease copd pt be combination budesonide ics glycopyrronium long act muscarinic antagonist lama formoterol fumarate laba therapy pt be be develop deliver astrazeneca aerosphere delivery technology krono study compare pt dual combination therapy bevespi aerosphere symbicort turbuhaler pt company present krono trial result forthcoming medical meeting study demonstrated pt efficacy improve lung function study show significant improvement compare dual combination therapy lung function primary endpoint study be base force expiratory volume second fev assessment patient moderate very severe copd share astrazeneca have gain year industry register increase astrazeneca expect make regulatory submission japan china second half follow potential submission unite state europe remind investor last year fda approve glaxosmithkline gsk free report partner innoviva once daily single inhaler triple combination therapy trelegy ellipta treatment copd trelegy ellipta be combination fluticasone furoate ics umeclidinium long act muscarinic antagonist lama vilanterol laba therapy trelegy ellipta be deliver glaxo ellipta dry powder inhaler astrazeneca plc price astrazeneca plc price astrazeneca plc quote zack rank stock have zack rank hold better rank stock health care space be abbvie inc abbv free report carry zack rank buy see complete list today zack rank strong buy stock here abbvie earning share estimate have moved last day company deliver positive earning surprise last quarters average be share price company surge year zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2180,ABBV,johnson johnson jnj free report report better expect third quarter result beating zack consensus estimate earning sale drug consumer product giant raise sale profit outlook send share pre market trading fact year so far share price be be almost line increase witness industry earning beatj third quarter earning come share beating zack consensus estimate increase year period include amortization expense special item report third quarter earning share year period sale beatsale come beating zack consensus estimate sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis third quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow organically exclude impact acquisition divestiture sale increase operational basis new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara invega sustenna sale concerta zytiga improve quarter quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june diversify revenue pah category however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition regard mention pfizer inc pfe free report file lawsuit district court recently lawsuit pfizer allege resort unfair practice prevent sale inflectra pfizer biosimilar version remicade be launch unite state november last year pharma segment achieve clinical milestone quarter include label expansion unite state pulmonary arterial hypertension pah drug tracleer pediatric use imbruvica chronic graft versus host disease gvhd drug first indication outside cancer market imbruvica partnership abbvie inc abbv free report call company also mentioned not file global regulatory application rheumatoid arthritis candidate sirukumab remind investor last month receive complete response letter crl fda sirukumab want additional safety datum medical device segment sale come year period include operational increase positive currency movement sale gain mainly inclusion abbott medical optic acquisition add operational sale growth exclude impact acquisition divestiture operational basis worldwide sale increase domestic market sale rise year year international market sale increase operational increase year year operational growth be drive wound closure product general surgery business product cardiovascular business acuvue contact lense vision care business make weaker sale performance diabetes care consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period slower growth baby care product due competitive pressure be partially offset growth beauty counter product international smoking cessation aids meanwhile international segment record increase reflect operational increase positive currency impact guidance raisedj raise adjust earning sale outlook year expect adjust earning share range compare expect previously revenue guidance be raise range compare expect previouslyour takea indicated last quarter sale growth accelerate third quarter lead company post first positive sale surprise almost year higher sale pharmaceutical segment well positive contribution actelion deal pull top line quarter actelion acquisition add impressive operational sale growth quarter quite few key product portfolio remicade concerta be face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend go forward carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2181,ABBV,spin activity have step lately biggy honeywell international hon free report pfizer pfe free report be most active one lately industrial giant honeywell announce plan spin home global distribution unit transportation system unit publicly trade company end read etfs buy year high manufacturing activity other hand pfizer be explore strategic alternative possibly bid good bye consumer healthcare segment sale spin consumer health unit be expect next year pfizer consumer sale have be essentially flat past year clearly explain pfizer intend concentrate more promising innovative pharmaceutical unit separate consumer healthcare move also signify likely introduction more deal make wall street journal however company also keep open chance retain business spin offssometime business form autonomous entity exist business division believe separated line add more value independent company such situation parent focus core business management new entity focus relative different goal profitable spin off be investor accord cantor fitzgerald spinoff complete outperformed first year trading average more percent article publish benzinga spun entity have be perform better parent company lately paypal pypl free report generate higher gain parent ebay ebay free report last year post spin whitewave food co gain last year decline dean food co df free report whitewave food be spun abbot laboratory free report cut ty part business form new company call abbvie abbv free report jan abbv be gain last year oct recent surge spin offa chicago base partner boston consult group recently comment bull market be witness currently equity be overvalue make materialization merger acquisition difficult instead high valuation better justify spin asset divest asset logic hold good be likely see more such action come day read bargain etfs pricey market notably unite state see complete spinoff fall dot com bubble burst number further decline number action again rise slide financial crisis kick datum provide dealogic quote cnbc momentum again gain momentum value have be subdue etfs play be always way play such corporate action highlight spin etfs detail etfs get further boost honeywell pfizer announcement guggenheim spin etf csd free report stock fund look track spin index paypal holding hewlett packard enterprise synchrony financial be top holding fund csd charge bps fee read paypal strong result put etfs focus vaneck vector global spin etf spun free report stock fund follow horizon kinetic global spin index be rule base equal weight index intend track performance list publicly hold spin off be domicile trade develop market western europe asia net expense ratio fund be unite state account fund gannett co time inc timkensteel be top stock fund want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2182,ABBV,company amgen amgn free report regeneron regn free report be news amgen provide pipeline regulatory update regeneron partner sanofi get good news appeal court ruling favor pcsk inhibitor lawsuit amgen recap week most important storiesphase ii combination datum amgen imlygic publish positive datum amgen oncolytic viral therapy imlygic used combination bristol myer squibb yervoy be publish journal clinical oncology result mid stage study show objective response rate orr more double imlygic be used combination yervoy compare yervoy alone patient unresectable stage iiib iv melanoma versus moreover complete response rate be almost double combination arm compare yervoy alone versus response be observed inject uninjected lesion include visceral lesion advanced melanoma be highly aggressive most dangerous type skin cancer be need multiple treatment approach course disease datum be encourage open new avenue revenue imlygic eventually gain approval use combination checkpoint inhibitor sale imlygic approve october be yet pick meanwhile amgen say fda have accept regulatory application seek label expansion use prolium glucocorticoid induced osteoporosis most common form secondary osteoporosis response agency be prolium bring sale second quarter be important growth driver amgen company work improve diagnosis treatment rate duration order drive access greater number patient read more amgen label expansion application prolium accept fda amgen be zack rank buy stock share amgen have gain year date significantly outperform industry rally see complete list today zack rank strong buy stock here breather amgen neulasta biosimilar approval delay amgen get bit breather fda issue complete response letter crl mylan biocon biosimilar version amgen blockbuster drug neulasta pegfilgrastim agency do not raise query regard biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity myl crl relate pending update regulatory application certain cmc datum facility requalification activity post recent plant modification note mylan biocon be not only company get crl fda biosimilar version neulasta novartis sandoz have receive crl last year coherus be issue crl year june regeneron sanofi score pcsk inhibitor litigation regeneron partner sanofi get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state read more regeneron sanofi get favorable ruling amgen abbvie immuno oncology deal abbvie abbv free report have enter research option license agreement clinical stage immuno oncology company turnstone biologic deal provide abbvie exclusive option license turnstone next generation oncolytic viral immunotherapy turnstone ad mg magea therapy be couple phase ii study different solid tumor indication alone well combination approve pd checkpoint inhibitor promising new datum biogen spinraza new phase iii datum present biogen biib free report spinraza show earlier initiation treatment therapy improve motor function outcome infant child spinal muscular atrophy sma biogen ionis spinraza be first approve medicine treatment sma spinraza be promising start unite state bring sale second quarter clovis seek label expansion parp inhibitor clovis oncology clvs free report have file label expansion parp inhibitor rubraca unite state company be look get drug approve maintenance treatment patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy company have present impressive late stage datum earlier year june rubraca show treatment significantly improve progression free survival ovarian cancer patient population evaluate ariel study rubraca have gain accelerate fda approval december use advanced ovarian cancer patient have be treat more chemotherapy have deleterious germline somatic brca mutation broader label boost rubraca sale potential read more clovis submit snda ovarian cancer drug rubraca biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen gain celgene celg free report lose last month vertex vrtx free report be see last biotech stock roundup here endocyte shoot deal amgen abbvie settle humira litigation next biotech world sector gear third quarter earning watch usual regulatory pipeline update spark therapeutic voretigene neparvovec be review fda cellular tissue gene therapy advisory committee ctgtac october spark be seek fda approval treatment patient vision loss due confirm biallelic rpe mutation associate retinal dystrophy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2183,ABBV,key index close record level friday follow better expect earning intel abbvie honeywell additionally continue economic growth optimism weaker dollar have positive impact investor sentiment have finished record level trading day so far month best such feat month june index also post best day rise march additionally dow post rise more point friday nasdaq register biggest day gain jan further index advanced more week post fourth straight week gain benchmark fared dow jone industrial average dji increase point close rise close tech laden nasdaq composite index close gain fear gauge cboe volatility index vix decrease close total share be trade friday lower last session average share advancer outnumber decliner nyse ratio nasdaq ratio favore advance issue upbeat earning boost earning result intel corporation intc free report abbvie inc abbv free report honeywell international inc hon free report lend further impetus market rally intel share climb chipmaker post fourth quarter earning share ep revenue beat respective zack consensus estimate intel guide first quarter gaap revenue year year exclude mcafee read more share abbvie jump pharmaceutical product manufacturer report fourth quarter ep revenue surpass respective zack consensus estimate abbvie raise adjust ep range compare predict earlier zack consensus estimate current year earning be peg share read more honeywell share increase diversify technology companypost solid fourth quarter result healthy year year increase revenue adjust earning further honeywell revise full year earning guidance better reflect favorable impact tax reform read more economic datau gdp increase seasonally adjust annual rate final month follow gain more previous quarters advance estimate release bureau economic analysis fact marked economy strongest stretch growth expansion start mid economy be boost solid consumer spending increase quarter gain third quarter consumer outlay register fastest pace growth fourth quarter almost year company also ramp spending fourth quarter other bright spot government spending also increase clip weak dollar bode well large week treasury secretary steven mnuchin say weakness dollar be beneficial trade comment lead ice dollar index fall lowest level dec wednesday later mnuchin say remark regard dollar be misinterpret meanwhile president trump world economic forum davos switzerland say dollar be go get stronger stronger eventually wish greenback strengthen however ice dollar index fall week settle follow mnuchin comment weaker dollar bode well large cap multinational generate revenue mainly buyer outside weekly week dow nasdaq gain respectively benchmark register fourth straight weekly increase senate give consent pass bill end recent government shutdown additionally encourage earning result netflix inc nflx free report traveler company inc trv free report company mmm free report caterpillar inc cat free report also boost market stock make headlinesdiageo interim earning sale year yeardiageo plc deo free report recently announce interim result half yearly period end jul read more zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
2184,ABBV,johnson johnson jnj free report fourth quarter result be mixed beat estimate earning miss same sale announce fourth quarter result jan market open expect sale growth accelerate second half year backed higher sale pharmaceutical segment improve performance medical device organically exclude impact acquisition divestiture sale increase operational basis fourth quarter better increase see third quarter first half meanwhile acceleration underlie sale growth pharma segment see third quarter continue fourth quarter pharmaceutical segment sale rise year year fourth quarter also drug medical device giant issue bullish profit outlook estimate adjust earning share range reflect operational growth rate company guidance exceed then zack consensus estimate share positive factor share have decline earning release seem be investor disappointment revenue guidance expect revenue range reflect operational constant currency sale growth range however sale guidance fall slightly short then zack consensus estimate organic sale growth exclude impact acquisition divestiture be expect be range slightly higher see be short record fourth quarter organic sale growth outlook fall short investor expectation result share price drop understand investor concern project decline revenue growth however do believe outlook be conservative consider have history issue cautious outlook especially begin year believe be several tailwind year coax improve projection year progress new drug be approve last year guselkumab tremfya unite state well eu plaque psoriasis first dual treatment hiv juluca dolutegravir rilpivirine partnership glaxosmithkline gsk free report unite state juluca be review eu also gain fda approval several line extension lower dose xarelto new indication simponi aria use adolescent stelara combination use darzalex celgene celg free report multiple myeloma drug pomalyst sixth indication imbruvica other please note market imbruvica partnership abbvie inc abbv free report line extension expand eligible patient population drug drive sale higher newly approve product also contribute sale also submit regulatory application label expansion key drug include darzalex first line set multiple myeloma xarelto chronic coronary artery disease peripheral artery disease invokana include cardiovascular indication zytiga earlier stage metastatic prostate cancer get fda nod line extension year provide top line support launch year expect file approval depression candidate esketamine apalutamide pre metastatic prostate cancer symtuza darunavir base once daily single tablet regimen hiv be approve fda also several pivotal datum readout regulatory milestone be expect meanwhile pharma segment sale accelerate second half weak first half management seem confident positive trend continue also say call consumer medical device segment continue improve believe new product segment label expansion drug imbruvica darzalex contribution acquisition mainly actelion support top line growth wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2185,ABBV,late last week merck mrk free report announce decision discontinue development couple candidate hepatitis virus hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company decision be base review available phase ii efficacy datum grow competition hcv market merck have market product hcv market form zepatier elbasvir grazoprevir bring sale first month include favorable adjustment rebate accrual due mix business merck continue work expand zepatier utilization world uptake be impact ongoing decline overall patient volume many market increase competition gilead abbvie hcv spotlightmerck announcement have now put spotlight firmly gilead science gild free report abbvie abbv free report key player market gilead be undisputed leader hcv market hcv product bring sale first half company revolutionize treatment paradigm hcv market introduction sovaldi cut duration treatment few week instead prior standard care week moreover need peg interferon injection come several side effect be reduce eliminate completely gilead launch harvoni next first once daily single tablet regimen treatment most prevalent hcv genotype unite state be follow launch epclusa first oral pan genotypic single tablet regimen treatment adult genotype chronic hcv infection year gilead gain approval yet hcv treatment vosevi gilead rule hcv market quite few year sale be decline give intense pricing pressure grow competition pricing scrutiny decline patient population approval newer hcv product have result rapid increase number patient be treat cure follow decline number patient seek care be able access hcv treatment gilead expect hcv net product sale range announce result represent quite drop last year hcv product sale meanwhile abbvie hcv product include mavyret glecaprevir pibrentasivr viekira pak ombitasvir paritaprevir ritonavir tablet co package dasabuvir tablet viekira xr dasabuvir ombitasvir paritaprevir ritonavir mavyret be approve recently viekira sale be first half mavyret company next generation hcv offer be meaningful contributor sale other hcv drug include bristol myer squibb company bmy free report daklinza daclastavir janssen therapeutic olysio simeprevir remind investor merck be not only company have take decision halt development hcv candidate last month johnson johnson jnj free report have announce decision terminate collaboration agreement achillion pharmaceutical achn free report hcv janssen pharmaceutical say be discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir merck drop investigational hcv treatment gilead abbvie benefit lack additional competition enter market least term company continue face challenge decline patient volume intense pricing pressure lack additional entrant market slow rate decline sale gilead have be work expand hcv market encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer start initiative increase testing have lead increase diagnosis person be newly diagnosed hcv represent significant opportunity exist player hcv market gilead abbvie be zack rank hold stock see complete list today zack rank strong buy stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2186,ABBV,merck co inc mrk free report announce be discontinue further development next generation hepatitis hcv program mk mk market be become extremely crowd mk be oral triple combination regimen uprifosbuvir combination grazoprevir ruzasvir develop treatment chronic hcv infection mk be combination ruzasvir uprifosbuvir merck share have rise year so far compare increase industry company now focus grow sale key hcv drug market zeptier be approve use ribavirin treat chronic hcv genotype infection zepatier once daily fix dose combination tablet contain ns inhibitor elbasvir ns protease inhibitor grazoprevir be gradually become key top line driver merck cancer drug keytruda medicine record sale second quarter much higher first quarter attributable strong underlie demand trend unite state europe japan company continue launch zepatier globally however remind investor second quarter conference call management have warn zepatier uptake go forward be impact ongoing decline overall patient volume many market increase competition hcv market be get crowd be thus see increase pricing pressure gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer daklinza johnson johnson jnj free report olysio moreover other company be also look bring new improve shorter duration hcv treatment market abbvie pan genotypic shorter duration hcv regimen glecaprevir pibrentasvir mavyret receive approval unite state canada eu july august meanwhile gilead already market epclusa oral pan genotypic single tablet hcv regimen meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor merck carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2187,ABBV,expect pfizer inc pfe free report beat expectation report fourth quarter full year result jan market open last quarter company deliver positive earning surprise pharma giant have fairly decent record earning surprise company earning surpass expectation last quarters miss result average positive surprise pfizer share have rise past year compare unfavorably increase industry factor playnew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain chantix smoking cessation eliquis blood thinner be likely contribute meaningfully top line however loss exclusivity associate generic competition product primarily pristiq unite state vfend lyrica develop europe supply shortage legacy hospira product divesture hospira infusion system unit continue hamper top line growth blockbuster drug enbrel sale continue decline quarter due biosimilar competition prevnar prevenar vaccine franchise be likely see lower sale lower demand be expect hurt sale viagra third quarter call pfizer say be face supply shortage product legacy hospira portfolio mainly due capacity constraint technical issue time acquire hospira september pfizer have estimate take couple year integrate manufacturing plant resolve majority supply chain issue company also state remediation business have take longer expect expect supply shortage hurt sale fourth quarter meanwhile bottom line be likely be drive cost saving share buyback leukemia treatment besponsa inotuzumab ozogamicin approve eu june unite state august relapse refractory acute lymphoblastic leukemia mylotarg newly diagnosed cd positive acute myeloid leukemia aml be approve third quarter xeljanz sutent bosulif be approve line extension fourth quarter ixifi pfizer second biosimilar version johnson johnson jnj free report blockbuster drug remicade be also launch december new product line extension bring additional sale fourth quarter also expect management update plan new approve oral sglt inhibitor steglatro ertugliflozin tablet conference call apart be approve monotherapy treat type ii diabetes steglatro have also be approve use combination metformin brand name segluromet januvia brand name steglujan model proven model show pfizer be likely beat earning have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate zack consensus estimate be be meaningful indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank pfizer have zack rank combination pfizer zack rank positive esp make confident earning beat upcoming release sell rate stock zack rank other hand never be consider go earning announcement especially company be see negative estimate revision other stock considerhere be other health care stock worth consider model have right combination element beat earning time abbvie inc abbv free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning feb pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2188,ABBV,investor be always look stock be poise beat earning season abbvie inc abbv free report be such company firm have earning come pretty soon event be shape quite nicely report be abbvieis see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface abbv report fact most accurate estimate current quarter be currently share abbv compare broader zack consensus estimate share suggest analyst have very recently bump estimate abbv give stock zack earning esp head earning season be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give abbv have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead abbvie beat be card upcoming report today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2189,ABBV,expect abbvie inc abbv free report beat expectation report fourth quarter result jan market open last quarter company deliver positive earning surprise abbvie share have soar year time ahead industry rally notably abbvie earning history be quite impressive pharmaceutical company outpace estimate last quarters meeting same overall abbvie have average beat let see thing be shape company quarter factor considerabbvie expect fourth quarter earning range share revenue be estimate grow approximately operational basis foreign exchange be anticipate have favorable impact sale period be report company key drug humira be likely remain growth driver fourth quarter backed strong demand trend drug abbvie expect humira full year sale growth mid high teen range internationally metric be project mid single digit range operational basis zack consensus estimate humira be be report quarter significantly fourth quarter conference call investor focus also be performance label expansion update abbvie cancer drug imbruvica drug have be record strong sale past few quarters trend expect continue even quarter be report zack consensus estimate imbruvica be period other drug duopa creon be also likely continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue see decline sale impact intense pricing competitive pressure hcv market notably abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret gain approval unite state eu canada japan third quarter mavyret record global sale quarter initial uptake drug have be impressive expect higher sale fourth quarter earning whispersour proven model show stock be likely beat earning quarter have right combination key ingredient positive earning esp favorable zack rank strong buy buy hold happen zack esp abbvieha earning esp represent difference most accurate estimate share zack consensus estimate moreover positive esp indicate likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank abbvie have zack rank increase predictive power esp together positive esp chance beating estimate stock upcoming release be always peg higher caution sell rate stock go earning announcement especially company be see negative estimate revision abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote other stock warrant lookhere be other health care stock worth consider model comprise right combination element beat earning time pfizer inc pfe free report be schedule release result jan company have earning esp zack rank see complete list today zack rank stock here merck co inc mrk free report have earning esp zack rank company be schedule report earning number feb astrazeneca plc azn free report be slate announce financial figure feb company have earning esp be zack rank player hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2190,ABBV,novartis ag nvs free report report encourage result fourth quarter earning revenue beat estimate drive strong performance cosentyx entresto novartis ag price ep surprise novartis ag price ep surprise novartis ag quote fourth quarter core earning share beat zack consensus estimate be record year quarter revenue increase volume growth drive cosentyx entresto be partially offset negative impact generic competition pricing revenue also beat zack consensus estimate novartis stock have rally last month compare industry gain growth rate mentioned be year year basis constant exchange rate quarter detailnovartis operate segment innovative medicine pharmaceutical alcon ophthalmology unit sandoz generic innovative medicine division record sale generic competition impact sale segment primarily due entry generic gleevec unite state europe pricing too impact sale nevertheless growth product cosentyx entresto promacta revolade jakavi tafinlar mekinist gilenya boost sale psoriasis cosentyx achieve multus blockbuster drug status back strong growth approve indication entresto sale benefit continue access improvement expansion sale force unite state cosentyx generate sale entresto sale come oncology franchise exclude gleevec grow sale sandoz division be volume growth be offset price erosion unite state sale unite state decline due pricing pressure sale grow mainly drive zarxio unite state launch rixathon biosimilar version roche holding inc rhhby free report rituxan rituximab erelzi biosimilar amgen inc amgn free report enbrel eu sale alcon division be surgical sale increase drive broad recovery most market segment include strong growth vitreoretinal product vision care sale be fuel continue double digit growth daily total earlier novartis announce be mull strategic option lag eye care unit alcon include retain business separation capital market transaction such spin initial public offer company update strategic plan announce have potential grow sale market deliver profitability line industry company also make significant progress develop potential capital market solution include financial carve out tax legal entity structuring identify list incorporation location final decision be take depend alcon sale performance be not likely happen first half meanwhile novartis have moved ophthalmic otc product alcon division effective jan allow innovative medicine division focus pharmaceutical pipeline resultssale come beat zack consensus estimate earning share come beating zack consensus estimate share outlooknovartis expect net sale grow low mid single digit innovative medicine be project grow mid single digit revenue sandoz be expect be broadly line decline slightly alcon sale be estimate grow low mid single digit pipeline updatenovartis pipeline candidate progress have be encourage be good year novartis major approval oncology portfolio continue gain traction significant boost fda approve breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse kymriah have be launch unite state novartis be seek expand kymriah label novartis supplemental biologic license application kymriah suspension intravenous infusion treatment adult patient relapse refractory diffuse large cell lymphoma be ineligible relapse autologous stem cell transplant have be accept fda priority review breast cancer drug kisqali be approve europe first line option hr advanced metastatic breast cancer combination inhibitor drug be already approve unite state company also receive approval rydapt europe treatment newly diagnosed flt mutate acute myeloid leukemia type systemic mastocytosis sandoz continue progress biosimilar pipeline propose biosimilar version abbvie inc abbv free report humira adalimumab have also be accept review fda biosimilar version humira be already review eu tasigna be approve europe treatment pediatric patient newly diagnosed philadelphia chromosome positive chronic myeloid leukemia chronic phase ph cml cp pediatric patient ph cml cp resistance intolerance prior therapy include imatinib takenovartis fourth quarter result beat earning sale estimate strong performance cosentyx entresto generic division sandoz also combat pricing pressure strongly buoy biosimilar launch rixathin erelzi meanwhile strategic decision alcon retain business separation capital market transaction such spin initial public offer have be postpone company believe alcon division have revive well now hence decision possible spin be take recent approval kymriah kisqali further boost oncology portfolio drive growth zack ranknovartis currently carry zack rank hold see complete list today zack rank strong buy stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2191,ABBV,stryker corporation syk free report fourth quarter result be schedule release jan market close say quarter company be expect witness year year revenue growth other business segment apart orthopedic medsurg neurotechnology spine report year year decline revenue last quarter company beat zack consensus estimate cent positive earning surprise further company deliver positive earning surprise trail quarters average also favorable price performance last year be also encourage stock have gain compare industry rally company announce upbeat preliminary result stryker recently announce better expect preliminary net sale result fourth quarter full year net sale be estimate year quarter constant currency basis figure beat zack consensus estimate stryker corporation price consensus stryker corporation price consensus stryker corporation quoteper company prediction orthopaedic segment be expect generate higher revenue constant exchange rate cer medsurg neurotechnology spine segment be expect see revenue improve respectively cer read more stryker post upbeat preliminary sale figure zack consensus estimate revenue sale be peg reflect increase year quarter also zack consensus estimate revenue international sale be peg reflect increase prior year quarter factor playrobust fundamental growth management be opinion recent acquisition novadaq vexim ensure high end organic sale growth full year organic sale growth be expect range moreover recent definitive merger entellus medical be likely offer more comprehensive portfolio product enable physician conveniently perform broad range ent procedure company continue update robot field total knee application preliminary sale result system stryker have be upgrade mako total knee application continue momentum contribute net sale orthopaedic segment company diversify product portfolio stryker broad spectrum product cushion company significant sale shortfall company pipeline include product hip knee mako robotic arm assist surgery additionally various platform bone cement sport medicine bone substitute etc fortify company market position product recall negative recently stryker announce voluntary recall product oral care lineup offer sage product unit additionally company have place temporary hold certain cloth base product however be encourage note product recall issue not dampen management intention improve growth trajectory fourth quarter quantitative model conclusively show earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank favorable zack rank increase predictive power esp company positive esp make surprise prediction feasible stock worth lookhere be other medical stock worth consider have right combination element post earning beat quarter abbvie inc abbv free report have earning esp zack rank fibrocell science inc fcsc free report have earning esp zack rank bio techne corp tech free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2192,ABBV,novartis ag nvs free report announce positive result phase iiib study liberty assessed efficacy safety erenumab amg mg patient episodic migraine have experience previous preventive treatment failure due lack efficacy intolerable side effect study meet primary endpoint significantly more patient take erenumab experience least reduction baseline monthly migraine day compare placebo trial meet secondary endpoint include reduction monthly migraine day lower day need acute rescue medication improvement score migraine physical function impact diary mpfid tool responder rate number patient experience least reduction monthly migraine day compare placebo safety datum be consistent previous study erenumab date show placebo safety profile novartis present full datum upcoming scientific meeting novartis stock have rally last month compare industry gain erenumab investigational fully human monoclonal antibody be design selectively block calcitonin gene related peptide cgrp receptor play critical role migraine activation candidate be be develop novartis collaboration amgen inc amgn free report candidate be first investigational therapy target cgrp pathway have receive food drug administration european medicine agency ema regulatory filing acceptance approval novartis amgen co commercialize erenumab unite state amgen have exclusive right drug japan novartis have exclusive right commercialize rest world novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen enbrel zack rank key picknovartis currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here exelixis earning share estimate have moved cent cent last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2193,ABBV,fourth quarter earning season be full swing trend so far appear impressive notably company have post result jan earning revenue growth latest earning preview also company top earning revenue focuse attention large cap pharma sector be yet witness main show space only company have report quarterly result now so far large cap pharma sub industry carry zack industry rank place first zack industry back testing show top zack rank industry outperform bottom half factor more remind investor drug stock have prolific run courtesy slew fda approval regulatory body approve novel drug last year easily surpass total tally particularly large cap player industry rake stellar return last month upbeat quarterly result rise demand new product sale successful innovation product line expansion strong clinical study result well continue strong performance legacy product propel large cap drug sector scale new high moreover tailwind be expect drive sector growth meanwhile jubilant republican pass tax overhaul bill first time year tax bill be sign law president donald trump only last month dec corporate tax rate have be slash now boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash stash overseas time tax rate also tax cut be expect prevent earlier inversion rampant drug industry importantly outlook upcoming fourth quarter result look bright earning preview broader medical sector inclusive drug biotech well medical device company be expect record year year growth revenue rise earning time pick likely winnersgiven enormity healthcare space task select stock potential beat estimate appear quite daunting proprietary methodology make job fairly simple way taper list choice earning season be look stock combination favorable zack rank zack rank strong buy buy hold positive earning esp more often not positive earning surprise deliver company lead stock price appreciation well research quantitative model earning esp be used identify stock higher chance deliver positive surprise upcoming earning announcement show percentage difference most accurate estimate zack consensus estimate uncover best stock buy sell re report earning esp filter investing stock large market cap be much more reliable investment same control large portion respective industry also company larger market cap have evidently perform well here be large cap pharma stock poise surpass estimate fourth quarter accord methodology first pick be abbvie inc abbv free report north chicago il base company have earning esp zack rank see complete list today zack rank stock here stock have see zack consensus estimate fourth quarter earning be peg share company boast positive earning surprise record have exceed expectation last quarters average beat abbvie be schedule report result jan next choice be merck co inc mrk free report stock have earning esp zack rank consensus mark fourth quarter earning stand cent share base kenilworth nj merck have encourage positive earning surprise history company average beat trail quarters be merck be slate announce result feb astrazeneca plc azn free report too have please earning profile company have consistently outpaced earning expectation last quarters average beat look perfectly poise repeat winning streak fourth quarter well london uk base company be zack rank player have earning esp zack consensus estimate be peg cent share astrazeneca be schedule release earning performance feb wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2194,ABBV,johnson johnson jnj free report report mixed fourth quarter result beating zack consensus estimate earning slightly miss same sale drug consumer product giant issue decent outlook share be pre market trading fact past year share have return compare favorably increase witness industry earning beatj fourth quarter earning come share beating zack consensus estimate increase year period adjust earning exclude amortization expense special item include charge related recent tax law change include item report fourth quarter net loss share versus earning share year period sale miss slightlysale come slightly miss zack consensus estimate nonetheless sale increase year quarter reflect operational increase positive currency impact organically exclude impact acquisition divestiture sale increase operational basis better see third quarter first half pharmaceutical segment continue positive momentum see third quarter fourth quarter sale grow domestic market international market reflect operational growth positive currency impact sale segment sale rise year year reflect operational growth positive currency impact sale rise domestic international market sale domestic market rise international sale grow new product imbruvica cancer darzalex multiple myeloma continue perform well other growth driver be core product xarelto stelara zytiga invega sustenna please note market imbruvica partnership abbvie inc abbv free report quarter record pulmonary arterial hypertension pah revenue acquisition swiss biotech actelion june last year diversify revenue pah category add sale growth however sale invokana invokamet decline due higher manage care discounting importantly sale blockbuster rheumatoid arthritis drug remicade market partnership merck co inc mrk free report decline quarter sale decline international sale decline due biosimilar competition pharma segment achieve clinical milestone quarter include approval tremfya guselkumab eu november plaque psoriasis juluca dolutegravir rilpivirine first dual treatment hiv unite state please note juluca have be develop partnership glaxosmithkline gsk free report juluca be review eu tremfya be approve unite state july last year quarter also gain fda approval several line extension lower dose xarelto new indication simponi aria psoriatic arthritis ankylose spondylitis use adolescent stelara medical device segment sale come year period include operational increase positive currency movement domestic market sale rise year year international market sale increase operational increase year year consumer segment record revenue report quarter year year operational increase foreign currency movement positively impact sale segment sale domestic market decline year period meanwhile international segment record increase reflect operational increase positive currency impact resultsfull year sale rise fall slightly short zack consensus estimate adjust earning be share zack consensus estimate year year earning be higher end guidance range share outlook issuedj issue decent guidance earning range be consensus estimate sale fall slightly short same expect adjust earning share range reflect operational growth rate company guidance exceed thezack consensus estimate share expect revenue range reflect operational constant currency sale growth rate range however sale guidance fall slightly short zack consensus estimate acceleration underlie sale growth see third quarter continue fourth quarter quite few key product portfolio remicade concerta face generic competition believe new product segment label expansion drug imbruvica darzalex contribution actelion lead better sale trend second half compare first half profit outlook be also quite upbeat carry zack rank hold see complete list today zack rank strong buy stock here johnson johnson price consensus ep surprise johnson johnson price consensus ep surprise johnson johnson quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2195,ABBV,thank encourage industry trend hope favorable policy environment healthcare be top perform sector year notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far read healthcare etf hit new week high bullish trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive value style score growth momentum style score respectively look disappointing pfizer be schedule report earning oct open bell pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result oct market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision cent past day be report quarter merck have strong momentum style score value growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning oct market close read keep portfolio healthy biotech etfs amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see negative earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report oct open bell abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning oct market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision nickel past month be report quarter have solid value style score growth momentum style score respectively look ugly see healthcare etfs here gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning oct open bell have zack rank earning esp stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision couple cent be report quarter have solid growth style score unfavorable value momentum style score respectively bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum earning surprise well card healthcare sector be expect witness earning growth third quarter have strong zack rank top suggest further upside healthcare etfs particular etfs have zack etf rank read top rank healthcare etfs long term investor want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2196,ABBV,sanofi inc sny free report partner regeneron pharmaceutical inc regn free report announce phase ii study evaluate injection dupixent treatment adult active moderate severe eosinophilic esophagitis meet primary endpoint sanofi share have rise year so far compare increase industry dupixent be already market treat atopic dermatitis ad eczema unite state march year be approve ad eu last month eosinophilic esophagitis be chronic allergic inflammatory disease patient suffer difficulty swallow presently condition mainly cause food allergy be treat only diet modification corticosteroid surgery datum study show patient treat dupixent injection weekly experience significant improvement ability swallow compare placebo meanwhile treatment dupilumab weekly also lead significant improvement severity inflammation esophagus endoscopic sign disease please note dupixent enjoy orphan drug designation indication be optimistic sale prospect dupixent prove be important growth driver company dupixent generate sale second quarter backed strong demand apart ad eosinophilic esophagitis dupixent be also be evaluate other inflammatory indication include asthma nasal polyposis late stage study last month sanofi regeneron announce dupixent meet primary endpoint phase iii asthma study datum liberty asthma quest study show dupixent add standard therapy reduce severe asthma attack improve lung function base positive datum company plan submit supplemental biologic license application sbla fda end year sanofi have zack rank strong sell better rank stock large cap pharma sector include abbvie inc abbv free report nordisk nvo free report carry zack rank buy see complete list today zack rank strong buy stock here abbvie share have rise year earning estimate have go respectively past day nordisk have see share price go look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2197,ABBV,janssen subsidiary johnson johnson jnj free report announce fda have approve label expansion plaque psoriasis drug stelara use adolescent year age older drug be approve adult indication company believe label expansion be significant achievement plaque psoriasis develop age year approximately third patient moreover number treatment available adolescent be limit patient be administer only dose year starter dose stelara have become lead therapeutic option share company be so far year almost line industry performance industry have gain same time frame latest approval stelara be base datum phase iii study evaluate subcutaneous administration drug adolescent patient datum show drug achieve minimal psoriasis clear skin least third patient safety datum be also consistent be achieve adult patient be almost person suffering psoriasis unite state american academy dermatology moreover national center biotechnology information state majority psoriasis patient suffer plaque psoriasis number represent huge opportunity drug follow label expansion moreover approval stelara have gain edge compete drug abbvie inc abbv free report humira novartis ag cosentyx celgene corporation celg free report otezla be only approve adult plaque psoriasis patient however pfizer inc pfe free report enbrel compete stelara adolescent segment johnson johnson price consensus johnson johnson price consensus johnson johnson quotejohnson johnson carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2198,ABBV,healthcare be perform well start new year thank encourage industry trend favorable policy environment notably popular etfs health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain nearly so far bullish trend be likely continue head earning season big name johnson johnson jnj free report pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc read tax bill etf investor need know let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stocksjnj have zack rank earning esp indicate lower chance beating estimate quarter stock have see earning estimate revision yet be report quarter deliver average negative earning surprise past quarters have impressive momentum style score value growth style score johnson johnson be slate release earning jan open bell see healthcare etfs here pfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock have see positive earning estimate revision penny be report quarter deliver average negative earning surprise past quarters have impressive growth value momentum style score respectively pfizer be schedule report earning jan open bell merck be expect report result feb market open have zack rank earning esp stock deliver positive earning surprise last quarters average beat witness negative earning estimate revision couple cent past day be report quarter merck have value growth momentum style score respectively amgen carry zack rank have earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision cent past day quarter be report stock have solid value style score growth momentum style score look dull amgen report earning feb market close read wave push biotech etfs higher abbvie have zack rank earning esp company deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter stock have solid value growth style score momentum style score be unimpressive company be schedule report jan open bell gilead be expect release earning feb market close have zack rank earning esp gilead deliver positive earning surprise last quarters see negative earning estimate revision cent past month be report quarter have solid value style score growth momentum style score look ugly bristol myer likely report earning feb open bell have zack rank earning esp stock deliver average positive earning surprise past quarter witness positive earning estimate revision cent be report quarter have solid momentum growth style score respectively unfavorable value style score sum earning surprise well card healthcare sector be expect witness earning growth fourth quarter suggest upside healthcare etfs particular etfs have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2199,ABBV,varian medical system inc var free report be set report first quarter fiscal result jan market close previous quarter company report adjust earning share miss zack consensus estimate further adjust earning decline year quarter average company deliver negative earning surprise trail quarters also lackluster price performance be woe last year stock have return compare industry rally let see thing be shape prior announcement varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotefactor playdecline financial varian medical experience decline revenue fourth quarter trend be expect continue quarter be report well lackluster performance company halcyon cancer treatment device hamper sale latin america fact sale halcyon platform decline latin america fourth quarter thank several tender push mainly public sector deal revenue asia pacific japan be also expect decline significantly due plummet order halcyon further softness market freestand clinic be headwind varian medical be report quarter performance proton therapy unit have be dampen due intense competition niche space be anticipate be major concern varian medical narrowing customer base majority varian medical ray tube flat panel detector sale cater small number large imaging system original equipment manufacturer oem customer equipment manufacturing major incorporate ray product own medical diagnostic imaging system industrial imaging system due pattern client concentration loss client have adverse effect varian medical operate result earning whispersbuoy factor proven model do not conclusively indicate earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate be peg cent zack consensus estimate be cent uncover best stock buy sell re report earning esp filter zack rank varian medical currently carry zack rank sell decrease predictive power esp make surprise prediction difficult caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company want consider model have right combination element post earning beat quarter abbvie inc abbv free report have earning esp zack rank agio pharmaceutical inc agio free report have earning esp zack rank see complete list today zack rank stock here alexion pharmaceutical alxn free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2200,ABBV,novartis ag nvs free report be schedule report fourth quarter result jan swiss pharmaceutical company stock have rally last month compare industry gain novartis have excellent track record last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent third quarter result novartis reiterate annual guidance net sale be expect be line level include impact continue genericization gleevec glivec unite state europe novartis operate segment innovative medicine pharmaceutical alcon sandoz generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space sale division be expect grow marginally new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale entresto be expect record revenue sale cosentyx be project reach additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure impact fourth quarter result company now expect sale decline broadly line meanwhile loss exclusivity key drug novartis portfolio continue hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu further oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale performance ophthalmology division alcon business be weak due competition face intraocular lens slowdown demand equipment purchase consequently novartis take few step revive business turnaround have be encourage management believe create standalone company capital market exit create additional shareholder value decision be expect first half depend alcon performance future earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release fourth quarter result jan complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2201,ABBV,be good year pharma biotech stock sector witness positive development lead much await recovery key reason sector improve performance be willingness investor look drug pricing controversy focus more fundamental instead drug pricing controversy be major overhang remain headline risk investor seem more comfortable issue moreover significantly higher number fda approval have restore investor confidence sector approval first gene cell therapy last year be major breakthrough sector hope more merger acquisition have also go tax reform place big player lookout company innovative pipeline technology have already be quite bit buzz year potential deal celgene rumore be interested buy juno biogen biib free report acorda sanofi sny free report bioverativ meanwhile nordisk recently confirm be look acquire belgium base biopharma company ablynx ablynx reject nordisk offer look forward new product sale ramp success innovation continue strong performance key product more activity grow demand drug especially rare treat disease age population increase health care spending be factor keep momentum headwind include drug pricing scrutiny pricing pressure increase competition grow presence biosimilar generic competition slowdown growth legacy product concern regard amazon interest enter healthcare arena major pipeline setback biotech pharma stock keep eye earning seasonaccording zack earning trend article medical sector have be better perform sector last several quarters be expect record earning growth revenue growth fourth quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc alxn free report alexion have strong presence rare disease market market drug include soliris treatment patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus acetylcholine receptor achr antibody positive generalized myasthenia gravis gmg strensiq enzyme replacement therapy patient hpp kanuma enzyme replacement therapy patient lysosomal acid lipase deficiency lal alexion be focuse grow maximize presence rare disease business core area focus include hematology nephrology neurology metabolic disorder alexion have consistently surpass earning expectation last quarters average surprise zack rank stock report fourth quarter result february have earning esp quarter soliris revenue be expect range metabolic revenue be expect range celgene corporation celg free report celgene be focuse discovery development treatment cancer inflammatory disease next generation solution protein homeostasis immuno oncology epigenetic immunology neuro inflammation earlier month company announce preliminary result fourth quarter revenue expect be earning be approximately share celgene have surpass earning last quarters average surprise zack rank stock be report fourth quarter result january have earning esp abbvie abbv free report abbvie be know blockbuster drug humira be focuse development treatment primary therapeutic area immunology oncology virology neuroscience earning be expect be share revenue growth approximately humira be expect remain key growth driver sale expect cross abbvie be report fourth quarter result january company have decent track record have surpass earning expectation last quarters average surprise zack rank stock have earning esp fourth quarter abbvie share be last year significantly surpass rally industry belong merck mrk free report merck be report fourth quarter result february company have strong earning track record be expect deliver surprise fourth quarter growth driver include keytruda gardasil few hospital specialty product animal health division help offset impact genericization zetia vytorin merck be also zack rank stock hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2202,ABBV,hepatitis be infectious disease cause hepatitis virus hcv primarily affect liver gilead science inc gild free report market blockbuster hcv drug sovaldi harvoni other well know name market be abbvie inc abbv free report viekira pak bristol myer bmy free report daklinza johnson johnson jnj free report olysio accord center disease control prevention cdc person unite state be live chronic hepatitis infection many remain unaware be infected be new hepatitis case year unite state many go unreported consider number be not surprise quite few pharma biotech company be work bring new improve shorter duration hcv treatment market market be thus get crowd see increase pricing pressure lot have happened hcv space late september gilead science sovaldi receive approval china component combination antiviral treatment regimen be first gilead hcv drug be approve china meanwhile gilead single tablet regimen str sovaldi velpatasvir voxilaprevir vosevi receive approval unite state eu canada july august vosevi become first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor gilead share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank hold see complete list today zack rank strong buy stock here meanwhile abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie share have outperformed industry year date stock have rally compare industry gain same time frame stock carry zack rank however last week pharmaceutical giant merck mrk free report announce be discontinue further development next generation hepatitis hcv program mk grazoprevir ruzasvir uprifosbuvir mk ruzasvir uprifosbuvir company make decision base review available phase ii efficacy datum heavily crowd hcv market merck share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank merck giant johnson johnson also discontinue development investigational hcv treatment regimen jnj combination direct act antiviral al odalasvir simeprevir company take decision consider be several highly effective therapy available indication johnson johnson share have underperform industry year date stock have gain compare industry gain same time frame stock carry zack rank be believe discontinuation merck combination hcv regimen act favor gilead abbvie gilead abbvie benefit lack additional competition enter market least term however company continue face challenge form decline patient volume intense pricing pressure lack additional entrant market also slow rate decline sale do zack investment idea come be welcome download full minute list zack rank strong buy stock free charge be better place start own stock search access full list avoid zack rank strong sell other private research see stock free
2203,ABBV,abbvie inc abbv free report share have gain impressive past month compare favorably gain record industry share price surge be support series positive news company past few week last week abbvie announce resolution ongoing patent dispute amgen inc amgn free report have delay launch latter biosimilar version abbvie blockbuster arthritis drug humira settlement abbvie grant exclusive license amgen allow latter sell amjevita unite state jan most country eu oct other market different date license amgen pay abbvie pre specify royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market secondly abbvie week pan genotypic ribavirin free once daily hcv treatment mavyret maviret gain approval unite state eu canada past couple month mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor maviret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history abbvie announce positive datum phase iii murano study venclexta rituxan relapse refractory cll last month datum show venclexta roche rhhby free report rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll label expansion indication expand patient population venclexta significantly boost commercial potential abbvie also announce collaboration bristol myer squibb bmy free report evaluate combination investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc lastly abbvie oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment ra highly statistically significant clinically meaningful result dose mg mg upadacitinib compare placebo upadacitinib also meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year datum upadacitinib study be announce last month fact so far year abbvie share price have increase also compare favorably gain industry abbvie carry zack rank hold see complete list today zack rank strong buy stock here stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2204,ABBV,gilead science inc gild free report announce blockbuster hepatitis virus hcv infection drug sovaldi have now be approve china food drug administration cfda also drug be approve treatment adult adolescent age year infected hcv genotype component combination antiviral treatment regimen note sovaldi be first gilead hcv drug approve china note hcv be fourth most commonly report infectious disease china approximately patient hence approval country hold promise growth note sovaldi be approve unite state europe drug be currently approve country addition gilead be evaluate hcv single tablet regimen harvoni epclusa clinical trial site china gilead be know presence hcv market thank blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost approval epclusa unite state june eu july become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection fda approval vosevi sovaldi velpatasvir mg voxilaprevir mg tablet also boost company portfolio drug be single tablet regimen str re treatment chronic hepatitis virus infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor however hcv franchise be pressure due competition pricing issue note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr other competition well pricing pressure intensified further launch merck co inc mrk free report zepatier gilead recently announce plan acquire kite pharma inc foray emerge field cell therapy kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio poise company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hcv market due competitive pressure more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2205,ABBV,key development week be fda approval first cancer biosimilar amgen amgn free report allergan mvasi biosimilar version roche blockbuster cancer drug avastin other update include important datum presentation company nabriva therapeutic nbrv free report abbvie abbv free report recap week most important storiesfirst cancer biosimilar get fda nod fda approve amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu read more amgen allergan avastin biosimilar secure fda approval nabriva positive antibiotic datum nabriva get major boost company post positive top line result oral lefamulin patient community acquire bacterial pneumonia cabp lead cause infectious death unite state leap study first pivotal late stage study be conduct lefamulin meet fda primary endpoint inferiority compare moxifloxacin adjunctive linezolid early clinical response european medicine agency ema criterium be also meet nabriva be look position lefamulin first line empiric monotherapy second pivotal study be currently enrolling topline result expect next year spring positive result allow company file fda approval second half nabriva have gain year date significantly outperform industry rally read more nabriva lefamulin positive pivotal study stock surge fda advisory panel meeting biomarin drug biomarin pharmaceutical bmrn free report know strong presence market serious life threaten rare disorder say fda be not look hold advisory panel meeting company biologic license application bla pegvaliase biomarin be look get pegvaliase approve reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management pegvaliase be currently priority review response fda expect feb however well be push month agency have ask biomarin additional chemistry manufacturing control cmc information read more biomarin say fda not plan adcom pegvaliase bla tesaro zejula step closer eu nod cancer focuse tesaro tsro free report get good news ema committee medicinal product human use chmp issue positive opinion zejula niraparib monotherapy maintenance treatment adult patient platinum sensitive relapse high grade serous epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy give positive opinion chance gain eu approval look high approval make zejula first oral once daily parp inhibitor europe use patient regardless brca mutation biomarker status zejula be already approve unite state read more tesaro ovarian cancer drug zejula get positive chmp opinion abbvie roche cancer drug positive late stage study abbvie partner roche be look expand label cancer therapy venclexta venclyxto result late stage study murano help effort venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll murano study independent datum monitoring committee have recommend unblind study base positive result label expansion indication expand patient population venclexta significantly boost commercial potential read more roche announce positive datum leukemia drug halozyme sign deal raise view halozyme therapeutic halo free report share shot company announce deal roche bristol myer squibb enhanze drug delivery technology raise outlook year roche agreement halozyme stand receive upfront achievement specify development regulatory sale base milestone company also receive tiered mid single digit royalty sale commercialize product bristol myer deal see company get upfront future milestone royalty payment base licensing deal halozyme up revenue guidance expect exit year cash balance more previous guidance read more bristol myer collaborate halozyme enhanze halozyme be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock celgene be biogen lose last month vertex vrtx free report be see last biotech stock roundup here alexion cut job streamline operation kura cancer datum next biotech world watch usual regulatory pipeline update more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2206,ABBV,roche holding ag rhhby free report announce positive result phase iii study murano study evaluate venclexta combination rituxan patient suffering relapse refractory chronic lymphocytic leukemia cll datum show study meet primary endpoint result depict statistically significant improvement time patient live disease progress progression free survival pfs treat venclexta rituxan compare treanda rituxan note roche be develop venclexta collaboration abbvie inc abbv free report company be commercialize drug unite state abbvie commercialize outside country remind investor fda approve venclexta april treatment person cll have receive least prior therapy deletion detected fda approve test fda also grant breakthrough therapy designation venclexta combination rituxan treatment relapse refractory cll base promising result phase ib study company be conduct murano study convert current accelerate approval venclexta full approval datum study be present upcoming medical meeting submit global health authority estimate be more new case cll diagnosed unite state cll be most common type adult leukemia hence potential approval indication boost sale potential roche hematology portfolio include approve drug mabthera rituxan gazyva tecentriq venclexta pipeline candidate polatuzumab vedotin rg small molecule antagonist mdm idasanutlin rg last week fda place partial clinical hold phase ib phase ii trial evaluate immuno oncology drug tecentriq due safety issue partial hold be put due emerge safety datum clinical trial evaluate merck co mrk free report keytruda combination celgene corp celg free report revlimid pomalyst note fda have put hold several trial fusion program celgene roche stock have gain compare industry gain year so far roche have strong presence oncology market company dominate breast cancer space due strong demand franchise drug herceptin perjeta kadcyla however sale avastin tarceva continue decline generic competition xeloda continue hurt sale competition biosimilar loom large roche key drug herceptin avastin rituxan zack rankroche currently carry zack rank hold see complete list today zack rank stock here promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
2207,ABBV,johnson johnson jnj free report announce european medicine agency ema committee medicinal product human use chmp have grant positive opinion recommend approval pipeline candidate guselkumab treatment moderate severe plaque psoriasis eu drug be approve unite state july year be market trade name tremfya treatment immune system related skin disorder decision european commission ec be expect later year so far year share price have increase compare favorably gain record industry belong application eu be base study phase iii voyage voyage navigate evaluate efficacy safety guselkumab il human monoclonal antibody administer subcutaneous injection treatment adult moderate severe plaque psoriasis datum voyage trial show significantly higher proportion patient moderate severe plaque psoriasis treat guselkumab achieve high rate skin clearance compare receive placebo patient receive guselkumab achieve least clearer skin versus placebo voyage trial evaluate guselkumab versus abbvie inc abbv free report blockbuster drug humira study demonstrated statistically significant efficacy guselkumab compare humira week be maintain week treatment almost patient treat humira achieve least clearer skin versus guselkumab navigate study evaluate efficacy safety switch guselkumab moderate severe plaque psoriasis patient be not achieve clear almost clear skin other plaque psoriasis medicine stelara datum study show patient switch guselkumab show significantly greater improvement skin clearance compare patient continue receive stelara meanwhile phase iii head head study tremfya novartis ag nvs free report cosentyx moderate severe plaque psoriasis be ongoing also phase iii study evaluate guselkumab moderate severely active psoriatic arthritis be also ongoing have previously mentioned tremfya have blockbuster potential rake sale more carry zack rank hold stock considera better rank biotech stock be alexion pharmaceutical inc alxn free report sporting zack rank strong buy see complete list today zack rank stock here share alexion have gain year date zack consensus estimate increase respectively past day new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
2208,ABBV,novartis ag nvs free report announce long last skin clearance rate cosentyx plaque psoriasis patient phase iii study evaluate drug year cosentyx be first only fully human il inhibitor achieve sustain skin clearance rate year reinforce long term favorable impact datum study show cosentyx maintain psoriasis area severity index pasi pasi measure skin clearance year year patient moderate severe plaque psoriasis datum study be present european academy dermatology venereology eadv congress geneva switzerland share company have outperformed industry have surge so far year industry increase drug be approve unite sate treatment adult active ankylose spondylitis active psoriatic arthritis psa moderate severe plaque psoriasis launch drug have be prescribe more patient cosentyx achieve blockbuster status record sale first half generate solid sale long term safety efficacy datum drug be expect further boost growth meanwhile second quarter drug be grant approval europe label update include week datum clear study demonstrated long term superiority cosentyx compare johnson johnson jnj free report stelara psoriasis also patient recruitment be underway new head head clinical trial exceed evaluate superiority cosentyx versus abbvie abbv free report humira psa novartis expect next growth phase begin drive cosentyx psoriasis psoriatic arthritis ankylose spondylitis indication entresto kisqali deep pipeline candidate baf amg rth moreover approval kymriah ctl august make novartis first company bring car cell therapy treat cancer go forward expect approval new drug label expansion exist one bode well novartis novartis ag price consensus novartis ag price consensus novartis ag quotezack rank stock have zack rank hold aduro biotech inc adro free report be better rank biomedical company zack rank buy see complete list today zack rank strong buy stock here aduro loss estimate narrow last day company deliver average earning beat trail quarters trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2209,ABBV,abbvie abbv free report share increase almost company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iii study treatment patient rheumatoid arthritis ra fact abbvie share have rally outperform industry rise so far year phase iii select study be multus center randomize double blind placebo controlled parallel group study be design evaluate efficacy safety dose mg mg upadacitinib compare placebo week patient moderate severe ra be stable dose conventional synthetic dmard have have show inadequate response dosage study meet primary endpoint highly statistically significant clinically meaningful result dose compare placebo trial primary endpoint be acr response low disease activity lda result show patient receive mg patient administer mg dose once daily upadacitinib achieve acr response week treatment comparison patient receive placebo lda be achieve patient mg mg dose arm respectively compare patient receive placebo additionally study meet secondary endpoint too notably select be second ongoing phase iii study select ra clinical trial program conduct upadacitinib other research be also underway upadacitinib treat crohn disease ulcerative colitis atopic dermatitis remind investor last week company announce upadacitinib have meet primary endpoint phase iib study atopic dermatitis company plan advance candidate phase iii study next year give indication note abbvie already have strong presence ra market blockbuster drug humira however several company be work develop biosimilar version humira induce competition market company also ra market be extremely crowd include drug johnson johnson simponi ucb cimzia other significantly eli lilly lly free report jak inhibitor olumiant be recently approve eu pfizer pfe free report xeljanz be market unite state treat ra strong competition upadacitinib approval also amgen amgn free report have already receive approval market humira biosimilar drug have not be launch yet due ongoing litigation upadacitinib be approve reduce potential negative impact humira generic abbvie top line abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2210,ABBV,regeneron pharmaceutical inc regn free report partner sanofi sny free report announce fda have grant breakthrough therapy status experimental candidate cemiplimab regn sanofi regeneron be look get cemiplimab checkpoint inhibitor target pd programme death approve treat adult advanced metastatic cutaneous squamous cell carcinoma cscc type skin cancer company anticipate submit biologic license application bla cemiplimab fda first quarter fda breakthrough therapy designation aim expedite development review drug intend treat serious life threaten condition provide access patient soon possible significantly share regeneron have decline almost good news abbvie abbv free report announce skin treatment candidate upadacitinib have meet primary endpoint phase iib study turn increase market competition cemiplimab however share company have outperformed industry year date stock have surge compare industry rally period remind investor june company report positive preliminary result expansion cohort phase study evaluate cemiplimab patient advanced cscc datum study show treatment cemiplimab achieve overall response rate orr disease control rate dcr datum be present american society clinical oncology annual meeting phase ii trial empower cscc be examine regn metastatic cscc be currently enrolment phase additionally phase iii study evaluate regn first line treatment small cell lung cancer be initiate second quarter notably cemiplimab be put joint development program regeneron sanofi post global collaboration agreement enter july regeneron have also inked clinical study agreement other pharmacy biggy namely inovio pharmaceutical inc ino free report sillajen inc second quarter assess cemiplimab combination respective cancer candidate company press release cscc be second most common deadliest skin cancer melanoma unite state disease be also responsible most death melanoma skin cancer patient be easier apprehend condition early stage become quite difficult treat same once progressed advanced stage hence candidate be expect provide company access market promising huge potential regeneron pharmaceutical inc price regeneron pharmaceutical inc price regeneron pharmaceutical inc quotezack rankregeneron currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2211,ABBV,abbvie inc abbv free report partner neurocrine bioscience announce new drug application nda pipeline candidate elagolix have be submit fda abbvie be look get elagolix approve oral medicine management pain associate endometriosis nda filing be support positive result replicate pivotal phase iii trial evaluate elagolix gonadotropin release hormone gnrh antagonist indication detailed datum study present october last year show treatment elagolix result statistically significant reduction menstrual menstrual pelvic pain associate endometriosis compare placebo datum study also demonstrated superiority compare placebo reduce painful intercourse associate endometriosis endometriosis affect estimate woman reproductive age be associate pain symptom present be cure endometriosis pain associate endometriosis be currently manage oral contraceptive progestin danazol nsaid opioid gnrh agonist many medicine be not specifically indicated treatment endometriosis so far year abbvie share price have increase compare favorably gain record industry elagolix be also be evaluate phase iii study reduce heavy menstrual bleed premenopausal woman uterine fibroid datum pivotal study be expect end apart elagolix abbvie have several candidate different stage development wide range therapeutic area have partnership company roche rhhby free report bristol myer bmy free report biogen biib free report abbvie carry zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2212,ABBV,major news cancer segment week be failure eli lilly company lly free report newly approve breast cancer drug verzenio pivotal lung cancer study latest failure lilly join list large pharma company have fail respective lung cancer pivotal study recent past however verzenio be grant priority review status first line treatment breast cancer meanwhile fda grant breakthrough therapy designation astrazeneca plc azn free report tagrisso egfr mutation positive small cell lung cancer nsclc well astella leukemia candidate gilteritinib also abbvie seattle genetic announce collaboration agreement strengthen oncology pipeline let see news detail key newseli lilly company face yet pipeline setback phase iii juniper study fail meet primary endpoint overall survival study be compare verzenio roche astella pharma tarceva patient stage iv nsclc have kra mutation lilly announce fda have grant priority review new drug application nda seek approval first line treatment advanced breast cancer verzenio be approve treat metastatic breast cancer last month patient disease progressed platinum base chemotherapy read more verzenio fail phase iii lung cancer study eli lilly company price consensus eli lilly company price consensus eli lilly company tagrisso be grant breakthrough therapy designation first line treatment metastatic nsclc egfr mutation week company be develop drug phase iii study flaura compare standard care soc egfr tyrosine kinase inhibitor tki therapy datum study be present earlier astrazeneca also announce european medicine agency have accept marketing authorization application maa imfinzi treatment locally advanced unresectable small cell lung cancer astrazeneca plc price consensus astrazeneca plc price consensus astrazeneca plc quoteseattle genetic inc sgen free report partner astella pharma initiate phase ii study enfortumab vedotinin locally advanced metastatic urothelial cancer meanwhile seattle genetic announce clinical collaboration evaluate sgn liv triple negative breast cancer tnbc study evaluate sgn liv combination merck co mrk free report keytruda other study evaluate candidate combination standard chemotherapy neoadjuvant treatment read more seattle genetic inks clinical collaboration cancer drug seattle genetic inc price consensus seattle genetic inc price consensus seattle genetic inc quoteother week also see application submit clovis oncology clvs free report label expansion rubracaas maintenance treatment patient platinum sensitive recurrent ovarian cancer fda also grant fast track designation expedite development astella pharma gilteritinib adult patient relapse refractory acute myeloid leukemia be flt mutation positive meanwhile abbvie abbv free report enter research option license agreement turnstone biologic gain right latter next generation oncolytic viral immunotherapy deal be expect boost abbvie immuno oncology potential stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
2213,ABBV,investor abbvie inc abbv free report need pay close attention stock base move option market lately be oct call have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move abbvie share be fundamental picture company currently abbvie be zack rank hold large cap pharmaceutical industry rank bottom zack industry rank last day analyst have increase earning estimate current quarter none have drop estimate net effect have take zack consensus estimate current quarter share period give way analyst feel abbvie right now huge imply volatility mean trade develop oftentimes option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here bartosiak trading netflix nflx earning option check embed video more detail
2214,ABBV,allergan plc agn free report announce fda have accept new drug application nda pipeline candidate ulipristal acetate allergan be look get ulipristal acetate approve treatment abnormal uterine bleed fibroid organ company expect fda give decision first half once approve ulipristal acetate be first once daily surgical oral treatment option approve condition allergan share have decline compare industry decline be other company have pipeline candidate be evaluate uterine fibroid july bayer bayry free report be evaluate vilaprisan woman suffering uterine fibroid july initiate phase iii study asteroid same abbvie inc abbv free report neurocrine bioscience inc be evaluate pipeline candidate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid april year company announce positive result phase iib study show elagolix meet primary endpoint significantly reduce number heavy bleed day rapidly assessment period month baseline comparison placebo utilize alkaline hematin method allergan plc price allergan plc price allergan plc quote zack rank stock allergan carry zack rank hold better rank stock health care sector be acadium pharmaceutical inc acad free report carry zack rank buy see complete list today zack rank strong buy stock here last day acadium loss share estimate narrow company deliver positive earning surprise trail quarters average beat year date share price company have climb wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
2215,ABBV,company amgen amgn free report endocyte ecyt free report be news amgen signing deal abbvie abbv free report related entry biosimilar version humira endocyte signing licensing deal prove be company recap week most important storiesendocyte soar licensing deal endocyte share have shot whopping follow company announcement have get exclusive worldwide license psma abx gmbh endocyte say quickly move lu psma phase iii development lu psma be radioligand therapeutic rlt target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc deal provide endocyte most advanced target radioligand therapy development prostate cancer represent market opportunity more company hope start phase iii development first half complete program early term deal include upfront payment well issuance share abx warrant purchase additional share endocyte common stock abx also stand receive milestone payment tiered royalty start mid teen endocyte bear future development expense read more endocyte inks deal prostate cancer candidate share abbvie amgen sign deal delay humira biosimilar entry abbvie have gain breathe space enter settlement agreement amgen related biosimilar competition abbvie multus dollar drug humira amgen gain fda approval amjevita biosimilar version humira have acknowledge validity abbvie extensive intellectual property portfolio humira accord deal exclusive license humira commence jan unite state different date other market include oct most country eu amgen also pay royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august humira generate sale first half include unite state remain key market drug humira continue perform well remain major contributor top line come year moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market expectation be high abbvie boehringer ingelheim announce similar settlement agreement dismiss patent litigation abbvie be zack rank hold stock amgen be zack rank buy stock see complete list today zack rank strong buy stock here ablynx positive phase iii result ablynx share shot positive topline result late stage study caplacizumab company von factor vwf nanobody be be develop treatment acquire thrombotic purpura attp ablynx be currently seek approval caplacizumab eu expect submit regulatory application unite state first half caplacizumab have fast track designation unite state treatment attp timely approval make first therapeutic specifically indicated treatment attp acute life threaten autoimmune blood clot disorder cytomx immuno oncology deal amgen cytomx therapeutic ctmx free report have enter immune oncology focuse strategic collaboration amgen development cytomx probody cell engage bispecific epidermal growth factor receptor egfr early development be lead cytomx amgen lead later development company share global late stage development cost deal see cytomx get upfront payment issue common stock amgen cytomx also earn development regulatory commercial milestone egfr program global commercial activity be lead amgen cytomx have option opt profit share unite state receive tiered double digit royalty net product sale outside unite state agreement also cover additional undisclosed target amgen decide pursue target cytomx get additional upfront milestone payment high single digit mid double digit royalty payment cytomx also receive right undisclosed preclinical cell engage bispecific program amgen make milestone royalty payment result product arrangement expect investor react favorably deal regeneron sanofi eczema drug get eu nod regeneron regn free report partner sanofi gain eu approval eczema treatment dupixent make dupixent first target biologic be approve use adult moderate severe atopic dermatitis ad be candidate systemic therapy dupixent approve unite state earlier year have blockbuster potential be be investigate other indication well include asthma eosinophilic esophagitis nasal polyp share regeneron have gain year date significantly outperform industry rally biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index gain almost last trading session major biotech stock regeneron be gilead gild free report lose last month vertex vrtx free report be see last biotech stock roundup here amgen reiterate outlook intercept hit ocaliva safety issue next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2216,ABBV,abbvie abbv free report bristol myer squibb company bmy free report enter deal evaluate combination abbvie investigational antibody drug conjugate abbv bristol myer squibb immune oncology drug opdivo nivolumab meet overexpressing small cell lung cancer nsclc currently combination be phase study evaluate patient second line treatment have fail prior line chemotherapy specific term deal be not disclose notably abbvie be sponsor conduct trial abbvie share have outperformed industry year date stock have be compare industry gain same time frame remind investor opdivo be approve varied indication eu unite state drug have also receive approval several indication include melanoma head neck lung kidney blood cancer abbv be meet antibody drug conjugate target meet amplify meet overexpressing tumor be currently be develop treat advanced solid tumor fact opdivo continue be launch globally approval label expansion label expansion additional indication give product access higher patient population increase commercial potential drug significantly markedly opdivo be be study combination bristol myer other drug yevroy melanoma indication opdivo yervoy regimen be contribute growth opdivo yervoy also drug become first pd inhibitor be approve hematological malignancy classical hodgkin lymphoma unite state eu november second quarter opdivo generate revenue year period abbvie inc price abbvie inc price abbvie inc quotezack rank stock considerabbvie currently carry zack rank hold better rank stock health care sector include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report sporting zack rank strong buy see complete list today zack rank stock here alexion pharmaceutical earning share estimate have moved last day company deliver positive earning surprise trail quarters average beat share price company have increase year date regeneron earning share estimate have increase last day company pull positive earning surprise trail quarters average beat share price company have increase year date look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2217,ABBV,gilead science inc gild free report announce health canada have grant notice compliance noc update label hepatitis virus drug epclusa drug label have be expand extend drug use patient co infected hiv drug be approve canada july treatment adult genotype chronic hcv infection cirrhosis compensate cirrhosis decompensate cirrhosis combination ribavirin expect drug sale increase label expansion hcv co infection remain major cause morbidity hiv infected individual last month health canada grant noc single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg chronic hcv infection gilead be know presence hcv market courtesy blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval unite state june eu july become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval vosevi be expect boost gilead strong hcv portfolio further however hcv franchise be pressure due competition pricing issue note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr other competition well pricing pressure intensified further launch merck co inc mrk free report zepatier gilead stock have gain year date industry gilead recently announce plan acquire kite pharma inc foray emerge field cell therapy kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer acquisition diversify gilead portfolio poise company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hcv market due competitive pressure zack rankgilead currently carry zack rank hold see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2218,ABBV,biotech stock amgen amgn free report intercept pharmaceutical icpt free report be news amgen provide update impact hurricane marium intercept continue be impact ocaliva safety concern recap week most important storiesamgen maintain outlook amgen provide update impact hurricane marium impact company manufacturing facility puerto rico maintain outlook company say product process inventory be lose company have enough stock meet patient demand time release second quarter result amgen have guide earning share total revenue ocaliva safety issue continue hit intercept intercept continue be impact safety issue surround sole market product ocaliva company share be initially hit dear doctor letter earlier month see share fall almost drug safety communication issue fda last week communication layer emphasis importance use recommend dosage label liver injury liver decompensation liver failure death be report ocaliva be dose more frequently recommend ocaliva be approve use primary biliary cholangitis pbc patient company be work fda ensure appropriate safe use ocaliva ocaliva approve bring sale second quarter intercept share be year date compare industry rally infinity bristol myer clinical trial collaboration expand infinity pharmaceutical infi free report exist clinical collaboration bristol myer squibb ipi pi gamma inhibitor opdivo pd immune checkpoint inhibitor have be expand include patient triple negative breast cancer tnbc have not be previously expose pd pd therapy ipi be currently phase ib study patient advanced solid tumor abbvie bristol myer clinical trial collaboration abbvie abbv free report be collaborate bristol myer squibb evaluate combination abbvie investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc phase ib study be ongoing cancer remain challenge medical condition several company be enter clinical trial collaboration evaluate different combination address disease abbvie be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gild free report be vertex lose last month vertex vrtx free report be see last biotech stock roundup here fda nod first cancer biosimilar halo deal raise outlook next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
2219,ABBV,be quite few major development week alexion pharmaceutical alxn free report announce restructure plan see company cut job streamline operation meanwhile datum be present company regeneron pharmaceutical regn free report abbvie abbv free report kura oncology kura free report other recap week most important storiesalexion cut job shift headquarters alexion announce restructure plan see company cut global workforce close several site include rhode island manufacturing facility certain regional country base office shift headquarters boston mid effort company expect generate annual pre tax saving saving be used growth opportunity optimization alexion be guide operate margin growth expect reinvest year start alexion be focuse grow maximize presence rare disease business core area focus include hematology nephrology neurology metabolic disorder result restructure company expect incur pre tax cost be record year alexion be zack rank strong buy stock see complete list today zack rank stock here company have gain year date outperform industry rally regeneron sanofi asthma drug positive phase iii regeneron partner sanofi announce positive top line result late stage study dupixent dupilumab uncontrolled persistent asthma dupixent be find reduce severe asthma attack improve lung function overall result be good less activity be observed patient lower eosinophilic cell regeneron sanofi intend file fda approval year end asthma market be huge person unite state live uncontrolled persistent asthma be treat standard therapy dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication pediatric atopic dermatitis nasal polyp eosinophilic esophagitis read more regeneron sanofi dupixent asthma study meet endpoint abbvie upadacitinib positive study abbvie come positive datum company say experimental oral jak selective inhibitor upadacitinib meet primary rank secondary endpoint late stage study moderate severe rheumatoid arthritis read more abbvie ra candidate meet primary endpoint phase iii company also present promising datum upadacitinib atopic dermatitis eczema phase iib study read more abbvie upadacitinib meet primary endpoint phase iib upadacitinib be be evaluate additional indication include psoriatic arthritis crohn disease ulcerative colitis ankylose spondylitis intercept hit dear doctor letter intercept pharmaceutical icpt free report share be dear doctor letter issue company related use sole market product ocaliva letter layer emphasis use recommend dosage label liver injury liver decompensation liver failure death be report ocaliva be dose more frequently recommend ocaliva approve primary biliary cholangitis pbc patient moderate severe hepatic impairment child pugh bring sale second quarter intercept share be company say recent call do not expect label change box warning sage drug disappoint late stage study sage therapeutic sage free report share be disappointing top line datum late stage study brexanolone sage treatment super refractory status epilepticus srse study fail meet primary endpoint brexanolone be currently late stage development treatment postpartum depression ppd kura soar promising cancer study datum kura share jump more positive topline result mid stage study lead pipeline candidate tipifarnib patient hra mutant relapse refractory squamous cell carcinoma head neck hnscc primary endpoint be achieve completion enrollment biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock amgen be regeneron lose last month vertex vrtx free report be see last biotech stock roundup here cellectis clinical hold insm soar positive datum next biotech world watch usual regulatory pipeline update response fda regard approval status amgen allergan biosimilar version roche cancer drug avastin bevacizumab be shortly company get favorable vote fda advisory panel recently more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2220,ABBV,abbvie abbv free report share have increase more company announce oral jak selective inhibitor upadacitinib meet primary endpoint phase iib study treatment adult patient atopic dermatitis also know eczema company plan advance candidate phase iii study next year abbvie share have outperformed industry year date stock have surge compare industry rally period phase iib randomize placebo controlled dose range study be design evaluate safety efficacy dose mg mg mg once daily upadacitinib patient aforementioned indication study meet primary endpoint dose group highly statistically significant clinically meaningful result compare placebo study primary outcome be mean percentage change eczema area severity index easi score tool used measure extent disease severity trial greater mean percentage change baseline easi score compare placebo week also patient receive mg once daily dose upadacitinib show almost clear skin additionally study meet secondary endpoint demonstrate significant reduction skin itch upadacitinib be also be investigate phase iii study rheumatoid arthritis other research be also underway treatment crohn disease ulcerative colitis psoriatic arthritis national eczema association person unite state have form atopic dermatitis child be affected disease hence approval drug provide company access huge patient population suffering disease unite state notably march regeneron pharmaceutical inc regn free report partner sanofi sny free report have launch dupixent dupilumab injection treat atopic dermatitis thus upadacitinib await combat competitive pressure market once approve abbvie inc priceabbvie inc price abbvie inc quotezack rank stock considerabbvie currently carry zack rank hold better rank stock pharma sector be aduro biotech inc adro free report carry zack rank buy see complete list today zack rank strong buy stock here aduro biotech loss share estimate reduce last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2221,ABBV,abbvie inc abbv free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session continue recent uptrend company stock be now past month time frame move come company announce solid top line result phase study upadacitinib cover latest research medication eczema company have not see estimate revision past month zack consensus estimate current quarter have moved lower same time period recent price action be encourage so make sure keep close watch firm future abbvie currently have zack rank hold earning esp be negative abbvie inc price abbvie inc price abbvie inc quoteinvestor interested medical sector consider better rank stock merit medical system inc mmsi free report carry zack rank strong buy see complete list today zack rank stock here be abbv go predict see other think stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2222,ABBV,cancer be second most common cause death precede only heart disease traditional cancer treatment include surgery radiation chemotherapy however immunotherapy gene therapy other new novel therapy be be develop improve supplement replace traditional cancer treatment target reduce remove cancerous growth accord report american cancer society almost new cancer case be expect be diagnosed create significant need effective cancer medication go say big pharma company be gear develop bring innovative cancer treatment market well expand label market oncology drug pharma biotech giant have significant financial resource disposal have even collaborate pool resource technology here discuss pharma giant possess industry strongest oncology pipeline portfolio astrazeneca azn free report astrazeneca be work strengthen oncology product portfolio have several candidate pipeline company target be launch least new oncology medicine include lynparza tagrisso imfinzi be already approve market interesting candidate company immuno oncology pipeline be imfinzi durvalumab be evaluate multiple cancer alone combination other regimen include phase iii trial combination tremelimumab first line urothelial cancer nsclc small cell lung cancer head neck squamous cell carcinoma hnscc other imfinzi be launch first indication second line advanced bladder cancer other phase iii oncology candidate astrazeneca pipeline include acalabrutinib blood cancer moxetumomab pasudotox leukaemia selumetinib thyroid cancer savolitinib kidney cancer lynparza presently market advanced ovarian cancer be also different study range tumor type include breast prostate pancreatic cancer well earlier line setting ovarian cancer tagrisso be also be evaluate earlier line setting lung cancer astrazeneca carry zack rank hold see complete list today zack rank strong buy stock here so far year astrazeneca share have moved compare unfavorably increase large cap pharma industry pfizer pfe free report pfizer newly approve immunotherapy bavencio be be consider significant top line driver new york base pharma giant bavencio avelumab receive fda approval metastatic merkel cell carcinoma mcc march advanced bladder cancer bavencio be review eu mcc decision expect third quarter pfizer be focuse continuously grow expand bavencio new indication market globally pfizer have also initiate avelumab double triple combination study chemotherapy target therapy have avelumab combination therapy immuno oncology agent development pfizer other oncology candidate have also be approve fda recently besponsa relapse refractory acute lymphoblastic leukemia august mylotarg new relapse cd positive acute myeloid leukemia september other cancer candidate pfizer pipeline include talazoparib advanced breast cancer dacomitinib advanced nsclc egfr activate mutation pfizer be also aggressively work expand label approve cancer drug ibrance xalkori pfizer also carry zack rank hold so far year pfizer share have moved abbvie abbv free report abbvie be work expand accelerate presence oncology build grow position hematological oncologyabbvie imbruvica currently approve several cancer indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease abbvie be position imbruvica pipeline molecule treatment be several company sponsored study acquisition cancer drugmaker stemcentrx abbvie gain late stage candidate rovalpituzumab tesirine rova additional early stage compound solid tumor indication significant portfolio pre clinical asset rova be currently registrational study small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing accord abbvie candidate have blockbuster potential be launch abbvie intend study candidate additional indication estimate peak sale close abbvie be also study market cancer drug venclyxto venclexta expand label address broader relapse refractory cll patient population expand earlier line therapy broaden other hematologic malignancy abbvie also carry zack rank so far year abbvie share have moved bristol myer bmy free report bristol myer pd inhibitor opdivo have be perform impressively bristol myer be work expand label opdivo further alone combination therapy yervoy other cancer agent further bristol myer cancer portfolio include multiple myeloma drug empliciti leukemia drug sprycel contribute top line addition bristol myer be evaluate other immune system pathway treatment cancer pathway help company bring market potentially immunotherapy combination monotherapy help fight different type cancer bristol myer also carry zack rank so far year bristol myer share have moved other not far behindmerck mrk free report be also conduct numerous study evaluate highly successful pd therapy keytruda more type cancer more study include more combination study roche rhhby free report dominate breast cancer space strong demand franchise drug herceptin perjeta kadcyla apart strong breast cancer franchise roche oncology portfolio also boast lung cancer drug avastin tarceva immuno oncology drug tecentriq newly approve multiple sclerosis drug ocrevus label expansion effort be ongoing cancer drug swiss drugmaker novartis nvs free report also boast many experimental cancer drug pipeline include couple biosimilar version popular cancer drug novartis cancer pipeline be bolster deal buy most glaxo gsk free report oncology portfolio lilly lly free report also layer oncology strategy call hold july involve build key treatment cyramza lartruvo abemaciclib foundational agent focuse develop new standard care change therapy combination regimen include immuno therapy cancer market be fierce not pipeline candidate be successful however pharma biggy have enough late stage cancer program portfolio be chance quite few rollout come year surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2223,ABBV,biotech giant gilead science inc gild free report announce buy kite pharma inc foray emerge field cell therapy term agreement agreement gilead pay share cash transaction value approximately price represent premium close share price kite aug transaction be approve shareholder company be expect close fourth quarter acquisition be expect be neutral bottom line third year accretive thereafter strategic benefitwe note kite be pioneer cell therapy have develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer most advanced therapy candidate kite pipeline be axicabtagene ciloleucel axi cel be be develop treatment refractory aggressive hodgkin lymphoma include diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl biologic license application bla candidate be submit mar car therapy be currently priority review unite state fda be expect give decision nov candidate be also review eu tentative approval expect kite be prepared commercial launch unite state manufacturing preparation be complete company be currently build infrastructure europe remind investor pipeline candidate clinical trial hematologic cancer solid tumor be kite car therapy candidate target bcma expressed multiple myeloma acquisition diversify gilead portfolio position company dominant position cellular therapy space note investor be expect gilead announce acquisition term give decline once lucrative hepatitis hcv market due competitive pressure gilead be know presence hcv market blockbuster hcv drug sovaldi harvoni however hcv franchise be pressure competition pricing issue note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr other moreover gilead be sit cash short term marketable security hence acquisition announcement be lurk car be manufacture individual patient used own cell thereby make different typical small molecule biologic therapy treatment process cell be draw patient blood cell be then reprogram manufacturing facility create cell be genetically code express chimeric antigen receptor recognize fight cancer cell other bcell express specific antigen deal look expensive give premium gilead paid kite car space be expect be revolutionary treatment cancer car space represent immense potential juncture potential approval axi cell be significant boost gilead prospect have dampen late gilead stock have decline year so far industry apart kite novartis ag nvs free report be company be focus car treatment july fda oncologic drug advisory committee odac unanimously recommend approval immunocellular therapy candidate ctl decision be expect shortly september october ctl become first car cell therapy approve ctl investigational car therapy be be evaluate treatment relapse refractory pediatric young adult patient cell acute lymphoblastic leukemia potential approval also open new frontier treatment cancer advance immunocellular therapy child young adult cell other hand share kite be news company immensely benefit gilead dominant position biotech space anticipate approval lead candidate fact year so far kite pharma stock be compare favorably increase register industry zack rankgilead currently carry zack rank buy see complete list today zack rank strong buy stock here zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
2224,ABBV,roche hold ag rhhby free report announce fda have accept company supplemental biologic license application sbla grant priority review gazyva combination chemotherapy follow gazyva alone patient suffering previously untreated follicular lymphoma fda be expect announce final decision dec remind investor priority review be give drug fda believe have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease note gazyva combination chlorambucil be approve patient suffering previously untreated chronic lymphocytic leukaemia cll potential approval follicular lymphoma be expect boost sale further drug be also be evaluate other approve investigational medicine include cancer immunotherapy small molecule inhibitor roche stock have gain industry gain roche hematology portfolio present consist mabthera rituxan gazyva gazyvaro venclextatm venclyxtotm collaboration abbvie inc abbv free report pipeline have small molecule antagonist mdm idasanutlin rg polatuzumab vedotin company also have hemophilia candidate emicizumab pipeline last week fda grant emicizumab prophylaxis preventative priority review once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor fda be expect announce final decision feb remind investor fda grant breakthrough therapy designation emicizumab adult adolescent haemophilium inhibitor september approval new drug further boost roche hematology portfolio zack rank stock considerroche currently carry zack rank hold better rank stock healthcare sector be gilead science inc gild free report aduro biotech inc adro free report stock carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat aduro biotech loss share estimate have narrow last day company deliver positive surprise trail quarters average beat more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2225,ABBV,gilead science inc gild free report announce health canada have grant notice compliance single tablet regimen vosevi sofosbuvir mg velpatasvir mg voxilaprevir mg treatment chronic hepatitis virus hcv infection vosevi have be approve treatment hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sofosbuvir contain regimen ns inhibitor drug be already approve gilead be know presence hcv market blockbuster hcv drug sovaldi harvoni hcv portfolio receive huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection approval voseviwill further boost gilead strong hcv portfolio however hcv franchise be pressure result competition pricing issue note harvoni sovaldi epclusa face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza other competition well pricing pressure intensified further launch merck mrk free report zepatier gilead stock have moved year so far compare industry gain meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu now represent total prescription volume genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set be expect further boost sale however gilead lose exclusivity viread country outside impact sale zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2226,ABBV,lately medtech space have be face brunt frequent regulatory change trump administration be face socio economic upheaval investor be apprehensive impact stock historic trend suggest investor sentiment have always be partially incline fancy brand name volatile economic backdrop result company solid brand value robust fundamental generally enjoy sail even political turbulence such bigwig medtech space be abbott laboratory free report have greatly evolved recent year company have pursue slew merger divestment have also see solid growth diabetic business strategic buyout acquisition cfr pharmaceutical tendyne holding st jude medical be worth mentioningafter spin proprietary pharmaceutical product division form abbvie inc abbv free report abbott have gain traction establish pharmaceutical division then revenue have see cagr last year period company have more less report strong quarterly number indicate fundamental strength share lack lusterhowever share price performance abbott have be disappointing same time frame company represent meager return just lower broader industry gain return same time frame main issue plague abbott foreign exchange be major headwind strengthen euro other develop market currency have constantly hampered company performance international market abbott currently expect currency exchange have negative impact sale apart business environment continue be challenge globe slow growth nutrition business china economic problem venezuela be expect remain unresolved time dampening company top line growth bleak prospectswhile abbott boast solid fundamental company prospect be dull note company promise long term earning growth just lower broader industry estimate growth rate furthermore abbott revenue have decline last year compare broader industry revenue growth secondly abbott historical cash flow growth have be extremely low compare unfavorably broader industry positive growth unfavorable growth metric be indicative fact solid brand value abbott not prove be lucrative pick long haul growth stock long term growth parameter be not favor abbott hold zack rank hold now so instead opt brand value let take look follow not so fancy medtech stock be expect gain long haul apart flaunt strong zack rank strong buy buy stock promise long term expect growth rate higher compare favorably broader industry also have take growth style score consideration growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity lonza group ltd lzagy free report lonza group sport zack rank have long term expect earning growth rate company have growth score see complete list today zack rank stock here lonza group supply product service pharmaceutical biotech specialty ingredient market worldwide outstanding first half year lonza group continue expect strong performance pharma biotech specialty ingredient segment company strategic initiative improve customer relationship management process innovation operational improvement program area automation streamline instill investor confidence stock have gain last year orasure technology inc osur free report zack rank stock promise long term expect earning growth notably orasure have growth style score company develop manufacture market sell oral fluid diagnostic product specimen collection device unite state europe internationally orasure bank solid growth infectious disease business unit higher sale company molecular product oraquick hcv product be primary growth driver company have also be banking flagship oragene product line orasure have have impressive run last year company have return significantly higher broader industry same time frame idexx laboratory inc idxx free report zack rank company continue demonstrate solid growth globally strong international expansion long term expect earning growth rate growth score idexx laboratory exit second quarter solid note beating zack consensus estimate count headquarter delaware nj idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market major fraction idexx laboratory revenue be derive companion animal group segment drive expand premium instrument base unite state international market company be expect grow extensively long haul idexx laboratory boast stellar return last year furthermore estimate revision trend next year be promising notably analyst moved north last month zack consensus estimate next year increase share same time framee lemaitre vascular inc lmat free report lemaitre have zack rank promise long term expect earning growth rate growth score company xenosure platform be key catalyst moment stock have gain last year headquarter burlington company market sell service support medical device implant treatment peripheral vascular disease worldwide company expect sale rise almost organically next quarter strong margin expansion lemaitre estimate revision trend next year be quite encourage notably analyst moved north compare movement opposite direction result zack consensus estimate increase almost same time frame surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2227,ABBV,biogen inc biib free report announce biosimilar version abbvie inc abbv free report top selling blockbuster drug humira have be approve european commission biosimilar be market trade name imraldi imraldi sb be used whole range indication include rheumatoid arthritis axial ankylose spondylitis plaque psoriasis psoriatic arthritis crohn disease ulcerative colitis polyarticular juvenile idiopathic arthritis active enthesitis related arthritis hidradenitis suppurativa infectious uveitis remind investor biosimilar be grant positive opinion committee medicinal product human use chmp june year biogen have joint venture samsung biologic biosimilar samsung bioepis joint venture company already marketsa couple biosimilar eu flixabi biosimilar reference merck co inc mrk free report remicade benepali biosimilar reference amgen pfizer enbrel make imraldi third tnf biosimilar biogen receive marketing authorization eu benepali be do quite well generate sale first half flixabi record sale same period note earlier year amgen inc amgn free report gain eu approval amgevita biosimilar version humira biogen share have rise year so far industry record increase biogen carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2228,ABBV,roche hold ag rhhby free report announce fda have accept company biologic license application bla grant priority review hemophilia candidate emicizumab fda have grant emicizumab prophylaxis preventative priority review once weekly subcutaneous treatment adult adolescent child hemophilia factor viii inhibitor priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease bla emicizumab be base result phase iii study haven adult adolescent year older well interim result phase iii study haven study child younger year age note result haven be publish new england journal medicine nejm result study be present international society thrombosis haemostasis isth congress july fda be expect give decision feb remind investor fda grant breakthrough therapy designation emicizumab adult adolescent haemophilium inhibitor september meanwhile roche be evaluate emicizumab patient hemophilia inhibitor evaluate less frequent dose regimen well roche stock have lose so far industry gain emicizumab roche hematology portfolio present consist mabthera rituxan gazyva gazyvaro venclextatm venclyxtotm collaboration abbvie inc abbv free report pipeline have small molecule antagonist mdm idasanutlin rg polatuzumab vedotin few other company be also develop treatment hemophilia shire plc shpg free report also file investigational new drug ind application fda seek approval recombinant factor viii fviii gene therapy candidate shp drug be used treatment patient hemophilia zack rank stock considerroche currently carry zack rank hold better rank stock health care sector be gilead science inc gild free report carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day company deliver positive earning surprise trail quarters average beat simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
2229,ABBV,abbvie inc abbv free report announce pan genotypic regimen glecaprevir pibrentasvir mavyret have be approve canada treat chronic hepatitis virus hcv infection major genotype gt be important note ribavirin free mavyret recently gain approval unite state eu combination medicine be priority review japan same indication abbvie share have marginally outperformed industry so far year stock have rally compare broader industry increase approval canada be backed datum registration study abbvie clinical development program clinical trial be conduct more patient major hcv genotype datum study show week treatment achieve cure rate major genotype chronic hcv significantly glecaprevir gle be potent protease inhibitor pibrentasvir pib be new ns inhibitor glecaprevir be discover collaboration agreement enanta pharmaceutical enta free report hcv protease inhibitor company press release canadian be chronically infected hcv more new case hepatitis be report approximately patient estimate be unaware disease also gt be most common genotype canada gt be most difficult treat cure hence drug approval be expect provide company access market huge potential remind investor gilead science inc gild free report launch epclusa first oral pan genotypic single tablet regimen treat adult genotype hcv infection unite state eu last year lend strong competition mavyret not inform merck co inc mrk free report be also evaluate oral triple combination therapy mk mix mk grazoprevir ruzasvir treatment chronic hcv genotype gt infection pricing pressure hcv market be increase company say experience market share loss price erosion due competitive dynamic hcv arena downturn continue year viekira hcv treatment sale expect decline abbvie inc priceabbvie inc price abbvie inc quotezack rankabbvie currently carry zack rank hold see complete list today zack rank strong buy stock here surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
2230,ABBV,gilead science inc gild free report announce fda have grant priority review company new drug application nda investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv infection nda be file jun fda have set target action date prescription drug user fee act pdufa feb marketing application bic ftc taf be also review european union be validate european medicine agency ema july potential approval be expect toboost gilead hiv gilead be dominant player hiv market impressive portfolio same newly launch taf base product genvoya odefsey descovy be perform well strong adoption eu genvoya have already become most prescribe regimen treatment naïve switch patient launch nov taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy genvoya be now company bestselling hiv product surpass truvada atripla fourth quarter genvoya be now company bestselling hiv product treatment naïve patient share gilead expect use truvada pre exposure prophylaxis prep continue boost sale hiv franchise go forward particularly strong uptake truvada use pre exposure prophylaxis set also boost sale company see significant uptick prep usage estimate patient used truvada end second quarter meanwhile gilead stock have gain only year so far industry gain uptake hiv franchise help company combat persistent decline hcv franchise due competitive pressure hcv business see improvement second quarter hcv franchise be boost fda approval vosevi hcv patient start first half be better expectation see gradual decline second half due increase competition harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza competition well pricing pressure intensified further launch merck mrk free report zepatier zack rank gilead currently carry zack rank buy see complete list today zack rank strong buy stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2231,ABBV,regeneron regn free report several mid small cap biotech stock report earning result company dynavax dvax free report abbvie abbv free report provide regulatory update recap week most important storiesa look earning result regeneron report strong quarter company surpass earning revenue estimate back eylea sale company raise outlook eylea well read more regeneron beat earning sale raise view immuno oncology focuse company juno read more juno therapeutic loss widen revenue surpass kite also report second quarter result kite have key regulatory event come later year fda expect respond approval status company car treatment axicabtagene ciloleucel nov investigational treatment have be submit review eu well treatment relapse refractory diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl patient be ineligible autologous stem cell transplant regeneron be zack rank strong buy stock see complete list today zack rank stock here dynavax hepatitis vaccine pdufa date push back month dynavax get favorable vote fda advisory panel investigational hepatitis vaccine heplisav be face delay get vaccine approve fda ask detailed information company propose post marketing study treatment advisory panel have vote favor safety datum heplisav have comment design dynavax propose post marketing study base company fda agree more time be need finalize key detail post marketing study result fda action date be push back month nov company still expect launch heplisav early dynavax share be whopping year date significantly outperform industry rally abbvie new hcv treatment get fda nod abbvie week pan genotypic ribavirin free once daily hepatitis virus hcv treatment mavyret gain fda approval use hcv patient cirrhosis be new treatment approval competition hcv market be go heat further accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history company say american be chronically infected hcv mavyret gain eu approval recently fibrogen hit week high ipf drug datum fibrogen fgen free report share shot positive datum company investigational idiopathic pulmonary fibrosis ipf drug pamrevlumab mid stage study well combination safety sub study proprietary first class connective tissue growth factor ctgf antibody be be evaluate fibrotic disease cancer ipf indication represent huge commercial potential ipf abnormal scarring lung be rare serious lung disease survival rate comparable deadliest cancer approve pamrevlumab bring significant sale fibrogen currently approve ipf drug include esbriet ofev read more do fibrogen stock hit time high today biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene celg free report vertex vrtx free report record minimal gain gilead lose reflect impact approval abbvie new hcv drug last month vertex be see last biotech stock roundup here earning gilead celg more dynavax panel vote next biotech world watch earning report small mid cap biotechs well usual regulatory pipeline update more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2232,ABBV,infinity pharmaceutical inc infi free report report loss cent share second quarter wider zack consensus estimate loss cent company have report loss cent year quarter infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc price consensus ep surprise infinity pharmaceutical inc quotesince infinity do not have approve product portfolio company earn revenue form royalty license milestone payment well research development support fee paid partner infinity do not record revenue second quarter however record collaboration revenue year quarter related infinity previous collaboration agreement abbvie inc abbv free report infinity share price have increase year date compare industry gain quarter detailin report quarter expense plummet decline be mainly related decrease clinical development expense duvelisib addition company restructure activity general administrative expense be report quarter year quarter decrease be mainly due company restructure activity outlook expect net loss be range company anticipate end year end cash cash equivalent available sale security balance band moreover infinity expect exist cash cash equivalent jun be adequate fund company capital need first quarter pipeline updatecurrently infinity be evaluate ipi monotherapy combination bristol myer squibb company bmy free report opdivo nivolumab phase study patient advanced solid tumor company complete evaluation escalate monotherapy dose ipi range mg qd once daily have determine mg dose evaluation expansion component study selection mentioned dose be base pharmacokinetic pharmacokinetic analysis show ipi maintain full suppression pi gamma dose level further datum study also show ipi dose mg qd be well tolerate dose limit toxicity be observed subsequently monotherapy expansion component study be now available enrolment study evaluate safety activity ipi dose qd approximately patient meanwhile dose escalation evaluate ipi combination opdivo be currently ongoing company plan initiate combination expansion component study second half other hand company amend license agreement takeda oncology jul ipi amend agreement company longer have obligation pay takeda future royalty worldwide net sale selective inhibitor pi gamma include ipi lieu infinity issue unsecured convertible note takeda mature accrue interest annual rate wider expect loss second quarter be disappointing infinity receive huge setback abbvie terminate collaboration agreement development duvelisib hence expect investor focus pipeline progress upcoming quarters zack rank key pickinfinity currently hold zack rank hold better rank stock healthcare sector be gilead science inc gild free report currently carry zack rank buy see complete list today zack rank strong buy stock here gilead earning share estimate increase last day follow strong result second quarter company deliver positive earning surprise trail quarters average beat today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
2233,ABBV,major biotech stock gilead gild free report celgene celg free report alexion abbvie abbv free report vertex vrtx free report report second quarter result last few day company gilead amgen amgn free report also provide regulatory update recap week most important storiesa look earning result gilead result be strong company hiv franchise putt strong performance hepatitis virus hcv franchise perform better expect company raise revenue outlook include hcv franchise read more gilead top earning revenue estimate stock celgene also top estimate raise earning guidance year read more celgene beat earning sale estimate up view do alexion read more alexion top earning revenue up view vertex read more vertex earning top solid cystic fibrosis sale abbvie too top expectation read more abbvie top earning revenue outlook intact earlier expect fda approval celgene agio cancer drug celgene partner agio agio free report gain fda approval idhifa enasidenib treatment adult patient relapse refractory acute myeloid leukemia aml idh mutation detected fda approve test approval come ahead fda action date aug make idhifa first only fda approve therapy patient population represent aml patient information provide company more new case aml be detected year majority patient see disease relapse eventually prognosis aml be poor overall survival patient population estimate be less month idhifa come box warning regard differentiation syndrome uptake be strong give significant unmet medical need be third time lucky dynavax heplisav dynavax dvax free report share shot favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter nov other feb decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share be whopping year date significantly outperform industry rally read more dynavax share jump fda committee approval vertex up cf outlook kalydeco label expansion vertex cystic fibrosis cf drug kalydeco label have be expand now be used more cf patient year older have residual function mutation result splice defect cystic fibrosis transmembrane conductance regulator cftr gene label expansion vertex up sale guidance drug old guidance vertex now expect total cf product revenue old guidance include orkambi sale unchanged regulatory update amgen gilead amgen provide quite few regulatory update last few day company say have submit regulatory application seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop prolium bring sale first half amgen partner allergan also say have file fda approval abp biosimilar candidate roche herceptin trastuzumab herceptin be approve treatment adjuvant breast cancer metastatic breast cancer metastatic gastric cancer meanwhile amgen pcsk inhibitor repatha get priority review inclusion fourier cardiovascular outcome study datum reduction risk cardiovascular event decision agency be expect dec amgen say second application expansion lipid lower indication include additional patient population study be also accept agency gilead also have update regulatory front company say hcv drug epclusa label be update include use patient co infected hiv epclusa initially gain approval jun be oral pan genotypic once daily single tablet regimen label expansion provide co infected patient convenient pill day regimen work hcv genotype be compatible widely used antiretroviral regimen epclusa sale crossed first half moreover gilead latest hcv offer vosevi gain approval eu treatment genotype marketing authorization harvoni eu be also extend allow use adolescent population vosevi be approve few week back july gilead be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion gain regeneron lose last month vertex be see last biotech stock roundup here amgen biogen top estimate update incyte ra drug next biotech world watch earning report company biomarin regeneron other more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2234,ABBV,momenta pharmaceutical inc mnta free report report loss cent share second quarter line zack consensus estimate report loss be however wider year loss cent momenta pharmaceutical inc price ep surprise momenta pharmaceutical inc price ep surprise momenta pharmaceutical inc quoterevenue quarter improve top zack consensus estimate momenta stock have rally year date compare industry rally quarter detailmomenta top line comprise product revenue earn sandoz sale glatopa generic version copaxone mg compare year quarter decrease be primarily due lower sale deduction second quarter well legal reimbursement second quarter collaborative research development revenue come year quarter decline revenue be mainly due termination baxalta collaboration agreement effective dec research development expense be general administrative expense increase outlook updatedmomenta now expect operate expense exclude stock base compensation net collaborative revenue range compare previous guidance guidance also include approximately capital expenditure operate expense third quarter be project momenta expect generate revenue mylan myl free report upfront payment quarterly basis jul momenta earn milestone payment sandoz glatopa mg continue be sole fda approve generic copaxone mg pipeline updatesandoz abbreviated new drug application anda mg thrice weekly formulation copaxone glatopa mg be fda review however momenta suffer setback fda issue warning letter pfizer inc pfe free report feb be sandoz contract fill finish manufacturing partner glatopa pfizer have submit comprehensive response observation cite warning letter anda approval be now contingent satisfactory resolution compliance observation state warning letter issue pfizer meanwhile momenta continue progress other pipeline candidate currently momenta biosimilar version abbvie inc abbv free report humira be be evaluate phase iii study patient suffering moderate severe chronic plaque psoriasis move ahead company plan submit candidate approval regulatory body fourth quarter also expect first commercial launch be early timeframe company complete enrolment phase study biosimilar version orencia apr collaboration mylan top line datum study be expect second half furthermore momenta novel autoimmune portfolio include selective immunomodulator fc receptor sif fcrn monoclonal antibody jan company enter research collaboration license agreement csl potential future fc multimer program candidate be expect enter clinic momenta successfully complete phase single ascend dose study healthy volunteer multiple ascend dose portion study be initiate jan expect be complete aug datum single multiple ascend dose portion study be project second half takemomenta loss share come line estimate second quarter sale beat estimate anda approval glatopa be contingent satisfactory resolution compliance observation state warning letter issue fda result delay approval expect warning letter remain drag company share issue be solve nevertheless sale glatopa mg continue do well glatopa mg have capture approximately market addition potential approval boost investor confidence zack rankmomenta currently carry zack rank hold see complete list today zack strong buy rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2235,ABBV,fda approve treatment last year have give approval drug so far include july key approval year include gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month august new indication bristol myer opdivo bristol myer squibb bmy free report be look get label pd inhibitor expand use patient mismatch repair deficient dmmr microsatellite instability high msi metastatic colorectal cancer crc prior oxaliplatin irinotecan base chemotherapy regulatory application be currently priority review response expect aug opidivo be currently approve wide range indication bring sale first half bristol myer have lose value year date ytd versus growth industry ra drug support fda panel fda arthritis advisory committee be meeting tomorrow discuss bla johnson johnson jnj free report investigational rheumatoid arthritis ra treatment plivensia sirukumab il inhibitor company be look get plivensia approve treatment adult patient moderately severely active ra have have inadequate response be intolerant more disease modify rheumatic drug dmard ra be common chronic life long autoimmune disease affect person new treatment option have enter market last couple decade ra patient be still not adequately manage many left fewer therapeutic option due loss response available agent poor compliance due inconvenient dose earlier week fda have release briefing document meeting indicate lot emphasis be place safety profile drug especially imbalance cause death plivensia placebo approve plivensia enter pretty crowd market give presence drug humira actemra kevzara other once monthly dose schedule give advantage share have gain ytd outperform industry rally fda follow eu path give green signal abbvie maviret abbvie abbv free report also have important regulatory event come fda expect respond approval status company latest hepatitis virus hcv offer month maviret investigational pan genotypic regimen glecaprevir pibrentasvir be once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch note maviret gain eu approval just last week share abbvie have gain ytd outperform industry rally third time lucky dynavax heplisav be great week clinical stage immunology company dynavax technology corp dvax free report get favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote be third time lucky company have previously receive complete response letter heplisav nov other feb fda decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share shot positive panel vote be whopping ytd significantly outperform industry rally pfizer xeljanz be review fda advisory panelpfizer pfe free report have regulatory event month first be fda advisory panel meeting other pdufa date fda arthritis advisory committee be meeting aug discuss supplemental new drug application snda submit company jak inhibitor xeljanz xeljanz xr treatment adult patient active psoriatic arthritis efficacy safety datum benefit risk consideration be discuss panel xeljanz currently approve ra bring sale meanwhile fda be expect give response regard approval status pfizer besponsa recently gain approval eu approve besponsa provide new treatment option adult patient relapse refractory cell precursor acute lymphoblastic leukemia aggressive type blood cancer poor prognosis adult accord information provide pfizer year overall survival rate patient relapse refractory adult be less pfizer stock have gain ytd lag industry belong pfizer be zack rank hold stock see complete list today zack rank strong buy stock here other fda decision schedule month include response regard agio pharmaceutical inc agio free report partner celgene celg free report idhifa priority review relapse refractory acute myeloid leukemia aml idh mutation aug meanwhile fda be expect decide approval status valeant eye drug vesneo latanoprostene bunod ad treatment levodopa induced dyskinesia person parkinson disease aug make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2236,ABBV,north chicago il base abbvie inc abbv free report be best know autoimmune disease drug humira abbvie flagship product humira be approve several indication rheumatoid arthritis moderate severe moderately severely active polyarticular juvenile idiopathic arthritis active psoriatic arthritis active ankylose spondylitis crohn disease moderate severe ulcerative colitis moderate severe axial pediatric crohn disease chronic plaque psoriasis moderate severe hidradenitis suppurativa moderate severe other key product include imbruvica cancer viekira pak hepatitis virus hcv treatment humira be major contributor abbvie top line humira remain key growth driver abbvie come quarters see investor focus remain primarily viekira performance well pipeline update meanwhile pharmacyclic acquisition have diversify abbvie product portfolio addition imbruvica abbvie performance have be mixed pharmaceutical company deliver positive surprise past quarter record line earning other average earning beat last quarters be abbvie inc price ep surpriseabbvie inc price ep surprise abbvie inc quotecurrently abbvie have zack rank hold definitely change follow company earning report be just release have highlighted key stat just reveal announcement earning abbvie second quarter earning come share beating zack consensus estimate revenue abbvie post revenue marginally beating zack consensus estimate key stat humira sale come year year exclude currency impact second quarter imbruvica net revenue be year year outlook abbvie reiterate previously issue outlook company maintain adjust ep range zack consensus estimate be currently peg share share price impact share be almost pre market trading check back later full abbvie earning report hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
2237,ABBV,earning season be mean countless publicly trade company continue release quarterly earning report update investor company financial result provide insight economy have perform past quarter however insane amount press release earning season make easy investor become lose ocean report fortunately zack earning calendar list company be expect report earning give calendar date make useful organizational tool investor say let break few most important upcoming report check major company release earning report friday july exxon mobil corporation xom free report friday july market opencrude oil giant exxon mobil release quarterly earning report tomorrow morning market open zack consensus estimate call revenue represent year year growth additionally company be project report earning share constitute year year growth whopping exxon have collaborate russia explore potential commercial reserve country yet tension unite state russia lead sanction country thwart attempt exxon make capitalize oil reserve russia also exxon feature dividend yield be lowest major energy firm sit industry average fact zack rank sell turn head wrong reason company prepare release earning report chevron corporation cvx free report friday july market openenergy behemoth chevron be expect post quarterly earning report market open july zack consensus estimate call chevron real revenue report earning share constitute strong year year growth respectively however first quarter chevron generate just operate cash flow deal dividend capital expenditure trend be detrimental company continue next few quarters company be rely asset sale debt fill deficit also chevron mass production violence prone region nigeria pose additional risk investor chevron currently hold zack rank sell provide gloomy financial outlook move forward merck company inc mrk free report friday july market openmerck company be large global research drive pharmaceutical company discover develop manufacture vaccine medicine address unmet medical need more importantly company be expect release quarterly earning report tomorrow morning accord latest zack consensus estimate merck company be project report sale earning share merck feature impressive product portfolio pipeline include many candidate advanced stage development target multiple disease such atherosclerosis cancer diabetes cardiovascular disease company have continue prioritize pipeline so candidate highest potential get require support investor feel sense optimism merck currently sport zack rank buy have beaten earning estimate past operational quarters date back abbvie inc abbv free report friday july market openabbvie be global research base company focus develop marketing advanced therapy address world most complex disease accord zack consensus estimate abbvie be project report revenue earning share constitute year year growth respectively abbvie flagship product humira continue drive revenue inflammatory product have witness sale increase company expect humira real total sale more fact abbvie have defeat earning projection past operational quarters date back couple adequate zack rank hold instill confidence investor approach report more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2238,ABBV,second quarter report cycle be full swing quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig eli lilly company lly free report biogen inc biib free report release second quarter result week company beat earning revenue estimate raise sale earning expectation full year moreover vertex pharmaceutical incorporate vrtx free report amgen inc amgn free report report encourage second quarter result jul beating estimate count however glaxosmithkline plc gsk free report report mixed second quarter result same day beating earning miss sale let take look large cap pharma company be set report second quarter result jul abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter abbvie earning performance have be mixed earning beating expectation last quarters meeting same remain result average positive surprise quarter abbvie have earning esp zack rank hold do not conclusively show abbvieis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quoteabbvie key drug humira be perform well be expect continue do well second quarter imbruvica have be record strong sale past few quarters expect trend continue however hcv franchise continue be pricing pressure read more abbvie earning disappointment store merck co inc mrk free report merck be also schedule announce result open bell merck have beaten estimate last quarters result average positive surprise last report quarter merck deliver positive surprise merck company inc price ep surprise merck company inc price ep surprise merck company inc company have earning esp zack rank buy thus do not look poise deliver beat time see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter however company be expect face headwind form genericization increase competition negative impact currency exchange read more merck pull surprise earning season more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2239,ABBV,vertex pharmaceutical incorporate vrtx free report report second quarter earning share cent include impact stock base compensation expense beat zack consensus estimate cent notably company have post loss cent year quarter strong product revenue lead higher profit quarter exclude stock base compensation expense second quarter adjust earning be cent share compare year figure cent vertex report revenue second quarter year year drive strong product revenue revenue also beat zack consensus estimate cf franchise sale strongvertex second quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be second quarter year year kalydeco sale rise gain inventory stocking ahead jul holiday year kalydeco be approve use cf patient year older have residual function mutation cftr gene more person have mutation expand indication boost sale drug future quarters orkambi lumacaftor ivacaftor deliver sale year year sequential basis orkambi sale rise almost second quarter support continue uptake globally further uptake pediatric indication approval be receive sep meanwhile inventory stocking ahead jul holiday also benefit sale second quarter cost riseadjust include stock base compensation expense research development expense increase second quarter due higher cost related development triple combination cf regimen adjust include stock base compensation expense selling general administrative sg expense increase due increase investment support global launch orkambi maintain guidancevertex maintain guidance orkambi kalydeco sale raise guidance combine operate cost orkambi revenue be expect range kalydeco revenue be estimate range remind investor follow approval additional indication kalydeco revenue guidance be up total cf product revenue be expect range combine adjust research development selling general administrative sg expense be anticipate range higher expect previously cost be expect be higher due accelerate development triple combination cf pipeline investment develop ctp focus triple combination cf regimensvertex be evaluate next generation cftr corrector vx vx vx vx part triple combination withvx tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination study conduct cf patient have del mutation minimal function mutation del min be present last week datum demonstrated combination lead pronounce improvement lung function fact be first datum show potential treat underlie cause cf patient have severe difficult treat type disease follow discussion regulatory agency vertex initiate pivotal phase iii study triple combination regimen first half other cf pipeline updatein march positive datum phase iii study evolve expand evaluate kalydeco combination vx tezacaftor cf patient copy del mutation be also announce study meet primary endpoint demonstrated statistically significant improvement lung function base positive outcome study company recently submit regulatory application eu encouragingly combination be also grant orphan drug designation fda june earlier week vertex announce have close previously announce agreement buy concert pharmaceutical inc cnce free report cf pipeline candidate ctp vertex plan develop ctp potential use future once daily regimen combination other pipeline drug treat underlie cause cf takevertex second quarter result be encourage top estimate count sale cf drug rise share decline slightly hour trading probably response hike operate cost expectation year however so far year vertex share priceis massive compare favorably increase industry meanwhile vertex cf pipeline be quite strong broad portfolio next generation cf corrector triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient cf future however forget potential competition vertex triple combo belgian company galapago nv glpg free report abbvie inc abbv free report be also develop triple cftr combination therapy cf vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotevertex sport zack rank strong buy see complete list today zack rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2240,ABBV,have already crossed halfway mark second quarter report cycle earn season have show broad base growth record earning quarter jul member accounting index total market capitalization report result accord earning preview company beat count compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue medical segment have also perform well so far earning increase revenue report total earning company second quarter be expect grow year year higher revenue plenty result still come actual earning growth quarter exceed mark follow earning growth first quarter increase revenue highest almost year johnson johnson jnj free report begin earning season pharma sector mixed second quarter result performance novartis nvs free report lilly lly free report biogen inc biib free report be encourage company beat earning revenue estimate lilly biogen also raise earning revenue estimate other pharma bigwig report last week abbvie inc abbv free report report better expect result earning sale surpass expectation lymphoma drug imbruvica record record growth merck co inc mrk free report also beat estimate earning sale second quarter mainly backed strong sale pd inhibitor keytruda let take look pharma biotech company be set report second quarter result aug let see thing be shape quarter pfizer inc pfe free report pfizer be schedule release earning open bell deliver positive earning surprise last quarter pfizer earning performance have be mixed earning miss expectation last quarters beating same twice result average negative surprise quarter pfizer have earning esp zack rank hold indicate likely beat zack consensus estimate be peg cent share uncover best stock buy sell re report earning esp filter pfizer inc price ep surprise pfizer inc price ep surprise pfizer inc quotenew product xeljanz rheumatoid arthritis ibrance breast cancer well older product lyrica neuropathic pain eliquis blood thinner be likely contribute top line meaningfully read more be beat card pfizer earning aerie pharmaceutical inc aeri free report aerie pharma be schedule announce result close bell aerie pharma have miss estimate past quarters have average negative earning surprise company have earning esp zack rank buy see complete list today zack rank strong buy stock here aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc price ep surprise aerie pharmaceutical inc approve product portfolio aerie depend heavily late stage candidate rhopressa roclatan aerie have submit regulatory application rhopressa expect submit same eu second half hence expect investor focus remain pipeline update read more card aerie earning season incyte corporation incy free report company be expect report market open incyte deliver earning surprise last quarter incyte performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank zack consensus estimate be peg loss cent share incyte corporation price ep surprise incyte corporation price ep surprise incyte corporation quotemore stock news company verge apple rundid miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
2241,ABBV,year jul world hepatitis day whd be observed raise awareness viral hepatitis lead cause death world accord world health organization viral hepatitis cause death world many person remain unaware be infected same be type hepatitis hepatitis be main killer person live hepatitis person live hepatitis person live hepatitis live hepatitis be unaware status hepatitis together account liver cancer case world consider number be not surprise quite few pharma biotech company be work bring innovative treatment area market however challenge hepatitis virus hcv market exist form intense competition pricing pressure stock focushere be look key player hepatitis market biotech major gilead science inc gild free report be perhaps most well know name hcv market hcv drug include harvoni sovaldi epclusa recently approve vosevi hbv offering include viread vemlidy however foster city base company have see lot up down market gilead hcv franchise be major revenue contributor bring multus dollar sale increase competition pricing pressure result significant decline hcv product sale even gilead recently raise guidance hcv franchise sale be nevertheless expect witness significant decline gilead launch educational campaign encourage baby boomer get test accord company have be increase hcv antibody screening baby boomer campaign start result increase diagnosis well company estimate person be newly diagnosed hcv gilead be conduct additional study harvoni well vemlidy have early stage hbv candidate pipeline gs tlr agonist gilead be zack rank buy stock year date ytd company stock be lag rally industry belong see complete list today zack rank strong buy stock here large cap pharma company merck co inc mrk free report be big name hcv market accord information provide merck person have chronic hcv infection merck hcv portfolio comprise zepatier be launch last year pegintron victreli however company hcv franchise be not major revenue generator earlier year merck take major impairment charge related hcv candidate become part pipeline follow acquisition idenix decision be take base change product profile well change company expectation pricing market opportunity merck be zack rank stock ytd company stock be lag rally industry belong abbvie inc abbv free report also have major presence hcv market company hcv product include viekira pak technivie abbvie be currently seek approval maviret investigational pan genotypic regimen glecaprevir pibrentasvir once daily ribavirin free treatment have potential provide faster path virologic cure major hcv genotype gt maviret represent blockbuster potential help abbvie gain major market share once approve launch abbvie be zack rank hold stock abbvie stock have gain ytd perform better industry belong watertown base enanta pharmaceutical inc enta free report have collaboration abbvie protease inhibitor paritaprevir glecaprevir paritaprevir be key compound abbvie direct act antiviral daa regimen viekira pak other daa daa treatment regimen currently market hcv glecaprevir combination pibrentasvir maviret be currently regulatory review enanta earn royalty abbvie product sale meanwhile enanta be also work develop hbv pipeline focus be currently core inhibitor clinical candidate identification plan enanta be zack rank stock ytd enanta stock have gain outperform rally industry belong bottom linethe hcv market continue face challenge more treatment enter market result increase competition additional pricing pressure fact hcv drug have face immense scrutiny due high price say market nevertheless represent significant commercial opportunity information provide enanta market hcv therapy be worth hcv patient start usually witness surge follow introduction new drug market major part hcv infected person remain undiagnosed remain significant opportunity market awareness increase newly diagnosed patient seek treatment hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2242,ABBV,gilead science inc gild free report report result second quarter earning revenue surpass expectation second quarter earning include impact stock base compensation expense share beat zack consensus estimate however earning be year quarter figure moreover total revenue report quarter be top zack consensus estimate however revenue decline year year share be market hour trading follow release second quarter result however share gilead have underperform zack classify industry year so far stock gain period compare industry gain hiv impress yet againproduct sale come year year decline be due lower hepatitis virus hcv sale partially offset higher sale hiv other therapeutic area antiviral product sale include gilead hiv liver disease portfolio come report quarter hcv product sale include harvoni sovaldi recently launch epclusa be report year quarter downside be mainly attribute lower sale harvoni sovaldi major market partially offset sale epclusa launch various location sale harvoni decline year year report quarter decline be mainly due lower sale europe further sovaldi sale record steep year year decline epclusa garner sale report quarter lower prior quarter figure note epclusa be launch europe june jul respectively meanwhile hiv hbv product sale come year year increase be primarily drive continuous strong uptake tenofoviral afenamide taf base product such genvoya generate sale year quarter descovy record sale odefsey register sale hiv treatment stribild complera eviplera sale decline viread sale be atripla sale tank truvada sale fall other product letairis ranexa zydelig record sale respectively research development expense decline due purchase nimbus apollo inc food drug administration fda priority review voucher other hand selling general administrative sg expense be roughly flat adjust product gross margin be year period guidance updatedbased better expect performance first half specifically gilead raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project cent earlier projection cent dividend share gilead declare cash dividend cent share common stock third quarter dividend be payable sep stockholder record close business sep second quarter company paid cash dividend repurchase share gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quoteour better expect performance second quarter be drive positive trend hcv business better expect result hcv business market share particularly due rapid uptake epclusa hcv franchise be boost fda approval vosevi hcv patient start first month be better company expectation company however expect gradual decline second half year market start due increase competition note harvoni sovaldi epclusa face competition abbvie inc abbv free report viekira pak viekira xr bristol myer squibb company bmy free report daklinza other meanwhile hiv franchise maintain momentum drive rapid adoption taf base regimen eu taf base regimen now represent total gilead hiv prescription volume follow launch genvoya launch odefsey descovy genvoya be now company bestselling hiv product treatment naïve patient share strong uptake truvada use pre exposure prophylaxis set be alsoexpect toboost sale company see significant uptick prep usage estimate patient used truvada end second quarter however gilead lose exclusivity viread country outside impact sale zack rank key pickgilead currently carry zack rank hold better rank stock healthcare sector be exelixis inc exel free report currently sport zack rank strong buy see complete list today zack rank stock here exelixis have deliver positive earning surprise trail quarters average beat exelixis share have soar so far year more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2243,ABBV,abbvie inc abbv free report report better expect result second quarter company surpass earning sale expectation year so far abbvie share have rally thus favorably compare industry increase company report second quarter earning share marginally beat zack consensus estimate share earning grow year year company post revenue report quarter again narrowly surpass zack consensus estimate revenue also increase year year operational basis revenue increase quarter detailkey drug humira record sale growth operational basis revenue come sale increase humira sale ex market be operational basis report basis growth major market category drive upside increase competition new class drug well indirect biosimilar competition international market second quarter net revenue imbruvica stand year year sale imbruvica be compare year figure abbvie record international profit sharing johnson johnson jnj free report other product deliver impressive performance include duodopa show revenue operational report basis product call creon report revenue operational report basis hcv product viekira record sale sequentially sale be also operational report basis respectively due intense pricing competitive pressure hcv market adjust sg expense dip expense escalate quarter adjust operate margin be sale report quarter outlookabbvie reiterate previously issue outlook company maintain adjust ep range thus reflect year year growth mid point abbvie inc price consensus ep surpriseabbvie inc price consensus ep surprise abbvie inc quotezack rank key picksabbvie currently carry zack rank hold better rank stock health care sector be eli lilly company lly free report sanofi sny free report carry zack rank buy see complete list today zack rank stock here eli lilly earning share estimate inched last day company share have shot so far year sanofi earning share estimate increase last day company deliver positive earning surprise trail quarters average beat share company have rise so far year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
2244,ABBV,abbvie inc abbv free report be schedule release second quarter earning open bell jul abbvie share have rally so far year industry have record increase last quarter company deliver positive surprise note abbvie earning history be mixed bag pharmaceutical company deliver positive surprise last quarters record line earning other average earning beat last quarters be abbvie inc price ep surpriseabbvie inc price ep surprise abbvie inc quotelet see thing be shape company quarter factor considerat first quarter conference call management reveal expect second quarter earning range share revenue be expect grow report basis currency headwind be expect hurt revenue company key drug humira be likely remain main growth driver second quarter increase awareness favorable clinical datum additional indication expansion new market be expect help product continue make significant contribution top line quarter abbvie also expect humira sale growth mid high teen range internationally humira sale be expect rise mid single digit range operational basis humira be do well company be concern product long term prospect owing potential biosimilar competition area focus be performance imbruvica add abbvie portfolio follow acquisition pharmacyclic drug record strong sale past few quarters trend expect continue imbruvica have multus dollar potential company be look expand drug label solid tumor autoimmune disease company expect imbruvica sale growth approach second quarter imbruvica have huge commercial potential investor know revenue be share johnson johnson jnj free report have collaboration agreement pharmacyclic other drug duopa creon be also expect continue perform well soon be report quarter however abbvie hepatitis virus hcv treatment viekira continue be adversely impact intense pricing competitive pressure hcv market notably last month company announce committee medicinal product human use chmp recommend marketing approval investigational hepatitis virus hcv combo regimen glecaprevir pibrentasvir candidate be market trade name maviret decision european commission be expect third quarter approval definitely provide company stronger presence competitive dynamic hcv market earning whispersour proven model do not conclusively show abbvie be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp abbvie be most accurate estimate be peg share zack consensus estimate stand higher uncover best stock buy sell re report earning esp filter zack rank abbvie zack rank increase predictive power esp earning esp make surprise prediction difficult caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be better rank health care stock want consider model show have right combination element post earning beat quarter nordisk nvo free report be schedule release result aug company have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report schedule release result aug have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
2245,ABBV,gilead science inc gild free report announce fda have approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet drug be single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor approval come back positive datum phase iii study polaris polaris study study evaluate week vosevi direct act antiviral experience chronic hcv infected patient cirrhosis compensate cirrhosis however vosevi have be warn product label regard risk hepatitis virus hbv reactivation hcv hbv co infected patient nevertheless approval make vosevi first once daily str available salvage therapy patient infected hcv genotype have fail prior treatment daa regimen include ns inhibitor approval be expect boost gilead strong hcv portfolio gilead have strong presence hcv market due blockbuster hcv drug sovaldi harvoni sovaldi continue be very important product company harvoni label have be expand twice approval be now approve use broader range patient population hcv portfolio get huge boost epclusa gain approval jun eu jul become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track gilead expect launch epclusa other large eu market once pricing reimbursement be place second half boost sale further last month committee medicinal product human use chmp adopt positive opinion company marketing authorization application maa vosevi follow accelerate assessment procedure gilead hcv franchise be pressure due intense competition pricing issue hcv product sale be weaker expect mainly due fewer new patient start harvoni lower revenue patient harvoni sovaldi epclusa have be face competition abbvie abbv free report viekira pak viekira xr bristol myer bmy free report daklinza johnson johnson jnj free report olysio company expect persistent decline hcv patient start be primary factor year year decrease revenue increase competition impact patient share pricing share gilead have underperform zack classify medical biomedical genetic industry year so far stock lose period industry gain nevertheless hiv franchise gilead be perform well be expect help company combat persistent decline hcv franchise zack rank gilead currently carry zack rank hold see complete list today zack rank stock here look stock skyrocket upsizack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2246,ABBV,repro therapeutic inc announce receive preliminary feedback fda clinical development program proellex treat uterine fibroid oral mechanism fda review proellex remain partial clinical hold company be require accumulate large pre approval safety datum base order candidate be evaluate further meet fda requirement company be require conduct much larger clinical study be time consume also expensive share company plunge monday news be announce note repro share have underperform zack classify medical biomedical genetic industry last year stock have decline industry gain same period remind investor proellex study oral dose treatment endometriosis uterine fibroid be place clinical hold later fda allow study be conduct partial clinical hold low oral dosage note company be also evaluate proellex selective progesterone modulator sprm phase iib study uterine fibroid vaginal delivery however study have clinical hold issue company say now increase focus study company present positive top line datum study november last year meanwhile repro also mentioned receive notice aug be grant european patent relate use sprm particular proellex drug interval odi treatment estrogen dependent uterine condition such uterine fibroid endometriosis notably repro other key pipeline candidate enclomiphene be be evaluate treatment low testosterone level overweight man company submit marketing authorization application maa european medicine agency ema enclomiphene secondary hypogonadism europe sep be other company have be evaluate candidate uterine fibroid apr abbvie inc abbv free report neurocrine biosciencesis also evaluate elagolix reduce heavy menstrual bleed premenopausal woman uterine fibroid be mid stage study company bayer bayry free report be evaluate vilaprisan woman suffering uterine fibroid be late stage study repro therapeutic inc price consensus repro therapeutic inc price consensus repro therapeutic inc quotezack rank other stock considerrepro currently hold zack rank hold other top rank health care stock same space include enzo inc sporting zack rank strong buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2247,ABBV,swiss pharmaceutical company novartis ag nvs free report be schedule report second quarter result jul look novartis share price movement year date show stock have outperformed zack classify large cap pharma industry share have rally compare industry gain last report quarter novartis deliver positive earning surprise company have post average positive earning surprise trail quarters let see thing be shape announcement factor impact quarternovartis operate segment innovative medicine pharmaceutical alcon sandoz generic new product cosentyx entresto boost top line cosentyx have be strong company have grab market share rival abbvie abbv free report humira amgen amgn free report enbrel cosentyx achieve blockbuster status record sale novartis have broaden oncology portfolio acquisition fda recent approval kisqali use combination inhibitor first line treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced metastatic breast cancer further boost company oncology portfolio meanwhile fda have also recently approve label expansion zykadia first line treatment patient metastatic small cell lung cancer additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure due delay launch glatopa mg be expect impact second quarter result also exclusivity key drug novartis portfolio be hurt company top line company blockbuster drug diovan be face stiff generic competition eu japan gleevec lose exclusivity feb eu dec thereby lead generic competition exforge be also face generic competition eu furthermore oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale company ophthalmologic division alcon continue face challenge due lower surgical equipment sale stiff competition face intraocular lens slowdown demand equipment purchase continue act dampener do not expect improve trend division sale be report quarter earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price ep surprise novartis ag price ep surprise novartis ag quotestock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
2248,ABBV,biogen inc biib free report well know name multiple sclerosis ms market surpass expectation earning sale second quarter drugmaker also raise revenue guidance sale newest drug spinraza spinal muscular atrophy witness faster expect adoption share biogen rise almost pre market trading response strong result however note biogen share have inched so far year compare unfavorably industry increase biogen report second quarter earning share beat zack consensus estimate however earning decrease year year sale come year period sale also surpass zack consensus estimate top line exclude hemophilia revenue grow year year company spun hemophilia business february quarter detail biogen ms revenue grow year year second quarter stable global share tecfidera sale rally year period drug record sequential surge revenue include sale ex sale tecfidera revenue benefit seasonal recovery unit volume discount well allowance second quarter tysabri revenue be flat year year same decrease sequentially ex note tysabri revenue first quarter benefit approximately ex market due agreement price reimbursement committee italian national medicine agency aifa related tysabri sale benefit be miss second quarter lead sequential decline combine interferon revenue avonex plegridy second quarter be ex year period avonex revenue decline year period plegridy contribute second quarter revenue year year sequentially interferon revenue be experience decline trend due patient transition other oral ms therapy well higher discount allowance zinbryta launch collaboration abbvie inc abbv free report august last year contribute revenue second quarter compare first quarter newly launch spinraza bring revenue revenue second quarter register massive growth sequentially drug witness strong demand spinraza revenue include approximately related inventory build company be work expand access patient notably jun spinraza be grant marketing authorization eu treatment spinal muscular atrophy sma be also approve japan canada recently quarter biogen record biosimilar revenue compare first quarter company market benepali biosimilar reference amgen inc amgn free report enbrel europe benepali record revenue thus register growth rate sequentially biogen also market flixabi biosimilar reference johnson johnson jnj free report blockbuster drug remicade record revenue report quarter compare first quarter revenue cd therapeutic program include biogen share rituxan gazyva operate profit climb year period second quarter spend soar report quarter sg spend decrease year year quarter company repurchase share worth share repurchase program outlookbiogen raise earning revenue outlook biogen now expect earning range share old guidance share revenue be now expect range comapr earlier guidance increase prior guidance be primarily attribute faster anticipate adoption spinraza term percentage total revenue company sg expense be expect be respectively biogen inc price consensus ep surprisebiogen inc price consensus ep surprise biogen inc quotezack rankbiogen currently carry zack rank hold see complete list today zack rank strong buy stock here more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
2249,ABBV,hurdle trump plan repeal replace obamacare healthcare be second best perform sector year lag technology optimism come especially encourage industry trend hope favorable policy environment trump administration plan focus ease regulatory hurdle rather lower drug price expedite new drug approval additionally shift investor sentiment defensive sector healthcare generally outperform period low moderate growth rise geopolitical uncertainty have lead rally healthcare stock read top rank healthcare etfs long term investor such popular fund health care select sector spdr fund xlv free report vanguard health care etf vht free report ishare healthcare etf iyh free report fidelity msci health care index etf fhlc free report have gain least so far year trend be likely continue head earning season big name pfizer pfe free report merck mrk free report amgen amgn free report abbvie abbv free report gilead science gild free report bristol myer squibb bmy free report be line report week next stock collectively account share xlv iyh vht fhlc let dig deeper earning picture company drive performance mentioned fund come day accord methodology zack rank strong buy buy hold combine positive earning esp increase chance predict earning beat zack rank sell rate be best avoid uncover best stock buy sell re report earning esp filter surprise prediction stockspfizer have zack rank earning esp indicate reasonable chance beating estimate quarter stock see earning estimate revision yet be report quarter deliver negative earning surprise past quarters additionally have impressive growth momentum style score respectively value style score be favorable pfizer be schedule report earning august open bell read build winning etf portfolio second half pfizer inc price consensus ep surprise pfizer inc price consensus ep surprise pfizer inc quotemerck be expect report result july market open have zack rank earning esp make surprise prediction difficult stock witness positive earning estimate revision penny past day be report quarter deliver positive earning surprise last quarters average beat merck have strong value momentum style score unfavorable growth style score merck company inc price consensus ep surprise merck company inc price consensus ep surprise merck company inc quoteamgen have zack rank earning esp indicate less chance beating estimate quarter earning surprise track past quarters be robust average positive surprise amgen witness negative earning estimate revision couple cent past day yet be report quarter stock have solid value momentum style score respectively growth style score look dull amgen report earning july market close amgen inc price consensus ep surprise amgen inc price consensus ep surprise amgen inc quoteabbvie have zack rank earning esp indicate less chance beating estimate quarter company deliver positive earning surprise last quarters average beat see positive earning estimate revision couple cent past month be report quarter stock have solid value style score growth momentum style score respectively be unimpressive company be schedule report july open bell read brighten outlook healthcare etfs focus abbvie inc price consensus ep surprise abbvie inc price consensus ep surprise abbvie inc quotegilead be expect release earning july market close have zack rank earning esp indicate reasonable chance beating estimate gilead deliver positive earning surprise last quarters average beat see earning estimate revision past month be report quarter have solid value momentum style score respectively growth style score look ugly gilead science inc price consensus ep surprise gilead science inc price consensus ep surprise gilead science inc quotebristol myer likely report earning july open bell have zack rank earning esp make surprise prediction difficult stock deliver positive earning surprise past quarters average beat witness positive earning estimate revision cent be report quarter have unfavorable value growth momentum style score respectively see healthcare etfs here bristol myer squibb company price consensus ep surprise bristol myer squibb company price consensus ep surprise bristol myer squibb company quotesum healthcare sector be expect post earning decline second quarter have dismal zack rank bottom surprise well be card suggest upside healthcare etfs particular xlv vht iyh have zack etf rank fhlc have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
2250,ABBV,gilead science inc gild free report be schedule report second quarter result jul market close last quarter company beat expectation gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotegilead track record be pretty mixed company beating estimate last miss other overall company record average positive earning surprise share gilead have moved year so far underperform zack classify medical biomedical genetic industry gain let see thing be shape biotech major announcement earning whispersour proven model show gilead be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg lower uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision factor playconcurrent first quarter earning call gilead reiterate guidance annual guidance gilead expect net product sale range hcv product sale be project hcv product sale be project strong performance hiv other antiviral product sale drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey continue boost sale expect trend continue second quarter well genvoya have already become most prescribe regimen treatment naïve switch patient launch end first quarter taf base regimen make gilead hiv prescription volume treatment market strong uptake truvada use pre exposure prophylaxis set be also expect boost sale however gilead lose exclusivity viread country outside impact sale however hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr other higher discount payer mix continue impact sale adversely total hcv treatment start be estimate approximately less company expect further decline patient start positive note hcv portfolio receive major boost epclusa gain approval become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track recently approve hbv drug vemlidy be also expect start contribute top line fda recently approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor second quarter call investor be likely keep eye gilead performance pipeline update also be keenly await focus also be performance epclusa taf base regimen other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
2251,ABBV,biogen inc biib free report well know name multiple sclerosis ms market report second quarter result jul market open last quarter company deliver positive earning surprise biogen share have decline year so far zack classify biom genetic industry record increase biogen earning performance have be pretty impressive so far have deliver back back positive surprise average earning beat last quarters be let see thing be shape announcement factor considerat first quarter call company have say expect relatively stable demand tecfidera tysabri multiple sclerosis drug patient growth ex market offset modest decline due rise competition drug roche ocrevus remain be see second quarter performance reflect trend meanwhile combine number patient used avonex plegridy be decline patient transition other oral multiple sclerosis therapy other high efficacy product zinbryta launch collaboration abbvie inc abbv free report aug be expect continue contribute revenue eu drug benefit increase use high efficacy product spinraza approve spinal muscular atrophy dec be promising start backed robust underlie demand notably spinraza add top line first quarter contribute further sale conference call company have say be work expand access spinraza patient however call company have warn possible logistic coverage restriction drug well other market expect management provide update issue second quarter conference call biogen biosimilar product flixabi biosimilar reference remicade benepali biosimilar reference enbrel be also generate higher revenue trend continue quarter well headcount reduction restructure initiative be expect continue lower operate expense meanwhile expense be expect increase due increase business development payment second quarter call investor focus remain tecfidera scrip trend sale ramp spinraza pipeline progress acquisition plan earning whispersour proven model do not conclusively show biogen be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate stand zack consensus estimate be peg higher uncover best stock buy sell re report earning esp filter zack rank biogen zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision biogen inc price ep surprise biogen inc price ep surprise biogen inc quotestock considerstock pharmaceutical sector have positive esp favorable zack rank includeeli lilly company lly free report schedule release result jul earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report earning esp zack rank company be schedule release result aug look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
2252,ABBV,perrigo company plc prgo free report announce have receive final approval fda ab rate generic version abbvie inc abbv free report androgel topical gel drug be indicated replacement therapy male condition associate deficiency absence endogenous testosterone annual market sale androgel topical gel packet month end be share perrigo have significantly underperform zack classify medical product industry so far year stock have decline broader industry gain simultaneously perrigo also declare subsidiary have file paragraph iv abbreviated new drug application anda fda generic version galderma soolantra ivermectin cream indicated treatment inflammatory lesion rosacea soolantra annual market sale month end be however same date perrigo settle litigation related meda pharmaceutical inc cipla ltd generic version dymista azelastine hydrochloride fluticasone propionate nasal spray dymista be indicated relief symptom seasonal allergic rhinitis patient year age older require treatment azelastine hydrochloride fluticasone propionate symptomatic relief approval generic version drug bode well company help boost revenue anda once approve also lead increase revenue meanwhile company have be constantly make acquisition expand business drive growth fact be impressed perrigo growth acquisition strategy perrigo have also undertake certain restructure initiative be expect support bottom line go forward perrigo company price consensus perrigo company price consensus perrigo company quotezack rank stock considerperrigo currently carry zack rank hold better rank health care stock same space include enzo inc sanofi sny free report enzo sport zack rank strong buy sanofi hold zack rank buy see complete list today zack rank stock here enzo loss share estimate narrow cent cent cent cent last day company deliver positive earning surprise trail quarters average beat share price company have increase year date sanofi earning share estimate increase last day company come positive earning surprise trail quarters average beat share price company have increase year date trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
2253,ABBV,johnson johnson jnj free report healthcare bellwether announce fda have approve pipeline candidate guselkumab treatment moderate severe plaque psoriasis drug be market trade name tremfya drug be approve accelerate process follow filing priority voucher share have gain so far year significantly ahead increase witness zack classify large cap pharma industry come back latest news fda approval be base study phase iii voyage voyage navigate evaluate efficacy safety guselkumab il human monoclonal antibody administer subcutaneous injection treatment adult moderate severe plaque psoriasis datum voyage trial announce earlier have show significantly higher proportion patient moderate severe plaque psoriasis treat guselkumab achieve high rate skin clearance compare receive placebo patient receive guselkumab achieve least clearer skin versus placebo voyage trial evaluate guselkumab versus abbvie inc abbv free report humira study demonstrated statistically significant efficacy guselkumab compare humira week be maintain week treatment almost patient treat humira achieve least clearer skin versus guselkumab navigate study evaluate efficacy safety switch guselkumab moderate severe plaque psoriasis patient be not achieve clear almost clear skin other plaque psoriasis medicine stelara datum study show patient switch guselkumab show significantly greater improvement skin clearance compare patient continue receive stelara company press release american suffer disease overproduction skin cell cause itch pain burn sensation skin tightness hence approval guselkumab have give company access wide patient population guselkumab be review eu japan plaque psoriasis indication phase iii head head study tremfya novartis ag nvs free report cosentyx moderate severe plaque psoriasis be ongoing meanwhile phase ii trial evaluate guselkumab moderate severely active psoriatic arthritis be also ongoing have previously mentioned tremfya have blockbuster potential rake sale more other tremfya expect key pipeline candidate sirukumab rheumatoid arthritis also gain fda approval year sirukumab be also review eu carry zack rank hold better rank stock same space be astrazeneca plc azn free report sporting zack rank strong buy see complete list today zack rank stock here share astrazeneca have rally so far year also earning estimate moved same climb last day earning performance have be pretty impressive well consistent positive surprise company deliver average earning beat last quarters more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
